2021-01-23 10:27:03 | INFO | fairseq_cli.generate | Namespace(all_gather_list_size=16384, beam=5, bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', cpu=False, criterion='cross_entropy', data='../../../data-bin/custom_EMEA/long_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eval_bleu=True, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, left_pad_source='True', left_pad_target='False', lenpen=1, load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_sentences=128, max_source_positions=1024, max_target_positions=1024, max_tokens=None, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, momentum=0.99, nbest=1, no_beamable_mm=False, no_early_stop=False, no_progress_bar=False, no_repeat_ngram_size=0, no_seed_provided=True, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer='nag', path='../checkpoints/EMEA_11/checkpoint_best.pt', prefix_size=0, print_alignment=False, print_step=False, profile=False, quantization_config_path=None, quiet=False, remove_bpe='@@ ', replace_unk=None, required_batch_size_multiple=8, results_path=None, retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, score_reference=False, scoring='sacrebleu', seed=1, shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, target_lang=None, task='translation', temperature=1.0, tensorboard_logdir='', threshold_loss_scale=None, tokenizer=None, tpu=False, truncate_source=False, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, warmup_updates=0, weight_decay=0.0)
2021-01-23 10:27:03 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-01-23 10:27:03 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-01-23 10:27:03 | INFO | fairseq.data.data_utils | loaded 822 examples from: ../../../data-bin/custom_EMEA/long_EMEA/test.de-en.de
2021-01-23 10:27:03 | INFO | fairseq.data.data_utils | loaded 822 examples from: ../../../data-bin/custom_EMEA/long_EMEA/test.de-en.en
2021-01-23 10:27:03 | INFO | fairseq.tasks.translation | ../../../data-bin/custom_EMEA/long_EMEA test de-en 822 examples
2021-01-23 10:27:03 | INFO | fairseq_cli.generate | loading model(s) from ../checkpoints/EMEA_11/checkpoint_best.pt
S-382	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-382	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-382	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
D-382	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
P-382	-1.5013 -0.3335 -0.1580 -0.2073 -0.6667 -0.2210 -0.1871 -0.0755 -1.0290 -0.1494 -0.1533 -1.0196 -0.0662 -0.1816 -0.1195 -0.1422 -0.1658 -0.1122 -0.2002 -0.1876 -0.0655 -0.8089 -0.1631 -0.3847 -0.1517 -1.0389 -0.0808 -0.1906 -0.0559 -0.1367 -0.1337 -0.1744
S-312	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-312	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-312	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
D-312	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
P-312	-1.5013 -0.3335 -0.1580 -0.2073 -0.6667 -0.2210 -0.1871 -0.0755 -1.0290 -0.1494 -0.1533 -1.0196 -0.0662 -0.1816 -0.1195 -0.1422 -0.1658 -0.1122 -0.2002 -0.1876 -0.0655 -0.8089 -0.1631 -0.3847 -0.1517 -1.0389 -0.0808 -0.1906 -0.0559 -0.1367 -0.1337 -0.1744
S-662	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-662	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-662	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
D-662	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
P-662	-1.5013 -0.3335 -0.1580 -0.2073 -0.6667 -0.2210 -0.1871 -0.0755 -1.0290 -0.1494 -0.1533 -1.0196 -0.0662 -0.1816 -0.1195 -0.1422 -0.1658 -0.1122 -0.2002 -0.1876 -0.0655 -0.8089 -0.1631 -0.3847 -0.1517 -1.0389 -0.0808 -0.1906 -0.0559 -0.1367 -0.1337 -0.1744
S-592	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-592	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-592	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
D-592	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
P-592	-1.5013 -0.3335 -0.1580 -0.2073 -0.6667 -0.2210 -0.1871 -0.0755 -1.0290 -0.1494 -0.1533 -1.0196 -0.0662 -0.1816 -0.1195 -0.1422 -0.1658 -0.1122 -0.2002 -0.1876 -0.0655 -0.8089 -0.1631 -0.3847 -0.1517 -1.0389 -0.0808 -0.1906 -0.0559 -0.1367 -0.1337 -0.1744
S-522	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-522	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-522	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
D-522	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
P-522	-1.5013 -0.3335 -0.1580 -0.2073 -0.6667 -0.2210 -0.1871 -0.0755 -1.0290 -0.1494 -0.1533 -1.0196 -0.0662 -0.1816 -0.1195 -0.1422 -0.1658 -0.1122 -0.2002 -0.1876 -0.0655 -0.8089 -0.1631 -0.3847 -0.1517 -1.0389 -0.0808 -0.1906 -0.0559 -0.1367 -0.1337 -0.1744
S-320	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-320	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-320	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-320	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-320	-1.6769 -0.3021 -0.1280 -0.0728 -0.1904 -0.0935 -0.0128 -0.1337 -0.1700 -0.1888 -0.2122 -0.2322 -0.1244 -0.1321 -0.1266 -0.0761 -0.1223 -0.0895 -1.0816 -0.5240 -0.1779 -0.1295 -0.9370 -0.1365 -0.4538 -0.1126 -0.0677 -0.0623 -0.1553 -0.1353 -0.1432 -0.1063 -0.1736
S-793	Am 30 Juli 2007 erteilte die Europäische Kommission dem Unternehmen SP Europe eine Genehmigung für das Inverkehrbringen von Aerinaze in der gesamten Europäischen Union .
T-793	The European Commission granted a marketing authorisation valid throughout the European Union for Aerinaze to SP Europe on 30 July 2007.
H-793	-0.23542536795139313	The European Commission granted a marketing authorisation valid throughout the European Union , for Aerinaze to SP Europe on 30 July 2007 .
D-793	-0.23542536795139313	The European Commission granted a marketing authorisation valid throughout the European Union , for Aerinaze to SP Europe on 30 July 2007 .
P-793	-0.1174 -0.0706 -0.1562 -0.0467 -0.1273 -0.1448 -0.0313 -0.0887 -0.0002 -0.0613 -0.0842 -0.1236 -0.0587 -0.1044 -1.0795 -0.2599 -0.2802 -0.1344 -0.1436 -0.3695 -0.0893 -0.1391 -1.1820 -0.1310 -0.2609 -0.0949 -0.1515 -1.2131 -0.1422 -0.1763
S-165	Die klinische Einschätzung durch den behandelnden Arzt ist maßgebend für die Therapieplanung bei jedem Patienten auf Basis einer individuellen Nutzen-Risiko-Bewertung .
T-165	Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/ risk assessment .
H-165	-0.43662914633750916	The clinical judgement of the treating physician is instrumental in the planning of therapy for each patient on the basis of individual benefit-risk assessment .
D-165	-0.43662914633750916	The clinical judgement of the treating physician is instrumental in the planning of therapy for each patient on the basis of individual benefit-risk assessment .
P-165	-1.2133 -0.1287 -0.0812 -0.0590 -0.1440 -0.1191 -2.3253 -0.0296 -0.0711 -0.0824 -2.5671 -0.1714 -0.1966 -0.4838 -1.9198 -0.1456 -0.8034 -0.3675 -0.2924 -0.0506 -0.5356 -0.1113 -0.1921 -0.1425 -0.2011 -0.0327 -0.0301 -0.6256 -0.0446 -0.4923 -0.1338 -0.1786
S-66	Die klinische Einschätzung durch den behandelnden Arzt ist maßgebend für die Therapieplanung bei jedem Patienten auf Basis einer individuellen Nutzen-Risiko-Bewertung .
T-66	Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/ risk assessment .
H-66	-0.43662914633750916	The clinical judgement of the treating physician is instrumental in the planning of therapy for each patient on the basis of individual benefit-risk assessment .
D-66	-0.43662914633750916	The clinical judgement of the treating physician is instrumental in the planning of therapy for each patient on the basis of individual benefit-risk assessment .
P-66	-1.2133 -0.1287 -0.0812 -0.0590 -0.1440 -0.1191 -2.3253 -0.0296 -0.0711 -0.0824 -2.5671 -0.1714 -0.1966 -0.4838 -1.9198 -0.1456 -0.8034 -0.3675 -0.2924 -0.0506 -0.5356 -0.1113 -0.1921 -0.1425 -0.2011 -0.0327 -0.0301 -0.6256 -0.0446 -0.4923 -0.1338 -0.1786
S-728	Wenn Sie die Anwendung von ADVATE vergessen haben Injizieren Sie nicht die doppelte Dosis , wenn Sie die vorherige Anwendung vergessen haben .
T-728	If you forget to use ADVATE Do not inject a double dose to make up for a forgotten dose .
H-728	-0.32779809832572937	If you forget to use ADVATE , do not inject an extra dose to make up for any forgotten dose .
D-728	-0.32779809832572937	If you forget to use ADVATE , do not inject an extra dose to make up for any forgotten dose .
P-728	-0.0647 -0.1394 -0.1521 -0.1566 -0.2775 -0.1675 -0.1765 -0.0649 -0.1347 -0.4624 -0.1205 -0.1051 -0.6721 -0.1341 -1.2352 -0.2060 -0.9114 -0.9370 -0.0220 -0.2299 -0.1054 -1.4893 -0.1722 -0.0225 -0.1881 -0.1758
S-452	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-452	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-452	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
D-452	-0.3206813931465149	Of these , 4 had a high titre ( 5 Bethesda units ) and 1 a low titre ( <unk> 5 Bethesda units ) .
P-452	-1.5013 -0.3335 -0.1580 -0.2073 -0.6667 -0.2210 -0.1871 -0.0755 -1.0290 -0.1494 -0.1533 -1.0196 -0.0662 -0.1816 -0.1195 -0.1422 -0.1658 -0.1122 -0.2002 -0.1876 -0.0655 -0.8089 -0.1631 -0.3847 -0.1517 -1.0389 -0.0808 -0.1906 -0.0559 -0.1367 -0.1337 -0.1744
S-492	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-492	Under certain circumstances ( e. g. presence of a low-titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-492	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
D-492	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
P-492	-1.0270 -0.5122 -0.0770 -0.1944 -0.1419 -0.1107 -0.1032 -0.1358 -0.1361 -0.1551 -0.3464 -0.2504 -0.0573 -0.0603 -0.2272 -0.0739 -0.6509 -0.1569 -1.0742 -0.0577 -0.3073 -0.1958 -0.2883 -1.5550 -0.3794 -0.1272 -0.6175 -0.1367 -0.2752 -0.1143 -0.1316 -0.0352 -0.1477 -0.1713
S-352	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-352	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-352	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
D-352	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
P-352	-1.0270 -0.5122 -0.0770 -0.1944 -0.1419 -0.1107 -0.1032 -0.1358 -0.1361 -0.1551 -0.3464 -0.2504 -0.0573 -0.0603 -0.2272 -0.0739 -0.6509 -0.1569 -1.0742 -0.0577 -0.3073 -0.1958 -0.2883 -1.5550 -0.3794 -0.1272 -0.6175 -0.1367 -0.2752 -0.1143 -0.1316 -0.0352 -0.1477 -0.1713
S-422	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-422	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-422	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
D-422	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
P-422	-1.0270 -0.5122 -0.0770 -0.1944 -0.1419 -0.1107 -0.1032 -0.1358 -0.1361 -0.1551 -0.3464 -0.2504 -0.0573 -0.0603 -0.2272 -0.0739 -0.6509 -0.1569 -1.0742 -0.0577 -0.3073 -0.1958 -0.2883 -1.5550 -0.3794 -0.1272 -0.6175 -0.1367 -0.2752 -0.1143 -0.1316 -0.0352 -0.1477 -0.1713
S-632	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-632	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-632	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
D-632	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
P-632	-1.0270 -0.5122 -0.0770 -0.1944 -0.1419 -0.1107 -0.1032 -0.1358 -0.1361 -0.1551 -0.3464 -0.2504 -0.0573 -0.0603 -0.2272 -0.0739 -0.6509 -0.1569 -1.0742 -0.0577 -0.3073 -0.1958 -0.2883 -1.5550 -0.3794 -0.1272 -0.6175 -0.1367 -0.2752 -0.1143 -0.1316 -0.0352 -0.1477 -0.1713
S-191	Wegen des Risikos einer ösophagealen Irritation sollten keine Maßnahmen zum Erbrechen eingeleitet werden und der Patient sollte sich vollständig aufrecht halten .
T-191	Owing to the risk of oesophageal irritation , vomiting should not be induced and the patient should remain fully upright .
H-191	-0.43631216883659363	No vomiting therapy should be initiated and the patient should remain fully upright because of the risk of oesophageal irritation .
D-191	-0.43631216883659363	No vomiting therapy should be initiated and the patient should remain fully upright because of the risk of oesophageal irritation .
P-191	-0.1641 -1.5923 -0.0509 -0.1033 -2.8211 -0.1399 -0.1342 -1.0609 -0.1262 -0.5038 -0.1929 -0.0432 -0.2641 -0.8400 -2.5103 -0.6974 -0.1111 -0.1546 -0.8360 -0.1467 -0.1555 -0.0986 -0.1471 -0.2896 -0.0621 -0.1254 -0.0529 -0.1633 -0.1234 -0.2635 -0.1169 -0.1294 -0.1777
S-92	Wegen des Risikos einer ösophagealen Irritation sollten keine Maßnahmen zum Erbrechen eingeleitet werden und der Patient sollte sich vollständig aufrecht halten .
T-92	Owing to the risk of oesophageal irritation , vomiting should not be induced and the patient should remain fully upright .
H-92	-0.43631216883659363	No vomiting therapy should be initiated and the patient should remain fully upright because of the risk of oesophageal irritation .
D-92	-0.43631216883659363	No vomiting therapy should be initiated and the patient should remain fully upright because of the risk of oesophageal irritation .
P-92	-0.1641 -1.5923 -0.0509 -0.1033 -2.8211 -0.1399 -0.1342 -1.0609 -0.1262 -0.5038 -0.1929 -0.0432 -0.2641 -0.8400 -2.5103 -0.6974 -0.1111 -0.1546 -0.8360 -0.1467 -0.1555 -0.0986 -0.1471 -0.2896 -0.0621 -0.1254 -0.0529 -0.1633 -0.1234 -0.2635 -0.1169 -0.1294 -0.1777
S-670	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-670	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-670	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-670	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-670	-1.6769 -0.3021 -0.1280 -0.0728 -0.1904 -0.0935 -0.0128 -0.1337 -0.1700 -0.1888 -0.2122 -0.2322 -0.1244 -0.1321 -0.1266 -0.0761 -0.1223 -0.0895 -1.0816 -0.5240 -0.1779 -0.1295 -0.9370 -0.1365 -0.4538 -0.1126 -0.0677 -0.0623 -0.1553 -0.1353 -0.1432 -0.1063 -0.1736
S-390	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-390	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-390	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-390	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-390	-1.6769 -0.3021 -0.1280 -0.0728 -0.1904 -0.0935 -0.0128 -0.1337 -0.1700 -0.1888 -0.2122 -0.2322 -0.1244 -0.1321 -0.1266 -0.0761 -0.1223 -0.0895 -1.0816 -0.5240 -0.1779 -0.1295 -0.9370 -0.1365 -0.4538 -0.1126 -0.0677 -0.0623 -0.1553 -0.1353 -0.1432 -0.1063 -0.1736
S-600	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-600	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-600	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-600	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-600	-1.6769 -0.3021 -0.1280 -0.0728 -0.1904 -0.0935 -0.0128 -0.1337 -0.1700 -0.1888 -0.2122 -0.2322 -0.1244 -0.1321 -0.1266 -0.0761 -0.1223 -0.0895 -1.0816 -0.5240 -0.1779 -0.1295 -0.9370 -0.1365 -0.4538 -0.1126 -0.0677 -0.0623 -0.1553 -0.1353 -0.1432 -0.1063 -0.1736
S-562	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-562	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-562	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
D-562	-0.2950288653373718	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
P-562	-1.0270 -0.5122 -0.0770 -0.1944 -0.1419 -0.1107 -0.1032 -0.1358 -0.1361 -0.1551 -0.3464 -0.2504 -0.0573 -0.0603 -0.2272 -0.0739 -0.6509 -0.1569 -1.0742 -0.0577 -0.3073 -0.1958 -0.2883 -1.5550 -0.3794 -0.1272 -0.6175 -0.1367 -0.2752 -0.1143 -0.1316 -0.0352 -0.1477 -0.1713
S-530	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-530	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-530	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-530	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-530	-1.6769 -0.3021 -0.1280 -0.0728 -0.1904 -0.0935 -0.0128 -0.1337 -0.1700 -0.1888 -0.2122 -0.2322 -0.1244 -0.1321 -0.1266 -0.0761 -0.1223 -0.0895 -1.0816 -0.5240 -0.1779 -0.1295 -0.9370 -0.1365 -0.4538 -0.1126 -0.0677 -0.0623 -0.1553 -0.1353 -0.1432 -0.1063 -0.1736
S-460	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-460	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-460	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
D-460	-0.2569984793663025	The activated factor VIII acts as a cofactor for the activated factor IX and accelerates the formation of activated factor X from factor X.
P-460	-1.6769 -0.3021 -0.1280 -0.0728 -0.1904 -0.0935 -0.0128 -0.1337 -0.1700 -0.1888 -0.2122 -0.2322 -0.1244 -0.1321 -0.1266 -0.0761 -0.1223 -0.0895 -1.0816 -0.5240 -0.1779 -0.1295 -0.9370 -0.1365 -0.4538 -0.1126 -0.0677 -0.0623 -0.1553 -0.1353 -0.1432 -0.1063 -0.1736
S-419	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-419	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-419	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
D-419	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
P-419	-0.3822 -0.0441 -0.1186 -0.7762 -3.0306 -0.1884 -0.1577 -0.1226 -0.1875 -0.3454 -0.1155 -0.1968 -0.1356 -0.9722 -0.1892 -1.1615 -0.1320 -0.1372 -0.1915 -0.4365 -0.0600 -0.1574 -0.1209 -0.1446 -2.2004 -0.4806 -0.1067 -0.0634 -0.1241 -0.9285 -0.1405 -0.1728
S-349	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-349	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-349	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
D-349	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
P-349	-0.3822 -0.0441 -0.1186 -0.7762 -3.0306 -0.1884 -0.1577 -0.1226 -0.1875 -0.3454 -0.1155 -0.1968 -0.1356 -0.9722 -0.1892 -1.1615 -0.1320 -0.1372 -0.1915 -0.4365 -0.0600 -0.1574 -0.1209 -0.1446 -2.2004 -0.4806 -0.1067 -0.0634 -0.1241 -0.9285 -0.1405 -0.1728
S-280	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-280	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-280	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
D-280	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
P-280	-0.3822 -0.0441 -0.1186 -0.7762 -3.0306 -0.1884 -0.1577 -0.1226 -0.1875 -0.3454 -0.1155 -0.1968 -0.1356 -0.9722 -0.1892 -1.1615 -0.1320 -0.1372 -0.1915 -0.4365 -0.0600 -0.1574 -0.1209 -0.1446 -2.2004 -0.4806 -0.1067 -0.0634 -0.1241 -0.9285 -0.1405 -0.1728
S-166	Bei einem Teil der Patienten traten die Symptome erneut auf , wenn die Therapie mit demselben Arzneimittel oder einem anderen Bisphosphonat wieder aufgenommen wurde .
T-166	A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate .
H-166	-0.511431097984314	In some of the patients , symptoms returned when resumed therapy with the same medicinal product or with another bisphosphonate .
D-166	-0.511431097984314	In some of the patients , symptoms returned when resumed therapy with the same medicinal product or with another bisphosphonate .
P-166	-0.3205 -0.1844 -1.4960 -0.1092 -0.1395 -0.1754 -0.2364 -2.6773 -0.2905 -1.9791 -1.9792 -0.2431 -0.5703 -0.1468 -0.1377 -0.1715 -1.2490 -0.0619 -0.0787 -0.1819 -0.4681 -0.8340 -0.0593 -0.0429 -0.0379 -0.1051 -0.1720 -0.1724
S-67	Bei einem Teil der Patienten traten die Symptome erneut auf , wenn die Therapie mit demselben Arzneimittel oder einem anderen Bisphosphonat wieder aufgenommen wurde .
T-67	A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate .
H-67	-0.511431097984314	In some of the patients , symptoms returned when resumed therapy with the same medicinal product or with another bisphosphonate .
D-67	-0.511431097984314	In some of the patients , symptoms returned when resumed therapy with the same medicinal product or with another bisphosphonate .
P-67	-0.3205 -0.1844 -1.4960 -0.1092 -0.1395 -0.1754 -0.2364 -2.6773 -0.2905 -1.9791 -1.9792 -0.2431 -0.5703 -0.1468 -0.1377 -0.1715 -1.2490 -0.0619 -0.0787 -0.1819 -0.4681 -0.8340 -0.0593 -0.0429 -0.0379 -0.1051 -0.1720 -0.1724
S-750	Dabei handelt es sich um eine Art von Virus , das genetisch so verändert wurde , dass es ein Gen in die Zellen des Körpers tragen kann .
T-750	This is a type of virus that has been altered genetically so that it can carry a gene into the cells of the body .
H-750	-0.48046374320983887	It is a type of virus that has been genetically modified to carry a gene into the cells of the body .
D-750	-0.48046374320983887	It is a type of virus that has been genetically modified to carry a gene into the cells of the body .
P-750	-0.2665 -0.2033 -0.2796 -0.1652 -0.1301 -1.3727 -0.4073 -0.4835 -0.1307 -0.5401 -3.8291 -1.1748 -0.1133 -0.1746 -0.2375 -0.1530 -0.1386 -0.4647 -0.1100 -0.7312 -0.2255 -0.1334 -0.2154 -0.1524 -0.1791
S-559	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-559	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-559	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
D-559	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
P-559	-0.3822 -0.0441 -0.1186 -0.7762 -3.0306 -0.1884 -0.1577 -0.1226 -0.1875 -0.3454 -0.1155 -0.1968 -0.1356 -0.9722 -0.1892 -1.1615 -0.1320 -0.1372 -0.1915 -0.4365 -0.0600 -0.1574 -0.1209 -0.1446 -2.2004 -0.4806 -0.1067 -0.0634 -0.1241 -0.9285 -0.1405 -0.1728
S-644	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-644	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-644	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
D-644	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
P-644	-0.1759 -0.2105 -0.4834 -0.1349 -0.2774 -0.1214 -0.1251 -0.2499 -0.0498 -0.1249 -0.1604 -0.1594 -0.2096 -0.1614 -0.1021 -1.0302 -0.4936 -0.1145 -0.1186 -0.1651 -0.1565 -0.4716 -0.4924 -0.7203 -0.1562 -0.0595 -0.0798 -0.1606 -0.1737 -0.1542 -0.1493 -0.1728
S-574	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-574	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-574	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
D-574	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
P-574	-0.1759 -0.2105 -0.4834 -0.1349 -0.2774 -0.1214 -0.1251 -0.2499 -0.0498 -0.1249 -0.1604 -0.1594 -0.2096 -0.1614 -0.1021 -1.0302 -0.4936 -0.1145 -0.1186 -0.1651 -0.1565 -0.4716 -0.4924 -0.7203 -0.1562 -0.0595 -0.0798 -0.1606 -0.1737 -0.1542 -0.1493 -0.1728
S-504	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-504	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-504	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
D-504	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
P-504	-0.1759 -0.2105 -0.4834 -0.1349 -0.2774 -0.1214 -0.1251 -0.2499 -0.0498 -0.1249 -0.1604 -0.1594 -0.2096 -0.1614 -0.1021 -1.0302 -0.4936 -0.1145 -0.1186 -0.1651 -0.1565 -0.4716 -0.4924 -0.7203 -0.1562 -0.0595 -0.0798 -0.1606 -0.1737 -0.1542 -0.1493 -0.1728
S-434	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-434	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-434	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
D-434	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
P-434	-0.1759 -0.2105 -0.4834 -0.1349 -0.2774 -0.1214 -0.1251 -0.2499 -0.0498 -0.1249 -0.1604 -0.1594 -0.2096 -0.1614 -0.1021 -1.0302 -0.4936 -0.1145 -0.1186 -0.1651 -0.1565 -0.4716 -0.4924 -0.7203 -0.1562 -0.0595 -0.0798 -0.1606 -0.1737 -0.1542 -0.1493 -0.1728
S-364	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-364	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-364	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
D-364	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
P-364	-0.1759 -0.2105 -0.4834 -0.1349 -0.2774 -0.1214 -0.1251 -0.2499 -0.0498 -0.1249 -0.1604 -0.1594 -0.2096 -0.1614 -0.1021 -1.0302 -0.4936 -0.1145 -0.1186 -0.1651 -0.1565 -0.4716 -0.4924 -0.7203 -0.1562 -0.0595 -0.0798 -0.1606 -0.1737 -0.1542 -0.1493 -0.1728
S-295	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-295	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-295	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
D-295	-0.23797011375427246	In the event of anaphylactic shock , shock therapy should be conducted in accordance with the current medical standard ( see section 4.8 ) .
P-295	-0.1759 -0.2105 -0.4834 -0.1349 -0.2774 -0.1214 -0.1251 -0.2499 -0.0498 -0.1249 -0.1604 -0.1594 -0.2096 -0.1614 -0.1021 -1.0302 -0.4936 -0.1145 -0.1186 -0.1651 -0.1565 -0.4716 -0.4924 -0.7203 -0.1562 -0.0595 -0.0798 -0.1606 -0.1737 -0.1542 -0.1493 -0.1728
S-640	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-640	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-640	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
D-640	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
P-640	-0.8217 -1.4985 -0.0989 -0.2125 -0.2043 -0.1128 -0.5985 -0.0946 -0.3988 -0.0512 -0.0562 -0.6982 -0.1803 -0.1137 -0.1553 -0.9716 -0.1380 -0.3751 -0.1480 -0.1846 -0.0610 -0.2820 -1.7455 -0.9027 -0.2426
S-489	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-489	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-489	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
D-489	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
P-489	-0.3822 -0.0441 -0.1186 -0.7762 -3.0306 -0.1884 -0.1577 -0.1226 -0.1875 -0.3454 -0.1155 -0.1968 -0.1356 -0.9722 -0.1892 -1.1615 -0.1320 -0.1372 -0.1915 -0.4365 -0.0600 -0.1574 -0.1209 -0.1446 -2.2004 -0.4806 -0.1067 -0.0634 -0.1241 -0.9285 -0.1405 -0.1728
S-767	Welche Konsequenzen hat die Rücknahme für Patienten , die derzeit an klinischen Studien bzw. Compassionate-Use -Programmen mit Advexin teilnehmen ?
T-767	What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Advexin ?
H-767	-0.7310863733291626	What is the consequence of withdrawal for patients currently participating in clinical trials or in Compassion Use Programs with Advexin ?
D-767	-0.7310863733291626	What is the consequence of withdrawal for patients currently participating in clinical trials or in Compassion Use Programs with Advexin ?
P-767	-0.2241 -4.2964 -0.1394 -1.0145 -0.1374 -0.1342 -2.9568 -0.1653 -0.2257 -0.2746 -1.1613 -0.2098 -0.1469 -0.0800 -0.0491 -0.3469 -1.4793 -1.9335 -0.8690 -0.0860 -1.2849 -0.0663 -0.7790 -1.7833 -0.1255 -0.1565 -0.1631 -0.1816
S-629	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-629	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-629	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
D-629	-0.4287857115268707	Repeat every 8-24 hours ( 6-12 hours for patients less than 6 years of age ) until the risk to the patient is over .
P-629	-0.3822 -0.0441 -0.1186 -0.7762 -3.0306 -0.1884 -0.1577 -0.1226 -0.1875 -0.3454 -0.1155 -0.1968 -0.1356 -0.9722 -0.1892 -1.1615 -0.1320 -0.1372 -0.1915 -0.4365 -0.0600 -0.1574 -0.1209 -0.1446 -2.2004 -0.4806 -0.1067 -0.0634 -0.1241 -0.9285 -0.1405 -0.1728
S-570	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-570	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-570	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
D-570	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
P-570	-0.8217 -1.4985 -0.0989 -0.2125 -0.2043 -0.1128 -0.5985 -0.0946 -0.3988 -0.0512 -0.0562 -0.6982 -0.1803 -0.1137 -0.1553 -0.9716 -0.1380 -0.3751 -0.1480 -0.1846 -0.0610 -0.2820 -1.7455 -0.9027 -0.2426
S-565	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-565	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-565	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
D-565	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
P-565	-1.7993 -0.0330 -0.1327 -0.4436 -0.1680 -1.0505 -0.1320 -0.1476 -0.0957 -1.1546 -0.1628 -0.2465 -0.1754 -0.0887 -0.1467 -1.1644 -1.3898 -0.1770 -0.0538 -0.0497 -0.0617 -1.7775 -0.5534 -0.5583 -0.1503 -0.0264 -0.1646 -0.1233 -0.1286 -0.1729
S-779	Wenn die Rezeptoren blockiert sind , kann Histamin seine Wirkung nicht entfalten , und dies führt zur Linderung der Allergiesymptome .
T-779	Wenn die Rezeptoren blockiert sind , kann Histamin seine Wirkung nicht entfalten , und dies führt zur Linderung der Allergiesymptome . This reduces the amount of fluid released from the vessels , resulting in less swelling and less mucus production in the nose .
H-779	-0.5781869888305664	When the receptors are blocked , histamine cannot unfold its effect and this helps to relieve the symptoms of allergia .
D-779	-0.5781869888305664	When the receptors are blocked , histamine cannot unfold its effect and this helps to relieve the symptoms of allergia .
P-779	-0.1396 -1.9993 -0.0703 -0.0530 -0.1155 -0.1247 -0.5236 -0.1433 -0.0908 -0.0600 -0.3421 -1.6358 -0.1430 -0.0843 -0.0609 -2.1798 -0.0896 -0.9918 -0.1521 -2.1265 -0.0926 -0.5187 -0.0313 -0.1280 -0.6676 -3.3204 -0.1344 -0.1704
S-226	Die Bioverfügbarkeit war minimal , wenn Alendronat mit oder bis zu zwei Stunden nach einem standardisierten Frühstück angewendet wurde .
T-226	Bioavailability was negligible whether alendronate was administered with , or up to two hours after , a standardised breakfast .
H-226	-0.2707507014274597	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
D-226	-0.2707507014274597	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
P-226	-0.7243 -0.0610 -0.1110 -0.2577 -0.1016 -1.2584 -0.1315 -0.1051 -0.0717 -0.1610 -0.3360 -0.1051 -0.1676 -0.1419 -0.3240 -0.1455 -0.0905 -0.0810 -0.2877 -0.3718 -1.0281 -0.2364 -0.2679 -0.0852 -0.2109 -0.1763
S-123	Die Bioverfügbarkeit war minimal , wenn Alendronat mit oder bis zu zwei Stunden nach einem standardisierten Frühstück angewendet wurde .
T-123	Bioavailability was negligible whether alendronate was administered with , or up to two hours after , a standardised breakfast .
H-123	-0.2707507014274597	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
D-123	-0.2707507014274597	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
P-123	-0.7243 -0.0610 -0.1110 -0.2577 -0.1016 -1.2584 -0.1315 -0.1051 -0.0717 -0.1610 -0.3360 -0.1051 -0.1676 -0.1419 -0.3240 -0.1455 -0.0905 -0.0810 -0.2877 -0.3718 -1.0281 -0.2364 -0.2679 -0.0852 -0.2109 -0.1763
S-635	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-635	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-635	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
D-635	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
P-635	-1.7993 -0.0330 -0.1327 -0.4436 -0.1680 -1.0505 -0.1320 -0.1476 -0.0957 -1.1546 -0.1628 -0.2465 -0.1754 -0.0887 -0.1467 -1.1644 -1.3898 -0.1770 -0.0538 -0.0497 -0.0617 -1.7775 -0.5534 -0.5583 -0.1503 -0.0264 -0.1646 -0.1233 -0.1286 -0.1729
S-500	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-500	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-500	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
D-500	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
P-500	-0.8217 -1.4985 -0.0989 -0.2125 -0.2043 -0.1128 -0.5985 -0.0946 -0.3988 -0.0512 -0.0562 -0.6982 -0.1803 -0.1137 -0.1553 -0.9716 -0.1380 -0.3751 -0.1480 -0.1846 -0.0610 -0.2820 -1.7455 -0.9027 -0.2426
S-286	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-286	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-286	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
D-286	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
P-286	-1.7993 -0.0330 -0.1327 -0.4436 -0.1680 -1.0505 -0.1320 -0.1476 -0.0957 -1.1546 -0.1628 -0.2465 -0.1754 -0.0887 -0.1467 -1.1644 -1.3898 -0.1770 -0.0538 -0.0497 -0.0617 -1.7775 -0.5534 -0.5583 -0.1503 -0.0264 -0.1646 -0.1233 -0.1286 -0.1729
S-291	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-291	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-291	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
D-291	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
P-291	-0.8217 -1.4985 -0.0989 -0.2125 -0.2043 -0.1128 -0.5985 -0.0946 -0.3988 -0.0512 -0.0562 -0.6982 -0.1803 -0.1137 -0.1553 -0.9716 -0.1380 -0.3751 -0.1480 -0.1846 -0.0610 -0.2820 -1.7455 -0.9027 -0.2426
S-495	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-495	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-495	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
D-495	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
P-495	-1.7993 -0.0330 -0.1327 -0.4436 -0.1680 -1.0505 -0.1320 -0.1476 -0.0957 -1.1546 -0.1628 -0.2465 -0.1754 -0.0887 -0.1467 -1.1644 -1.3898 -0.1770 -0.0538 -0.0497 -0.0617 -1.7775 -0.5534 -0.5583 -0.1503 -0.0264 -0.1646 -0.1233 -0.1286 -0.1729
S-430	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-430	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-430	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
D-430	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
P-430	-0.8217 -1.4985 -0.0989 -0.2125 -0.2043 -0.1128 -0.5985 -0.0946 -0.3988 -0.0512 -0.0562 -0.6982 -0.1803 -0.1137 -0.1553 -0.9716 -0.1380 -0.3751 -0.1480 -0.1846 -0.0610 -0.2820 -1.7455 -0.9027 -0.2426
S-425	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-425	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-425	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
D-425	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
P-425	-1.7993 -0.0330 -0.1327 -0.4436 -0.1680 -1.0505 -0.1320 -0.1476 -0.0957 -1.1546 -0.1628 -0.2465 -0.1754 -0.0887 -0.1467 -1.1644 -1.3898 -0.1770 -0.0538 -0.0497 -0.0617 -1.7775 -0.5534 -0.5583 -0.1503 -0.0264 -0.1646 -0.1233 -0.1286 -0.1729
S-360	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-360	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-360	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
D-360	-0.4138675034046173	These therapies should only be administered by physicians with experience in the treatment of patients with haemophilia .
P-360	-0.8217 -1.4985 -0.0989 -0.2125 -0.2043 -0.1128 -0.5985 -0.0946 -0.3988 -0.0512 -0.0562 -0.6982 -0.1803 -0.1137 -0.1553 -0.9716 -0.1380 -0.3751 -0.1480 -0.1846 -0.0610 -0.2820 -1.7455 -0.9027 -0.2426
S-355	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-355	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-355	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
D-355	-0.417629212141037	Isolated patients may vary in their reaction to factor VIII , achieve various in vivo recovery and have varying half-lives .
P-355	-1.7993 -0.0330 -0.1327 -0.4436 -0.1680 -1.0505 -0.1320 -0.1476 -0.0957 -1.1546 -0.1628 -0.2465 -0.1754 -0.0887 -0.1467 -1.1644 -1.3898 -0.1770 -0.0538 -0.0497 -0.0617 -1.7775 -0.5534 -0.5583 -0.1503 -0.0264 -0.1646 -0.1233 -0.1286 -0.1729
S-270	Am 2. März 2004 erteilte die Europäische Kommission dem Unternehmen Baxter AG eine Genehmigung für das Inverkehrbringen von Advate in der gesamten Europäischen Union .
T-270	The European Commission granted a marketing authorisation valid throughout the EU for Advate to Baxter AG on 2 March 2004.
H-270	-0.3625738322734833	The European Commission granted a marketing authorisation valid throughout the European Union , for Advate to Baxter AG on 2 March 2004.
D-270	-0.3625738322734833	The European Commission granted a marketing authorisation valid throughout the European Union , for Advate to Baxter AG on 2 March 2004.
P-270	-0.1068 -0.0696 -0.1595 -0.0515 -0.1396 -0.1253 -0.0308 -0.0889 -0.0004 -0.0619 -0.0793 -0.1178 -0.0601 -0.1047 -0.8048 -0.1743 -2.0633 -0.0659 -0.2649 -1.1003 -0.1217 -0.1958 -1.8961 -0.8667 -0.1388 -1.2251 -0.0928 -0.1249 -0.1830
S-512	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-512	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-512	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
D-512	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
P-512	-1.7432 -0.0448 -0.0941 -0.6905 -0.0918 -0.1995 -0.0679 -0.1461 -0.1661 -0.1756 -0.0839 -0.1349 -0.0418 -2.5478 -0.0413 -0.4247 -0.1645 -0.1433 -0.1068 -0.2759 -0.0814 -0.1319 -0.4325 -0.4184 -0.1218 -0.1220 -1.1639 -0.1474 -0.1953 -0.0651 -0.3314 -0.4224 -0.2130 -0.1672 -0.1755
S-372	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-372	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-372	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
D-372	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
P-372	-1.7432 -0.0448 -0.0941 -0.6905 -0.0918 -0.1995 -0.0679 -0.1461 -0.1661 -0.1756 -0.0839 -0.1349 -0.0418 -2.5478 -0.0413 -0.4247 -0.1645 -0.1433 -0.1068 -0.2759 -0.0814 -0.1319 -0.4325 -0.4184 -0.1218 -0.1220 -1.1639 -0.1474 -0.1953 -0.0651 -0.3314 -0.4224 -0.2130 -0.1672 -0.1755
S-442	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-442	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-442	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
D-442	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
P-442	-1.7432 -0.0448 -0.0941 -0.6905 -0.0918 -0.1995 -0.0679 -0.1461 -0.1661 -0.1756 -0.0839 -0.1349 -0.0418 -2.5478 -0.0413 -0.4247 -0.1645 -0.1433 -0.1068 -0.2759 -0.0814 -0.1319 -0.4325 -0.4184 -0.1218 -0.1220 -1.1639 -0.1474 -0.1953 -0.0651 -0.3314 -0.4224 -0.2130 -0.1672 -0.1755
S-777	Eine Behandlungsdauer von mehr als 10 Tagen wird nicht empfohlen , weil die Wirkungen des Arzneimittels auf die Verstopfung der Nase nachlassen können .
T-777	Treatment for more than 10 days is not advisable , as the medicine s effects on nasal congestion may wear off .
H-777	-0.4454820156097412	Treatment of more than 10 days is not recommended because of the potential for a decrease in nasal constipation .
D-777	-0.4454820156097412	Treatment of more than 10 days is not recommended because of the potential for a decrease in nasal constipation .
P-777	-1.4122 -0.0639 -0.0690 -0.3447 -1.1707 -0.1126 -0.1526 -0.2300 -0.1400 -0.1239 -0.0554 -0.3595 -0.1766 -0.4761 -2.3739 -0.2341 -1.9586 -0.4613 -0.5453 -0.1132 -0.9695 -0.1233 -0.1940 -0.4851 -0.0300 -0.1122 -0.1186 -0.1378 -0.1746
S-582	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-582	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-582	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
D-582	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
P-582	-1.7432 -0.0448 -0.0941 -0.6905 -0.0918 -0.1995 -0.0679 -0.1461 -0.1661 -0.1756 -0.0839 -0.1349 -0.0418 -2.5478 -0.0413 -0.4247 -0.1645 -0.1433 -0.1068 -0.2759 -0.0814 -0.1319 -0.4325 -0.4184 -0.1218 -0.1220 -1.1639 -0.1474 -0.1953 -0.0651 -0.3314 -0.4224 -0.2130 -0.1672 -0.1755
S-652	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-652	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-652	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
D-652	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
P-652	-1.7432 -0.0448 -0.0941 -0.6905 -0.0918 -0.1995 -0.0679 -0.1461 -0.1661 -0.1756 -0.0839 -0.1349 -0.0418 -2.5478 -0.0413 -0.4247 -0.1645 -0.1433 -0.1068 -0.2759 -0.0814 -0.1319 -0.4325 -0.4184 -0.1218 -0.1220 -1.1639 -0.1474 -0.1953 -0.0651 -0.3314 -0.4224 -0.2130 -0.1672 -0.1755
S-32	Dies tritt dann ein , wenn nicht genug neues Knochengewebe nachwächst , um die natürlich abgebaute Knochensubstanz zu ersetzen .
T-32	Dies tritt dann ein , wenn nicht genug neues Knochengewebe nachwächst , um die natürlich abgebaute Knochensubstanz zu ersetzen . The active substances in ADROVANCE are alendronate and vitamin D3 .
H-32	-0.4779672920703888	This occurs when not enough new bone tissue grows to make up for the naturally broken down bone .
D-32	-0.4779672920703888	This occurs when not enough new bone tissue grows to make up for the naturally broken down bone .
P-32	-0.1023 -0.1188 -0.1027 -0.3224 -0.2389 -0.1483 -0.1503 -0.0233 -0.9923 -0.5427 -0.2588 -0.2369 -3.2862 -0.1056 -0.1187 -0.4827 -0.4370 -1.0830 -0.5358 -0.0232 -1.0366 -0.1689
S-303	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-303	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-303	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
D-303	-0.33067813515663147	During clinical trials with ADVATE , a total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients .
P-303	-1.7432 -0.0448 -0.0941 -0.6905 -0.0918 -0.1995 -0.0679 -0.1461 -0.1661 -0.1756 -0.0839 -0.1349 -0.0418 -2.5478 -0.0413 -0.4247 -0.1645 -0.1433 -0.1068 -0.2759 -0.0814 -0.1319 -0.4325 -0.4184 -0.1218 -0.1220 -1.1639 -0.1474 -0.1953 -0.0651 -0.3314 -0.4224 -0.2130 -0.1672 -0.1755
S-71	Eine bestehende Hypocalcämie muss ausgeglichen werden , bevor die Therapie mit ADROVANCE begonnen wird ( siehe Abschnitt 4.3 ) .
T-71	Hypocalcaemia must be corrected before initiating therapy with ADROVANCE ( see section 4.3 ) .
H-71	-0.23343206942081451	Existing hypocalcaemia must be corrected before instituting therapy with ADROVANCE ( see section 4.3 ) .
D-71	-0.23343206942081451	Existing hypocalcaemia must be corrected before instituting therapy with ADROVANCE ( see section 4.3 ) .
P-71	-0.1149 -0.5213 -0.0547 -0.0560 -0.1681 -0.0841 -0.1564 -0.5204 -0.1438 -1.1994 -0.1054 -0.1943 -1.3512 -0.1373 -0.0909 -0.1506 -0.1515 -0.0521 -0.1764 -0.0988 -0.0918 -0.1547 -0.0754 -0.0969 -0.1667 -0.1890 -0.1525 -0.1387 -0.1763
S-170	Eine bestehende Hypocalcämie muss ausgeglichen werden , bevor die Therapie mit ADROVANCE begonnen wird ( siehe Abschnitt 4.3 ) .
T-170	Hypocalcaemia must be corrected before initiating therapy with ADROVANCE ( see section 4.3 ) .
H-170	-0.23343206942081451	Existing hypocalcaemia must be corrected before instituting therapy with ADROVANCE ( see section 4.3 ) .
D-170	-0.23343206942081451	Existing hypocalcaemia must be corrected before instituting therapy with ADROVANCE ( see section 4.3 ) .
P-170	-0.1149 -0.5213 -0.0547 -0.0560 -0.1681 -0.0841 -0.1564 -0.5204 -0.1438 -1.1994 -0.1054 -0.1943 -1.3512 -0.1373 -0.0909 -0.1506 -0.1515 -0.0521 -0.1764 -0.0988 -0.0918 -0.1547 -0.0754 -0.0969 -0.1667 -0.1890 -0.1525 -0.1387 -0.1763
S-59	Es ist sehr wichtig , dass alle Dosierungsanweisungen an den Patienten weitergegeben werden und vom Patienten verstanden werden ( siehe Abschnitt 4.2 ) .
T-59	It is very important that the full dosing instructions are provided to , and are understood by the patient ( see section 4.2 ) .
H-59	-0.45653852820396423	It is very important that all dosing instructions are transmitted to the patient and understood by the patient ( see section 4.2 ) .
D-59	-0.45653852820396423	It is very important that all dosing instructions are transmitted to the patient and understood by the patient ( see section 4.2 ) .
P-59	-0.1130 -0.0961 -1.0153 -0.0649 -0.1179 -0.1191 -0.0851 -0.3848 -1.0442 -0.1284 -2.9627 -0.2726 -0.1886 -0.3770 -0.0826 -0.1498 -2.7275 -1.5152 -0.1259 -0.1115 -0.1582 -0.0495 -0.0936 -0.1747 -0.1505 -0.1572 -0.1448 -0.1723
S-729	Wenn Sie die Anwendung von ADVATE abbrechen Brechen Sie die Anwendung von ADVATE nicht ab ohne Ihren Arzt zu befragen .
T-729	If you stop using ADVATE Do not stop using ADVATE without consulting your doctor .
H-729	-0.26880568265914917	If you discontinue the administration of ADVATE , do not discontinue the administration of ADVATE without consulting your doctor .
D-729	-0.26880568265914917	If you discontinue the administration of ADVATE , do not discontinue the administration of ADVATE without consulting your doctor .
P-729	-0.1116 -0.1361 -0.6551 -0.0519 -2.1403 -0.4636 -0.1455 -0.1455 -0.1855 -0.0694 -0.1327 -0.2790 -0.1118 -0.0994 -0.1877 -0.0384 -0.3759 -0.2238 -0.1442 -0.1373 -0.1921 -0.0639 -0.1217 -0.1430 -0.8505 -0.1559 -0.1756 -0.2069 -0.1425 -0.1774
S-26	Der Hersteller von FOSAVANCE hat zugestimmt , dass die wissenschaftlichen Daten dieses Produkts auch für ADROVANCE verwendet werden können .
T-26	The company that makes FOSAVANCE has agreed that its scientific data can be used for ADROVANCE .
H-26	-0.28737837076187134	The manufacturer of FOSAVANCE has agreed that the scientific data of this product may also be used for ADROVANCE .
D-26	-0.28737837076187134	The manufacturer of FOSAVANCE has agreed that the scientific data of this product may also be used for ADROVANCE .
P-26	-0.1334 -1.1928 -0.1560 -0.1695 -0.0793 -0.1268 -0.1403 -0.0996 -0.0789 -0.2641 -0.4521 -0.1733 -0.2763 -0.6652 -0.1787 -1.1060 -0.2591 -0.2495 -0.7877 -0.1296 -0.1392 -0.2685 -0.5583 -0.1216 -0.0666 -0.1590 -0.1204 -0.0760 -0.2071 -0.1865
S-754	Da Krebszellen beschädigte DNA enthalten , hilft das p53-Protein , die DNA wiederherzustellen oder verursacht , dass die Zellen absterben .
T-754	Because cancer cells contain damaged DNA , the p53 protein either helps to repair the DNA or causes the cells to die .
H-754	-0.3779761493206024	Because cancer cells contain damaged DNA , the p53 protein helps to recover DNA or causes the cells to die .
D-754	-0.3779761493206024	Because cancer cells contain damaged DNA , the p53 protein helps to recover DNA or causes the cells to die .
P-754	-1.0033 -0.1199 -0.0627 -0.0641 -1.0694 -0.0305 -0.1465 -0.7585 -0.2066 -0.0540 -0.0826 -0.0140 -0.3029 -1.1068 -1.6465 -0.2281 -0.0677 -0.9364 -0.0744 -0.1380 -0.1904 -0.2197 -0.1703
S-736	Verwenden Sie ADVATE nicht mehr nach dem Verfalldatum , das auf dem Etikett nach verwendbar bis angegeben ist . .
T-736	Do not use ADVATE after the expiry date , which is stated on the label after EXP .
H-736	-0.3574199080467224	Do not use ADVATE after the expiry date stated on the label after .
D-736	-0.3574199080467224	Do not use ADVATE after the expiry date stated on the label after .
P-736	-0.0584 -0.1110 -0.0858 -0.2675 -0.1808 -0.0665 -0.1322 -0.1404 -0.1224 -0.0743 -0.0310 -0.1058 -0.7653 -0.1378 -0.1282 -0.2615 -0.6751 -3.2637 -0.1832
S-250	Name und Anschrift des ( der ) Hersteller<unk> s ) , der ( die ) für die Chargenfreigabe verantwortlich ist ( sind )
T-250	Name and address of the manufacturer<<unk>> s ) responsible for batch release
H-250	-0.23581050336360931	Name and address of the manufacturer ( s ) responsible for batch release
D-250	-0.23581050336360931	Name and address of the manufacturer ( s ) responsible for batch release
P-250	-0.6617 -0.1548 -0.0912 -0.1637 -0.1214 -0.7062 -0.1892 -0.2105 -0.1375 -0.1119 -0.1363 -0.1310 -0.1211 -0.0307 -0.5701
S-337	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-337	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-337	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
D-337	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
P-337	-3.2097 -0.0599 -0.1155 -0.1754 -0.8180 -0.0297 -0.2006 -0.1970 -0.9473 -2.7677 -0.1152 -1.4100 -0.0991 -0.8558 -0.1130 -0.0760 -0.1396 -2.7843 -0.3592 -0.3387 -0.5518 -0.1306 -0.9790 -0.1816 -0.1479 -0.1578 -0.2216 -0.1804
S-687	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-687	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-687	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
D-687	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
P-687	-3.2097 -0.0599 -0.1155 -0.1754 -0.8180 -0.0297 -0.2006 -0.1970 -0.9473 -2.7677 -0.1152 -1.4100 -0.0991 -0.8558 -0.1130 -0.0760 -0.1396 -2.7843 -0.3592 -0.3387 -0.5518 -0.1306 -0.9790 -0.1816 -0.1479 -0.1578 -0.2216 -0.1804
S-764	Der Ausschuss hatte ferner Bedenken bezüglich der Verarbeitung des Arzneimittels im Körper , der Art der Verabreichung sowie der Sicherheit des Arzneimittels .
T-764	The Committee also had concerns over what happens to the medicine in the body , how it should be given and how safe it is .
H-764	-0.5235839486122131	The Committee also had concerns over the treatment of the product in the body , the method of administration and safety of the product .
D-764	-0.5235839486122131	The Committee also had concerns over the treatment of the product in the body , the method of administration and safety of the product .
P-764	-0.1382 -0.0483 -0.1192 -1.7998 -0.1449 -1.1553 -0.4020 -2.2286 -0.2207 -0.1253 -0.9412 -0.1960 -0.1125 -0.1878 -0.4258 -1.7010 -0.9865 -0.1486 -0.0295 -0.1808 -0.6988 -0.2794 -0.1237 -0.9208 -0.1274 -0.1712
S-756	Advexin hätte die Krankheit heilen oder deren Fortschreiten verlangsamen sollen , indem die normale Schutzfunktion der Zellen wiederhergestellt wird .
T-756	Advexin was expected to cure or slow down the disease by restoring the normal protective function of the cells .
H-756	-0.5269339084625244	Advexin should have cured the disease or slowed its progression by restoring normal , protective cellular function .
D-756	-0.5269339084625244	Advexin should have cured the disease or slowed its progression by restoring normal , protective cellular function .
P-756	-2.5803 -0.1096 -0.1460 -0.5773 -0.1226 -3.2422 -0.1480 -0.3954 -0.1271 -0.1697 -0.2517 -0.0857 -0.3370 -0.1369 -0.1359 -0.0800 -0.5405 -0.3223 -1.5231 -0.4729 -0.2533 -1.1416 -0.3128 -0.1551 -0.1589 -0.1745
S-819	Es wurden keine Studien zu den Auswirkungen von Aerinaze auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-819	No studies on the effects on the ability to drive and use machines have been performed with Aerinaze .
H-819	-0.16648662090301514	No studies on the effect of Aerinaze on ability to drive and use machines have been performed .
D-819	-0.16648662090301514	No studies on the effect of Aerinaze on ability to drive and use machines have been performed .
P-819	-0.0383 -0.0437 -0.0486 -0.1423 -0.1216 -0.1556 -0.4131 -0.1282 -0.1356 -0.3329 -0.1125 -0.0940 -0.8411 -0.1531 -0.0679 -0.2009 -0.0500 -0.1311 -0.1889 -0.1124 -0.0199 -0.1142 -0.1833
S-547	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-547	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-547	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
D-547	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
P-547	-3.2097 -0.0599 -0.1155 -0.1754 -0.8180 -0.0297 -0.2006 -0.1970 -0.9473 -2.7677 -0.1152 -1.4100 -0.0991 -0.8558 -0.1130 -0.0760 -0.1396 -2.7843 -0.3592 -0.3387 -0.5518 -0.1306 -0.9790 -0.1816 -0.1479 -0.1578 -0.2216 -0.1804
S-617	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-617	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-617	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
D-617	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
P-617	-3.2097 -0.0599 -0.1155 -0.1754 -0.8180 -0.0297 -0.2006 -0.1970 -0.9473 -2.7677 -0.1152 -1.4100 -0.0991 -0.8558 -0.1130 -0.0760 -0.1396 -2.7843 -0.3592 -0.3387 -0.5518 -0.1306 -0.9790 -0.1816 -0.1479 -0.1578 -0.2216 -0.1804
S-809	Deshalb ist es im Falle eines operativen Eingriffs vorzuziehen , die Behandlung 24 Stunden vor der Einleitung der Narkose abzusetzen .
T-809	Therefore , if surgery is scheduled , it is preferable to discontinue treatment 24 hours before anaesthesia .
H-809	-0.40561193227767944	It is therefore preferable , in the perisurgical setting , to discontinue the treatment 24 hours prior to the initiation of the anaesthesia .
D-809	-0.40561193227767944	It is therefore preferable , in the perisurgical setting , to discontinue the treatment 24 hours prior to the initiation of the anaesthesia .
P-809	-1.9810 -0.0966 -0.2337 -0.2148 -0.0839 -0.8578 -0.2223 -0.0983 -0.2651 -0.3173 -0.0032 -0.0798 -0.0988 -0.3239 -2.2809 -0.1880 -0.0900 -0.0480 -0.7009 -0.6557 -0.5204 -0.0930 -0.2433 -0.1487 -0.4408 -0.2698 -0.1011 -0.1395 -0.8272 -0.0943 -0.8550 -0.7841 -0.0981 -0.5645 -0.1765
S-60	Die Patienten sollen darüber informiert werden , dass das Risiko ösophagealer Probleme erhöht sein kann , wenn sie diese Anweisungen nicht einhalten .
T-60	Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems .
H-60	-0.46716684103012085	Patients should be informed that oesophageal problems may occur in surgical patients if they do not follow these instructions .
D-60	-0.46716684103012085	Patients should be informed that oesophageal problems may occur in surgical patients if they do not follow these instructions .
P-60	-0.6005 -0.0985 -0.2566 -0.1616 -0.8637 -0.1694 -1.7317 -0.1198 -0.1012 -0.0536 -0.0809 -0.1270 -1.9762 -0.1216 -0.7099 -1.1612 -0.3033 -0.0230 -0.0867 -0.0286 -1.0085 -0.3030 -0.3572 -0.1166 -1.1149 -0.9735 -0.5846 -0.1422 -0.1721
S-719	Treten irgendwelche dieser Symptome auf , brechen Sie die Injektion sofort ab und kontaktieren Sie Ihren Arzt . Schwere Symptome wie z.
T-719	If any of these symptoms occur , stop the injection immediately and contact your doctor .
H-719	-0.36382973194122314	If any of these symptoms occurs , discontinue the injection immediately and contact your doctor .
D-719	-0.36382973194122314	If any of these symptoms occurs , discontinue the injection immediately and contact your doctor .
P-719	-0.0517 -0.1690 -0.1171 -0.2098 -0.7516 -3.0979 -0.0833 -0.1558 -0.5339 -0.0472 -0.1048 -0.2580 -0.1449 -0.0521 -0.1288 -0.0701 -0.1823 -0.1306 -0.1847 -0.8031
S-407	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-407	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-407	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
D-407	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
P-407	-3.2097 -0.0599 -0.1155 -0.1754 -0.8180 -0.0297 -0.2006 -0.1970 -0.9473 -2.7677 -0.1152 -1.4100 -0.0991 -0.8558 -0.1130 -0.0760 -0.1396 -2.7843 -0.3592 -0.3387 -0.5518 -0.1306 -0.9790 -0.1816 -0.1479 -0.1578 -0.2216 -0.1804
S-771	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-771	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-771	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
D-771	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
P-771	-0.0508 -0.1520 -0.0736 -0.0921 -0.1107 -1.4096 -0.2688 -1.1509 -0.1674 -0.4794 -0.0245 -0.1225 -0.3881 -0.0215 -0.1590 -0.0164 -0.0862 -0.0524 -0.0608 -0.0109 -0.1311 -0.0628 -0.0888 -0.1492 -0.1225 -0.1334 -0.0495 -0.1372 -0.1867 -0.1660
S-502	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-502	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-502	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
D-502	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
P-502	-0.6430 -0.0981 -0.2367 -0.1425 -0.9655 -0.7516 -0.1947 -0.1226 -0.0992 -0.0751 -0.3971 -0.1591 -1.8347 -1.1725 -0.1381 -0.0691 -0.1554 -0.4110 -2.3235 -0.1597 -2.7915 -1.1336 -2.1981 -0.1686 -0.1571 -0.1612 -0.0525 -0.1316 -0.1753 -0.0846 -0.1686 -0.1736
S-362	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-362	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-362	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
D-362	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
P-362	-0.6430 -0.0981 -0.2367 -0.1425 -0.9655 -0.7516 -0.1947 -0.1226 -0.0992 -0.0751 -0.3971 -0.1591 -1.8347 -1.1725 -0.1381 -0.0691 -0.1554 -0.4110 -2.3235 -0.1597 -2.7915 -1.1336 -2.1981 -0.1686 -0.1571 -0.1612 -0.0525 -0.1316 -0.1753 -0.0846 -0.1686 -0.1736
S-758	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden .
T-758	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden . The effectiveness of the medicine was assessed by using scans to look at how the tumours responded to treatment .
H-758	-0.2818007171154022	The patient received 12 Advexin injections , injected into some of the tumours , over a period of five months .
D-758	-0.2818007171154022	The patient received 12 Advexin injections , injected into some of the tumours , over a period of five months .
P-758	-0.0846 -0.0762 -0.5811 -0.1087 -2.0496 -0.1915 -0.1407 -0.0998 -0.1088 -0.3059 -0.2386 -0.7695 -0.3480 -0.1003 -0.1457 -0.1221 -0.0662 -0.0572 -0.1815 -0.1112 -0.6370 -0.1469 -0.1432 -0.3860 -0.1095 -0.1353 -0.1633
S-642	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-642	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-642	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
D-642	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
P-642	-0.6430 -0.0981 -0.2367 -0.1425 -0.9655 -0.7516 -0.1947 -0.1226 -0.0992 -0.0751 -0.3971 -0.1591 -1.8347 -1.1725 -0.1381 -0.0691 -0.1554 -0.4110 -2.3235 -0.1597 -2.7915 -1.1336 -2.1981 -0.1686 -0.1571 -0.1612 -0.0525 -0.1316 -0.1753 -0.0846 -0.1686 -0.1736
S-572	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-572	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-572	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
D-572	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
P-572	-0.6430 -0.0981 -0.2367 -0.1425 -0.9655 -0.7516 -0.1947 -0.1226 -0.0992 -0.0751 -0.3971 -0.1591 -1.8347 -1.1725 -0.1381 -0.0691 -0.1554 -0.4110 -2.3235 -0.1597 -2.7915 -1.1336 -2.1981 -0.1686 -0.1571 -0.1612 -0.0525 -0.1316 -0.1753 -0.0846 -0.1686 -0.1736
S-2	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-2	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-2	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
D-2	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
P-2	-0.0508 -0.1520 -0.0736 -0.0921 -0.1107 -1.4096 -0.2688 -1.1509 -0.1674 -0.4794 -0.0245 -0.1225 -0.3881 -0.0215 -0.1590 -0.0164 -0.0862 -0.0524 -0.0608 -0.0109 -0.1311 -0.0628 -0.0888 -0.1492 -0.1225 -0.1334 -0.0495 -0.1372 -0.1867 -0.1660
S-432	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-432	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-432	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
D-432	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
P-432	-0.6430 -0.0981 -0.2367 -0.1425 -0.9655 -0.7516 -0.1947 -0.1226 -0.0992 -0.0751 -0.3971 -0.1591 -1.8347 -1.1725 -0.1381 -0.0691 -0.1554 -0.4110 -2.3235 -0.1597 -2.7915 -1.1336 -2.1981 -0.1686 -0.1571 -0.1612 -0.0525 -0.1316 -0.1753 -0.0846 -0.1686 -0.1736
S-477	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-477	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-477	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
D-477	-0.6200879812240601	Solution should be given slowly at a rate that is convenient for the patient and reaches a maximum of 10 ml/ minute .
P-477	-3.2097 -0.0599 -0.1155 -0.1754 -0.8180 -0.0297 -0.2006 -0.1970 -0.9473 -2.7677 -0.1152 -1.4100 -0.0991 -0.8558 -0.1130 -0.0760 -0.1396 -2.7843 -0.3592 -0.3387 -0.5518 -0.1306 -0.9790 -0.1816 -0.1479 -0.1578 -0.2216 -0.1804
S-293	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-293	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-293	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
D-293	-0.5483028888702393	For the benefit of the patient , it is recommended that the product name and batch number should be noted when administration of ADVATE occurs .
P-293	-0.6430 -0.0981 -0.2367 -0.1425 -0.9655 -0.7516 -0.1947 -0.1226 -0.0992 -0.0751 -0.3971 -0.1591 -1.8347 -1.1725 -0.1381 -0.0691 -0.1554 -0.4110 -2.3235 -0.1597 -2.7915 -1.1336 -2.1981 -0.1686 -0.1571 -0.1612 -0.0525 -0.1316 -0.1753 -0.0846 -0.1686 -0.1736
S-24	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-24	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-24	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
D-24	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
P-24	-0.0508 -0.1520 -0.0736 -0.0921 -0.1107 -1.4096 -0.2688 -1.1509 -0.1674 -0.4794 -0.0245 -0.1225 -0.3881 -0.0215 -0.1590 -0.0164 -0.0862 -0.0524 -0.0608 -0.0109 -0.1311 -0.0628 -0.0888 -0.1492 -0.1225 -0.1334 -0.0495 -0.1372 -0.1867 -0.1660
S-253	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-253	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-253	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
D-253	-0.20415593683719635	If you want more information about your medical condition or your treatment , read the Scientific Discussion ( also part of the EPAR ) .
P-253	-0.0508 -0.1520 -0.0736 -0.0921 -0.1107 -1.4096 -0.2688 -1.1509 -0.1674 -0.4794 -0.0245 -0.1225 -0.3881 -0.0215 -0.1590 -0.0164 -0.0862 -0.0524 -0.0608 -0.0109 -0.1311 -0.0628 -0.0888 -0.1492 -0.1225 -0.1334 -0.0495 -0.1372 -0.1867 -0.1660
S-738	102 Falls weitere Informationen über das Arzneimittel gewünscht werden , setzen Sie sich bitte mit dem örtlichen Vertreter des Zulassungsinhabers in Verbindung .
T-738	96 For any information about this medicine , please contact the local representative of the Marketing Authorisation Holder :
H-738	-0.2876066565513611	For any information about this medicine , please contact the local representative of the MAH .
D-738	-0.2876066565513611	For any information about this medicine , please contact the local representative of the MAH .
P-738	-0.0680 -0.1257 -0.0624 -0.1132 -0.1586 -0.3551 -0.1235 -0.1294 -0.0986 -0.1238 -0.0653 -0.1591 -0.1545 -0.1266 -1.9736 -0.0113 -1.1393 -0.1889
S-350	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-350	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-350	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-350	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-350	-4.2833 -0.3472 -0.1214 -0.1722 -0.3497 -0.1007 -0.2440 -0.1646 -0.3591 -0.1989 -1.0851 -0.3005 -0.1858 -0.4845 -0.0613 -0.1430 -0.1335 -0.1092 -0.1086 -0.4919 -0.4837 -0.2740 -3.4498 -0.3062 -0.1583 -0.1164 -0.5172 -0.2270 -0.1754
S-7	Das Arzneimittel wird nicht empfohlen bei Kindern und bei Patienten , die eine Organtransplantation hatten , da es für diese Gruppen nicht untersucht wurde .
T-7	It is not recommended for use in children or in patients who have had an organ transplant because it has not been studied in these groups .
H-7	-0.3859127163887024	The medicine is not recommended for use in children or in patients who have had organ transplants as it has not been studied in these groups .
D-7	-0.3859127163887024	The medicine is not recommended for use in children or in patients who have had organ transplants as it has not been studied in these groups .
P-7	-0.5026 -0.3997 -0.1285 -0.1254 -0.0649 -1.0044 -0.2840 -0.1282 -0.2316 -0.6231 -0.3484 -0.2520 -0.1239 -0.1340 -0.6954 -0.7971 -1.3778 -0.2166 -0.3918 -0.1820 -0.1158 -0.0951 -0.0898 -0.1921 -0.1194 -0.6192 -1.6410 -0.1315 -0.1762
S-281	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-281	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-281	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-281	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-281	-4.2833 -0.3472 -0.1214 -0.1722 -0.3497 -0.1007 -0.2440 -0.1646 -0.3591 -0.1989 -1.0851 -0.3005 -0.1858 -0.4845 -0.0613 -0.1430 -0.1335 -0.1092 -0.1086 -0.4919 -0.4837 -0.2740 -3.4498 -0.3062 -0.1583 -0.1164 -0.5172 -0.2270 -0.1754
S-265	Ein Antikörper ist ein Protein , das vom Körper aufgrund seines natürlichen Schutzmechanismus als Reaktion auf unbekannte Stoffe gebildet wird .
T-265	An antibody is a protein produced by the body in reaction to unknown agents as part of the natural defence system of the body .
H-265	-0.42517349123954773	Antibodies are proteins made by the body by its natural protective mechanism in response to unknown substances .
D-265	-0.42517349123954773	Antibodies are proteins made by the body by its natural protective mechanism in response to unknown substances .
P-265	-0.0678 -0.2981 -0.1132 -0.2807 -0.0743 -2.0180 -0.1501 -0.1256 -0.1236 -0.8396 -0.3839 -0.1100 -0.7948 -0.1092 -0.1277 -0.1269 -0.8112 -0.1505 -0.5702 -2.1108 -0.0467 -0.1679 -0.1783
S-420	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-420	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-420	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-420	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-420	-4.2833 -0.3472 -0.1214 -0.1722 -0.3497 -0.1007 -0.2440 -0.1646 -0.3591 -0.1989 -1.0851 -0.3005 -0.1858 -0.4845 -0.0613 -0.1430 -0.1335 -0.1092 -0.1086 -0.4919 -0.4837 -0.2740 -3.4498 -0.3062 -0.1583 -0.1164 -0.5172 -0.2270 -0.1754
S-490	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-490	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-490	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-490	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-490	-4.2833 -0.3472 -0.1214 -0.1722 -0.3497 -0.1007 -0.2440 -0.1646 -0.3591 -0.1989 -1.0851 -0.3005 -0.1858 -0.4845 -0.0613 -0.1430 -0.1335 -0.1092 -0.1086 -0.4919 -0.4837 -0.2740 -3.4498 -0.3062 -0.1583 -0.1164 -0.5172 -0.2270 -0.1754
S-560	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-560	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-560	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-560	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-560	-4.2833 -0.3472 -0.1214 -0.1722 -0.3497 -0.1007 -0.2440 -0.1646 -0.3591 -0.1989 -1.0851 -0.3005 -0.1858 -0.4845 -0.0613 -0.1430 -0.1335 -0.1092 -0.1086 -0.4919 -0.4837 -0.2740 -3.4498 -0.3062 -0.1583 -0.1164 -0.5172 -0.2270 -0.1754
S-630	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-630	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-630	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-630	-0.5224958658218384	All 24 hours ( 12-24 hours in patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-630	-4.2833 -0.3472 -0.1214 -0.1722 -0.3497 -0.1007 -0.2440 -0.1646 -0.3591 -0.1989 -1.0851 -0.3005 -0.1858 -0.4845 -0.0613 -0.1430 -0.1335 -0.1092 -0.1086 -0.4919 -0.4837 -0.2740 -3.4498 -0.3062 -0.1583 -0.1164 -0.5172 -0.2270 -0.1754
S-267	Bei einigen Patienten , die mit Arzneimitteln behandelt wurden , welche Faktor VIII enthalten , wurde Überempfindlichkeit ( allergische Reaktion ) beobachtet .
T-267	Hypersensitivity ( allergic reactions ) has sometimes been seen in patients treated with factor VIII-containing products .
H-267	-0.2784522771835327	Hypersensitivity ( allergic reaction ) has been observed in some patients treated with agents containing factor VIII .
D-267	-0.2784522771835327	Hypersensitivity ( allergic reaction ) has been observed in some patients treated with agents containing factor VIII .
P-267	-0.0727 -0.0508 -0.0527 -0.0844 -0.1567 -0.0326 -0.0822 -0.0816 -0.1552 -0.2636 -0.1093 -0.9070 -0.1280 -0.1503 -0.3177 -0.1511 -0.1242 -2.7515 -0.0419 -0.3051 -0.1882 -0.0880 -0.2048 -0.1833
S-367	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-367	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-367	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
D-367	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
P-367	-1.6874 -0.2638 -1.0033 -0.3842 -0.5161 -0.2181 -0.0990 -0.0596 -0.1520 -1.7069 -0.2711 -0.2016 -0.0923 -0.1395 -0.6185 -0.2002 -2.4312 -0.1088 -0.8115 -0.0725 -1.2064 -0.0711 -0.5393 -0.1388 -0.1763
S-437	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-437	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-437	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
D-437	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
P-437	-1.6874 -0.2638 -1.0033 -0.3842 -0.5161 -0.2181 -0.0990 -0.0596 -0.1520 -1.7069 -0.2711 -0.2016 -0.0923 -0.1395 -0.6185 -0.2002 -2.4312 -0.1088 -0.8115 -0.0725 -1.2064 -0.0711 -0.5393 -0.1388 -0.1763
S-577	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-577	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-577	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
D-577	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
P-577	-1.6874 -0.2638 -1.0033 -0.3842 -0.5161 -0.2181 -0.0990 -0.0596 -0.1520 -1.7069 -0.2711 -0.2016 -0.0923 -0.1395 -0.6185 -0.2002 -2.4312 -0.1088 -0.8115 -0.0725 -1.2064 -0.0711 -0.5393 -0.1388 -0.1763
S-298	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-298	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-298	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
D-298	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
P-298	-1.6874 -0.2638 -1.0033 -0.3842 -0.5161 -0.2181 -0.0990 -0.0596 -0.1520 -1.7069 -0.2711 -0.2016 -0.0923 -0.1395 -0.6185 -0.2002 -2.4312 -0.1088 -0.8115 -0.0725 -1.2064 -0.0711 -0.5393 -0.1388 -0.1763
S-52	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-52	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-52	-0.3399401605129242	Patients should receive supplemental calcium if dietary supplementation is insufficient ( see section 4.4 ) .
D-52	-0.3399401605129242	Patients should receive supplemental calcium if dietary supplementation is insufficient ( see section 4.4 ) .
P-52	-0.1140 -0.0985 -0.3182 -0.7850 -0.1059 -2.2254 -0.0376 -0.0570 -0.0674 -0.1299 -0.7387 -0.5510 -0.0266 -1.6581 -0.3159 -0.0981 -0.1129 -0.3754 -0.2690 -0.1390 -0.0498 -0.0876 -0.1748 -0.1731 -0.1515 -0.1411 -0.1769
S-21	Am 21.April 2008 erteilte die Europäische Kommission eine Genehmigung für das Inverkehrbringen von Adenuric in der gesamten Europäischen Union .
T-21	The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
H-21	-0.1999426782131195	The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
D-21	-0.1999426782131195	The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
P-21	-0.1117 -0.0763 -0.1610 -0.1162 -0.1391 -0.1166 -0.0435 -0.0875 -0.0013 -0.0738 -0.0832 -0.1216 -0.0595 -0.0861 -1.3006 -0.3737 -0.2576 -0.1077 -0.1479 -0.6439 -0.2498 -0.2027 -0.1163 -0.1365 -0.1843
S-507	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-507	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-507	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
D-507	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
P-507	-1.6874 -0.2638 -1.0033 -0.3842 -0.5161 -0.2181 -0.0990 -0.0596 -0.1520 -1.7069 -0.2711 -0.2016 -0.0923 -0.1395 -0.6185 -0.2002 -2.4312 -0.1088 -0.8115 -0.0725 -1.2064 -0.0711 -0.5393 -0.1388 -0.1763
S-153	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-153	12 Patients should not lie down for at least 30 minutes after taking ADROVANCE .
H-153	-0.3399401605129242	Patients should receive supplemental calcium if dietary supplementation is insufficient ( see section 4.4 ) .
D-153	-0.3399401605129242	Patients should receive supplemental calcium if dietary supplementation is insufficient ( see section 4.4 ) .
P-153	-0.1140 -0.0985 -0.3182 -0.7850 -0.1059 -2.2254 -0.0376 -0.0570 -0.0674 -0.1299 -0.7387 -0.5510 -0.0266 -1.6581 -0.3159 -0.0981 -0.1129 -0.3754 -0.2690 -0.1390 -0.0498 -0.0876 -0.1748 -0.1731 -0.1515 -0.1411 -0.1769
S-647	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-647	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-647	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
D-647	-0.5267767906188965	In patients who are developing inhibitors against factor VIII , this may constitute an inadequate clinical response .
P-647	-1.6874 -0.2638 -1.0033 -0.3842 -0.5161 -0.2181 -0.0990 -0.0596 -0.1520 -1.7069 -0.2711 -0.2016 -0.0923 -0.1395 -0.6185 -0.2002 -2.4312 -0.1088 -0.8115 -0.0725 -1.2064 -0.0711 -0.5393 -0.1388 -0.1763
S-330	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-330	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-330	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
D-330	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
P-330	-4.3258 -0.5334 -0.0948 -0.1033 -0.1653 -0.1859 -0.1512 -0.0838 -0.0035 -0.1357 -0.1405 -0.1534 -0.5860 -0.1498 -0.2810 -0.3086 -1.0178 -0.1862
S-400	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-400	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-400	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
D-400	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
P-400	-4.3258 -0.5334 -0.0948 -0.1033 -0.1653 -0.1859 -0.1512 -0.0838 -0.0035 -0.1357 -0.1405 -0.1534 -0.5860 -0.1498 -0.2810 -0.3086 -1.0178 -0.1862
S-470	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-470	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-470	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
D-470	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
P-470	-4.3258 -0.5334 -0.0948 -0.1033 -0.1653 -0.1859 -0.1512 -0.0838 -0.0035 -0.1357 -0.1405 -0.1534 -0.5860 -0.1498 -0.2810 -0.3086 -1.0178 -0.1862
S-540	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-540	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-540	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
D-540	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
P-540	-4.3258 -0.5334 -0.0948 -0.1033 -0.1653 -0.1859 -0.1512 -0.0838 -0.0035 -0.1357 -0.1405 -0.1534 -0.5860 -0.1498 -0.2810 -0.3086 -1.0178 -0.1862
S-610	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-610	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-610	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
D-610	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
P-610	-4.3258 -0.5334 -0.0948 -0.1033 -0.1653 -0.1859 -0.1512 -0.0838 -0.0035 -0.1357 -0.1405 -0.1534 -0.5860 -0.1498 -0.2810 -0.3086 -1.0178 -0.1862
S-680	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-680	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-680	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
D-680	-0.4781121611595154	Store at room temperature ( up to 25<unk> C ) for up to 2 months .
P-680	-4.3258 -0.5334 -0.0948 -0.1033 -0.1653 -0.1859 -0.1512 -0.0838 -0.0035 -0.1357 -0.1405 -0.1534 -0.5860 -0.1498 -0.2810 -0.3086 -1.0178 -0.1862
S-212	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-212	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-212	-0.26090511679649353	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % CI :
D-212	-0.26090511679649353	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % CI :
P-212	-0.0692 -0.1407 -0.1654 -0.1485 -0.2042 -0.1472 -0.1709 -0.1454 -0.1140 -0.3229 -0.0730 -0.1953 -0.5306 -0.4334 -0.1989 -0.1100 -1.1263 -0.1703 -0.5814 -0.1707
S-109	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-109	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-109	-0.26090511679649353	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % CI :
D-109	-0.26090511679649353	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % CI :
P-109	-0.0692 -0.1407 -0.1654 -0.1485 -0.2042 -0.1472 -0.1709 -0.1454 -0.1140 -0.3229 -0.0730 -0.1953 -0.5306 -0.4334 -0.1989 -0.1100 -1.1263 -0.1703 -0.5814 -0.1707
S-805	Diese Wirkungen sind bei Kindern , älteren Patienten oder im Falle einer Überdosierung wahrscheinlicher ( siehe Abschnitt 4.9 ) .
T-805	These effects may be more likely to occur in children , elderly patients , or in cases of overdose ( see section 4.9 ) .
H-805	-0.21190787851810455	These effects are more likely in children , elderly patients or in the event of an overdose ( see section 4.9 ) .
D-805	-0.21190787851810455	These effects are more likely in children , elderly patients or in the event of an overdose ( see section 4.9 ) .
P-805	-0.1786 -0.0511 -0.1647 -0.0870 -0.6908 -0.1061 -0.1367 -0.1250 -0.6147 -0.1326 -0.1481 -0.2806 -0.2446 -0.6313 -0.1398 -0.3001 -0.3546 -0.0471 -0.1558 -0.0459 -0.0789 -0.1563 -0.1716 -0.1549 -0.1402 -0.1725
S-766	Das Schreiben , in dem das Unternehmen die EMEA über die Rücknahme des Antrags informiert , kann hier aufgerufen werden .
T-766	The letter from the company notifying the EMEA of the withdrawal of the application is available here .
H-766	-0.46488964557647705	The letter informing the EMEA of the withdrawal of the application is available here .
D-766	-0.46488964557647705	The letter informing the EMEA of the withdrawal of the application is available here .
P-766	-0.1632 -2.4242 -0.8615 -0.7394 -0.3045 -0.1118 -0.0706 -0.1073 -0.5790 -0.1564 -1.1027 -0.1191 -0.1900 -0.2619 -0.3685 -0.1415 -0.5922 -0.3539 -0.1852
S-255	Die Behandlung mit Advate sollte von einem Arzt eingeleitet werden , der über Erfahrung in der Behandlung von Hämophilie verfügt .
T-255	Advate should be started by a doctor who has experience in the treatment of haemophilia .
H-255	-0.26933807134628296	Treatment with Advate should be initiated by a physician with experience in the management of haemophilia .
D-255	-0.26933807134628296	Treatment with Advate should be initiated by a physician with experience in the management of haemophilia .
P-255	-0.0481 -0.0899 -0.0783 -0.1341 -1.1234 -0.0679 -0.1979 -0.1429 -0.0769 -0.1082 -0.0845 -0.1405 -0.0304 -0.1768 -0.4607 -0.2513 -0.1120 -0.1479 -0.7355 -0.1448 -0.1245 -0.0755 -0.2215 -1.9006 -0.1477 -0.1810
S-256	Advate wird durch eine Injektion in eine Vene mit einer Geschwindigkeit von bis zu 10 ml pro Minute verabreicht .
T-256	Advate is given by injection into a vein at a rate of up to 10 ml per minute .
H-256	-0.31820642948150635	Administer by injection into a vein at speeds up to 10 ml per minute .
D-256	-0.31820642948150635	Administer by injection into a vein at speeds up to 10 ml per minute .
P-256	-1.1780 -0.0296 -0.1277 -0.1050 -0.0580 -0.1881 -0.1563 -0.1449 -0.0488 -0.0996 -2.4297 -0.0765 -0.2066 -0.1504 -0.1169 -0.0976 -0.1082 -0.0834 -0.7812 -0.1778
S-760	Nachdem der CHMP die Antworten des Unternehmens auf die ihm gestellten Fragen geprüft hatte , waren immer noch einige Fragen ungeklärt .
T-760	After the CHMP had assessed the responses from the company to a list of questions , there were still some unresolved issues outstanding .
H-760	-0.6708122491836548	After the CHMP reviewed the company s responses to the questions asked of it , some questions were still unexplained .
D-760	-0.6708122491836548	After the CHMP reviewed the company s responses to the questions asked of it , some questions were still unexplained .
P-760	-1.3461 -0.1729 -0.0486 -0.0418 -2.0754 -0.1009 -0.3897 -1.1894 -1.0388 -0.1589 -0.1585 -0.2649 -2.4840 -0.1614 -2.5453 -0.1536 -0.2260 -0.5112 -0.9545 -0.2473 -0.3981 -1.1254 -0.1353 -0.1716
S-264	In den zusätzlichen Studien , einschließlich der Studie mit Kindern unter sechs Jahren , wurde die Wirksamkeit von Advate bestätigt .
T-264	The additional studies confirmed Advate s effectiveness , including in children under six years of age .
H-264	-0.3942035734653473	The effectiveness of Advate was acknowledged in the additional studies , including the study in children less than six years of age .
D-264	-0.3942035734653473	The effectiveness of Advate was acknowledged in the additional studies , including the study in children less than six years of age .
P-264	-0.8351 -1.3953 -0.0826 -0.1348 -1.1329 -0.0743 -0.5988 -0.5834 -0.1189 -0.3513 -0.1092 -0.2667 -0.1660 -0.1557 -0.2636 -1.1268 -0.1922 -0.2299 -1.1184 -0.1318 -0.4433 -0.1783 -0.1941 -0.0713 -0.1214 -0.1732
S-796	Die Dauer der Anwendung ist so kurz wie möglich zu halten und sollte nach Abklingen der Symptome nicht fortgesetzt werden .
T-796	The duration of treatment should be kept as short as possible and should not be continued after the symptoms have disappeared .
H-796	-0.4468081295490265	Duration of administration should be as short as possible and should not be continued after resolution of symptoms .
D-796	-0.4468081295490265	Duration of administration should be as short as possible and should not be continued after resolution of symptoms .
P-796	-0.7375 -0.1115 -0.1322 -1.0659 -0.1705 -0.1776 -0.9319 -1.1362 -0.1918 -0.1735 -0.1381 -0.1995 -0.1230 -0.5966 -0.1785 -0.7806 -1.4126 -0.1414 -0.6791 -0.1293 -0.1758
S-505	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-505	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-505	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
D-505	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
P-505	-0.4639 -0.4114 -0.1369 -1.2603 -0.7188 -0.4128 -0.0473 -0.0526 -0.1519 -0.1397 -0.1050 -0.0463 -0.1415 -0.1404 -0.1794 -0.4561 -0.2190 -0.0744 -0.1521 -0.1566 -0.3635 -0.0866 -0.1302 -0.1224 -0.1160 -0.2136 -0.1348 -0.4700 -0.1384 -0.1799 -0.0661 -0.2853 -1.5892 -0.7369 -0.1869
S-296	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-296	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-296	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
D-296	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
P-296	-0.4639 -0.4114 -0.1369 -1.2603 -0.7188 -0.4128 -0.0473 -0.0526 -0.1519 -0.1397 -0.1050 -0.0463 -0.1415 -0.1404 -0.1794 -0.4561 -0.2190 -0.0744 -0.1521 -0.1566 -0.3635 -0.0866 -0.1302 -0.1224 -0.1160 -0.2136 -0.1348 -0.4700 -0.1384 -0.1799 -0.0661 -0.2853 -1.5892 -0.7369 -0.1869
S-321	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-321	2 paediatric patients ( age 0 16 years ) and adult patients ( age over 16 years )
H-321	-0.2262803614139557	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
D-321	-0.2262803614139557	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
P-321	-0.2216 -1.2018 -0.1911 -0.2121 -1.1533 -0.0605 -0.0058 -1.2647 -0.1873 -0.1163 -0.0623 -0.0464 -0.1507 -0.1321 -0.2404 -0.2645 -0.0342 -0.0963 -0.1461 -0.1639 -0.0443 -0.0307 -0.4132 -0.1807 -0.2139 -0.1549 -0.0998 -0.1008 -0.1383 -0.1556 -0.0970 -0.1595 -0.2622 -0.0956 -0.1002 -0.0874 -0.1368 -0.1766
S-208	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden- Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-208	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-208	-0.3198210299015045	There were no differences between treatment groups regarding the mean values of serum calcium , phosphate or calcium in 24 hour urine .
D-208	-0.3198210299015045	There were no differences between treatment groups regarding the mean values of serum calcium , phosphate or calcium in 24 hour urine .
P-208	-0.0530 -0.9871 -0.0729 -0.0948 -0.2688 -1.2131 -0.2171 -1.9448 -0.4496 -0.5119 -0.6617 -0.1695 -0.0586 -0.1361 -0.0819 -0.0664 -0.1320 -0.1438 -0.1219 -0.0927 -0.0918 -0.2832 -0.0440 -0.0576 -0.1234 -0.1391 -1.1112 -0.1940 -0.0866 -0.2819 -0.1635 -0.1803
S-735	Informieren Sie Ihren Arzt , wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder wenn Sie Nebenwirkungen bemerken , die nicht in dieser Packungsbeilage aufgeführt sind .
T-735	If any of these side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor .
H-735	-0.12902721762657166	If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , tell your doctor .
D-735	-0.12902721762657166	If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , tell your doctor .
P-735	-0.0631 -0.1434 -0.1420 -0.1296 -0.0819 -0.1652 -0.0949 -0.0203 -0.1234 -0.1174 -0.0969 -0.1390 -0.0720 -0.1101 -0.1944 -0.3142 -0.1375 -0.0520 -0.1369 -0.1666 -0.0890 -0.0548 -0.0995 -0.1238 -0.2799 -0.1716 -0.1122 -0.1280 -0.1820
S-69	Sie sollen keine zwei Tabletten am selben Tag einnehmen , sondern die Einnahme von einer Tablette pro Woche wie ursprünglich geplant am dafür vorgesehenen Wochentag weiterführen .
T-69	They should not take two tablets on the same day but should return to taking one tablet once a week , as originally scheduled on their chosen day .
H-69	-0.38924863934516907	Do not take two tablets on the same day but continue to take one tablet per week on the day of the week as planned .
D-69	-0.38924863934516907	Do not take two tablets on the same day but continue to take one tablet per week on the day of the week as planned .
P-69	-0.5768 -0.1087 -0.1374 -0.1035 -0.0521 -0.1082 -0.1418 -0.1348 -0.2175 -0.2904 -1.1190 -0.4866 -2.0947 -0.0993 -0.1201 -0.0705 -0.0592 -0.3183 -0.1126 -1.4810 -0.1225 -1.0459 -0.1501 -0.1939 -0.3653 -0.1221 -1.1617 -0.1195 -0.1745
S-168	Sie sollen keine zwei Tabletten am selben Tag einnehmen , sondern die Einnahme von einer Tablette pro Woche wie ursprünglich geplant am dafür vorgesehenen Wochentag weiterführen .
T-168	They should not take two tablets on the same day but should return to taking one tablet once a week , as originally scheduled on their chosen day .
H-168	-0.38924863934516907	Do not take two tablets on the same day but continue to take one tablet per week on the day of the week as planned .
D-168	-0.38924863934516907	Do not take two tablets on the same day but continue to take one tablet per week on the day of the week as planned .
P-168	-0.5768 -0.1087 -0.1374 -0.1035 -0.0521 -0.1082 -0.1418 -0.1348 -0.2175 -0.2904 -1.1190 -0.4866 -2.0947 -0.0993 -0.1201 -0.0705 -0.0592 -0.3183 -0.1126 -1.4810 -0.1225 -1.0459 -0.1501 -0.1939 -0.3653 -0.1221 -1.1617 -0.1195 -0.1745
S-18	Adenuric darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen Feboxustat oder einen der sonstigen Bestandteile sind .
T-18	Adenuric should not be used in people who may be hypersensitive ( allergic ) to feboxustat or any of the other ingredients .
H-18	-0.27313753962516785	Adenuric should not be used in people who may be allergic ( hypersensitive ) to feboxustat or any of the excipients .
D-18	-0.27313753962516785	Adenuric should not be used in people who may be allergic ( hypersensitive ) to feboxustat or any of the excipients .
P-18	-0.0929 -0.2046 -0.0714 -0.1571 -0.1998 -0.1196 -0.1531 -0.1519 -0.1240 -0.2387 -0.1019 -0.1746 -0.1341 -0.2941 -0.0441 -0.1681 -0.1131 -0.0909 -0.1376 -0.1564 -1.1461 -1.4111 -0.1806 -0.1108 -0.8174 -0.4161 -0.1299 -0.5396 -0.1372 -0.1298 -1.1627 -0.1687 -0.1001 -0.1283 -0.1407 -0.1859
S-365	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-365	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-365	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
D-365	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
P-365	-0.4639 -0.4114 -0.1369 -1.2603 -0.7188 -0.4128 -0.0473 -0.0526 -0.1519 -0.1397 -0.1050 -0.0463 -0.1415 -0.1404 -0.1794 -0.4561 -0.2190 -0.0744 -0.1521 -0.1566 -0.3635 -0.0866 -0.1302 -0.1224 -0.1160 -0.2136 -0.1348 -0.4700 -0.1384 -0.1799 -0.0661 -0.2853 -1.5892 -0.7369 -0.1869
S-435	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-435	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-435	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
D-435	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
P-435	-0.4639 -0.4114 -0.1369 -1.2603 -0.7188 -0.4128 -0.0473 -0.0526 -0.1519 -0.1397 -0.1050 -0.0463 -0.1415 -0.1404 -0.1794 -0.4561 -0.2190 -0.0744 -0.1521 -0.1566 -0.3635 -0.0866 -0.1302 -0.1224 -0.1160 -0.2136 -0.1348 -0.4700 -0.1384 -0.1799 -0.0661 -0.2853 -1.5892 -0.7369 -0.1869
S-391	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-391	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 17 spontaneously or as a result of accidental or surgical trauma .
H-391	-0.2262803614139557	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
D-391	-0.2262803614139557	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
P-391	-0.2216 -1.2018 -0.1911 -0.2121 -1.1533 -0.0605 -0.0058 -1.2647 -0.1873 -0.1163 -0.0623 -0.0464 -0.1507 -0.1321 -0.2404 -0.2645 -0.0342 -0.0963 -0.1461 -0.1639 -0.0443 -0.0307 -0.4132 -0.1807 -0.2139 -0.1549 -0.0998 -0.1008 -0.1383 -0.1556 -0.0970 -0.1595 -0.2622 -0.0956 -0.1002 -0.0874 -0.1368 -0.1766
S-575	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-575	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-575	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
D-575	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
P-575	-0.4639 -0.4114 -0.1369 -1.2603 -0.7188 -0.4128 -0.0473 -0.0526 -0.1519 -0.1397 -0.1050 -0.0463 -0.1415 -0.1404 -0.1794 -0.4561 -0.2190 -0.0744 -0.1521 -0.1566 -0.3635 -0.0866 -0.1302 -0.1224 -0.1160 -0.2136 -0.1348 -0.4700 -0.1384 -0.1799 -0.0661 -0.2853 -1.5892 -0.7369 -0.1869
S-150	Folgende Hinweise sind genau zu befolgen , um das Risiko für ösophageale Reizungen und damit verbundene Nebenwirkungen zu verringern ( siehe Abschnitt 4.4 ) :
T-150	The following instructions should be followed exactly in order to minimize the risk of oesophageal irritation and related adverse reactions ( see section 4.4 ) :
H-150	-0.31828829646110535	The following advice should be followed closely to reduce the risk of oesophageal irritation and related undesirable effects ( see section 4.4 ) :
D-150	-0.31828829646110535	The following advice should be followed closely to reduce the risk of oesophageal irritation and related undesirable effects ( see section 4.4 ) :
P-150	-1.2742 -0.0664 -0.4693 -0.5049 -0.1657 -0.1671 -0.8125 -0.6422 -1.1539 -0.6009 -0.0997 -0.1816 -0.2454 -0.1595 -0.0797 -0.0559 -0.1133 -0.1416 -0.0658 -0.1201 -0.1532 -1.9359 -0.1760 -0.0748 -0.0418 -0.1918 -0.1482 -0.0455 -0.0846 -0.1818 -0.1713 -0.1538 -0.1642 -0.1790
S-815	Das für den Metabolismus von Desloratadin verantwortliche Enzym wurde noch nicht identifiziert , so dass Wechselwirkungen mit anderen Arzneimitteln nicht ganz ausgeschlossen werden können .
T-815	The enzyme responsible for the metabolism of desloratadine has not been identified yet , and therefore , some interactions with other medicinal products can not be fully excluded .
H-815	-0.32958850264549255	The enzyme responsible for the metabolism of desloratadine has not been identified and interactions with other medicinal products cannot be entirely excluded .
D-815	-0.32958850264549255	The enzyme responsible for the metabolism of desloratadine has not been identified and interactions with other medicinal products cannot be entirely excluded .
P-815	-0.1210 -0.0245 -0.1328 -0.1307 -0.2037 -0.1229 -0.1896 -0.0190 -0.0496 -0.0372 -0.1396 -1.6287 -0.0457 -0.1646 -0.3246 -0.5063 -0.1391 -0.0956 -0.3558 -0.1150 -2.5782 -0.0304 -0.3124 -0.1265 -0.1236 -0.1582 -0.0562 -0.1456 -0.0902 -0.2268 -2.3153 -0.4237 -0.1025 -0.1223 -0.1774
S-15	Im Vergleich dazu war dies bei 22 % ( 60 von 268 ) der Patienten unter Allopurinol und bei keinem der 134 Patienten unter Placebo der Fall .
T-15	This was compared with 22 % of the patients taking allopurinol ( 60 out of 268 ) and none of the 134 patients taking placebo .
H-15	-0.31429246068000793	This compares with 22 % ( 60 out of 268 ) of the patients receiving allopurinol and none of the 134 receiving placebo .
D-15	-0.31429246068000793	This compares with 22 % ( 60 out of 268 ) of the patients receiving allopurinol and none of the 134 receiving placebo .
P-15	-0.4658 -0.5792 -0.1907 -0.9172 -0.1766 -0.1180 -0.2137 -0.0799 -0.4366 -0.1414 -0.1243 -0.1553 -0.2156 -0.1419 -0.5254 -0.1923 -1.0283 -1.0044 -1.1044 -0.1367 -0.1690 -0.2754 -0.8378 -0.1374 -0.1150 -0.0718 -0.2055 -0.1179 -0.0810 -0.1517 -0.0963 -0.1326 -0.1743 -0.1730
S-743	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
T-743	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <<unk>> 44 1635 206345
H-743	-0.31849566102027893	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
D-743	-0.31849566102027893	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
P-743	-0.0508 -0.0549 -1.0816 -0.1322 -0.2159 -0.1190 -0.1205 -0.0723 -0.1441 -1.2450 -0.1189 -1.4941 -0.0435 -0.1563 -0.0467 -0.0649 -1.0572 -0.8673 -0.0877 -0.0256 -0.1768 -2.0715 -0.1417 -0.1042 -1.0109 -0.1366 -0.1093 -0.0591 -0.1561 -0.0349 -0.0636 -0.0852 -0.0787 -0.1337 -0.0976 -0.1375 -0.1414 -0.1657
S-739	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <unk> 44 1635 206345
T-739	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <<unk>> 44 1635 206345
H-739	-0.3219219744205475	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <unk> 44 1635 206345
D-739	-0.3219219744205475	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <unk> 44 1635 206345
P-739	-0.0351 -0.8738 -0.1348 -0.2182 -0.1081 -0.1175 -0.0734 -0.1323 -1.2031 -0.1170 -1.4319 -0.0440 -0.1550 -0.0471 -0.0624 -1.0993 -0.8385 -0.0933 -0.0254 -0.1676 -2.1480 -0.1519 -0.1011 -0.9977 -0.1329 -0.1139 -0.0734 -0.4460 -0.1548 -0.0263 -0.0611 -0.0875 -0.0768 -0.1388 -0.0976 -0.1355 -0.1462 -0.1655
S-645	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-645	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-645	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
D-645	-0.293898344039917	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A.
P-645	-0.4639 -0.4114 -0.1369 -1.2603 -0.7188 -0.4128 -0.0473 -0.0526 -0.1519 -0.1397 -0.1050 -0.0463 -0.1415 -0.1404 -0.1794 -0.4561 -0.2190 -0.0744 -0.1521 -0.1566 -0.3635 -0.0866 -0.1302 -0.1224 -0.1160 -0.2136 -0.1348 -0.4700 -0.1384 -0.1799 -0.0661 -0.2853 -1.5892 -0.7369 -0.1869
S-49	Folgende Hinweise sind genau zu befolgen , um das Risiko für ösophageale Reizungen und damit verbundene Nebenwirkungen zu verringern ( siehe Abschnitt 4.4 ) :
T-49	The following instructions should be followed exactly in order to minimize the risk of oesophageal irritation and related adverse reactions ( see section 4.4 ) :
H-49	-0.31828829646110535	The following advice should be followed closely to reduce the risk of oesophageal irritation and related undesirable effects ( see section 4.4 ) :
D-49	-0.31828829646110535	The following advice should be followed closely to reduce the risk of oesophageal irritation and related undesirable effects ( see section 4.4 ) :
P-49	-1.2742 -0.0664 -0.4693 -0.5049 -0.1657 -0.1671 -0.8125 -0.6422 -1.1539 -0.6009 -0.0997 -0.1816 -0.2454 -0.1595 -0.0797 -0.0559 -0.1133 -0.1416 -0.0658 -0.1201 -0.1532 -1.9359 -0.1760 -0.0748 -0.0418 -0.1918 -0.1482 -0.0455 -0.0846 -0.1818 -0.1713 -0.1538 -0.1642 -0.1790
S-78	Daher müssen die Patienten nach der Einnahme von Alendronat mindestens 30 Minuten warten , bevor sie andere Arzneimittel einnehmen ( siehe Abschnitte 4.2 und 5.2 ) .
T-78	Therefore , patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product ( see sections 4.2 and 5.2 ) .
H-78	-0.2884867787361145	Patients should therefore wait at least 30 minutes after receiving alendronate before taking any other medicinal products ( see sections 4.2 and 5.2 ) .
D-78	-0.2884867787361145	Patients should therefore wait at least 30 minutes after receiving alendronate before taking any other medicinal products ( see sections 4.2 and 5.2 ) .
P-78	-1.1272 -0.1054 -1.0011 -0.2528 -1.2431 -0.1378 -0.0983 -0.1219 -0.0864 -0.2938 -1.7283 -0.1142 -0.1361 -0.1083 -0.0501 -0.1548 -0.1737 -0.3328 -0.1235 -0.0705 -0.1852 -0.1426 -0.1757 -0.0531 -0.0797 -0.2140 -0.1637 -0.1697 -0.2132 -0.1733 -0.1593 -0.1583 -0.1721
S-177	Daher müssen die Patienten nach der Einnahme von Alendronat mindestens 30 Minuten warten , bevor sie andere Arzneimittel einnehmen ( siehe Abschnitte 4.2 und 5.2 ) .
T-177	Therefore , patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product ( see sections 4.2 and 5.2 ) .
H-177	-0.2884867787361145	Patients should therefore wait at least 30 minutes after receiving alendronate before taking any other medicinal products ( see sections 4.2 and 5.2 ) .
D-177	-0.2884867787361145	Patients should therefore wait at least 30 minutes after receiving alendronate before taking any other medicinal products ( see sections 4.2 and 5.2 ) .
P-177	-1.1272 -0.1054 -1.0011 -0.2528 -1.2431 -0.1378 -0.0983 -0.1219 -0.0864 -0.2938 -1.7283 -0.1142 -0.1361 -0.1083 -0.0501 -0.1548 -0.1737 -0.3328 -0.1235 -0.0705 -0.1852 -0.1426 -0.1757 -0.0531 -0.0797 -0.2140 -0.1637 -0.1697 -0.2132 -0.1733 -0.1593 -0.1583 -0.1721
S-381	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-381	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-381	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
D-381	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
P-381	-0.1798 -0.4874 -0.0711 -0.0288 -0.1418 -0.2176 -0.2007 -0.0929 -0.1207 -0.1689 -0.1576 -0.2547 -1.3576 -0.1610 -0.1392 -0.1729 -0.1538 -0.1198 -0.1461 -1.6366 -0.2642 -0.0703 -0.3236 -0.0670 -0.1697 -2.2334 -0.1422 -0.0830 -0.0525 -0.1587 -0.6898 -0.2718 -0.4795 -0.1760 -0.1987 -0.1843
S-591	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-591	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-591	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
D-591	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
P-591	-0.1798 -0.4874 -0.0711 -0.0288 -0.1418 -0.2176 -0.2007 -0.0929 -0.1207 -0.1689 -0.1576 -0.2547 -1.3576 -0.1610 -0.1392 -0.1729 -0.1538 -0.1198 -0.1461 -1.6366 -0.2642 -0.0703 -0.3236 -0.0670 -0.1697 -2.2334 -0.1422 -0.0830 -0.0525 -0.1587 -0.6898 -0.2718 -0.4795 -0.1760 -0.1987 -0.1843
S-521	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-521	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-521	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
D-521	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
P-521	-0.1798 -0.4874 -0.0711 -0.0288 -0.1418 -0.2176 -0.2007 -0.0929 -0.1207 -0.1689 -0.1576 -0.2547 -1.3576 -0.1610 -0.1392 -0.1729 -0.1538 -0.1198 -0.1461 -1.6366 -0.2642 -0.0703 -0.3236 -0.0670 -0.1697 -2.2334 -0.1422 -0.0830 -0.0525 -0.1587 -0.6898 -0.2718 -0.4795 -0.1760 -0.1987 -0.1843
S-451	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-451	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-451	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
D-451	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
P-451	-0.1798 -0.4874 -0.0711 -0.0288 -0.1418 -0.2176 -0.2007 -0.0929 -0.1207 -0.1689 -0.1576 -0.2547 -1.3576 -0.1610 -0.1392 -0.1729 -0.1538 -0.1198 -0.1461 -1.6366 -0.2642 -0.0703 -0.3236 -0.0670 -0.1697 -2.2334 -0.1422 -0.0830 -0.0525 -0.1587 -0.6898 -0.2718 -0.4795 -0.1760 -0.1987 -0.1843
S-3	Adenuric wird zur Behandlung der chronischen ( langfristigen ) Hyperurikämie ( hohe Harnsäure- bzw. Uratspiegel im Blut ) angewendet .
T-3	Adenuric is used to treat chronic ( long-term ) hyperuricaemia ( high levels of uric acid or urate in the blood ) .
H-3	-0.3237834870815277	Adenuric is an anti-diabetic medicine used to treat chronic ( long-term ) hyperuricaemia ( high levels of uric acid or urine in the blood ) .
D-3	-0.3237834870815277	Adenuric is an anti-diabetic medicine used to treat chronic ( long-term ) hyperuricaemia ( high levels of uric acid or urine in the blood ) .
P-3	-0.0713 -0.2410 -0.0482 -0.1669 -0.1275 -1.4569 -0.0014 -0.0864 -1.8470 -0.1704 -0.0689 -0.0604 -0.2525 -0.2279 -0.0490 -0.2741 -0.3052 -1.6137 -0.2074 -0.1783 -0.1594 -0.0358 -0.0655 -0.4317 -0.0482 -0.1542 -0.3027 -0.5820 -0.4976 -0.1468 -0.6230 -0.2030 -0.1991 -0.8172 -0.1236 -0.7911 -0.1604 -0.1181 -0.0531 -0.1329 -0.3186 -0.1803
S-311	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-311	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-311	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
D-311	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
P-311	-0.1798 -0.4874 -0.0711 -0.0288 -0.1418 -0.2176 -0.2007 -0.0929 -0.1207 -0.1689 -0.1576 -0.2547 -1.3576 -0.1610 -0.1392 -0.1729 -0.1538 -0.1198 -0.1461 -1.6366 -0.2642 -0.0703 -0.3236 -0.0670 -0.1697 -2.2334 -0.1422 -0.0830 -0.0525 -0.1587 -0.6898 -0.2718 -0.4795 -0.1760 -0.1987 -0.1843
S-721	Wichtige Informationen über bestimmte sonstige Bestandteile von ADVATE Dieses Arzneimittel enthält 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-721	Important information about some of the ingredients of ADVATE This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-721	-0.14764384925365448	Wichtige Informationen über bestimmte sonstige Bestandteile von ADVATE Dieses Arzneimittel enthält 0.45 mmol Sodium ( 10 mg ) pro Vial . This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-721	-0.14764384925365448	Wichtige Informationen über bestimmte sonstige Bestandteile von ADVATE Dieses Arzneimittel enthält 0.45 mmol Sodium ( 10 mg ) pro Vial . This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-721	-0.0013 -0.0127 -0.0102 -0.0258 -0.0273 -0.0096 -0.0033 -0.1247 -0.0158 -0.1607 -0.0552 -0.1658 -0.0493 -0.0874 -0.1420 -0.0182 -0.0273 -0.0905 -0.3940 -0.1478 -0.1324 -0.1352 -0.0806 -0.1796 -0.2938 -0.1528 -0.1445 -0.0733 -0.1234 -0.0079 -1.8219 -0.3899 -0.1969 -0.3110 -0.4633 -0.0819 -0.0884 -0.0687 -0.0854 -0.1601 -0.1239 -0.1363 -0.0901 -0.0176 -0.0493 -0.1278 -0.1214 -0.0651 -0.1560 -0.0524 -0.0558 -0.0824 -0.1698 -0.1650
S-713	ADVATE wird bei Patienten mit Hämophilie A eingesetzt zur Vorbeugung oder Behandlung von Sponatanblutungen oder Blutungen nach chirurgischen Eingriffen .
T-713	ADVATE is used in patients with haemophilia A for prevention or treatment of spontaneous or surgery-related bleeding .
H-713	-0.34762123227119446	ADVATE is used to prevent or treat spontaneous haemorrhage or haemorrhage following surgery in patients with haemophilia A .
D-713	-0.34762123227119446	ADVATE is used to prevent or treat spontaneous haemorrhage or haemorrhage following surgery in patients with haemophilia A .
P-713	-0.3462 -0.2029 -0.0617 -0.1428 -0.1127 -0.5443 -0.9344 -0.1212 -0.2182 -0.0918 -0.0455 -0.5829 -0.0896 -0.6039 -0.0638 -0.0110 -0.8922 -0.1338 -0.5781 -0.1096 -0.0106 -0.2202 -0.3654 -1.5541 -0.1046 -0.4132 -0.1288 -0.3698 -0.1018 -0.2998 -1.6713 -0.3335 -0.1761 -0.1832
S-211	Die Anstiege über die Ausgangswerte der BMD an der Lendenwirbelsäule betrugen nach einem Jahr im Mittel 5,1 % ( 95 % CI :
T-211	The mean increases from baseline in lumbar spine BMD at one year were 5.1 % ( 95 % CI :
H-211	-0.4308091700077057	Increases in lumbar spine BMD at one year were on average 5.1 % ( 95 % CI :
D-211	-0.4308091700077057	Increases in lumbar spine BMD at one year were on average 5.1 % ( 95 % CI :
P-211	-3.5964 -0.0973 -0.2867 -1.9076 -0.4474 -0.0394 -0.0076 -0.0348 -0.1103 -0.1106 -0.1046 -0.8241 -0.0458 -0.1483 -1.2914 -0.6656 -0.1178 -0.2261 -0.1423 -0.1608 -0.2180 -0.2765 -0.1684 -0.1325 -0.1593 -0.1543 -0.1580
S-260	Es wird von einer Zelle produziert , in die ein Gen ( DNA ) eingebracht wurde , das sie zur Bildung des menschlichen Gerinnungsfaktors VIII befähigt .
T-260	Es wird von einer Zelle produziert , in die ein Gen ( DNA ) eingebracht wurde , das sie zur Bildung des menschlichen Gerinnungsfaktors VIII befähigt . Advate is similar to another medicine approved in the European Union ( EU ) called Recombinate , but it is prepared differently so that there are no human- or animal-derived proteins in the medicine .
H-260	-0.3152555823326111	It is produced by a cell into which a gene ( DNA ) has been introduced that enables it to produce human clotting factor VIII .
D-260	-0.3152555823326111	It is produced by a cell into which a gene ( DNA ) has been introduced that enables it to produce human clotting factor VIII .
P-260	-0.0625 -0.1333 -0.0846 -0.1383 -0.1506 -0.1291 -0.6319 -0.1347 -1.2011 -0.0845 -0.1653 -0.0289 -0.1389 -0.2956 -0.1230 -1.0522 -0.2593 -0.6208 -0.1970 -0.5111 -0.1641 -1.6855 -0.8398 -0.0862 -0.0325 -0.1716 -0.0975 -0.1537 -0.0557 -0.1690 -0.1744
S-661	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-661	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-661	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
D-661	-0.32149556279182434	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) ADVATE treated patients used inhibitors of factor VIII .
P-661	-0.1798 -0.4874 -0.0711 -0.0288 -0.1418 -0.2176 -0.2007 -0.0929 -0.1207 -0.1689 -0.1576 -0.2547 -1.3576 -0.1610 -0.1392 -0.1729 -0.1538 -0.1198 -0.1461 -1.6366 -0.2642 -0.0703 -0.3236 -0.0670 -0.1697 -2.2334 -0.1422 -0.0830 -0.0525 -0.1587 -0.6898 -0.2718 -0.4795 -0.1760 -0.1987 -0.1843
S-727	Wenn Sie eine größere Menge von ADVATE angewendet haben , als Sie sollten Wenden Sie ADVATE immer genauso an , wie es Ihnen Ihr Arzt empfohlen hat .
T-727	If you use more ADVATE than you should Always take ADVATE exactly as your doctor has told you .
H-727	-0.3181394040584564	If you take more ADVATE than you should , always use ADVATE exactly as your doctor has recommended .
D-727	-0.3181394040584564	If you take more ADVATE than you should , always use ADVATE exactly as your doctor has recommended .
P-727	-0.0473 -0.1513 -1.0834 -0.0668 -0.2298 -0.1916 -0.0689 -0.1285 -0.1624 -0.1154 -0.2050 -0.4878 -0.8136 -0.2484 -1.3323 -0.1976 -0.0655 -0.1371 -0.8110 -0.2307 -0.1273 -0.0398 -0.1281 -0.2967 -0.7313 -0.1740
S-48	Andere Getränke ( einschließlich Mineralwasser ) , Nahrungsmittel und manche Arzneimittel können möglicherweise die Resorption von Alendronat beeinträchtigen ( siehe Abschnitt 4.5 ) .
T-48	Other beverages ( including mineral water ) , food and some medicinal products are likely to reduce the absorption of alendronate ( see section 4.5 ) .
H-48	-0.2597854733467102	Other beverages ( including mineral water ) , food and some medicinal products may impair the absorption of alendronate ( see section 4.5 ) .
D-48	-0.2597854733467102	Other beverages ( including mineral water ) , food and some medicinal products may impair the absorption of alendronate ( see section 4.5 ) .
P-48	-0.0716 -0.9940 -0.6012 -0.1662 -0.2232 -0.1347 -0.1438 -0.0579 -0.1103 -0.1495 -0.1649 -1.4392 -0.2247 -0.2066 -0.2535 -0.0894 -0.0733 -0.1037 -1.9619 -0.0170 -0.1242 -0.2148 -0.0718 -0.1497 -0.1870 -0.1311 -0.1016 -0.0602 -0.1484 -0.0517 -0.0987 -0.1951 -0.1638 -0.1550 -0.1377 -0.1746
S-536	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-536	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-536	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
D-536	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
P-536	-0.1547 -0.0752 -0.1521 -0.1208 -0.0717 -0.1572 -0.0661 -0.1407 -0.3204 -1.4930 -0.1025 -0.1608 -1.9477 -0.3031 -1.6712 -0.1983 -0.1552 -0.4896 -0.1457 -0.1811 -0.0406 -0.1618 -0.5144 -0.3304 -0.1623 -0.1808 -0.0446 -0.0812 -0.7675 -0.1810
S-785	Während der Studie trugen die Patienten ihre Symptome alle 12 Stunden in ein Tagebuch ein und bewerteten mit einer Standardskala , wie schwer die Symptome in den letzten 12 Stunden waren .
T-785	The patients recorded their symptoms in a diary every 12 hours during the study , scoring on a standard symptom scale how severe the symptoms were over the previous 12-hour period .
H-785	-0.3263337314128876	During the trial , patients entered their symptoms in a diary every 12 hours and used a standard scale to assess how serious the symptoms were over the last 12 hours .
D-785	-0.3263337314128876	During the trial , patients entered their symptoms in a diary every 12 hours and used a standard scale to assess how serious the symptoms were over the last 12 hours .
P-785	-0.4128 -0.1351 -0.6179 -0.2777 -0.1417 -0.3845 -0.1252 -0.0491 -0.1614 -0.1508 -0.2542 -0.1813 -0.7278 -0.2812 -0.0954 -0.2829 -0.3620 -0.1295 -0.0524 -0.1022 -0.1406 -0.9837 -0.0966 -1.0861 -0.9226 -0.0851 -0.8300 -0.1956 -0.1294 -1.0282 -0.2407 -0.1311 -0.1333 -0.1676
S-676	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-676	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-676	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
D-676	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
P-676	-0.1547 -0.0752 -0.1521 -0.1208 -0.0717 -0.1572 -0.0661 -0.1407 -0.3204 -1.4930 -0.1025 -0.1608 -1.9477 -0.3031 -1.6712 -0.1983 -0.1552 -0.4896 -0.1457 -0.1811 -0.0406 -0.1618 -0.5144 -0.3304 -0.1623 -0.1808 -0.0446 -0.0812 -0.7675 -0.1810
S-466	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-466	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-466	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
D-466	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
P-466	-0.1547 -0.0752 -0.1521 -0.1208 -0.0717 -0.1572 -0.0661 -0.1407 -0.3204 -1.4930 -0.1025 -0.1608 -1.9477 -0.3031 -1.6712 -0.1983 -0.1552 -0.4896 -0.1457 -0.1811 -0.0406 -0.1618 -0.5144 -0.3304 -0.1623 -0.1808 -0.0446 -0.0812 -0.7675 -0.1810
S-606	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-606	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-606	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
D-606	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
P-606	-0.1547 -0.0752 -0.1521 -0.1208 -0.0717 -0.1572 -0.0661 -0.1407 -0.3204 -1.4930 -0.1025 -0.1608 -1.9477 -0.3031 -1.6712 -0.1983 -0.1552 -0.4896 -0.1457 -0.1811 -0.0406 -0.1618 -0.5144 -0.3304 -0.1623 -0.1808 -0.0446 -0.0812 -0.7675 -0.1810
S-149	Andere Getränke ( einschließlich Mineralwasser ) , Nahrungsmittel und manche Arzneimittel können möglicherweise die Resorption von Alendronat beeinträchtigen ( siehe Abschnitt 4.5 ) .
T-149	Other beverages ( including mineral water ) , food and some medicinal products are likely to reduce the absorption of alendronate ( see section 4.5 ) .
H-149	-0.2597854733467102	Other beverages ( including mineral water ) , food and some medicinal products may impair the absorption of alendronate ( see section 4.5 ) .
D-149	-0.2597854733467102	Other beverages ( including mineral water ) , food and some medicinal products may impair the absorption of alendronate ( see section 4.5 ) .
P-149	-0.0716 -0.9940 -0.6012 -0.1662 -0.2232 -0.1347 -0.1438 -0.0579 -0.1103 -0.1495 -0.1649 -1.4392 -0.2247 -0.2066 -0.2535 -0.0894 -0.0733 -0.1037 -1.9619 -0.0170 -0.1242 -0.2148 -0.0718 -0.1497 -0.1870 -0.1311 -0.1016 -0.0602 -0.1484 -0.0517 -0.0987 -0.1951 -0.1638 -0.1550 -0.1377 -0.1746
S-795	Aerinaze sollte aufgrund des Fehlens von Daten zur Unbedenklichkeit und Wirksamkeit ( siehe Abschnitt 5.1 ) nicht bei Kindern unter 12 Jahren angewendet werden .
T-795	Aerinaze should not be used in children below the age of 12 years due to a lack of data on safety and efficacy ( see section 5.1 ) .
H-795	-0.24130767583847046	Aerinaze should not be used in children under 12 due to a lack of data on safety and efficacy ( see section 5.1 ) .
D-795	-0.24130767583847046	Aerinaze should not be used in children under 12 due to a lack of data on safety and efficacy ( see section 5.1 ) .
P-795	-0.4822 -0.1454 -0.1278 -0.3752 -0.0849 -0.2723 -0.1196 -0.1509 -0.2288 -0.1218 -0.3038 -0.9468 -0.2346 -1.4231 -0.1615 -0.8330 -0.1089 -0.1356 -0.0272 -0.0802 -0.0650 -0.1594 -0.0420 -0.0774 -0.0923 -0.1600 -0.0614 -0.0821 -0.2373 -0.1479 -0.1527 -0.1390 -0.1833
S-396	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-396	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-396	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
D-396	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
P-396	-0.1547 -0.0752 -0.1521 -0.1208 -0.0717 -0.1572 -0.0661 -0.1407 -0.3204 -1.4930 -0.1025 -0.1608 -1.9477 -0.3031 -1.6712 -0.1983 -0.1552 -0.4896 -0.1457 -0.1811 -0.0406 -0.1618 -0.5144 -0.3304 -0.1623 -0.1808 -0.0446 -0.0812 -0.7675 -0.1810
S-326	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-326	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-326	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
D-326	-0.3523963689804077	Cmax ( IU/ dl ) Cclearance ( dl ) MRT ( h ) VSS ( dl ) * Geometric mean
P-326	-0.1547 -0.0752 -0.1521 -0.1208 -0.0717 -0.1572 -0.0661 -0.1407 -0.3204 -1.4930 -0.1025 -0.1608 -1.9477 -0.3031 -1.6712 -0.1983 -0.1552 -0.4896 -0.1457 -0.1811 -0.0406 -0.1618 -0.5144 -0.3304 -0.1623 -0.1808 -0.0446 -0.0812 -0.7675 -0.1810
S-223	Die Bioverfügbarkeit nahm entsprechend auf etwa 0,46 % und 0,39 % ab , wenn Alendronat eine oder eine halbe Stunde vor einem standardisierten Frühstück
T-223	Bioavailability was decreased similarly to an estimated 0.46 % and 0.39 % when alendronate was administered one hour or half an hour before a standardised breakfast .
H-223	-0.4373989999294281	Bioavailability decreased corresponding to about 0.46 % and 0.39 % when administered alendronate one and a half hours prior to a standardized breakfast .
D-223	-0.4373989999294281	Bioavailability decreased corresponding to about 0.46 % and 0.39 % when administered alendronate one and a half hours prior to a standardized breakfast .
P-223	-0.6223 -0.0610 -0.1527 -0.0893 -1.0045 -0.2011 -0.1575 -1.0805 -0.2032 -0.0797 -0.1261 -0.1548 -0.1950 -0.1373 -0.1357 -0.1294 -2.3026 -0.1089 -0.7314 -0.1251 -0.1394 -0.0727 -0.8802 -0.8579 -0.2906 -0.1957 -0.3334 -0.2231 -0.1420 -0.7545 -1.5486 -0.2037 -0.2693 -0.1255 -1.7035 -0.2082
S-108	Die Anstiege über die Ausgangswerte der BMD an der Lendenwirbelsäule betrugen nach einem Jahr im Mittel 5,1 % ( 95 % CI :
T-108	The mean increases from baseline in lumbar spine BMD at one year were 5.1 % ( 95 % CI :
H-108	-0.4308091700077057	Increases in lumbar spine BMD at one year were on average 5.1 % ( 95 % CI :
D-108	-0.4308091700077057	Increases in lumbar spine BMD at one year were on average 5.1 % ( 95 % CI :
P-108	-3.5964 -0.0973 -0.2867 -1.9076 -0.4474 -0.0394 -0.0076 -0.0348 -0.1103 -0.1106 -0.1046 -0.8241 -0.0458 -0.1483 -1.2914 -0.6656 -0.1178 -0.2261 -0.1423 -0.1608 -0.2180 -0.2765 -0.1684 -0.1325 -0.1593 -0.1543 -0.1580
S-46	Kapselförmige , weiße bis gebrochen weiße Tabletten , gekennzeichnet mit dem Umriss eines Knochens auf der einen Seite und 710 auf der anderen Seite .
T-46	Capsule-shaped , white to off-white tablets , marked with an outline of a bone image on one side , and <<unk>> 710 <<unk>> on the other .
H-46	-0.3829227089881897	Capsular , white to broken white tablets marked with the outline of a bone on one face and 710 on the other face .
D-46	-0.3829227089881897	Capsular , white to broken white tablets marked with the outline of a bone on one face and 710 on the other face .
P-46	-1.8113 -0.5309 -1.2186 -0.3844 -0.1312 -0.1643 -0.5876 -0.6826 -0.0809 -0.0980 -1.8552 -0.1688 -0.1432 -0.2143 -0.4732 -0.1502 -0.1582 -0.0287 -0.1006 -0.6461 -0.2811 -0.1359 -0.0803 -0.1591 -0.0758 -0.1240 -0.1587 -0.5268 -0.1432 -0.1745
S-275	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-275	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-275	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
D-275	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
P-275	-0.7744 -0.4217 -0.8772 -0.4496 -2.7496 -0.1740 -0.1086 -0.1793 -0.0901 -0.7844 -0.1248 -0.2338 -0.1384 -0.1382 -0.1506 -0.1022 -0.0368 -0.1324 -1.0003 -0.7758 -0.8725 -0.0929 -0.4477 -0.0736 -0.1418 -1.3031 -1.0078 -1.1253 -0.1720 -0.1501 -0.1846
S-285	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-285	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma factor VIII activity assay is indispensable .
H-285	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
D-285	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
P-285	-0.5792 -0.7098 -0.5744 -0.1413 -1.8837 -0.0692 -0.1796 -0.1005 -2.8842 -0.5100 -0.0501 -0.1378 -1.8502 -1.4794 -0.3613 -0.0272 -0.1199 -0.2111 -0.0932 -0.0717 -0.4239 -3.4181 -0.1019 -0.2512 -0.1362 -0.2193 -0.2518 -0.1205 -1.1826 -1.1498 -0.1431 -0.1744
S-354	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-354	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 13 factor VIII activity assay is indispensable .
H-354	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
D-354	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
P-354	-0.5792 -0.7098 -0.5744 -0.1413 -1.8837 -0.0692 -0.1796 -0.1005 -2.8842 -0.5100 -0.0501 -0.1378 -1.8502 -1.4794 -0.3613 -0.0272 -0.1199 -0.2111 -0.0932 -0.0717 -0.4239 -3.4181 -0.1019 -0.2512 -0.1362 -0.2193 -0.2518 -0.1205 -1.1826 -1.1498 -0.1431 -0.1744
S-620	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-620	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-620	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
D-620	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
P-620	-0.5280 -1.3775 -0.1351 -1.5219 -0.1341 -0.3731 -0.2038 -0.0784 -0.2370 -0.8320 -0.1500 -0.1008 -0.1688 -0.0639 -0.0728 -0.0923 -0.6957 -0.5585 -0.0267 -0.2113 -0.2241 -0.2086 -0.1748 -0.1086 -0.2725 -0.9377 -0.0519 -0.0816 -0.2044 -0.1782
S-550	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-550	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-550	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
D-550	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
P-550	-0.5280 -1.3775 -0.1351 -1.5219 -0.1341 -0.3731 -0.2038 -0.0784 -0.2370 -0.8320 -0.1500 -0.1008 -0.1688 -0.0639 -0.0728 -0.0923 -0.6957 -0.5585 -0.0267 -0.2113 -0.2241 -0.2086 -0.1748 -0.1086 -0.2725 -0.9377 -0.0519 -0.0816 -0.2044 -0.1782
S-480	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-480	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-480	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
D-480	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
P-480	-0.5280 -1.3775 -0.1351 -1.5219 -0.1341 -0.3731 -0.2038 -0.0784 -0.2370 -0.8320 -0.1500 -0.1008 -0.1688 -0.0639 -0.0728 -0.0923 -0.6957 -0.5585 -0.0267 -0.2113 -0.2241 -0.2086 -0.1748 -0.1086 -0.2725 -0.9377 -0.0519 -0.0816 -0.2044 -0.1782
S-343	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-343	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-343	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
D-343	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
P-343	-0.7744 -0.4217 -0.8772 -0.4496 -2.7496 -0.1740 -0.1086 -0.1793 -0.0901 -0.7844 -0.1248 -0.2338 -0.1384 -0.1382 -0.1506 -0.1022 -0.0368 -0.1324 -1.0003 -0.7758 -0.8725 -0.0929 -0.4477 -0.0736 -0.1418 -1.3031 -1.0078 -1.1253 -0.1720 -0.1501 -0.1846
S-340	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-340	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-340	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
D-340	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
P-340	-0.5280 -1.3775 -0.1351 -1.5219 -0.1341 -0.3731 -0.2038 -0.0784 -0.2370 -0.8320 -0.1500 -0.1008 -0.1688 -0.0639 -0.0728 -0.0923 -0.6957 -0.5585 -0.0267 -0.2113 -0.2241 -0.2086 -0.1748 -0.1086 -0.2725 -0.9377 -0.0519 -0.0816 -0.2044 -0.1782
S-413	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-413	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-413	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
D-413	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
P-413	-0.7744 -0.4217 -0.8772 -0.4496 -2.7496 -0.1740 -0.1086 -0.1793 -0.0901 -0.7844 -0.1248 -0.2338 -0.1384 -0.1382 -0.1506 -0.1022 -0.0368 -0.1324 -1.0003 -0.7758 -0.8725 -0.0929 -0.4477 -0.0736 -0.1418 -1.3031 -1.0078 -1.1253 -0.1720 -0.1501 -0.1846
S-424	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-424	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 23 factor VIII activity assay is indispensable .
H-424	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
D-424	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
P-424	-0.5792 -0.7098 -0.5744 -0.1413 -1.8837 -0.0692 -0.1796 -0.1005 -2.8842 -0.5100 -0.0501 -0.1378 -1.8502 -1.4794 -0.3613 -0.0272 -0.1199 -0.2111 -0.0932 -0.0717 -0.4239 -3.4181 -0.1019 -0.2512 -0.1362 -0.2193 -0.2518 -0.1205 -1.1826 -1.1498 -0.1431 -0.1744
S-483	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-483	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-483	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
D-483	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
P-483	-0.7744 -0.4217 -0.8772 -0.4496 -2.7496 -0.1740 -0.1086 -0.1793 -0.0901 -0.7844 -0.1248 -0.2338 -0.1384 -0.1382 -0.1506 -0.1022 -0.0368 -0.1324 -1.0003 -0.7758 -0.8725 -0.0929 -0.4477 -0.0736 -0.1418 -1.3031 -1.0078 -1.1253 -0.1720 -0.1501 -0.1846
S-494	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-494	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 33 factor VIII activity assay is indispensable .
H-494	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
D-494	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
P-494	-0.5792 -0.7098 -0.5744 -0.1413 -1.8837 -0.0692 -0.1796 -0.1005 -2.8842 -0.5100 -0.0501 -0.1378 -1.8502 -1.4794 -0.3613 -0.0272 -0.1199 -0.2111 -0.0932 -0.0717 -0.4239 -3.4181 -0.1019 -0.2512 -0.1362 -0.2193 -0.2518 -0.1205 -1.1826 -1.1498 -0.1431 -0.1744
S-553	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-553	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-553	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
D-553	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
P-553	-0.7744 -0.4217 -0.8772 -0.4496 -2.7496 -0.1740 -0.1086 -0.1793 -0.0901 -0.7844 -0.1248 -0.2338 -0.1384 -0.1382 -0.1506 -0.1022 -0.0368 -0.1324 -1.0003 -0.7758 -0.8725 -0.0929 -0.4477 -0.0736 -0.1418 -1.3031 -1.0078 -1.1253 -0.1720 -0.1501 -0.1846
S-564	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-564	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 43 factor VIII activity assay is indispensable .
H-564	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
D-564	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
P-564	-0.5792 -0.7098 -0.5744 -0.1413 -1.8837 -0.0692 -0.1796 -0.1005 -2.8842 -0.5100 -0.0501 -0.1378 -1.8502 -1.4794 -0.3613 -0.0272 -0.1199 -0.2111 -0.0932 -0.0717 -0.4239 -3.4181 -0.1019 -0.2512 -0.1362 -0.2193 -0.2518 -0.1205 -1.1826 -1.1498 -0.1431 -0.1744
S-623	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-623	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-623	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
D-623	-0.48431268334388733	Need for treatment Factor VIII dose is presented in International Units ( IU ) as per the WHO standard for factor VIII products .
P-623	-0.7744 -0.4217 -0.8772 -0.4496 -2.7496 -0.1740 -0.1086 -0.1793 -0.0901 -0.7844 -0.1248 -0.2338 -0.1384 -0.1382 -0.1506 -0.1022 -0.0368 -0.1324 -1.0003 -0.7758 -0.8725 -0.0929 -0.4477 -0.0736 -0.1418 -1.3031 -1.0078 -1.1253 -0.1720 -0.1501 -0.1846
S-634	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-634	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 53 factor VIII activity assay is indispensable .
H-634	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
D-634	-0.6127052307128906	Close monitoring of substitution therapy by measurement of factor VIII activity in plasma is indispensable , especially in major surgery .
P-634	-0.5792 -0.7098 -0.5744 -0.1413 -1.8837 -0.0692 -0.1796 -0.1005 -2.8842 -0.5100 -0.0501 -0.1378 -1.8502 -1.4794 -0.3613 -0.0272 -0.1199 -0.2111 -0.0932 -0.0717 -0.4239 -3.4181 -0.1019 -0.2512 -0.1362 -0.2193 -0.2518 -0.1205 -1.1826 -1.1498 -0.1431 -0.1744
S-410	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-410	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-410	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
D-410	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
P-410	-0.5280 -1.3775 -0.1351 -1.5219 -0.1341 -0.3731 -0.2038 -0.0784 -0.2370 -0.8320 -0.1500 -0.1008 -0.1688 -0.0639 -0.0728 -0.0923 -0.6957 -0.5585 -0.0267 -0.2113 -0.2241 -0.2086 -0.1748 -0.1086 -0.2725 -0.9377 -0.0519 -0.0816 -0.2044 -0.1782
S-724	Behandlung von Blutungen Die Dosis von Octocog alfa wird in Abhängigkeit vom Körpergewicht und den angestrebten Faktor VIII-Spiegeln errechnet .
T-724	Treatment of bleeding The dose of octocog alfa is calculated depending on you body weight and the factor VIII levels to be achieved .
H-724	-0.3997415006160736	Treatment of haemorrhage Dosage of octocog alfa is calculated using body weight and the desired factor VIII levels .
D-724	-0.3997415006160736	Treatment of haemorrhage Dosage of octocog alfa is calculated using body weight and the desired factor VIII levels .
P-724	-0.1805 -0.1326 -0.0842 -0.1458 -0.8800 -0.1193 -0.0091 -0.9789 -0.1046 -0.8060 -0.1121 -0.1624 -0.5979 -0.1361 -0.1267 -0.1219 -0.0847 -0.0831 -0.1069 -0.0807 -0.1240 -1.1350 -1.7343 -0.0736 -0.1408 -1.6074 -0.5371 -0.1077 -0.6428 -0.5169 -0.9377 -0.1529 -0.6499 -0.1778
S-272	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-272	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-272	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
D-272	-0.3334682285785675	Prepared without addition of any ( exogenous ) human or animal protein during the cell culture process , purification and final formulation .
P-272	-0.5280 -1.3775 -0.1351 -1.5219 -0.1341 -0.3731 -0.2038 -0.0784 -0.2370 -0.8320 -0.1500 -0.1008 -0.1688 -0.0639 -0.0728 -0.0923 -0.6957 -0.5585 -0.0267 -0.2113 -0.2241 -0.2086 -0.1748 -0.1086 -0.2725 -0.9377 -0.0519 -0.0816 -0.2044 -0.1782
S-481	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-481	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-481	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
D-481	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
P-481	-0.3887 -0.0626 -0.0992 -0.1960 -0.1048 -0.1065 -0.1003 -0.1223 -0.1370 -0.1049 -0.0894 -0.1008 -0.1391 -0.1206 -0.3520 -1.2808 -1.2956 -0.0681 -0.0989 -0.1982 -0.1296 -0.1841 -1.4033 -0.2058 -0.1376 -0.0904 -0.5176 -0.1608 -0.1562 -0.2053 -0.1928 -0.1997 -0.1335 -0.1709
S-551	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-551	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-551	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
D-551	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
P-551	-0.3887 -0.0626 -0.0992 -0.1960 -0.1048 -0.1065 -0.1003 -0.1223 -0.1370 -0.1049 -0.0894 -0.1008 -0.1391 -0.1206 -0.3520 -1.2808 -1.2956 -0.0681 -0.0989 -0.1982 -0.1296 -0.1841 -1.4033 -0.2058 -0.1376 -0.0904 -0.5176 -0.1608 -0.1562 -0.2053 -0.1928 -0.1997 -0.1335 -0.1709
S-135	Kleinere Mengen verteilen sich in Fett- und Muskelgewebe und werden dort als Vitamin D3 gespeichert , um später in den Kreislauf abgegeben zu werden .
T-135	Lesser amounts are distributed to adipose and muscle tissue and stored as vitamin D3 at
H-135	-0.5095095038414001	Small amounts are dispersed into fat and muscle tissue , where they are stored as vitamin D3 for distribution into the circulation .
D-135	-0.5095095038414001	Small amounts are dispersed into fat and muscle tissue , where they are stored as vitamin D3 for distribution into the circulation .
P-135	-0.6970 -0.3246 -2.1791 -2.2837 -0.1120 -0.1724 -0.7547 -0.1425 -0.1484 -0.0435 -0.2084 -0.7672 -0.1188 -0.0594 -0.1254 -0.3924 -0.1382 -0.1876 -0.1987 -0.0621 -0.1082 -0.2040 -1.4838 -2.7298 -0.9387 -0.1447 -0.0505 -0.0987 -0.2373 -0.1735
S-209	Es gab keinen statistisch signifikanten Unterschied zwischen den Behandlungsgruppen beim Anteil der Patientinnen mit Hypercalciurie am Ende der 24-wöchigen Verlängerung .
T-209	The percentage of patients with hypercalciuria at the end of the 24-week extension was not statistically different between treatment groups .
H-209	-0.17662037909030914	There was no statistically significant difference between treatment groups in the proportion of patients with hypercalciuria at the end of the 24 week extension .
D-209	-0.17662037909030914	There was no statistically significant difference between treatment groups in the proportion of patients with hypercalciuria at the end of the 24 week extension .
P-209	-0.0658 -0.1546 -0.0741 -0.0260 -0.0751 -0.1057 -0.2181 -0.0919 -0.2663 -0.1748 -0.3481 -0.1050 -0.1089 -0.0995 -0.1404 -0.7837 -0.1348 -0.0595 -0.0749 -0.1508 -0.0419 -0.1387 -0.0830 -0.1264 -0.1088 -0.1408 -0.1472 -0.1923 -0.1094 -0.8938 -0.2359 -0.1755
S-273	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-273	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-273	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
D-273	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
P-273	-0.3887 -0.0626 -0.0992 -0.1960 -0.1048 -0.1065 -0.1003 -0.1223 -0.1370 -0.1049 -0.0894 -0.1008 -0.1391 -0.1206 -0.3520 -1.2808 -1.2956 -0.0681 -0.0989 -0.1982 -0.1296 -0.1841 -1.4033 -0.2058 -0.1376 -0.0904 -0.5176 -0.1608 -0.1562 -0.2053 -0.1928 -0.1997 -0.1335 -0.1709
S-341	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-341	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-341	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
D-341	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
P-341	-0.3887 -0.0626 -0.0992 -0.1960 -0.1048 -0.1065 -0.1003 -0.1223 -0.1370 -0.1049 -0.0894 -0.1008 -0.1391 -0.1206 -0.3520 -1.2808 -1.2956 -0.0681 -0.0989 -0.1982 -0.1296 -0.1841 -1.4033 -0.2058 -0.1376 -0.0904 -0.5176 -0.1608 -0.1562 -0.2053 -0.1928 -0.1997 -0.1335 -0.1709
S-121	In Osteoporosestudien war Alendronat wirksam , wenn es mindestens 30 Minuten vor dem ersten Essen oder Trinken des Tages eingenommen wurde .
T-121	In osteoporosis studies , alendronate was effective when administered at least 30 minutes before the first food or beverage of the day .
H-121	-0.22474855184555054	In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first food or drink of the day .
D-121	-0.22474855184555054	In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first food or drink of the day .
P-121	-0.1079 -0.1063 -0.1898 -0.1403 -0.0976 -0.1087 -0.0947 -0.2299 -0.2352 -0.1599 -0.1432 -0.1035 -0.0786 -0.3609 -0.0438 -0.1082 -0.5181 -0.0820 -0.1080 -0.1238 -0.0966 -0.9891 -0.1310 -0.0832 -1.7531 -0.1061 -0.0250 -0.1283 -0.1382 -0.2923 -0.1399 -0.1689
S-411	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-411	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-411	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
D-411	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
P-411	-0.3887 -0.0626 -0.0992 -0.1960 -0.1048 -0.1065 -0.1003 -0.1223 -0.1370 -0.1049 -0.0894 -0.1008 -0.1391 -0.1206 -0.3520 -1.2808 -1.2956 -0.0681 -0.0989 -0.1982 -0.1296 -0.1841 -1.4033 -0.2058 -0.1376 -0.0904 -0.5176 -0.1608 -0.1562 -0.2053 -0.1928 -0.1997 -0.1335 -0.1709
S-621	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-621	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-621	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
D-621	-0.2662818729877472	After reconstitution , the solution is clear , colourless , free of extraneous particles and has a pH of 6.7 to 7.3 .
P-621	-0.3887 -0.0626 -0.0992 -0.1960 -0.1048 -0.1065 -0.1003 -0.1223 -0.1370 -0.1049 -0.0894 -0.1008 -0.1391 -0.1206 -0.3520 -1.2808 -1.2956 -0.0681 -0.0989 -0.1982 -0.1296 -0.1841 -1.4033 -0.2058 -0.1376 -0.0904 -0.5176 -0.1608 -0.1562 -0.2053 -0.1928 -0.1997 -0.1335 -0.1709
S-238	Kleinere Mengen verteilen sich in Fett- und Muskelgewebe und werden dort als Vitamin D3 gespeichert , um später in den Kreislauf abgegeben zu werden .
T-238	Lesser amounts are distributed to adipose and muscle tissue and stored as vitamin D3 at these sites for later release into the circulation .
H-238	-0.5095095038414001	Small amounts are dispersed into fat and muscle tissue , where they are stored as vitamin D3 for distribution into the circulation .
D-238	-0.5095095038414001	Small amounts are dispersed into fat and muscle tissue , where they are stored as vitamin D3 for distribution into the circulation .
P-238	-0.6970 -0.3246 -2.1791 -2.2837 -0.1120 -0.1724 -0.7547 -0.1425 -0.1484 -0.0435 -0.2084 -0.7672 -0.1188 -0.0594 -0.1254 -0.3924 -0.1382 -0.1876 -0.1987 -0.0621 -0.1082 -0.2040 -1.4838 -2.7298 -0.9387 -0.1447 -0.0505 -0.0987 -0.2373 -0.1735
S-73	Bei Patienten mit diesen Erkrankungen sollten unter der Therapie mit ADROVANCE das Serum-Calcium sowie Symptome einer Hypocalcämie überwacht werden .
T-73	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
H-73	-0.32292109727859497	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
D-73	-0.32292109727859497	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
P-73	-0.3500 -0.2547 -0.1275 -0.2210 -0.7672 -0.4072 -0.1007 -0.1286 -0.0693 -0.0461 -0.1229 -0.1178 -0.6491 -0.1321 -0.0987 -0.0540 -0.0560 -0.0742 -0.1580 -0.2471 -0.1616 -0.2533 -0.0803 -3.1628 -1.8736 -0.1243 -0.1331 -0.0717 -0.1645 -0.0839 -0.0680 -0.1219 -0.1751
S-172	Bei Patienten mit diesen Erkrankungen sollten unter der Therapie mit ADROVANCE das Serum-Calcium sowie Symptome einer Hypocalcämie überwacht werden .
T-172	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
H-172	-0.32292109727859497	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
D-172	-0.32292109727859497	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
P-172	-0.3500 -0.2547 -0.1275 -0.2210 -0.7672 -0.4072 -0.1007 -0.1286 -0.0693 -0.0461 -0.1229 -0.1178 -0.6491 -0.1321 -0.0987 -0.0540 -0.0560 -0.0742 -0.1580 -0.2471 -0.1616 -0.2533 -0.0803 -3.1628 -1.8736 -0.1243 -0.1331 -0.0717 -0.1645 -0.0839 -0.0680 -0.1219 -0.1751
S-129	Die terminale Halbwertszeit beim Menschen wird unter Berücksichtigung der Freisetzung von Alendronat aus dem Skelett auf über zehn Jahre geschätzt .
T-129	The terminal half-life in humans is estimated to exceed ten years , reflecting release of alendronate from the skeleton .
H-129	-0.32613179087638855	The terminal half-life in humans is estimated about ten years after the release of alendronate from the skeleton .
D-129	-0.32613179087638855	The terminal half-life in humans is estimated about ten years after the release of alendronate from the skeleton .
P-129	-0.1872 -0.3721 -0.0744 -0.1965 -0.0773 -0.1143 -0.7041 -0.1182 -0.0450 -0.5977 -1.0243 -0.1291 -1.1099 -1.2558 -1.0528 -0.1417 -0.1760 -0.1303 -0.1377 -0.2015 -0.1103 -0.1091 -0.0539 -0.1279 -0.2391 -0.1446 -0.1746
S-232	Die terminale Halbwertszeit beim Menschen wird unter Berücksichtigung der Freisetzung von Alendronat aus dem Skelett auf über zehn Jahre geschätzt .
T-232	The terminal half-life in humans is estimated to exceed ten years , reflecting release of alendronate from the skeleton .
H-232	-0.32613179087638855	The terminal half-life in humans is estimated about ten years after the release of alendronate from the skeleton .
D-232	-0.32613179087638855	The terminal half-life in humans is estimated about ten years after the release of alendronate from the skeleton .
P-232	-0.1872 -0.3721 -0.0744 -0.1965 -0.0773 -0.1143 -0.7041 -0.1182 -0.0450 -0.5977 -1.0243 -0.1291 -1.1099 -1.2558 -1.0528 -0.1417 -0.1760 -0.1303 -0.1377 -0.2015 -0.1103 -0.1091 -0.0539 -0.1279 -0.2391 -0.1446 -0.1746
S-17	Insbesondere bei Patienten mit Herzbeschwerden in der Vorgeschichte besteht möglicherweise auch ein erhöhtes Risiko bestimmter Nebenwirkungen , die das Herz und die Blutgefäße betreffen .
T-17	There may also be an increased risk of certain side effects affecting the heart and blood vessels , particularly in patients with a history of heart problems .
H-17	-0.4315764307975769	There may also be an increased risk of certain side effects affecting the heart and blood vessels , especially in patients with a history of cardiac problems .
D-17	-0.4315764307975769	There may also be an increased risk of certain side effects affecting the heart and blood vessels , especially in patients with a history of cardiac problems .
P-17	-1.0041 -0.1652 -0.0519 -0.1449 -0.0572 -0.1053 -0.0844 -0.3026 -0.8360 -2.7106 -0.1756 -1.1734 -0.1114 -0.1077 -0.1509 -0.6574 -0.0625 -0.0948 -0.1644 -0.4309 -0.1081 -0.2597 -0.1181 -0.1767 -1.0862 -0.1456 -0.3213 -0.0528 -2.2079 -0.1341 -0.1769
S-717	Es besteht die geringe Möglichkeit , dass Sie eine anaphylaktische Reaktion ( eine plötzliche , schwere , allergische Reaktion ) auf ADVATE entwickeln .
T-717	There is a rare chance that you may experience an anaphylactic reaction ( a severe , sudden allergic reaction ) to ADVATE .
H-717	-0.230871319770813	There is a small possibility that you may develop anaphylactic reaction ( sudden , severe , allergic reaction ) to ADVATE .
D-717	-0.230871319770813	There is a small possibility that you may develop anaphylactic reaction ( sudden , severe , allergic reaction ) to ADVATE .
P-717	-0.2018 -0.1709 -0.1932 -0.4213 -0.3046 -0.2607 -0.1301 -1.1218 -0.1547 -0.1531 -0.1181 -0.0956 -0.2628 -0.0330 -1.1023 -0.1394 -0.2829 -0.1564 -0.1348 -0.2174 -0.0409 -0.0662 -0.0504 -0.1544 -0.1653 -0.1299 -0.2045 -0.0647 -0.1254 -0.3173 -0.1833
S-292	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-292	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-292	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
D-292	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
P-292	-4.0794 -0.3097 -0.1433 -0.1182 -0.1866 -0.1134 -0.4274 -0.1685 -0.0975 -0.2240 -0.0822 -0.1076 -2.0497 -1.2339 -0.7501 -0.0912 -0.0911 -0.1711 -0.1814 -0.1819 -1.3076 -0.2845 -0.2664 -0.1111 -0.1661 -0.1157 -0.1198 -0.0799 -0.1303 -0.0892 -0.0761 -0.1785 -0.1775
S-96	7 konzentriert . Die Aktivität der Osteoklasten wird gehemmt , Rekrutierung und Anbindung der Osteoklasten sind jedoch nicht betroffen .
T-96	Activity of osteoclasts is inhibited , but recruitment or attachment of osteoclasts is not affected .
H-96	-0.2576746642589569	It inhibits the activity of the osteoclasts , but does not affect the recruiting and binding of the osteoclasts .
D-96	-0.2576746642589569	It inhibits the activity of the osteoclasts , but does not affect the recruiting and binding of the osteoclasts .
P-96	-1.0009 -0.3663 -0.0326 -0.1292 -0.2931 -0.1769 -0.1299 -0.2208 -0.2222 -0.1313 -0.1951 -0.0245 -0.1401 -0.3383 -0.7976 -0.1625 -0.1169 -0.0329 -0.1842 -0.5687 -0.3845 -0.9110 -0.4869 -0.1425 -0.1462 -0.2382 -0.2006 -0.0860 -0.1657 -0.0257 -0.1321 -0.1377 -0.1825
S-80	ADROVANCE ist nur für die Anwendung bei postmenopausalen Frauen vorgesehen und ist daher weder während der Schwangerschaft noch von stillenden Frauen anzuwenden .
T-80	ADROVANCE is only intended for use in postmenopausal women and therefore it should not be used during pregnancy or in breast-feeding women .
H-80	-0.2194763869047165	ADROVANCE is designed to be used in post-menopausal women only and therefore should not be used in pregnancy or in breast-feeding women .
D-80	-0.2194763869047165	ADROVANCE is designed to be used in post-menopausal women only and therefore should not be used in pregnancy or in breast-feeding women .
P-80	-0.2435 -0.0554 -0.1633 -0.1089 -0.0898 -0.1070 -1.8575 -0.1777 -0.1220 -0.2539 -0.8772 -0.0182 -0.3304 -0.0784 -0.1616 -0.0226 -0.0981 -0.0866 -0.1383 -0.1561 -0.0827 -0.9570 -0.1412 -0.1381 -0.2412 -0.1648 -0.0540 -0.2586 -0.1199 -0.1082 -0.0395 -0.0888 -0.0250 -0.0338 -0.1221 -0.1797
S-694	Der Inhaber dieser Arzneimittelzulassung wird PSURs im Abstand von 6 Monaten vorlegen , es sei denn , dass der CHMP andere Zeiträume festlegt .
T-694	The holder of this marketing authorisation holder will submit PSURs every 6 months unless otherwise specified by the CHMP .
H-694	-0.38129714131355286	The MAH will submit PSURs at intervals of 6 months unless the CHMP specifies otherwise .
D-694	-0.38129714131355286	The MAH will submit PSURs at intervals of 6 months unless the CHMP specifies otherwise .
P-694	-0.4253 -0.0110 -0.0298 -0.3808 -1.4286 -0.0577 -0.1856 -0.0959 -0.0726 -0.1398 -0.8467 -0.0879 -0.0465 -0.1350 -0.4554 -0.0913 -0.3215 -0.1232 -0.0825 -0.0503 -2.3776 -0.1553 -1.6225 -0.1316 -0.1781
S-641	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-641	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-641	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
D-641	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
P-641	-4.0794 -0.3097 -0.1433 -0.1182 -0.1866 -0.1134 -0.4274 -0.1685 -0.0975 -0.2240 -0.0822 -0.1076 -2.0497 -1.2339 -0.7501 -0.0912 -0.0911 -0.1711 -0.1814 -0.1819 -1.3076 -0.2845 -0.2664 -0.1111 -0.1661 -0.1157 -0.1198 -0.0799 -0.1303 -0.0892 -0.0761 -0.1785 -0.1775
S-571	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-571	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-571	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
D-571	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
P-571	-4.0794 -0.3097 -0.1433 -0.1182 -0.1866 -0.1134 -0.4274 -0.1685 -0.0975 -0.2240 -0.0822 -0.1076 -2.0497 -1.2339 -0.7501 -0.0912 -0.0911 -0.1711 -0.1814 -0.1819 -1.3076 -0.2845 -0.2664 -0.1111 -0.1661 -0.1157 -0.1198 -0.0799 -0.1303 -0.0892 -0.0761 -0.1785 -0.1775
S-501	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-501	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-501	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
D-501	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
P-501	-4.0794 -0.3097 -0.1433 -0.1182 -0.1866 -0.1134 -0.4274 -0.1685 -0.0975 -0.2240 -0.0822 -0.1076 -2.0497 -1.2339 -0.7501 -0.0912 -0.0911 -0.1711 -0.1814 -0.1819 -1.3076 -0.2845 -0.2664 -0.1111 -0.1661 -0.1157 -0.1198 -0.0799 -0.1303 -0.0892 -0.0761 -0.1785 -0.1775
S-431	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-431	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-431	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
D-431	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
P-431	-4.0794 -0.3097 -0.1433 -0.1182 -0.1866 -0.1134 -0.4274 -0.1685 -0.0975 -0.2240 -0.0822 -0.1076 -2.0497 -1.2339 -0.7501 -0.0912 -0.0911 -0.1711 -0.1814 -0.1819 -1.3076 -0.2845 -0.2664 -0.1111 -0.1661 -0.1157 -0.1198 -0.0799 -0.1303 -0.0892 -0.0761 -0.1785 -0.1775
S-361	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-361	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-361	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
D-361	-0.421537309885025	The rate of administration should be determined by the patient <unk> s status and a maximum rate of injection not exceeding 10 ml/ min should be used .
P-361	-4.0794 -0.3097 -0.1433 -0.1182 -0.1866 -0.1134 -0.4274 -0.1685 -0.0975 -0.2240 -0.0822 -0.1076 -2.0497 -1.2339 -0.7501 -0.0912 -0.0911 -0.1711 -0.1814 -0.1819 -1.3076 -0.2845 -0.2664 -0.1111 -0.1661 -0.1157 -0.1198 -0.0799 -0.1303 -0.0892 -0.0761 -0.1785 -0.1775
S-763	Nach Ansicht des CHMP wurde nicht ausreichend nachgewiesen , dass die Injektion von Advexin in Li-Fraumeni-Tumore Vorteile für die Patienten bringt .
T-763	The CHMP was concerned that there was not enough evidence to show that the injection of Advexin into Li-Fraumeni tumours led to benefits for patients .
H-763	-0.6159857511520386	The CHMP considers that insufficient evidence exists that injection of Advexin into Li-Fraumeni tumours is beneficial for patients .
D-763	-0.6159857511520386	The CHMP considers that insufficient evidence exists that injection of Advexin into Li-Fraumeni tumours is beneficial for patients .
P-763	-0.4700 -0.0549 -0.0340 -3.7715 -0.1543 -0.5172 -0.1426 -0.3368 -0.0023 -0.0599 -0.9547 -0.2833 -0.1326 -1.5985 -0.1242 -0.1510 -0.6068 -0.8121 -0.1380 -2.5469 -0.0919 -0.1274 -0.7736 -0.2707 -1.5899 -0.3258 -1.6501 -0.8023 -0.2760 -0.1188 -0.1776
S-12	In beiden Studien wurde Allopurinol in einer Dosis von einmal täglich 300 mg angewendet ; Patienten mit Nierenproblemen erhielten nur 100 mg pro Tag .
T-12	In both studies , allopurinol was used at a dose of 300 mg once a day , except for patients with kidney problems , who took 100 mg .
H-12	-0.40581652522087097	In both studies , allopurinol was administered at doses of 300 mg once a day ; renal problem patients received only 100 mg daily .
D-12	-0.40581652522087097	In both studies , allopurinol was administered at doses of 300 mg once a day ; renal problem patients received only 100 mg daily .
P-12	-0.2606 -0.0600 -0.6724 -0.2103 -2.2374 -1.0000 -0.1530 -0.2096 -0.1568 -0.4678 -0.0815 -0.2337 -1.2743 -0.1110 -0.1448 -0.1363 -0.0795 -0.0102 -0.6664 -0.2937 -0.9718 -0.3575 -0.1561 -0.8401 -0.1511 -0.3811 -0.5428 -0.1031 -0.0500 -0.6641 -0.1360 -0.1731
S-83	Es liegen jedoch keine Informationen vor , die nahelegen , dass ADROVANCE die Verkehrstüchtigkeit oder die Fähigkeit zum Bedienen von Maschinen beeinträchtigt .
T-83	However , there is no information to indicate that ADROVANCE affects a patient s ability to drive or operate machines .
H-83	-0.3426194190979004	However , there is no information to suggest that ADROVANCE imweighs ability to drive or use machines .
D-83	-0.3426194190979004	However , there is no information to suggest that ADROVANCE imweighs ability to drive or use machines .
P-83	-0.1684 -0.1245 -0.2361 -0.1008 -0.1045 -0.0853 -0.2624 -0.0236 -0.0952 -0.1824 -0.0651 -0.1594 -0.0893 -0.1063 -0.9021 -3.4509 -0.0709 -1.3038 -0.1592 -0.0682 -0.1197 -0.0737 -0.2961 -0.1371 -0.1806
S-179	ADROVANCE ist nur für die Anwendung bei postmenopausalen Frauen vorgesehen und ist daher weder während der Schwangerschaft noch von stillenden Frauen anzuwenden .
T-179	ADROVANCE is only intended for use in postmenopausal women and therefore it should not be used during pregnancy or in breast-feeding women .
H-179	-0.2194763869047165	ADROVANCE is designed to be used in post-menopausal women only and therefore should not be used in pregnancy or in breast-feeding women .
D-179	-0.2194763869047165	ADROVANCE is designed to be used in post-menopausal women only and therefore should not be used in pregnancy or in breast-feeding women .
P-179	-0.2435 -0.0554 -0.1633 -0.1089 -0.0898 -0.1070 -1.8575 -0.1777 -0.1220 -0.2539 -0.8772 -0.0182 -0.3304 -0.0784 -0.1616 -0.0226 -0.0981 -0.0866 -0.1383 -0.1561 -0.0827 -0.9570 -0.1412 -0.1381 -0.2412 -0.1648 -0.0540 -0.2586 -0.1199 -0.1082 -0.0395 -0.0888 -0.0250 -0.0338 -0.1221 -0.1797
S-511	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-511	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-511	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
D-511	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
P-511	-1.5574 -0.0693 -0.1546 -0.7484 -0.2955 -0.0459 -0.0744 -0.1342 -0.1558 -0.2324 -0.1394 -0.2373 -1.3979 -0.1411 -0.1323 -0.4229 -0.1402 -0.1424 -0.1497 -0.1666 -0.2982 -0.9583 -1.2240 -0.1534 -0.0992 -0.2376 -0.0862 -0.2692 -0.0390 -0.8482 -1.1278 -0.0168 -0.0503 -0.0921 -0.0459 -0.1031 -0.1601 -0.1774
S-371	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-371	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-371	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
D-371	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
P-371	-1.5574 -0.0693 -0.1546 -0.7484 -0.2955 -0.0459 -0.0744 -0.1342 -0.1558 -0.2324 -0.1394 -0.2373 -1.3979 -0.1411 -0.1323 -0.4229 -0.1402 -0.1424 -0.1497 -0.1666 -0.2982 -0.9583 -1.2240 -0.1534 -0.0992 -0.2376 -0.0862 -0.2692 -0.0390 -0.8482 -1.1278 -0.0168 -0.0503 -0.0921 -0.0459 -0.1031 -0.1601 -0.1774
S-220	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt .
T-220	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt . 2.2 % , a reduction of 51 % ) .
H-220	-0.2304101139307022	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % vs. 2.2 % ; 51 % reduction ) .
D-220	-0.2304101139307022	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % vs. 2.2 % ; 51 % reduction ) .
P-220	-0.4190 -0.1355 -0.1706 -0.2156 -0.0476 -0.0986 -0.3588 -0.1043 -0.0371 -0.0759 -0.1306 -0.0319 -0.0274 -0.0899 -0.6460 -0.4103 -0.1620 -0.0912 -0.0972 -1.9610 -0.1441 -0.1543 -0.1639 -0.2957 -0.1111 -0.1277 -0.1377 -0.1586 -0.1308 -0.1776
S-117	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt .
T-117	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt . 2.2 % , a reduction of 51 % ) .
H-117	-0.2304101139307022	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % vs. 2.2 % ; 51 % reduction ) .
D-117	-0.2304101139307022	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % vs. 2.2 % ; 51 % reduction ) .
P-117	-0.4190 -0.1355 -0.1706 -0.2156 -0.0476 -0.0986 -0.3588 -0.1043 -0.0371 -0.0759 -0.1306 -0.0319 -0.0274 -0.0899 -0.6460 -0.4103 -0.1620 -0.0912 -0.0972 -1.9610 -0.1441 -0.1543 -0.1639 -0.2957 -0.1111 -0.1277 -0.1377 -0.1586 -0.1308 -0.1776
S-147	Rechteckartige , weiße bis gebrochen weiße Tabletten , gekennzeichnet mit dem Umriss eines Knochens auf der einen Seite und 270 auf der anderen Seite .
T-147	Modified rectangle-shaped , white to off-white tablets , marked with an outline of a bone image on one side , and <<unk>> 270 <<unk>> on the other .
H-147	-0.285715252161026	Rectangular , white to broken white tablets marked with the outline of a bone on one face and 270 on the other face .
D-147	-0.285715252161026	Rectangular , white to broken white tablets marked with the outline of a bone on one face and 270 on the other face .
P-147	-0.2600 -0.0677 -0.1103 -0.1062 -0.3286 -0.1067 -0.1733 -0.4922 -0.6619 -0.0792 -0.1131 -1.4533 -0.1789 -0.1496 -0.2034 -0.4269 -0.1480 -0.1550 -0.0280 -0.1006 -0.4752 -0.2922 -0.1310 -1.1790 -0.0784 -0.1246 -0.1592 -0.4664 -0.1492 -0.1734
S-651	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-651	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-651	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
D-651	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
P-651	-1.5574 -0.0693 -0.1546 -0.7484 -0.2955 -0.0459 -0.0744 -0.1342 -0.1558 -0.2324 -0.1394 -0.2373 -1.3979 -0.1411 -0.1323 -0.4229 -0.1402 -0.1424 -0.1497 -0.1666 -0.2982 -0.9583 -1.2240 -0.1534 -0.0992 -0.2376 -0.0862 -0.2692 -0.0390 -0.8482 -1.1278 -0.0168 -0.0503 -0.0921 -0.0459 -0.1031 -0.1601 -0.1774
S-581	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-581	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-581	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
D-581	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
P-581	-1.5574 -0.0693 -0.1546 -0.7484 -0.2955 -0.0459 -0.0744 -0.1342 -0.1558 -0.2324 -0.1394 -0.2373 -1.3979 -0.1411 -0.1323 -0.4229 -0.1402 -0.1424 -0.1497 -0.1666 -0.2982 -0.9583 -1.2240 -0.1534 -0.0992 -0.2376 -0.0862 -0.2692 -0.0390 -0.8482 -1.1278 -0.0168 -0.0503 -0.0921 -0.0459 -0.1031 -0.1601 -0.1774
S-714	ADVATE wird ohne Zusatz eines menschlichen oder tierischen Proteins während des Zellkultur- Prozesses , der Reinigung und der Endformulierung hergestellt .
T-714	ADVATE is prepared without the addition of any human- or animal-derived protein in the cell culture process , purification or final formulation .
H-714	-0.3171095550060272	ADVATE is produced without the addition of a human or animal protein during the cell culture process , purification and final formulation .
D-714	-0.3171095550060272	ADVATE is produced without the addition of a human or animal protein during the cell culture process , purification and final formulation .
P-714	-0.6476 -0.1932 -0.0655 -0.1388 -0.1253 -0.9328 -0.4672 -1.2281 -0.1341 -0.1401 -0.8204 -0.1223 -0.1448 -0.0576 -0.0750 -0.0698 -0.4602 -1.0258 -0.0229 -0.3508 -0.2206 -0.2075 -0.1685 -0.1114 -0.2609 -0.8475 -0.0528 -0.0822 -0.1603 -0.1793
S-441	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-441	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-441	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
D-441	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
P-441	-1.5574 -0.0693 -0.1546 -0.7484 -0.2955 -0.0459 -0.0744 -0.1342 -0.1558 -0.2324 -0.1394 -0.2373 -1.3979 -0.1411 -0.1323 -0.4229 -0.1402 -0.1424 -0.1497 -0.1666 -0.2982 -0.9583 -1.2240 -0.1534 -0.0992 -0.2376 -0.0862 -0.2692 -0.0390 -0.8482 -1.1278 -0.0168 -0.0503 -0.0921 -0.0459 -0.1031 -0.1601 -0.1774
S-781	Dies führt dazu , dass weniger Flüssigkeit aus den Gefäßen austritt , sodass die Schwellung abnimmt und die Nase weniger Schleim absondert .
T-781	Aerinaze tablets have two layers , one containing desloratadine , and the other containing pseudoephedrine .
H-781	-0.5020900368690491	As a consequence , less liquid is excreted from the vessels , the swelling decreases and the nose excretes less mucus .
D-781	-0.5020900368690491	As a consequence , less liquid is excreted from the vessels , the swelling decreases and the nose excretes less mucus .
P-781	-2.0571 -0.1356 -0.1981 -0.0707 -0.1977 -0.0597 -1.1533 -0.7220 -0.6206 -1.0377 -0.0904 -0.1934 -0.0973 -0.3320 -0.1000 -0.2097 -3.5462 -0.0459 -0.1254 -0.8378 -0.1172 -0.1117 -0.5226 -0.5690 -1.2890 -0.0617 -0.3527 -0.0721 -0.6448 -0.1995 -0.1230 -0.1729
S-302	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-302	Based on the rare occurrence of haemophilia A in women , experience regarding the use of Factor VIII during pregnancy and breast-feeding is not available .
H-302	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
D-302	-0.3295882046222687	Due to rare occurrence of haemophilia A in women , there is no experience with use of factor VIII during pregnancy and in breast-feeding women .
P-302	-1.5574 -0.0693 -0.1546 -0.7484 -0.2955 -0.0459 -0.0744 -0.1342 -0.1558 -0.2324 -0.1394 -0.2373 -1.3979 -0.1411 -0.1323 -0.4229 -0.1402 -0.1424 -0.1497 -0.1666 -0.2982 -0.9583 -1.2240 -0.1534 -0.0992 -0.2376 -0.0862 -0.2692 -0.0390 -0.8482 -1.1278 -0.0168 -0.0503 -0.0921 -0.0459 -0.1031 -0.1601 -0.1774
S-169	ADROVANCE wird für Patienten mit Niereninsuffizienz mit einer GFR unter 35 ml<unk> min nicht empfohlen ( siehe Abschnitt 4.2 ) .
T-169	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min ( see section 4.2 ) .
H-169	-0.2369733452796936	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
D-169	-0.2369733452796936	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
P-169	-0.1886 -0.0629 -0.1644 -0.1020 -0.0804 -0.1249 -0.1356 -0.0729 -0.5514 -0.3962 -0.1301 -0.2947 -0.1834 -0.1549 -0.7098 -1.2372 -0.7951 -0.1225 -0.1147 -0.1341 -0.1416 -0.0831 -0.1703 -0.0559 -0.0906 -0.1788 -0.1447 -0.1508 -0.1544 -0.1832
S-740	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Wien Tel . : <unk> 43 1 71120 0
T-740	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 / Top 2A A-1031 Wien Tel . : <<unk>> 43 1 71120 0
H-740	-0.4638288617134094	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Vienna Tel . : <unk> 43 1 71120 0
D-740	-0.4638288617134094	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Vienna Tel . : <unk> 43 1 71120 0
P-740	-0.0022 -1.1349 -0.1159 -0.2107 -2.7108 -0.1429 -0.0796 -0.0694 -1.4834 -2.1959 -0.2578 -1.0181 -1.7644 -0.2411 -0.0345 -0.0917 -1.2320 -0.1245 -0.1137 -0.1448 -0.2337 -0.0969 -0.0875 -1.2830 -0.0437 -0.1853 -0.1508 -0.0190 -0.1456 -0.1638 -0.1530 -0.0731 -0.0706 -0.1796 -0.1799
S-70	ADROVANCE wird für Patienten mit Niereninsuffizienz mit einer GFR unter 35 ml<unk> min nicht empfohlen ( siehe Abschnitt 4.2 ) .
T-70	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min ( see section 4.2 ) .
H-70	-0.2369733452796936	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
D-70	-0.2369733452796936	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
P-70	-0.1886 -0.0629 -0.1644 -0.1020 -0.0804 -0.1249 -0.1356 -0.0729 -0.5514 -0.3962 -0.1301 -0.2947 -0.1834 -0.1549 -0.7098 -1.2372 -0.7951 -0.1225 -0.1147 -0.1341 -0.1416 -0.0831 -0.1703 -0.0559 -0.0906 -0.1788 -0.1447 -0.1508 -0.1544 -0.1832
S-798	Nach Rückgang der Schwellung der Schleimhäute in den oberen Atemwegen kann die Behandlung bei Bedarf mit Desloratadin als Monotherapie fortgesetzt werden .
T-798	After improvement of the congestive condition of the mucosae of the upper airway , treatment may be maintained with desloratadine alone , if necessary .
H-798	-0.3815328776836395	Following reduction in the swelling of the mucous membranes in the upper respiratory tract , continued treatment with desloratadine as monotherapy as necessary .
D-798	-0.3815328776836395	Following reduction in the swelling of the mucous membranes in the upper respiratory tract , continued treatment with desloratadine as monotherapy as necessary .
P-798	-0.3042 -1.4991 -0.5121 -0.3940 -0.6972 -0.1172 -0.1358 -0.1255 -0.7117 -1.3048 -0.0119 -0.0425 -0.1232 -0.1849 -0.3796 -0.1016 -0.1860 -0.2982 -0.0311 -0.0764 -0.0332 -0.0417 -0.1576 -1.0574 -1.0269 -0.4533 -1.7353 -0.0517 -0.1575 -0.3548 -0.1809 -0.3539 -0.2330 -0.1579 -0.0821 -0.9779 -0.2476 -0.1642 -0.1755
S-182	Es liegen jedoch keine Informationen vor , die nahelegen , dass ADROVANCE die Verkehrstüchtigkeit oder die Fähigkeit zum Bedienen von Maschinen beeinträchtigt .
T-182	However , there is no information to indicate that ADROVANCE affects a patient s ability to drive or operate machines .
H-182	-0.3426194190979004	However , there is no information to suggest that ADROVANCE imweighs ability to drive or use machines .
D-182	-0.3426194190979004	However , there is no information to suggest that ADROVANCE imweighs ability to drive or use machines .
P-182	-0.1684 -0.1245 -0.2361 -0.1008 -0.1045 -0.0853 -0.2624 -0.0236 -0.0952 -0.1824 -0.0651 -0.1594 -0.0893 -0.1063 -0.9021 -3.4509 -0.0709 -1.3038 -0.1592 -0.0682 -0.1197 -0.0737 -0.2961 -0.1371 -0.1806
S-761	Basierend auf der Prüfung der anfänglich eingereichten Unterlagen erstellt der CHMP an Tag 120 eine Liste von Fragen , die dem Unternehmen zugesandt wird .
T-761	Based on the review of the initial documentation , the CHMP prepares a list of questions at day 120 , which is sent to the company .
H-761	-0.46555519104003906	Based on an examination of the initial submission , the CHMP will make a list of questions to be sent to the company on day 120 .
D-761	-0.46555519104003906	Based on an examination of the initial submission , the CHMP will make a list of questions to be sent to the company on day 120 .
P-761	-0.1936 -0.0982 -0.8896 -1.3766 -0.1282 -0.8818 -0.1941 -2.5044 -0.3553 -0.3034 -0.2166 -0.0772 -0.0427 -0.9122 -1.1182 -0.1592 -0.1512 -0.1372 -0.2250 -0.3469 -0.2032 -1.3289 -0.1601 -0.1245 -0.2458 -0.1165 -0.8416 -0.2894 -0.1742 -0.1708
S-141	Daher ist bei Patienten mit eingeschränkter Nierenfunktion eine etwas erhöhte Kumulation von Alendronat im Knochen zu erwarten ( siehe Abschnitt 4.2 ) .
T-141	Therefore , somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function ( see section 4.2 ) .
H-141	-0.3101060092449188	Therefore , in patients with renal impairment a somewhat increased accumulation of alendronate in the bone may be expected ( see section 4.2 ) .
D-141	-0.3101060092449188	Therefore , in patients with renal impairment a somewhat increased accumulation of alendronate in the bone may be expected ( see section 4.2 ) .
P-141	-2.6285 -0.0555 -0.1471 -0.8998 -0.4215 -0.1446 -0.0390 -0.1554 -0.0058 -0.0139 -0.0743 -0.0830 -1.0168 -0.5079 -0.2930 -0.5329 -0.0755 -0.1372 -0.4114 -0.1363 -0.1256 -0.0564 -0.1705 -0.2845 -0.0264 -1.4599 -0.1117 -0.0626 -0.1371 -0.0438 -0.1043 -0.1757 -0.1499 -0.1527 -0.1423 -0.1810
S-778	Desloratadin blockiert die Rezeptoren , an denen Histamin , eine körpereigene Substanz , die allergische Symptome verursacht , normalerweise andockt .
T-778	When the receptors are blocked , histamine cannot have its effect , and this leads to a decrease in the symptoms of allergy .
H-778	-0.47059565782546997	Desloratadine blocks the receptors at which histamine , an endogenous substance that causes allergic symptoms , usually docks .
D-778	-0.47059565782546997	Desloratadine blocks the receptors at which histamine , an endogenous substance that causes allergic symptoms , usually docks .
P-778	-1.6923 -0.0370 -0.1627 -0.2274 -0.2258 -0.1300 -0.1600 -0.0412 -0.0552 -0.0801 -0.5678 -0.1353 -0.0922 -0.0447 -0.1535 -2.4173 -0.2041 -0.1467 -0.0127 -0.9081 -2.0717 -0.1239 -0.0809 -0.0807 -0.0917 -0.1116 -2.9676 -1.0462 -0.2179 -0.1297 -0.1724
S-288	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-288	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-288	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-288	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-288	-0.2319 -0.2204 -1.2015 -0.1955 -0.1559 -0.1091 -0.0685 -0.2113 -1.4936 -1.2306 -0.1291 -0.1740 -0.1233 -1.2669 -0.1769 -0.1516 -0.1475 -0.1059 -0.1043 -0.0677 -0.3262 -2.1172 -0.2109 -0.0584 -0.0990 -0.1009 -0.1882 -0.0683 -0.2522 -0.9318 -0.0664 -0.9411 -0.0889 -0.0717 -0.1265 -0.1700
S-30	Knochengewebe ist ein lebendes Gewebe , das ständig erneuert wird , indem altes Knochengewebe abgebaut und durch neues ersetzt wird .
T-30	Bone is a living tissue that is constantly renewed by a process that erodes old bone and replaces it with new bone at the same rate .
H-30	-0.37311094999313354	Bone tissue is a living tissue that is continually renewed by the breakdown of old bone tissue and replacement with new bone tissue .
D-30	-0.37311094999313354	Bone tissue is a living tissue that is continually renewed by the breakdown of old bone tissue and replacement with new bone tissue .
P-30	-0.1028 -0.1602 -0.2011 -0.1125 -0.1247 -0.7902 -0.0644 -0.3192 -0.0956 -0.8915 -1.1710 -0.3733 -0.4610 -0.8946 -0.8451 -0.7132 -0.2250 -0.0300 -0.5896 -0.1157 -0.1645 -0.1948 -0.1127 -0.6792 -0.3438 -0.1161 -0.1822
S-752	Advexin hätte direkt in die Tumore gespritzt werden und so den Krebszellen ermöglichen sollen , das normale p53-Protein erneut zu bilden .
T-752	Advexin was expected to be injected directly into the tumours , thus allowing the cancer cells to produce normal p53 protein again .
H-752	-0.45868560671806335	Advexin should have been injected directly into the tumours , thus enabling the cancer cells to reproduce the normal p53 protein .
D-752	-0.45868560671806335	Advexin should have been injected directly into the tumours , thus enabling the cancer cells to reproduce the normal p53 protein .
P-752	-3.0973 -0.1146 -0.1498 -0.4264 -0.1155 -0.0836 -1.3450 -0.0610 -0.5088 -0.2017 -0.5438 -0.0668 -0.5684 -0.4356 -1.6666 -1.5383 -0.1050 -0.6588 -0.0959 -0.0621 -0.1599 -0.4669 -0.6070 -0.1105 -0.0366 -0.1222 -0.0547 -0.0638 -0.1220 -0.1720
S-8	Er wirkt durch Hemmung eines Enzyms , der so genannten Xanthinoxidase , das für die Harnsäureproduktion im Körper erforderlich ist .
T-8	It works by blocking an enzyme called xanthine oxidase , which is needed to make uric acid in the body .
H-8	-0.2389221042394638	It acts by inhibition of an enzyme called xanthine oxidase , which is necessary for the production of uric acid in the body .
D-8	-0.2389221042394638	It acts by inhibition of an enzyme called xanthine oxidase , which is necessary for the production of uric acid in the body .
P-8	-0.0228 -0.5156 -0.0765 -0.4455 -1.2925 -0.1273 -0.0749 -0.0502 -0.1595 -0.1851 -0.2045 -0.0800 -0.0634 -0.1961 -0.0265 -0.1544 -0.0616 -0.5965 -0.7241 -0.0753 -0.6151 -0.1608 -0.2104 -0.1547 -0.1418 -0.4134 -0.1450 -0.2169 -0.1407 -0.1219 -0.1097 -0.1468 -0.1751
S-245	Daher ist bei Patienten mit eingeschränkter Nierenfunktion eine etwas erhöhte Kumulation von Alendronat im Knochen zu erwarten ( siehe Abschnitt 4.2 ) .
T-245	Therefore , somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function ( see section 4.2 ) .
H-245	-0.3101060092449188	Therefore , in patients with renal impairment a somewhat increased accumulation of alendronate in the bone may be expected ( see section 4.2 ) .
D-245	-0.3101060092449188	Therefore , in patients with renal impairment a somewhat increased accumulation of alendronate in the bone may be expected ( see section 4.2 ) .
P-245	-2.6285 -0.0555 -0.1471 -0.8998 -0.4215 -0.1446 -0.0390 -0.1554 -0.0058 -0.0139 -0.0743 -0.0830 -1.0168 -0.5079 -0.2930 -0.5329 -0.0755 -0.1372 -0.4114 -0.1363 -0.1256 -0.0564 -0.1705 -0.2845 -0.0264 -1.4599 -0.1117 -0.0626 -0.1371 -0.0438 -0.1043 -0.1757 -0.1499 -0.1527 -0.1423 -0.1810
S-725	Dosis ( I.E. ) = Körpergewicht ( kg ) x erwünschter Faktor VIII-Anstieg ( % des Normalwertes ) x 0,5
T-725	Dose ( IU ) = body weight ( kg ) x desired Factor VIII rise ( % of normal ) x 0.5
H-725	-0.24897225201129913	Weight ( kg ) x desired factor VII-increase ( % of normal ) x 0.5
D-725	-0.24897225201129913	Weight ( kg ) x desired factor VII-increase ( % of normal ) x 0.5
P-725	-0.0020 -0.0562 -0.1841 -0.1147 -0.1451 -0.1059 -0.2656 -0.6733 -0.2251 -0.4103 -0.4736 -0.8153 -0.1537 -0.1939 -0.1744 -0.1507 -0.0250 -0.3386 -0.1140 -0.0979 -0.5089
S-357	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-357	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-357	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-357	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-357	-0.2319 -0.2204 -1.2015 -0.1955 -0.1559 -0.1091 -0.0685 -0.2113 -1.4936 -1.2306 -0.1291 -0.1740 -0.1233 -1.2669 -0.1769 -0.1516 -0.1475 -0.1059 -0.1043 -0.0677 -0.3262 -2.1172 -0.2109 -0.0584 -0.0990 -0.1009 -0.1882 -0.0683 -0.2522 -0.9318 -0.0664 -0.9411 -0.0889 -0.0717 -0.1265 -0.1700
S-427	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-427	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-427	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-427	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-427	-0.2319 -0.2204 -1.2015 -0.1955 -0.1559 -0.1091 -0.0685 -0.2113 -1.4936 -1.2306 -0.1291 -0.1740 -0.1233 -1.2669 -0.1769 -0.1516 -0.1475 -0.1059 -0.1043 -0.0677 -0.3262 -2.1172 -0.2109 -0.0584 -0.0990 -0.1009 -0.1882 -0.0683 -0.2522 -0.9318 -0.0664 -0.9411 -0.0889 -0.0717 -0.1265 -0.1700
S-497	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-497	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-497	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-497	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-497	-0.2319 -0.2204 -1.2015 -0.1955 -0.1559 -0.1091 -0.0685 -0.2113 -1.4936 -1.2306 -0.1291 -0.1740 -0.1233 -1.2669 -0.1769 -0.1516 -0.1475 -0.1059 -0.1043 -0.0677 -0.3262 -2.1172 -0.2109 -0.0584 -0.0990 -0.1009 -0.1882 -0.0683 -0.2522 -0.9318 -0.0664 -0.9411 -0.0889 -0.0717 -0.1265 -0.1700
S-567	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-567	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-567	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-567	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-567	-0.2319 -0.2204 -1.2015 -0.1955 -0.1559 -0.1091 -0.0685 -0.2113 -1.4936 -1.2306 -0.1291 -0.1740 -0.1233 -1.2669 -0.1769 -0.1516 -0.1475 -0.1059 -0.1043 -0.0677 -0.3262 -2.1172 -0.2109 -0.0584 -0.0990 -0.1009 -0.1882 -0.0683 -0.2522 -0.9318 -0.0664 -0.9411 -0.0889 -0.0717 -0.1265 -0.1700
S-637	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-637	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-637	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
D-637	-0.3717619478702545	In patients under 6 years of age , the use of doses ranging from 20 to 50 IU of factor VIII per kg bodyweight 3 4 times weekly is recommended .
P-637	-0.2319 -0.2204 -1.2015 -0.1955 -0.1559 -0.1091 -0.0685 -0.2113 -1.4936 -1.2306 -0.1291 -0.1740 -0.1233 -1.2669 -0.1769 -0.1516 -0.1475 -0.1059 -0.1043 -0.0677 -0.3262 -2.1172 -0.2109 -0.0584 -0.0990 -0.1009 -0.1882 -0.0683 -0.2522 -0.9318 -0.0664 -0.9411 -0.0889 -0.0717 -0.1265 -0.1700
S-737	Während der Laufzeit kann die Pulver-Durchstechflasche einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) aufbewahrt werden .
T-737	During the shelf life the powder vial may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-737	-0.3910123109817505	During runtime , the vial can be stored at room temperature ( up to 25<unk> C ) for up to 2 months .
D-737	-0.3910123109817505	During runtime , the vial can be stored at room temperature ( up to 25<unk> C ) for up to 2 months .
P-737	-2.6529 -1.1959 -0.1894 -0.1805 -0.1073 -0.5778 -0.0955 -1.9940 -0.1385 -0.8207 -0.1383 -0.2753 -0.0675 -0.1080 -0.1566 -0.1651 -0.1529 -0.1102 -0.0031 -0.1426 -0.1431 -0.1338 -0.2992 -0.1521 -0.2452 -0.3243 -0.1971 -0.1814
S-807	Außerdem ist bei der Anwendung bei Patienten mit Migräne , die gleichzeitig mit gefäßverengenden Ergotalkaloiden behandelt werden , Vorsicht geboten .
T-807	Caution should be exercised in patients suffering from migraine who are currently being treated with ergot alkaloid vasoconstrictors .
H-807	-0.3979361951351166	Caution is also advised during use in patients with migraine treated concomitantly with vascular constricting ergotalkaloids .
D-807	-0.3979361951351166	Caution is also advised during use in patients with migraine treated concomitantly with vascular constricting ergotalkaloids .
P-807	-0.0413 -0.1055 -0.5972 -0.0994 -1.0106 -0.6240 -0.6098 -0.1203 -0.2635 -0.1707 -0.0794 -0.0818 -0.6587 -1.2135 -0.5976 -0.2782 -0.0133 -0.0965 -0.1384 -1.3111 -0.0042 -0.3946 -2.6973 -0.2105 -0.4054 -0.2477 -0.4294 -0.0948 -0.2402 -0.1529 -0.1265 -0.0745 -0.1616 -0.1796
S-801	Bei Patienten ab 60 Jahren ist die Wahrscheinlichkeit für das Auftreten von unerwünschten Ereignissen unter Sympathomimetika wie Pseudoephedrin höher .
T-801	Patients of 60 years or older are more likely to experience adverse reactions to sympathomimetic medicinal products , such as pseudoephedrine .
H-801	-0.43352651596069336	Patients who are 60 years of age or older are more likely to experience adverse events with sympathomimetics such as pseudoephedrine .
D-801	-0.43352651596069336	Patients who are 60 years of age or older are more likely to experience adverse events with sympathomimetics such as pseudoephedrine .
P-801	-0.1974 -0.1000 -0.6218 -0.8129 -1.6293 -0.2383 -0.1897 -0.0859 -0.2036 -0.1864 -0.5462 -0.1008 -0.2950 -0.1418 -1.3044 -0.1201 -0.0235 -0.1674 -0.9196 -0.1934 -0.0750 -0.0746 -0.2593 -0.2741 -0.1470 -0.1978 -4.2322 -0.1972 -0.0666 -0.1197 -0.5933 -0.0816 -0.1734 -0.1708
S-283	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-283	Under certain circumstances ( e. g. presence of a low-titre inhibitor ) , doses larger than those calculated using the formula may be necessary .
H-283	-0.29489123821258545	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
D-283	-0.29489123821258545	In some circumstances ( e. g. presence of a low inhibitor titre ) , higher doses than those calculated with the formula may be necessary .
P-283	-1.0270 -0.5136 -0.0772 -0.1929 -0.1419 -0.1105 -0.1024 -0.1357 -0.1361 -0.1563 -0.3439 -0.2506 -0.0577 -0.0607 -0.2255 -0.0739 -0.6471 -0.1579 -1.0727 -0.0572 -0.3095 -0.1969 -0.2885 -1.5551 -0.3771 -0.1281 -0.6183 -0.1368 -0.2754 -0.1143 -0.1317 -0.0349 -0.1478 -0.1711
S-254	Advate wird zur Behandlung und Vorbeugung von Blutungen bei Patienten mit Hämophilie A ( eine durch den Mangel an Faktor VIII bedingte , angeborene Blutgerinnungsstörung ) verwendet .
T-254	Advate is used for the treatment and prevention of bleeding in patients with haemophilia A ( an inherited bleeding disorder caused by lack of factor VIII ) .
H-254	-0.5083184838294983	Advate is used to treat and prevent haemorrhage in patients with haemophilia A ( a congenital blood clotting disorder caused by deficiency of factor VIII ) .
D-254	-0.5083184838294983	Advate is used to treat and prevent haemorrhage in patients with haemophilia A ( a congenital blood clotting disorder caused by deficiency of factor VIII ) .
P-254	-2.6536 -0.0840 -0.0975 -0.2286 -0.2580 -0.1459 -0.1530 -0.0458 -1.1639 -0.2104 -0.0220 -0.3798 -0.1043 -0.2296 -0.1198 -0.1029 -0.0923 -0.2581 -1.7895 -0.1289 -0.5318 -1.6098 -0.3329 -0.7870 -0.8748 -1.1175 -0.2116 -0.0267 -0.1325 -0.7461 -1.1775 -0.0932 -2.3871 -0.3906 -0.1354 -1.0576 -0.2758 -0.2100 -0.0933 -0.5592 -0.1532 -0.1779
S-462	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-462	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-462	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
D-462	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
P-462	-1.1656 -0.5055 -0.2813 -0.1645 -0.0691 -0.0658 -0.0133 -0.0236 -0.0714 -0.1377 -0.1911 -0.1744 -2.1139 -0.0623 -0.0790 -0.1629 -3.0498 -0.1387 -0.3133 -0.0236 -0.1017 -0.1565 -0.3526 -0.5107 -0.3042 -0.0840 -0.0525 -0.0958 -0.1409 -1.8839 -0.1543 -0.0462 -0.2001 -1.3022 -0.1780
S-803	Die Sicherheit und die Wirksamkeit von Aerinaze wurden bei Patienten mit Nieren- oder Leberfunktionsstörung nicht geprüft und die Daten reichen nicht aus , um entsprechende Empfehlungen zur Dosierung auszusprechen .
T-803	The safety and efficacy of Aerinaze has not been established in patients with impaired renal or hepatic function , and there are insufficient data to give adequate dose recommendations .
H-803	-0.2342851310968399	The safety and efficacy of Aerinaze have not been evaluated in patients with renal or hepatic impairment and data are insufficient to make appropriate dose recommendations .
D-803	-0.2342851310968399	The safety and efficacy of Aerinaze have not been evaluated in patients with renal or hepatic impairment and data are insufficient to make appropriate dose recommendations .
P-803	-0.2011 -0.0533 -0.1485 -0.3889 -0.1333 -0.0844 -0.1414 -0.1760 -0.1275 -0.1361 -0.3061 -0.0944 -0.2690 -0.1085 -0.1015 -0.1584 -0.1256 -0.1278 -0.6625 -0.1157 -0.0336 -0.1281 -0.1188 -0.1117 -0.0256 -0.1481 -0.0501 -0.0217 -0.1213 -0.0970 -0.2952 -0.2270 -0.0891 -0.0285 -0.0603 -0.1485 -2.4046 -0.4685 -1.2500 -0.0352 -0.1407 -0.1762
S-138	Die mittlere Halbwertszeit von Vitamin D3 im Serum beträgt ca. 24 Stunden nach einer oralen Dosis von ADROVANCE ( 70 mg<unk> 2.800 I.E . ) .
T-138	The mean half-life of vitamin D3 in the serum following an oral dose of ADROVANCE ( 70 mg/ 2800 IU ) is approximately 24 hours .
H-138	-0.15623030066490173	The mean half-life of serum vitamin D3 is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
D-138	-0.15623030066490173	The mean half-life of serum vitamin D3 is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
P-138	-0.2130 -0.0929 -0.1242 -0.1509 -0.0835 -0.1431 -0.5417 -0.2116 -0.1074 -0.0689 -0.1094 -0.2033 -0.0868 -0.3432 -0.1093 -0.0988 -0.1710 -0.3963 -0.0252 -0.0582 -0.1523 -0.1371 -0.0695 -0.1706 -0.0947 -0.0693 -0.1367 -0.1099 -0.1208 -0.1045 -0.1034 -0.6078 -0.0781 -0.1074 -0.0684 -0.1508 -0.1388 -0.1779
S-241	Die mittlere Halbwertszeit von Vitamin D3 im Serum beträgt ca. 24 Stunden nach einer oralen Dosis von ADROVANCE ( 70 mg<unk> 2.800 I.E . ) .
T-241	The mean half-life of vitamin D3 in the serum following an oral dose of ADROVANCE ( 70 mg/ 2800 IU ) is approximately 24 hours .
H-241	-0.15623030066490173	The mean half-life of serum vitamin D3 is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
D-241	-0.15623030066490173	The mean half-life of serum vitamin D3 is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
P-241	-0.2130 -0.0929 -0.1242 -0.1509 -0.0835 -0.1431 -0.5417 -0.2116 -0.1074 -0.0689 -0.1094 -0.2033 -0.0868 -0.3432 -0.1093 -0.0988 -0.1710 -0.3963 -0.0252 -0.0582 -0.1523 -0.1371 -0.0695 -0.1706 -0.0947 -0.0693 -0.1367 -0.1099 -0.1208 -0.1045 -0.1034 -0.6078 -0.0781 -0.1074 -0.0684 -0.1508 -0.1388 -0.1779
S-322	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-322	7 increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-322	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
D-322	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
P-322	-1.1656 -0.5055 -0.2813 -0.1645 -0.0691 -0.0658 -0.0133 -0.0236 -0.0714 -0.1377 -0.1911 -0.1744 -2.1139 -0.0623 -0.0790 -0.1629 -3.0498 -0.1387 -0.3133 -0.0236 -0.1017 -0.1565 -0.3526 -0.5107 -0.3042 -0.0840 -0.0525 -0.0958 -0.1409 -1.8839 -0.1543 -0.0462 -0.2001 -1.3022 -0.1780
S-392	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-392	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-392	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
D-392	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
P-392	-1.1656 -0.5055 -0.2813 -0.1645 -0.0691 -0.0658 -0.0133 -0.0236 -0.0714 -0.1377 -0.1911 -0.1744 -2.1139 -0.0623 -0.0790 -0.1629 -3.0498 -0.1387 -0.3133 -0.0236 -0.1017 -0.1565 -0.3526 -0.5107 -0.3042 -0.0840 -0.0525 -0.0958 -0.1409 -1.8839 -0.1543 -0.0462 -0.2001 -1.3022 -0.1780
S-532	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-532	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-532	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
D-532	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
P-532	-1.1656 -0.5055 -0.2813 -0.1645 -0.0691 -0.0658 -0.0133 -0.0236 -0.0714 -0.1377 -0.1911 -0.1744 -2.1139 -0.0623 -0.0790 -0.1629 -3.0498 -0.1387 -0.3133 -0.0236 -0.1017 -0.1565 -0.3526 -0.5107 -0.3042 -0.0840 -0.0525 -0.0958 -0.1409 -1.8839 -0.1543 -0.0462 -0.2001 -1.3022 -0.1780
S-602	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-602	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-602	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
D-602	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
P-602	-1.1656 -0.5055 -0.2813 -0.1645 -0.0691 -0.0658 -0.0133 -0.0236 -0.0714 -0.1377 -0.1911 -0.1744 -2.1139 -0.0623 -0.0790 -0.1629 -3.0498 -0.1387 -0.3133 -0.0236 -0.1017 -0.1565 -0.3526 -0.5107 -0.3042 -0.0840 -0.0525 -0.0958 -0.1409 -1.8839 -0.1543 -0.0462 -0.2001 -1.3022 -0.1780
S-672	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-672	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-672	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
D-672	-0.4105816185474396	Factor VIII plasma concentrations are increased by substitution therapy , resulting in temporary correction of factor VIII deficiency and haemorrhage .
P-672	-1.1656 -0.5055 -0.2813 -0.1645 -0.0691 -0.0658 -0.0133 -0.0236 -0.0714 -0.1377 -0.1911 -0.1744 -2.1139 -0.0623 -0.0790 -0.1629 -3.0498 -0.1387 -0.3133 -0.0236 -0.1017 -0.1565 -0.3526 -0.5107 -0.3042 -0.0840 -0.0525 -0.0958 -0.1409 -1.8839 -0.1543 -0.0462 -0.2001 -1.3022 -0.1780
S-755	Bei Li-Fraumeni-Krebs , bei dem das p53-Gen defekt ist , arbeitet das p53-Protein nicht richtig , und die Krebszellen können weiter wachsen und sich teilen .
T-755	In Li-Fraumeni cancer , where the p53 gene is defective , the p53 protein does not work properly and the cancer cells can continue to grow and divide .
H-755	-0.36130836606025696	In Li-Fraumeni cancer , in which the p53 gene is defective , the p53 protein does not work properly and cancer cells can continue to grow and divide .
D-755	-0.36130836606025696	In Li-Fraumeni cancer , in which the p53 gene is defective , the p53 protein does not work properly and cancer cells can continue to grow and divide .
P-755	-0.1965 -0.9646 -0.1472 -3.3138 -0.0891 -0.2149 -0.4432 -0.1180 -1.0123 -0.1973 -0.1754 -0.1788 -0.3925 -0.1475 -0.0880 -0.1920 -0.5238 -0.1483 -0.1178 -0.1582 -0.1308 -0.0665 -0.0811 -0.1027 -0.1090 -0.0422 -0.1967 -0.2505 -0.0613 -0.8275 -0.5026 -0.1487 -1.4995 -0.1292 -0.1104 -0.1182 -0.1723
S-698	ADVATE 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-698	ADVATE 500 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-698	-0.3335440754890442	ADVATE 500 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
D-698	-0.3335440754890442	ADVATE 500 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
P-698	-0.4542 -0.1952 -0.0713 -0.1239 -0.1072 -0.0964 -0.0649 -1.2327 -0.1203 -0.1551 -0.1674 -2.0461 -0.2310 -0.2726 -1.0076 -1.7766 -0.1387 -1.2338 -0.1093 -0.1279 -0.0987 -0.1664 -0.0969 -0.1294 -0.1038 -0.1121 -0.0662 -0.1482 -0.4646 -0.1413 -0.1582 -0.1720 -0.1709 -0.9654 -0.0300 -0.1325 -0.0682 -0.2141 -0.0645 -0.1831 -0.2567
S-695	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-695	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-695	-0.33596915006637573	ADVATE 250 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
D-695	-0.33596915006637573	ADVATE 250 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
P-695	-0.3957 -0.1941 -0.0729 -0.1224 -0.2220 -0.0972 -0.0620 -1.4214 -0.1120 -0.1559 -0.1603 -2.0472 -0.2267 -0.2726 -0.9213 -1.7733 -0.1376 -1.2182 -0.1096 -0.1285 -0.0983 -0.1751 -0.0963 -0.1296 -0.1040 -0.1157 -0.0667 -0.1489 -0.4490 -0.1430 -0.1602 -0.1695 -0.1710 -0.9670 -0.0298 -0.1328 -0.0673 -0.2116 -0.0631 -0.1709 -0.2540
S-701	ADVATE 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-701	ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-701	-0.3389720320701599	ADVATE 1000 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
D-701	-0.3389720320701599	ADVATE 1000 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
P-701	-0.4922 -0.1944 -0.0698 -0.1239 -0.1177 -0.0971 -0.0620 -1.3244 -0.1332 -0.1554 -0.1664 -2.0053 -0.2260 -0.2891 -0.9522 -1.8285 -0.1395 -1.2525 -0.1091 -0.1267 -0.1000 -0.1805 -0.0969 -0.1292 -0.1044 -0.1215 -0.0671 -0.1484 -0.4993 -0.1404 -0.1615 -0.1742 -0.1707 -0.9790 -0.0298 -0.1323 -0.0704 -0.2174 -0.0652 -0.1813 -0.2630
S-710	ADVATE 3000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-710	ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-710	-0.3429638147354126	ADVATE 3000 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
D-710	-0.3429638147354126	ADVATE 3000 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
P-710	-0.4735 -0.1928 -0.0672 -0.1335 -0.1170 -0.1021 -0.0645 -1.6357 -0.1331 -0.1551 -0.1694 -1.9281 -0.2171 -0.2768 -0.9880 -1.8184 -0.1389 -1.2371 -0.1087 -0.1268 -0.0993 -0.1800 -0.0968 -0.1283 -0.1044 -0.1244 -0.0666 -0.1499 -0.4528 -0.1403 -0.1605 -0.1745 -0.1708 -0.9621 -0.0292 -0.1333 -0.0716 -0.2143 -0.0656 -0.1894 -0.2637
S-751	Bei dem Virus in Advexin handelt es sich um ein Adenovirus , das so verändert wurde , dass es keine Kopien von sich selbst herstellen und somit keine Infektionen beim Menschen auslösen kann .
T-751	The virus in Advexin is an adenovirus that has been engineered so that it cannot make copies of itself and therefore does not cause infections in humans .
H-751	-0.5557398200035095	The virus in Advexin is an adenovirus that has been modified not to make copies of itself , thus not to cause infections in humans .
D-751	-0.5557398200035095	The virus in Advexin is an adenovirus that has been modified not to make copies of itself , thus not to cause infections in humans .
P-751	-0.1273 -1.7833 -0.1445 -1.5182 -0.1186 -0.1529 -0.1086 -0.2276 -0.0385 -0.1978 -1.1648 -1.4533 -0.6694 -0.1320 -1.4016 -0.1120 -1.1375 -0.1582 -0.3398 -1.2289 -0.1430 -0.5032 -0.1749 -1.5112 -1.2561 -0.4944 -0.0796 -1.2171 -0.0465 -0.1471 -0.2400 -0.1302 -0.1812
S-776	Die Dauer der Behandlung sollte so kurz wie möglich sein und beendet werden , sobald die Symptome , vor allem die Schwellung der Nasenschleimhaut ( verstopfte Nase ) , abgeklungen sind .
T-776	Treatment should continue for as short a time as possible and should stop when symptoms , chiefly the congestion ( blocked nose ) , have disappeared .
H-776	-0.42966127395629883	Duration of treatment should be as short as possible and should be stopped as soon as the symptoms , primarily swelling of the nasal mucosa ( nasal constipation ) resolve .
D-776	-0.42966127395629883	Duration of treatment should be as short as possible and should be stopped as soon as the symptoms , primarily swelling of the nasal mucosa ( nasal constipation ) resolve .
P-776	-0.8574 -0.1069 -0.1260 -0.0951 -0.1576 -0.1583 -0.2566 -1.1026 -0.2014 -0.1813 -0.1515 -1.1054 -0.0851 -1.7967 -0.4045 -0.1247 -0.1651 -0.9171 -0.0352 -0.1190 -2.2074 -1.2845 -0.1192 -0.5142 -0.1101 -0.2337 -0.0739 -0.1473 -0.8122 -0.0183 -0.3447 -0.1420 -0.2289 -0.0701 -0.1253 -0.6784 -0.2445 -0.1097 -0.0973 -0.1466 -2.3166 -0.1250 -0.1780
S-167	Die Patienten sollen angewiesen werden , dass sie beim Versäumnis der Einnahme einer Dosis ADROVANCE die Tablette am nächsten Morgen einnehmen sollen , nachdem sie ihr Versäumnis bemerkt haben .
T-167	Patients should be instructed that if they miss a dose of ADROVANCE they should take one tablet on the morning after they remember .
H-167	-0.392818808555603	Patients should be advised that if they miss a dose of ADROVANCE , they should take the tablet the next morning after they realise their failure .
D-167	-0.392818808555603	Patients should be advised that if they miss a dose of ADROVANCE , they should take the tablet the next morning after they realise their failure .
P-167	-0.2099 -0.1099 -0.2978 -0.1778 -0.2688 -0.7903 -0.2092 -0.1849 -1.5052 -0.1594 -0.0222 -0.2107 -0.1860 -0.0612 -0.1618 -0.0863 -0.0924 -0.1449 -0.1225 -0.1577 -0.2206 -0.1324 -0.1431 -0.0667 -0.2120 -0.5045 -0.2870 -0.2850 -0.8877 -2.9440 -0.2030 -0.7431 -1.3893 -0.1786
S-68	Die Patienten sollen angewiesen werden , dass sie beim Versäumnis der Einnahme einer Dosis ADROVANCE die Tablette am nächsten Morgen einnehmen sollen , nachdem sie ihr Versäumnis bemerkt haben .
T-68	Patients should be instructed that if they miss a dose of ADROVANCE they should take one tablet on the morning after they remember .
H-68	-0.392818808555603	Patients should be advised that if they miss a dose of ADROVANCE , they should take the tablet the next morning after they realise their failure .
D-68	-0.392818808555603	Patients should be advised that if they miss a dose of ADROVANCE , they should take the tablet the next morning after they realise their failure .
P-68	-0.2099 -0.1099 -0.2978 -0.1778 -0.2688 -0.7903 -0.2092 -0.1849 -1.5052 -0.1594 -0.0222 -0.2107 -0.1860 -0.0612 -0.1618 -0.0863 -0.0924 -0.1449 -0.1225 -0.1577 -0.2206 -0.1324 -0.1431 -0.0667 -0.2120 -0.5045 -0.2870 -0.2850 -0.8877 -2.9440 -0.2030 -0.7431 -1.3893 -0.1786
S-704	ADVATE 1500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-704	ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-704	-0.3564585745334625	ADVATE 1500 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
D-704	-0.3564585745334625	ADVATE 1500 IU of powder and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
P-704	-0.4462 -0.1962 -0.0678 -0.1267 -0.5007 -0.1038 -0.0571 -1.7164 -0.1236 -0.1564 -0.1648 -2.0444 -0.2346 -0.2956 -0.9578 -1.8484 -0.1389 -1.2221 -0.1083 -0.1279 -0.1000 -0.1837 -0.0968 -0.1283 -0.1040 -0.1298 -0.0661 -0.1503 -0.4587 -0.1384 -0.1614 -0.1729 -0.1722 -0.9396 -0.0295 -0.1324 -0.0700 -0.2152 -0.0654 -0.1986 -0.2636
S-453	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-453	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-453	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
D-453	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
P-453	-0.8676 -0.1153 -0.3979 -0.1607 -0.8725 -0.2074 -0.1436 -1.9824 -0.4618 -0.2930 -0.1765 -0.0607 -0.4753 -1.2287 -0.1161 -0.1967 -3.3035 -0.1664 -0.0120 -1.4927 -0.0610 -0.7649 -1.0272 -0.4055 -0.0321 -0.0396 -0.1355 -0.1337 -0.0330 -0.0502 -0.0725 -0.1045 -0.1901 -0.3590 -0.2730 -0.0684 -0.0609 -0.3886 -0.1333 -0.1737
S-663	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-663	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-663	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
D-663	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
P-663	-0.8676 -0.1153 -0.3979 -0.1607 -0.8725 -0.2074 -0.1436 -1.9824 -0.4618 -0.2930 -0.1765 -0.0607 -0.4753 -1.2287 -0.1161 -0.1967 -3.3035 -0.1664 -0.0120 -1.4927 -0.0610 -0.7649 -1.0272 -0.4055 -0.0321 -0.0396 -0.1355 -0.1337 -0.0330 -0.0502 -0.0725 -0.1045 -0.1901 -0.3590 -0.2730 -0.0684 -0.0609 -0.3886 -0.1333 -0.1737
S-718	Diese Symptome können frühe Anzeichen eines anaphylaktischen Schocks darstellen , der zusätzlich folgende Symptome einschließen kann : extremer Schwindel , Bewusstseinsverlust und extreme Atembeschwerden .
T-718	92 symptom of an anaphylactic shock , manifestations of which may additionally include extreme dizziness , loss of consciousness , and extreme difficulty in breathing .
H-718	-0.21815723180770874	These symptoms may be early signs of anaphylactic shock , which in addition may include extreme dizziness , loss of consciousness and difficulties in breathing .
D-718	-0.21815723180770874	These symptoms may be early signs of anaphylactic shock , which in addition may include extreme dizziness , loss of consciousness and difficulties in breathing .
P-718	-0.1311 -0.3169 -0.3390 -0.4122 -0.2834 -0.2520 -0.1380 -0.1185 -0.1090 -0.0859 -0.2709 -0.0456 -0.0678 -0.1403 -0.2364 -0.1840 -0.1041 -0.3036 -0.0635 -0.5482 -0.3126 -0.0556 -0.0920 -0.1624 -0.0516 -0.1554 -0.0554 -0.0853 -0.3965 -1.4114 -0.1410 -0.0414 -0.1310 -0.1751
S-53	Die Äquivalenz der Einnahme von 2.800 I.E. Vitamin D3 einmal pro Woche in ADROVANCE und von 400 I.E. Vitamin D einmal pro Tag wurde nicht untersucht .
T-53	The equivalence of intake of 2800 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 400 IU has not been studied .
H-53	-0.19033046066761017	The equivalent of taking 2,800 IU of vitamin D3 once a week in ADROVANCE and 400 IU of vitamin D once a day has not been studied .
D-53	-0.19033046066761017	The equivalent of taking 2,800 IU of vitamin D3 once a week in ADROVANCE and 400 IU of vitamin D once a day has not been studied .
P-53	-0.1563 -0.2508 -0.1240 -0.5800 -0.4186 -0.1233 -0.1139 -0.0624 -0.1553 -0.0654 -0.0587 -0.0995 -0.1878 -0.0757 -0.1810 -0.1091 -0.1297 -0.0973 -0.0650 -0.1593 -0.1065 -0.0563 -0.1891 -0.2329 -0.1320 -0.0738 -0.1499 -0.0491 -0.0535 -0.1059 -0.0109 -0.5024 -0.2856 -0.5994 -0.0971 -0.1140 -1.1464 -0.1292 -0.1760
S-707	ADVATE 2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-707	ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-707	-0.35088178515434265	ADVATE 2000 IU Powders and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
D-707	-0.35088178515434265	ADVATE 2000 IU Powders and solvents for the production of solution for injection Octocog alfa ( human recombinant clotting factor VIII )
P-707	-0.4365 -0.1974 -0.0647 -0.1355 -0.0583 -0.1098 -0.0582 -3.2829 -0.1047 -1.1921 -0.1528 -0.1094 -0.1666 -0.1137 -0.3448 -0.9781 -1.6887 -0.1399 -1.2097 -0.1095 -0.1277 -0.1014 -0.1743 -0.0951 -0.1287 -0.1046 -0.1186 -0.0661 -0.1454 -0.4996 -0.1442 -0.1601 -0.1713 -0.1741 -0.9622 -0.0281 -0.1324 -0.0722 -0.2170 -0.0663 -0.1445 -0.2495
S-383	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-383	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-383	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
D-383	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
P-383	-0.8676 -0.1153 -0.3979 -0.1607 -0.8725 -0.2074 -0.1436 -1.9824 -0.4618 -0.2930 -0.1765 -0.0607 -0.4753 -1.2287 -0.1161 -0.1967 -3.3035 -0.1664 -0.0120 -1.4927 -0.0610 -0.7649 -1.0272 -0.4055 -0.0321 -0.0396 -0.1355 -0.1337 -0.0330 -0.0502 -0.0725 -0.1045 -0.1901 -0.3590 -0.2730 -0.0684 -0.0609 -0.3886 -0.1333 -0.1737
S-784	Die Hauptwirksamkeitsmaße waren die Veränderungen des Schweregrades der Heuschnupfensymptome , die von den Patienten vor Beginn der Behandlung und während der 15-tägigen Behandlung berichtet wurden .
T-784	The main measures of effectiveness were the change in the severity of hayfever symptoms reported by the patients between before treatment started , and over the entire 15 days of treatment .
H-784	-0.4038747549057007	The main measure of efficacy was the change in the severity of hayfever symptoms reported by patients prior to and during 15-day treatment .
D-784	-0.4038747549057007	The main measure of efficacy was the change in the severity of hayfever symptoms reported by patients prior to and during 15-day treatment .
P-784	-0.1605 -0.2413 -0.9048 -0.1418 -1.3430 -0.0806 -0.0748 -1.0925 -0.3269 -0.4609 -0.1277 -0.1705 -1.1966 -0.0988 -0.1347 -0.2655 -1.8168 -0.1218 -0.0443 -0.2015 -0.1634 -0.1901 -0.1762 -0.8952 -0.1604 -0.4595 -0.1606 -1.2048 -0.1147 -0.2752 -0.1953 -0.1544 -0.1727
S-313	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-313	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-313	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
D-313	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
P-313	-0.8676 -0.1153 -0.3979 -0.1607 -0.8725 -0.2074 -0.1436 -1.9824 -0.4618 -0.2930 -0.1765 -0.0607 -0.4753 -1.2287 -0.1161 -0.1967 -3.3035 -0.1664 -0.0120 -1.4927 -0.0610 -0.7649 -1.0272 -0.4055 -0.0321 -0.0396 -0.1355 -0.1337 -0.0330 -0.0502 -0.0725 -0.1045 -0.1901 -0.3590 -0.2730 -0.0684 -0.0609 -0.3886 -0.1333 -0.1737
S-523	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-523	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-523	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
D-523	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
P-523	-0.8676 -0.1153 -0.3979 -0.1607 -0.8725 -0.2074 -0.1436 -1.9824 -0.4618 -0.2930 -0.1765 -0.0607 -0.4753 -1.2287 -0.1161 -0.1967 -3.3035 -0.1664 -0.0120 -1.4927 -0.0610 -0.7649 -1.0272 -0.4055 -0.0321 -0.0396 -0.1355 -0.1337 -0.0330 -0.0502 -0.0725 -0.1045 -0.1901 -0.3590 -0.2730 -0.0684 -0.0609 -0.3886 -0.1333 -0.1737
S-593	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-593	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-593	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
D-593	-0.4309348165988922	Immune response to traces of contaminating proteins was analysed by examining antibody titers to these proteins , laboratory parameters and reported undesirable effects .
P-593	-0.8676 -0.1153 -0.3979 -0.1607 -0.8725 -0.2074 -0.1436 -1.9824 -0.4618 -0.2930 -0.1765 -0.0607 -0.4753 -1.2287 -0.1161 -0.1967 -3.3035 -0.1664 -0.0120 -1.4927 -0.0610 -0.7649 -1.0272 -0.4055 -0.0321 -0.0396 -0.1355 -0.1337 -0.0330 -0.0502 -0.0725 -0.1045 -0.1901 -0.3590 -0.2730 -0.0684 -0.0609 -0.3886 -0.1333 -0.1737
S-41	Bei Patienten mit etwaiger Überempfindlichkeit ( Allergie ) gegen Alendronat , Vitamin D3 oder einen der sonstigen Bestandteile darf ADROVANCE nicht angewendet werden .
T-41	ADROVANCE should not be used in people who may be hypersensitive ( allergic ) to alendronate , vitamin D3 or any of the other ingredients .
H-41	-0.3556225001811981	In patients with possible hypersensitivity ( allergy ) to alendronate , vitamin D3 or any of the excipients , ADROVANCE should not be used .
D-41	-0.3556225001811981	In patients with possible hypersensitivity ( allergy ) to alendronate , vitamin D3 or any of the excipients , ADROVANCE should not be used .
P-41	-1.6482 -0.3692 -0.5454 -1.7978 -0.2516 -0.0742 -0.0613 -0.1553 -1.0608 -2.9282 -0.1422 -0.1685 -0.2906 -0.1312 -0.1248 -0.0683 -0.1292 -0.1281 -0.0548 -0.0978 -0.2158 -0.9945 -0.1173 -0.1311 -0.1298 -0.2071 -0.1321 -0.0918 -0.1222 -0.2045 -0.2627 -0.0625 -0.1640 -0.0818 -0.0931 -0.5575 -0.1142 -0.1657 -0.1755 -0.1411 -0.1889
S-180	Tierstudien mit Alendronat lassen keinen Hinweis auf direkt schädigende Wirkungen im Hinblick auf die Schwangerschaft , die embryonale<unk> fetale oder postnatale Entwicklung erkennen .
T-180	Animal studies with alendronate do not indicate direct harmful effects with respect to pregnancy , embryonal/ foetal development , or postnatal development .
H-180	-0.32552871108055115	Animal studies with alendronate show no evidence of any direct damage to pregnancy , embryonal/ foetal or post-natal development .
D-180	-0.32552871108055115	Animal studies with alendronate show no evidence of any direct damage to pregnancy , embryonal/ foetal or post-natal development .
P-180	-0.2026 -0.0505 -0.0861 -0.4953 -0.1432 -0.1330 -0.0890 -0.0733 -0.5678 -0.0985 -0.0796 -0.1617 -1.5160 -1.3370 -2.5500 -0.2474 -0.0988 -0.1544 -0.3824 -0.0969 -0.2426 -0.1143 -0.1013 -0.1884 -0.2540 -0.1254 -0.2929 -0.0302 -0.5998 -0.0358 -0.1195 -0.0920 -0.1270 -0.1812
S-348	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-348	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-348	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
D-348	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
P-348	-0.4492 -0.0327 -0.1168 -0.9279 -1.1520 -1.1854 -0.0926 -0.1619 -0.5669 -0.1018 -0.1310 -0.5351 -0.2063 -1.4922 -0.1412 -0.1376 -0.1668 -0.4828 -0.0624 -0.1511 -0.2172 -0.3214 -1.3599 -0.2354 -0.1818 -0.1334 -0.5943 -0.3689 -0.5221 -0.1656 -0.1473 -0.1644 -0.0331 -0.5866 -0.0604 -0.0856 -0.0947 -1.2651 -1.1699 -0.1361 -0.1715
S-81	Tierstudien mit Alendronat lassen keinen Hinweis auf direkt schädigende Wirkungen im Hinblick auf die Schwangerschaft , die embryonale<unk> fetale oder postnatale Entwicklung erkennen .
T-81	Animal studies with alendronate do not indicate direct harmful effects with respect to pregnancy , embryonal/ foetal development , or postnatal development .
H-81	-0.32552871108055115	Animal studies with alendronate show no evidence of any direct damage to pregnancy , embryonal/ foetal or post-natal development .
D-81	-0.32552871108055115	Animal studies with alendronate show no evidence of any direct damage to pregnancy , embryonal/ foetal or post-natal development .
P-81	-0.2026 -0.0505 -0.0861 -0.4953 -0.1432 -0.1330 -0.0890 -0.0733 -0.5678 -0.0985 -0.0796 -0.1617 -1.5160 -1.3370 -2.5500 -0.2474 -0.0988 -0.1544 -0.3824 -0.0969 -0.2426 -0.1143 -0.1013 -0.1884 -0.2540 -0.1254 -0.2929 -0.0302 -0.5998 -0.0358 -0.1195 -0.0920 -0.1270 -0.1812
S-772	Aerinaze ist ein Arzneimittel , das die arzneilich wirksamen Bestandteile Desloratadin ( 2,5 mg ) und Pseudoephedrin ( 120 mg ) enthält .
T-772	Aerinaze is a medicine containing the active substances desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
H-772	-0.35127025842666626	Aerinaze is a medicine containing the active ingredients desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
D-772	-0.35127025842666626	Aerinaze is a medicine containing the active ingredients desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
P-772	-0.1083 -0.1392 -0.1274 -0.3717 -0.0927 -0.1579 -0.1610 -0.7623 -0.0211 -0.1271 -0.2001 -0.8965 -2.2618 -0.0455 -0.1583 -0.5243 -0.4105 -0.1334 -0.0913 -0.0542 -0.1571 -0.1689 -0.1938 -3.3932 -0.1709 -0.0514 -0.1470 -0.1631 -0.0887 -0.1576 -0.1804 -0.0605 -0.1477 -0.1857 -0.1838
S-279	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-279	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-279	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
D-279	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
P-279	-0.4492 -0.0327 -0.1168 -0.9279 -1.1520 -1.1854 -0.0926 -0.1619 -0.5669 -0.1018 -0.1310 -0.5351 -0.2063 -1.4922 -0.1412 -0.1376 -0.1668 -0.4828 -0.0624 -0.1511 -0.2172 -0.3214 -1.3599 -0.2354 -0.1818 -0.1334 -0.5943 -0.3689 -0.5221 -0.1656 -0.1473 -0.1644 -0.0331 -0.5866 -0.0604 -0.0856 -0.0947 -1.2651 -1.1699 -0.1361 -0.1715
S-768	Das Unternehmen setzte den CHMP nicht davon in Kenntnis , ob die Rücknahme Konsequenzen für Patienten hat , die derzeit an klinischen Studien oder Compassionate-Use -Programmen mit Advexin teilnehmen .
T-768	The company did not inform the CHMP whether there were any consequences of the withdrawal for patients in clinical trials or compassionate use programmes with Advexin .
H-768	-0.5963475704193115	The company did not notify the CHMP of whether the repeal will affect patients currently participating in clinical trials or in Compassion Use programs with Advexin .
D-768	-0.5963475704193115	The company did not notify the CHMP of whether the repeal will affect patients currently participating in clinical trials or in Compassion Use programs with Advexin .
P-768	-0.0843 -0.0722 -0.1277 -0.1111 -0.8377 -0.0969 -0.1538 -0.0726 -0.0378 -1.4991 -0.5252 -0.4972 -2.9324 -0.1444 -1.7399 -0.2681 -0.1797 -0.4270 -1.7521 -0.2109 -0.1438 -0.0528 -0.0353 -0.1262 -1.5417 -2.8159 -0.7312 -0.0564 -1.5537 -0.3784 -1.0404 -0.1130 -0.1550 -0.1722 -0.1859
S-418	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-418	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-418	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
D-418	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
P-418	-0.4492 -0.0327 -0.1168 -0.9279 -1.1520 -1.1854 -0.0926 -0.1619 -0.5669 -0.1018 -0.1310 -0.5351 -0.2063 -1.4922 -0.1412 -0.1376 -0.1668 -0.4828 -0.0624 -0.1511 -0.2172 -0.3214 -1.3599 -0.2354 -0.1818 -0.1334 -0.5943 -0.3689 -0.5221 -0.1656 -0.1473 -0.1644 -0.0331 -0.5866 -0.0604 -0.0856 -0.0947 -1.2651 -1.1699 -0.1361 -0.1715
S-488	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-488	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-488	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
D-488	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
P-488	-0.4492 -0.0327 -0.1168 -0.9279 -1.1520 -1.1854 -0.0926 -0.1619 -0.5669 -0.1018 -0.1310 -0.5351 -0.2063 -1.4922 -0.1412 -0.1376 -0.1668 -0.4828 -0.0624 -0.1511 -0.2172 -0.3214 -1.3599 -0.2354 -0.1818 -0.1334 -0.5943 -0.3689 -0.5221 -0.1656 -0.1473 -0.1644 -0.0331 -0.5866 -0.0604 -0.0856 -0.0947 -1.2651 -1.1699 -0.1361 -0.1715
S-558	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-558	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-558	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
D-558	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
P-558	-0.4492 -0.0327 -0.1168 -0.9279 -1.1520 -1.1854 -0.0926 -0.1619 -0.5669 -0.1018 -0.1310 -0.5351 -0.2063 -1.4922 -0.1412 -0.1376 -0.1668 -0.4828 -0.0624 -0.1511 -0.2172 -0.3214 -1.3599 -0.2354 -0.1818 -0.1334 -0.5943 -0.3689 -0.5221 -0.1656 -0.1473 -0.1644 -0.0331 -0.5866 -0.0604 -0.0856 -0.0947 -1.2651 -1.1699 -0.1361 -0.1715
S-628	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-628	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-628	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
D-628	-0.3977701663970947	Repeat every 12 24 hours ( 8 24 hours in patients less than 6 years of age ) for 3 to 4 days or longer until the pain and acute impairment are removed .
P-628	-0.4492 -0.0327 -0.1168 -0.9279 -1.1520 -1.1854 -0.0926 -0.1619 -0.5669 -0.1018 -0.1310 -0.5351 -0.2063 -1.4922 -0.1412 -0.1376 -0.1668 -0.4828 -0.0624 -0.1511 -0.2172 -0.3214 -1.3599 -0.2354 -0.1818 -0.1334 -0.5943 -0.3689 -0.5221 -0.1656 -0.1473 -0.1644 -0.0331 -0.5866 -0.0604 -0.0856 -0.0947 -1.2651 -1.1699 -0.1361 -0.1715
S-742	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
T-742	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <<unk>> 371 67 784 784
H-742	-0.24135653674602509	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
D-742	-0.24135653674602509	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
P-742	-0.0872 -0.0826 -0.0756 -1.3079 -0.1714 -0.1420 -0.1089 -0.6321 -0.0570 -0.0928 -0.6741 -0.1739 -0.0791 -0.1136 -0.1050 -0.0835 -0.1526 -0.1442 -0.1236 -0.2106 -0.1560 -0.1375 -0.0668 -0.1480 -0.0722 -3.0472 -0.1537 -0.1904 -0.1510 -0.1148 -0.1064 -0.0674 -0.4263 -0.1616 -0.0225 -0.1402 -0.0683 -0.0586 -0.1400 -0.0312 -0.1237 -0.0372 -0.1398
S-775	Bei Erwachsenen und Jugendlichen ab 12 Jahren ist die empfohlene Dosis von Aerinaze zweimal täglich eine Tablette , die ganz mit einem Glas Wasser mit oder ohne Nahrung eingenommen werden soll .
T-775	In adults and adolescents over 12 years of age , the recommended dose of Aerinaze is one tablet twice a day , taken whole with a full glass of water , with or without food .
H-775	-0.3839644491672516	In adults and adolescents aged 12 years and over , the recommended dose of Aerinaze twice a day is a tablet to be taken whole with a glass of water with or without food .
D-775	-0.3839644491672516	In adults and adolescents aged 12 years and over , the recommended dose of Aerinaze twice a day is a tablet to be taken whole with a glass of water with or without food .
P-775	-0.4114 -0.8916 -0.1775 -0.3543 -0.0469 -0.5684 -0.7796 -0.9130 -0.3888 -1.8533 -0.2440 -0.1397 -0.1175 -0.2182 -0.2247 -0.1422 -0.1277 -0.1189 -0.1403 -0.3113 -0.1052 -0.9652 -0.7406 -0.2979 -0.1225 -0.1507 -0.1550 -0.0557 -1.4226 -0.2287 -0.0761 -1.5064 -0.2971 -0.2493 -0.0415 -0.1459 -0.1013 -0.9241 -0.1044 -0.1435 -0.2151 -0.1227 -0.1697
S-715	Besondere Vorsicht bei der Anwendung von ADVATE ist erforderlich Sie sollten Ihren Arzt informieren , wenn Sie kürzlich mit Faktor VIII-Produkten behandelt wurden , besonders wenn Sie Inhibitoren entwickelt haben .
T-715	Take special care with ADVATE You should tell your doctor if you have been previously treated with Factor VIII products , especially if you developed inhibitors , since there might be a higher risk that it happens again .
H-715	-0.3828248679637909	Take special care with ADVATE You should tell your doctor if you have recently been treated with factor VIII products , especially if you have developed inhibitors .
D-715	-0.3828248679637909	Take special care with ADVATE You should tell your doctor if you have recently been treated with factor VIII products , especially if you have developed inhibitors .
P-715	-0.2951 -0.0826 -0.0645 -0.1240 -0.2064 -0.1769 -0.0576 -0.1329 -0.8616 -0.3129 -0.4659 -0.1678 -0.1987 -0.0880 -0.1190 -0.5031 -2.3302 -0.1318 -0.0282 -0.1285 -0.9902 -2.0316 -0.7085 -0.5216 -0.2905 -0.3587 -0.1137 -0.1179 -0.3474 -1.0602 -0.1767 -0.0637 -0.0628 -0.1353 -0.1555 -0.1716
S-808	Bei Anwendung von leicht flüchtigen halogenierten Anästhetika während der Therapie mit indirekten Sympathomimetika kann es perioperativ zu einer akuten Hypertonie kommen .
T-808	3 Perioperative acute hypertension can occur if volatile halogenated anaesthetics are used during treatment with indirect sympathomimetic agents .
H-808	-0.4045940041542053	Acute hypertension may occur perioperatively with the use of mildly volatile halogenated anaesthetics during therapy with indirect sympathomimetics .
D-808	-0.4045940041542053	Acute hypertension may occur perioperatively with the use of mildly volatile halogenated anaesthetics during therapy with indirect sympathomimetics .
P-808	-0.3795 -0.1411 -0.0367 -0.0190 -0.3031 -0.1384 -0.8934 -1.9232 -0.5394 -0.3163 -0.5986 -0.8361 -0.1449 -2.7634 -0.1931 -0.1149 -2.6394 -0.1125 -0.0524 -0.1659 -0.1112 -0.0802 -0.0625 -0.4836 -0.2389 -0.0534 -0.1661 -0.4544 -0.1286 -0.1752 -0.1435 -0.0116 -0.0516 -0.0781 -0.1159 -0.1248 -0.1792
S-476	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-476	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-476	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
D-476	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
P-476	-0.5271 -0.0391 -0.0957 -0.6886 -0.1908 -0.0629 -0.1569 -0.0966 -1.8533 -0.2598 -0.1817 -0.9128 -0.7724 -0.8423 -1.2577 -0.7624 -0.1842 -0.0523 -0.2792 -0.4062 -0.0973 -0.1657 -1.9099 -0.1502 -0.1313 -1.0480 -0.1818 -2.3539 -0.1256 -0.6399 -0.0773 -0.1088 -0.0913 -0.1731 -0.1719
S-616	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-616	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-616	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
D-616	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
P-616	-0.5271 -0.0391 -0.0957 -0.6886 -0.1908 -0.0629 -0.1569 -0.0966 -1.8533 -0.2598 -0.1817 -0.9128 -0.7724 -0.8423 -1.2577 -0.7624 -0.1842 -0.0523 -0.2792 -0.4062 -0.0973 -0.1657 -1.9099 -0.1502 -0.1313 -1.0480 -0.1818 -2.3539 -0.1256 -0.6399 -0.0773 -0.1088 -0.0913 -0.1731 -0.1719
S-546	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-546	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-546	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
D-546	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
P-546	-0.5271 -0.0391 -0.0957 -0.6886 -0.1908 -0.0629 -0.1569 -0.0966 -1.8533 -0.2598 -0.1817 -0.9128 -0.7724 -0.8423 -1.2577 -0.7624 -0.1842 -0.0523 -0.2792 -0.4062 -0.0973 -0.1657 -1.9099 -0.1502 -0.1313 -1.0480 -0.1818 -2.3539 -0.1256 -0.6399 -0.0773 -0.1088 -0.0913 -0.1731 -0.1719
S-133	Die Bioverfügbarkeit von 2.800 I.E. Vitamin D3 in ADROVANCE ist der von allein eingenommenem 2.800 I.E. Vitamin D3 vergleichbar .
T-133	The bioavailability of the 2800 IU vitamin D3 in ADROVANCE is similar to 2800 IU vitamin D3 administered alone .
H-133	-0.24663135409355164	The bioavailability of 2,800 IU of vitamin D3 in ADROVANCE is comparable to that of 2,800 IU of vitamin D3 taken on its own .
D-133	-0.24663135409355164	The bioavailability of 2,800 IU of vitamin D3 in ADROVANCE is comparable to that of 2,800 IU of vitamin D3 taken on its own .
P-133	-0.2163 -0.0567 -0.0664 -0.1499 -0.3585 -0.1108 -0.1074 -0.0643 -0.1445 -0.0788 -0.0557 -0.0934 -0.1902 -0.1192 -0.0793 -0.0560 -0.1565 -0.0788 -0.0590 -0.0744 -0.8298 -0.1292 -0.1691 -0.2694 -0.1325 -2.9988 -0.0949 -0.1522 -0.0738 -0.1416 -0.0786 -0.0616 -0.1024 -0.2164 -1.4306 -0.1943 -0.0541 -0.1023 -0.1432 -0.1744
S-406	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-406	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-406	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
D-406	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
P-406	-0.5271 -0.0391 -0.0957 -0.6886 -0.1908 -0.0629 -0.1569 -0.0966 -1.8533 -0.2598 -0.1817 -0.9128 -0.7724 -0.8423 -1.2577 -0.7624 -0.1842 -0.0523 -0.2792 -0.4062 -0.0973 -0.1657 -1.9099 -0.1502 -0.1313 -1.0480 -0.1818 -2.3539 -0.1256 -0.6399 -0.0773 -0.1088 -0.0913 -0.1731 -0.1719
S-336	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-336	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-336	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
D-336	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
P-336	-0.5271 -0.0391 -0.0957 -0.6886 -0.1908 -0.0629 -0.1569 -0.0966 -1.8533 -0.2598 -0.1817 -0.9128 -0.7724 -0.8423 -1.2577 -0.7624 -0.1842 -0.0523 -0.2792 -0.4062 -0.0973 -0.1657 -1.9099 -0.1502 -0.1313 -1.0480 -0.1818 -2.3539 -0.1256 -0.6399 -0.0773 -0.1088 -0.0913 -0.1731 -0.1719
S-181	Alendronat , das an trächtige Ratten gegeben wurde , verursachte Dystokie , die mit einer Hypocalcämie in Zusammenhang stand ( siehe Abschnitt 5.3 ) .
T-181	Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia ( see section 5.3 ) .
H-181	-0.2895210087299347	Alendronate administered to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
D-181	-0.2895210087299347	Alendronate administered to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
P-181	-0.1517 -0.1372 -0.1015 -0.0685 -1.6144 -0.0826 -0.1618 -0.1000 -0.0567 -0.8611 -1.7272 -0.1091 -0.6365 -0.6161 -0.1267 -0.0609 -0.0552 -0.0415 -0.0643 -0.1525 -0.1221 -0.0427 -0.1103 -0.2364 -0.1928 -0.1514 -0.1477 -0.1777
S-686	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-686	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-686	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
D-686	-0.487085223197937	Ensure that ADVATE is completely solved , otherwise the total reconstituted solution will not be pressed through the filter in BAXJECT II .
P-686	-0.5271 -0.0391 -0.0957 -0.6886 -0.1908 -0.0629 -0.1569 -0.0966 -1.8533 -0.2598 -0.1817 -0.9128 -0.7724 -0.8423 -1.2577 -0.7624 -0.1842 -0.0523 -0.2792 -0.4062 -0.0973 -0.1657 -1.9099 -0.1502 -0.1313 -1.0480 -0.1818 -2.3539 -0.1256 -0.6399 -0.0773 -0.1088 -0.0913 -0.1731 -0.1719
S-82	Alendronat , das an trächtige Ratten gegeben wurde , verursachte Dystokie , die mit einer Hypocalcämie in Zusammenhang stand ( siehe Abschnitt 5.3 ) .
T-82	Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia ( see section 5.3 ) .
H-82	-0.2895210087299347	Alendronate administered to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
D-82	-0.2895210087299347	Alendronate administered to pregnant rats caused dystocia associated with hypocalcaemia ( see section 5.3 ) .
P-82	-0.1517 -0.1372 -0.1015 -0.0685 -1.6144 -0.0826 -0.1618 -0.1000 -0.0567 -0.8611 -1.7272 -0.1091 -0.6365 -0.6161 -0.1267 -0.0609 -0.0552 -0.0415 -0.0643 -0.1525 -0.1221 -0.0427 -0.1103 -0.2364 -0.1928 -0.1514 -0.1477 -0.1777
S-236	Die Bioverfügbarkeit von 5.600 I.E. Vitamin D3 in ADROVANCE ist der von allein eingenommenem 5.600 I.E. Vitamin D3 vergleichbar .
T-236	The bioavailability of the 5600 IU vitamin D3 in ADROVANCE is similar to 5600 IU vitamin D3 administered alone .
H-236	-0.2664209008216858	The bioavailability of 5,600 IU of vitamin D3 in ADROVANCE is comparable to that of 5,600 IU of vitamin D3 taken on its own .
D-236	-0.2664209008216858	The bioavailability of 5,600 IU of vitamin D3 in ADROVANCE is comparable to that of 5,600 IU of vitamin D3 taken on its own .
P-236	-0.2291 -0.0617 -0.0645 -0.1507 -0.1278 -0.1004 -0.1071 -0.0649 -0.1454 -0.0818 -0.0564 -0.0925 -0.1950 -0.1170 -0.0782 -0.0551 -0.1567 -0.0800 -0.0593 -0.0746 -0.8677 -0.1287 -0.1732 -0.1725 -0.1297 -4.0984 -0.1128 -0.1460 -0.0749 -0.1423 -0.0834 -0.0625 -0.1006 -0.2259 -1.3776 -0.1894 -0.0562 -0.1004 -0.1406 -0.1759
S-139	Charakteristika bei Patienten Präklinische Studien haben gezeigt , dass der Anteil von Alendronat , der nicht im Knochen abgelagert wird , schnell über den Urin ausgeschieden wird .
T-139	Characteristics in patients Preclinical studies show that alendronate that is not deposited in bone is rapidly excreted in the urine .
H-139	-0.35444176197052	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in bone is rapidly excreted via the urine .
D-139	-0.35444176197052	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in bone is rapidly excreted via the urine .
P-139	-1.1331 -0.2786 -0.0758 -0.3227 -0.1386 -0.1892 -0.3936 -0.4783 -1.8112 -0.0029 -0.0771 -0.6522 -0.1093 -0.0304 -0.1254 -0.2587 -0.4942 -0.1403 -0.2862 -0.1296 -0.1072 -0.0635 -0.2737 -2.2004 -0.1222 -0.1873 -0.5203 -0.1289 -0.5224 -0.0898 -0.0251 -0.1012 -1.3541 -0.1103 -0.0575 -0.1401 -0.1567 -0.1808
S-242	Charakteristika bei Patienten Präklinische Studien haben gezeigt , dass der Anteil von Alendronat , der nicht im Knochen abgelagert wird , schnell über den Urin ausgeschieden wird .
T-242	Characteristics in patients Preclinical studies show that alendronate that is not deposited in bone is rapidly excreted in the urine .
H-242	-0.35444176197052	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in bone is rapidly excreted via the urine .
D-242	-0.35444176197052	Characteristics in patients Preclinical studies have shown that the proportion of alendronate not deposited in bone is rapidly excreted via the urine .
P-242	-1.1331 -0.2786 -0.0758 -0.3227 -0.1386 -0.1892 -0.3936 -0.4783 -1.8112 -0.0029 -0.0771 -0.6522 -0.1093 -0.0304 -0.1254 -0.2587 -0.4942 -0.1403 -0.2862 -0.1296 -0.1072 -0.0635 -0.2737 -2.2004 -0.1222 -0.1873 -0.5203 -0.1289 -0.5224 -0.0898 -0.0251 -0.1012 -1.3541 -0.1103 -0.0575 -0.1401 -0.1567 -0.1808
S-44	Am 4. Januar2007 erteilte die Europäische Kommission dem Unternehmen Merck Sharp <unk> Dohme Ltd. eine Genehmigung für das Inverkehrbringen von ADROVANCE in der gesamten Europäischen Union .
T-44	The European Commission granted a marketing authorisation valid throughout the European Union for ADROVANCE to Merck Sharp <<unk>> Dohme Ltd. on 4 January 2007.
H-44	-0.24879756569862366	The European Commission granted a marketing authorisation valid throughout the European Union , for ADROVANCE to Merck Sharp <unk> Dohme Ltd. on 4 January 2007 .
D-44	-0.24879756569862366	The European Commission granted a marketing authorisation valid throughout the European Union , for ADROVANCE to Merck Sharp <unk> Dohme Ltd. on 4 January 2007 .
P-44	-0.1102 -0.0646 -0.1619 -0.0444 -0.1331 -0.1394 -0.0409 -0.0939 -0.0003 -0.0622 -0.0785 -0.1200 -0.0604 -0.1007 -0.6172 -0.1643 -0.1876 -0.0692 -0.1744 -0.1227 -0.0978 -0.1243 -1.0692 -0.1156 -0.6103 -0.0822 -0.4309 -1.4257 -0.2624 -0.2461 -0.1994 -0.0559 -0.0631 -0.5351 -0.3532 -0.9167 -0.1438 -0.1766
S-243	Es wurden keine Hinweise auf eine Sättigung der Aufnahmefähigkeit des Knochens nach Langzeitdosierung von kumulativen intravenösen Dosen bis zu 35 mg<unk> kg bei Tieren gefunden .
T-243	No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/ kg in animals .
H-243	-0.29241424798965454	No evidence exists that indicates saturation of the ability to absorb bone at long-term doses of cumulative intravenous doses up to 35 mg/ kg in animals .
D-243	-0.29241424798965454	No evidence exists that indicates saturation of the ability to absorb bone at long-term doses of cumulative intravenous doses up to 35 mg/ kg in animals .
P-243	-0.0394 -0.0217 -0.2466 -0.0899 -1.8859 -0.1960 -0.7766 -0.1196 -0.1420 -0.1481 -0.4926 -1.8203 -0.1653 -1.0582 -0.1108 -0.1029 -0.6058 -1.0180 -0.1355 -0.1851 -0.3270 -0.2658 -0.1303 -0.0761 -0.0754 -0.1096 -0.1554 -0.0418 -0.0531 -0.0988 -0.0831 -0.1335 -0.1813 -0.1525 -0.1069 -0.1202 -0.1068 -0.1204 -0.0732 -0.1039 -0.4105 -0.1069 -0.1811
S-263	In der Hauptstudie wurde die Wirksamkeit von Advate bei der Vorbeugung von Blutungen in 86 % von 510 neuen Blutungsepisoden mit ausgezeichnet bzw. mit gut bewertet .
T-263	In the main study , the effectiveness of Advate in the prevention of bleeding was rated as excellent or good in 86 % of the 510 new bleeding episodes .
H-263	-0.5325875878334045	In the main study , in preventing haemorrhage , the effectiveness of Advate in preventing haemorrhage was rated excellent or good , respectively , in 86 % of 510 new haemorrhage episodes .
D-263	-0.5325875878334045	In the main study , in preventing haemorrhage , the effectiveness of Advate in preventing haemorrhage was rated excellent or good , respectively , in 86 % of 510 new haemorrhage episodes .
P-263	-0.2343 -0.1338 -0.1125 -0.1528 -0.1996 -4.0289 -0.6805 -1.3971 -0.1028 -0.0047 -0.2563 -0.1751 -0.2719 -0.1286 -0.1052 -0.1450 -0.8676 -0.0786 -0.0974 -0.0258 -1.3088 -0.1588 -0.0050 -0.1973 -0.1333 -3.0045 -1.9659 -0.9070 -1.9037 -1.6733 -0.4580 -0.1434 -0.1205 -0.1517 -0.1134 -0.1456 -0.6051 -0.1606 -0.1357 -1.0178 -0.3297 -0.0139 -0.1891 -0.0750 -0.2106 -0.1727
S-258	Patienten mit Hämophilie A leiden an einem Faktor VIII-Mangel , was Blutgerinnungsprobleme wie Blutungen in den Gelenken , Muskeln oder inneren Organen verursacht .
T-258	Patients with haemophilia A lack factor VIII , and this causes blood coagulation problems , such as bleeding in the joints , muscles or internal organs .
H-258	-0.3148020803928375	Patients with haemophilia A suffer from factor VIII deficiency , which causes blood clotting problems such as haemorrhage in the joints , muscles or internal organs .
D-258	-0.3148020803928375	Patients with haemophilia A suffer from factor VIII deficiency , which causes blood clotting problems such as haemorrhage in the joints , muscles or internal organs .
P-258	-0.1115 -0.1007 -0.1261 -0.1500 -0.1090 -0.3094 -1.5083 -0.1250 -0.4903 -0.1319 -1.7689 -1.0652 -0.5243 -0.2198 -0.0928 -0.0905 -0.1240 -0.1661 -0.1594 -0.9118 -0.0385 -0.0470 -0.1771 -0.3075 -0.1356 -0.1545 -1.6651 -0.0434 -0.0057 -0.6432 -0.2095 -0.1257 -0.1569 -0.0480 -0.1453 -0.1867 -0.2344 -0.1745 -0.0309 -0.0892 -0.1419 -0.1758
S-33	Osteoporose tritt vor allem bei postmenopausalen Frauen ( nach der 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-33	Osteoporose tritt vor allem bei postmenopausalen Frauen ( nach der 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel. 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-33	-0.18105529248714447	Osteoporosis occurs mainly in post-menopausal women ( after 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-33	-0.18105529248714447	Osteoporosis occurs mainly in post-menopausal women ( after 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-33	-0.1314 -0.1423 -0.1160 -0.1065 -0.1032 -0.1103 -0.8041 -0.1015 -1.2553 -0.1271 -0.0106 -0.3477 -0.0409 -0.1621 -0.0248 -0.0986 -0.0396 -0.1533 -0.2819 -0.6013 -0.0500 -0.0716 -0.0909 -0.0703 -0.0532 -0.1357 -0.0795 -0.1250 -0.1418 -0.1348 -0.1648 -0.1467 -0.0911 -0.0965 -0.1526 -0.1878 -0.1468 -0.1045 -0.1540 -0.0788 -0.4214 -0.1387 -0.1903
S-31	Osteoporose ist eine Krankheit , bei der die Knochen allmählich dünn und brüchig werden ; es kommt zu einer erhöhten Anfälligkeit für Frakturen ( Brüche ) .
T-31	Osteoporose ist eine Krankheit , bei der die Knochen allmählich dünn und brüchig werden ; es kommt zu einer erhöhten Anfälligkeit für Frakturen ( Brüche ) . It happens when not enough new bone grows to replace the bone that is naturally broken down .
H-31	-0.26262518763542175	Osteoporosis is a disease in which bones gradually become thin and fragile , becoming more susceptible to fracture ( fractures ) .
D-31	-0.26262518763542175	Osteoporosis is a disease in which bones gradually become thin and fragile , becoming more susceptible to fracture ( fractures ) .
P-31	-0.0855 -0.1509 -0.1286 -0.1133 -0.1208 -0.0973 -0.1527 -0.1267 -0.2167 -0.1742 -0.1157 -0.5152 -0.5894 -0.3485 -0.3635 -0.1384 -0.3804 -0.0246 -0.1451 -1.6178 -0.2258 -0.7689 -0.1522 -0.0813 -0.0944 -0.0903 -0.1627 -0.7218 -0.0617 -0.2440 -0.4452 -0.0966 -0.1402 -0.1245 -0.1769
S-557	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-557	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-557	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
D-557	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
P-557	-0.6674 -0.3409 -0.4056 -0.6915 -0.1490 -0.1469 -0.1053 -0.1521 -0.4749 -0.1027 -0.1263 -0.1389 -0.4674 -0.1788 -1.4284 -0.1416 -0.1359 -0.1783 -0.4898 -0.0637 -0.1457 -0.2594 -0.0969 -0.1143 -0.1720 -0.4156 -0.5549 -1.1833 -0.8976 -0.2912 -0.1127 -1.1814 -0.1872 -0.1397 -0.1760
S-627	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-627	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-627	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
D-627	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
P-627	-0.6674 -0.3409 -0.4056 -0.6915 -0.1490 -0.1469 -0.1053 -0.1521 -0.4749 -0.1027 -0.1263 -0.1389 -0.4674 -0.1788 -1.4284 -0.1416 -0.1359 -0.1783 -0.4898 -0.0637 -0.1457 -0.2594 -0.0969 -0.1143 -0.1720 -0.4156 -0.5549 -1.1833 -0.8976 -0.2912 -0.1127 -1.1814 -0.1872 -0.1397 -0.1760
S-723	Vorbeugung von Blutungen Die übliche Dosierung mit Octocog alfa beträgt 20-40 I.E.pro kg Köprergewicht , verabreicht alle 2-3 Tage .
T-723	Prevention of bleeding The usual dose of octocog alfa is 20 to 40 IU per kg body weight , administered every 2 to 3 days.
H-723	-0.3985040783882141	Prevention of haemorrhage The usual dose of octocog alfa is 20 to 40 IUper kg body weight , given every 2 to 3 days .
D-723	-0.3985040783882141	Prevention of haemorrhage The usual dose of octocog alfa is 20 to 40 IUper kg body weight , given every 2 to 3 days .
P-723	-2.5325 -0.4870 -0.1512 -1.3559 -0.0566 -0.0058 -0.2890 -0.4689 -0.1160 -0.3426 -0.1444 -0.6748 -0.1288 -0.1210 -0.1223 -0.0707 -0.0940 -0.0636 -0.1462 -1.0271 -0.1648 -0.1461 -0.0854 -0.4244 -0.1423 -1.7151 -0.0380 -1.2492 -0.2989 -0.2393 -0.2222 -0.4471 -0.1408 -0.3079 -0.1509 -0.1756
S-684	65 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-684	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-684	-0.43897297978401184	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
D-684	-0.43897297978401184	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
P-684	-0.0337 -0.1089 -0.0438 -0.5356 -2.2515 -0.1433 -0.8192 -0.0831 -0.1025 -0.1153 -2.1468 -0.1860 -0.2465 -0.1345 -0.0757 -0.0864 -0.1290 -0.3946 -0.1762 -0.2372 -1.0450 -0.3177 -0.5698 -0.1713 -2.2192 -0.6785 -0.2153 -0.1383 -0.5806 -0.0231 -0.0471 -0.4491 -0.2399 -0.1802
S-334	10 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-334	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-334	-0.4456136226654053	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
D-334	-0.4456136226654053	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
P-334	-0.0308 -0.1080 -0.0418 -0.5332 -2.3105 -0.1412 -0.8302 -0.0836 -0.1023 -0.1219 -2.2544 -0.1985 -0.2568 -0.1382 -0.0735 -0.0826 -0.1321 -0.3956 -0.1775 -0.2280 -0.9923 -0.3292 -0.5530 -0.1703 -2.3007 -0.6696 -0.2205 -0.1386 -0.5747 -0.0220 -0.0462 -0.4490 -0.2682 -0.1760
S-404	21 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-404	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-404	-0.4476601183414459	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or there are signs of tampering .
D-404	-0.4476601183414459	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or there are signs of tampering .
P-404	-0.0341 -0.1096 -0.0434 -0.5584 -2.2976 -0.1441 -0.8281 -0.0851 -0.1034 -0.1160 -2.2783 -0.2039 -0.2517 -0.1369 -0.0743 -0.0835 -0.1281 -0.3930 -0.1792 -0.2304 -1.0027 -0.3113 -0.5771 -0.1737 -1.2234 -0.8243 -0.1844 -0.1207 -0.4611 -0.0136 -0.0456 -0.4231 -1.4017 -0.1784
S-474	32 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-474	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-474	-0.4436410367488861	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
D-474	-0.4436410367488861	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
P-474	-0.0298 -0.1088 -0.0433 -0.5696 -2.2894 -0.1437 -0.8292 -0.0837 -0.1020 -0.1221 -2.2023 -0.2067 -0.2602 -0.1404 -0.0732 -0.0838 -0.1298 -0.3937 -0.1778 -0.2299 -0.9850 -0.3297 -0.5547 -0.1708 -2.2472 -0.6821 -0.2283 -0.1384 -0.5687 -0.0223 -0.0461 -0.4528 -0.2593 -0.1789
S-794	Die Tablette kann mit einem Glas Wasser eingenommen werden , ist jedoch im Ganzen zu schlucken ( d. h. ohne sie zu zerbeißen , zu zerbrechen oder zu kauen ) .
T-794	The tablet may be taken with a full glass of water but must be swallowed entirely ( without crushing , breaking or chewing it ) .
H-794	-0.3346518278121948	Taking the tablet with a glass of water , swallowing the entire tablet ( i. e. without breaking , breaking or chewing it ) .
D-794	-0.3346518278121948	Taking the tablet with a glass of water , swallowing the entire tablet ( i. e. without breaking , breaking or chewing it ) .
P-794	-0.8250 -0.1240 -0.1065 -0.0596 -0.1104 -0.1753 -0.0447 -0.1460 -0.0940 -0.2383 -0.7289 -0.8278 -0.7402 -0.8743 -0.0767 -0.0564 -0.1636 -0.7061 -0.1313 -0.1565 -0.1553 -0.2229 -0.9120 -0.3104 -0.9064 -0.1471 -0.4420 -0.0538 -0.5759 -0.1298 -0.2968 -0.1708
S-614	54 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-614	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-614	-0.4435945153236389	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
D-614	-0.4435945153236389	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
P-614	-0.0356 -0.1081 -0.0422 -0.5657 -2.2899 -0.1434 -0.8424 -0.0841 -0.1027 -0.1234 -2.1734 -0.1974 -0.2542 -0.1370 -0.0743 -0.0842 -0.1302 -0.3847 -0.1788 -0.2399 -0.9815 -0.3244 -0.5709 -0.1741 -2.2566 -0.6858 -0.2244 -0.1385 -0.5784 -0.0230 -0.0469 -0.4520 -0.2564 -0.1777
S-544	43 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-544	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-544	-0.4430588185787201	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
D-544	-0.4430588185787201	Do not use the BAXJECT II unit if its sterile barrier is broken , its package is damaged or it shows signs of tampering .
P-544	-0.0326 -0.1086 -0.0420 -0.5412 -2.3042 -0.1464 -0.8455 -0.0843 -0.1029 -0.1181 -2.1377 -0.2011 -0.2592 -0.1377 -0.0729 -0.0827 -0.1301 -0.3942 -0.1775 -0.2424 -0.9838 -0.3213 -0.5640 -0.1720 -2.2880 -0.6765 -0.2207 -0.1391 -0.5731 -0.0233 -0.0460 -0.4528 -0.2648 -0.1773
S-744	Benutzen Sie zum Auflösen ausschließlich das sterilisierte Wasser für Injektionszwecke und das Rekonstitutions-Gerät , das jeder Packung ADVATE beigepackt ist .
T-744	Use only the sterilised water for injections and the reconstitution device for preparation of the solution that are provided with each package of ADVATE .
H-744	-0.4770236611366272	For dispersion , use only the sterilised water for injections and the reconstitution unit , which is packed with each pack of ADVATE .
D-744	-0.4770236611366272	For dispersion , use only the sterilised water for injections and the reconstitution unit , which is packed with each pack of ADVATE .
P-744	-0.7050 -0.2626 -0.1352 -0.8051 -0.2012 -0.5527 -0.1704 -0.1487 -0.8743 -0.0856 -0.3775 -0.1166 -0.1248 -0.1210 -0.5745 -0.1540 -0.1077 -0.9170 -0.5073 -2.6856 -2.1303 -0.6544 -0.1823 -0.6688 -0.9018 -0.6438 -0.3102 -0.1516 -0.2493 -0.1983 -0.0536 -0.1478 -0.1291 -0.1709
S-224	20 eingenommen wurde . In Osteoporosestudien war Alendronat wirksam , wenn es mindestens 30 Minuten vor dem ersten Essen oder Trinken des Tages eingenommen wurde .
T-224	In osteoporosis studies , alendronate was effective when administered at least 30 minutes before the first food or beverage of the day .
H-224	-0.25292831659317017	In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first food or drink of the day .
D-224	-0.25292831659317017	In osteoporosis studies , alendronate was effective when taken at least 30 minutes before the first food or drink of the day .
P-224	-0.1369 -0.1196 -0.1762 -0.1515 -0.0918 -0.1054 -0.0899 -0.2135 -0.3055 -0.1874 -0.1451 -0.1023 -0.1212 -0.9753 -0.0522 -0.1049 -0.7339 -0.0836 -0.1063 -0.1281 -0.0978 -0.9243 -0.1494 -0.0779 -1.7167 -0.1034 -0.0274 -0.1260 -0.1376 -0.2916 -0.1393 -0.1716
S-487	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-487	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-487	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
D-487	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
P-487	-0.6674 -0.3409 -0.4056 -0.6915 -0.1490 -0.1469 -0.1053 -0.1521 -0.4749 -0.1027 -0.1263 -0.1389 -0.4674 -0.1788 -1.4284 -0.1416 -0.1359 -0.1783 -0.4898 -0.0637 -0.1457 -0.2594 -0.0969 -0.1143 -0.1720 -0.4156 -0.5549 -1.1833 -0.8976 -0.2912 -0.1127 -1.1814 -0.1872 -0.1397 -0.1760
S-338	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-338	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-338	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-338	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-338	-1.1225 -0.4419 -0.1336 -0.1251 -1.8950 -0.4653 -0.1103 -0.2749 -0.4803 -0.3761 -0.1249 -2.4027 -0.1806 -0.2446 -0.6470 -0.0886 -0.4071 -3.6686 -1.4159 -0.0293 -0.1183 -0.1929 -0.1110 -0.2458 -0.1035 -0.1197 -0.0482 -0.0938 -0.2082 -0.1808 -0.1603 -0.1571 -0.1791 -0.1528 -0.1377 -0.1756
S-278	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-278	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-278	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
D-278	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
P-278	-0.6674 -0.3409 -0.4056 -0.6915 -0.1490 -0.1469 -0.1053 -0.1521 -0.4749 -0.1027 -0.1263 -0.1389 -0.4674 -0.1788 -1.4284 -0.1416 -0.1359 -0.1783 -0.4898 -0.0637 -0.1457 -0.2594 -0.0969 -0.1143 -0.1720 -0.4156 -0.5549 -1.1833 -0.8976 -0.2912 -0.1127 -1.1814 -0.1872 -0.1397 -0.1760
S-548	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-548	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-548	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-548	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-548	-1.1225 -0.4419 -0.1336 -0.1251 -1.8950 -0.4653 -0.1103 -0.2749 -0.4803 -0.3761 -0.1249 -2.4027 -0.1806 -0.2446 -0.6470 -0.0886 -0.4071 -3.6686 -1.4159 -0.0293 -0.1183 -0.1929 -0.1110 -0.2458 -0.1035 -0.1197 -0.0482 -0.0938 -0.2082 -0.1808 -0.1603 -0.1571 -0.1791 -0.1528 -0.1377 -0.1756
S-618	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-618	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-618	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-618	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-618	-1.1225 -0.4419 -0.1336 -0.1251 -1.8950 -0.4653 -0.1103 -0.2749 -0.4803 -0.3761 -0.1249 -2.4027 -0.1806 -0.2446 -0.6470 -0.0886 -0.4071 -3.6686 -1.4159 -0.0293 -0.1183 -0.1929 -0.1110 -0.2458 -0.1035 -0.1197 -0.0482 -0.0938 -0.2082 -0.1808 -0.1603 -0.1571 -0.1791 -0.1528 -0.1377 -0.1756
S-688	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-688	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-688	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-688	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-688	-1.1225 -0.4419 -0.1336 -0.1251 -1.8950 -0.4653 -0.1103 -0.2749 -0.4803 -0.3761 -0.1249 -2.4027 -0.1806 -0.2446 -0.6470 -0.0886 -0.4071 -3.6686 -1.4159 -0.0293 -0.1183 -0.1929 -0.1110 -0.2458 -0.1035 -0.1197 -0.0482 -0.0938 -0.2082 -0.1808 -0.1603 -0.1571 -0.1791 -0.1528 -0.1377 -0.1756
S-120	Die Bioverfügbarkeit nahm entsprechend auf etwa 0,46 % und 0,39 % ab , wenn Alendronat eine oder eine halbe Stunde vor einem standardisierten Frühstück eingenommen wurde .
T-120	Bioavailability was decreased similarly to an estimated 0.46 % and 0.39 % when alendronate was administered one hour or half an hour before a standardised breakfast .
H-120	-0.3561021685600281	Bioavailability decreased corresponding to approximately 0.46 % and 0.39 % when taking alendronate one and a half hours prior to a standardized breakfast .
D-120	-0.3561021685600281	Bioavailability decreased corresponding to approximately 0.46 % and 0.39 % when taking alendronate one and a half hours prior to a standardized breakfast .
P-120	-0.7510 -0.0592 -0.2480 -0.0887 -0.7368 -0.2488 -0.1526 -1.1574 -0.2190 -0.0784 -0.1420 -0.1461 -0.1900 -0.1344 -0.1332 -0.5031 -1.0623 -0.1930 -0.1332 -0.1176 -0.0570 -0.5632 -0.9132 -0.3342 -0.1914 -0.2151 -0.6761 -0.1430 -0.5154 -1.3797 -0.2677 -0.2655 -0.0789 -0.1940 -0.1744
S-408	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-408	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-408	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-408	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-408	-1.1225 -0.4419 -0.1336 -0.1251 -1.8950 -0.4653 -0.1103 -0.2749 -0.4803 -0.3761 -0.1249 -2.4027 -0.1806 -0.2446 -0.6470 -0.0886 -0.4071 -3.6686 -1.4159 -0.0293 -0.1183 -0.1929 -0.1110 -0.2458 -0.1035 -0.1197 -0.0482 -0.0938 -0.2082 -0.1808 -0.1603 -0.1571 -0.1791 -0.1528 -0.1377 -0.1756
S-347	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-347	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-347	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
D-347	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
P-347	-0.6674 -0.3409 -0.4056 -0.6915 -0.1490 -0.1469 -0.1053 -0.1521 -0.4749 -0.1027 -0.1263 -0.1389 -0.4674 -0.1788 -1.4284 -0.1416 -0.1359 -0.1783 -0.4898 -0.0637 -0.1457 -0.2594 -0.0969 -0.1143 -0.1720 -0.4156 -0.5549 -1.1833 -0.8976 -0.2912 -0.1127 -1.1814 -0.1872 -0.1397 -0.1760
S-417	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-417	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-417	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
D-417	-0.3575190603733063	Injection every 12-24 hours ( 8-24 hours in patients less than 6 years of age ) for at least 1 day until indicated by pain or healing .
P-417	-0.6674 -0.3409 -0.4056 -0.6915 -0.1490 -0.1469 -0.1053 -0.1521 -0.4749 -0.1027 -0.1263 -0.1389 -0.4674 -0.1788 -1.4284 -0.1416 -0.1359 -0.1783 -0.4898 -0.0637 -0.1457 -0.2594 -0.0969 -0.1143 -0.1720 -0.4156 -0.5549 -1.1833 -0.8976 -0.2912 -0.1127 -1.1814 -0.1872 -0.1397 -0.1760
S-478	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-478	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-478	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-478	-0.47275230288505554	A significant increase in the pulse rate can usually be reduced immediately by slowing or temporary discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-478	-1.1225 -0.4419 -0.1336 -0.1251 -1.8950 -0.4653 -0.1103 -0.2749 -0.4803 -0.3761 -0.1249 -2.4027 -0.1806 -0.2446 -0.6470 -0.0886 -0.4071 -3.6686 -1.4159 -0.0293 -0.1183 -0.1929 -0.1110 -0.2458 -0.1035 -0.1197 -0.0482 -0.0938 -0.2082 -0.1808 -0.1603 -0.1571 -0.1791 -0.1528 -0.1377 -0.1756
S-257	Die Dosierung und Häufigkeit der Anwendung richten sich danach , ob Advate zur Behandlung von Blutungen oder zur Vorbeugung von Blutungen bei chirurgischen Eingriffen angewendet wird .
T-257	The dose and frequency depend on whether Advate is used to treat haemorrhage ( bleeding ) or to prevent it during surgery .
H-257	-0.3601706624031067	Dosage and frequency of administration are determined by whether Advate is used to treat haemorrhage or to prevent haemorrhage during surgery .
D-257	-0.3601706624031067	Dosage and frequency of administration are determined by whether Advate is used to treat haemorrhage or to prevent haemorrhage during surgery .
P-257	-0.2680 -0.2082 -0.1361 -0.2832 -0.1144 -0.0798 -0.1411 -0.3082 -0.9556 -0.6786 -0.0873 -0.4855 -2.6169 -0.0693 -0.0923 -0.2232 -0.1842 -0.0412 -0.4410 -0.1022 -0.0174 -0.7354 -0.1090 -0.1314 -0.0598 -1.2952 -0.0520 -0.0048 -0.1649 -0.2136 -1.2129 -0.1954 -0.1776
S-134	Vitamin D3 wird rasch verteilt , hauptsächlich in die Leber , wo es zu 25-Hydroxyvitamin D3 , der Hauptspeicherform , metabolisiert wird .
T-134	Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3 , the major storage form .
H-134	-0.252811074256897	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised to 25-hydroxy vitamin D3 , the main storage .
D-134	-0.252811074256897	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised to 25-hydroxy vitamin D3 , the main storage .
P-134	-0.1346 -0.0509 -0.1030 -0.2289 -0.1194 -0.0451 -0.5368 -0.0870 -0.1993 -0.4463 -0.3512 -0.1112 -0.0675 -0.1484 -0.0973 -0.1152 -0.1986 -0.0899 -0.0654 -0.2164 -0.7746 -0.0780 -0.0983 -0.0501 -0.7679 -0.1751 -0.0657 -0.1035 -0.2442 -0.1612 -0.2173 -0.2118 -1.7534 -0.5590 -0.1758
S-11	In der zweiten Studie wurden zwei Dosierungen von Adenuric ( einmal täglich 80 und 120 mg ) ein Jahr lang an 762 Patienten jeweils mit Allopurinol verglichen .
T-11	The second study compared two doses of Adenuric ( 80 and 120 mg once a day ) with allopurinol over one year in 762 patients .
H-11	-0.33559903502464294	The second compared two doses of adenuric ( 80 and 120 mg once daily ) to allopurinol in 762 patients for one year .
D-11	-0.33559903502464294	The second compared two doses of adenuric ( 80 and 120 mg once daily ) to allopurinol in 762 patients for one year .
P-11	-0.2080 -0.1243 -0.3129 -0.9225 -0.2388 -0.1194 -0.1597 -0.2160 -0.0777 -0.1423 -0.1189 -0.7136 -0.1582 -0.1209 -0.0971 -0.1169 -0.5558 -0.3853 -0.3575 -0.3219 -1.4314 -0.1626 -0.1767 -0.2808 -0.2477 -0.0759 -0.2781 -1.5827 -0.2317 -0.1335 -0.5042 -0.1662
S-126	Die Plasmakonzentrationen nach Aufnahme oraler therapeutischer Dosen von Alendronat sind zu niedrig für einen analytischen Nachweis ( <unk> 5 ng<unk> ml ) .
T-126	Concentrations of alendronate in plasma following therapeutic oral doses are too low for analytical detection ( <<unk>> 5 ng/ ml ) .
H-126	-0.26403573155403137	Plasma concentrations following initiation of oral therapeutic doses of alendronate are too low for analytic detection ( <unk> 5 ng/ ml ) .
D-126	-0.26403573155403137	Plasma concentrations following initiation of oral therapeutic doses of alendronate are too low for analytic detection ( <unk> 5 ng/ ml ) .
P-126	-0.1839 -0.1021 -0.0622 -0.0171 -0.0423 -0.0648 -0.3681 -1.8769 -0.0888 -0.1383 -0.1279 -0.0684 -0.1277 -0.0608 -0.1012 -0.1498 -0.1581 -0.1426 -0.1017 -0.0688 -0.1365 -0.1487 -0.1171 -0.5382 -0.9744 -0.8054 -1.7632 -0.1702 -0.1339 -0.0092 -0.1447 -0.1475 -0.1670 -0.1395 -0.0669 -0.1509 -0.1883 -0.1803
S-747	Advexin ist eine Injektionssuspension , die Contusugene Ladenovec , ein genetisch verändertes Virus enthält , welches das p53-Gen trägt .
T-747	Advexin is a suspension for injection that contains contusugene ladenovec , a genetically modified virus which carries the p53 gene .
H-747	-0.5345860123634338	Advexin is a suspension for injection containing Contusugene Ladovec , a genetically modified virus carrying the p53 gene .
D-747	-0.5345860123634338	Advexin is a suspension for injection containing Contusugene Ladovec , a genetically modified virus carrying the p53 gene .
P-747	-1.8433 -0.1141 -0.1579 -0.1128 -0.6587 -0.0313 -0.1199 -0.1214 -0.1303 -0.0217 -1.9322 -0.4160 -0.1038 -0.1881 -2.0343 -0.1923 -0.1497 -0.1267 -0.1560 -0.1279 -0.6296 -3.6518 -0.6839 -0.1014 -0.9614 -1.5909 -0.1200 -0.2119 -0.0611 -0.0397 -0.1404 -0.1762
S-229	Die Plasmakonzentrationen nach Aufnahme oraler therapeutischer Dosen von Alendronat sind zu niedrig für einen analytischen Nachweis ( <unk> 5 ng<unk> ml ) .
T-229	Concentrations of alendronate in plasma following therapeutic oral doses are too low for analytical detection ( <<unk>> 5 ng/ ml ) .
H-229	-0.26403573155403137	Plasma concentrations following initiation of oral therapeutic doses of alendronate are too low for analytic detection ( <unk> 5 ng/ ml ) .
D-229	-0.26403573155403137	Plasma concentrations following initiation of oral therapeutic doses of alendronate are too low for analytic detection ( <unk> 5 ng/ ml ) .
P-229	-0.1839 -0.1021 -0.0622 -0.0171 -0.0423 -0.0648 -0.3681 -1.8769 -0.0888 -0.1383 -0.1279 -0.0684 -0.1277 -0.0608 -0.1012 -0.1498 -0.1581 -0.1426 -0.1017 -0.0688 -0.1365 -0.1487 -0.1171 -0.5382 -0.9744 -0.8054 -1.7632 -0.1702 -0.1339 -0.0092 -0.1447 -0.1475 -0.1670 -0.1395 -0.0669 -0.1509 -0.1883 -0.1803
S-237	Vitamin D3 wird rasch verteilt , hauptsächlich in die Leber , wo es zu 25-Hydroxyvitamin D3 , der Hauptspeicherform , metabolisiert wird .
T-237	Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3 , the major storage form .
H-237	-0.252811074256897	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised to 25-hydroxy vitamin D3 , the main storage .
D-237	-0.252811074256897	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised to 25-hydroxy vitamin D3 , the main storage .
P-237	-0.1346 -0.0509 -0.1030 -0.2289 -0.1194 -0.0451 -0.5368 -0.0870 -0.1993 -0.4463 -0.3512 -0.1112 -0.0675 -0.1484 -0.0973 -0.1152 -0.1986 -0.0899 -0.0654 -0.2164 -0.7746 -0.0780 -0.0983 -0.0501 -0.7679 -0.1751 -0.0657 -0.1035 -0.2442 -0.1612 -0.2173 -0.2118 -1.7534 -0.5590 -0.1758
S-23	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) , oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-23	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-23	-0.10799112170934677	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
D-23	-0.10799112170934677	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
P-23	-0.0739 -0.1478 -0.0685 -0.1027 -0.1098 -0.0897 -0.1230 -0.1410 -0.0746 -0.0968 -0.0720 -0.0503 -0.1509 -0.0639 -0.1273 -0.0406 -0.1279 -0.0847 -0.0241 -0.1067 -0.1510 -0.0554 -0.1737 -0.1561 -0.1249 -0.1093 -0.0544 -0.1453 -0.1543 -0.1061 -0.1588 -0.0629 -0.1302 -0.1165 -0.0811 -0.1720 -0.1672
S-770	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) , oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-770	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-770	-0.10799112170934677	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
D-770	-0.10799112170934677	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
P-770	-0.0739 -0.1478 -0.0685 -0.1027 -0.1098 -0.0897 -0.1230 -0.1410 -0.0746 -0.0968 -0.0720 -0.0503 -0.1509 -0.0639 -0.1273 -0.0406 -0.1279 -0.0847 -0.0241 -0.1067 -0.1510 -0.0554 -0.1737 -0.1561 -0.1249 -0.1093 -0.0544 -0.1453 -0.1543 -0.1061 -0.1588 -0.0629 -0.1302 -0.1165 -0.0811 -0.1720 -0.1672
S-749	Normalerweise sind jedoch die Brust , das Gehirn , die Knochen oder die Weichteile ( Gewebe , das andere Strukturen im Körper verbindet , umgibt und stützt ) davon betroffen .
T-749	Li-Fraumeni cancer can occur in many areas of the body but usually affects the breast , brain , bone or soft tissue ( tissue that connects , surrounds and supports other structures in the body ) .
H-749	-0.49913260340690613	However , it usually affects the chest , the brain , the bones or the soft tissues ( tissue that surrounds and supports other structures in the body ) .
D-749	-0.49913260340690613	However , it usually affects the chest , the brain , the bones or the soft tissues ( tissue that surrounds and supports other structures in the body ) .
P-749	-0.6384 -0.1493 -0.6848 -0.2809 -0.2700 -0.0696 -0.5120 -0.1533 -1.5003 -0.0961 -0.1336 -0.1035 -0.7711 -0.1131 -0.1835 -1.5446 -0.7439 -0.0490 -0.1327 -0.1855 -0.3674 -0.1936 -1.3115 -1.8986 -0.1183 -1.1538 -0.1245 -2.6461 -0.1455 -0.1221 -0.0904 -0.1597 -0.1510 -0.1726
S-499	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-499	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-499	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-499	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-499	-0.2162 -0.1913 -0.1164 -0.4705 -0.2809 -0.2001 -0.0948 -0.6270 -1.8441 -0.0427 -0.0758 -0.1459 -2.0594 -1.7016 -0.8119 -0.3006 -0.0743 -0.2743 -0.2607 -0.1107 -0.1740 -0.3428 -0.1306 -0.0862 -1.2304 -0.6011 -0.9157 -0.1392 -0.1389 -0.0302 -0.1267 -0.1776
S-429	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-429	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-429	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-429	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-429	-0.2162 -0.1913 -0.1164 -0.4705 -0.2809 -0.2001 -0.0948 -0.6270 -1.8441 -0.0427 -0.0758 -0.1459 -2.0594 -1.7016 -0.8119 -0.3006 -0.0743 -0.2743 -0.2607 -0.1107 -0.1740 -0.3428 -0.1306 -0.0862 -1.2304 -0.6011 -0.9157 -0.1392 -0.1389 -0.0302 -0.1267 -0.1776
S-543	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-543	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-543	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
D-543	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
P-543	-1.0816 -0.1323 -0.6440 -0.1426 -0.7908 -2.2622 -0.1355 -0.7663 -0.0420 -0.1239 -0.0877 -0.0632 -2.7844 -0.1226 -1.7812 -0.0530 -0.1101 -0.3167 -0.8925 -0.1790 -0.1639 -0.1061 -0.1900 -0.1258 -1.0992 -0.1616 -0.3144 -1.1059 -0.1937 -0.0931 -0.1472 -0.1302 -0.1712
S-569	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-569	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-569	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-569	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-569	-0.2162 -0.1913 -0.1164 -0.4705 -0.2809 -0.2001 -0.0948 -0.6270 -1.8441 -0.0427 -0.0758 -0.1459 -2.0594 -1.7016 -0.8119 -0.3006 -0.0743 -0.2743 -0.2607 -0.1107 -0.1740 -0.3428 -0.1306 -0.0862 -1.2304 -0.6011 -0.9157 -0.1392 -0.1389 -0.0302 -0.1267 -0.1776
S-473	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-473	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-473	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
D-473	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
P-473	-1.0816 -0.1323 -0.6440 -0.1426 -0.7908 -2.2622 -0.1355 -0.7663 -0.0420 -0.1239 -0.0877 -0.0632 -2.7844 -0.1226 -1.7812 -0.0530 -0.1101 -0.3167 -0.8925 -0.1790 -0.1639 -0.1061 -0.1900 -0.1258 -1.0992 -0.1616 -0.3144 -1.1059 -0.1937 -0.0931 -0.1472 -0.1302 -0.1712
S-639	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-639	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-639	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-639	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-639	-0.2162 -0.1913 -0.1164 -0.4705 -0.2809 -0.2001 -0.0948 -0.6270 -1.8441 -0.0427 -0.0758 -0.1459 -2.0594 -1.7016 -0.8119 -0.3006 -0.0743 -0.2743 -0.2607 -0.1107 -0.1740 -0.3428 -0.1306 -0.0862 -1.2304 -0.6011 -0.9157 -0.1392 -0.1389 -0.0302 -0.1267 -0.1776
S-403	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-403	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-403	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
D-403	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
P-403	-1.0816 -0.1323 -0.6440 -0.1426 -0.7908 -2.2622 -0.1355 -0.7663 -0.0420 -0.1239 -0.0877 -0.0632 -2.7844 -0.1226 -1.7812 -0.0530 -0.1101 -0.3167 -0.8925 -0.1790 -0.1639 -0.1061 -0.1900 -0.1258 -1.0992 -0.1616 -0.3144 -1.1059 -0.1937 -0.0931 -0.1472 -0.1302 -0.1712
S-359	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-359	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-359	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-359	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-359	-0.2162 -0.1913 -0.1164 -0.4705 -0.2809 -0.2001 -0.0948 -0.6270 -1.8441 -0.0427 -0.0758 -0.1459 -2.0594 -1.7016 -0.8119 -0.3006 -0.0743 -0.2743 -0.2607 -0.1107 -0.1740 -0.3428 -0.1306 -0.0862 -1.2304 -0.6011 -0.9157 -0.1392 -0.1389 -0.0302 -0.1267 -0.1776
S-333	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-333	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-333	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
D-333	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
P-333	-1.0816 -0.1323 -0.6440 -0.1426 -0.7908 -2.2622 -0.1355 -0.7663 -0.0420 -0.1239 -0.0877 -0.0632 -2.7844 -0.1226 -1.7812 -0.0530 -0.1101 -0.3167 -0.8925 -0.1790 -0.1639 -0.1061 -0.1900 -0.1258 -1.0992 -0.1616 -0.3144 -1.1059 -0.1937 -0.0931 -0.1472 -0.1302 -0.1712
S-290	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-290	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-290	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-290	-0.4372650980949402	In patients with high inhibitor concentrations , factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-290	-0.2162 -0.1913 -0.1164 -0.4705 -0.2809 -0.2001 -0.0948 -0.6270 -1.8441 -0.0427 -0.0758 -0.1459 -2.0594 -1.7016 -0.8119 -0.3006 -0.0743 -0.2743 -0.2607 -0.1107 -0.1740 -0.3428 -0.1306 -0.0862 -1.2304 -0.6011 -0.9157 -0.1392 -0.1389 -0.0302 -0.1267 -0.1776
S-802	Die Sicherheit und die Wirksamkeit dieser Kombinationstherapie wurden für dieses Patientenkollektiv nicht geprüft und die Daten reichen nicht aus , um entsprechende Empfehlungen zur Dosierung auszusprechen .
T-802	The safety and efficacy of the combination have not been established in this population , and there are insufficient data to give adequate dose recommendations .
H-802	-0.3022129535675049	The safety and efficacy of this combination therapy have not been evaluated in this population and data are insufficient to make appropriate dose recommendations .
D-802	-0.3022129535675049	The safety and efficacy of this combination therapy have not been evaluated in this population and data are insufficient to make appropriate dose recommendations .
P-802	-0.1519 -0.0563 -0.1483 -0.4023 -0.1291 -0.0797 -0.1383 -0.2234 -0.0521 -0.0554 -0.7148 -0.1046 -0.0998 -0.1304 -0.1225 -0.7146 -0.1889 -0.8346 -0.1626 -0.1995 -0.0734 -0.0295 -0.0662 -0.1488 -1.9065 -0.4917 -1.2891 -0.0411 -0.1353 -0.1755
S-13	Hauptindikator für die Wirksamkeit war die Anzahl der Patienten , deren Harnsäurespiegel im Blut bei den letzten drei Messungen unter 6 mg<unk> dl lag .
T-13	The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/ dl .
H-13	-0.3435150980949402	The main measure of effectiveness was the number of patients whose blood uric acid was below 6 mg/ dl in the last three measurements .
D-13	-0.3435150980949402	The main measure of effectiveness was the number of patients whose blood uric acid was below 6 mg/ dl in the last three measurements .
P-13	-0.1036 -0.1315 -0.0725 -0.1483 -0.2732 -0.1167 -0.4317 -0.1134 -0.3638 -0.1293 -0.2019 -0.2012 -0.9066 -0.3212 -0.1627 -0.2202 -1.4381 -0.1432 -0.1530 -0.1510 -0.0973 -0.1396 -0.0384 -0.7637 -0.1210 -0.3379 -0.1574 -2.1909 -0.0862 -0.9493 -0.1525 -0.1750
S-613	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-613	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-613	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
D-613	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
P-613	-1.0816 -0.1323 -0.6440 -0.1426 -0.7908 -2.2622 -0.1355 -0.7663 -0.0420 -0.1239 -0.0877 -0.0632 -2.7844 -0.1226 -1.7812 -0.0530 -0.1101 -0.3167 -0.8925 -0.1790 -0.1639 -0.1061 -0.1900 -0.1258 -1.0992 -0.1616 -0.3144 -1.1059 -0.1937 -0.0931 -0.1472 -0.1302 -0.1712
S-159	14 werden ( siehe Abschnitt 4.2 ) . Die Patienten sollen darüber informiert werden , dass das Risiko ösophagealer Probleme erhöht sein kann , wenn sie diese Anweisungen nicht einhalten .
T-159	Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems .
H-159	-0.3856607675552368	Patients should be advised that the risk of oesophageal problems may be increased if they do not follow these instructions .
D-159	-0.3856607675552368	Patients should be advised that the risk of oesophageal problems may be increased if they do not follow these instructions .
P-159	-0.3428 -0.0846 -0.2321 -0.1653 -1.1603 -0.1853 -1.3813 -0.1287 -0.1639 -0.3845 -0.0810 -0.0582 -0.0589 -0.0848 -0.1378 -0.3925 -0.1799 -0.2041 -0.1790 -0.9035 -0.4435 -0.3268 -0.1226 -1.4445 -1.0598 -0.5773 -0.1343 -0.1810
S-545	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-545	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-545	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
D-545	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
P-545	-1.6842 -0.1800 -0.1602 -0.0483 -1.3118 -0.7619 -0.0988 -0.2515 -2.5175 -0.1230 -0.7108 -0.0803 -0.1114 -0.0995 -0.2599 -0.1173 -1.3831 -0.2597 -0.6418 -0.9140 -0.0638 -0.1440 -0.9561 -0.7982 -0.8207 -0.5609 -0.3743 -1.5213 -0.2629 -1.2692 -0.0616 -0.2827 -2.1207 -1.3229 -0.0823 -0.4938 -0.8576 -0.2820 -0.1555 -0.1725
S-405	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-405	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-405	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
D-405	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
P-405	-1.6842 -0.1800 -0.1602 -0.0483 -1.3118 -0.7619 -0.0988 -0.2515 -2.5175 -0.1230 -0.7108 -0.0803 -0.1114 -0.0995 -0.2599 -0.1173 -1.3831 -0.2597 -0.6418 -0.9140 -0.0638 -0.1440 -0.9561 -0.7982 -0.8207 -0.5609 -0.3743 -1.5213 -0.2629 -1.2692 -0.0616 -0.2827 -2.1207 -1.3229 -0.0823 -0.4938 -0.8576 -0.2820 -0.1555 -0.1725
S-252	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-252	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-252	-0.1072503924369812	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
D-252	-0.1072503924369812	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
P-252	-0.0719 -0.1476 -0.0687 -0.1031 -0.1106 -0.0901 -0.1231 -0.1489 -0.0718 -0.0978 -0.0730 -0.0487 -0.1506 -0.0588 -0.1307 -0.0421 -0.1296 -0.0818 -0.0238 -0.1057 -0.1527 -0.0561 -0.1660 -0.1570 -0.1245 -0.1104 -0.0551 -0.1452 -0.1408 -0.0950 -0.1585 -0.0632 -0.1299 -0.1162 -0.0813 -0.1704 -0.1678
S-1	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-1	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-1	-0.1072503924369812	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
D-1	-0.1072503924369812	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
P-1	-0.0719 -0.1476 -0.0687 -0.1031 -0.1106 -0.0901 -0.1231 -0.1489 -0.0718 -0.0978 -0.0730 -0.0487 -0.1506 -0.0588 -0.1307 -0.0421 -0.1296 -0.0818 -0.0238 -0.1057 -0.1527 -0.0561 -0.1660 -0.1570 -0.1245 -0.1104 -0.0551 -0.1452 -0.1408 -0.0950 -0.1585 -0.0632 -0.1299 -0.1162 -0.0813 -0.1704 -0.1678
S-685	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-685	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-685	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
D-685	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
P-685	-1.6842 -0.1800 -0.1602 -0.0483 -1.3118 -0.7619 -0.0988 -0.2515 -2.5175 -0.1230 -0.7108 -0.0803 -0.1114 -0.0995 -0.2599 -0.1173 -1.3831 -0.2597 -0.6418 -0.9140 -0.0638 -0.1440 -0.9561 -0.7982 -0.8207 -0.5609 -0.3743 -1.5213 -0.2629 -1.2692 -0.0616 -0.2827 -2.1207 -1.3229 -0.0823 -0.4938 -0.8576 -0.2820 -0.1555 -0.1725
S-615	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-615	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-615	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
D-615	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
P-615	-1.6842 -0.1800 -0.1602 -0.0483 -1.3118 -0.7619 -0.0988 -0.2515 -2.5175 -0.1230 -0.7108 -0.0803 -0.1114 -0.0995 -0.2599 -0.1173 -1.3831 -0.2597 -0.6418 -0.9140 -0.0638 -0.1440 -0.9561 -0.7982 -0.8207 -0.5609 -0.3743 -1.5213 -0.2629 -1.2692 -0.0616 -0.2827 -2.1207 -1.3229 -0.0823 -0.4938 -0.8576 -0.2820 -0.1555 -0.1725
S-683	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-683	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-683	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
D-683	-0.5004204511642456	Open the package of the BAXJECT II by removing the protective foil without touching the contents of the pack ( Fig . A ) .
P-683	-1.0816 -0.1323 -0.6440 -0.1426 -0.7908 -2.2622 -0.1355 -0.7663 -0.0420 -0.1239 -0.0877 -0.0632 -2.7844 -0.1226 -1.7812 -0.0530 -0.1101 -0.3167 -0.8925 -0.1790 -0.1639 -0.1061 -0.1900 -0.1258 -1.0992 -0.1616 -0.3144 -1.1059 -0.1937 -0.0931 -0.1472 -0.1302 -0.1712
S-475	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-475	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-475	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
D-475	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
P-475	-1.6842 -0.1800 -0.1602 -0.0483 -1.3118 -0.7619 -0.0988 -0.2515 -2.5175 -0.1230 -0.7108 -0.0803 -0.1114 -0.0995 -0.2599 -0.1173 -1.3831 -0.2597 -0.6418 -0.9140 -0.0638 -0.1440 -0.9561 -0.7982 -0.8207 -0.5609 -0.3743 -1.5213 -0.2629 -1.2692 -0.0616 -0.2827 -2.1207 -1.3229 -0.0823 -0.4938 -0.8576 -0.2820 -0.1555 -0.1725
S-757	Das Unternehmen legte Daten aus einer Studie mit einem Patienten vor , bei dem Li-Fraumeni-Krebs im Bereich des Unterbauchs , in den Knochen und im Gehirn auftrat .
T-757	The company presented information from a study on one patient with Li-Fraumeni cancer in the lower abdomen , the bones and the brain .
H-757	-0.4999420940876007	The company presented data from a study in a patient with Li-Women <unk> s cancer of the lower abdominal , bone and brain .
D-757	-0.4999420940876007	The company presented data from a study in a patient with Li-Women <unk> s cancer of the lower abdominal , bone and brain .
P-757	-0.0870 -0.0591 -0.0971 -0.0872 -0.0809 -0.2129 -0.7553 -0.1355 -0.1654 -0.1070 -1.3635 -2.0035 -0.2511 -2.9656 -0.5527 -0.0920 -2.0116 -0.3770 -0.1100 -0.5594 -0.1339 -0.0440 -0.2370 -0.3515 -0.4736 -0.1612 -0.3158 -0.5264 -0.1813
S-335	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-335	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-335	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
D-335	-0.607958972454071	Turn the system , comprising the BAXJECT II and the solvent-vial , over and over again , and the solvent-filled vial is on top .
P-335	-1.6842 -0.1800 -0.1602 -0.0483 -1.3118 -0.7619 -0.0988 -0.2515 -2.5175 -0.1230 -0.7108 -0.0803 -0.1114 -0.0995 -0.2599 -0.1173 -1.3831 -0.2597 -0.6418 -0.9140 -0.0638 -0.1440 -0.9561 -0.7982 -0.8207 -0.5609 -0.3743 -1.5213 -0.2629 -1.2692 -0.0616 -0.2827 -2.1207 -1.3229 -0.0823 -0.4938 -0.8576 -0.2820 -0.1555 -0.1725
S-797	Es wird empfohlen , die Anwendungsdauer auf 10 Tage zu begrenzen , da bei Langzeitanwendung die Aktivität von Pseudoephedrin mit der Zeit abnehmen kann .
T-797	It is advisable to limit treatment to about 10 days , as during chronic administration the activity of pseudoephedrine may diminish .
H-797	-0.3755992352962494	It is recommended to limit the duration of administration to 10 days as long-term use may have a decrease in the activity of pseudoephedrine over time .
D-797	-0.3755992352962494	It is recommended to limit the duration of administration to 10 days as long-term use may have a decrease in the activity of pseudoephedrine over time .
P-797	-0.2338 -0.1026 -0.0508 -0.5102 -0.2278 -0.1012 -0.4569 -0.1183 -0.3992 -0.6028 -0.1511 -0.1498 -0.2024 -1.6060 -0.3985 -0.1425 -0.0794 -0.2608 -0.0918 -1.0882 -0.1933 -0.0625 -1.3085 -0.1413 -0.4459 -0.1060 -0.1401 -0.2045 -3.2860 -0.2211 -0.0622 -0.1554 -0.3013 -0.0852 -0.1026 -0.1679 -0.1384 -0.1765
S-163	Wenn Patienten während einer Bisphosphonattherapie eine Osteonekrose des Kiefers entwickeln , kann ein kieferchirurgischer Eingriff zu einer Verschlechterung führen .
T-163	For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy , dental surgery may exacerbate the condition .
H-163	-0.21947471797466278	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may exacerbate the condition .
D-163	-0.21947471797466278	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may exacerbate the condition .
P-163	-0.2933 -0.1903 -0.0671 -0.1117 -0.1128 -0.1195 -0.1473 -0.0438 -0.1850 -0.1542 -0.1084 -0.2128 -0.0941 -0.2172 -0.3140 -0.0489 -0.0324 -0.2553 -0.1732 -0.1450 -1.8441 -0.1261 -0.2571 -0.1670 -0.5254 -0.0139 -0.1092 -0.1695 -0.2478 -0.1426 -0.1750
S-64	Wenn Patienten während einer Bisphosphonattherapie eine Osteonekrose des Kiefers entwickeln , kann ein kieferchirurgischer Eingriff zu einer Verschlechterung führen .
T-64	For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy , dental surgery may exacerbate the condition .
H-64	-0.21947471797466278	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may exacerbate the condition .
D-64	-0.21947471797466278	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may exacerbate the condition .
P-64	-0.2933 -0.1903 -0.0671 -0.1117 -0.1128 -0.1195 -0.1473 -0.0438 -0.1850 -0.1542 -0.1084 -0.2128 -0.0941 -0.2172 -0.3140 -0.0489 -0.0324 -0.2553 -0.1732 -0.1450 -1.8441 -0.1261 -0.2571 -0.1670 -0.5254 -0.0139 -0.1092 -0.1695 -0.2478 -0.1426 -0.1750
S-601	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-601	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 47 spontaneously or as a result of accidental or surgical trauma .
H-601	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
D-601	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
P-601	-0.2217 -1.2019 -0.1911 -0.2121 -1.1496 -0.0610 -0.0058 -1.2648 -0.1872 -0.1163 -0.0619 -0.0467 -0.1516 -0.1317 -0.2407 -0.2645 -0.0339 -0.0970 -0.1454 -0.1641 -0.0446 -0.0309 -0.4135 -0.1808 -0.2142 -0.1538 -0.0990 -0.1008 -0.1373 -0.1544 -0.0977 -0.1582 -0.2606 -0.0955 -0.1009 -0.0868 -0.1369 -0.1764
S-531	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-531	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 37 spontaneously or as a result of accidental or surgical trauma .
H-531	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
D-531	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
P-531	-0.2217 -1.2019 -0.1911 -0.2121 -1.1496 -0.0610 -0.0058 -1.2648 -0.1872 -0.1163 -0.0619 -0.0467 -0.1516 -0.1317 -0.2407 -0.2645 -0.0339 -0.0970 -0.1454 -0.1641 -0.0446 -0.0309 -0.4135 -0.1808 -0.2142 -0.1538 -0.0990 -0.1008 -0.1373 -0.1544 -0.0977 -0.1582 -0.2606 -0.0955 -0.1009 -0.0868 -0.1369 -0.1764
S-671	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-671	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 57 spontaneously or as a result of accidental or surgical trauma .
H-671	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
D-671	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
P-671	-0.2217 -1.2019 -0.1911 -0.2121 -1.1496 -0.0610 -0.0058 -1.2648 -0.1872 -0.1163 -0.0619 -0.0467 -0.1516 -0.1317 -0.2407 -0.2645 -0.0339 -0.0970 -0.1454 -0.1641 -0.0446 -0.0309 -0.4135 -0.1808 -0.2142 -0.1538 -0.0990 -0.1008 -0.1373 -0.1544 -0.0977 -0.1582 -0.2606 -0.0955 -0.1009 -0.0868 -0.1369 -0.1764
S-259	Octocog alfa wird nicht aus menschlichem Plasma extrahiert , sondern nach einer Methode hergestellt , die als rekombinante DNA-Technologie bezeichnet wird :
T-259	Octocog alfa is not extracted from human plasma but produced by a method known as recombinant DNA technology : it is made by a cell that has received a gene ( DNA ) , which makes it able to produce human coagulation factor VIII .
H-259	-0.22956158220767975	Octocog alfa is not extracted from human plasma but produced using a method termed recombinant DNA technology :
D-259	-0.22956158220767975	Octocog alfa is not extracted from human plasma but produced using a method termed recombinant DNA technology :
P-259	-0.0252 -0.1093 -0.1328 -0.1241 -0.0833 -0.0589 -0.1397 -0.1628 -0.0708 -0.1273 -0.1253 -0.0931 -0.1485 -0.1064 -0.0756 -1.0594 -1.6179 -0.2222 -0.1435 -0.5427 -0.6841 -0.0355 -0.1224 -0.1425 -0.1307 -0.1584 -0.0230 -0.0606 -0.1664 -0.1946
S-461	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-461	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 27 spontaneously or as a result of accidental or surgical trauma .
H-461	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
D-461	-0.22608570754528046	This leads to severe haemorrhages in the joints , muscles or internal organs , either spontaneously or as a consequence of accidental or surgical trauma .
P-461	-0.2217 -1.2019 -0.1911 -0.2121 -1.1496 -0.0610 -0.0058 -1.2648 -0.1872 -0.1163 -0.0619 -0.0467 -0.1516 -0.1317 -0.2407 -0.2645 -0.0339 -0.0970 -0.1454 -0.1641 -0.0446 -0.0309 -0.4135 -0.1808 -0.2142 -0.1538 -0.0990 -0.1008 -0.1373 -0.1544 -0.0977 -0.1582 -0.2606 -0.0955 -0.1009 -0.0868 -0.1369 -0.1764
S-94	ADROVANCE ist eine Kombinationstablette mit den beiden arzneilich wirksamen Bestandteilen Natriumalendronat 3 H2O und Colecalciferol ( Vitamin D3 ) .
T-94	ADROVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-94	-0.26281195878982544	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
D-94	-0.26281195878982544	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
P-94	-0.7030 -0.0575 -0.1593 -0.0914 -0.0790 -0.1090 -0.1809 -0.1114 -0.2630 -0.0701 -0.8497 -0.2164 -2.0940 -1.4352 -0.0172 -0.0320 -0.1593 -0.1256 -0.2667 -0.1153 -0.4332 -0.1250 -0.2271 -0.1373 -0.2022 -0.1258 -0.1847 -0.2724 -0.1246 -0.0765 -0.0840 -0.1241 -0.1469 -0.0720 -0.0853 -0.2167 -0.1448 -0.1487 -0.1823
S-146	Jede Tablette enthält 70 mg Alendronsäure als Natriumalendronat 3 H2O und 140 Mikrogramm ( 5.600 I.E. ) Colecalciferol ( Vitamin D3 ) .
T-146	Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate and 140 micrograms ( 5600 IU ) colecalciferol ( vitamin D3 ) .
H-146	-0.18765677511692047	Each tablet contains 70 mg of alendronic acid as sodium alendronate 3 H2O and 140 micrograms ( 5,600 IU ) of colecalciferol ( vitamin D3 ) .
D-146	-0.18765677511692047	Each tablet contains 70 mg of alendronic acid as sodium alendronate 3 H2O and 140 micrograms ( 5,600 IU ) of colecalciferol ( vitamin D3 ) .
P-146	-0.0260 -0.0960 -0.0539 -0.0711 -0.0886 -0.1498 -1.1590 -0.3735 -0.1562 -0.1294 -0.1220 -0.1267 -0.6589 -0.0058 -0.0379 -0.1358 -0.1174 -0.3180 -0.0580 -0.2426 -0.1296 -0.7771 -0.1437 -0.1803 -0.1511 -0.1122 -0.0597 -0.1428 -0.1554 -0.1163 -0.1082 -0.0672 -0.1306 -0.4480 -0.1940 -0.1675 -0.3071 -0.1350 -0.0811 -0.1636 -0.1272 -0.1799 -0.0534 -0.0899 -0.2124 -0.1372 -0.1425 -0.1678
S-193	ADROVANCE ist eine Kombinationstablette mit den beiden arzneilich wirksamen Bestandteilen Natriumalendronat 3 H2O und Colecalciferol ( Vitamin D3 ) .
T-193	ADROVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-193	-0.26281195878982544	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
D-193	-0.26281195878982544	ADROVANCE is a combination tablet with the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
P-193	-0.7030 -0.0575 -0.1593 -0.0914 -0.0790 -0.1090 -0.1809 -0.1114 -0.2630 -0.0701 -0.8497 -0.2164 -2.0940 -1.4352 -0.0172 -0.0320 -0.1593 -0.1256 -0.2667 -0.1153 -0.4332 -0.1250 -0.2271 -0.1373 -0.2022 -0.1258 -0.1847 -0.2724 -0.1246 -0.0765 -0.0840 -0.1241 -0.1469 -0.0720 -0.0853 -0.2167 -0.1448 -0.1487 -0.1823
S-722	Ihr Arzt wird Ihre Dosis ADVATE ( in internationalen Einheiten oder I.E. ) berechnen , abhängig von Ihrem körperlichen Befinden und Ihrem Körpergewicht , und ob es zur Vorbeugung oder zur Behandlung von Blutungen eingesetzt wird .
T-722	Your doctor will calculate your dose of ADVATE ( in international units or IU ) depending on your condition and body weight , and on whether it is used for prevention or treatment of bleeding .
H-722	-0.2716227173805237	Your doctor will calculate your dose of ADVATE ( in international units or IU ) based on your physical status and weight , and whether it is used to prevent or treat haemorrhage .
D-722	-0.2716227173805237	Your doctor will calculate your dose of ADVATE ( in international units or IU ) based on your physical status and weight , and whether it is used to prevent or treat haemorrhage .
P-722	-0.1872 -0.0910 -0.3186 -0.6185 -0.1459 -0.1285 -0.0689 -0.2315 -0.1327 -0.1817 -0.0714 -0.1275 -0.1385 -0.1890 -0.5167 -0.1044 -0.1382 -0.1080 -0.0381 -0.1416 -0.4812 -0.0940 -0.1288 -0.7685 -0.8407 -0.1346 -0.5170 -0.2719 -0.1331 -0.8827 -0.1426 -0.1543 -0.2540 -0.4160 -0.2239 -0.1410 -0.0895 -1.2750 -0.0778 -0.0181 -0.6560 -0.1295 -0.1715
S-465	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-465	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-465	-0.28661292791366577	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-465	-0.28661292791366577	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-465	-0.1263 -0.1975 -0.1167 -0.0617 -0.1368 -1.2048 -0.0476 -0.4901 -0.1247 -0.0566 -0.1086 -0.4876 -0.0499 -0.1266 -0.1981 -0.1219 -0.1915 -0.0495 -0.1140 -0.1204 -0.1573 -0.4084 -0.1502 -0.2181 -0.3963 -0.1117 -0.1426 -0.1300 -0.2851 -1.5192 -0.1475 -0.1466 -1.8387 -0.1927 -0.0723 -0.1964 -0.1266 -0.1145 -0.5542 -0.3114 -0.2105 -0.7704 -0.0920 -0.1350 -0.2710 -1.2495 -0.0712 -0.0462 -0.0671 -0.1406 -0.2132
S-128	Nach intravenöser Gabe einer einzelnen Dosis von 10 mg betrug die renale Clearance von Alendronat 71 ml<unk> min und die systemische Clearance überschritt nicht 200 ml<unk> min .
T-128	Following a single 10 mg intravenous dose , the renal clearance of alendronate was 71 ml/ min , and systemic clearance did not exceed 200 ml/ min .
H-128	-0.1685986965894699	Following a single intravenous dose of 10 mg , renal clearance of alendronate was 71 ml/ min and systemic clearance did not exceed 200 ml/ min .
D-128	-0.1685986965894699	Following a single intravenous dose of 10 mg , renal clearance of alendronate was 71 ml/ min and systemic clearance did not exceed 200 ml/ min .
P-128	-0.0625 -0.7078 -0.0296 -0.2257 -0.0406 -0.0400 -0.0950 -0.0610 -0.1450 -0.1327 -0.0487 -0.1457 -0.7531 -0.1161 -0.0622 -0.0908 -0.1426 -0.2596 -0.1353 -0.1185 -0.0961 -0.3041 -0.0697 -0.1142 -0.1488 -0.1331 -0.1261 -0.1844 -0.1578 -0.0990 -0.1039 -0.0782 -0.0958 -1.2097 -0.0943 -0.0233 -0.0497 -0.0995 -0.1454 -0.1158 -0.1382 -0.1018 -0.1398 -0.1771
S-231	Nach intravenöser Gabe einer einzelnen Dosis von 10 mg betrug die renale Clearance von Alendronat 71 ml<unk> min und die systemische Clearance überschritt nicht 200 ml<unk> min .
T-231	Following a single 10 mg intravenous dose , the renal clearance of alendronate was 71 ml/ min , and systemic clearance did not exceed 200 ml/ min .
H-231	-0.1685986965894699	Following a single intravenous dose of 10 mg , renal clearance of alendronate was 71 ml/ min and systemic clearance did not exceed 200 ml/ min .
D-231	-0.1685986965894699	Following a single intravenous dose of 10 mg , renal clearance of alendronate was 71 ml/ min and systemic clearance did not exceed 200 ml/ min .
P-231	-0.0625 -0.7078 -0.0296 -0.2257 -0.0406 -0.0400 -0.0950 -0.0610 -0.1450 -0.1327 -0.0487 -0.1457 -0.7531 -0.1161 -0.0622 -0.0908 -0.1426 -0.2596 -0.1353 -0.1185 -0.0961 -0.3041 -0.0697 -0.1142 -0.1488 -0.1331 -0.1261 -0.1844 -0.1578 -0.0990 -0.1039 -0.0782 -0.0958 -1.2097 -0.0943 -0.0233 -0.0497 -0.0995 -0.1454 -0.1158 -0.1382 -0.1018 -0.1398 -0.1771
S-45	Jede Tablette enthält 70 mg Alendronsäure als Natriumalendronat 3 H2O und 70 Mikrogramm ( 2.800 I.E. ) Colecalciferol ( Vitamin D3 ) .
T-45	Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate , and 70 micrograms ( 2800 IU ) colecalciferol ( vitamin D3 ) .
H-45	-0.1863703578710556	Each tablet contains 70 mg of alendronic acid as sodium alendronate 3 H2O and 70 micrograms ( 2,800 IU ) of colecalciferol ( vitamin D3 ) .
D-45	-0.1863703578710556	Each tablet contains 70 mg of alendronic acid as sodium alendronate 3 H2O and 70 micrograms ( 2,800 IU ) of colecalciferol ( vitamin D3 ) .
P-45	-0.0276 -0.0934 -0.0538 -0.0715 -0.0847 -0.1431 -1.2437 -0.3822 -0.1564 -0.1303 -0.1217 -0.1267 -0.6386 -0.0057 -0.0396 -0.1334 -0.1167 -0.3104 -0.0599 -0.2540 -0.1274 -0.6475 -0.1501 -0.1772 -0.0825 -0.1078 -0.0532 -0.1468 -0.2934 -0.1207 -0.1065 -0.0582 -0.1314 -0.3875 -0.1965 -0.1684 -0.3038 -0.1357 -0.0814 -0.1647 -0.1275 -0.1817 -0.0540 -0.0900 -0.2076 -0.1388 -0.1431 -0.1692
S-395	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-395	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-395	-0.28661292791366577	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-395	-0.28661292791366577	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-395	-0.1263 -0.1975 -0.1167 -0.0617 -0.1368 -1.2048 -0.0476 -0.4901 -0.1247 -0.0566 -0.1086 -0.4876 -0.0499 -0.1266 -0.1981 -0.1219 -0.1915 -0.0495 -0.1140 -0.1204 -0.1573 -0.4084 -0.1502 -0.2181 -0.3963 -0.1117 -0.1426 -0.1300 -0.2851 -1.5192 -0.1475 -0.1466 -1.8387 -0.1927 -0.0723 -0.1964 -0.1266 -0.1145 -0.5542 -0.3114 -0.2105 -0.7704 -0.0920 -0.1350 -0.2710 -1.2495 -0.0712 -0.0462 -0.0671 -0.1406 -0.2132
S-39	Das Unternehmen legte außerdem Daten vor , die darlegen , dass die in ADROVANCE enthaltene Alendronat-Dosis genau der Dosis entspricht , die für die Verhinderung eines Knochenverlusts benötigt wird .
T-39	The company also presented evidence that the dose of alendronate included in ADROVANCE was the same as the dose needed to prevent bone loss .
H-39	-0.29781973361968994	The company also presented data indicating that the dose of alendronate in ADROVANCE is exactly the dose needed to prevent bone loss .
D-39	-0.29781973361968994	The company also presented data indicating that the dose of alendronate in ADROVANCE is exactly the dose needed to prevent bone loss .
P-39	-0.0958 -0.0547 -0.0999 -0.1944 -0.1267 -2.0825 -0.2662 -0.1133 -0.1152 -0.9092 -0.1369 -0.2567 -0.1273 -0.1599 -0.1583 -0.6229 -0.1136 -0.0657 -0.1557 -0.0985 -0.0745 -0.1932 -0.6821 -0.1822 -0.1722 -1.4502 -0.1463 -0.2502 -0.0315 -0.0585 -0.1582 -0.1778
S-79	Obwohl spezifische Interaktionsstudien nicht durchgeführt wurden , wurde Alendronat in klinischen Studien gemeinsam mit einer Vielzahl von gewöhnlich verschriebenen Arzneimitteln eingenommen , ohne dass klinisch relevante Wechselwirkungen auftraten .
T-79	Although specific interaction studies were not performed , in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of interactions of clinical relevance .
H-79	-0.3080693781375885	Although specific interaction studies have not been conducted , in clinical trials , alendronate has been administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions .
D-79	-0.3080693781375885	Although specific interaction studies have not been conducted , in clinical trials , alendronate has been administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions .
P-79	-0.0680 -0.9710 -0.3556 -0.0663 -0.5781 -0.7859 -0.0798 -0.0697 -1.3306 -0.1499 -0.2788 -0.1023 -0.2808 -1.3079 -0.2483 -0.1462 -0.0947 -0.0912 -0.3053 -0.0921 -1.9042 -0.0860 -0.8314 -0.0997 -0.0166 -0.0725 -0.1349 -0.1404 -0.0851 -0.1466 -0.0836 -0.1176 -0.0556 -0.1433 -0.1100 -0.0936 -0.3492 -0.1668 -0.0909 -0.1171 -0.4077 -0.0489 -0.6738 -0.1770
S-276	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-276	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-276	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
D-276	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
P-276	-1.7852 -0.6480 -0.3507 -0.1571 -0.1215 -0.1614 -0.1192 -0.0676 -0.0896 -0.7373 -1.6221 -0.4186 -0.2241 -0.1439 -0.1793 -0.0217 -0.1469 -0.8139 -0.0597 -0.1010 -0.1082 -0.0426 -0.0594 -0.1402 -0.1430 -0.4987 -0.1016 -0.0680 -0.1760 -0.0508 -0.1533 -0.3228 -0.1191 -0.6578 -0.2101 -2.2232 -0.2410 -0.0531 -2.6740 -0.1976 -0.1055 -0.1945 -0.1308 -0.1784
S-329	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-329	Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-329	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
D-329	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
P-329	-0.0651 -0.3066 -0.0929 -0.0981 -2.3384 -0.0625 -0.1013 -0.0835 -0.3324 -0.2247 -0.0537 -0.2015 -0.1517 -0.5263 -0.2116 -0.1466 -1.6350 -0.3368 -0.4264 -0.2782 -0.1756 -0.1169 -0.5454 -0.3847 -0.0790 -0.0799 -0.1276 -0.1192 -0.4281 -0.6771 -0.0851 -0.3432 -0.1135 -0.6089 -0.2090 -0.1288 -0.1799
S-178	Obwohl spezifische Interaktionsstudien nicht durchgeführt wurden , wurde Alendronat in klinischen Studien gemeinsam mit einer Vielzahl von gewöhnlich verschriebenen Arzneimitteln eingenommen , ohne dass klinisch relevante Wechselwirkungen auftraten .
T-178	Although specific interaction studies were not performed , in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of interactions of clinical relevance .
H-178	-0.3080693781375885	Although specific interaction studies have not been conducted , in clinical trials , alendronate has been administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions .
D-178	-0.3080693781375885	Although specific interaction studies have not been conducted , in clinical trials , alendronate has been administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions .
P-178	-0.0680 -0.9710 -0.3556 -0.0663 -0.5781 -0.7859 -0.0798 -0.0697 -1.3306 -0.1499 -0.2788 -0.1023 -0.2808 -1.3079 -0.2483 -0.1462 -0.0947 -0.0912 -0.3053 -0.0921 -1.9042 -0.0860 -0.8314 -0.0997 -0.0166 -0.0725 -0.1349 -0.1404 -0.0851 -0.1466 -0.0836 -0.1176 -0.0556 -0.1433 -0.1100 -0.0936 -0.3492 -0.1668 -0.0909 -0.1171 -0.4077 -0.0489 -0.6738 -0.1770
S-648	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-648	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-648	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
D-648	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
P-648	-0.4834 -0.1101 -0.2251 -0.5020 -0.1108 -0.0710 -0.0590 -0.1411 -0.1254 -0.5698 -0.0696 -0.1511 -0.1367 -1.2823 -0.1433 -0.5713 -0.1960 -0.1600 -0.0836 -0.1973 -0.0947 -0.1264 -1.2461 -0.1318 -2.2906 -0.6085 -0.1895 -0.0886 -0.5956 -0.1148 -0.1518 -0.1470 -0.4878 -0.1250 -0.0472 -1.1124 -0.8133 -0.4046 -0.9268 -0.0910 -0.3294 -0.1472 -0.2373 -0.1211 -0.1300 -0.1730
S-344	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-344	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-344	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
D-344	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
P-344	-1.7852 -0.6480 -0.3507 -0.1571 -0.1215 -0.1614 -0.1192 -0.0676 -0.0896 -0.7373 -1.6221 -0.4186 -0.2241 -0.1439 -0.1793 -0.0217 -0.1469 -0.8139 -0.0597 -0.1010 -0.1082 -0.0426 -0.0594 -0.1402 -0.1430 -0.4987 -0.1016 -0.0680 -0.1760 -0.0508 -0.1533 -0.3228 -0.1191 -0.6578 -0.2101 -2.2232 -0.2410 -0.0531 -2.6740 -0.1976 -0.1055 -0.1945 -0.1308 -0.1784
S-399	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-399	18 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-399	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
D-399	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
P-399	-0.0651 -0.3066 -0.0929 -0.0981 -2.3384 -0.0625 -0.1013 -0.0835 -0.3324 -0.2247 -0.0537 -0.2015 -0.1517 -0.5263 -0.2116 -0.1466 -1.6350 -0.3368 -0.4264 -0.2782 -0.1756 -0.1169 -0.5454 -0.3847 -0.0790 -0.0799 -0.1276 -0.1192 -0.4281 -0.6771 -0.0851 -0.3432 -0.1135 -0.6089 -0.2090 -0.1288 -0.1799
S-414	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-414	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-414	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
D-414	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
P-414	-1.7852 -0.6480 -0.3507 -0.1571 -0.1215 -0.1614 -0.1192 -0.0676 -0.0896 -0.7373 -1.6221 -0.4186 -0.2241 -0.1439 -0.1793 -0.0217 -0.1469 -0.8139 -0.0597 -0.1010 -0.1082 -0.0426 -0.0594 -0.1402 -0.1430 -0.4987 -0.1016 -0.0680 -0.1760 -0.0508 -0.1533 -0.3228 -0.1191 -0.6578 -0.2101 -2.2232 -0.2410 -0.0531 -2.6740 -0.1976 -0.1055 -0.1945 -0.1308 -0.1784
S-217	In der Zwei-Jahres-Verlängerung dieser Studien hielten die Anstiege der BMD von Wirbelsäule und Trochanter weiterhin an ; auch die BMD des Femurhalses und des gesamten Körpers wurde aufrechterhalten .
T-217	In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained .
H-217	-0.4684107005596161	In the bi-year renewal of these trials , spine and trochanter BMD continued to increase and the BMD of the femoral neck and the entire body was also sustained .
D-217	-0.4684107005596161	In the bi-year renewal of these trials , spine and trochanter BMD continued to increase and the BMD of the femoral neck and the entire body was also sustained .
P-217	-1.0735 -0.1535 -1.3042 -0.4006 -0.1683 -1.4607 -0.1103 -0.1357 -0.2164 -0.8495 -0.1879 -1.0069 -0.0725 -0.1373 -0.0386 -0.7340 -0.2165 -0.1749 -0.1581 -1.1948 -0.1813 -0.6490 -0.2323 -1.6660 -1.2156 -0.0853 -0.1418 -0.1143 -0.1362 -1.0291 -0.0568 -0.1336 -1.1743 -0.8770 -0.2298 -0.2215 -0.2821 -0.2127 -0.1268 -0.1768
S-235	Die mittlere maximale Konzentration im Serum ( Cmax ) von Vitamin D3 betrug 12,2 ng<unk> ml und die Medianzeit bis zum Erreichen der maximalen Serumkonzentration ( Tmax ) 10,6 Stunden .
T-235	The mean maximal serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to maximal serum concentration ( Tmax ) was 10.6 hours .
H-235	-0.23422613739967346	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to reach the maximum serum concentration ( Tmax ) 10.6 hours .
D-235	-0.23422613739967346	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to reach the maximum serum concentration ( Tmax ) 10.6 hours .
P-235	-0.1389 -0.0393 -0.1316 -0.6027 -0.1239 -1.2651 -0.1395 -0.1370 -0.0510 -0.1401 -0.1412 -0.0790 -0.0855 -0.1208 -0.1872 -0.1263 -0.1398 -0.1727 -0.1259 -0.1869 -0.1353 -0.0554 -0.1807 -0.1188 -0.1124 -0.0318 -0.4136 -0.2151 -1.8609 -0.3879 -0.1602 -0.2627 -0.1193 -0.1374 -0.1419 -0.1676 -0.0341 -0.1382 -0.6802 -0.1651 -0.1078 -0.1395 -0.1715
S-484	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-484	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-484	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
D-484	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
P-484	-1.7852 -0.6480 -0.3507 -0.1571 -0.1215 -0.1614 -0.1192 -0.0676 -0.0896 -0.7373 -1.6221 -0.4186 -0.2241 -0.1439 -0.1793 -0.0217 -0.1469 -0.8139 -0.0597 -0.1010 -0.1082 -0.0426 -0.0594 -0.1402 -0.1430 -0.4987 -0.1016 -0.0680 -0.1760 -0.0508 -0.1533 -0.3228 -0.1191 -0.6578 -0.2101 -2.2232 -0.2410 -0.0531 -2.6740 -0.1976 -0.1055 -0.1945 -0.1308 -0.1784
S-578	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-578	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-578	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
D-578	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
P-578	-0.4834 -0.1101 -0.2251 -0.5020 -0.1108 -0.0710 -0.0590 -0.1411 -0.1254 -0.5698 -0.0696 -0.1511 -0.1367 -1.2823 -0.1433 -0.5713 -0.1960 -0.1600 -0.0836 -0.1973 -0.0947 -0.1264 -1.2461 -0.1318 -2.2906 -0.6085 -0.1895 -0.0886 -0.5956 -0.1148 -0.1518 -0.1470 -0.4878 -0.1250 -0.0472 -1.1124 -0.8133 -0.4046 -0.9268 -0.0910 -0.3294 -0.1472 -0.2373 -0.1211 -0.1300 -0.1730
S-658	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-658	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-658	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
D-658	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
P-658	-0.5073 -0.0825 -0.1233 -0.0401 -0.1628 -0.2389 -0.2953 -0.2356 -2.4155 -1.2455 -0.1383 -0.2195 -0.2991 -1.7021 -0.3204 -0.0742 -0.0584 -0.3142 -1.4042 -0.8327 -0.7454 -0.2029 -0.0927 -0.3616 -2.2693 -1.4974 -0.1152 -0.8396 -0.3287 -0.3187 -1.5799 -0.1228 -0.6493 -0.7446 -0.4481 -0.5685 -0.1296 -0.1756
S-114	In der Zwei-Jahres-Verlängerung dieser Studien hielten die Anstiege der BMD von Wirbelsäule und Trochanter weiterhin an ; auch die BMD des Femurhalses und des gesamten Körpers wurde aufrechterhalten .
T-114	In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained .
H-114	-0.4684107005596161	In the bi-year renewal of these trials , spine and trochanter BMD continued to increase and the BMD of the femoral neck and the entire body was also sustained .
D-114	-0.4684107005596161	In the bi-year renewal of these trials , spine and trochanter BMD continued to increase and the BMD of the femoral neck and the entire body was also sustained .
P-114	-1.0735 -0.1535 -1.3042 -0.4006 -0.1683 -1.4607 -0.1103 -0.1357 -0.2164 -0.8495 -0.1879 -1.0069 -0.0725 -0.1373 -0.0386 -0.7340 -0.2165 -0.1749 -0.1581 -1.1948 -0.1813 -0.6490 -0.2323 -1.6660 -1.2156 -0.0853 -0.1418 -0.1143 -0.1362 -1.0291 -0.0568 -0.1336 -1.1743 -0.8770 -0.2298 -0.2215 -0.2821 -0.2127 -0.1268 -0.1768
S-448	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-448	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-448	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
D-448	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
P-448	-0.5073 -0.0825 -0.1233 -0.0401 -0.1628 -0.2389 -0.2953 -0.2356 -2.4155 -1.2455 -0.1383 -0.2195 -0.2991 -1.7021 -0.3204 -0.0742 -0.0584 -0.3142 -1.4042 -0.8327 -0.7454 -0.2029 -0.0927 -0.3616 -2.2693 -1.4974 -0.1152 -0.8396 -0.3287 -0.3187 -1.5799 -0.1228 -0.6493 -0.7446 -0.4481 -0.5685 -0.1296 -0.1756
S-518	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-518	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-518	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
D-518	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
P-518	-0.5073 -0.0825 -0.1233 -0.0401 -0.1628 -0.2389 -0.2953 -0.2356 -2.4155 -1.2455 -0.1383 -0.2195 -0.2991 -1.7021 -0.3204 -0.0742 -0.0584 -0.3142 -1.4042 -0.8327 -0.7454 -0.2029 -0.0927 -0.3616 -2.2693 -1.4974 -0.1152 -0.8396 -0.3287 -0.3187 -1.5799 -0.1228 -0.6493 -0.7446 -0.4481 -0.5685 -0.1296 -0.1756
S-588	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-588	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-588	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
D-588	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
P-588	-0.5073 -0.0825 -0.1233 -0.0401 -0.1628 -0.2389 -0.2953 -0.2356 -2.4155 -1.2455 -0.1383 -0.2195 -0.2991 -1.7021 -0.3204 -0.0742 -0.0584 -0.3142 -1.4042 -0.8327 -0.7454 -0.2029 -0.0927 -0.3616 -2.2693 -1.4974 -0.1152 -0.8396 -0.3287 -0.3187 -1.5799 -0.1228 -0.6493 -0.7446 -0.4481 -0.5685 -0.1296 -0.1756
S-508	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-508	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-508	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
D-508	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
P-508	-0.4834 -0.1101 -0.2251 -0.5020 -0.1108 -0.0710 -0.0590 -0.1411 -0.1254 -0.5698 -0.0696 -0.1511 -0.1367 -1.2823 -0.1433 -0.5713 -0.1960 -0.1600 -0.0836 -0.1973 -0.0947 -0.1264 -1.2461 -0.1318 -2.2906 -0.6085 -0.1895 -0.0886 -0.5956 -0.1148 -0.1518 -0.1470 -0.4878 -0.1250 -0.0472 -1.1124 -0.8133 -0.4046 -0.9268 -0.0910 -0.3294 -0.1472 -0.2373 -0.1211 -0.1300 -0.1730
S-438	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-438	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-438	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
D-438	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
P-438	-0.4834 -0.1101 -0.2251 -0.5020 -0.1108 -0.0710 -0.0590 -0.1411 -0.1254 -0.5698 -0.0696 -0.1511 -0.1367 -1.2823 -0.1433 -0.5713 -0.1960 -0.1600 -0.0836 -0.1973 -0.0947 -0.1264 -1.2461 -0.1318 -2.2906 -0.6085 -0.1895 -0.0886 -0.5956 -0.1148 -0.1518 -0.1470 -0.4878 -0.1250 -0.0472 -1.1124 -0.8133 -0.4046 -0.9268 -0.0910 -0.3294 -0.1472 -0.2373 -0.1211 -0.1300 -0.1730
S-84	<unk> Häufig ( 1<unk> 100 , <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 , <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 , <unk> 1<unk> 1.000 ) , sehr selten ( <unk> 1<unk> 10.000 ) <unk>
T-84	<<unk>> Common ( 1/ 100 , <<unk>> 1/ 10 ) , uncommon ( 1/ 1000 , <<unk>> 1/ 100 ) , rare ( 1/ 10,000 , <<unk>> 1/ 1000 ) , very rare ( <<unk>> 1/ 10,000 ) <<unk>>
H-84	-0.1710047423839569	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , uncommon ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
D-84	-0.1710047423839569	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , uncommon ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
P-84	-0.1570 -0.1725 -0.1047 -0.1837 -0.0499 -0.1420 -0.0992 -0.1498 -0.8097 -0.0983 -0.1136 -0.2647 -0.1334 -0.1511 -1.2675 -0.0141 -0.1718 -0.0754 -0.1121 -0.6225 -0.1430 -0.0832 -0.0792 -0.1092 -0.1311 -0.1273 -0.1477 -0.0892 -0.1814 -0.0571 -0.1244 -0.1056 -0.1466 -0.0624 -0.2648 -0.1150 -0.0589 -0.1299 -0.1498 -0.0905 -0.0623 -0.1900 -0.0145 -0.0789 -0.1208 -0.0803 -0.1374 -0.1361 -0.2697
S-299	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-299	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-299	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
D-299	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
P-299	-0.4834 -0.1101 -0.2251 -0.5020 -0.1108 -0.0710 -0.0590 -0.1411 -0.1254 -0.5698 -0.0696 -0.1511 -0.1367 -1.2823 -0.1433 -0.5713 -0.1960 -0.1600 -0.0836 -0.1973 -0.0947 -0.1264 -1.2461 -0.1318 -2.2906 -0.6085 -0.1895 -0.0886 -0.5956 -0.1148 -0.1518 -0.1470 -0.4878 -0.1250 -0.0472 -1.1124 -0.8133 -0.4046 -0.9268 -0.0910 -0.3294 -0.1472 -0.2373 -0.1211 -0.1300 -0.1730
S-368	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-368	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-368	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
D-368	-0.35479193925857544	The risk of developing inhibitors is correlated with the size of the exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure , and is dependent on genetic and other factors .
P-368	-0.4834 -0.1101 -0.2251 -0.5020 -0.1108 -0.0710 -0.0590 -0.1411 -0.1254 -0.5698 -0.0696 -0.1511 -0.1367 -1.2823 -0.1433 -0.5713 -0.1960 -0.1600 -0.0836 -0.1973 -0.0947 -0.1264 -1.2461 -0.1318 -2.2906 -0.6085 -0.1895 -0.0886 -0.5956 -0.1148 -0.1518 -0.1470 -0.4878 -0.1250 -0.0472 -1.1124 -0.8133 -0.4046 -0.9268 -0.0910 -0.3294 -0.1472 -0.2373 -0.1211 -0.1300 -0.1730
S-469	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-469	28 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-469	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
D-469	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
P-469	-0.0651 -0.3066 -0.0929 -0.0981 -2.3384 -0.0625 -0.1013 -0.0835 -0.3324 -0.2247 -0.0537 -0.2015 -0.1517 -0.5263 -0.2116 -0.1466 -1.6350 -0.3368 -0.4264 -0.2782 -0.1756 -0.1169 -0.5454 -0.3847 -0.0790 -0.0799 -0.1276 -0.1192 -0.4281 -0.6771 -0.0851 -0.3432 -0.1135 -0.6089 -0.2090 -0.1288 -0.1799
S-308	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-308	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-308	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
D-308	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
P-308	-0.5073 -0.0825 -0.1233 -0.0401 -0.1628 -0.2389 -0.2953 -0.2356 -2.4155 -1.2455 -0.1383 -0.2195 -0.2991 -1.7021 -0.3204 -0.0742 -0.0584 -0.3142 -1.4042 -0.8327 -0.7454 -0.2029 -0.0927 -0.3616 -2.2693 -1.4974 -0.1152 -0.8396 -0.3287 -0.3187 -1.5799 -0.1228 -0.6493 -0.7446 -0.4481 -0.5685 -0.1296 -0.1756
S-398	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-398	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-398	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
D-398	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
P-398	-0.2702 -0.3322 -0.1564 -0.2140 -0.0783 -0.1414 -0.1048 -0.8254 -0.9377 -0.7344 -0.1793 -0.7851 -0.9174 -0.1933 -0.6335 -0.6340 -0.5214 -0.1940 -0.1403 -0.8548 -0.2175 -0.6002 -0.1807 -0.1365 -0.3875 -0.2910 -0.0629 -0.4712 -0.1548 -0.1437 -0.4145 -0.6277 -0.1474 -0.1567 -0.0915 -0.0554 -0.0644 -0.1309 -0.8586 -0.0725 -0.1347 -0.1531 -0.2103 -0.1239 -0.1798
S-468	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-468	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-468	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
D-468	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
P-468	-0.2702 -0.3322 -0.1564 -0.2140 -0.0783 -0.1414 -0.1048 -0.8254 -0.9377 -0.7344 -0.1793 -0.7851 -0.9174 -0.1933 -0.6335 -0.6340 -0.5214 -0.1940 -0.1403 -0.8548 -0.2175 -0.6002 -0.1807 -0.1365 -0.3875 -0.2910 -0.0629 -0.4712 -0.1548 -0.1437 -0.4145 -0.6277 -0.1474 -0.1567 -0.0915 -0.0554 -0.0644 -0.1309 -0.8586 -0.0725 -0.1347 -0.1531 -0.2103 -0.1239 -0.1798
S-198	Bone mineral density ) an Wirbelsäule oder Hüfte , die 2,5 Standardabweichungen unter dem Mittelwert für eine normale , junge Bevölkerung liegt , oder ungeachtet der Knochendichte als vorliegende pathologische Fraktur .
T-198	Osteoporosis is defined as bone mineral density ( BMD ) of the spine or hip 2.5 standard deviations ( SD ) below the mean value of a normal young population or as a previous fragility fracture , irrespective of BMD .
H-198	-0.31036198139190674	bone mineral density ) at the spine or hip , which is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as the underlying pathological fracture .
D-198	-0.31036198139190674	bone mineral density ) at the spine or hip , which is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as the underlying pathological fracture .
P-198	-1.0205 -0.0621 -0.0530 -0.1358 -0.0865 -0.2500 -1.4790 -0.1998 -0.6793 -0.0352 -0.1215 -0.0329 -0.5154 -0.5505 -0.1241 -0.0685 -0.0841 -1.4781 -0.2688 -0.0251 -0.1256 -0.0733 -0.3291 -0.1692 -0.0480 -0.8641 -0.4633 -0.1405 -0.1417 -0.1151 -0.0658 -0.1379 -0.0392 -0.9000 -0.0541 -0.1823 -0.7415 -0.7621 -0.0465 -0.4778 -0.1542 -0.0316 -0.1319 -0.1910
S-42	Es darf nicht angewendet werden bei Erkrankungen der Speiseröhre , bei Patienten mit Hypocalcämie ( geringem Kalziumspiegel ) oder bei Patienten , die nicht mindestens 30 Minuten lang aufrecht stehen oder sitzen können .
T-42	It should not be used where there are abnormalities of the oesophagus ( gullet ) , in patients who have hypocalcaemia ( low calcium levels ) , or in patients who cannot stand or sit upright for at least 30 minutes .
H-42	-0.27415362000465393	It should not be used in oesophageal disorders , in patients with hypocalcaemia ( low calcium level ) or in patients who cannot stand or sit upright for at least 30 minutes .
D-42	-0.27415362000465393	It should not be used in oesophageal disorders , in patients with hypocalcaemia ( low calcium level ) or in patients who cannot stand or sit upright for at least 30 minutes .
P-42	-0.4652 -0.3104 -0.1191 -0.1750 -0.1045 -0.1547 -0.9414 -0.0318 -0.0430 -0.0113 -0.0825 -0.1532 -2.0338 -0.0751 -0.1396 -0.7398 -0.4132 -0.1269 -0.0488 -0.0612 -0.0525 -0.0763 -0.1534 -0.1450 -0.1008 -0.0961 -0.1915 -0.1198 -0.6357 -0.1649 -0.1719 -0.1697 -0.2773 -0.1864 -0.4255 -0.1346 -0.2042 -1.5136 -0.9666 -0.1914 -0.1163 -0.1370 -0.0937 -0.0938 -0.1154 -0.0923 -0.1243 -0.1785
S-328	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-328	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-328	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
D-328	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
P-328	-0.2702 -0.3322 -0.1564 -0.2140 -0.0783 -0.1414 -0.1048 -0.8254 -0.9377 -0.7344 -0.1793 -0.7851 -0.9174 -0.1933 -0.6335 -0.6340 -0.5214 -0.1940 -0.1403 -0.8548 -0.2175 -0.6002 -0.1807 -0.1365 -0.3875 -0.2910 -0.0629 -0.4712 -0.1548 -0.1437 -0.4145 -0.6277 -0.1474 -0.1567 -0.0915 -0.0554 -0.0644 -0.1309 -0.8586 -0.0725 -0.1347 -0.1531 -0.2103 -0.1239 -0.1798
S-711	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-711	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-711	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-711	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-711	-0.0093 -0.2987 -0.1344 -0.1144 -0.1463 -0.1759 -0.1035 -0.0798 -0.1501 -0.0076 -0.0343 -0.0520 -0.0970 -0.0888 -0.0700 -0.1431 -0.0707 -0.3226 -0.1007 -0.1415 -0.0748 -0.0792 -1.0594 -0.1477 -0.0522 -0.0636 -0.1562 -0.0507 -0.0892 -0.0921 -0.0714 -0.1422 -0.2158 -0.0680 -0.1338 -0.2070 -0.1484 -0.1394 -0.0024 -0.0320 -0.0655 -0.0728 -0.1394 -0.1909 -0.0765 -0.0681 -0.0946 -0.1958 -0.3140 -0.1635 -0.1635 -0.1901
S-708	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-708	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-708	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-708	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-708	-0.0093 -0.2987 -0.1344 -0.1144 -0.1463 -0.1759 -0.1035 -0.0798 -0.1501 -0.0076 -0.0343 -0.0520 -0.0970 -0.0888 -0.0700 -0.1431 -0.0707 -0.3226 -0.1007 -0.1415 -0.0748 -0.0792 -1.0594 -0.1477 -0.0522 -0.0636 -0.1562 -0.0507 -0.0892 -0.0921 -0.0714 -0.1422 -0.2158 -0.0680 -0.1338 -0.2070 -0.1484 -0.1394 -0.0024 -0.0320 -0.0655 -0.0728 -0.1394 -0.1909 -0.0765 -0.0681 -0.0946 -0.1958 -0.3140 -0.1635 -0.1635 -0.1901
S-538	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-538	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-538	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
D-538	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
P-538	-0.2702 -0.3322 -0.1564 -0.2140 -0.0783 -0.1414 -0.1048 -0.8254 -0.9377 -0.7344 -0.1793 -0.7851 -0.9174 -0.1933 -0.6335 -0.6340 -0.5214 -0.1940 -0.1403 -0.8548 -0.2175 -0.6002 -0.1807 -0.1365 -0.3875 -0.2910 -0.0629 -0.4712 -0.1548 -0.1437 -0.4145 -0.6277 -0.1474 -0.1567 -0.0915 -0.0554 -0.0644 -0.1309 -0.8586 -0.0725 -0.1347 -0.1531 -0.2103 -0.1239 -0.1798
S-608	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-608	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-608	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
D-608	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
P-608	-0.2702 -0.3322 -0.1564 -0.2140 -0.0783 -0.1414 -0.1048 -0.8254 -0.9377 -0.7344 -0.1793 -0.7851 -0.9174 -0.1933 -0.6335 -0.6340 -0.5214 -0.1940 -0.1403 -0.8548 -0.2175 -0.6002 -0.1807 -0.1365 -0.3875 -0.2910 -0.0629 -0.4712 -0.1548 -0.1437 -0.4145 -0.6277 -0.1474 -0.1567 -0.0915 -0.0554 -0.0644 -0.1309 -0.8586 -0.0725 -0.1347 -0.1531 -0.2103 -0.1239 -0.1798
S-678	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-678	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-678	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
D-678	-0.33144694566726685	The recovery and measured half-life in infants ( below age 6 ) was approximately 20 % lower than in adults , which may be due to the higher volume of plasma per kg bodyweight in younger patients .
P-678	-0.2702 -0.3322 -0.1564 -0.2140 -0.0783 -0.1414 -0.1048 -0.8254 -0.9377 -0.7344 -0.1793 -0.7851 -0.9174 -0.1933 -0.6335 -0.6340 -0.5214 -0.1940 -0.1403 -0.8548 -0.2175 -0.6002 -0.1807 -0.1365 -0.3875 -0.2910 -0.0629 -0.4712 -0.1548 -0.1437 -0.4145 -0.6277 -0.1474 -0.1567 -0.0915 -0.0554 -0.0644 -0.1309 -0.8586 -0.0725 -0.1347 -0.1531 -0.2103 -0.1239 -0.1798
S-100	Bone mineral density ) an Wirbelsäule oder Hüfte , die 2,5 Standardabweichungen unter dem Mittelwert für eine normale , junge Bevölkerung liegt , oder ungeachtet der Knochendichte als vorliegende pathologische Fraktur .
T-100	Osteoporosis is defined as bone mineral density ( BMD ) of the spine or hip 2.5 standard deviations ( SD ) below the mean value of a normal young population or as a previous fragility fracture , irrespective of BMD .
H-100	-0.31036198139190674	bone mineral density ) at the spine or hip , which is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as the underlying pathological fracture .
D-100	-0.31036198139190674	bone mineral density ) at the spine or hip , which is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as the underlying pathological fracture .
P-100	-1.0205 -0.0621 -0.0530 -0.1358 -0.0865 -0.2500 -1.4790 -0.1998 -0.6793 -0.0352 -0.1215 -0.0329 -0.5154 -0.5505 -0.1241 -0.0685 -0.0841 -1.4781 -0.2688 -0.0251 -0.1256 -0.0733 -0.3291 -0.1692 -0.0480 -0.8641 -0.4633 -0.1405 -0.1417 -0.1151 -0.0658 -0.1379 -0.0392 -0.9000 -0.0541 -0.1823 -0.7415 -0.7621 -0.0465 -0.4778 -0.1542 -0.0316 -0.1319 -0.1910
S-539	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-539	38 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-539	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
D-539	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
P-539	-0.0651 -0.3066 -0.0929 -0.0981 -2.3384 -0.0625 -0.1013 -0.0835 -0.3324 -0.2247 -0.0537 -0.2015 -0.1517 -0.5263 -0.2116 -0.1466 -1.6350 -0.3368 -0.4264 -0.2782 -0.1756 -0.1169 -0.5454 -0.3847 -0.0790 -0.0799 -0.1276 -0.1192 -0.4281 -0.6771 -0.0851 -0.3432 -0.1135 -0.6089 -0.2090 -0.1288 -0.1799
S-183	<unk> Häufig ( 1<unk> 100 , <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 , <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 , <unk> 1<unk> 1.000 ) , sehr selten ( <unk> 1<unk> 10.000 ) <unk>
T-183	<<unk>> Common ( 1/ 100 , <<unk>> 1/ 10 ) , uncommon ( 1/ 1000 , <<unk>> 1/ 100 ) , rare ( 1/ 10,000 , <<unk>> 1/ 1000 ) , very rare ( <<unk>> 1/ 10,000 ) <<unk>>
H-183	-0.1710047423839569	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , uncommon ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
D-183	-0.1710047423839569	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , uncommon ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
P-183	-0.1570 -0.1725 -0.1047 -0.1837 -0.0499 -0.1420 -0.0992 -0.1498 -0.8097 -0.0983 -0.1136 -0.2647 -0.1334 -0.1511 -1.2675 -0.0141 -0.1718 -0.0754 -0.1121 -0.6225 -0.1430 -0.0832 -0.0792 -0.1092 -0.1311 -0.1273 -0.1477 -0.0892 -0.1814 -0.0571 -0.1244 -0.1056 -0.1466 -0.0624 -0.2648 -0.1150 -0.0589 -0.1299 -0.1498 -0.0905 -0.0623 -0.1900 -0.0145 -0.0789 -0.1208 -0.0803 -0.1374 -0.1361 -0.2697
S-790	Es darf nicht angewendet werden bei Patienten , die einen Monoaminooxidasehemmer ( wie z. B. einige Arzneimittel gegen Depressionen ) einnehmen oder die Einnahme eines solchen Arzneimittels in den letzten zwei Wochen beendet haben .
T-790	It should not be used in people who are taking a monoamine oxidase inhibitor ( such as some medicines used to treat depression ) or who have stopped taking one of these medicines within the last two weeks .
H-790	-0.3190311789512634	It should not be used in people who are taking monoamine oxidase inhibitors ( such as some anti-depressant medicines ) or who have stopped taking such a medicine for the last two weeks .
D-790	-0.3190311789512634	It should not be used in people who are taking monoamine oxidase inhibitors ( such as some anti-depressant medicines ) or who have stopped taking such a medicine for the last two weeks .
P-790	-0.4647 -0.2821 -0.1203 -0.1645 -0.1176 -0.1353 -1.0794 -0.4476 -0.3372 -0.0275 -1.3188 -0.1738 -0.1861 -0.3204 -0.1568 -0.1228 -0.1524 -0.0722 -0.0497 -0.1052 -0.2221 -0.9770 -0.1648 -0.0981 -0.0537 -0.4434 -0.1107 -0.1893 -0.8853 -0.6635 -0.4089 -0.1541 -0.2303 -0.4431 -0.1242 -0.5211 -0.0457 -0.2219 -0.2714 -0.5706 -0.9603 -0.1279 -0.6825 -0.2053 -0.0712 -0.1317 -0.1819
S-624	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-624	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-624	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
D-624	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
P-624	-1.7852 -0.6480 -0.3507 -0.1571 -0.1215 -0.1614 -0.1192 -0.0676 -0.0896 -0.7373 -1.6221 -0.4186 -0.2241 -0.1439 -0.1793 -0.0217 -0.1469 -0.8139 -0.0597 -0.1010 -0.1082 -0.0426 -0.0594 -0.1402 -0.1430 -0.4987 -0.1016 -0.0680 -0.1760 -0.0508 -0.1533 -0.3228 -0.1191 -0.6578 -0.2101 -2.2232 -0.2410 -0.0531 -2.6740 -0.1976 -0.1055 -0.1945 -0.1308 -0.1784
S-609	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-609	48 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-609	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
D-609	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
P-609	-0.0651 -0.3066 -0.0929 -0.0981 -2.3384 -0.0625 -0.1013 -0.0835 -0.3324 -0.2247 -0.0537 -0.2015 -0.1517 -0.5263 -0.2116 -0.1466 -1.6350 -0.3368 -0.4264 -0.2782 -0.1756 -0.1169 -0.5454 -0.3847 -0.0790 -0.0799 -0.1276 -0.1192 -0.4281 -0.6771 -0.0851 -0.3432 -0.1135 -0.6089 -0.2090 -0.1288 -0.1799
S-679	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-679	58 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-679	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
D-679	-0.32635483145713806	Non-clinical data , based on studies of safety pharmacology , acute , repeated and local toxicity and genotoxicity , show no special risk to humans .
P-679	-0.0651 -0.3066 -0.0929 -0.0981 -2.3384 -0.0625 -0.1013 -0.0835 -0.3324 -0.2247 -0.0537 -0.2015 -0.1517 -0.5263 -0.2116 -0.1466 -1.6350 -0.3368 -0.4264 -0.2782 -0.1756 -0.1169 -0.5454 -0.3847 -0.0790 -0.0799 -0.1276 -0.1192 -0.4281 -0.6771 -0.0851 -0.3432 -0.1135 -0.6089 -0.2090 -0.1288 -0.1799
S-554	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-554	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-554	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
D-554	-0.3822426497936249	Factor VIII activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Plasma Factor VIII ) .
P-554	-1.7852 -0.6480 -0.3507 -0.1571 -0.1215 -0.1614 -0.1192 -0.0676 -0.0896 -0.7373 -1.6221 -0.4186 -0.2241 -0.1439 -0.1793 -0.0217 -0.1469 -0.8139 -0.0597 -0.1010 -0.1082 -0.0426 -0.0594 -0.1402 -0.1430 -0.4987 -0.1016 -0.0680 -0.1760 -0.0508 -0.1533 -0.3228 -0.1191 -0.6578 -0.2101 -2.2232 -0.2410 -0.0531 -2.6740 -0.1976 -0.1055 -0.1945 -0.1308 -0.1784
S-705	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-705	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-705	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-705	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-705	-0.0093 -0.2987 -0.1344 -0.1144 -0.1463 -0.1759 -0.1035 -0.0798 -0.1501 -0.0076 -0.0343 -0.0520 -0.0970 -0.0888 -0.0700 -0.1431 -0.0707 -0.3226 -0.1007 -0.1415 -0.0748 -0.0792 -1.0594 -0.1477 -0.0522 -0.0636 -0.1562 -0.0507 -0.0892 -0.0921 -0.0714 -0.1422 -0.2158 -0.0680 -0.1338 -0.2070 -0.1484 -0.1394 -0.0024 -0.0320 -0.0655 -0.0728 -0.1394 -0.1909 -0.0765 -0.0681 -0.0946 -0.1958 -0.3140 -0.1635 -0.1635 -0.1901
S-696	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-696	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-696	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-696	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-696	-0.0093 -0.2987 -0.1344 -0.1144 -0.1463 -0.1759 -0.1035 -0.0798 -0.1501 -0.0076 -0.0343 -0.0520 -0.0970 -0.0888 -0.0700 -0.1431 -0.0707 -0.3226 -0.1007 -0.1415 -0.0748 -0.0792 -1.0594 -0.1477 -0.0522 -0.0636 -0.1562 -0.0507 -0.0892 -0.0921 -0.0714 -0.1422 -0.2158 -0.0680 -0.1338 -0.2070 -0.1484 -0.1394 -0.0024 -0.0320 -0.0655 -0.0728 -0.1394 -0.1909 -0.0765 -0.0681 -0.0946 -0.1958 -0.3140 -0.1635 -0.1635 -0.1901
S-699	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-699	Exipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-699	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-699	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-699	-0.0093 -0.2987 -0.1344 -0.1144 -0.1463 -0.1759 -0.1035 -0.0798 -0.1501 -0.0076 -0.0343 -0.0520 -0.0970 -0.0888 -0.0700 -0.1431 -0.0707 -0.3226 -0.1007 -0.1415 -0.0748 -0.0792 -1.0594 -0.1477 -0.0522 -0.0636 -0.1562 -0.0507 -0.0892 -0.0921 -0.0714 -0.1422 -0.2158 -0.0680 -0.1338 -0.2070 -0.1484 -0.1394 -0.0024 -0.0320 -0.0655 -0.0728 -0.1394 -0.1909 -0.0765 -0.0681 -0.0946 -0.1958 -0.3140 -0.1635 -0.1635 -0.1901
S-702	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-702	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-702	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-702	-0.13655570149421692	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-702	-0.0093 -0.2987 -0.1344 -0.1144 -0.1463 -0.1759 -0.1035 -0.0798 -0.1501 -0.0076 -0.0343 -0.0520 -0.0970 -0.0888 -0.0700 -0.1431 -0.0707 -0.3226 -0.1007 -0.1415 -0.0748 -0.0792 -1.0594 -0.1477 -0.0522 -0.0636 -0.1562 -0.0507 -0.0892 -0.0921 -0.0714 -0.1422 -0.2158 -0.0680 -0.1338 -0.2070 -0.1484 -0.1394 -0.0024 -0.0320 -0.0655 -0.0728 -0.1394 -0.1909 -0.0765 -0.0681 -0.0946 -0.1958 -0.3140 -0.1635 -0.1635 -0.1901
S-378	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-378	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-378	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
D-378	-0.5763167142868042	Blood clotting was sustained throughout this duration and both the plasma factor VII and clearance rates returned satisfactory values on the 15-post-operative day .
P-378	-0.5073 -0.0825 -0.1233 -0.0401 -0.1628 -0.2389 -0.2953 -0.2356 -2.4155 -1.2455 -0.1383 -0.2195 -0.2991 -1.7021 -0.3204 -0.0742 -0.0584 -0.3142 -1.4042 -0.8327 -0.7454 -0.2029 -0.0927 -0.3616 -2.2693 -1.4974 -0.1152 -0.8396 -0.3287 -0.3187 -1.5799 -0.1228 -0.6493 -0.7446 -0.4481 -0.5685 -0.1296 -0.1756
S-116	In dieser Studie reduzierte die tägliche Gabe von Alendronat das Auftreten von mindestens einer neuen Wirbelfraktur um 47 % ( Alendronat 7,9 % gegenüber Plazebo 15,0 % ) .
T-116	In this study alendronate daily reduced the incidence of 1 new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
H-116	-0.225871279835701	In this study , daily administration of alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
D-116	-0.225871279835701	In this study , daily administration of alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
P-116	-0.0723 -0.1968 -0.4929 -0.8935 -0.0402 -0.8856 -0.1399 -0.1963 -0.1486 -0.1000 -0.0898 -0.1635 -0.5452 -0.5215 -0.0586 -0.0602 -0.1214 -0.1376 -0.0751 -0.1144 -0.2021 -0.0748 -0.8503 -0.0764 -0.0279 -0.1003 -0.2054 -0.0557 -0.0897 -0.0650 -0.1509 -0.1529 -0.6309 -0.1336 -0.1520 -0.0909 -0.1742 -0.1752 -0.1180 -1.1414 -0.2060 -0.1912 -0.2017 -0.1380 -0.0989 -0.1701 -0.1231 -0.1413 -0.1252 -0.1774
S-812	Von den folgenden Begleittherapien wird abgeraten : Bromocriptin Cabergolin Lisurid , Pergolid : Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie .
T-812	The following combinations are not recommended : bromocriptine cabergoline lisuride , pergolide : risk of vasoconstriction and increase in blood pressure .
H-812	-0.6136677265167236	The following concomitant therapies are not recommended : bromocriptin Cabergolin Lisuride , pergolide : risk for vessel constriction and hypertension .
D-812	-0.6136677265167236	The following concomitant therapies are not recommended : bromocriptin Cabergolin Lisuride , pergolide : risk for vessel constriction and hypertension .
P-812	-1.3870 -0.0682 -2.5182 -0.0571 -0.0553 -0.1587 -1.8778 -0.0772 -0.1220 -0.8674 -0.2755 -0.1521 -0.1271 -0.1555 -0.0724 -0.1406 -0.4684 -3.6752 -2.1993 -1.8509 -0.1467 -0.2132 -0.1107 -1.6330 -0.1704 -0.1025 -0.3708 -0.0978 -0.7082 -0.1578 -0.1284 -1.0380 -1.0453 -1.7091 -0.4245 -0.2409 -0.1515 -0.0421 -0.0216 -0.1647 -0.1772
S-132	Die mittlere maximale Konzentration im Serum ( Cmax ) von Vitamin D3 betrug 5,9 ng<unk> ml und die Medianzeit bis zum Erreichen der maximalen Serumkonzentration ( Tmax ) 12 Stunden .
T-132	The mean maximal serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml , and the median time to maximal serum concentration ( Tmax ) was 12 hours .
H-132	-0.23876439034938812	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml and the median time to reach the maximum serum concentration ( Tmax ) was 12 hours .
D-132	-0.23876439034938812	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml and the median time to reach the maximum serum concentration ( Tmax ) was 12 hours .
P-132	-0.1405 -0.0422 -0.1426 -0.5648 -0.1230 -1.3063 -0.1395 -0.1353 -0.0508 -0.1412 -0.1419 -0.0723 -0.0854 -0.1231 -0.1890 -0.1351 -0.2118 -0.1580 -0.1341 -0.2027 -0.1339 -0.0566 -0.1839 -0.1198 -0.1205 -0.0310 -0.5398 -0.2304 -1.6144 -0.4822 -0.1533 -0.2627 -0.1194 -0.1395 -0.1419 -0.1666 -0.0325 -0.1398 -0.7759 -0.1556 -0.1216 -0.1344 -0.1715
S-219	In dieser Studie reduzierte die tägliche Gabe von Alendronat das Auftreten von mindestens einer neuen Wirbelfraktur um 47 % ( Alendronat 7,9 % gegenüber Plazebo 15,0 % ) .
T-219	In this study alendronate daily reduced the incidence of 1 new 18 vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
H-219	-0.225871279835701	In this study , daily administration of alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
D-219	-0.225871279835701	In this study , daily administration of alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
P-219	-0.0723 -0.1968 -0.4929 -0.8935 -0.0402 -0.8856 -0.1399 -0.1963 -0.1486 -0.1000 -0.0898 -0.1635 -0.5452 -0.5215 -0.0586 -0.0602 -0.1214 -0.1376 -0.0751 -0.1144 -0.2021 -0.0748 -0.8503 -0.0764 -0.0279 -0.1003 -0.2054 -0.0557 -0.0897 -0.0650 -0.1509 -0.1529 -0.6309 -0.1336 -0.1520 -0.0909 -0.1742 -0.1752 -0.1180 -1.1414 -0.2060 -0.1912 -0.2017 -0.1380 -0.0989 -0.1701 -0.1231 -0.1413 -0.1252 -0.1774
S-195	18 Colecalciferol ( Vitamin D3 ) Vitamin D3 wird in der Haut durch UV-Licht über die Umwandlung von 7-Dehydrocholesterol zu Vitamin D3 produziert .
T-195	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by conversion of 7-dehydrocholesterol to vitamin D3 by ultraviolet light .
H-195	-0.3222026228904724	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light transferring 7 dehydrocholesterol to vitamin D3 .
D-195	-0.3222026228904724	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light transferring 7 dehydrocholesterol to vitamin D3 .
P-195	-1.1870 -0.1891 -0.2036 -0.1360 -0.0844 -0.1898 -0.1551 -0.1474 -0.0582 -0.1048 -0.2191 -0.1526 -0.2763 -0.0363 -0.1027 -0.2055 -0.1335 -0.0506 -0.1875 -0.1159 -0.0445 -0.0930 -0.1777 -0.4946 -0.1062 -0.6773 -2.6148 -0.0424 -1.2587 -0.8804 -0.1014 -1.2191 -0.0928 -0.1156 -0.2621 -0.3232 -0.0527 -0.1075 -0.2672 -0.1586 -0.1849
S-626	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-626	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-626	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
D-626	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
P-626	-0.8095 -1.4394 -0.1577 -1.4582 -0.1171 -2.0401 -0.0379 -0.3575 -0.0908 -0.0728 -0.1519 -0.1894 -0.7201 -1.0228 -0.3409 -0.0917 -0.2322 -0.1131 -1.3207 -0.0063 -0.2442 -2.0855 -0.2186 -0.0443 -0.0472 -0.0346 -0.0267 -0.0652 -0.1783 -1.3528 -0.1164 -0.1414 -0.9140 -0.1082 -0.3281 -0.0893 -0.1578 -0.0549 -0.1645 -1.2677 -0.1262 -0.7434 -0.1475 -0.1117 -0.1820 -0.1794
S-486	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-486	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-486	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
D-486	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
P-486	-0.8095 -1.4394 -0.1577 -1.4582 -0.1171 -2.0401 -0.0379 -0.3575 -0.0908 -0.0728 -0.1519 -0.1894 -0.7201 -1.0228 -0.3409 -0.0917 -0.2322 -0.1131 -1.3207 -0.0063 -0.2442 -2.0855 -0.2186 -0.0443 -0.0472 -0.0346 -0.0267 -0.0652 -0.1783 -1.3528 -0.1164 -0.1414 -0.9140 -0.1082 -0.3281 -0.0893 -0.1578 -0.0549 -0.1645 -1.2677 -0.1262 -0.7434 -0.1475 -0.1117 -0.1820 -0.1794
S-556	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-556	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-556	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
D-556	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
P-556	-0.8095 -1.4394 -0.1577 -1.4582 -0.1171 -2.0401 -0.0379 -0.3575 -0.0908 -0.0728 -0.1519 -0.1894 -0.7201 -1.0228 -0.3409 -0.0917 -0.2322 -0.1131 -1.3207 -0.0063 -0.2442 -2.0855 -0.2186 -0.0443 -0.0472 -0.0346 -0.0267 -0.0652 -0.1783 -1.3528 -0.1164 -0.1414 -0.9140 -0.1082 -0.3281 -0.0893 -0.1578 -0.0549 -0.1645 -1.2677 -0.1262 -0.7434 -0.1475 -0.1117 -0.1820 -0.1794
S-674	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-674	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-674	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
D-674	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
P-674	-0.9501 -0.0217 -0.1855 -0.1124 -0.0529 -0.1369 -0.1420 -0.0892 -0.1313 -0.4650 -0.7300 -0.6671 -2.1442 -0.2120 -0.0610 -0.6833 -0.4993 -0.1620 -0.0966 -0.1988 -0.0565 -0.1202 -0.1100 -0.0966 -0.1743 -0.1737 -0.3092 -0.0873 -0.4308 -0.0821 -0.4938 -0.1497 -0.6829 -0.1682 -0.1388 -1.1546 -0.0871 -1.1721 -0.1219 -0.4336 -0.9275 -0.0700 -0.1463 -0.1790
S-370	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-370	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-370	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
D-370	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
P-370	-0.0264 -0.2546 -0.2121 -0.1381 -0.4499 -0.0300 -0.1390 -0.0776 -0.1632 -0.0749 -0.1649 -0.2029 -1.0500 -0.4072 -0.1138 -0.5874 -0.0973 -0.1617 -0.5504 -0.4113 -0.9229 -0.0600 -2.2099 -0.2435 -0.2404 -0.0697 -0.1383 -0.1481 -0.0870 -0.0545 -0.1312 -0.4752 -0.2220
S-394	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-394	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-394	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
D-394	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
P-394	-0.9501 -0.0217 -0.1855 -0.1124 -0.0529 -0.1369 -0.1420 -0.0892 -0.1313 -0.4650 -0.7300 -0.6671 -2.1442 -0.2120 -0.0610 -0.6833 -0.4993 -0.1620 -0.0966 -0.1988 -0.0565 -0.1202 -0.1100 -0.0966 -0.1743 -0.1737 -0.3092 -0.0873 -0.4308 -0.0821 -0.4938 -0.1497 -0.6829 -0.1682 -0.1388 -1.1546 -0.0871 -1.1721 -0.1219 -0.4336 -0.9275 -0.0700 -0.1463 -0.1790
S-464	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-464	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-464	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
D-464	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
P-464	-0.9501 -0.0217 -0.1855 -0.1124 -0.0529 -0.1369 -0.1420 -0.0892 -0.1313 -0.4650 -0.7300 -0.6671 -2.1442 -0.2120 -0.0610 -0.6833 -0.4993 -0.1620 -0.0966 -0.1988 -0.0565 -0.1202 -0.1100 -0.0966 -0.1743 -0.1737 -0.3092 -0.0873 -0.4308 -0.0821 -0.4938 -0.1497 -0.6829 -0.1682 -0.1388 -1.1546 -0.0871 -1.1721 -0.1219 -0.4336 -0.9275 -0.0700 -0.1463 -0.1790
S-534	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-534	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-534	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
D-534	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
P-534	-0.9501 -0.0217 -0.1855 -0.1124 -0.0529 -0.1369 -0.1420 -0.0892 -0.1313 -0.4650 -0.7300 -0.6671 -2.1442 -0.2120 -0.0610 -0.6833 -0.4993 -0.1620 -0.0966 -0.1988 -0.0565 -0.1202 -0.1100 -0.0966 -0.1743 -0.1737 -0.3092 -0.0873 -0.4308 -0.0821 -0.4938 -0.1497 -0.6829 -0.1682 -0.1388 -1.1546 -0.0871 -1.1721 -0.1219 -0.4336 -0.9275 -0.0700 -0.1463 -0.1790
S-604	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-604	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-604	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
D-604	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
P-604	-0.9501 -0.0217 -0.1855 -0.1124 -0.0529 -0.1369 -0.1420 -0.0892 -0.1313 -0.4650 -0.7300 -0.6671 -2.1442 -0.2120 -0.0610 -0.6833 -0.4993 -0.1620 -0.0966 -0.1988 -0.0565 -0.1202 -0.1100 -0.0966 -0.1743 -0.1737 -0.3092 -0.0873 -0.4308 -0.0821 -0.4938 -0.1497 -0.6829 -0.1682 -0.1388 -1.1546 -0.0871 -1.1721 -0.1219 -0.4336 -0.9275 -0.0700 -0.1463 -0.1790
S-820	Die Patienten sollten jedoch darüber aufgeklärt werden , dass es in sehr seltenen Fällen zu einer Benommenheit kommen kann , die zu einer Beeinträchtigung der Verkehrstüchtigkeit oder der Fähigkeit zum Bedienen von Maschinen führen kann .
T-820	However , patients should be informed that very rarely some people experience drowsiness , which may affect their ability to drive or use machines .
H-820	-0.29500237107276917	However , patients should be advised that in very rare cases light-headedness may occur which may impair the ability to drive or use machines .
D-820	-0.29500237107276917	However , patients should be advised that in very rare cases light-headedness may occur which may impair the ability to drive or use machines .
P-820	-0.1700 -0.2548 -0.1631 -0.2538 -0.2054 -0.7902 -0.1601 -0.3298 -0.1444 -0.0447 -0.1911 -1.3690 -0.0100 -0.0031 -0.0003 -0.0215 -0.5043 -0.0800 -1.0480 -0.1463 -1.4457 -0.0329 -0.6308 -0.0271 -0.1726 -0.0580 -0.1295 -0.0516 -0.3926 -0.1348 -0.1799
S-115	FIT bestand aus zwei plazebokontrollierten Studien , bei denen Alendronat täglich ( 5 mg täglich über 2 Jahre und anschließend 10 mg täglich weiterhin entweder über 1 oder 2 Jahre ) eingenommen wurde :
T-115	FIT consisted of two placebo-controlled studies using alendronate daily ( 5 mg daily for two years and 10 mg daily for either one or two additional years ) :
H-115	-0.2502007484436035	FIT consisted of two placebo-controlled trials in which alendronate was administered daily ( 5 mg daily for 2 years and than 10 mg daily for either 1 or 2 years ) :
D-115	-0.2502007484436035	FIT consisted of two placebo-controlled trials in which alendronate was administered daily ( 5 mg daily for 2 years and than 10 mg daily for either 1 or 2 years ) :
P-115	-0.0876 -0.0991 -0.0932 -0.1022 -0.1439 -0.2144 -0.1487 -0.1434 -0.0581 -0.1000 -0.1866 -0.3546 -0.5480 -0.1118 -0.2837 -0.1380 -0.0845 -0.0875 -0.1822 -0.8564 -0.0885 -0.0951 -0.1303 -0.3532 -0.0433 -0.0173 -0.1543 -0.2033 -0.1415 -0.3188 -2.2109 -0.1544 -0.0705 -0.2759 -0.5314 -0.9497 -0.0642 -0.1113 -0.1480 -0.1722 -0.1324 -0.1813 -0.1867
S-218	FIT bestand aus zwei plazebokontrollierten Studien , bei denen Alendronat täglich ( 5 mg täglich über 2 Jahre und anschließend 10 mg täglich weiterhin entweder über 1 oder 2 Jahre ) eingenommen wurde :
T-218	FIT consisted of two placebo-controlled studies using alendronate daily ( 5 mg daily for two years and 10 mg daily for either one or two additional years ) :
H-218	-0.2502007484436035	FIT consisted of two placebo-controlled trials in which alendronate was administered daily ( 5 mg daily for 2 years and than 10 mg daily for either 1 or 2 years ) :
D-218	-0.2502007484436035	FIT consisted of two placebo-controlled trials in which alendronate was administered daily ( 5 mg daily for 2 years and than 10 mg daily for either 1 or 2 years ) :
P-218	-0.0876 -0.0991 -0.0932 -0.1022 -0.1439 -0.2144 -0.1487 -0.1434 -0.0581 -0.1000 -0.1866 -0.3546 -0.5480 -0.1118 -0.2837 -0.1380 -0.0845 -0.0875 -0.1822 -0.8564 -0.0885 -0.0951 -0.1303 -0.3532 -0.0433 -0.0173 -0.1543 -0.2033 -0.1415 -0.3188 -2.2109 -0.1544 -0.0705 -0.2759 -0.5314 -0.9497 -0.0642 -0.1113 -0.1480 -0.1722 -0.1324 -0.1813 -0.1867
S-416	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-416	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-416	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
D-416	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
P-416	-0.8095 -1.4394 -0.1577 -1.4582 -0.1171 -2.0401 -0.0379 -0.3575 -0.0908 -0.0728 -0.1519 -0.1894 -0.7201 -1.0228 -0.3409 -0.0917 -0.2322 -0.1131 -1.3207 -0.0063 -0.2442 -2.0855 -0.2186 -0.0443 -0.0472 -0.0346 -0.0267 -0.0652 -0.1783 -1.3528 -0.1164 -0.1414 -0.9140 -0.1082 -0.3281 -0.0893 -0.1578 -0.0549 -0.1645 -1.2677 -0.1262 -0.7434 -0.1475 -0.1117 -0.1820 -0.1794
S-301	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-301	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-301	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
D-301	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
P-301	-0.0264 -0.2546 -0.2121 -0.1381 -0.4499 -0.0300 -0.1390 -0.0776 -0.1632 -0.0749 -0.1649 -0.2029 -1.0500 -0.4072 -0.1138 -0.5874 -0.0973 -0.1617 -0.5504 -0.4113 -0.9229 -0.0600 -2.2099 -0.2435 -0.2404 -0.0697 -0.1383 -0.1481 -0.0870 -0.0545 -0.1312 -0.4752 -0.2220
S-440	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-440	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-440	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
D-440	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
P-440	-0.0264 -0.2546 -0.2121 -0.1381 -0.4499 -0.0300 -0.1390 -0.0776 -0.1632 -0.0749 -0.1649 -0.2029 -1.0500 -0.4072 -0.1138 -0.5874 -0.0973 -0.1617 -0.5504 -0.4113 -0.9229 -0.0600 -2.2099 -0.2435 -0.2404 -0.0697 -0.1383 -0.1481 -0.0870 -0.0545 -0.1312 -0.4752 -0.2220
S-510	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-510	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-510	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
D-510	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
P-510	-0.0264 -0.2546 -0.2121 -0.1381 -0.4499 -0.0300 -0.1390 -0.0776 -0.1632 -0.0749 -0.1649 -0.2029 -1.0500 -0.4072 -0.1138 -0.5874 -0.0973 -0.1617 -0.5504 -0.4113 -0.9229 -0.0600 -2.2099 -0.2435 -0.2404 -0.0697 -0.1383 -0.1481 -0.0870 -0.0545 -0.1312 -0.4752 -0.2220
S-580	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-580	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-580	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
D-580	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
P-580	-0.0264 -0.2546 -0.2121 -0.1381 -0.4499 -0.0300 -0.1390 -0.0776 -0.1632 -0.0749 -0.1649 -0.2029 -1.0500 -0.4072 -0.1138 -0.5874 -0.0973 -0.1617 -0.5504 -0.4113 -0.9229 -0.0600 -2.2099 -0.2435 -0.2404 -0.0697 -0.1383 -0.1481 -0.0870 -0.0545 -0.1312 -0.4752 -0.2220
S-650	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-650	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-650	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
D-650	-0.31259089708328247	All patients treated with clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for the development of inhibitors .
P-650	-0.0264 -0.2546 -0.2121 -0.1381 -0.4499 -0.0300 -0.1390 -0.0776 -0.1632 -0.0749 -0.1649 -0.2029 -1.0500 -0.4072 -0.1138 -0.5874 -0.0973 -0.1617 -0.5504 -0.4113 -0.9229 -0.0600 -2.2099 -0.2435 -0.2404 -0.0697 -0.1383 -0.1481 -0.0870 -0.0545 -0.1312 -0.4752 -0.2220
S-97	Colecalciferol ( Vitamin D3 ) Vitamin D3 wird in der Haut durch UV-Licht über die Umwandlung von 7-Dehydrocholesterol zu Vitamin D3 produziert .
T-97	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by conversion of 7-dehydrocholesterol to vitamin D3 by ultraviolet light .
H-97	-0.3145589232444763	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light transferring 7 dehydrocholesterol to vitamin D3 .
D-97	-0.3145589232444763	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light transferring 7 dehydrocholesterol to vitamin D3 .
P-97	-0.9099 -0.1793 -0.2347 -0.1363 -0.0837 -0.2031 -0.1425 -0.1317 -0.0574 -0.1084 -0.2219 -0.1546 -0.2847 -0.0371 -0.1044 -0.2076 -0.1323 -0.0518 -0.1709 -0.1170 -0.0461 -0.0915 -0.1747 -0.5006 -0.1023 -0.6537 -2.6744 -0.0415 -1.2381 -0.9363 -0.1056 -1.0676 -0.0922 -0.1219 -0.2650 -0.3647 -0.0490 -0.1072 -0.2642 -0.1503 -0.1807
S-277	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-277	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-277	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
D-277	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
P-277	-0.8095 -1.4394 -0.1577 -1.4582 -0.1171 -2.0401 -0.0379 -0.3575 -0.0908 -0.0728 -0.1519 -0.1894 -0.7201 -1.0228 -0.3409 -0.0917 -0.2322 -0.1131 -1.3207 -0.0063 -0.2442 -2.0855 -0.2186 -0.0443 -0.0472 -0.0346 -0.0267 -0.0652 -0.1783 -1.3528 -0.1164 -0.1414 -0.9140 -0.1082 -0.3281 -0.0893 -0.1578 -0.0549 -0.1645 -1.2677 -0.1262 -0.7434 -0.1475 -0.1117 -0.1820 -0.1794
S-346	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-346	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-346	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
D-346	-0.43260830640792847	In case of subsequent haemorrhagic events , the factor VIII activity should not fall below the stated plasma concentrations ( as % of normal or IU/ dl ) during the corresponding period .
P-346	-0.8095 -1.4394 -0.1577 -1.4582 -0.1171 -2.0401 -0.0379 -0.3575 -0.0908 -0.0728 -0.1519 -0.1894 -0.7201 -1.0228 -0.3409 -0.0917 -0.2322 -0.1131 -1.3207 -0.0063 -0.2442 -2.0855 -0.2186 -0.0443 -0.0472 -0.0346 -0.0267 -0.0652 -0.1783 -1.3528 -0.1164 -0.1414 -0.9140 -0.1082 -0.3281 -0.0893 -0.1578 -0.0549 -0.1645 -1.2677 -0.1262 -0.7434 -0.1475 -0.1117 -0.1820 -0.1794
S-324	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-324	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-324	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
D-324	-0.3478947877883911	Pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or equal to <unk> 10 years and are listed in Table 3 below .
P-324	-0.9501 -0.0217 -0.1855 -0.1124 -0.0529 -0.1369 -0.1420 -0.0892 -0.1313 -0.4650 -0.7300 -0.6671 -2.1442 -0.2120 -0.0610 -0.6833 -0.4993 -0.1620 -0.0966 -0.1988 -0.0565 -0.1202 -0.1100 -0.0966 -0.1743 -0.1737 -0.3092 -0.0873 -0.4308 -0.0821 -0.4938 -0.1497 -0.6829 -0.1682 -0.1388 -1.1546 -0.0871 -1.1721 -0.1219 -0.4336 -0.9275 -0.0700 -0.1463 -0.1790
S-673	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-673	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-673	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
D-673	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
P-673	-0.0168 -0.2376 -0.0617 -0.0552 -0.3863 -0.6857 -0.3241 -0.1125 -0.2068 -0.0595 -0.1294 -0.9480 -0.2952 -0.1312 -0.1001 -0.0472 -0.1066 -0.2355 -0.1304 -0.1109 -0.1947 -0.4556 -0.2901 -0.1216 -0.2793 -1.5142 -0.1558 -0.5214 -0.0560 -0.0497 -1.8841 -1.2969 -1.1202 -0.0256 -0.0515 -0.1344 -0.2687 -0.2223 -0.1758
S-88	Eine Krebsdiagnose , Chemotherapie , Strahlentherapie , Kortikosteroide und unzureichende Mundhygiene gelten ebenfalls als Risikofaktoren ( siehe Abschnitt 4.4 ) . Gelenkschwellungen .
T-88	Diagnosis of cancer , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also deemed as risk factors ( see section 4.4 ) ; joint swelling .
H-88	-0.15126167237758636	Cancer diagnosis , chemotherapy , radiation therapy , corticosteroids and inadequate oral hygiene are also considered risk factors ( see section 4.4 ) .
D-88	-0.15126167237758636	Cancer diagnosis , chemotherapy , radiation therapy , corticosteroids and inadequate oral hygiene are also considered risk factors ( see section 4.4 ) .
P-88	-0.2657 -0.2004 -0.1453 -0.0949 -0.0635 -0.0778 -0.1369 -0.3497 -0.0720 -0.1339 -0.0990 -0.0692 -0.0968 -0.1871 -0.1835 -0.0230 -0.2235 -0.4048 -0.2148 -0.1637 -0.1414 -0.0597 -0.1387 -0.0559 -0.1290 -0.1414 -0.1422 -0.1799 -0.0484 -0.0843 -0.1807 -0.1705 -0.1617 -0.2585 -0.1963
S-810	Aerinaze ist mindestens 48 Stunden vor der Durchführung dermatologischer Tests abzusetzen , da Antihistaminika ansonsten positive Reaktionen auf Indikatoren für Hautreaktionen verhindern bzw. in ihrem Ausmaß reduzieren können .
T-810	The administration of Aerinaze should be discontinued at least 48 hours before skin tests since antihistamines maybe prevent or reduce other wise positive reaction to dermal reactivity index .
H-810	-0.35103389620780945	Aerinaze should be discontinued at least 48 hours prior to performing dermatologic tests , otherwise antihistamines may prevent or reduce positive reactions to indicators of skin reaction .
D-810	-0.35103389620780945	Aerinaze should be discontinued at least 48 hours prior to performing dermatologic tests , otherwise antihistamines may prevent or reduce positive reactions to indicators of skin reaction .
P-810	-0.3413 -0.1492 -0.1299 -0.3434 -0.0929 -0.3188 -0.1578 -0.6139 -0.0320 -0.1273 -0.1370 -0.0915 -0.1344 -0.2749 -0.1470 -1.4753 -0.4232 -0.2417 -0.6087 -0.1462 -0.4363 -0.2539 -0.8066 -0.1266 -0.0650 -0.3077 -0.5405 -0.2636 -0.7055 -0.1896 -0.0911 -0.4995 -0.2253 -0.0580 -0.1447 -3.3460 -0.1555 -0.1450 -0.1442 -0.1013 -0.1689 -0.1574 -0.1762
S-29	Um eine Reizung der Speiseröhre zu vermeiden , darf die Patientin sich bis nach der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , nicht hinlegen .
T-29	To avoid irritation of the oesophagus ( gullet ) , the patient should not lie down until after their first food of the day , which should be at least 30 minutes after taking the tablet .
H-29	-0.36610299348831177	In order to avoid irritation of the oesophagus , the patient should not lie down until after the first dose of food of the day , which should not be given until 30 minutes after the tablet has been taken .
D-29	-0.36610299348831177	In order to avoid irritation of the oesophagus , the patient should not lie down until after the first dose of food of the day , which should not be given until 30 minutes after the tablet has been taken .
P-29	-0.7510 -0.2216 -0.1700 -0.1027 -0.4082 -0.1331 -0.1635 -0.1014 -0.7166 -0.0322 -1.1844 -0.1265 -0.0780 -0.1580 -0.0723 -0.0867 -0.6089 -0.1073 -0.1688 -0.1451 -0.1951 -0.1383 -0.1763 -0.1052 -2.1568 -0.1290 -0.5692 -0.9554 -0.1460 -0.3030 -0.1547 -0.1281 -0.3521 -0.4181 -0.1494 -0.8626 -1.8516 -0.1617 -0.0885 -0.1820 -0.1741 -0.8525 -0.0715 -0.7609 -0.1038 -0.5593 -0.1158 -0.1756
S-603	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-603	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-603	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
D-603	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
P-603	-0.0168 -0.2376 -0.0617 -0.0552 -0.3863 -0.6857 -0.3241 -0.1125 -0.2068 -0.0595 -0.1294 -0.9480 -0.2952 -0.1312 -0.1001 -0.0472 -0.1066 -0.2355 -0.1304 -0.1109 -0.1947 -0.4556 -0.2901 -0.1216 -0.2793 -1.5142 -0.1558 -0.5214 -0.0560 -0.0497 -1.8841 -1.2969 -1.1202 -0.0256 -0.0515 -0.1344 -0.2687 -0.2223 -0.1758
S-533	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-533	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-533	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
D-533	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
P-533	-0.0168 -0.2376 -0.0617 -0.0552 -0.3863 -0.6857 -0.3241 -0.1125 -0.2068 -0.0595 -0.1294 -0.9480 -0.2952 -0.1312 -0.1001 -0.0472 -0.1066 -0.2355 -0.1304 -0.1109 -0.1947 -0.4556 -0.2901 -0.1216 -0.2793 -1.5142 -0.1558 -0.5214 -0.0560 -0.0497 -1.8841 -1.2969 -1.1202 -0.0256 -0.0515 -0.1344 -0.2687 -0.2223 -0.1758
S-463	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-463	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-463	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
D-463	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
P-463	-0.0168 -0.2376 -0.0617 -0.0552 -0.3863 -0.6857 -0.3241 -0.1125 -0.2068 -0.0595 -0.1294 -0.9480 -0.2952 -0.1312 -0.1001 -0.0472 -0.1066 -0.2355 -0.1304 -0.1109 -0.1947 -0.4556 -0.2901 -0.1216 -0.2793 -1.5142 -0.1558 -0.5214 -0.0560 -0.0497 -1.8841 -1.2969 -1.1202 -0.0256 -0.0515 -0.1344 -0.2687 -0.2223 -0.1758
S-393	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-393	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-393	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
D-393	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
P-393	-0.0168 -0.2376 -0.0617 -0.0552 -0.3863 -0.6857 -0.3241 -0.1125 -0.2068 -0.0595 -0.1294 -0.9480 -0.2952 -0.1312 -0.1001 -0.0472 -0.1066 -0.2355 -0.1304 -0.1109 -0.1947 -0.4556 -0.2901 -0.1216 -0.2793 -1.5142 -0.1558 -0.5214 -0.0560 -0.0497 -1.8841 -1.2969 -1.1202 -0.0256 -0.0515 -0.1344 -0.2687 -0.2223 -0.1758
S-187	Eine Krebsdiagnose , Chemotherapie , Strahlentherapie , Kortikosteroide und unzureichende Mundhygiene gelten ebenfalls als Risikofaktoren ( siehe Abschnitt 4.4 ) . Gelenkschwellungen .
T-187	Diagnosis of cancer , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also deemed as risk factors ( see section 4.4 ) ; joint swelling .
H-187	-0.15126167237758636	Cancer diagnosis , chemotherapy , radiation therapy , corticosteroids and inadequate oral hygiene are also considered risk factors ( see section 4.4 ) .
D-187	-0.15126167237758636	Cancer diagnosis , chemotherapy , radiation therapy , corticosteroids and inadequate oral hygiene are also considered risk factors ( see section 4.4 ) .
P-187	-0.2657 -0.2004 -0.1453 -0.0949 -0.0635 -0.0778 -0.1369 -0.3497 -0.0720 -0.1339 -0.0990 -0.0692 -0.0968 -0.1871 -0.1835 -0.0230 -0.2235 -0.4048 -0.2148 -0.1637 -0.1414 -0.0597 -0.1387 -0.0559 -0.1290 -0.1414 -0.1422 -0.1799 -0.0484 -0.0843 -0.1807 -0.1705 -0.1617 -0.2585 -0.1963
S-323	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-323	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-323	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
D-323	-0.3384281098842621	All pharmacokinetic trials of ADVATE were conducted in pre-treated patients with severe or moderate haemophilia A ( baseline factor VII activity 2 % ) .
P-323	-0.0168 -0.2376 -0.0617 -0.0552 -0.3863 -0.6857 -0.3241 -0.1125 -0.2068 -0.0595 -0.1294 -0.9480 -0.2952 -0.1312 -0.1001 -0.0472 -0.1066 -0.2355 -0.1304 -0.1109 -0.1947 -0.4556 -0.2901 -0.1216 -0.2793 -1.5142 -0.1558 -0.5214 -0.0560 -0.0497 -1.8841 -1.2969 -1.1202 -0.0256 -0.0515 -0.1344 -0.2687 -0.2223 -0.1758
S-584	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 9 gemeldet .
T-584	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 9 gemeldet . 9
H-584	-0.35018789768218994	Of the total of 56 undesirable effects , none were seen in newborns , with 16 reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults .
D-584	-0.35018789768218994	Of the total of 56 undesirable effects , none were seen in newborns , with 16 reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults .
P-584	-1.3222 -0.1705 -0.2240 -0.4299 -0.0812 -1.0794 -0.1901 -0.0494 -0.1351 -0.0998 -0.6404 -1.4629 -0.6184 -0.1293 -0.8220 -1.0823 -0.9935 -0.6546 -0.9222 -0.1597 -0.7549 -0.1356 -0.1450 -0.1816 -0.1648 -0.2603 -0.1316 -0.1282 -0.1902 -0.1347 -0.2973 -0.1073 -0.1025 -0.1430 -0.1405 -0.1878 -0.1505 -0.1424 -0.1261 -0.0903 -0.4394 -0.0307 -0.5772 -0.7380 -0.2653 -0.1023 -0.1336 -0.1018 -0.1098 -0.1096 -0.5308 -0.2530 -0.1873
S-514	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 7 gemeldet .
T-514	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 7 gemeldet . 7
H-514	-0.3550121784210205	Of the total of 56 undesirable effects , none were seen in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 7 .
D-514	-0.3550121784210205	Of the total of 56 undesirable effects , none were seen in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 7 .
P-514	-1.3213 -0.1722 -0.2196 -0.4240 -0.0809 -1.0267 -0.1847 -0.0489 -0.1330 -0.1004 -0.6089 -1.4711 -0.6149 -0.1300 -0.8332 -1.0888 -0.9915 -0.7273 -1.5337 -0.2170 -0.0635 -0.1315 -0.1344 -0.1702 -0.1616 -0.2615 -0.1376 -0.1368 -0.1814 -0.1507 -0.2607 -0.1069 -0.1034 -0.1372 -0.1416 -0.1868 -0.1534 -0.1319 -0.1267 -0.0906 -0.3776 -0.0312 -0.5816 -0.3601 -0.2614 -0.1061 -0.1363 -0.0977 -0.1091 -0.1185 -0.6278 -1.0727 -0.2219 -0.1725
S-654	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 11 gemeldet .
T-654	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 11 gemeldet . 11
H-654	-0.344795823097229	Of the total of 56 undesirable effects , none were seen in newborns , with 16 reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults .
D-654	-0.344795823097229	Of the total of 56 undesirable effects , none were seen in newborns , with 16 reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults .
P-654	-1.2559 -0.1697 -0.2313 -0.4227 -0.0812 -1.0615 -0.1862 -0.0489 -0.1323 -0.0999 -0.6305 -1.4945 -0.6113 -0.1296 -0.8176 -1.0829 -0.9874 -0.6461 -0.9792 -0.1095 -0.7073 -0.1351 -0.1502 -0.1819 -0.1640 -0.2545 -0.1336 -0.1285 -0.1908 -0.1331 -0.3151 -0.1066 -0.1033 -0.1411 -0.1405 -0.1866 -0.1522 -0.1484 -0.1259 -0.0896 -0.4473 -0.0316 -0.5823 -0.7319 -0.2769 -0.1024 -0.1316 -0.1021 -0.1079 -0.1117 -0.3748 -0.2431 -0.1644
S-692	Wie in der CHMP-Richtlinie zum Risiko-Managment-Plan für Human-Arzneimittel festgelegt , sollen diese Aktualisierungen gleichzeitig mit dem nächsten Periodic Safety Update Report ( PSUR ) eingereicht werden .
T-692	As per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
H-692	-0.25274989008903503	As stipulated in the CHMP Risk Management Plan for medicinal products for human use , updates should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
D-692	-0.25274989008903503	As stipulated in the CHMP Risk Management Plan for medicinal products for human use , updates should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
P-692	-0.1006 -1.9773 -0.3225 -0.1024 -0.1539 -0.1332 -0.1765 -0.0358 -0.6742 -0.0929 -0.1622 -0.0629 -0.2627 -1.7442 -0.0528 -0.2448 -0.1124 -0.2754 -0.1933 -0.1981 -0.6494 -0.2125 -0.1157 -0.3121 -0.2242 -0.1133 -0.2262 -0.1693 -0.1642 -0.1090 -0.1423 -0.0856 -0.1670 -0.1171 -0.0798 -0.0819 -0.1102 -0.1446 -0.1868 -0.0593 -0.0713 -0.1433 -0.1785 -0.1796
S-444	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 5 gemeldet .
T-444	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 5 gemeldet . 5
H-444	-0.3384508192539215	Of the total of 56 undesirable effects , none were seen in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 5 .
D-444	-0.3384508192539215	Of the total of 56 undesirable effects , none were seen in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 5 .
P-444	-1.3203 -0.1716 -0.2223 -0.4057 -0.0804 -1.0616 -0.1864 -0.0490 -0.1355 -0.0993 -0.6356 -1.5283 -0.6551 -0.1295 -0.8097 -1.0796 -0.9828 -0.6673 -1.4374 -0.2184 -0.0641 -0.1327 -0.1423 -0.1701 -0.1630 -0.2600 -0.1443 -0.1326 -0.1851 -0.1509 -0.2786 -0.1076 -0.1007 -0.1367 -0.1415 -0.1848 -0.1543 -0.1331 -0.1273 -0.0896 -0.3581 -0.0313 -0.5818 -0.3351 -0.2627 -0.1089 -0.1375 -0.0936 -0.1102 -0.1185 -0.7138 -0.1999 -0.1774 -0.1727
S-765	Darüber hinaus hatte das Unternehmen nicht ausreichend nachgewiesen , dass Advexin auf zuverlässige Weise hergestellt werden kann und dass es weder für die Umwelt noch für Menschen , die in engem Kontakt mit dem Patienten kommen , schädlich ist .
T-765	In addition , the company had not supplied enough evidence to demonstrate that Advexin could be made in a reliable manner , or that it would not be harmful to the environment or to people in close contact with the patient .
H-765	-0.36712172627449036	Moreover , the company had not sufficiently demonstrated that Advexin can be produced in a reliable manner and that it is not harmful to the environment or to people who come into close contact with the patient .
D-765	-0.36712172627449036	Moreover , the company had not sufficiently demonstrated that Advexin can be produced in a reliable manner and that it is not harmful to the environment or to people who come into close contact with the patient .
P-765	-0.2233 -0.1386 -0.1120 -0.0707 -0.3416 -0.2092 -0.7428 -0.0549 -0.1383 -1.4232 -0.0998 -1.2934 -0.1242 -0.1497 -0.2281 -0.1454 -0.9587 -0.3907 -0.5235 -0.7291 -0.3765 -0.2271 -0.2113 -0.1045 -0.0967 -0.6544 -0.0714 -0.1187 -0.5970 -0.3765 -0.1050 -0.1988 -0.3321 -1.2891 -1.0735 -0.8482 -0.1861 -0.3687 -0.1849 -0.1477 -0.1311 -0.0453 -0.1332 -0.1783
S-266	Die häufigsten Nebenwirkungen von Advate ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Schwindel , Kopfschmerzen , Pyrexie ( Fieber ) und die Bildung von Antikörpern gegenüber Faktor VIII.
T-266	The most common side effects with Advate ( seen in between 1 to 10 patients in 100 ) are dizziness , headache , pyrexia ( fever ) and the presence of antibodies against factor VIII .
H-266	-0.2979758381843567	The most common side effects with Advate ( seen in 1 to 10 patients in 100 ) are dizziness , headaches , pyrexia ( fever ) and antibody formation to factor VIII .
D-266	-0.2979758381843567	The most common side effects with Advate ( seen in 1 to 10 patients in 100 ) are dizziness , headaches , pyrexia ( fever ) and antibody formation to factor VIII .
P-266	-0.1585 -0.0983 -0.6030 -0.2234 -0.1865 -0.0861 -2.3044 -0.0750 -0.1575 -0.0306 -0.1270 -0.7957 -0.1415 -0.1234 -0.2973 -0.1094 -0.1216 -0.1435 -0.1074 -0.2747 -0.0484 -0.1230 -0.1599 -0.0540 -0.0281 -1.1555 -0.1454 -0.0402 -0.1244 -0.0970 -0.0409 -0.4522 -0.0577 -0.0604 -0.1444 -0.5959 -0.8249 -0.7115 -0.5122 -0.2550 -0.2162 -0.6601 -0.3725 -0.1781 -0.1859
S-268	Advate darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen den menschlichen Gerinnungsfaktor VIII , Maus- oder Hamsterprotein oder einen der sonstigen Bestandteile sind .
T-268	Advate should not be used in people who may be hypersensitive ( allergic ) to human coagulation factor VIII , to mouse or hamster protein , or to any of the other ingredients .
H-268	-0.3160107433795929	Advate should not be used in people who may be allergic ( hypersensitive ) to human clotting factor VIII , mouse or hamster protein or to any of the excipients .
D-268	-0.3160107433795929	Advate should not be used in people who may be allergic ( hypersensitive ) to human clotting factor VIII , mouse or hamster protein or to any of the excipients .
P-268	-5.7990 -0.0792 -0.2335 -0.1250 -0.1578 -0.1417 -0.1250 -0.2064 -0.0951 -0.2165 -0.1331 -0.3469 -0.0398 -0.2437 -0.0666 -0.0849 -0.1403 -0.1639 -0.2575 -0.2376 -0.0355 -0.1498 -0.2836 -0.1831 -0.0610 -0.1517 -0.3203 -0.1148 -0.3244 -0.0780 -0.0466 -0.0866 -0.8607 -0.5980 -0.0723 -0.1346 -0.1318 -0.3429 -0.1447 -0.1062 -0.1249 -0.1604 -0.1832
S-374	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 3 gemeldet .
T-374	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 3 gemeldet . 3
H-374	-0.33862999081611633	Of the total of 56 undesirable effects , none have been seen in neonatal patients ; 16 have been reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 3 .
D-374	-0.33862999081611633	Of the total of 56 undesirable effects , none have been seen in neonatal patients ; 16 have been reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 3 .
P-374	-1.3184 -0.1704 -0.2309 -0.4177 -0.0810 -1.0810 -0.1889 -0.0492 -0.1361 -0.0993 -0.6249 -1.9057 -0.1101 -0.7040 -0.1282 -2.4776 -0.0433 -0.0278 -0.1990 -0.6056 -1.5991 -0.1020 -0.2699 -0.1565 -0.0685 -0.1332 -0.3125 -0.1730 -0.1673 -0.2684 -0.1410 -0.1412 -0.1813 -0.1300 -0.2256 -0.1096 -0.0951 -0.1433 -0.1455 -0.1936 -0.1485 -0.1234 -0.1278 -0.0890 -0.3393 -0.0344 -0.5808 -0.2265 -0.2373 -0.0980 -0.1312 -0.0925 -0.1106 -0.1142 -0.8531 -0.6263 -0.1766 -0.1748
S-305	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 1 gemeldet .
T-305	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 1 gemeldet . 1
H-305	-0.3691287636756897	Of the total of 56 undesirable effects , none were seen in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 1 .
D-305	-0.3691287636756897	Of the total of 56 undesirable effects , none were seen in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents , and 25 in 14/ 94 adults 1 .
P-305	-1.3045 -0.1730 -0.2219 -0.4164 -0.0806 -1.0486 -0.1802 -0.0491 -0.1348 -0.0996 -0.6333 -1.5186 -0.6878 -0.1297 -0.8295 -1.0357 -0.9807 -0.6566 -1.3641 -0.2164 -0.0647 -0.1331 -0.1426 -0.1705 -0.1628 -0.2544 -0.1447 -0.1352 -0.1855 -0.1516 -0.2879 -0.1068 -0.1016 -0.1356 -0.1419 -0.1862 -0.1553 -0.1347 -0.1275 -0.0897 -0.3493 -0.0309 -0.5756 -0.2796 -0.2558 -0.1070 -0.1383 -0.0927 -0.1100 -0.1110 -2.2937 -0.3234 -0.3170 -0.1752
S-780	Pseudoephedrin regt die Nervenenden dazu an , den chemischen Botenstoff Noradrenalin freizusetzen , der eine Konstriktion ( Verengung ) der Blutgefäße verursacht .
T-780	In Aerinaze , the two active substances are used together , since an antihistamine alone may not provide adequate relief for patients with nasal congestion .
H-780	-0.46693792939186096	Pseudoephedrine stimulates nerve endpoints to release the chemical messenger noradrenaline , which causes constriction ( narrowing ) of the blood vessels .
D-780	-0.46693792939186096	Pseudoephedrine stimulates nerve endpoints to release the chemical messenger noradrenaline , which causes constriction ( narrowing ) of the blood vessels .
P-780	-0.1786 -2.9339 -0.2844 -0.0856 -0.1584 -0.2856 -0.0999 -1.0410 -0.1777 -0.9269 -0.1228 -1.1956 -0.1544 -0.1671 -0.2322 -0.1117 -0.2289 -1.8709 -0.4826 -1.7526 -0.2841 -0.0512 -0.2947 -0.1775 -0.9962 -0.1806 -0.0525 -0.9828 -0.2188 -0.1145 -0.1911 -1.6301 -0.1225 -0.1840 -0.1194 -0.4832 -0.0784 -0.0638 -0.1145 -0.1407 -0.1731
S-563	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-563	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-563	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
D-563	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
P-563	-1.1183 -0.0067 -0.0055 -0.1109 -3.0578 -0.0965 -0.0575 -0.1393 -1.7089 -2.0245 -0.9799 -0.2538 -0.0477 -0.0384 -0.0073 -0.0097 -0.0956 -0.7928 -0.7395 -0.4432 -0.1461 -0.0562 -0.2435 -0.8281 -1.4058 -0.3943 -0.1476 -1.9704 -0.1452 -0.0343 -0.5135 -0.1873 -0.4137 -0.1001 -0.1232 -0.1550 -0.0737 -0.0937 -0.1418 -0.3039 -0.1443 -0.1238 -0.1707
S-244	Obwohl keine klinischen Daten darüber vorliegen , ist dennoch damit zu rechnen , dass die renale Elimination von Alendronat wie in den Tierversuchen auch bei Patienten mit eingeschränkter Nierenfunktion reduziert sein wird .
T-244	Although no clinical information is available , it is likely that , as in animals , elimination of alendronate via the kidney will be reduced in patients with impaired renal function .
H-244	-0.3079337179660797	Although there are no clinical data on this , renal elimination of alendronate , as in animal studies , is also expected to be reduced in patients with renal impairment .
D-244	-0.3079337179660797	Although there are no clinical data on this , renal elimination of alendronate , as in animal studies , is also expected to be reduced in patients with renal impairment .
P-244	-0.3816 -1.2412 -0.1868 -0.1070 -0.1514 -0.0996 -0.1498 -0.6431 -0.2168 -0.3851 -0.1163 -0.0523 -0.1641 -0.1335 -0.1847 -0.1331 -0.1108 -0.0924 -0.0922 -0.2492 -1.2101 -0.1364 -0.5443 -0.1334 -0.7960 -2.1002 -0.2349 -0.1489 -0.1198 -0.2110 -0.1142 -0.8857 -0.1319 -0.0275 -0.1481 -0.0120 -0.0253 -0.0674 -0.0774 -0.4286 -0.1809
S-633	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-633	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-633	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
D-633	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
P-633	-1.1183 -0.0067 -0.0055 -0.1109 -3.0578 -0.0965 -0.0575 -0.1393 -1.7089 -2.0245 -0.9799 -0.2538 -0.0477 -0.0384 -0.0073 -0.0097 -0.0956 -0.7928 -0.7395 -0.4432 -0.1461 -0.0562 -0.2435 -0.8281 -1.4058 -0.3943 -0.1476 -1.9704 -0.1452 -0.0343 -0.5135 -0.1873 -0.4137 -0.1001 -0.1232 -0.1550 -0.0737 -0.0937 -0.1418 -0.3039 -0.1443 -0.1238 -0.1707
S-274	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-274	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-274	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
D-274	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
P-274	-0.1110 -0.1052 -0.1354 -1.5741 -0.1645 -0.1268 -0.3340 -0.2001 -0.1268 -0.3226 -0.0498 -0.1127 -0.1459 -1.3394 -0.1188 -1.2260 -1.2438 -0.0777 -0.1136 -0.5327 -0.1185 -0.1525 -1.0005 -0.7054 -1.0795 -0.8614 -0.0966 -0.0585 -0.0963 -0.3118 -0.3604 -0.6641 -0.1442 -0.2457 -0.1363 -0.1511 -0.8947 -0.0632 -0.0234 -0.1122 -0.1484 -0.4430 -0.2023 -0.2755 -0.0883 -0.0538 -0.1552 -0.1441 -0.1758
S-493	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-493	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-493	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
D-493	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
P-493	-1.1183 -0.0067 -0.0055 -0.1109 -3.0578 -0.0965 -0.0575 -0.1393 -1.7089 -2.0245 -0.9799 -0.2538 -0.0477 -0.0384 -0.0073 -0.0097 -0.0956 -0.7928 -0.7395 -0.4432 -0.1461 -0.0562 -0.2435 -0.8281 -1.4058 -0.3943 -0.1476 -1.9704 -0.1452 -0.0343 -0.5135 -0.1873 -0.4137 -0.1001 -0.1232 -0.1550 -0.0737 -0.0937 -0.1418 -0.3039 -0.1443 -0.1238 -0.1707
S-423	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-423	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-423	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
D-423	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
P-423	-1.1183 -0.0067 -0.0055 -0.1109 -3.0578 -0.0965 -0.0575 -0.1393 -1.7089 -2.0245 -0.9799 -0.2538 -0.0477 -0.0384 -0.0073 -0.0097 -0.0956 -0.7928 -0.7395 -0.4432 -0.1461 -0.0562 -0.2435 -0.8281 -1.4058 -0.3943 -0.1476 -1.9704 -0.1452 -0.0343 -0.5135 -0.1873 -0.4137 -0.1001 -0.1232 -0.1550 -0.0737 -0.0937 -0.1418 -0.3039 -0.1443 -0.1238 -0.1707
S-353	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-353	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-353	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
D-353	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
P-353	-1.1183 -0.0067 -0.0055 -0.1109 -3.0578 -0.0965 -0.0575 -0.1393 -1.7089 -2.0245 -0.9799 -0.2538 -0.0477 -0.0384 -0.0073 -0.0097 -0.0956 -0.7928 -0.7395 -0.4432 -0.1461 -0.0562 -0.2435 -0.8281 -1.4058 -0.3943 -0.1476 -1.9704 -0.1452 -0.0343 -0.5135 -0.1873 -0.4137 -0.1001 -0.1232 -0.1550 -0.0737 -0.0937 -0.1418 -0.3039 -0.1443 -0.1238 -0.1707
S-284	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-284	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-284	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
D-284	-0.45697951316833496	Adequate measurement of factor VII plasma concentrations is recommended throughout the course of therapy in order to control the dose to be administered and the frequency of injections .
P-284	-1.1183 -0.0067 -0.0055 -0.1109 -3.0578 -0.0965 -0.0575 -0.1393 -1.7089 -2.0245 -0.9799 -0.2538 -0.0477 -0.0384 -0.0073 -0.0097 -0.0956 -0.7928 -0.7395 -0.4432 -0.1461 -0.0562 -0.2435 -0.8281 -1.4058 -0.3943 -0.1476 -1.9704 -0.1452 -0.0343 -0.5135 -0.1873 -0.4137 -0.1001 -0.1232 -0.1550 -0.0737 -0.0937 -0.1418 -0.3039 -0.1443 -0.1238 -0.1707
S-36	Da Alendronat und Vitamin D3 bereits getrennt voneinander in Arzneimitteln verwendet werden , die in der Europäischen Union zugelassen sind , legte das Unternehmen Daten vor , die aus früheren Studien und der veröffentlichten Literatur stammen .
T-36	Because alendronate and vitamin D3 are already used separately in authorised medicines in the European Union , the company presented data obtained in earlier studies and from the published literature .
H-36	-0.2216276377439499	As alendronate and vitamin D3 are already used separately in medicinal products approved in the European Union , the company presented data from previous studies and published literature .
D-36	-0.2216276377439499	As alendronate and vitamin D3 are already used separately in medicinal products approved in the European Union , the company presented data from previous studies and published literature .
P-36	-0.7302 -0.3670 -0.1378 -0.0785 -0.0792 -0.1412 -0.1210 -0.0612 -0.0906 -0.2214 -0.0853 -0.2101 -0.5008 -0.5905 -0.0990 -0.1357 -0.2919 -0.4288 -0.0796 -0.6537 -0.3183 -0.1250 -0.0692 -0.1166 -0.1533 -0.1033 -0.0670 -0.1897 -0.0736 -0.1206 -0.6445 -0.0735 -0.1377 -0.7613 -0.0391 -0.0284 -0.1233 -0.1740
S-152	13 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden .
T-152	Patients should not lie down until after their first food of the day which should be at least 30 minutes after taking the tablet .
H-152	-0.2894271910190582	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
D-152	-0.2894271910190582	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
P-152	-0.0332 -0.1092 -0.2186 -0.0990 -0.2367 -0.1461 -0.1220 -0.0692 -0.0971 -0.1149 -0.0972 -0.3195 -1.2094 -0.1341 -0.0708 -0.1692 -0.1011 -0.0925 -0.2335 -0.4076 -0.0650 -0.1725 -0.1055 -0.0995 -0.1498 -0.1002 -0.1691 -0.1065 -0.2424 -0.7364 -0.2215 -0.5652 -2.5042 -0.1271 -0.2784 -0.1180 -0.1014 -0.0871 -1.3711 -0.1754
S-782	In Aerinaze werden zwei arzneilich wirksame Bestandteile kombiniert , weil ein Antihistaminikum allein bei Patienten mit Verstopfung der Nase häufig keine ausreichende Linderung der Symptome bewirkt .
T-782	In Aerinaze werden zwei arzneilich wirksame Bestandteile kombiniert , weil ein Antihistaminikum allein bei Patienten mit Verstopfung der Nase häufig keine ausreichende Linderung der Symptome bewirkt . This means that patients only need to take the tablet twice a day .
H-782	-0.5176059007644653	In Aerinaze , two medicinal active ingredients are combined because antihistamine alone frequently does not provide adequate relieve of symptoms in patients with nasal constipation .
D-782	-0.5176059007644653	In Aerinaze , two medicinal active ingredients are combined because antihistamine alone frequently does not provide adequate relieve of symptoms in patients with nasal constipation .
P-782	-1.4248 -0.1223 -0.1354 -0.1228 -0.3582 -0.0790 -0.4801 -0.1490 -2.4429 -0.0840 -1.4862 -0.2182 -0.1275 -0.2889 -0.1579 -0.7141 -0.0491 -0.5102 -0.4555 -1.9573 -0.8218 -0.1547 -0.3810 -0.2685 -3.1349 -2.1993 -0.1379 -0.5969 -0.1183 -0.2077 -0.1361 -0.1788 -0.0597 -0.1684 -0.1648 -0.0380 -0.1108 -0.1083 -0.1781 -0.1770
S-16	Die häufigsten Nebenwirkungen von Adenuric ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Kopfschmerzen , Durchfall , Übelkeit ( Nausea ) , Hautausschlag und abnormale Leberwerte .
T-16	The most common side effects with Adenuric ( seen in between 1 and 10 patients in 100 ) are headache , diarrhoea , nausea ( feeling sick ) , rash and abnormal liver test results .
H-16	-0.19852326810359955	The most common side effects with adenuric ( seen in between 1 and 10 patients in 100 ) are headaches , diarrhoea , nausea , skin rash and abnormal liver test values .
D-16	-0.19852326810359955	The most common side effects with adenuric ( seen in between 1 and 10 patients in 100 ) are headaches , diarrhoea , nausea , skin rash and abnormal liver test values .
P-16	-0.1385 -0.0917 -0.7403 -0.1694 -0.1976 -0.0782 -0.2839 -0.0498 -0.1471 -0.1907 -0.0693 -0.1293 -1.4724 -0.0962 -0.1503 -0.1408 -0.1615 -0.1082 -0.0990 -0.1016 -0.1254 -0.0666 -0.0199 -0.1687 -0.1437 -0.2028 -0.0532 -0.0417 -0.0514 -0.1443 -0.0047 -0.0397 -0.1553 -1.0867 -0.0785 -0.0437 -0.2484 -0.0903 -0.1425 -0.0414 -0.5946 -0.2613 -0.1373 -0.1770
S-186	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet .
T-186	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet . The majority of the reports refer to cancer patients , but such cases have also been reported in patients treated for osteoporosis .
H-186	-0.23998931050300598	Osteonecrosis of the jaw has been reported in patients receiving bisphosphonates ; most of the reports are from cancer patients , but it has also been reported in osteoporosis patients .
D-186	-0.23998931050300598	Osteonecrosis of the jaw has been reported in patients receiving bisphosphonates ; most of the reports are from cancer patients , but it has also been reported in osteoporosis patients .
P-186	-0.0725 -0.1069 -0.1184 -0.1420 -0.0294 -0.1853 -0.1296 -0.1020 -0.1820 -0.0878 -0.1698 -0.1264 -0.0923 -0.1276 -0.1747 -0.3947 -0.0836 -0.0436 -0.0685 -0.1069 -0.0888 -0.3542 -0.1896 -0.5596 -0.1101 -0.0648 -0.1268 -0.1436 -0.0519 -0.2298 -0.7423 -0.7635 -2.6142 -0.2184 -0.3458 -0.0787 -0.0563 -0.1215 -0.7963 -0.1320 -0.1481 -0.0853 -0.1555 -0.0739 -0.1756 -0.1366 -0.1723
S-87	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet .
T-87	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet . The majority of the reports refer to cancer patients , but such cases have also been reported in patients treated for osteoporosis .
H-87	-0.23998931050300598	Osteonecrosis of the jaw has been reported in patients receiving bisphosphonates ; most of the reports are from cancer patients , but it has also been reported in osteoporosis patients .
D-87	-0.23998931050300598	Osteonecrosis of the jaw has been reported in patients receiving bisphosphonates ; most of the reports are from cancer patients , but it has also been reported in osteoporosis patients .
P-87	-0.0725 -0.1069 -0.1184 -0.1420 -0.0294 -0.1853 -0.1296 -0.1020 -0.1820 -0.0878 -0.1698 -0.1264 -0.0923 -0.1276 -0.1747 -0.3947 -0.0836 -0.0436 -0.0685 -0.1069 -0.0888 -0.3542 -0.1896 -0.5596 -0.1101 -0.0648 -0.1268 -0.1436 -0.0519 -0.2298 -0.7423 -0.7635 -2.6142 -0.2184 -0.3458 -0.0787 -0.0563 -0.1215 -0.7963 -0.1320 -0.1481 -0.0853 -0.1555 -0.0739 -0.1756 -0.1366 -0.1723
S-51	2 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden .
T-51	2 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden . 2 ADROVANCE should not be taken at bedtime or before arising for the day .
H-51	-0.29343706369400024	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
D-51	-0.29343706369400024	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
P-51	-0.0439 -0.1068 -0.2094 -0.0977 -0.2433 -0.1459 -0.1247 -0.0692 -0.0973 -0.1129 -0.0956 -0.2903 -1.2706 -0.1369 -0.0722 -0.1699 -0.1014 -0.0950 -0.2290 -0.3843 -0.0658 -0.1741 -0.1074 -0.1036 -0.1488 -0.0996 -0.1688 -0.1069 -0.2422 -0.7046 -0.2199 -0.5681 -2.6800 -0.1256 -0.2710 -0.1181 -0.1012 -0.0872 -1.3751 -0.1732
S-342	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-342	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-342	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
D-342	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
P-342	-0.1110 -0.1052 -0.1354 -1.5741 -0.1645 -0.1268 -0.3340 -0.2001 -0.1268 -0.3226 -0.0498 -0.1127 -0.1459 -1.3394 -0.1188 -1.2260 -1.2438 -0.0777 -0.1136 -0.5327 -0.1185 -0.1525 -1.0005 -0.7054 -1.0795 -0.8614 -0.0966 -0.0585 -0.0963 -0.3118 -0.3604 -0.6641 -0.1442 -0.2457 -0.1363 -0.1511 -0.8947 -0.0632 -0.0234 -0.1122 -0.1484 -0.4430 -0.2023 -0.2755 -0.0883 -0.0538 -0.1552 -0.1441 -0.1758
S-412	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-412	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-412	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
D-412	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
P-412	-0.1110 -0.1052 -0.1354 -1.5741 -0.1645 -0.1268 -0.3340 -0.2001 -0.1268 -0.3226 -0.0498 -0.1127 -0.1459 -1.3394 -0.1188 -1.2260 -1.2438 -0.0777 -0.1136 -0.5327 -0.1185 -0.1525 -1.0005 -0.7054 -1.0795 -0.8614 -0.0966 -0.0585 -0.0963 -0.3118 -0.3604 -0.6641 -0.1442 -0.2457 -0.1363 -0.1511 -0.8947 -0.0632 -0.0234 -0.1122 -0.1484 -0.4430 -0.2023 -0.2755 -0.0883 -0.0538 -0.1552 -0.1441 -0.1758
S-622	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-622	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-622	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
D-622	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
P-622	-0.1110 -0.1052 -0.1354 -1.5741 -0.1645 -0.1268 -0.3340 -0.2001 -0.1268 -0.3226 -0.0498 -0.1127 -0.1459 -1.3394 -0.1188 -1.2260 -1.2438 -0.0777 -0.1136 -0.5327 -0.1185 -0.1525 -1.0005 -0.7054 -1.0795 -0.8614 -0.0966 -0.0585 -0.0963 -0.3118 -0.3604 -0.6641 -0.1442 -0.2457 -0.1363 -0.1511 -0.8947 -0.0632 -0.0234 -0.1122 -0.1484 -0.4430 -0.2023 -0.2755 -0.0883 -0.0538 -0.1552 -0.1441 -0.1758
S-552	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-552	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-552	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
D-552	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
P-552	-0.1110 -0.1052 -0.1354 -1.5741 -0.1645 -0.1268 -0.3340 -0.2001 -0.1268 -0.3226 -0.0498 -0.1127 -0.1459 -1.3394 -0.1188 -1.2260 -1.2438 -0.0777 -0.1136 -0.5327 -0.1185 -0.1525 -1.0005 -0.7054 -1.0795 -0.8614 -0.0966 -0.0585 -0.0963 -0.3118 -0.3604 -0.6641 -0.1442 -0.2457 -0.1363 -0.1511 -0.8947 -0.0632 -0.0234 -0.1122 -0.1484 -0.4430 -0.2023 -0.2755 -0.0883 -0.0538 -0.1552 -0.1441 -0.1758
S-482	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-482	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-482	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
D-482	-0.349465012550354	Dosage dosage dosage and duration of replacement therapy are determined by the seriousness of the factor VIII deficiency , the site and extent of the haemorrhage and the patient <unk> s clinical condition .
P-482	-0.1110 -0.1052 -0.1354 -1.5741 -0.1645 -0.1268 -0.3340 -0.2001 -0.1268 -0.3226 -0.0498 -0.1127 -0.1459 -1.3394 -0.1188 -1.2260 -1.2438 -0.0777 -0.1136 -0.5327 -0.1185 -0.1525 -1.0005 -0.7054 -1.0795 -0.8614 -0.0966 -0.0585 -0.0963 -0.3118 -0.3604 -0.6641 -0.1442 -0.2457 -0.1363 -0.1511 -0.8947 -0.0632 -0.0234 -0.1122 -0.1484 -0.4430 -0.2023 -0.2755 -0.0883 -0.0538 -0.1552 -0.1441 -0.1758
S-720	Bei Einnahme mit anderen Arzneimitteln Bitte informieren Sie Ihren Arzt , wenn Sie andere Arzneimittel einnehmen bzw. vor kurzem eingenommen haben , auch wenn es sich um nicht-verschreibungspflichtige Arzneimittel handelt .
T-720	Taking other medicines Please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
H-720	-0.17289572954177856	Taking other medicines Please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
D-720	-0.17289572954177856	Taking other medicines Please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
P-720	-0.0183 -0.2538 -0.4226 -0.3784 -0.0818 -0.1540 -0.1761 -0.0483 -0.0860 -0.1204 -0.1040 -0.0648 -0.1665 -0.1414 -0.0939 -0.2097 -0.0626 -0.1029 -0.2836 -0.1047 -0.1512 -0.4487 -0.4225 -0.1118 -0.0882 -0.3945 -0.1163 -0.0670 -0.1382 -0.1749
S-734	Seltene Nebenwirkungen Seit der Einführung des Arzneimittels auf dem Markt wurde vereinzelt über schwere und potentiell lebensbedrohliche Reaktionen ( Anaphylaxie ) und andere allergische Reaktionen berichtet ( siehe oben ) .
T-734	Rare side effects Since the medicine has been on the market , there have been rare reports of severe and potentially life-threatening reactions ( anaphylaxis ) and other allergic reactions ( see above ) .
H-734	-0.3475410044193268	Rare side effects Severe and potentially life-threatening reactions ( anaphylaxis ) and other allergic reactions have been reported sporadically in post-marketing use of the medicine ( see above ) .
D-734	-0.3475410044193268	Rare side effects Severe and potentially life-threatening reactions ( anaphylaxis ) and other allergic reactions have been reported sporadically in post-marketing use of the medicine ( see above ) .
P-734	-0.5683 -0.1024 -0.3053 -0.1978 -0.2069 -0.1387 -0.1698 -0.1140 -0.8747 -0.0708 -0.4606 -0.1082 -0.6824 -0.0637 -0.1547 -0.0859 -0.1438 -0.1011 -0.1607 -1.0133 -0.1429 -0.1357 -0.1502 -0.1296 -0.1333 -0.3028 -0.0576 -0.2090 -0.1238 -0.5697 -1.6643 -0.1525 -0.1794 -1.9036 -0.6525 -0.0726 -0.1168 -1.5587 -0.3137 -0.6426 -0.5211 -0.1449 -0.0452 -0.2088 -0.1505 -0.1478 -0.1821
S-821	In klinischen Prüfungen mit 414 Erwachsenen wurden als häufigste unerwünschte Ereignisse Schlaflosigkeit ( 8,9 % ) , Mundtrockenheit ( 7,2 % ) und Kopfschmerzen ( 3,1 % ) beobachtet .
T-821	In clinical trials involving 414 adults the most frequent of adverse events reported were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
H-821	-0.2579546570777893	In clinical trials in 414 adults , the most common adverse events observed were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
D-821	-0.2579546570777893	In clinical trials in 414 adults , the most common adverse events observed were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
P-821	-0.2828 -0.0770 -0.1556 -0.1735 -0.2085 -0.1778 -0.3395 -0.2418 -0.1041 -0.1116 -0.3248 -0.3094 -0.0242 -0.4296 -1.2603 -0.2939 -1.5086 -0.0183 -0.0157 -0.1441 -0.0641 -0.1753 -0.1434 -0.1515 -0.1467 -0.0389 -0.0128 -0.1475 -0.1588 -0.1631 -0.1651 -0.1562 -0.9316 -0.0607 -0.0351 -1.1860 -0.1511 -0.2409 -0.1465 -0.1679 -0.1464 -0.1287 -0.1726
S-436	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-436	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-436	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
D-436	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
P-436	-0.3768 -0.1260 -0.0442 -0.0504 -0.1373 -0.0814 -2.0083 -0.2934 -0.1637 -1.1882 -0.4684 -0.2036 -0.2889 -0.1039 -0.4225 -1.0413 -0.1229 -0.2067 -0.3319 -0.1846 -0.0666 -1.8394 -0.1928 -0.0599 -0.0825 -0.1478 -0.2470 -0.0730 -0.1228 -0.8073 -0.0616 -0.0874 -0.6245 -0.1575 -0.2106 -0.0594 -0.1291 -0.0586 -0.1528 -1.1241 -0.1487 -0.0915 -0.0837 -0.7154 -0.6090 -0.0822 -0.9953 -0.0600 -0.0881 -0.3202 -0.1802 -0.1477 -0.1771
S-576	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-576	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-576	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
D-576	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
P-576	-0.3768 -0.1260 -0.0442 -0.0504 -0.1373 -0.0814 -2.0083 -0.2934 -0.1637 -1.1882 -0.4684 -0.2036 -0.2889 -0.1039 -0.4225 -1.0413 -0.1229 -0.2067 -0.3319 -0.1846 -0.0666 -1.8394 -0.1928 -0.0599 -0.0825 -0.1478 -0.2470 -0.0730 -0.1228 -0.8073 -0.0616 -0.0874 -0.6245 -0.1575 -0.2106 -0.0594 -0.1291 -0.0586 -0.1528 -1.1241 -0.1487 -0.0915 -0.0837 -0.7154 -0.6090 -0.0822 -0.9953 -0.0600 -0.0881 -0.3202 -0.1802 -0.1477 -0.1771
S-261	Reproduction is authorised provided the source is acknowledged . Wie wurde Advate untersucht ? Advate ist einem anderen in der Europäischen Union zugelassenen Arzneimittel namens Recombinate , ähnlich , wird jedoch anders hergestellt , sodass das Arzneimittel keine Proteine humanen bzw. tierischen Ursprungs enthält .
T-261	Reproduction is authorised provided the source is acknowledged . of bleeding episodes and rated Advate s effectiveness in stopping bleeding on a scale from none to excellent in 107 patients , all of whom received Advate .
H-261	-0.17084023356437683	Reproduction is authorised provided the source is acknowledged .
D-261	-0.17084023356437683	Reproduction is authorised provided the source is acknowledged .
P-261	-0.1108 -0.2100 -0.1100 -0.0107 -0.0882 -0.0327 -0.1220 -0.0434 -0.1087 -0.0173 -1.0645 -0.1317
S-297	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-297	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-297	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
D-297	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
P-297	-0.3768 -0.1260 -0.0442 -0.0504 -0.1373 -0.0814 -2.0083 -0.2934 -0.1637 -1.1882 -0.4684 -0.2036 -0.2889 -0.1039 -0.4225 -1.0413 -0.1229 -0.2067 -0.3319 -0.1846 -0.0666 -1.8394 -0.1928 -0.0599 -0.0825 -0.1478 -0.2470 -0.0730 -0.1228 -0.8073 -0.0616 -0.0874 -0.6245 -0.1575 -0.2106 -0.0594 -0.1291 -0.0586 -0.1528 -1.1241 -0.1487 -0.0915 -0.0837 -0.7154 -0.6090 -0.0822 -0.9953 -0.0600 -0.0881 -0.3202 -0.1802 -0.1477 -0.1771
S-366	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-366	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-366	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
D-366	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
P-366	-0.3768 -0.1260 -0.0442 -0.0504 -0.1373 -0.0814 -2.0083 -0.2934 -0.1637 -1.1882 -0.4684 -0.2036 -0.2889 -0.1039 -0.4225 -1.0413 -0.1229 -0.2067 -0.3319 -0.1846 -0.0666 -1.8394 -0.1928 -0.0599 -0.0825 -0.1478 -0.2470 -0.0730 -0.1228 -0.8073 -0.0616 -0.0874 -0.6245 -0.1575 -0.2106 -0.0594 -0.1291 -0.0586 -0.1528 -1.1241 -0.1487 -0.0915 -0.0837 -0.7154 -0.6090 -0.0822 -0.9953 -0.0600 -0.0881 -0.3202 -0.1802 -0.1477 -0.1771
S-93	Colecalciferol Bei Langzeittherapie allgemein gesunder Erwachsener wurde für Dosierungen von weniger als 10.000 I.E.<unk> Tag keine Vitamin-D-Toxizität dokumentiert . In einer klinischen Studie bei gesunden Erwachsenen war eine tägliche Dosis von 4.000 I.E.
T-93	Colecalciferol Vitamin D toxicity has not been documented during chronic therapy in generally healthy adults at a dose less than 10,000 IU/ day .
H-93	-0.4313729703426361	Colecalciferol No vitamin D toxicity has been documented in long-term treatment of generally healthy adults at doses less than 10,000 IU/ day .
D-93	-0.4313729703426361	Colecalciferol No vitamin D toxicity has been documented in long-term treatment of generally healthy adults at doses less than 10,000 IU/ day .
P-93	-0.9149 -0.1547 -0.1981 -0.1315 -0.0872 -0.2009 -2.1729 -0.6831 -0.0470 -0.0758 -0.0530 -0.1357 -0.0976 -0.9867 -0.1395 -0.1261 -0.1996 -1.3167 -0.1051 -0.1362 -0.9364 -0.9798 -1.5584 -0.2256 -1.0521 -0.3395 -0.0569 -0.0819 -0.4807 -0.1295 -0.1073 -0.1416 -0.0712 -0.1432 -0.4317 -1.0253 -0.2373
S-506	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-506	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-506	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
D-506	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
P-506	-0.3768 -0.1260 -0.0442 -0.0504 -0.1373 -0.0814 -2.0083 -0.2934 -0.1637 -1.1882 -0.4684 -0.2036 -0.2889 -0.1039 -0.4225 -1.0413 -0.1229 -0.2067 -0.3319 -0.1846 -0.0666 -1.8394 -0.1928 -0.0599 -0.0825 -0.1478 -0.2470 -0.0730 -0.1228 -0.8073 -0.0616 -0.0874 -0.6245 -0.1575 -0.2106 -0.0594 -0.1291 -0.0586 -0.1528 -1.1241 -0.1487 -0.0915 -0.0837 -0.7154 -0.6090 -0.0822 -0.9953 -0.0600 -0.0881 -0.3202 -0.1802 -0.1477 -0.1771
S-0	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-0	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-0	-0.09181332588195801	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
D-0	-0.09181332588195801	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
P-0	-0.0046 -0.0053 -0.0140 -0.0069 -0.0116 -0.0439 -0.0047 -0.0126 -0.0978 -0.0145 -0.0135 -0.0109 -0.0320 -0.0006 -0.0328 -0.0165 -0.0912 -0.1491 -0.0621 -0.0338 -0.1328 -0.1392 -0.0881 -0.1000 -0.0293 -0.1617 -0.1374 -0.0157 -0.0847 -0.0030 -0.0257 -0.0355 -0.1064 -0.0090 -0.0193 -0.0085 -0.1285 -0.0666 -0.0444 -0.1314 -0.0627 -0.0367 -0.0707 -0.0060 -0.0165 -0.0578 -0.0143 -0.1397 -0.0023 -0.0481 -0.0213 -0.1673 -0.1080 -1.4724 -0.0102 -0.0782 -0.0139 -0.0628 -0.0297 -0.0193 -0.1225 -0.0219 -0.0204 -0.0818 -0.1087 -0.0579 -0.1382 -0.0122 -0.0416 -1.2559 -0.1431 -0.1196 -0.1706 -0.0213 -0.1441 -0.0584 -0.0343 -0.1434 -0.0320 -0.0150 -0.1160 -0.1095 -0.0303 -0.1405 -0.0864 -0.0318 -0.0875 -0.1030 -0.0483 -0.0373 -0.1592 -0.0509 -0.1187 -0.0901 -0.1319 -0.1666
S-646	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-646	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-646	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
D-646	-0.3367565870285034	These inhibitors are invariably anti-procoagulatory activity of factor VIII immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by modified Bethesda assay .
P-646	-0.3768 -0.1260 -0.0442 -0.0504 -0.1373 -0.0814 -2.0083 -0.2934 -0.1637 -1.1882 -0.4684 -0.2036 -0.2889 -0.1039 -0.4225 -1.0413 -0.1229 -0.2067 -0.3319 -0.1846 -0.0666 -1.8394 -0.1928 -0.0599 -0.0825 -0.1478 -0.2470 -0.0730 -0.1228 -0.8073 -0.0616 -0.0874 -0.6245 -0.1575 -0.2106 -0.0594 -0.1291 -0.0586 -0.1528 -1.1241 -0.1487 -0.0915 -0.0837 -0.7154 -0.6090 -0.0822 -0.9953 -0.0600 -0.0881 -0.3202 -0.1802 -0.1477 -0.1771
S-22	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-22	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-22	-0.09181332588195801	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
D-22	-0.09181332588195801	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
P-22	-0.0046 -0.0053 -0.0140 -0.0069 -0.0116 -0.0439 -0.0047 -0.0126 -0.0978 -0.0145 -0.0135 -0.0109 -0.0320 -0.0006 -0.0328 -0.0165 -0.0912 -0.1491 -0.0621 -0.0338 -0.1328 -0.1392 -0.0881 -0.1000 -0.0293 -0.1617 -0.1374 -0.0157 -0.0847 -0.0030 -0.0257 -0.0355 -0.1064 -0.0090 -0.0193 -0.0085 -0.1285 -0.0666 -0.0444 -0.1314 -0.0627 -0.0367 -0.0707 -0.0060 -0.0165 -0.0578 -0.0143 -0.1397 -0.0023 -0.0481 -0.0213 -0.1673 -0.1080 -1.4724 -0.0102 -0.0782 -0.0139 -0.0628 -0.0297 -0.0193 -0.1225 -0.0219 -0.0204 -0.0818 -0.1087 -0.0579 -0.1382 -0.0122 -0.0416 -1.2559 -0.1431 -0.1196 -0.1706 -0.0213 -0.1441 -0.0584 -0.0343 -0.1434 -0.0320 -0.0150 -0.1160 -0.1095 -0.0303 -0.1405 -0.0864 -0.0318 -0.0875 -0.1030 -0.0483 -0.0373 -0.1592 -0.0509 -0.1187 -0.0901 -0.1319 -0.1666
S-769	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-769	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-769	-0.09181332588195801	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
D-769	-0.09181332588195801	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
P-769	-0.0046 -0.0053 -0.0140 -0.0069 -0.0116 -0.0439 -0.0047 -0.0126 -0.0978 -0.0145 -0.0135 -0.0109 -0.0320 -0.0006 -0.0328 -0.0165 -0.0912 -0.1491 -0.0621 -0.0338 -0.1328 -0.1392 -0.0881 -0.1000 -0.0293 -0.1617 -0.1374 -0.0157 -0.0847 -0.0030 -0.0257 -0.0355 -0.1064 -0.0090 -0.0193 -0.0085 -0.1285 -0.0666 -0.0444 -0.1314 -0.0627 -0.0367 -0.0707 -0.0060 -0.0165 -0.0578 -0.0143 -0.1397 -0.0023 -0.0481 -0.0213 -0.1673 -0.1080 -1.4724 -0.0102 -0.0782 -0.0139 -0.0628 -0.0297 -0.0193 -0.1225 -0.0219 -0.0204 -0.0818 -0.1087 -0.0579 -0.1382 -0.0122 -0.0416 -1.2559 -0.1431 -0.1196 -0.1706 -0.0213 -0.1441 -0.0584 -0.0343 -0.1434 -0.0320 -0.0150 -0.1160 -0.1095 -0.0303 -0.1405 -0.0864 -0.0318 -0.0875 -0.1030 -0.0483 -0.0373 -0.1592 -0.0509 -0.1187 -0.0901 -0.1319 -0.1666
S-192	Colecalciferol Bei Langzeittherapie allgemein gesunder Erwachsener wurde für Dosierungen von weniger als 10.000 I.E.<unk> Tag keine Vitamin-D-Toxizität dokumentiert . In einer klinischen Studie bei gesunden Erwachsenen war eine tägliche Dosis von 4.000 I.E.
T-192	Colecalciferol Vitamin D toxicity has not been documented during chronic therapy in generally healthy adults at a dose less than 10,000 IU/ day .
H-192	-0.4313729703426361	Colecalciferol No vitamin D toxicity has been documented in long-term treatment of generally healthy adults at doses less than 10,000 IU/ day .
D-192	-0.4313729703426361	Colecalciferol No vitamin D toxicity has been documented in long-term treatment of generally healthy adults at doses less than 10,000 IU/ day .
P-192	-0.9149 -0.1547 -0.1981 -0.1315 -0.0872 -0.2009 -2.1729 -0.6831 -0.0470 -0.0758 -0.0530 -0.1357 -0.0976 -0.9867 -0.1395 -0.1261 -0.1996 -1.3167 -0.1051 -0.1362 -0.9364 -0.9798 -1.5584 -0.2256 -1.0521 -0.3395 -0.0569 -0.0819 -0.4807 -0.1295 -0.1073 -0.1416 -0.0712 -0.1432 -0.4317 -1.0253 -0.2373
S-38	Nach einer 15-wöchigen Behandlung war der Anteil der Patienten mit niedrigem Vitamin-D-Spiegel bei den Patienten , die mit ADROVANCE behandelt worden waren , geringer ( 11 % ) als bei denjenigen , die ausschließlich Alendronat einnahmen ( 32 % ) .
T-38	After 15 weeks of treatment , the proportion of patients with low vitamin D levels was lower among the patients treated with ADROVANCE ( 11 % ) than those taking alendronate only ( 32 % ) .
H-38	-0.31511276960372925	Following 15 weeks of treatment , the proportion of patients with low vitamin D concentrations was lower in patients treated with ADROVANCE ( 11 % ) than in those treated with alendronate alone ( 32 % ) .
D-38	-0.31511276960372925	Following 15 weeks of treatment , the proportion of patients with low vitamin D concentrations was lower in patients treated with ADROVANCE ( 11 % ) than in those treated with alendronate alone ( 32 % ) .
P-38	-0.5797 -1.9248 -0.0760 -0.1326 -0.3234 -0.1466 -0.1153 -0.1021 -0.1354 -0.1550 -0.1209 -0.1433 -0.6495 -0.0463 -0.0793 -1.5589 -0.0325 -0.0678 -0.8798 -1.2587 -0.5990 -0.4250 -0.0461 -0.1360 -0.1584 -0.0791 -0.1678 -0.1034 -0.0622 -0.1598 -0.0918 -0.1542 -0.1474 -0.2002 -0.1084 -0.1009 -1.6148 -0.1829 -0.2931 -0.1346 -0.1168 -0.0865 -0.4886 -0.1342 -0.1883 -0.1526 -0.1422 -0.4595 -0.1788
S-693	wenn neue Informationen vorliegen , die Einfluss auf die gültigen Sicherheitshinweise , den Pharmakovigilanz-Plan oder die Maßnahmen zur Risiko-Minimierung haben könnten innerhalb von 60 Tagen nach einem wichtigen Ereignis ( hinsichtlich der Pharmakovigilanz oder hinsichtlich einer Maßnahme zur Risiko-Minimierung )
T-693	In addition , an updated RMP should be submitted When new information is received that may impact on the current Safety Specification , Pharmacovigilance Plan or risk minimisation activities Within 60 days of an important ( pharmacovigilance or risk minimisation ) milestone being reached At the request of the EMEA
H-693	-0.3220061659812927	If new information is received that may impact on valid Safety Specification , Pharmacovigilance Plan or risk minimisation activities Within 60 days of an important event ( with regard to pharmacovigilance or risk minimisation activities )
D-693	-0.3220061659812927	If new information is received that may impact on valid Safety Specification , Pharmacovigilance Plan or risk minimisation activities Within 60 days of an important event ( with regard to pharmacovigilance or risk minimisation activities )
P-693	-1.2523 -0.4807 -0.1041 -1.1687 -0.1620 -0.1958 -0.3496 -0.5853 -0.2519 -0.2392 -0.0516 -1.9164 -2.5733 -0.4895 -0.1625 -0.0856 -0.0427 -0.1181 -0.1055 -0.0184 -0.0865 -0.1164 -0.0412 -0.2094 -0.0985 -0.0492 -0.0332 -0.0975 -0.1940 -0.5028 -0.0728 -0.0948 -0.2221 -0.1427 -0.0470 -0.0641 -0.1683 -2.3516 -0.4368 -0.1615 -0.0492 -0.0989 -0.0281 -0.0830 -0.1098 -0.1353 -0.0606 -0.0660 -0.0165 -0.0911 -0.4187 -0.1511 -0.2141
S-611	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-611	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-611	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
D-611	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
P-611	-0.0416 -1.0731 -0.8108 -0.0433 -1.3181 -0.1180 -0.1300 -1.0344 -0.0950 -0.0912 -0.4144 -0.2877 -0.9301 -0.0804 -0.2025 -0.0831 -0.1790 -0.3559 -0.0706 -0.0868 -0.6887 -0.5233 -0.7746 -1.0581 -0.9146 -1.1945 -0.1179 -0.0594 -0.1197 -0.1151 -0.0735 -0.0420 -0.3247 -0.1950 -0.9889 -0.1451 -0.1102 -2.5981 -0.1617 -0.9525 -0.0957 -0.2262 -2.3499 -0.1160 -0.6642 -0.0861 -0.1071 -0.0946 -0.1381 -0.1401 -0.1742
S-125	9 Verteilung Studien an Ratten haben ergeben , dass Alendronat sich nach intravenöser Gabe von 1 mg<unk> kg vorübergehend in Weichteilgeweben verteilt , sich aber dann rasch in den Knochen umverteilt oder mit dem Urin ausgeschieden wird .
T-125	Distribution Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/ kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine .
H-125	-0.3987847566604614	Distribution Studies in rats have shown that alendronate is transiently distributed in soft tissue after intravenous administration of 1 mg/ kg , and than rapidly redistributes to bone or is excreted in the urine .
D-125	-0.3987847566604614	Distribution Studies in rats have shown that alendronate is transiently distributed in soft tissue after intravenous administration of 1 mg/ kg , and than rapidly redistributes to bone or is excreted in the urine .
P-125	-0.0618 -0.0402 -1.4496 -0.1261 -0.0219 -0.2325 -0.1410 -0.1271 -0.3767 -0.1466 -0.0916 -0.1423 -1.3860 -2.5130 -0.0758 -0.5432 -0.8941 -0.0629 -0.7232 -2.2835 -0.1675 -1.0927 -0.3405 -0.0358 -0.0520 -0.1079 -0.0842 -0.1364 -0.1307 -0.1491 -0.1096 -0.1382 -0.0769 -0.5164 -2.0925 -1.2933 -0.1940 -0.4738 -0.0889 -0.3510 -0.3246 -0.4560 -0.1735 -0.2396 -0.0398 -0.0361 -0.1018 -0.1174 -0.1108 -0.0398 -0.1131 -0.1340 -0.1788
S-331	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-331	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-331	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
D-331	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
P-331	-0.0416 -1.0731 -0.8108 -0.0433 -1.3181 -0.1180 -0.1300 -1.0344 -0.0950 -0.0912 -0.4144 -0.2877 -0.9301 -0.0804 -0.2025 -0.0831 -0.1790 -0.3559 -0.0706 -0.0868 -0.6887 -0.5233 -0.7746 -1.0581 -0.9146 -1.1945 -0.1179 -0.0594 -0.1197 -0.1151 -0.0735 -0.0420 -0.3247 -0.1950 -0.9889 -0.1451 -0.1102 -2.5981 -0.1617 -0.9525 -0.0957 -0.2262 -2.3499 -0.1160 -0.6642 -0.0861 -0.1071 -0.0946 -0.1381 -0.1401 -0.1742
S-471	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-471	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-471	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
D-471	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
P-471	-0.0416 -1.0731 -0.8108 -0.0433 -1.3181 -0.1180 -0.1300 -1.0344 -0.0950 -0.0912 -0.4144 -0.2877 -0.9301 -0.0804 -0.2025 -0.0831 -0.1790 -0.3559 -0.0706 -0.0868 -0.6887 -0.5233 -0.7746 -1.0581 -0.9146 -1.1945 -0.1179 -0.0594 -0.1197 -0.1151 -0.0735 -0.0420 -0.3247 -0.1950 -0.9889 -0.1451 -0.1102 -2.5981 -0.1617 -0.9525 -0.0957 -0.2262 -2.3499 -0.1160 -0.6642 -0.0861 -0.1071 -0.0946 -0.1381 -0.1401 -0.1742
S-541	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-541	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-541	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
D-541	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
P-541	-0.0416 -1.0731 -0.8108 -0.0433 -1.3181 -0.1180 -0.1300 -1.0344 -0.0950 -0.0912 -0.4144 -0.2877 -0.9301 -0.0804 -0.2025 -0.0831 -0.1790 -0.3559 -0.0706 -0.0868 -0.6887 -0.5233 -0.7746 -1.0581 -0.9146 -1.1945 -0.1179 -0.0594 -0.1197 -0.1151 -0.0735 -0.0420 -0.3247 -0.1950 -0.9889 -0.1451 -0.1102 -2.5981 -0.1617 -0.9525 -0.0957 -0.2262 -2.3499 -0.1160 -0.6642 -0.0861 -0.1071 -0.0946 -0.1381 -0.1401 -0.1742
S-401	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-401	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-401	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
D-401	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
P-401	-0.0416 -1.0731 -0.8108 -0.0433 -1.3181 -0.1180 -0.1300 -1.0344 -0.0950 -0.0912 -0.4144 -0.2877 -0.9301 -0.0804 -0.2025 -0.0831 -0.1790 -0.3559 -0.0706 -0.0868 -0.6887 -0.5233 -0.7746 -1.0581 -0.9146 -1.1945 -0.1179 -0.0594 -0.1197 -0.1151 -0.0735 -0.0420 -0.3247 -0.1950 -0.9889 -0.1451 -0.1102 -2.5981 -0.1617 -0.9525 -0.0957 -0.2262 -2.3499 -0.1160 -0.6642 -0.0861 -0.1071 -0.0946 -0.1381 -0.1401 -0.1742
S-726	Patienten , die Faktor-VIII-Inhibitoren entwickeln Wenn die erwarteten FaktorVIII-Spiegel in Ihrem Plasma mit ADVATE nicht erreicht werden oder die Blutung nicht beherrscht werden kann , könnte dies an der Entwicklung von Faktor VIII-
T-726	93 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE , or if bleeding is not adequately controlled , it could be due to the development of Factor VIII inhibitors .
H-726	-0.3876620829105377	Patients who are developing factor VIII inhibitors If the expected factor VIII levels in your plasma are not reached with ADVATE , or if the haemorrhage cannot be controlled , there may be an increased possibility of factor VIII development in your plasma .
D-726	-0.3876620829105377	Patients who are developing factor VIII inhibitors If the expected factor VIII levels in your plasma are not reached with ADVATE , or if the haemorrhage cannot be controlled , there may be an increased possibility of factor VIII development in your plasma .
P-726	-0.1589 -0.1086 -0.5345 -0.2587 -0.3264 -0.4830 -1.1308 -0.4696 -0.1284 -0.0650 -0.0564 -0.1235 -0.0586 -0.9112 -0.1533 -0.6450 -0.1515 -1.2250 -0.3525 -0.1551 -0.2078 -0.1431 -0.0630 -0.0922 -0.1748 -0.1234 -0.5243 -1.0388 -0.1658 -0.1957 -0.0536 -0.1267 -1.2464 -0.1207 -0.1777 -0.8311 -0.8838 -0.0568 -0.0173 -0.1204 -0.4174 -0.1409 -0.1509 -0.2216 -1.4119 -0.2380 -0.0927 -0.3768 -0.0109 -0.0839 -0.6180 -0.4678 -0.2162 -0.8370 -1.3602 -1.6360 -0.2427 -0.3909 -0.0525 -0.0509 -0.9389 -0.2197
S-136	Biotransformation Vitamin D3 wird in der Leber rasch zu 25-Hydroxyvitamin D3 hydroxyliert und dann in der Niere zu 1,25-Dihydroxyvitamin D3 , der biologisch aktiven Form , metabolisiert .
T-136	Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3 , which represents the biologically active form .
H-136	-0.25133368372917175	Biotransformation Vitamin D3 is rapidly hydroxyvitamin D3 hydroxylated in the liver and then metabolised in the kidney to 1.25 dihydroxy vitamin D3 , which is biologically active .
D-136	-0.25133368372917175	Biotransformation Vitamin D3 is rapidly hydroxyvitamin D3 hydroxylated in the liver and then metabolised in the kidney to 1.25 dihydroxy vitamin D3 , which is biologically active .
P-136	-0.1725 -0.1029 -0.0453 -0.0287 -0.0578 -0.4572 -0.0562 -0.0947 -0.2233 -0.1533 -0.0398 -0.1812 -0.2434 -0.1668 -0.9822 -0.0425 -0.0903 -0.2116 -1.2607 -0.2098 -0.1736 -0.0018 -0.6053 -0.1148 -0.0991 -0.2152 -0.9988 -0.1031 -0.0504 -0.1460 -0.2146 -0.1238 -0.0758 -0.1479 -0.1641 -0.8501 -0.5273 -0.2009 -0.0848 -0.8403 -0.1749 -0.0594 -0.1060 -0.2286 -0.1814 -1.1743 -0.0969 -0.0791 -0.1154 -0.0993 -0.1327 -0.1394 -0.1750
S-681	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-681	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-681	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
D-681	-0.4469759464263916	Each unit carton consists of one vial of powder , one vial of 5 ml solvent<unk> both glass I with chlorobutyl rubber stopper ) and one unit of reconstitution ( BAXJECT II ) .
P-681	-0.0416 -1.0731 -0.8108 -0.0433 -1.3181 -0.1180 -0.1300 -1.0344 -0.0950 -0.0912 -0.4144 -0.2877 -0.9301 -0.0804 -0.2025 -0.0831 -0.1790 -0.3559 -0.0706 -0.0868 -0.6887 -0.5233 -0.7746 -1.0581 -0.9146 -1.1945 -0.1179 -0.0594 -0.1197 -0.1151 -0.0735 -0.0420 -0.3247 -0.1950 -0.9889 -0.1451 -0.1102 -2.5981 -0.1617 -0.9525 -0.0957 -0.2262 -2.3499 -0.1160 -0.6642 -0.0861 -0.1071 -0.0946 -0.1381 -0.1401 -0.1742
S-811	Im Rahmen von klinischen Prüfungen mit Desloratadin , bei denen Erythromycin oder Ketoconazol zusätzlich verabreicht wurden , wurden jedoch keine klinisch relevanten Wechselwirkungen oder Veränderungen der Plasmakonzentration von Desloratadin beobachtet .
T-811	However , no clinically relevant interactions or changes in desloratadine plasma concentrations were observed in clinical trials with desloratadine in which erythromycin or ketoconazole were co-administered .
H-811	-0.33379238843917847	However , in clinical trials with desloratadine added erythromycin or ketoconazole , no clinically relevant interactions or changes in plasma concentrations of desloratadine were observed .
D-811	-0.33379238843917847	However , in clinical trials with desloratadine added erythromycin or ketoconazole , no clinically relevant interactions or changes in plasma concentrations of desloratadine were observed .
P-811	-0.2165 -0.1205 -0.2036 -0.1977 -0.0739 -0.4894 -2.1033 -0.0588 -0.1455 -0.5638 -0.4572 -2.0553 -1.4304 -0.1309 -0.0402 -0.1374 -0.1386 -0.1371 -0.1242 -0.0404 -0.1337 -0.1005 -0.0355 -0.0353 -0.1207 -0.3890 -0.0278 -0.1012 -0.1389 -0.1090 -0.0780 -0.1396 -0.3491 -0.1276 -0.9473 -0.0562 -0.0291 -1.1230 -0.0560 -0.0878 -0.1266 -1.5549 -0.0700 -0.1740 -0.3026 -0.4973 -0.1619 -0.4472 -0.1266 -0.1786
S-160	Während in groß angelegten klinischen Studien mit Alendronat kein erhöhtes Risiko festgestellt wurde , wurden selten ( nach Markteinführung ) Magen- und Duodenalulzera , darunter manche schwerwiegend und mit Komplikationen , berichtet ( siehe Abschnitt 4.8 ) .
T-160	13 While no increased risk was observed in extensive clinical trials with alendronate , there have been rare ( post-marketing ) reports of gastric and duodenal ulcers , some of which were severe and with complications ( see section 4.8 ) .
H-160	-0.3143981397151947	While no increased risk was observed in large scale clinical trials of alendronate , rare post-marketing reports of stomach and duodenal alulcers , including some severe and with complications , have been received ( see section 4.8 ) .
D-160	-0.3143981397151947	While no increased risk was observed in large scale clinical trials of alendronate , rare post-marketing reports of stomach and duodenal alulcers , including some severe and with complications , have been received ( see section 4.8 ) .
P-160	-0.2508 -0.7569 -1.2155 -0.1065 -0.2436 -1.2764 -0.1191 -0.2616 -1.6070 -0.0575 -0.1572 -0.1908 -0.1854 -0.1411 -0.0995 -0.0460 -0.1222 -0.7485 -0.3140 -0.0901 -0.2853 -0.0350 -0.1213 -0.2716 -0.1626 -0.3652 -0.4632 -0.0772 -0.0579 -0.1124 -0.2026 -0.5399 -0.9809 -0.1077 -0.2651 -0.0824 -0.4243 -0.1853 -0.5031 -0.0997 -0.1780 -0.1092 -1.1038 -0.0855 -0.7673 -0.1346 -0.0445 -0.0834 -0.1761 -0.1864 -0.1466 -0.1397 -0.1761
S-61	Während in groß angelegten klinischen Studien mit Alendronat kein erhöhtes Risiko festgestellt wurde , wurden selten ( nach Markteinführung ) Magen- und Duodenalulzera , darunter manche schwerwiegend und mit Komplikationen , berichtet ( siehe Abschnitt 4.8 ) .
T-61	3 While no increased risk was observed in extensive clinical trials with alendronate , there have been rare ( post-marketing ) reports of gastric and duodenal ulcers , some of which were severe and with complications ( see section 4.8 ) .
H-61	-0.3143981397151947	While no increased risk was observed in large scale clinical trials of alendronate , rare post-marketing reports of stomach and duodenal alulcers , including some severe and with complications , have been received ( see section 4.8 ) .
D-61	-0.3143981397151947	While no increased risk was observed in large scale clinical trials of alendronate , rare post-marketing reports of stomach and duodenal alulcers , including some severe and with complications , have been received ( see section 4.8 ) .
P-61	-0.2508 -0.7569 -1.2155 -0.1065 -0.2436 -1.2764 -0.1191 -0.2616 -1.6070 -0.0575 -0.1572 -0.1908 -0.1854 -0.1411 -0.0995 -0.0460 -0.1222 -0.7485 -0.3140 -0.0901 -0.2853 -0.0350 -0.1213 -0.2716 -0.1626 -0.3652 -0.4632 -0.0772 -0.0579 -0.1124 -0.2026 -0.5399 -0.9809 -0.1077 -0.2651 -0.0824 -0.4243 -0.1853 -0.5031 -0.0997 -0.1780 -0.1092 -1.1038 -0.0855 -0.7673 -0.1346 -0.0445 -0.0834 -0.1761 -0.1864 -0.1466 -0.1397 -0.1761
S-762	Aufgrund der geprüften Daten und Antworten des Unternehmens auf die Liste von Fragen des CHMP bestanden seitens des CHMP zum Zeitpunkt der Rücknahme gewisse Bedenken . Der Ausschuss war der vorläufigen Ansicht , dass Advexin zur Behandlung von Li-Fraumeni-Krebs nicht hätte zugelassen werden können .
T-762	Based on the review of the data and the company s response to the CHMP list of questions , at the time of the withdrawal , the CHMP had some concerns and was of the provisional opinion that Advexin could not have been approved for the treatment of Li-Fraumeni cancer .
H-762	-0.5424308776855469	There was some concern from the CHMP at the time of retraction because of the data reviewed and the company s response to the list of questions .
D-762	-0.5424308776855469	There was some concern from the CHMP at the time of retraction because of the data reviewed and the company s response to the list of questions .
P-762	-0.1495 -0.7107 -0.6185 -0.1278 -1.0750 -0.1354 -0.1301 -0.0313 -0.1852 -0.1294 -0.1317 -0.1467 -1.6197 -1.3952 -0.0958 -3.4196 -0.1329 -0.1044 -0.2894 -0.6130 -0.1336 -0.2445 -0.5140 -0.4551 -0.4471 -0.1602 -0.1354 -0.8351 -0.1513 -0.3636 -2.5140 -0.1625
S-773	Es ist als blau-weiße Tabletten mit veränderter Wirkstofffreisetzung erhältlich . Veränderte Wirkstofffreisetzung bedeutet , dass die Tabletten so zusammengesetzt sind , dass einer der wirksamen Bestandteile sofort und der andere langsam über einige Stunden hinweg freigesetzt wird .
T-773	It is available as blue and white modified-release tablets . Modified-release means that the tablets have been made to allow one of the active substances to be released immediately and the other one released over a few hours .
H-773	-0.4663082957267761	It is supplied as blue and white tablets with altered release of the active substance . Changed release means that the tablets are made up to release one of the active ingredients immediately and the other slowly over a few hours .
D-773	-0.4663082957267761	It is supplied as blue and white tablets with altered release of the active substance . Changed release means that the tablets are made up to release one of the active ingredients immediately and the other slowly over a few hours .
P-773	-0.0762 -0.2525 -0.4861 -0.0844 -0.3068 -0.8147 -0.1809 -0.1865 -0.9205 -0.2093 -0.5108 -2.5212 -0.0348 -2.8513 -0.3573 -0.9189 -0.1589 -0.1809 -0.9551 -0.5755 -0.4069 -0.3028 -0.2370 -0.6045 -0.1572 -0.1419 -0.0316 -0.0768 -0.1264 -1.2939 -0.1752 -0.8399 -0.5001 -0.1378 -0.1309 -0.1161 -1.7545 -0.6518 -0.1277 -0.1494 -0.1561 -0.1927 -0.3393 -0.0568 -0.2392 -0.9235 -0.0933 -0.1351 -0.1683
S-799	Da Aerinaze Pseudoephedrin enthält , ist das Arzneimittel ebenfalls kontraindiziert bei Patienten , die mit einem Monoaminoxidase ( MAO<unk> -Hemmer behandelt werden bzw. innerhalb der 2 Wochen nach Beendigung einer solchen Therapie .
T-799	As Aerinaze contains pseudoephedrine , it is also contraindicated in patients who are receiving monoamine oxidase ( MAO ) inhibitor therapy or during the 2 weeks following the stopping of such treatment .
H-799	-0.3276580274105072	As Aerinaze contains pseudoephedrine , the medicinal product is also contraindicated in patients treated with monoamine oxidase ( MAOI ) inhibitors and within the 2 weeks following the end of such therapy .
D-799	-0.3276580274105072	As Aerinaze contains pseudoephedrine , the medicinal product is also contraindicated in patients treated with monoamine oxidase ( MAOI ) inhibitors and within the 2 weeks following the end of such therapy .
P-799	-1.7336 -0.1356 -0.1369 -0.1242 -0.3408 -0.1069 -0.1097 -0.2619 -3.1194 -0.2881 -0.1047 -0.1601 -0.3062 -0.0822 -0.1428 -1.2020 -1.1867 -0.0678 -0.0942 -0.1059 -0.1371 -0.1773 -0.0215 -0.4479 -0.3642 -0.0395 -0.1334 -0.4010 -0.1822 -0.0183 -0.0498 -0.1372 -0.0444 -0.1468 -0.1625 -0.3215 -0.2183 -0.1775 -0.1354 -0.1289 -0.0868 -0.9171 -0.4863 -0.1508 -0.2776 -0.4801 -0.2166 -0.5986 -0.2001 -0.5584 -0.1391 -0.0914 -0.2366 -0.1506 -0.1768
S-47	ADROVANCE ist nur mit Wasser ( nicht mit Mineralwasser ) mindestens 30 Minuten vor dem ersten Essen , Getränk oder Einnehmen von Arzneimitteln ( einschließlich Antazida , Calcium- und Vitaminergänzungsmitteln ) für den Tag einzunehmen .
T-47	ADROVANCE must be taken with water only ( not mineral water ) at least 30 minutes before the first food , beverage , or medicinal product ( including antacids , calcium supplements and vitamins ) of the day .
H-47	-0.3780273199081421	Always take ADROVANCE with water ( not mineral water ) at least 30 minutes before your first meal , drink or take any medicinal product , including antacids , calcium and vitamin supplements , for the day .
D-47	-0.3780273199081421	Always take ADROVANCE with water ( not mineral water ) at least 30 minutes before your first meal , drink or take any medicinal product , including antacids , calcium and vitamin supplements , for the day .
P-47	-3.9832 -0.0170 -0.1564 -0.2655 -0.0625 -0.1762 -0.1061 -0.0819 -0.1264 -0.6512 -0.1522 -0.5398 -1.1025 -0.0436 -0.0822 -0.1513 -0.1337 -0.0846 -0.1133 -0.1249 -0.7897 -0.9791 -0.0990 -0.8128 -0.1552 -0.0442 -0.1450 -0.8606 -0.2959 -0.9866 -0.8190 -0.5442 -0.3328 -0.1229 -0.3142 -0.1945 -0.1797 -0.1419 -0.0425 -0.0667 -0.1404 -0.3166 -0.0897 -0.0816 -0.0016 -0.0325 -0.2762 -1.2520 -0.2147 -0.8338 -0.1624 -0.1745
S-5	Adenuric senkt den Harnsäurespiegel im Blut üblicherweise innerhalb von zwei Wochen . Wenn der Harnsäurespiegel nach zwei bis vier Wochen immer noch über 6 mg pro Deziliter liegt , kann die Dosis auf einmal täglich 120 mg erhöht werden .
T-5	Adenuric usually reduces blood uric acid levels within two weeks , but the dose can be increased to 120 mg once a day if blood uric acid levels remain above 6 mg per decilitre after two to four weeks .
H-5	-0.4152145981788635	Adenuric usually lowers the level of the uric acid in the blood within two weeks .
D-5	-0.4152145981788635	Adenuric usually lowers the level of the uric acid in the blood within two weeks .
P-5	-0.1070 -0.2153 -0.0542 -0.1500 -0.4976 -1.4255 -2.2239 -0.0957 -0.4897 -0.1309 -0.4966 -0.3713 -0.1581 -0.1362 -0.1746 -0.1149 -0.0551 -0.3229 -0.2455 -0.0994 -1.1501 -0.4202
S-77	Alendronat Nahrungsmittel und Getränke ( einschließlich Mineralwasser ) , Calcium-Ergänzungsmittel , Antazida und einige orale Arzneimittel können die Resorption von Alendronat beeinträchtigen , wenn sie zur gleichen Zeit eingenommen werden .
T-77	Alendronate If taken at the same time , it is likely that food and beverages ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products will interfere with absorption of alendronate .
H-77	-0.2539048492908478	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products may impair the absorption of alendronate when taken at the same time .
D-77	-0.2539048492908478	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products may impair the absorption of alendronate when taken at the same time .
P-77	-0.0765 -0.1343 -0.1201 -0.0324 -3.8275 -0.1597 -0.0418 -0.1711 -0.0995 -0.1493 -0.0440 -0.1075 -0.1418 -0.1611 -0.0450 -0.0599 -0.1348 -0.0054 -0.0310 -0.1389 -0.2562 -0.0925 -0.1438 -0.1167 -0.1468 -0.1617 -0.1766 -0.9895 -0.5642 -0.0943 -0.1905 -0.8661 -0.0096 -0.0883 -0.2026 -0.0719 -0.1477 -0.2855 -0.1321 -0.1041 -0.0527 -0.3848 -0.4820 -0.1904 -0.1493 -0.1928 -0.1579 -0.1345 -0.1746
S-176	Alendronat Nahrungsmittel und Getränke ( einschließlich Mineralwasser ) , Calcium-Ergänzungsmittel , Antazida und einige orale Arzneimittel können die Resorption von Alendronat beeinträchtigen , wenn sie zur gleichen Zeit eingenommen werden .
T-176	Alendronate If taken at the same time , it is likely that food and beverages ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products will interfere with absorption of alendronate .
H-176	-0.2539048492908478	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products may impair the absorption of alendronate when taken at the same time .
D-176	-0.2539048492908478	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products may impair the absorption of alendronate when taken at the same time .
P-176	-0.0765 -0.1343 -0.1201 -0.0324 -3.8275 -0.1597 -0.0418 -0.1711 -0.0995 -0.1493 -0.0440 -0.1075 -0.1418 -0.1611 -0.0450 -0.0599 -0.1348 -0.0054 -0.0310 -0.1389 -0.2562 -0.0925 -0.1438 -0.1167 -0.1468 -0.1617 -0.1766 -0.9895 -0.5642 -0.0943 -0.1905 -0.8661 -0.0096 -0.0883 -0.2026 -0.0719 -0.1477 -0.2855 -0.1321 -0.1041 -0.0527 -0.3848 -0.4820 -0.1904 -0.1493 -0.1928 -0.1579 -0.1345 -0.1746
S-148	ADROVANCE ist nur mit Wasser ( nicht mit Mineralwasser ) mindestens 30 Minuten vor dem ersten Essen , Getränk oder Einnehmen von Arzneimitteln ( einschließlich Antazida , Calcium- und Vitaminergänzungsmitteln ) für den Tag einzunehmen .
T-148	ADROVANCE must be taken with water only ( not mineral water ) at least 30 minutes before the first food , beverage , or medicinal product ( including antacids , calcium supplements and vitamins ) of the day .
H-148	-0.3780273199081421	Always take ADROVANCE with water ( not mineral water ) at least 30 minutes before your first meal , drink or take any medicinal product , including antacids , calcium and vitamin supplements , for the day .
D-148	-0.3780273199081421	Always take ADROVANCE with water ( not mineral water ) at least 30 minutes before your first meal , drink or take any medicinal product , including antacids , calcium and vitamin supplements , for the day .
P-148	-3.9832 -0.0170 -0.1564 -0.2655 -0.0625 -0.1762 -0.1061 -0.0819 -0.1264 -0.6512 -0.1522 -0.5398 -1.1025 -0.0436 -0.0822 -0.1513 -0.1337 -0.0846 -0.1133 -0.1249 -0.7897 -0.9791 -0.0990 -0.8128 -0.1552 -0.0442 -0.1450 -0.8606 -0.2959 -0.9866 -0.8190 -0.5442 -0.3328 -0.1229 -0.3142 -0.1945 -0.1797 -0.1419 -0.0425 -0.0667 -0.1404 -0.3166 -0.0897 -0.0816 -0.0016 -0.0325 -0.2762 -1.2520 -0.2147 -0.8338 -0.1624 -0.1745
S-206	Vitamin D3 ( der Menge von Vitamin D3 in der höheren Dosis von ADROVANCE ) einmal wöchentlich entspricht , wurde in einer 24-wöchigen Verlängerungsstudie mit 619 postmenopausalen Frauen mit Osteoporose gezeigt .
T-206	Patients in the Vitamin D3 2800 group received ADROVANCE ( 70 mg/ 2800 IU ) ( n<<unk>> 299 ) and patients in the Vitamin D3 5600 group received ADROVANCE ( 70 mg/ 2800 IU ) plus an additional 2800 IU vitamin D3 ( n<<unk>> 309 ) once a week ; additional vitamin D supplements were allowed .
H-206	-0.5035820603370667	An extended study of 619 post-menopausal women with osteoporosis was conducted over 24 weeks in over 7,000 post-menopausal women whose
D-206	-0.5035820603370667	An extended study of 619 post-menopausal women with osteoporosis was conducted over 24 weeks in over 7,000 post-menopausal women whose
P-206	-3.1846 -2.1699 -0.1385 -0.2320 -0.3141 -0.1165 -0.0272 -0.3192 -0.0769 -0.1638 -0.0324 -0.1011 -0.0407 -0.1274 -0.0629 -0.1535 -0.1267 -0.0896 -0.1181 -0.0983 -0.4242 -1.9720 -1.0558 -0.3130 -0.0461 -0.1857 -1.9953 -0.2597 -1.6792 -0.2290 -0.2532 -0.1752 -0.0348 -0.1042 -0.0219 -1.2559 -0.9340
S-228	Verteilung Studien an Ratten haben ergeben , dass Alendronat sich nach intravenöser Gabe von 1 mg<unk> kg vorübergehend in Weichteilgeweben verteilt , sich aber dann rasch in den Knochen umverteilt oder mit dem Urin ausgeschieden wird .
T-228	Distribution Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/ kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine .
H-228	-0.4078580141067505	Distribution Studies in rats have shown that alendronate is transiently distributed in soft tissue after intravenous administration of 1 mg/ kg , but than rapidly redistributes to bone or is excreted in the urine .
D-228	-0.4078580141067505	Distribution Studies in rats have shown that alendronate is transiently distributed in soft tissue after intravenous administration of 1 mg/ kg , but than rapidly redistributes to bone or is excreted in the urine .
P-228	-0.0961 -0.0399 -1.6365 -0.1254 -0.0225 -0.2107 -0.1369 -0.1294 -0.3764 -0.1465 -0.0923 -0.1333 -1.4745 -2.5973 -0.0754 -0.5356 -0.8155 -0.0637 -0.6280 -2.3881 -0.1043 -1.1320 -0.3381 -0.0361 -0.0552 -0.1080 -0.0827 -0.1329 -0.1373 -0.1461 -0.1100 -0.1375 -0.0773 -0.4674 -1.2265 -1.8537 -0.2802 -0.5006 -0.0904 -0.2894 -0.5917 -0.7444 -0.1999 -0.1737 -0.0442 -0.0362 -0.1020 -0.1168 -0.1093 -0.0364 -0.1154 -0.1388 -0.1779
S-28	Die Patientin muss die Tablette mit einem vollen Glas Wasser ( kein Mineralwasser ) mindestens 30 Minuten vor dem Essen , Trinken oder Einnehmen anderer Arzneimittel ( einschließlich Antazida , Calcium- und Vitaminergänzungsmittel ) einnehmen .
T-28	The patient must take the tablet with a full glass of water ( not mineral water ) , at least 30 minutes before any food , drink , or other medicines ( including antacids , calcium supplements and vitamins ) .
H-28	-0.2848464250564575	Patients should take the tablet with a full glass of water ( not mineral water ) at least 30 minutes before eating , drinking or taking other medicinal products , including antacids , calcium and vitamin supplements .
D-28	-0.2848464250564575	Patients should take the tablet with a full glass of water ( not mineral water ) at least 30 minutes before eating , drinking or taking other medicinal products , including antacids , calcium and vitamin supplements .
P-28	-1.5855 -0.1102 -0.4404 -0.2669 -0.1381 -0.1167 -0.0659 -0.1393 -0.1684 -0.3016 -0.0748 -0.1533 -0.1059 -0.1412 -1.0985 -0.1428 -0.0485 -0.0763 -0.1504 -0.1476 -0.0922 -0.1038 -0.1306 -0.8050 -0.3801 -0.1505 -2.2686 -0.1385 -0.1495 -1.4103 -0.0762 -0.1464 -0.1016 -0.1671 -0.1468 -0.5724 -0.2510 -0.3107 -0.1467 -0.0347 -0.0553 -0.1483 -0.1697 -0.0856 -0.0819 -0.0015 -0.0358 -0.1511 -0.1733
S-746	Am 17 . Dezember 2008 teilte Gendux Molecular Limited dem Ausschuss für Humanarzneimittel ( CHMP ) offiziell mit , dass das Unternehmen seinen Antrag auf Genehmigung für das Inverkehrbringen von Advexin zur Behandlung von Li-Fraumeni-Krebs zurücknimmt .
T-746	On 17 December 2008 , Gendux Molecular Limited officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it wishes to withdraw its application for a marketing authorisation for Advexin for the treatment of Li-Fraumeni cancer .
H-746	-0.42106571793556213	On 17 December 2008 , Gendux Molecular Limited formally told the Committee for Medicinal Products for Human Use ( CHMP ) that it was withdrawing its application for marketing authorisation for Advexin for the treatment of Li-Fraumeni <unk> s cancer .
D-746	-0.42106571793556213	On 17 December 2008 , Gendux Molecular Limited formally told the Committee for Medicinal Products for Human Use ( CHMP ) that it was withdrawing its application for marketing authorisation for Advexin for the treatment of Li-Fraumeni <unk> s cancer .
P-746	-0.8575 -0.5676 -0.6284 -1.6297 -0.2585 -0.1019 -0.0762 -0.0914 -0.7070 -0.0433 -0.0927 -0.0542 -0.9768 -1.2732 -0.1317 -0.0366 -0.1430 -0.0070 -0.0527 -1.0666 -0.1307 -0.1191 -0.1444 -0.0442 -0.1552 -0.0665 -0.0407 -0.1396 -0.0749 -0.9385 -1.1589 -0.1764 -1.3889 -0.0994 -0.1389 -0.1113 -0.3961 -0.0126 -0.0773 -0.5813 -2.2725 -0.1107 -0.1511 -0.9909 -0.1140 -0.0466 -0.1354 -0.2473 -0.1558 -2.4556 -0.2052 -0.4257 -1.3130 -0.1426 -0.0735 -0.1843 -0.1855
S-58	3 Das Risiko schwerer ösophagealer Nebenwirkungen scheint bei Patienten erhöht zu sein , die das Arzneimittel nicht korrekt einnehmen und<unk> oder es nach dem Auftreten von Symptomen , die auf eine ösophageale Irritation hinweisen , weiter einnehmen .
T-58	The risk of severe oesophageal adverse reactions appears to be greater in patients who fail to take alendronate properly and/ or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation .
H-58	-0.39610981941223145	Severe oesophageal undesirable effects appear to be increased in patients who are not taking the medicine correctly and/ or are continuing to take it after experiencing symptoms suggesting oesophageal irritation .
D-58	-0.39610981941223145	Severe oesophageal undesirable effects appear to be increased in patients who are not taking the medicine correctly and/ or are continuing to take it after experiencing symptoms suggesting oesophageal irritation .
P-58	-2.3716 -0.1507 -0.1850 -0.1007 -0.1773 -0.0662 -0.1667 -0.1411 -2.2850 -0.0738 -0.0735 -0.1749 -0.2875 -0.1842 -0.1008 -0.5401 -0.1166 -0.1939 -0.3978 -0.8827 -0.1211 -0.7320 -0.1441 -0.7647 -0.5537 -1.0682 -0.0944 -0.1382 -0.1428 -1.7011 -0.0293 -0.1354 -0.1453 -0.2564 -0.1098 -1.7585 -0.0487 -0.9291 -0.1850 -0.0938 -0.1965 -0.0545 -0.1667 -0.1278 -0.1721 -0.1215 -0.1685 -0.1841
S-137	Ausscheidung Bei Gabe von radioaktiv markiertem Vitamin D3 an gesunde Probanden betrug die mittlere Ausscheidung der Radioaktivität im Urin nach 48 Stunden 2,4 % , in den Fäzes nach 4 Tagen 4,9 <unk> .
T-137	Elimination When radioactive vitamin D3 was administered to healthy subjects , the mean urinary excretion of radioactivity after 48 hours was 2.4 % , and the mean faecal excretion of radioactivity after 4 days was 4.9 % .
H-137	-0.333888441324234	Excretion Mean excretion of radioactivity in the urine after 48 hours was 2.4 % in the faeces and 4.9 % in the faeces .
D-137	-0.333888441324234	Excretion Mean excretion of radioactivity in the urine after 48 hours was 2.4 % in the faeces and 4.9 % in the faeces .
P-137	-0.1130 -0.0904 -0.1178 -0.4149 -0.0552 -1.2176 -0.0752 -0.1263 -0.1581 -0.4021 -0.1899 -0.1246 -0.1042 -0.0593 -0.1378 -1.0000 -0.1053 -0.1006 -1.0882 -0.1901 -0.1621 -0.1462 -0.2630 -0.1160 -0.0843 -0.0378 -0.1279 -2.6701 -0.1056 -0.2202 -0.4006 -0.0902 -0.1045 -0.3287 -0.0259 -0.1273 -1.6215 -0.1854
S-817	Die Unbedenklichkeit der Anwendung von Aerinaze während der Schwangerschaft ist nicht gesichert , Erfahrungen aus einer großen Anzahl von betroffenen Schwangerschaften ergaben jedoch keine Erhöhung der Frequenz von Missbildungen im Vergleich zur Häufigkeit bei der Normalbevölkerung .
T-817	The safe use of Aerinaze during pregnancy has not been established ; however experience from a large number of exposed pregnancies in humans does not reveal any increase in the frequency of malformations as compared to the incidence in the general population .
H-817	-0.528065025806427	The safety of the use of Aerinaze during pregnancy is not assured , but experience in a large number of affected pregnancies has not shown an increase in the frequency of malformations compared to the frequency in the normal population .
D-817	-0.528065025806427	The safety of the use of Aerinaze during pregnancy is not assured , but experience in a large number of affected pregnancies has not shown an increase in the frequency of malformations compared to the frequency in the normal population .
P-817	-1.7492 -0.0648 -0.1464 -1.9117 -0.2015 -0.1405 -0.2026 -0.1260 -0.1316 -0.3692 -0.1121 -0.4511 -0.0261 -0.2754 -0.1965 -0.8727 -0.6046 -0.6551 -0.1688 -0.6015 -0.1101 -0.5012 -0.1918 -0.1575 -0.7167 -3.0504 -0.0419 -0.0604 -1.2220 -0.8090 -0.5316 -0.0548 -0.1934 -0.1092 -1.3674 -1.1929 -0.0984 -0.1474 -0.1028 -0.0815 -0.1085 -0.3129 -0.1525 -0.6626 -2.2603 -0.1034 -0.1192 -0.1316 -0.2471 -3.2935 -0.1433 -0.1766
S-95	Alendronat Natriumalendronat 3 H2O ist ein Bisphosphonat , das die durch Osteoklasten vermittelte Knochenresorption hemmt , ohne eine direkte Wirkung auf die Knochenbildung auszuüben .
T-95	Alendronate Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation .
H-95	-0.1719997376203537	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
D-95	-0.1719997376203537	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
P-95	-0.1611 -0.1323 -0.1333 -0.0492 -0.2776 -0.0545 -0.1294 -0.1313 -0.1893 -0.0637 -0.6080 -0.1715 -0.0944 -0.1213 -0.1410 -0.1378 -0.0885 -0.0427 -0.0224 -0.1549 -0.1380 -0.1910 -0.0391 -0.1180 -0.3038 -0.5725 -0.1011 -0.0302 -0.0608 -0.1134 -0.1088 -0.1784 -0.1120 -0.2105 -0.1199 -0.1515 -0.1950 -0.7307 -0.1615 -0.3244 -0.0958 -0.1651 -0.0916 -0.0375 -0.5220 -0.1301 -0.1771
S-158	Das Risiko schwerer ösophagealer Nebenwirkungen scheint bei Patienten erhöht zu sein , die das Arzneimittel nicht korrekt einnehmen und<unk> oder es nach dem Auftreten von Symptomen , die auf eine ösophageale Irritation hinweisen , weiter einnehmen .
T-158	The risk of severe oesophageal adverse reactions appears to be greater in patients who fail to take alendronate properly and/ or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation .
H-158	-0.3619416654109955	The risk of severe oesophageal undesirable effects appears to be increased in patients who do not take the medicine correctly and/ or continue to take it after experiencing symptoms suggesting oesophageal irritation .
D-158	-0.3619416654109955	The risk of severe oesophageal undesirable effects appears to be increased in patients who do not take the medicine correctly and/ or continue to take it after experiencing symptoms suggesting oesophageal irritation .
P-158	-1.4068 -0.0911 -0.1369 -0.1634 -0.1862 -0.0859 -0.1668 -0.0660 -0.1345 -0.1421 -2.6008 -0.0720 -0.0734 -0.2024 -0.5732 -0.1727 -0.1290 -0.1774 -0.1482 -0.1833 -0.2852 -1.3813 -0.1328 -0.3364 -0.1449 -0.4503 -0.4591 -1.0607 -0.1142 -0.1223 -0.1402 -0.5081 -0.3537 -0.1732 -0.2482 -0.1200 -2.3174 -0.0521 -0.9544 -0.2048 -0.1059 -0.1950 -0.0536 -0.1654 -0.1289 -0.1536 -0.1227 -0.1590 -0.1798
S-240	Ausscheidung Bei Gabe von radioaktiv markiertem Vitamin D3 an gesunde Probanden betrug die mittlere Ausscheidung der Radioaktivität im Urin nach 48 Stunden 2,4 % , in den Fäzes nach 4 Tagen 4,9 <unk> .
T-240	Elimination When radioactive vitamin D3 was administered to healthy subjects , the mean urinary excretion of radioactivity after 48 hours was 2.4 % , and the mean faecal excretion of radioactivity after 4 days was 4.9 % .
H-240	-0.333888441324234	Excretion Mean excretion of radioactivity in the urine after 48 hours was 2.4 % in the faeces and 4.9 % in the faeces .
D-240	-0.333888441324234	Excretion Mean excretion of radioactivity in the urine after 48 hours was 2.4 % in the faeces and 4.9 % in the faeces .
P-240	-0.1130 -0.0904 -0.1178 -0.4149 -0.0552 -1.2176 -0.0752 -0.1263 -0.1581 -0.4021 -0.1899 -0.1246 -0.1042 -0.0593 -0.1378 -1.0000 -0.1053 -0.1006 -1.0882 -0.1901 -0.1621 -0.1462 -0.2630 -0.1160 -0.0843 -0.0378 -0.1279 -2.6701 -0.1056 -0.2202 -0.4006 -0.0902 -0.1045 -0.3287 -0.0259 -0.1273 -1.6215 -0.1854
S-194	Alendronat Natriumalendronat 3 H2O ist ein Bisphosphonat , das die durch Osteoklasten vermittelte Knochenresorption hemmt , ohne eine direkte Wirkung auf die Knochenbildung auszuüben .
T-194	Alendronate Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation .
H-194	-0.1719997376203537	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
D-194	-0.1719997376203537	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
P-194	-0.1611 -0.1323 -0.1333 -0.0492 -0.2776 -0.0545 -0.1294 -0.1313 -0.1893 -0.0637 -0.6080 -0.1715 -0.0944 -0.1213 -0.1410 -0.1378 -0.0885 -0.0427 -0.0224 -0.1549 -0.1380 -0.1910 -0.0391 -0.1180 -0.3038 -0.5725 -0.1011 -0.0302 -0.0608 -0.1134 -0.1088 -0.1784 -0.1120 -0.2105 -0.1199 -0.1515 -0.1950 -0.7307 -0.1615 -0.3244 -0.0958 -0.1651 -0.0916 -0.0375 -0.5220 -0.1301 -0.1771
S-140	10 35 mg<unk> kg bei Tieren gefunden . Obwohl keine klinischen Daten darüber vorliegen , ist dennoch damit zu rechnen , dass die renale Elimination von Alendronat wie in den Tierversuchen auch bei Patienten mit eingeschränkter Nierenfunktion reduziert sein wird .
T-140	Although no clinical information is available , it is likely that , as in animals , elimination of alendronate via the kidney will be reduced in patients with impaired renal function .
H-140	-0.29289931058883667	Although there are no clinical data on this , renal elimination of alendronate , as in animal studies , is expected to be reduced in patients with renal impairment as well .
D-140	-0.29289931058883667	Although there are no clinical data on this , renal elimination of alendronate , as in animal studies , is expected to be reduced in patients with renal impairment as well .
P-140	-0.0861 -0.8622 -0.2160 -0.1195 -0.1682 -0.0894 -0.1789 -1.2807 -0.1898 -0.2733 -0.1199 -0.0357 -0.1398 -0.1367 -0.1968 -0.1364 -0.1183 -0.1018 -0.1005 -0.2082 -0.9690 -0.3091 -0.7334 -0.1249 -0.7095 -1.0938 -0.1430 -0.1572 -0.4024 -0.2244 -0.6152 -0.1334 -0.0292 -0.1448 -0.0106 -0.0290 -0.0673 -0.0733 -0.4805 -0.7108 -0.1955 -0.1874
S-709	1 Durchstechflasche mit ADVATE 2000 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Mediziprodukt
T-709	1 vial with 2000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-709	-0.36480265855789185	1 vial of ADVATE 2000 IU of Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medicine
D-709	-0.36480265855789185	1 vial of ADVATE 2000 IU of Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medicine
P-709	-0.1400 -0.1277 -0.0921 -0.4476 -0.3957 -0.2059 -0.0722 -0.1628 -0.0787 -0.0808 -0.0454 -1.0715 -0.8828 -0.1033 -0.1207 -0.0996 -0.0760 -0.0823 -0.2177 -0.1237 -0.1314 -0.0836 -0.1734 -0.2559 -0.0686 -1.0361 -0.0792 -0.0963 -0.1547 -0.1248 -0.1373 -0.1463 -0.1284 -0.1471 -4.8619 -0.1484 -0.7779 -0.0952 -0.0944 -0.1002 -1.2260 -0.6281
S-712	1 Durchstechflasche mit ADVATE 3000 I.E.Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt .
T-712	1 vial with 3000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-712	-0.30095189809799194	1 vial of ADVATE 3000 IUOctocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
D-712	-0.30095189809799194	1 vial of ADVATE 3000 IUOctocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
P-712	-0.1521 -0.1296 -0.1012 -0.3839 -0.3328 -0.2002 -0.0739 -0.1501 -0.0728 -0.1429 -0.0470 -0.7285 -0.0977 -0.1329 -0.1190 -0.0784 -0.0875 -0.1765 -0.1262 -0.1499 -0.0911 -0.1781 -0.2423 -0.0696 -0.9704 -0.0827 -0.0949 -0.1722 -0.1252 -0.1310 -0.1639 -0.1301 -0.1412 -4.7050 -0.1469 -0.7846 -0.0961 -0.0973 -0.0894 -0.2413 -0.2576 -0.2703 -0.1764
S-700	1 Durchstechflasche mit ADVATE 500 I.E Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt .
T-700	1 vial with 500 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-700	-0.30362337827682495	1 vial of ADVATE 500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
D-700	-0.30362337827682495	1 vial of ADVATE 500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
P-700	-0.1586 -0.1195 -0.0998 -0.4163 -0.6335 -0.1984 -0.0759 -0.1490 -0.0941 -0.0953 -0.0397 -0.5838 -0.0984 -0.1202 -0.0991 -0.0801 -0.0815 -0.1788 -0.1257 -0.1470 -0.0894 -0.1787 -0.2411 -0.0689 -0.9469 -0.0825 -0.0988 -0.1687 -0.1256 -0.1345 -0.1527 -0.1275 -0.1400 -4.7921 -0.1480 -0.7517 -0.0958 -0.0961 -0.0838 -0.2418 -0.2616 -0.2585 -0.1765
S-110	Die mittleren BMD-Zunahmen betrugen 2,3 % bzw. 2,9 % am Femurhals und 2,9 % bzw. 3,1 % an der gesamten Hüfte in der Gruppe mit 70 mg einmal wöchentlich bzw. in der mit 10 mg täglich . Die zwei
T-110	The mean BMD increases were 2.3 % and 2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the 70 mg once weekly and 10 mg daily groups , respectively .
H-110	-0.2648414373397827	Mean increases in BMD were 2.3 % and 2.9 % for the femoral neck , and 2.9 % and 3.1 % for the total hip , respectively , in the 70 mg weekly and 10 mg daily group .
D-110	-0.2648414373397827	Mean increases in BMD were 2.3 % and 2.9 % for the femoral neck , and 2.9 % and 3.1 % for the total hip , respectively , in the 70 mg weekly and 10 mg daily group .
P-110	-0.6876 -0.0685 -1.3353 -0.1098 -0.0177 -0.0743 -0.1671 -0.2045 -0.1510 -0.1150 -0.1811 -0.1206 -0.1820 -0.1094 -0.2601 -0.1021 -0.1730 -1.2801 -0.0521 -0.6566 -0.4891 -0.2142 -0.1256 -0.1132 -0.1419 -0.1581 -0.1455 -0.1163 -0.1067 -0.1074 -0.0965 -0.0604 -0.2717 -0.1358 -0.1832 -0.1187 -0.1149 -0.3317 -0.1042 -0.3220 -0.2758 -0.1752 -0.0716 -0.0747 -1.9539 -0.1950 -0.1964
S-239	21 Vitamin D3 wird in der Leber rasch zu 25-Hydroxyvitamin D3 hydroxyliert und dann in der Niere zu 1,25-Dihydroxyvitamin D3 , der biologisch aktiven Form , metabolisiert .
T-239	Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3 , which represents the biologically active form .
H-239	-0.2642568349838257	Vitamin D3 is rapidly hydroxylated in the liver to 25-hydroxy vitamin D3 , and then metabolised in the kidney to 1.25 dihydroxy vitamin D3 , the biologically active form .
D-239	-0.2642568349838257	Vitamin D3 is rapidly hydroxylated in the liver to 25-hydroxy vitamin D3 , and then metabolised in the kidney to 1.25 dihydroxy vitamin D3 , the biologically active form .
P-239	-0.2492 -0.0752 -0.1027 -0.2227 -0.1453 -0.0316 -0.3564 -0.2421 -0.1802 -0.0026 -1.0147 -0.1107 -0.0719 -0.2436 -0.1846 -0.1079 -0.0602 -0.2805 -0.1620 -0.0692 -0.1002 -0.2124 -1.1528 -0.3545 -1.1953 -0.1155 -0.0507 -0.1781 -0.1935 -0.1243 -0.0588 -0.1391 -0.1549 -0.4941 -0.5449 -1.5001 -0.0787 -0.3192 -0.1490 -0.0454 -0.1097 -0.2410 -0.1771 -0.8451 -0.0797 -0.1355 -0.1125 -0.1171 -0.2688 -0.1401 -0.1757
S-730	Wenn plötzliche , schwere ( anaphylaktische ) Nebenwirkungen auftreten , muss die Injektion sofort abgebrochen werden.Sie müssen sofort Kontakt mit Ihrem Arzt aufnehmen , wenn Sieeins der folgenden Frühsymptome für allergische ( überempfindliche ) Reaktionen haben :
T-730	Wenn plötzliche , schwere ( anaphylaktische ) Nebenwirkungen auftreten , muss die Injektion sofort abgebrochen werden.Sie müssen sofort Kontakt mit Ihrem Arzt aufnehmen , wenn Sieeins der folgenden Frühsymptome für allergische ( überempfindliche ) Reaktionen haben : You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitivity ) reactions :
H-730	-0.31656864285469055	If sudden , severe ( anaphylactic ) side effects occur , the injection should be discontinued immediately . If you experience any of the following early symptoms of allergic ( hypersensitive ) reactions , contact your doctor immediately :
D-730	-0.31656864285469055	If sudden , severe ( anaphylactic ) side effects occur , the injection should be discontinued immediately . If you experience any of the following early symptoms of allergic ( hypersensitive ) reactions , contact your doctor immediately :
P-730	-0.0579 -0.0728 -0.7872 -0.1709 -0.2311 -0.0742 -0.1168 -0.0952 -0.2634 -0.0417 -0.1560 -0.8569 -0.1664 -0.7154 -0.1483 -0.6213 -0.2062 -0.1338 -1.3181 -0.1337 -1.3906 -0.0365 -0.0673 -0.1539 -0.9669 -0.1638 -0.3813 -0.2952 -0.1590 -0.1365 -0.1205 -0.5070 -0.1614 -0.1507 -0.7723 -0.0742 -0.1550 -0.4740 -0.0566 -0.1449 -0.8467 -0.0646 -0.1266 -0.5556 -0.1681 -0.1120 -0.4809 -0.2336 -0.1894
S-205	Die Wirkung der niedrigeren Dosis von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) mit zusätzlicher Gabe von 2.800 I.E. Vitamin D3 , was insgesamt 5.600 I.E.
T-205	The effect of the lower dose of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) plus an additional 2800 IU Vitamin D3 for a total of 5600 IU ( the amount of vitamin D3 in the higher dose of ADROVANCE ) once weekly was demonstrated in a 24-week , extension study that enrolled 619 osteoporotic post-menopausal women .
H-205	-0.25842779874801636	The effect of the lower dose of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) with an additional dose of 2,800 IU of vitamin D3 , for a total of 5,600 IU .
D-205	-0.25842779874801636	The effect of the lower dose of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) with an additional dose of 2,800 IU of vitamin D3 , for a total of 5,600 IU .
P-205	-0.5737 -0.1144 -0.1425 -0.2807 -0.2082 -0.1022 -0.1534 -0.1093 -0.0622 -0.1691 -0.0944 -0.0712 -0.1421 -0.0822 -0.0424 -0.3703 -0.1195 -0.0905 -0.2456 -1.3044 -0.1667 -0.3364 -0.1077 -0.1062 -0.0776 -0.2220 -0.0855 -0.0564 -0.1171 -0.2012 -0.1421 -0.2012 -1.5498 -0.2742 -0.5459 -0.1452 -0.3261 -0.1047 -0.1318 -0.0746 -0.1469 -0.0778 -0.0486 -0.1113 -0.2327 -0.2743 -2.4624 -0.1246 -0.0752 -0.2330 -0.1379 -0.1115 -0.1362 -0.0591 -0.6146 -0.1750
S-345	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-345	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-345	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
D-345	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
P-345	-0.0176 -1.2725 -0.2768 -0.1417 -1.2944 -1.8174 -0.1762 -0.1176 -0.0241 -0.0845 -0.0625 -0.1004 -0.9964 -0.6267 -0.1383 -0.6065 -0.1421 -0.0448 -0.1182 -0.1135 -0.1058 -0.0557 -0.2300 -1.1434 -0.1905 -0.1074 -0.0539 -0.1113 -0.2819 -0.0597 -0.8019 -0.7968 -1.5258 -0.6310 -0.0097 -0.1168 -0.1981 -0.0994 -0.0625 -0.1030 -0.1470 -0.1350 -0.0597 -0.1421 -0.0526 -0.1417 -0.1762
S-485	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-485	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-485	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
D-485	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
P-485	-0.0176 -1.2725 -0.2768 -0.1417 -1.2944 -1.8174 -0.1762 -0.1176 -0.0241 -0.0845 -0.0625 -0.1004 -0.9964 -0.6267 -0.1383 -0.6065 -0.1421 -0.0448 -0.1182 -0.1135 -0.1058 -0.0557 -0.2300 -1.1434 -0.1905 -0.1074 -0.0539 -0.1113 -0.2819 -0.0597 -0.8019 -0.7968 -1.5258 -0.6310 -0.0097 -0.1168 -0.1981 -0.0994 -0.0625 -0.1030 -0.1470 -0.1350 -0.0597 -0.1421 -0.0526 -0.1417 -0.1762
S-656	11 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-656	11 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-656	-0.4406997859477997	11 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
D-656	-0.4406997859477997	11 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
P-656	-5.1202 -0.6431 -0.6904 -0.9331 -0.1643 -0.9435 -0.1117 -0.1473 -0.1399 -0.7492 -0.0474 -0.1522 -0.1974 -0.5314 -0.3012 -0.1850 -0.4340 -0.1208 -0.9283 -0.1529 -0.1544 -0.6491 -0.0926 -0.1513 -0.1478 -0.1430 -0.1868 -0.2631 -1.1212 -0.1531 -0.7540 -0.0899 -0.1578 -0.1476 -0.7864 -0.0471 -0.6562 -0.1789 -0.2844 -0.4201 -0.2296 -0.2872 -0.0840 -0.1709 -0.1716 -0.1858 -0.1798 -1.9822 -0.1271 -0.1523 -0.4718 -0.0978 -0.1672 -0.2121
S-415	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-415	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-415	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
D-415	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
P-415	-0.0176 -1.2725 -0.2768 -0.1417 -1.2944 -1.8174 -0.1762 -0.1176 -0.0241 -0.0845 -0.0625 -0.1004 -0.9964 -0.6267 -0.1383 -0.6065 -0.1421 -0.0448 -0.1182 -0.1135 -0.1058 -0.0557 -0.2300 -1.1434 -0.1905 -0.1074 -0.0539 -0.1113 -0.2819 -0.0597 -0.8019 -0.7968 -1.5258 -0.6310 -0.0097 -0.1168 -0.1981 -0.0994 -0.0625 -0.1030 -0.1470 -0.1350 -0.0597 -0.1421 -0.0526 -0.1417 -0.1762
S-516	7 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-516	7 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-516	-0.37167173624038696	7 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
D-516	-0.37167173624038696	7 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
P-516	-1.3528 -0.6531 -0.7667 -0.9526 -0.1635 -0.8854 -0.1089 -0.1463 -0.1375 -0.7606 -0.0464 -0.1522 -0.1935 -0.5396 -0.2674 -0.1853 -0.4114 -0.1212 -0.9089 -0.1536 -0.1551 -0.6663 -0.0931 -0.1514 -0.1477 -0.1429 -0.1877 -0.2620 -1.1094 -0.1549 -0.7583 -0.0914 -0.1576 -0.1486 -0.8140 -0.0482 -0.6705 -0.1793 -0.2833 -0.4104 -0.2359 -0.2937 -0.0841 -0.1708 -0.1749 -0.1829 -0.1803 -1.9690 -0.1281 -0.1518 -0.4742 -0.0983 -0.1677 -0.2196
S-555	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-555	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-555	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
D-555	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
P-555	-0.0176 -1.2725 -0.2768 -0.1417 -1.2944 -1.8174 -0.1762 -0.1176 -0.0241 -0.0845 -0.0625 -0.1004 -0.9964 -0.6267 -0.1383 -0.6065 -0.1421 -0.0448 -0.1182 -0.1135 -0.1058 -0.0557 -0.2300 -1.1434 -0.1905 -0.1074 -0.0539 -0.1113 -0.2819 -0.0597 -0.8019 -0.7968 -1.5258 -0.6310 -0.0097 -0.1168 -0.1981 -0.0994 -0.0625 -0.1030 -0.1470 -0.1350 -0.0597 -0.1421 -0.0526 -0.1417 -0.1762
S-625	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-625	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-625	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
D-625	-0.3342837989330292	Calculating the necessary factor VIII dose is based on the empirical finding that 1 IU of factor VIII per kg bodyweight increases factor VIII activity in plasma by 2 IU/ dl .
P-625	-0.0176 -1.2725 -0.2768 -0.1417 -1.2944 -1.8174 -0.1762 -0.1176 -0.0241 -0.0845 -0.0625 -0.1004 -0.9964 -0.6267 -0.1383 -0.6065 -0.1421 -0.0448 -0.1182 -0.1135 -0.1058 -0.0557 -0.2300 -1.1434 -0.1905 -0.1074 -0.0539 -0.1113 -0.2819 -0.0597 -0.8019 -0.7968 -1.5258 -0.6310 -0.0097 -0.1168 -0.1981 -0.0994 -0.0625 -0.1030 -0.1470 -0.1350 -0.0597 -0.1421 -0.0526 -0.1417 -0.1762
S-86	Hautausschlag , Pruritus , Erythem . Selten : Ausschlag mit Photosensitivität . Sehr selten : schwere Hautreaktionen einschließlich Stevens-Johnson- Syndrom und toxische epidermale Nekrolyse .
T-86	Uncommon : rash , pruritus , erythema Rare : rash with photosensitivity Very rare : severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
H-86	-0.437533438205719	Skin rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson <unk> s syndrome and toxic epidermal necrolysis .
D-86	-0.437533438205719	Skin rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson <unk> s syndrome and toxic epidermal necrolysis .
P-86	-3.7445 -0.1205 -0.0488 -0.0237 -0.1611 -0.2724 -0.0136 -0.0247 -0.0951 -0.1519 -0.0780 -0.0998 -0.2253 -0.2746 -0.1507 -0.1511 -0.1547 -0.1512 -0.0392 -0.6697 -0.3148 -1.7735 -0.1590 -0.1268 -0.1292 -0.1589 -0.0767 -0.0570 -0.1542 -0.0688 -0.0907 -0.2515 -0.1034 -0.1029 -0.5322 -2.8810 -0.3573 -1.1871 -1.6570 -0.1007 -0.7311 -0.0402 -0.1604 -1.1964 -0.1209 -0.1384 -0.3212 -0.0908 -0.1025 -3.2669 -0.0924 -0.0983 -0.1434 -0.1907
S-185	Hautausschlag , Pruritus , Erythem . Selten : Ausschlag mit Photosensitivität . Sehr selten : schwere Hautreaktionen einschließlich Stevens-Johnson- Syndrom und toxische epidermale Nekrolyse .
T-185	Uncommon : rash , pruritus , erythema Rare : rash with photosensitivity Very rare : severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
H-185	-0.437533438205719	Skin rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson <unk> s syndrome and toxic epidermal necrolysis .
D-185	-0.437533438205719	Skin rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevens Johnson <unk> s syndrome and toxic epidermal necrolysis .
P-185	-3.7445 -0.1205 -0.0488 -0.0237 -0.1611 -0.2724 -0.0136 -0.0247 -0.0951 -0.1519 -0.0780 -0.0998 -0.2253 -0.2746 -0.1507 -0.1511 -0.1547 -0.1512 -0.0392 -0.6697 -0.3148 -1.7735 -0.1590 -0.1268 -0.1292 -0.1589 -0.0767 -0.0570 -0.1542 -0.0688 -0.0907 -0.2515 -0.1034 -0.1029 -0.5322 -2.8810 -0.3573 -1.1871 -1.6570 -0.1007 -0.7311 -0.0402 -0.1604 -1.1964 -0.1209 -0.1384 -0.3212 -0.0908 -0.1025 -3.2669 -0.0924 -0.0983 -0.1434 -0.1907
S-586	9 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-586	9 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-586	-0.4195789396762848	9 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
D-586	-0.4195789396762848	9 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
P-586	-3.8850 -0.6629 -0.6667 -0.9904 -0.1602 -0.9408 -0.1131 -0.1463 -0.1376 -0.7958 -0.0472 -0.1508 -0.1980 -0.5184 -0.2919 -0.1844 -0.4182 -0.1234 -0.9186 -0.1527 -0.1542 -0.6648 -0.0937 -0.1503 -0.1478 -0.1447 -0.1882 -0.2574 -1.1512 -0.1550 -0.7765 -0.0923 -0.1572 -0.1487 -0.7835 -0.0473 -0.6586 -0.1782 -0.2824 -0.4248 -0.2333 -0.2963 -0.0850 -0.1698 -0.1727 -0.1826 -0.1792 -1.9486 -0.1273 -0.1518 -0.4790 -0.0976 -0.1667 -0.2079
S-376	3 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-376	3 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-376	-0.39634236693382263	3 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
D-376	-0.39634236693382263	3 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
P-376	-2.5715 -0.5628 -0.8656 -0.9436 -0.1621 -1.0052 -0.1134 -0.1478 -0.1322 -0.7463 -0.0469 -0.1513 -0.1892 -0.5148 -0.2895 -0.1852 -0.4253 -0.1202 -0.8677 -0.1533 -0.1540 -0.6773 -0.0941 -0.1505 -0.1489 -0.1498 -0.1883 -0.2571 -1.0558 -0.1551 -0.8069 -0.0911 -0.1580 -0.1478 -0.8433 -0.0459 -0.6622 -0.1790 -0.2833 -0.4173 -0.2432 -0.2976 -0.0857 -0.1716 -0.1772 -0.1854 -0.1784 -1.9491 -0.1272 -0.1529 -0.4853 -0.0977 -0.1678 -0.2236
S-446	5 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-446	5 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-446	-0.377209335565567	5 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
D-446	-0.377209335565567	5 newborns ( 0-1 month of age ) , infants ( 1 month - 2 years of age ) , children ( 2 12 years of age ) , adolescents ( 12 16 years of age ) , adults ( over 16 years of age )
P-446	-1.5274 -0.6077 -0.7528 -0.9181 -0.1628 -1.0537 -0.1099 -0.1464 -0.1321 -0.7358 -0.0473 -0.1519 -0.1978 -0.5439 -0.2962 -0.1837 -0.4362 -0.1194 -0.8391 -0.1544 -0.1534 -0.6839 -0.0932 -0.1518 -0.1474 -0.1464 -0.1884 -0.2642 -1.1422 -0.1539 -0.7850 -0.0902 -0.1569 -0.1475 -0.8392 -0.0462 -0.6580 -0.1789 -0.2857 -0.4286 -0.2329 -0.3006 -0.0848 -0.1695 -0.1742 -0.1872 -0.1795 -1.9140 -0.1291 -0.1523 -0.4992 -0.0980 -0.1677 -0.2226
S-706	1 Durchstechflasche mit ADVATE 1500 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-706	1 vial with 1500 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-706	-0.326893150806427	1 vial of ADVATE 1500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-706	-0.326893150806427	1 vial of ADVATE 1500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-706	-0.1484 -0.1296 -0.0896 -0.4266 -0.3349 -0.2054 -0.0741 -0.1559 -0.5285 -0.0840 -0.0418 -1.4960 -0.0984 -0.1197 -0.0945 -0.0874 -0.0857 -0.1792 -0.1263 -0.1276 -0.0824 -0.1701 -0.2452 -0.0675 -0.9555 -0.0859 -0.0996 -0.1761 -0.1277 -0.1353 -0.1543 -0.1273 -0.1510 -4.6166 -0.1488 -0.7489 -0.0943 -0.0957 -0.0921 -0.2346 -0.3032 -0.1837
S-703	1 Durchstechflasche mit ADVATE 1000 I.E Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-703	1 vial with 1000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-703	-0.3095673620700836	1 vial of ADVATE 1000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-703	-0.3095673620700836	1 vial of ADVATE 1000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-703	-0.1492 -0.1318 -0.0892 -0.4768 -0.5650 -0.2012 -0.0738 -0.1457 -0.0903 -0.0867 -0.0383 -0.7612 -0.0979 -0.1216 -0.0975 -0.0797 -0.0852 -0.1820 -0.1283 -0.1292 -0.0813 -0.1738 -0.2462 -0.0678 -0.9995 -0.0814 -0.0953 -0.1664 -0.1244 -0.1346 -0.1539 -0.1263 -0.1459 -4.7274 -0.1484 -0.7591 -0.1029 -0.0983 -0.0997 -0.2402 -0.3069 -0.1913
S-697	1 Durchstechflasche mit ADVATE 250 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-697	1 vial with 250 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-697	-0.33006927371025085	1 vial of ADVATE 250 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-697	-0.33006927371025085	1 vial of ADVATE 250 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-697	-0.1470 -0.1408 -0.0916 -0.4189 -0.5708 -0.2032 -0.0789 -0.1529 -0.2884 -0.0778 -0.0460 -1.7730 -0.0979 -0.1197 -0.0940 -0.0850 -0.0859 -0.1740 -0.1242 -0.1298 -0.0833 -0.1697 -0.2323 -0.0666 -0.9530 -0.0843 -0.0990 -0.1727 -0.1291 -0.1356 -0.1524 -0.1278 -0.1493 -4.5292 -0.1484 -0.7369 -0.0942 -0.0957 -0.0930 -0.2270 -0.2993 -0.1842
S-753	Das p53-Protein , das aus dem nicht defekten im menschlichen Körper vorhandenen p53-Gen gebildet wird , trägt normalerweise zur Wiederherstellung beschädigter DNA und zum Abtöten der Zellen bei , wenn die DNA nicht wiederhergestellt werden kann .
T-753	The p53 protein , which is produced from the non-defective p53 gene present in the human body , normally contributes to the repair of damaged DNA and causes cell death when the DNA cannot be repaired .
H-753	-0.41499805450439453	The p53 protein , made up from the non-defective p53 gene present in the human body , usually helps to recover damaged DNA and to kill cells when DNA cannot be recovered .
D-753	-0.41499805450439453	The p53 protein , made up from the non-defective p53 gene present in the human body , usually helps to recover damaged DNA and to kill cells when DNA cannot be recovered .
P-753	-0.9371 -0.1682 -0.2462 -0.0749 -1.0277 -1.0297 -0.2016 -0.9135 -0.1027 -0.9501 -0.4744 -0.1554 -0.2407 -0.1970 -0.0981 -0.0800 -0.5446 -0.1647 -0.1304 -0.1165 -0.1988 -0.1166 -1.1510 -0.8247 -0.3336 -1.0618 -0.8632 -0.0291 -0.1335 -0.4652 -1.3304 -0.1711 -0.7970 -0.1317 -0.0203 -0.1899 -0.2136 -0.1285 -0.1713
S-318	7 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-318	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-318	-0.2738077938556671	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
D-318	-0.2738077938556671	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
P-318	-0.1246 -0.1138 -0.0805 -0.1681 -0.0494 -0.0548 -0.1025 -0.2358 -0.1526 -0.6843 -0.0819 -0.0698 -0.2308 -0.1116 -0.2899 -1.7451 -0.0730 -0.1353 -0.6197 -0.2458 -0.0951 -0.0835 -0.1240 -0.0772 -0.3014 -0.0445 -0.2597 -0.0560 -0.1090 -0.1106 -0.1743 -2.3240 -0.2813 -0.2866 -0.6748 -0.1764 -0.4246 -0.0736 -0.2614 -0.0443 -0.1489 -0.2524 -0.1216 -0.0806 -0.8851 -0.2993 -0.1866 -0.0548 -0.1466 -0.2511 -0.1856
S-27	ADROVANCE wird zur Behandlung von Osteoporose ( einer Erkrankung , bei der die Knochen brüchig werden ) bei Frauen nach der Menopause eingesetzt , bei denen ein Risiko für einen geringen Vitamin-D-Spiegel besteht .
T-27	ADROVANCE is used to treat osteoporosis ( a disease that makes bones fragile ) in post-menopausal women at risk of low vitamin D levels .
H-27	-0.2751622498035431	ADROVANCE is used to treat osteoporosis ( a disease in which bones break ) in post-menopausal women , who are at risk for low levels of vitamin D .
D-27	-0.2751622498035431	ADROVANCE is used to treat osteoporosis ( a disease in which bones break ) in post-menopausal women , who are at risk for low levels of vitamin D .
P-27	-0.3456 -0.0580 -0.1607 -0.0959 -0.1161 -0.0960 -0.3642 -0.2678 -0.0607 -0.0825 -0.1735 -0.1431 -0.1139 -0.1182 -0.1022 -0.1806 -0.1379 -1.2369 -0.7441 -0.1089 -0.3082 -0.4288 -0.2019 -0.7421 -0.0561 -0.1458 -0.0802 -0.1462 -0.2240 -0.1135 -0.0581 -1.2672 -0.1956 -0.1602 -0.1643 -0.0803 -0.1945 -1.0330 -0.7689 -0.1507 -0.0873 -0.0402 -0.1368 -0.7103 -0.1811
S-213	Die mittleren BMD-Zunahmen betrugen 2,3 % bzw. 2,9 % am Femurhals und 2,9 % bzw. 3,1 % an der gesamten Hüfte in der Gruppe mit 70 mg einmal wöchentlich bzw. in der mit 10 mg täglich .
T-213	The mean BMD increases were 2.3 % and 2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the 70 mg once weekly and 10 mg daily groups , respectively .
H-213	-0.2575553357601166	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck , and 2.9 % and 3.1 % for the total hip , respectively , in the 70 mg weekly and 10 mg daily group .
D-213	-0.2575553357601166	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck , and 2.9 % and 3.1 % for the total hip , respectively , in the 70 mg weekly and 10 mg daily group .
P-213	-0.3485 -0.0677 -1.0500 -0.0802 -0.1320 -0.1074 -0.1442 -0.1533 -0.1224 -0.1601 -0.1268 -0.1832 -0.1125 -0.2545 -0.1056 -0.2471 -1.8150 -0.0470 -0.8062 -0.3888 -0.2059 -0.1288 -0.1175 -0.1396 -0.1488 -0.1458 -0.1180 -0.1070 -0.1084 -0.1098 -0.0589 -0.2335 -0.1321 -0.1803 -0.1225 -0.1173 -0.2712 -0.1016 -0.2638 -0.3944 -0.1628 -0.0865 -0.0853 -1.5576 -0.1291 -0.1684
S-528	40 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-528	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-528	-0.2751029133796692	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
D-528	-0.2751029133796692	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
P-528	-0.1045 -0.1143 -0.0803 -0.1764 -0.0499 -0.0544 -0.1025 -0.2404 -0.1538 -0.7325 -0.0811 -0.0693 -0.2222 -0.1114 -0.2797 -1.6937 -0.0695 -0.1321 -0.6105 -0.2141 -0.0931 -0.0825 -0.1234 -0.0769 -0.2978 -0.0420 -0.2664 -0.0566 -0.1097 -0.1110 -0.1733 -2.3337 -0.2706 -0.2863 -0.6639 -0.1764 -0.4182 -0.0745 -0.2561 -0.0437 -0.1475 -0.2278 -0.1232 -0.0819 -1.0601 -0.3117 -0.1871 -0.0553 -0.1466 -0.2542 -0.1859
S-716	Dann besteht nämlich ein erhöhtes Risiko , dass dies abermals auftritt . Inhibitoren sind neutralisierende Antikörper gegen Faktor VIII , die die Wirksamkeit von ADVATE , Blutungen zu verhindern oder zu kontrollieren , vermindern .
T-716	Inhibitors are blocking antibodies against factor VIII that reduce the efficacy of ADVATE to prevent or control bleeding .
H-716	-0.30003270506858826	Inhibitors are neutralizing antibodies to factor VIII that diminish the effectiveness of ADVATE in preventing or controlling haemorrhage .
D-716	-0.30003270506858826	Inhibitors are neutralizing antibodies to factor VIII that diminish the effectiveness of ADVATE in preventing or controlling haemorrhage .
P-716	-0.1130 -0.0474 -0.0566 -0.1142 -0.1066 -0.7788 -1.6675 -0.4153 -0.0174 -0.0645 -0.2431 -0.2833 -0.1899 -0.0595 -0.1988 -1.8465 -0.1846 -0.0312 -0.3107 -0.5759 -0.0981 -0.1572 -0.0945 -0.1846 -0.0709 -0.1324 -0.1317 -0.0334 -0.1264 -0.1411 -1.3127 -0.1094 -0.0151 -0.5681 -0.1411 -0.1795
S-37	Das Unternehmen führte außerdem eine Studie mit 35 Männern und 682 postmenopausalen Frauen mit Osteoporose durch , um die Wirksamkeit von ADROVANCE in Bezug auf die Steigerung des Vitamin-D-Spiegels nachzuweisen .
T-37	The company also carried out a study in 35 men and 682 post-menopausal women with osteoporosis to show ADROVANCE s effectiveness in increasing vitamin D levels .
H-37	-0.26488107442855835	The company also conducted a study in 35 men and 682 post-menopausal women with osteoporosis to determine that ADROVANCE was effective in increasing vitamin D concentrations .
D-37	-0.26488107442855835	The company also conducted a study in 35 men and 682 post-menopausal women with osteoporosis to determine that ADROVANCE was effective in increasing vitamin D concentrations .
P-37	-0.1166 -0.0712 -0.1413 -1.0254 -0.1556 -0.1036 -0.2094 -0.0943 -0.1080 -0.1176 -0.1280 -0.0515 -0.0321 -0.2803 -0.0707 -0.1488 -0.0226 -0.1028 -0.0398 -0.1468 -0.0911 -0.1541 -0.1479 -0.1250 -0.1082 -0.0886 -0.1758 -2.0506 -1.9550 -0.1884 -0.0742 -0.1695 -0.1084 -0.0700 -0.7834 -0.0858 -0.1218 -0.5059 -0.7220 -0.0368 -0.0428 -0.8143 -0.0136 -0.0786 -0.1318 -0.1745
S-787	Wenn nur die Schwellung der Nasenschleimhaut betrachtet wurde , zeigten die Patienten unter Aerinaze eine Linderung der Symptome um 37,4 % gegenüber 26,7 % bei den Patienten , die Desloratadin allein einnahmen .
T-787	When looking at nasal congestion , patients taking Aerinaze had a reduction in symptoms of 37.4 % , compared with 26.7 % in those taking desloratadine alone .
H-787	-0.36096054315567017	When looking only at the swelling of the nasal mucosa , patients receiving Aerinaze had a 37.4 % symptom reduction compared to 26.7 % in those taking desloratadine alone .
D-787	-0.36096054315567017	When looking only at the swelling of the nasal mucosa , patients receiving Aerinaze had a 37.4 % symptom reduction compared to 26.7 % in those taking desloratadine alone .
P-787	-0.3562 -1.3055 -0.4544 -0.0644 -0.1275 -0.7157 -0.1395 -0.2220 -0.1013 -0.3823 -0.0761 -0.1628 -0.2514 -0.0227 -0.3637 -0.1803 -0.1306 -0.2837 -0.1946 -0.1309 -0.1347 -0.3399 -0.1458 -0.1750 -0.1426 -0.1970 -0.1412 -0.1774 -0.1158 -2.0326 -0.0449 -2.0451 -0.8925 -0.2371 -0.0935 -0.2126 -0.1075 -0.6546 -0.6706 -0.2197 -0.8184 -0.0628 -0.1612 -0.3826 -0.7287 -0.3836 -0.1689 -0.1745
S-458	29 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-458	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-458	-0.27143651247024536	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
D-458	-0.27143651247024536	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
P-458	-0.1245 -0.1140 -0.0813 -0.1771 -0.0490 -0.0540 -0.1024 -0.2409 -0.1523 -0.7035 -0.0841 -0.0692 -0.2279 -0.1123 -0.2784 -1.6288 -0.0693 -0.1291 -0.5934 -0.2077 -0.0932 -0.0829 -0.1248 -0.0786 -0.3000 -0.0418 -0.2655 -0.0565 -0.1104 -0.1127 -0.1724 -2.3075 -0.2796 -0.2804 -0.6438 -0.1776 -0.4604 -0.0738 -0.2368 -0.0437 -0.1479 -0.2406 -0.1218 -0.0814 -0.9854 -0.3135 -0.1859 -0.0553 -0.1431 -0.2467 -0.1802
S-388	18 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-388	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-388	-0.27305784821510315	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
D-388	-0.27305784821510315	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
P-388	-0.1174 -0.1148 -0.0790 -0.1693 -0.0503 -0.0541 -0.1020 -0.2363 -0.1520 -0.7312 -0.0834 -0.0693 -0.2308 -0.1114 -0.2888 -1.6984 -0.0728 -0.1321 -0.6008 -0.2189 -0.0947 -0.0825 -0.1249 -0.0781 -0.2992 -0.0428 -0.2607 -0.0568 -0.1102 -0.1118 -0.1717 -2.3296 -0.2770 -0.2817 -0.6399 -0.1780 -0.4437 -0.0742 -0.2530 -0.0442 -0.1494 -0.2295 -0.1252 -0.0816 -0.9308 -0.3102 -0.1858 -0.0552 -0.1438 -0.2619 -0.1846
S-668	62 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-668	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-668	-0.2707449197769165	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
D-668	-0.2707449197769165	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
P-668	-0.1047 -0.1132 -0.0797 -0.1726 -0.0488 -0.0548 -0.1019 -0.2436 -0.1526 -0.6960 -0.0844 -0.0700 -0.2207 -0.1109 -0.2732 -1.6905 -0.0677 -0.1322 -0.5981 -0.2022 -0.0925 -0.0836 -0.1235 -0.0770 -0.2977 -0.0408 -0.2637 -0.0567 -0.1091 -0.1105 -0.1723 -2.3044 -0.2776 -0.2863 -0.6465 -0.1771 -0.4443 -0.0747 -0.2564 -0.0443 -0.1485 -0.2430 -0.1235 -0.0804 -0.9386 -0.3008 -0.1857 -0.0546 -0.1425 -0.2492 -0.1846
S-566	47 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-566	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-566	-0.3831530511379242	Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
D-566	-0.3831530511379242	Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
P-566	-2.2135 -0.0817 -0.1345 -0.1867 -0.0345 -1.4411 -0.0939 -0.0747 -0.4665 -0.0771 -0.1263 -0.1993 -0.0335 -0.1457 -0.8498 -0.8009 -0.0227 -1.1872 -0.1656 -0.3715 -0.1431 -0.0815 -0.2001 -0.1084 -0.1866 -1.6117 -0.1702 -0.2455 -0.1306 -0.1141 -0.2397 -0.1033 -0.1167 -0.3902 -0.1608 -0.1342 -0.1110 -0.0938 -0.0567 -0.1552 -0.4137 -0.2051 -0.0994 -0.0947 -0.1053 -0.8380 -0.0471 -0.7526 -2.4037 -0.3378 -0.1425 -0.1456 -1.8782 -0.4218 -0.1332 -0.1777
S-356	14 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-356	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-356	-0.3875884413719177	Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
D-356	-0.3875884413719177	Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
P-356	-2.4498 -0.0828 -0.1347 -0.1850 -0.0320 -1.4591 -0.0981 -0.0740 -0.5040 -0.0771 -0.1262 -0.2000 -0.0336 -0.1449 -0.8346 -0.8013 -0.0232 -1.1949 -0.1543 -0.3668 -0.1418 -0.0804 -0.1953 -0.1093 -0.1881 -1.5907 -0.1697 -0.2353 -0.1296 -0.1150 -0.2411 -0.1033 -0.1251 -0.3896 -0.1624 -0.1342 -0.1096 -0.0930 -0.0574 -0.1573 -0.4124 -0.2079 -0.0983 -0.0958 -0.1050 -0.8363 -0.0467 -0.7486 -2.3636 -0.3332 -0.1435 -0.1481 -1.9223 -0.4298 -0.1331 -0.1760
S-426	25 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-426	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-426	-0.3879922926425934	25 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
D-426	-0.3879922926425934	25 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
P-426	-1.0937 -0.5344 -0.0863 -0.1367 -0.1817 -0.0330 -2.5573 -0.0969 -0.0767 -0.4792 -0.0797 -0.1275 -0.2069 -0.0345 -0.1446 -0.8115 -0.8190 -0.0216 -1.1992 -0.1468 -0.3486 -0.1417 -0.0794 -0.1923 -0.1081 -0.1854 -1.5601 -0.1651 -0.2547 -0.1170 -0.1137 -0.2434 -0.1033 -0.1082 -0.4064 -0.1655 -0.1340 -0.1079 -0.0923 -0.0572 -0.1554 -0.4277 -0.2078 -0.0977 -0.0945 -0.1029 -0.8402 -0.0450 -0.7669 -2.4765 -0.3174 -0.1414 -0.1516 -2.0426 -0.3898 -0.1314 -0.1750
S-496	36 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-496	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-496	-0.4022809565067291	36 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
D-496	-0.4022809565067291	36 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
P-496	-1.8495 -0.4862 -0.0838 -0.1362 -0.1817 -0.0333 -2.7044 -0.0979 -0.0753 -0.4738 -0.0790 -0.1264 -0.2082 -0.0348 -0.1446 -0.8098 -0.8089 -0.0212 -1.2127 -0.1463 -0.3474 -0.1418 -0.0801 -0.1943 -0.1078 -0.1854 -1.6023 -0.1643 -0.2341 -0.1196 -0.1141 -0.2476 -0.1014 -0.1136 -0.4026 -0.1631 -0.1339 -0.1100 -0.0927 -0.0571 -0.1556 -0.4242 -0.2090 -0.0975 -0.0942 -0.1015 -0.8499 -0.0460 -0.7940 -2.4630 -0.3165 -0.1432 -0.1490 -1.9734 -0.3745 -0.1331 -0.1779
S-598	51 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-598	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-598	-0.2738352417945862	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
D-598	-0.2738352417945862	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reaction ( frequency not known ) have been reported in ADVATE .
P-598	-0.1169 -0.1125 -0.0802 -0.1731 -0.0487 -0.0545 -0.1018 -0.2445 -0.1519 -0.7710 -0.0839 -0.0691 -0.2235 -0.1124 -0.2729 -1.6046 -0.0728 -0.1331 -0.6001 -0.2006 -0.0917 -0.0809 -0.1244 -0.0769 -0.2983 -0.0424 -0.2589 -0.0567 -0.1093 -0.1113 -0.1699 -2.3307 -0.2779 -0.2829 -0.6554 -0.1796 -0.4694 -0.0739 -0.2368 -0.0441 -0.1491 -0.2335 -0.1233 -0.0805 -1.0667 -0.2997 -0.1849 -0.0544 -0.1427 -0.2465 -0.1847
S-636	58 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-636	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-636	-0.3991348445415497	58 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
D-636	-0.3991348445415497	58 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
P-636	-2.0936 -0.3729 -0.0831 -0.1362 -0.1850 -0.0356 -2.5484 -0.0952 -0.0768 -0.4339 -0.0797 -0.1268 -0.2039 -0.0358 -0.1439 -0.7954 -0.8029 -0.0215 -1.1971 -0.1505 -0.3394 -0.1410 -0.0789 -0.1895 -0.1064 -0.1813 -1.5836 -0.1640 -0.2410 -0.1216 -0.1126 -0.2514 -0.1014 -0.1031 -0.3949 -0.1629 -0.1341 -0.1110 -0.0926 -0.0560 -0.1540 -0.3962 -0.2043 -0.0982 -0.0946 -0.1017 -0.8033 -0.0462 -0.7952 -2.4305 -0.3148 -0.1413 -0.1474 -2.0515 -0.3781 -0.1314 -0.1768
S-287	3 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-287	3 Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-287	-0.4031234681606293	3 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
D-287	-0.4031234681606293	3 Prophylaxis Long-term prophylaxis of haemorrhages in patients with severe haemophilia A , doses should be given between 20 and 40 IU of factor VIII per kg bodyweight , intervals of 2 3 days .
P-287	-2.1197 -0.5038 -0.0853 -0.1369 -0.1898 -0.0326 -2.2903 -0.0960 -0.0758 -0.4403 -0.0806 -0.1272 -0.2103 -0.0365 -0.1444 -0.8132 -0.8456 -0.0217 -1.2133 -0.1443 -0.3480 -0.1418 -0.0780 -0.1950 -0.1090 -0.1868 -1.6178 -0.1619 -0.2608 -0.1180 -0.1148 -0.2577 -0.1014 -0.1028 -0.4052 -0.1659 -0.1350 -0.1111 -0.0917 -0.0568 -0.1574 -0.4428 -0.2085 -0.0997 -0.0976 -0.1024 -0.8345 -0.0469 -0.7516 -2.4744 -0.3286 -0.1430 -0.1459 -2.1152 -0.3546 -0.1325 -0.1752
S-72	Andere Erkrankungen , die den Mineralstoffwechsel beeinträchtigen ( wie Vitamin-D-Mangel und Hypoparathyreoidismus ) , sollten vor Beginn der Therapie mit ADROVANCE ebenfalls adäquat behandelt werden .
T-72	Other disorders affecting mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be effectively treated before starting ADROVANCE .
H-72	-0.2519567608833313	Other conditions that impair mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be treated appropriately before instituting therapy with ADROVANCE .
D-72	-0.2519567608833313	Other conditions that impair mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be treated appropriately before instituting therapy with ADROVANCE .
P-72	-0.0844 -1.5800 -0.7998 -0.9293 -0.0094 -0.2603 -0.0577 -0.0204 -0.0388 -0.0445 -0.2023 -0.5628 -0.1505 -0.0791 -0.0383 -0.0621 -0.0512 -0.0510 -0.1102 -0.1569 -0.1931 -0.0419 -0.2088 -0.1175 -0.1026 -0.1000 -0.0569 -0.1227 -0.1229 -0.1181 -0.1430 -0.5695 -0.0405 -0.1367 -0.5528 -1.2312 -0.0757 -1.2790 -0.4243 -0.1044 -0.2565 -0.1423 -0.1412 -0.0714 -0.1734 -0.1350 -0.0964 -0.1233 -0.1758
S-741	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <unk> 351 21 925 25 00
T-741	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <<unk>> 351 21 925 25 00
H-741	-0.368542343378067	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <unk> 351 21 925 25 00
D-741	-0.368542343378067	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <unk> 351 21 925 25 00
P-741	-0.0090 -0.8998 -0.1037 -0.2081 -0.1399 -0.1163 -0.1264 -0.5751 -0.0946 -0.0828 -0.0191 -0.1083 -2.7813 -0.1814 -0.0797 -0.5331 -0.2727 -0.0326 -0.0609 -0.1383 -2.2350 -0.1879 -0.0586 -0.2514 -0.4727 -0.5609 -0.0431 -0.1590 -2.1993 -0.0742 -0.1157 -1.7215 -0.1537 -0.1840 -0.1699 -0.0438 -1.1678 -0.1994 -0.0828 -0.0742 -0.6129 -0.3621 -0.0651 -0.1628 -0.0190 -0.1621 -0.0792 -0.0905 -0.1468 -0.1217 -0.0980 -0.7178 -0.1764
S-142	Alendronat Nicht-klinische Daten auf Grundlage konventioneller Studien zur Sicherheitspharmakologie , zur chronischen Toxizität , zur Genotoxizität und zum kanzerogenen Potenzial lassen keine besonderen Gefahren für den Menschen erkennen .
T-142	Alendronate Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology , repeated dose toxicity , genotoxicity and carcinogenic potential .
H-142	-0.2442568987607956	Alendronate Non-clinical data based on conventional studies of safety pharmacology , chronic toxicity , genotoxicity , carcinogenic potential , and toxicity to humans reveal no special hazard .
D-142	-0.2442568987607956	Alendronate Non-clinical data based on conventional studies of safety pharmacology , chronic toxicity , genotoxicity , carcinogenic potential , and toxicity to humans reveal no special hazard .
P-142	-0.1181 -0.1325 -0.0982 -0.0891 -0.1082 -0.2226 -0.0786 -0.1063 -0.7262 -0.1021 -0.0730 -0.3815 -0.1588 -0.2585 -0.0755 -0.1992 -0.1383 -0.0843 -0.3230 -0.1271 -0.1191 -0.1442 -0.1606 -0.1160 -0.0856 -0.1250 -0.1035 -0.1599 -0.0980 -0.0681 -0.0794 -0.0362 -0.0763 -0.1835 -0.2122 -0.1595 -0.2373 -0.1000 -0.1176 -0.1600 -2.6562 -2.3140 -0.1082 -0.0506 -0.0934 -0.0437 -0.1305 -0.1844
S-171	Andere Erkrankungen , die den Mineralstoffwechsel beeinträchtigen ( wie Vitamin-D-Mangel und Hypoparathyreoidismus ) , sollten vor Beginn der Therapie mit ADROVANCE ebenfalls adäquat behandelt werden .
T-171	Other disorders affecting mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be effectively treated before starting ADROVANCE .
H-171	-0.2519567608833313	Other conditions that impair mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be treated appropriately before instituting therapy with ADROVANCE .
D-171	-0.2519567608833313	Other conditions that impair mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be treated appropriately before instituting therapy with ADROVANCE .
P-171	-0.0844 -1.5800 -0.7998 -0.9293 -0.0094 -0.2603 -0.0577 -0.0204 -0.0388 -0.0445 -0.2023 -0.5628 -0.1505 -0.0791 -0.0383 -0.0621 -0.0512 -0.0510 -0.1102 -0.1569 -0.1931 -0.0419 -0.2088 -0.1175 -0.1026 -0.1000 -0.0569 -0.1227 -0.1229 -0.1181 -0.1430 -0.5695 -0.0405 -0.1367 -0.5528 -1.2312 -0.0757 -1.2790 -0.4243 -0.1044 -0.2565 -0.1423 -0.1412 -0.0714 -0.1734 -0.1350 -0.0964 -0.1233 -0.1758
S-669	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-669	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-669	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
D-669	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
P-669	-0.2641 -0.1951 -0.0693 -0.1537 -0.1089 -0.1517 -0.1323 -0.1240 -0.1495 -1.2259 -0.0362 -0.1027 -0.0692 -0.1816 -0.0919 -0.1516 -0.9858 -0.1214 -0.1011 -0.1279 -0.0696 -0.0761 -0.1452 -0.1855 -0.1491 -0.1000 -0.1313 -0.0859 -0.1007 -0.0416 -0.1862 -0.1612 -0.6818 -0.1047 -0.1338 -0.0714 -0.0525 -1.2198 -0.1340 -0.1486 -0.1236 -0.1014 -0.0919 -0.1263 -0.1783
S-389	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-389	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-389	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
D-389	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
P-389	-0.2641 -0.1951 -0.0693 -0.1537 -0.1089 -0.1517 -0.1323 -0.1240 -0.1495 -1.2259 -0.0362 -0.1027 -0.0692 -0.1816 -0.0919 -0.1516 -0.9858 -0.1214 -0.1011 -0.1279 -0.0696 -0.0761 -0.1452 -0.1855 -0.1491 -0.1000 -0.1313 -0.0859 -0.1007 -0.0416 -0.1862 -0.1612 -0.6818 -0.1047 -0.1338 -0.0714 -0.0525 -1.2198 -0.1340 -0.1486 -0.1236 -0.1014 -0.0919 -0.1263 -0.1783
S-459	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-459	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-459	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
D-459	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
P-459	-0.2641 -0.1951 -0.0693 -0.1537 -0.1089 -0.1517 -0.1323 -0.1240 -0.1495 -1.2259 -0.0362 -0.1027 -0.0692 -0.1816 -0.0919 -0.1516 -0.9858 -0.1214 -0.1011 -0.1279 -0.0696 -0.0761 -0.1452 -0.1855 -0.1491 -0.1000 -0.1313 -0.0859 -0.1007 -0.0416 -0.1862 -0.1612 -0.6818 -0.1047 -0.1338 -0.0714 -0.0525 -1.2198 -0.1340 -0.1486 -0.1236 -0.1014 -0.0919 -0.1263 -0.1783
S-529	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-529	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-529	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
D-529	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
P-529	-0.2641 -0.1951 -0.0693 -0.1537 -0.1089 -0.1517 -0.1323 -0.1240 -0.1495 -1.2259 -0.0362 -0.1027 -0.0692 -0.1816 -0.0919 -0.1516 -0.9858 -0.1214 -0.1011 -0.1279 -0.0696 -0.0761 -0.1452 -0.1855 -0.1491 -0.1000 -0.1313 -0.0859 -0.1007 -0.0416 -0.1862 -0.1612 -0.6818 -0.1047 -0.1338 -0.0714 -0.0525 -1.2198 -0.1340 -0.1486 -0.1236 -0.1014 -0.0919 -0.1263 -0.1783
S-599	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-599	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-599	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
D-599	-0.20320932567119598	ADVATE contains recombinant clotting factor VIII ( octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
P-599	-0.2641 -0.1951 -0.0693 -0.1537 -0.1089 -0.1517 -0.1323 -0.1240 -0.1495 -1.2259 -0.0362 -0.1027 -0.0692 -0.1816 -0.0919 -0.1516 -0.9858 -0.1214 -0.1011 -0.1279 -0.0696 -0.0761 -0.1452 -0.1855 -0.1491 -0.1000 -0.1313 -0.0859 -0.1007 -0.0416 -0.1862 -0.1612 -0.6818 -0.1047 -0.1338 -0.0714 -0.0525 -1.2198 -0.1340 -0.1486 -0.1236 -0.1014 -0.0919 -0.1263 -0.1783
S-246	Alendronat Nicht-klinische Daten auf Grundlage konventioneller Studien zur Sicherheitspharmakologie , zur chronischen Toxizität , zur Genotoxizität und zum kanzerogenen Potenzial lassen keine besonderen Gefahren für den Menschen erkennen .
T-246	Alendronate Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology , repeated dose toxicity , genotoxicity and carcinogenic potential .
H-246	-0.2442568987607956	Alendronate Non-clinical data based on conventional studies of safety pharmacology , chronic toxicity , genotoxicity , carcinogenic potential , and toxicity to humans reveal no special hazard .
D-246	-0.2442568987607956	Alendronate Non-clinical data based on conventional studies of safety pharmacology , chronic toxicity , genotoxicity , carcinogenic potential , and toxicity to humans reveal no special hazard .
P-246	-0.1181 -0.1325 -0.0982 -0.0891 -0.1082 -0.2226 -0.0786 -0.1063 -0.7262 -0.1021 -0.0730 -0.3815 -0.1588 -0.2585 -0.0755 -0.1992 -0.1383 -0.0843 -0.3230 -0.1271 -0.1191 -0.1442 -0.1606 -0.1160 -0.0856 -0.1250 -0.1035 -0.1599 -0.0980 -0.0681 -0.0794 -0.0362 -0.0763 -0.1835 -0.2122 -0.1595 -0.2373 -0.1000 -0.1176 -0.1600 -2.6562 -2.3140 -0.1082 -0.0506 -0.0934 -0.0437 -0.1305 -0.1844
S-527	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-527	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-527	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
D-527	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
P-527	-0.8479 -0.1862 -0.4518 -0.0512 -0.1218 -0.1365 -0.0484 -0.0834 -0.1391 -0.2799 -0.0180 -0.0370 -0.1043 -0.1358 -1.0280 -0.0421 -0.0312 -0.6262 -0.2739 -0.6418 -0.2083 -0.1725 -0.9131 -0.5131 -0.7037 -0.1594 -0.0992 -0.0631 -0.1011 -0.1482 -0.7559 -0.3392 -0.1135 -0.3482 -0.2688 -0.8033 -0.5566 -1.7646 -0.2300 -0.1047 -0.7530 -0.2572 -0.1345 -0.1488 -0.1470 -1.1812 -0.1433 -0.2962 -0.1195 -0.1731
S-387	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-387	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-387	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
D-387	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
P-387	-0.8479 -0.1862 -0.4518 -0.0512 -0.1218 -0.1365 -0.0484 -0.0834 -0.1391 -0.2799 -0.0180 -0.0370 -0.1043 -0.1358 -1.0280 -0.0421 -0.0312 -0.6262 -0.2739 -0.6418 -0.2083 -0.1725 -0.9131 -0.5131 -0.7037 -0.1594 -0.0992 -0.0631 -0.1011 -0.1482 -0.7559 -0.3392 -0.1135 -0.3482 -0.2688 -0.8033 -0.5566 -1.7646 -0.2300 -0.1047 -0.7530 -0.2572 -0.1345 -0.1488 -0.1470 -1.1812 -0.1433 -0.2962 -0.1195 -0.1731
S-597	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-597	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-597	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
D-597	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
P-597	-0.8479 -0.1862 -0.4518 -0.0512 -0.1218 -0.1365 -0.0484 -0.0834 -0.1391 -0.2799 -0.0180 -0.0370 -0.1043 -0.1358 -1.0280 -0.0421 -0.0312 -0.6262 -0.2739 -0.6418 -0.2083 -0.1725 -0.9131 -0.5131 -0.7037 -0.1594 -0.0992 -0.0631 -0.1011 -0.1482 -0.7559 -0.3392 -0.1135 -0.3482 -0.2688 -0.8033 -0.5566 -1.7646 -0.2300 -0.1047 -0.7530 -0.2572 -0.1345 -0.1488 -0.1470 -1.1812 -0.1433 -0.2962 -0.1195 -0.1731
S-667	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-667	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-667	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
D-667	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
P-667	-0.8479 -0.1862 -0.4518 -0.0512 -0.1218 -0.1365 -0.0484 -0.0834 -0.1391 -0.2799 -0.0180 -0.0370 -0.1043 -0.1358 -1.0280 -0.0421 -0.0312 -0.6262 -0.2739 -0.6418 -0.2083 -0.1725 -0.9131 -0.5131 -0.7037 -0.1594 -0.0992 -0.0631 -0.1011 -0.1482 -0.7559 -0.3392 -0.1135 -0.3482 -0.2688 -0.8033 -0.5566 -1.7646 -0.2300 -0.1047 -0.7530 -0.2572 -0.1345 -0.1488 -0.1470 -1.1812 -0.1433 -0.2962 -0.1195 -0.1731
S-457	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-457	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-457	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
D-457	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
P-457	-0.8479 -0.1862 -0.4518 -0.0512 -0.1218 -0.1365 -0.0484 -0.0834 -0.1391 -0.2799 -0.0180 -0.0370 -0.1043 -0.1358 -1.0280 -0.0421 -0.0312 -0.6262 -0.2739 -0.6418 -0.2083 -0.1725 -0.9131 -0.5131 -0.7037 -0.1594 -0.0992 -0.0631 -0.1011 -0.1482 -0.7559 -0.3392 -0.1135 -0.3482 -0.2688 -0.8033 -0.5566 -1.7646 -0.2300 -0.1047 -0.7530 -0.2572 -0.1345 -0.1488 -0.1470 -1.1812 -0.1433 -0.2962 -0.1195 -0.1731
S-818	Da sich Reproduktionsstudien an Tieren nicht immer auf den Menschen übertragen lassen und auf Grund der vasokonstriktorischen Eigenschaften von Pseudoephedrin sollte Aerinaze in der Schwangerschaft nicht angewendet werden .
T-818	4 Because animal reproduction studies are not always predictive of human response , and due to the vasoconstrictive properties of pseudoephedrine , Aerinaze should not be used during pregnancy .
H-818	-0.4684423804283142	Aerinaze should not be used in pregnancy as animal reproductive studies are not always transferable to humans and due to the vasoconstrictive nature of pseudoephedrine .
D-818	-0.4684423804283142	Aerinaze should not be used in pregnancy as animal reproductive studies are not always transferable to humans and due to the vasoconstrictive nature of pseudoephedrine .
P-818	-3.8200 -0.1503 -0.1263 -0.3873 -0.0881 -0.2557 -0.1198 -0.1632 -0.2193 -0.1225 -0.0310 -0.9245 -0.1342 -0.1541 -0.0493 -0.0830 -1.0281 -0.1190 -0.2719 -0.7068 -0.4850 -0.1591 -0.1745 -1.2649 -0.1720 -0.7388 -0.1562 -0.2483 -0.4024 -0.1374 -0.2398 -0.3009 -0.1196 -0.3979 -1.7317 -0.1523 -0.2316 -3.8372 -0.1844 -0.0507 -0.1696 -0.3351 -0.0901 -0.1638 -0.1822
S-317	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-317	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-317	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
D-317	-0.34009161591529846	Sporadic reports of urticaria , pruritus , skin rash and increased eosinophile granulocyte count were reported in four patients during multiple repeat-dose product exposures during the study .
P-317	-0.8479 -0.1862 -0.4518 -0.0512 -0.1218 -0.1365 -0.0484 -0.0834 -0.1391 -0.2799 -0.0180 -0.0370 -0.1043 -0.1358 -1.0280 -0.0421 -0.0312 -0.6262 -0.2739 -0.6418 -0.2083 -0.1725 -0.9131 -0.5131 -0.7037 -0.1594 -0.0992 -0.0631 -0.1011 -0.1482 -0.7559 -0.3392 -0.1135 -0.3482 -0.2688 -0.8033 -0.5566 -1.7646 -0.2300 -0.1047 -0.7530 -0.2572 -0.1345 -0.1488 -0.1470 -1.1812 -0.1433 -0.2962 -0.1195 -0.1731
S-225	Der Alendronatbestandteil der ADROVANCE Kombinationstablette ( 70 mg<unk> 5.600 I.E. ) und einer Tablette mit 70 mg Alendronat sind bioäquivalent .
T-225	The alendronate component in the ADROVANCE ( 70mg/ 5600 IU ) combination tablet is bioequivalent to the alendronate 70 mg tablet .
H-225	-0.20033712685108185	The alendronate constituent of the ADROVANCE combination tablet ( 70 mg/ 5,600 IU ) and a tablet of 70 mg alendronate are bioequivalent .
D-225	-0.20033712685108185	The alendronate constituent of the ADROVANCE combination tablet ( 70 mg/ 5,600 IU ) and a tablet of 70 mg alendronate are bioequivalent .
P-225	-0.2198 -0.2933 -0.1210 -0.1471 -0.0993 -1.3260 -0.2153 -0.1415 -0.1162 -0.3618 -0.0707 -0.1433 -0.0894 -0.0691 -0.0650 -0.1012 -0.0742 -0.1467 -0.0863 -0.1141 -0.1117 -0.1063 -0.1946 -0.1311 -0.1140 -0.0576 -0.1353 -0.1348 -1.9975 -0.1116 -0.0451 -0.2367 -0.0977 -0.0516 -0.2063 -0.1345 -0.1083 -0.0507 -0.1387 -0.0497 -0.0695 -0.1515 -0.1783
S-122	Der Alendronatbestandteil der ADROVANCE Kombinationstablette ( 70 mg<unk> 2.800 I.E. ) und der Tablette mit 70 mg Alendronat sind bioäquivalent .
T-122	The alendronate component in the ADROVANCE ( 70 mg/ 2800 IU ) combination tablet is bioequivalent to the alendronate 70 mg tablet .
H-122	-0.21666982769966125	The alendronate constituent of the ADROVANCE combination tablet ( 70 mg/ 2,800 IU ) and the tablet of 70 mg alendronate are bioequivalent .
D-122	-0.21666982769966125	The alendronate constituent of the ADROVANCE combination tablet ( 70 mg/ 2,800 IU ) and the tablet of 70 mg alendronate are bioequivalent .
P-122	-0.1632 -0.2681 -0.1243 -0.1479 -0.0996 -1.2034 -0.2108 -0.1441 -0.1103 -0.4497 -0.0709 -0.1444 -0.0926 -0.0686 -0.0659 -0.0973 -0.0771 -0.1453 -0.0863 -0.1214 -0.1129 -0.1127 -0.5727 -0.1057 -0.1148 -0.0547 -0.1333 -0.1440 -1.2209 -1.1933 -0.0461 -0.3978 -0.0913 -0.0483 -0.2012 -0.1355 -0.1066 -0.0457 -0.1368 -0.0489 -0.0773 -0.1483 -0.1770
S-164	Es stehen keine Daten zur Verfügung , die Hinweise geben , ob das Absetzen einer Bisphosphonattherapie bei Patienten , die einen kieferchirurgischen Eingriff benötigen , das Risiko einer Osteonekrose des Kiefers vermindert .
T-164	For patients requiring dental procedures , there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw .
H-164	-0.26862403750419617	There are no data available to suggest whether discontinuation of bisphosphonate therapy in patients requiring jaw surgery minimises the risk of osteonecrosis of the jaw .
D-164	-0.26862403750419617	There are no data available to suggest whether discontinuation of bisphosphonate therapy in patients requiring jaw surgery minimises the risk of osteonecrosis of the jaw .
P-164	-1.7843 -0.1004 -0.0965 -0.1328 -0.1227 -0.1444 -0.3264 -1.0633 -0.2850 -0.1171 -0.1239 -0.1385 -0.0813 -0.0572 -0.0546 -0.2931 -0.1707 -0.0973 -0.1868 -0.8555 -1.2165 -0.1652 -0.2026 -1.0277 -0.0354 -0.1557 -0.1113 -0.0604 -0.1487 -0.1560 -0.1532 -0.1313 -0.1128 -0.0198 -0.1661 -0.1419 -0.1048 -0.2820 -0.0786 -0.1343 -0.1774
S-65	Es stehen keine Daten zur Verfügung , die Hinweise geben , ob das Absetzen einer Bisphosphonattherapie bei Patienten , die einen kieferchirurgischen Eingriff benötigen , das Risiko einer Osteonekrose des Kiefers vermindert .
T-65	For patients requiring dental procedures , there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw .
H-65	-0.26862403750419617	There are no data available to suggest whether discontinuation of bisphosphonate therapy in patients requiring jaw surgery minimises the risk of osteonecrosis of the jaw .
D-65	-0.26862403750419617	There are no data available to suggest whether discontinuation of bisphosphonate therapy in patients requiring jaw surgery minimises the risk of osteonecrosis of the jaw .
P-65	-1.7843 -0.1004 -0.0965 -0.1328 -0.1227 -0.1444 -0.3264 -1.0633 -0.2850 -0.1171 -0.1239 -0.1385 -0.0813 -0.0572 -0.0546 -0.2931 -0.1707 -0.0973 -0.1868 -0.8555 -1.2165 -0.1652 -0.2026 -1.0277 -0.0354 -0.1557 -0.1113 -0.0604 -0.1487 -0.1560 -0.1532 -0.1313 -0.1128 -0.0198 -0.1661 -0.1419 -0.1048 -0.2820 -0.0786 -0.1343 -0.1774
S-6	Während der ersten Behandlungsmonate können immer noch Gichtanfälle auftreten ; deshalb wird empfohlen , dass die Patienten mindestens während der ersten sechs Monate unter Behandlung mit Adenuric noch weitere Arzneimittel zur Verhütung von Gichtanfällen einnehmen .
T-6	Attacks of gout can still occur during the first few months of treatment , so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Adenuric .
H-6	-0.5197672247886658	Gout may still occur during the first several months of therapy ; it is therefore recommended that patients continue to take medicines to prevent gout for at least the first six months of treatment with Adenuric .
D-6	-0.5197672247886658	Gout may still occur during the first several months of therapy ; it is therefore recommended that patients continue to take medicines to prevent gout for at least the first six months of treatment with Adenuric .
P-6	-0.8660 -1.3173 -2.2511 -0.3585 -0.0915 -0.0981 -0.1230 -0.1210 -1.5342 -0.0553 -0.1303 -0.2906 -0.7643 -0.7163 -0.1024 -0.6066 -0.0618 -0.1144 -0.6864 -1.1372 -0.1422 -0.0705 -2.3023 -0.4154 -0.2149 -0.1159 -1.9251 -1.3581 -1.0263 -0.0782 -0.0866 -0.1123 -0.2341 -0.0913 -0.0721 -0.6113 -0.8519 -0.1607 -0.7603 -0.2746 -0.0836 -0.1497 -0.1319 -0.1743
S-143	Studien an Ratten zeigten , dass die Gabe von Alendronat an trächtige Ratten mit dem Auftreten von Dystokie bei den Muttertieren einherging , die auf eine Hypocalcämie zurückzuführen war .
T-143	Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia .
H-143	-0.41262200474739075	Studies in rats found that the administration of alendronate to pregnant rats was associated with the occurrence of dystocia in the dam as a consequence of hypocalcaemia .
D-143	-0.41262200474739075	Studies in rats found that the administration of alendronate to pregnant rats was associated with the occurrence of dystocia in the dam as a consequence of hypocalcaemia .
P-143	-0.2111 -0.1224 -0.0313 -2.2748 -0.1086 -1.8411 -0.1749 -0.1444 -0.1686 -0.1379 -0.1020 -0.2012 -0.1518 -0.0685 -0.0367 -0.4585 -0.2189 -0.1225 -0.9811 -1.3105 -0.0334 -0.0708 -0.1073 -0.1631 -0.3511 -0.1109 -0.7091 -0.1531 -0.1749 -1.4419 -2.8328 -0.6834 -0.7134 -0.1005 -0.1456 -0.0543 -0.0500 -0.0450 -0.0508 -0.1637 -0.1308 -0.1773
S-402	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-402	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-402	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-402	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-402	-1.7196 -0.9794 -0.1291 -0.3886 -0.5315 -0.0755 -0.0920 -0.1357 -0.1598 -0.4702 -0.1837 -0.0844 -0.1501 -0.1659 -0.2935 -0.1796 -0.0525 -0.1107 -0.1200 -0.1496 -0.6038 -3.0577 -0.1002 -0.1074 -0.1299 -0.0404 -0.0898 -0.1092 -0.1534 -0.1198 -0.1781 -2.1251 -0.4608 -0.0917 -0.0884 -0.1276 -0.1534 -0.3587 -0.2437 -0.1075 -0.0042 -0.1617 -0.1497 -0.1209 -0.1704
S-332	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-332	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-332	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-332	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-332	-1.7196 -0.9794 -0.1291 -0.3886 -0.5315 -0.0755 -0.0920 -0.1357 -0.1598 -0.4702 -0.1837 -0.0844 -0.1501 -0.1659 -0.2935 -0.1796 -0.0525 -0.1107 -0.1200 -0.1496 -0.6038 -3.0577 -0.1002 -0.1074 -0.1299 -0.0404 -0.0898 -0.1092 -0.1534 -0.1198 -0.1781 -2.1251 -0.4608 -0.0917 -0.0884 -0.1276 -0.1534 -0.3587 -0.2437 -0.1075 -0.0042 -0.1617 -0.1497 -0.1209 -0.1704
S-682	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-682	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-682	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-682	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-682	-1.7196 -0.9794 -0.1291 -0.3886 -0.5315 -0.0755 -0.0920 -0.1357 -0.1598 -0.4702 -0.1837 -0.0844 -0.1501 -0.1659 -0.2935 -0.1796 -0.0525 -0.1107 -0.1200 -0.1496 -0.6038 -3.0577 -0.1002 -0.1074 -0.1299 -0.0404 -0.0898 -0.1092 -0.1534 -0.1198 -0.1781 -2.1251 -0.4608 -0.0917 -0.0884 -0.1276 -0.1534 -0.3587 -0.2437 -0.1075 -0.0042 -0.1617 -0.1497 -0.1209 -0.1704
S-612	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-612	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-612	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-612	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-612	-1.7196 -0.9794 -0.1291 -0.3886 -0.5315 -0.0755 -0.0920 -0.1357 -0.1598 -0.4702 -0.1837 -0.0844 -0.1501 -0.1659 -0.2935 -0.1796 -0.0525 -0.1107 -0.1200 -0.1496 -0.6038 -3.0577 -0.1002 -0.1074 -0.1299 -0.0404 -0.0898 -0.1092 -0.1534 -0.1198 -0.1781 -2.1251 -0.4608 -0.0917 -0.0884 -0.1276 -0.1534 -0.3587 -0.2437 -0.1075 -0.0042 -0.1617 -0.1497 -0.1209 -0.1704
S-542	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-542	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-542	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-542	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-542	-1.7196 -0.9794 -0.1291 -0.3886 -0.5315 -0.0755 -0.0920 -0.1357 -0.1598 -0.4702 -0.1837 -0.0844 -0.1501 -0.1659 -0.2935 -0.1796 -0.0525 -0.1107 -0.1200 -0.1496 -0.6038 -3.0577 -0.1002 -0.1074 -0.1299 -0.0404 -0.0898 -0.1092 -0.1534 -0.1198 -0.1781 -2.1251 -0.4608 -0.0917 -0.0884 -0.1276 -0.1534 -0.3587 -0.2437 -0.1075 -0.0042 -0.1617 -0.1497 -0.1209 -0.1704
S-472	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-472	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-472	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-472	-0.3383346498012543	If it is still refrigerated , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-472	-1.7196 -0.9794 -0.1291 -0.3886 -0.5315 -0.0755 -0.0920 -0.1357 -0.1598 -0.4702 -0.1837 -0.0844 -0.1501 -0.1659 -0.2935 -0.1796 -0.0525 -0.1107 -0.1200 -0.1496 -0.6038 -3.0577 -0.1002 -0.1074 -0.1299 -0.0404 -0.0898 -0.1092 -0.1534 -0.1198 -0.1781 -2.1251 -0.4608 -0.0917 -0.0884 -0.1276 -0.1534 -0.3587 -0.2437 -0.1075 -0.0042 -0.1617 -0.1497 -0.1209 -0.1704
S-289	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-289	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-289	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
D-289	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
P-289	-0.0930 -0.8928 -0.0607 -0.9449 -1.2572 -0.3593 -0.2473 -0.0782 -0.0376 -1.3512 -0.1573 -0.1245 -0.6869 -0.7054 -0.1518 -1.2245 -0.1756 -0.0046 -0.2069 -0.8310 -0.1136 -0.2650 -0.0459 -0.2203 -0.1553 -0.3461 -0.1647 -0.2300 -0.1192 -0.7970 -0.1328 -0.4132 -0.1530 -0.3780 -0.0727 -0.1747 -0.1973 -0.0918 -0.0808 -0.1501 -0.7952 -0.1139 -0.1320 -0.1700
S-358	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-358	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-358	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
D-358	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
P-358	-0.0930 -0.8928 -0.0607 -0.9449 -1.2572 -0.3593 -0.2473 -0.0782 -0.0376 -1.3512 -0.1573 -0.1245 -0.6869 -0.7054 -0.1518 -1.2245 -0.1756 -0.0046 -0.2069 -0.8310 -0.1136 -0.2650 -0.0459 -0.2203 -0.1553 -0.3461 -0.1647 -0.2300 -0.1192 -0.7970 -0.1328 -0.4132 -0.1530 -0.3780 -0.0727 -0.1747 -0.1973 -0.0918 -0.0808 -0.1501 -0.7952 -0.1139 -0.1320 -0.1700
S-638	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-638	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-638	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
D-638	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
P-638	-0.0930 -0.8928 -0.0607 -0.9449 -1.2572 -0.3593 -0.2473 -0.0782 -0.0376 -1.3512 -0.1573 -0.1245 -0.6869 -0.7054 -0.1518 -1.2245 -0.1756 -0.0046 -0.2069 -0.8310 -0.1136 -0.2650 -0.0459 -0.2203 -0.1553 -0.3461 -0.1647 -0.2300 -0.1192 -0.7970 -0.1328 -0.4132 -0.1530 -0.3780 -0.0727 -0.1747 -0.1973 -0.0918 -0.0808 -0.1501 -0.7952 -0.1139 -0.1320 -0.1700
S-568	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-568	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-568	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
D-568	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
P-568	-0.0930 -0.8928 -0.0607 -0.9449 -1.2572 -0.3593 -0.2473 -0.0782 -0.0376 -1.3512 -0.1573 -0.1245 -0.6869 -0.7054 -0.1518 -1.2245 -0.1756 -0.0046 -0.2069 -0.8310 -0.1136 -0.2650 -0.0459 -0.2203 -0.1553 -0.3461 -0.1647 -0.2300 -0.1192 -0.7970 -0.1328 -0.4132 -0.1530 -0.3780 -0.0727 -0.1747 -0.1973 -0.0918 -0.0808 -0.1501 -0.7952 -0.1139 -0.1320 -0.1700
S-498	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-498	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-498	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
D-498	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
P-498	-0.0930 -0.8928 -0.0607 -0.9449 -1.2572 -0.3593 -0.2473 -0.0782 -0.0376 -1.3512 -0.1573 -0.1245 -0.6869 -0.7054 -0.1518 -1.2245 -0.1756 -0.0046 -0.2069 -0.8310 -0.1136 -0.2650 -0.0459 -0.2203 -0.1553 -0.3461 -0.1647 -0.2300 -0.1192 -0.7970 -0.1328 -0.4132 -0.1530 -0.3780 -0.0727 -0.1747 -0.1973 -0.0918 -0.0808 -0.1501 -0.7952 -0.1139 -0.1320 -0.1700
S-428	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-428	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-428	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
D-428	-0.3432575762271881	If the expected factor VIII plasma activities are not achieved or if haemorrhage at an appropriate dose is not controlled , a test should be performed to detect an inhibitor if necessary .
P-428	-0.0930 -0.8928 -0.0607 -0.9449 -1.2572 -0.3593 -0.2473 -0.0782 -0.0376 -1.3512 -0.1573 -0.1245 -0.6869 -0.7054 -0.1518 -1.2245 -0.1756 -0.0046 -0.2069 -0.8310 -0.1136 -0.2650 -0.0459 -0.2203 -0.1553 -0.3461 -0.1647 -0.2300 -0.1192 -0.7970 -0.1328 -0.4132 -0.1530 -0.3780 -0.0727 -0.1747 -0.1973 -0.0918 -0.0808 -0.1501 -0.7952 -0.1139 -0.1320 -0.1700
S-247	Studien an Ratten zeigten , dass die Gabe von Alendronat an trächtige Ratten mit dem Auftreten von Dystokie bei den Muttertieren einherging , die auf eine Hypocalcämie zurückzuführen war .
T-247	Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia .
H-247	-0.41262200474739075	Studies in rats found that the administration of alendronate to pregnant rats was associated with the occurrence of dystocia in the dam as a consequence of hypocalcaemia .
D-247	-0.41262200474739075	Studies in rats found that the administration of alendronate to pregnant rats was associated with the occurrence of dystocia in the dam as a consequence of hypocalcaemia .
P-247	-0.2111 -0.1224 -0.0313 -2.2748 -0.1086 -1.8411 -0.1749 -0.1444 -0.1686 -0.1379 -0.1020 -0.2012 -0.1518 -0.0685 -0.0367 -0.4585 -0.2189 -0.1225 -0.9811 -1.3105 -0.0334 -0.0708 -0.1073 -0.1631 -0.3511 -0.1109 -0.7091 -0.1531 -0.1749 -1.4419 -2.8328 -0.6834 -0.7134 -0.1005 -0.1456 -0.0543 -0.0500 -0.0450 -0.0508 -0.1637 -0.1308 -0.1773
S-130	Alendronat wird bei Ratten nicht über das saure oder basische Transportsystem der Nieren ausgeschieden und daher wird nicht angenommen , dass es beim Menschen die Ausscheidung anderer Arzneimittel durch diese Transportsysteme beeinflusst .
T-130	Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats , and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans .
H-130	-0.37390369176864624	Alendronate is not excreted in rats by the acidic or alkaline kidney transport system and therefore is not expected to affect excretion of other medicinal products by these transport systems in humans .
D-130	-0.37390369176864624	Alendronate is not excreted in rats by the acidic or alkaline kidney transport system and therefore is not expected to affect excretion of other medicinal products by these transport systems in humans .
P-130	-0.1135 -0.1358 -0.0930 -0.0709 -0.2663 -0.1422 -0.0603 -0.0256 -0.1083 -0.5315 -0.0533 -1.4641 -0.6147 -0.4632 -0.2156 -0.1384 -0.5114 -0.3416 -0.1476 -2.4908 -0.0614 -1.0039 -0.1180 -0.2364 -0.1195 -0.5552 -0.2596 -1.4795 -0.1440 -0.0988 -1.0796 -0.0522 -0.1708 -0.1352 -0.1371 -0.1026 -0.0477 -0.0640 -0.5555 -0.6765 -1.3018 -0.0946 -0.2097 -0.1991 -0.1316 -0.1773
S-675	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-675	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-675	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-675	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-675	-0.1262 -0.1974 -0.1167 -0.0618 -0.1378 -1.2053 -0.0476 -0.4902 -0.1246 -0.0566 -0.1086 -0.4877 -0.0496 -0.1266 -0.1982 -0.1210 -0.1915 -0.0496 -0.1131 -0.1214 -0.1571 -0.4083 -0.1503 -0.2181 -0.3964 -0.1116 -0.1438 -0.1301 -0.2868 -1.5266 -0.1474 -0.1476 -1.8396 -0.1941 -0.0722 -0.1946 -0.1276 -0.1155 -0.5542 -0.3113 -0.2106 -0.7718 -0.0918 -0.1352 -0.2729 -1.2476 -0.0712 -0.0466 -0.0667 -0.1407 -0.2134
S-605	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-605	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-605	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-605	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-605	-0.1262 -0.1974 -0.1167 -0.0618 -0.1378 -1.2053 -0.0476 -0.4902 -0.1246 -0.0566 -0.1086 -0.4877 -0.0496 -0.1266 -0.1982 -0.1210 -0.1915 -0.0496 -0.1131 -0.1214 -0.1571 -0.4083 -0.1503 -0.2181 -0.3964 -0.1116 -0.1438 -0.1301 -0.2868 -1.5266 -0.1474 -0.1476 -1.8396 -0.1941 -0.0722 -0.1946 -0.1276 -0.1155 -0.5542 -0.3113 -0.2106 -0.7718 -0.0918 -0.1352 -0.2729 -1.2476 -0.0712 -0.0466 -0.0667 -0.1407 -0.2134
S-233	Alendronat wird bei Ratten nicht über das saure oder basische Transportsystem der Nieren ausgeschieden und daher wird nicht angenommen , dass es beim Menschen die Ausscheidung anderer Arzneimittel durch diese Transportsysteme beeinflusst .
T-233	Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats , and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans .
H-233	-0.37390369176864624	Alendronate is not excreted in rats by the acidic or alkaline kidney transport system and therefore is not expected to affect excretion of other medicinal products by these transport systems in humans .
D-233	-0.37390369176864624	Alendronate is not excreted in rats by the acidic or alkaline kidney transport system and therefore is not expected to affect excretion of other medicinal products by these transport systems in humans .
P-233	-0.1135 -0.1358 -0.0930 -0.0709 -0.2663 -0.1422 -0.0603 -0.0256 -0.1083 -0.5315 -0.0533 -1.4641 -0.6147 -0.4632 -0.2156 -0.1384 -0.5114 -0.3416 -0.1476 -2.4908 -0.0614 -1.0039 -0.1180 -0.2364 -0.1195 -0.5552 -0.2596 -1.4795 -0.1440 -0.0988 -1.0796 -0.0522 -0.1708 -0.1352 -0.1371 -0.1026 -0.0477 -0.0640 -0.5555 -0.6765 -1.3018 -0.0946 -0.2097 -0.1991 -0.1316 -0.1773
S-325	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-325	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-325	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-325	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-325	-0.1262 -0.1974 -0.1167 -0.0618 -0.1378 -1.2053 -0.0476 -0.4902 -0.1246 -0.0566 -0.1086 -0.4877 -0.0496 -0.1266 -0.1982 -0.1210 -0.1915 -0.0496 -0.1131 -0.1214 -0.1571 -0.4083 -0.1503 -0.2181 -0.3964 -0.1116 -0.1438 -0.1301 -0.2868 -1.5266 -0.1474 -0.1476 -1.8396 -0.1941 -0.0722 -0.1946 -0.1276 -0.1155 -0.5542 -0.3113 -0.2106 -0.7718 -0.0918 -0.1352 -0.2729 -1.2476 -0.0712 -0.0466 -0.0667 -0.1407 -0.2134
S-535	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-535	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-535	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-535	-0.28691622614860535	Table 3 Summary of Pharmacokinetic Parameters of ADVATE in 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-535	-0.1262 -0.1974 -0.1167 -0.0618 -0.1378 -1.2053 -0.0476 -0.4902 -0.1246 -0.0566 -0.1086 -0.4877 -0.0496 -0.1266 -0.1982 -0.1210 -0.1915 -0.0496 -0.1131 -0.1214 -0.1571 -0.4083 -0.1503 -0.2181 -0.3964 -0.1116 -0.1438 -0.1301 -0.2868 -1.5266 -0.1474 -0.1476 -1.8396 -0.1941 -0.0722 -0.1946 -0.1276 -0.1155 -0.5542 -0.3113 -0.2106 -0.7718 -0.0918 -0.1352 -0.2729 -1.2476 -0.0712 -0.0466 -0.0667 -0.1407 -0.2134
S-306	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-306	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-306	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
D-306	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
P-306	-1.2149 -0.0964 -0.0924 -2.8155 -0.1316 -0.0519 -0.0517 -0.1270 -0.0817 -0.0065 -0.1082 -0.5365 -0.1386 -0.1562 -0.0548 -0.1225 -0.1787 -0.1290 -0.1420 -0.3594 -0.1005 -0.1699 -0.0565 -0.1026 -0.0851 -0.1903 -0.9437 -0.0924 -0.1041 -0.4717 -0.1303 -0.1348 -0.5003 -0.0074 -0.1717 -0.0738 -0.1084 -0.1132 -0.1571 -0.0479 -0.1016 -0.1166 -0.0919 -0.1528 -0.1539 -0.1656 -0.1168 -0.1715 -0.0631 -0.1136 -0.0891 -0.1560 -0.0185 -0.2216 -0.1130 -0.2801 -0.1416 -0.1369 -0.1776 -0.0706 -0.0860 -0.3233 -0.1100 -0.1023 -0.1484 -0.1399 -0.4610 -0.0686 -0.1764 -0.1353 -0.0585 -0.0780 -0.1469 -0.0571 -0.0903 -0.1288 -0.1104 -0.0934 -0.1421 -0.1823 -0.1939
S-515	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-515	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-515	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
D-515	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
P-515	-1.2149 -0.0964 -0.0924 -2.8155 -0.1316 -0.0519 -0.0517 -0.1270 -0.0817 -0.0065 -0.1082 -0.5365 -0.1386 -0.1562 -0.0548 -0.1225 -0.1787 -0.1290 -0.1420 -0.3594 -0.1005 -0.1699 -0.0565 -0.1026 -0.0851 -0.1903 -0.9437 -0.0924 -0.1041 -0.4717 -0.1303 -0.1348 -0.5003 -0.0074 -0.1717 -0.0738 -0.1084 -0.1132 -0.1571 -0.0479 -0.1016 -0.1166 -0.0919 -0.1528 -0.1539 -0.1656 -0.1168 -0.1715 -0.0631 -0.1136 -0.0891 -0.1560 -0.0185 -0.2216 -0.1130 -0.2801 -0.1416 -0.1369 -0.1776 -0.0706 -0.0860 -0.3233 -0.1100 -0.1023 -0.1484 -0.1399 -0.4610 -0.0686 -0.1764 -0.1353 -0.0585 -0.0780 -0.1469 -0.0571 -0.0903 -0.1288 -0.1104 -0.0934 -0.1421 -0.1823 -0.1939
S-445	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-445	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-445	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
D-445	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
P-445	-1.2149 -0.0964 -0.0924 -2.8155 -0.1316 -0.0519 -0.0517 -0.1270 -0.0817 -0.0065 -0.1082 -0.5365 -0.1386 -0.1562 -0.0548 -0.1225 -0.1787 -0.1290 -0.1420 -0.3594 -0.1005 -0.1699 -0.0565 -0.1026 -0.0851 -0.1903 -0.9437 -0.0924 -0.1041 -0.4717 -0.1303 -0.1348 -0.5003 -0.0074 -0.1717 -0.0738 -0.1084 -0.1132 -0.1571 -0.0479 -0.1016 -0.1166 -0.0919 -0.1528 -0.1539 -0.1656 -0.1168 -0.1715 -0.0631 -0.1136 -0.0891 -0.1560 -0.0185 -0.2216 -0.1130 -0.2801 -0.1416 -0.1369 -0.1776 -0.0706 -0.0860 -0.3233 -0.1100 -0.1023 -0.1484 -0.1399 -0.4610 -0.0686 -0.1764 -0.1353 -0.0585 -0.0780 -0.1469 -0.0571 -0.0903 -0.1288 -0.1104 -0.0934 -0.1421 -0.1823 -0.1939
S-375	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-375	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-375	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
D-375	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
P-375	-1.2149 -0.0964 -0.0924 -2.8155 -0.1316 -0.0519 -0.0517 -0.1270 -0.0817 -0.0065 -0.1082 -0.5365 -0.1386 -0.1562 -0.0548 -0.1225 -0.1787 -0.1290 -0.1420 -0.3594 -0.1005 -0.1699 -0.0565 -0.1026 -0.0851 -0.1903 -0.9437 -0.0924 -0.1041 -0.4717 -0.1303 -0.1348 -0.5003 -0.0074 -0.1717 -0.0738 -0.1084 -0.1132 -0.1571 -0.0479 -0.1016 -0.1166 -0.0919 -0.1528 -0.1539 -0.1656 -0.1168 -0.1715 -0.0631 -0.1136 -0.0891 -0.1560 -0.0185 -0.2216 -0.1130 -0.2801 -0.1416 -0.1369 -0.1776 -0.0706 -0.0860 -0.3233 -0.1100 -0.1023 -0.1484 -0.1399 -0.4610 -0.0686 -0.1764 -0.1353 -0.0585 -0.0780 -0.1469 -0.0571 -0.0903 -0.1288 -0.1104 -0.0934 -0.1421 -0.1823 -0.1939
S-585	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-585	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-585	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
D-585	-0.19805456697940826	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
P-585	-1.2149 -0.0964 -0.0924 -2.8155 -0.1316 -0.0519 -0.0517 -0.1270 -0.0817 -0.0065 -0.1082 -0.5365 -0.1386 -0.1562 -0.0548 -0.1225 -0.1787 -0.1290 -0.1420 -0.3594 -0.1005 -0.1699 -0.0565 -0.1026 -0.0851 -0.1903 -0.9437 -0.0924 -0.1041 -0.4717 -0.1303 -0.1348 -0.5003 -0.0074 -0.1717 -0.0738 -0.1084 -0.1132 -0.1571 -0.0479 -0.1016 -0.1166 -0.0919 -0.1528 -0.1539 -0.1656 -0.1168 -0.1715 -0.0631 -0.1136 -0.0891 -0.1560 -0.0185 -0.2216 -0.1130 -0.2801 -0.1416 -0.1369 -0.1776 -0.0706 -0.0860 -0.3233 -0.1100 -0.1023 -0.1484 -0.1399 -0.4610 -0.0686 -0.1764 -0.1353 -0.0585 -0.0780 -0.1469 -0.0571 -0.0903 -0.1288 -0.1104 -0.0934 -0.1421 -0.1823 -0.1939
S-105	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant den Anteil an Patienten mit Vitamin-D-Mangel ( Serumwert von 25-Hydroxyvitamin D <unk> 22,5 nmol<unk> l <unk> <unk> 9 ng<unk> ml <unk> ) um 92 % im Vergleich zu Alendronat allein ( 1 % vs . 13 % ) .
T-105	The percentage of patients with vitamin D deficiency ( serum 25-hydroxyvitamin D <<unk>> 22.5 nmol/ l <<unk>> <<unk>> 9 ng/ ml <<unk>> ) was significantly reduced by 92 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 1 % vs 13 % , respectively ) .
H-105	-0.1868389993906021	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxy vitamin D <unk> 22.5 nmol/ l <unk> <unk> <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
D-105	-0.1868389993906021	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxy vitamin D <unk> 22.5 nmol/ l <unk> <unk> <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
P-105	-0.9171 -0.0592 -0.1729 -0.1019 -0.0758 -0.1602 -0.0773 -0.1371 -0.1054 -0.1063 -0.4041 -0.0997 -0.1123 -0.0554 -0.1354 -0.1848 -0.4737 -0.0995 -0.3987 -0.1316 -0.1467 -0.3043 -0.1257 -0.2038 -0.0424 -0.0557 -0.0268 -0.1001 -0.1325 -0.1465 -0.1300 -0.0897 -0.6121 -0.5468 -0.1660 -0.8369 -0.0550 -0.0836 -0.0791 -0.0199 -0.1316 -0.1308 -0.1346 -0.5367 -0.1719 -0.1086 -0.0148 -0.0757 -0.2470 -0.3301 -0.1857 -0.1794 -0.1140 -0.0635 -0.0393 -0.1374 -0.2905 -0.0824 -0.1567 -0.4007 -0.1604 -0.5867 -0.1330 -0.1388 -0.0563 -0.1327 -0.1296 -0.1190 -0.1683 -0.1974 -0.1259 -0.1376 -0.1488 -0.1390 -0.1961
S-203	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant den Anteil an Patienten mit Vitamin-D-Mangel ( Serumwert von 25-Hydroxyvitamin D <unk> 22,5 nmol<unk> l <unk> <unk> 9 ng<unk> ml <unk> ) um 92 % im Vergleich zu Alendronat allein ( 1 % vs . 13 % ) .
T-203	The percentage of patients with vitamin D deficiency ( serum 25- hydroxyvitamin D <<unk>> 22.5 nmol/ l <<unk>> <<unk>> 9 ng/ ml <<unk>> ) was significantly reduced by 92 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 1 % vs 13 % , respectively ) .
H-203	-0.1868389993906021	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxy vitamin D <unk> 22.5 nmol/ l <unk> <unk> <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
D-203	-0.1868389993906021	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxy vitamin D <unk> 22.5 nmol/ l <unk> <unk> <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
P-203	-0.9171 -0.0592 -0.1729 -0.1019 -0.0758 -0.1602 -0.0773 -0.1371 -0.1054 -0.1063 -0.4041 -0.0997 -0.1123 -0.0554 -0.1354 -0.1848 -0.4737 -0.0995 -0.3987 -0.1316 -0.1467 -0.3043 -0.1257 -0.2038 -0.0424 -0.0557 -0.0268 -0.1001 -0.1325 -0.1465 -0.1300 -0.0897 -0.6121 -0.5468 -0.1660 -0.8369 -0.0550 -0.0836 -0.0791 -0.0199 -0.1316 -0.1308 -0.1346 -0.5367 -0.1719 -0.1086 -0.0148 -0.0757 -0.2470 -0.3301 -0.1857 -0.1794 -0.1140 -0.0635 -0.0393 -0.1374 -0.2905 -0.0824 -0.1567 -0.4007 -0.1604 -0.5867 -0.1330 -0.1388 -0.0563 -0.1327 -0.1296 -0.1190 -0.1683 -0.1974 -0.1259 -0.1376 -0.1488 -0.1390 -0.1961
S-792	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatischen Behandlung der saisonalen allergischen Rhinitis mit Nasenschleimhautschwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen .
T-792	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatischen Behandlung der saisonalen allergischen Rhinitis mit Nasenschleimhautschwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen . The Committee recommended that Aerinaze be given marketing authorisation .
H-792	-0.3101370930671692	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatic Behandlung der seasonale allergic Rhinitis mit NasenmumschätSchwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen . It recommended that the company give marketing authorisation for the use of Aerinaze .
D-792	-0.3101370930671692	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatic Behandlung der seasonale allergic Rhinitis mit NasenmumschätSchwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen . It recommended that the company give marketing authorisation for the use of Aerinaze .
P-792	-0.0284 -0.0105 -0.0174 -0.0210 -0.1152 -0.0096 -0.0495 -0.0189 -0.1550 -0.0705 -0.0586 -0.1404 -0.0289 -0.0571 -0.0234 -0.0170 -0.0318 -0.1141 -0.0035 -0.0146 -0.1137 -0.0404 -0.1264 -0.1091 -0.1312 -0.2469 -0.1285 -0.0118 -0.0635 -0.0739 -0.1355 -2.2921 -0.0101 -0.1538 -2.6581 -0.7670 -0.8854 -0.9033 -0.2271 -0.1846 -0.0452 -0.1335 -0.0624 -0.0196 -1.4580 -0.1774 -1.8004 -0.2683 -3.7052 -0.2078 -1.0705 -0.0636 -0.0919 -0.0262 -0.1610 -0.0931 -0.0223 -0.0862 -0.1419 -0.0469 -0.1195 -0.0023 -0.1518 -0.0434 -0.0668 -0.0485 -0.1173 -0.0711 -0.0136 -0.0291 -0.0665 -0.1326 -0.1116 -0.1258 -0.2575 -0.0861 -0.0334 -0.0145 -0.0524 -0.1173 -0.5665 -0.2150 -0.1569 -0.1376 -2.1959 -0.6871 -0.4152 -0.0197 -0.0852 -0.2640 -0.7016 -2.0246 -0.1374 -0.2747 -0.2541 -0.1545 -0.3874 -0.0775 -0.4997 -0.1694
S-249	Etui mit versiegelten Aluminium<unk> Aluminium-Blisterpackungen in Umkartons zu 2 ( 1 Etui mit 2 Tabletten ) , 4 ( 1 Etui mit 4 Tabletten ) , 12 ( 3 Etuis mit 4 Tabletten ) oder 40 ( 10 Etuis mit 4 Tabletten ) Tabletten .
T-249	Wallet with sealed aluminium/ aluminium blisters , in cartons containing 2 ( 1 wallet x 2 tablets ) , 4 ( 1 wallet x 4 tablets ) , 12 ( 3 wallets x 4 tablets ) or 40 ( 10 wallets x 4 tablets ) tablets .
H-249	-0.16117128729820251	Case of sealed aluminium/ aluminium blisters in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
D-249	-0.16117128729820251	Case of sealed aluminium/ aluminium blisters in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
P-249	-0.3508 -0.3820 -0.1788 -0.1167 -0.0924 -0.3295 -0.1152 -0.1322 -0.1116 -0.0266 -0.1131 -0.0433 -0.1919 -0.0774 -0.1118 -0.0716 -0.0480 -0.1597 -0.1311 -0.1452 -0.1093 -0.8044 -0.1639 -0.1519 -0.0329 -0.0308 -0.1400 -0.1472 -0.2343 -0.1664 -0.1371 -0.2627 -0.1519 -0.1727 -0.0256 -0.0208 -0.1379 -0.1540 -0.1739 -0.1694 -0.1505 -0.6419 -0.1457 -0.1613 -0.0235 -0.0218 -0.1298 -0.2858 -0.1342 -0.1781 -0.1575 -0.5525 -0.1374 -0.2162 -0.0236 -0.0278 -0.1393 -0.0328 -0.0391 -0.1433 -0.1733
S-43	Der Ausschuss für Humanarzneimittel ( CHMP ) entschied , dass die Vorteile von ADROVANCE bei der Behandlung von Osteoporose bei postmenopausalen Patientinnen mit Risiko eines Vitamin-D- Mangels gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von ADROVANCE zu erteilen .
T-43	Der Ausschuss für Humanarzneimittel ( CHMP ) entschied , dass die Vorteile von ADROVANCE bei der Behandlung von Osteoporose bei postmenopausalen Patientinnen mit Risiko eines Vitamin-D- Mangels gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von ADROVANCE zu erteilen . The Committee recommended that ADROVANCE be given marketing authorisation .
H-43	-0.29653286933898926	Der Ausschuss für Humanarzneimittel ( CHMP ) decided that the benefits of ADROVANCE in the treatment of osteoporosis in post-menopausal female patients with risk of vitamin D deficiency are outweighed by the risks , and recommended that the company give marketing authorisation for the product .
D-43	-0.29653286933898926	Der Ausschuss für Humanarzneimittel ( CHMP ) decided that the benefits of ADROVANCE in the treatment of osteoporosis in post-menopausal female patients with risk of vitamin D deficiency are outweighed by the risks , and recommended that the company give marketing authorisation for the product .
P-43	-0.0378 -0.0084 -0.0234 -0.0283 -0.1161 -0.0132 -0.0360 -0.0152 -0.1563 -0.0709 -0.0514 -0.1392 -2.0963 -0.8265 -0.3140 -0.0888 -0.1594 -0.0996 -0.0463 -0.1462 -0.0913 -0.0752 -0.7995 -0.2825 -0.0527 -0.1463 -0.2568 -0.1635 -0.1479 -0.1309 -0.1691 -0.1290 -0.1799 -0.0174 -0.2900 -0.0549 -0.1676 -0.0105 -0.1085 -1.3078 -0.0948 -0.3330 -0.2171 -0.1727 -0.0714 -0.0535 -0.1006 -0.0182 -0.0380 -0.0698 -2.1991 -0.3626 -0.2640 -0.1227 -0.4413 -0.0669 -0.3031 -0.1530 -0.1433 -0.1368 -0.5312 -0.5824 -0.6578 -1.6538 -0.0290 -0.0845 -0.1060 -0.4159 -1.1833 -1.2219 -0.1721
S-9	Harnsäurespiegel im Blut senken und auf einem niedrigeren Niveau halten , so dass sich keine Kristalle mehr bilden können . Dadurch können die Symptome der Gicht gelindert werden . Wenn der Harnsäurespiegel lange genug auf niedrigem Niveau gehalten wird , können unter Umständen sogar bereits vorhandene Gichtknoten kleiner werden . Wie wurde Adenuric untersucht ?
T-9	How has Adenuric been studied ?
H-9	-0.5141353607177734	This helps to relieve the symptoms of gout .
D-9	-0.5141353607177734	This helps to relieve the symptoms of gout .
P-9	-1.6498 -0.1882 -0.1591 -2.5107 -0.0898 -0.3308 -0.0189 -0.1566 -0.2311 -0.3585 -0.2251 -0.2510
S-269	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Mangel an Faktor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen .
T-269	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Mangel an Faktor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen . The Committee recommended that Advate be given marketing authorisation .
H-269	-0.3038268983364105	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxis von Blutungen bei Patienten mit Hämophilie A ( innate lack of factor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen . It recommended that the Committee give marketing authorisation for the injection of Advate .
D-269	-0.3038268983364105	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxis von Blutungen bei Patienten mit Hämophilie A ( innate lack of factor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen . It recommended that the Committee give marketing authorisation for the injection of Advate .
P-269	-0.0183 -0.0077 -0.0168 -0.0302 -0.1182 -0.0110 -0.0360 -0.0187 -0.1537 -0.0760 -0.0585 -0.1409 -0.0309 -0.0494 -0.0156 -0.0116 -0.0297 -0.1130 -0.0029 -0.0094 -0.0831 -0.0342 -0.3761 -0.0820 -0.0131 -0.0343 -0.0058 -0.1042 -0.0361 -0.1628 -0.3347 -0.2264 -1.0993 -0.0603 -0.4344 -0.1919 -0.0196 -0.0060 -0.0129 -0.0476 -0.1074 -0.0624 -2.3460 -0.1963 -0.1475 -3.7113 -0.0813 -0.9912 -0.1509 -1.1353 -0.1605 -0.0458 -0.1490 -0.0486 -0.0333 -0.1125 -0.0274 -0.1094 -0.1482 -0.0584 -0.0973 -0.0025 -0.1481 -0.0290 -0.0828 -0.0431 -0.0550 -0.0829 -0.0122 -0.0264 -0.0618 -0.4932 -0.0951 -0.0780 -0.0163 -0.0482 -0.1140 -0.9541 -0.1286 -0.1327 -0.1706 -0.9719 -0.8377 -2.6484 -0.0146 -0.0789 -0.2383 -0.6706 -2.1724 -0.5316 -0.1210 -2.8672 -0.0899 -0.4450 -0.1680
S-10	In der ersten Studie , an der 1 072 Patienten teilnahmen , wurde die Wirksamkeit dreier verschiedener Adenuric-Dosierungen ( einmal täglich 80 , 120 und 240 mg ) mit der eines Placebo ( Scheinmedikaments ) und von Allopurinol ( einem anderen Arzneimittel zur Behandlung der Hyperurikämie ) verglichen .
T-10	The first study , carried out in 1,072 patients , compared the effectiveness of three doses of Adenuric ( 80 , 120 and 240 mg once a day ) with that of placebo ( a dummy treatment ) and of allopurinol ( another medicine used to treat hyperuricaemia ) .
H-10	-0.27343758940696716	The first involved 1,072 patients who compared the effectiveness of three different doses of adenuric ( 80 , 120 , and 240 mg once daily ) with placebo ( a dummy treatment ) and allopurinol , another medicine used to treat hyperuricaemia .
D-10	-0.27343758940696716	The first involved 1,072 patients who compared the effectiveness of three different doses of adenuric ( 80 , 120 , and 240 mg once daily ) with placebo ( a dummy treatment ) and allopurinol , another medicine used to treat hyperuricaemia .
P-10	-0.4026 -0.1829 -1.2251 -0.0656 -0.0650 -0.1564 -0.1958 -1.1653 -0.1505 -0.1125 -1.7879 -0.0833 -0.1259 -0.1558 -0.3035 -0.3773 -0.1018 -0.1411 -0.0986 -0.1207 -0.2339 -0.1093 -0.4949 -0.1392 -0.0641 -0.1301 -0.1277 -0.5695 -0.1119 -0.1003 -0.4917 -0.1278 -0.3637 -0.0737 -0.1453 -0.1534 -0.1424 -0.1546 -0.1232 -0.0107 -0.0210 -0.2214 -0.1601 -0.1785 -0.3413 -1.0269 -0.1446 -0.1365 -0.8843 -0.0792 -0.8100 -0.3256 -0.1940 -0.0486 -0.1237 -0.1019 -0.4620 -0.0450 -0.1602 -0.1611 -0.1689
S-54	Überempfindlichkeit gegen einen der arzneilich wirksamen Bestandteile oder der sonstigen Bestandteile . Erkrankungen des Ösophagus und andere Faktoren , welche die ösophageale Entleerung verzögern , wie Strikturen oder Achalasie . Unfähigkeit , für mindestens 30 Minuten aufrecht zu stehen oder zu sitzen . Hypocalcämie .
T-54	Inability to stand or sit upright for at least 30 minutes .
H-54	-0.38907280564308167	Hypersensitivity to any of the active ingredients or to any of the excipients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes .
D-54	-0.38907280564308167	Hypersensitivity to any of the active ingredients or to any of the excipients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes .
P-54	-0.8872 -0.0316 -0.0811 -0.1061 -0.1588 -0.1929 -0.2101 -0.1350 -0.5821 -0.6797 -0.1203 -0.1961 -1.6728 -0.1946 -0.1273 -0.0550 -0.1846 -0.0792 -0.1070 -0.4859 -0.0206 -0.0769 -0.1584 -0.1318 -0.1202 -1.5693 -0.0894 -0.1346 -0.1593 -0.4247 -0.2689 -0.0881 -0.6484 -0.0980 -0.1503 -0.0478 -0.0914 -0.1140 -2.4784 -0.1564 -0.3010 -0.1381 -0.2224 -0.1516 -2.3754 -0.6024 -0.1298 -0.0826 -0.2527 -0.9628 -0.9313 -0.1239 -2.0910 -0.2267 -0.1503 -0.1749 -0.1749 -1.4638 -0.4308 -0.1597 -0.0956 -0.1246 -0.0948 -0.0959 -0.1351 -0.1068 -0.1250 -1.2190
S-154	Überempfindlichkeit gegen einen der arzneilich wirksamen Bestandteile oder der sonstigen Bestandteile . Erkrankungen des Ösophagus und andere Faktoren , welche die ösophageale Entleerung verzögern , wie Strikturen oder Achalasie . Unfähigkeit , für mindestens 30 Minuten aufrecht zu stehen oder zu sitzen . Hypocalcämie .
T-154	Inability to stand or sit upright for at least 30 minutes .
H-154	-0.38907280564308167	Hypersensitivity to any of the active ingredients or to any of the excipients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes .
D-154	-0.38907280564308167	Hypersensitivity to any of the active ingredients or to any of the excipients . Oesophagus disorders and other factors that delay oesophageal emptying , such as stricture or achalasia . Inability to stand or sit upright for at least 30 minutes .
P-154	-0.8872 -0.0316 -0.0811 -0.1061 -0.1588 -0.1929 -0.2101 -0.1350 -0.5821 -0.6797 -0.1203 -0.1961 -1.6728 -0.1946 -0.1273 -0.0550 -0.1846 -0.0792 -0.1070 -0.4859 -0.0206 -0.0769 -0.1584 -0.1318 -0.1202 -1.5693 -0.0894 -0.1346 -0.1593 -0.4247 -0.2689 -0.0881 -0.6484 -0.0980 -0.1503 -0.0478 -0.0914 -0.1140 -2.4784 -0.1564 -0.3010 -0.1381 -0.2224 -0.1516 -2.3754 -0.6024 -0.1298 -0.0826 -0.2527 -0.9628 -0.9313 -0.1239 -2.0910 -0.2267 -0.1503 -0.1749 -0.1749 -1.4638 -0.4308 -0.1597 -0.0956 -0.1246 -0.0948 -0.0959 -0.1351 -0.1068 -0.1250 -1.2190
S-75	Colecalciferol Vitamin D3 kann das Ausmaß einer Hypercalcämie und<unk> oder Hypercalciurie verstärken , wenn es an Patienten mit Krankheiten , die mit einer unkontrollierten Überproduktion von Calcitriol in Verbindung stehen , gegeben wird ( z. B. Leukämie , Lymphom , Sarkoidose ) .
T-75	Colecalciferol Vitamin D3 may increase the magnitude of hypercalcaemia and/ or hypercalciuria when administered to patients with disease associated with unregulated overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
H-75	-0.3500395119190216	Colecalciferol Vitamin D3 may increase the risk of hypercalcaemia and/ or hypercalciuria when given to patients with conditions associated with uncontrolled hyperproduction of calcitriol ( e. g. leucaemia , lymphoma , sarcoidosis ) .
D-75	-0.3500395119190216	Colecalciferol Vitamin D3 may increase the risk of hypercalcaemia and/ or hypercalciuria when given to patients with conditions associated with uncontrolled hyperproduction of calcitriol ( e. g. leucaemia , lymphoma , sarcoidosis ) .
P-75	-1.1328 -0.1596 -0.2443 -0.1288 -0.0940 -0.1876 -0.6859 -0.0469 -0.0996 -0.2311 -0.1484 -0.6953 -0.1252 -3.4699 -0.2165 -0.0828 -0.0702 -0.0930 -0.0503 -0.3671 -0.0616 -0.1452 -0.1615 -0.0539 -0.0602 -0.1445 -0.1027 -0.1435 -0.1972 -0.6929 -0.1837 -0.2717 -0.1140 -1.1490 -0.1154 -0.1378 -0.0776 -0.2668 -1.5314 -1.1273 -0.1584 -0.0881 -0.1719 -0.1201 -0.2135 -0.4762 -0.1458 -0.1045 -0.0907 -0.0123 -0.9017 -0.0298 -0.1888 -0.1480 -0.0452 -0.0387 -0.1476 -2.2120 -1.4749 -0.2672 -0.0679 -0.0940 -0.1489 -0.1564 -0.1830
S-759	Wirksamkeit des Arzneimittels wurde mithilfe von Scans bewertet , wobei untersucht wurde , wie die Tumore auf die Behandlung ansprachen . Das Unternehmen legte ferner Ergebnisse mehrerer kleiner Studien vor , in denen die Wirkungen eines Dosisbereichs von Advexin bei verschiedenen Krebsarten untersucht wurden . In welchem Stadium der Beurteilung befand sich der Antrag zum Zeitpunkt der Rücknahme ?
T-759	How far into the evaluation was the application when it was withdrawn ?
H-759	-0.4298432469367981	The company also presented results of several small studies looking at the effect of a dose range of Advexin in a variety of cancer types .
D-759	-0.4298432469367981	The company also presented results of several small studies looking at the effect of a dose range of Advexin in a variety of cancer types .
P-759	-0.8141 -0.0453 -0.0812 -0.1502 -0.4770 -0.1750 -0.1352 -0.3905 -0.2016 -0.6405 -0.0789 -0.1167 -0.3616 -0.1315 -0.8711 -0.3303 -0.2563 -0.1360 -1.5793 -0.1299 -0.1471 -1.7955 -1.1039 -0.0883 -0.1448 -1.3898 -0.3190 -0.2596 -0.1153
S-174	Colecalciferol Vitamin D3 kann das Ausmaß einer Hypercalcämie und<unk> oder Hypercalciurie verstärken , wenn es an Patienten mit Krankheiten , die mit einer unkontrollierten Überproduktion von Calcitriol in Verbindung stehen , gegeben wird ( z. B. Leukämie , Lymphom , Sarkoidose ) .
T-174	Colecalciferol Vitamin D3 may increase the magnitude of hypercalcaemia and/ or hypercalciuria when administered to patients with disease associated with unregulated overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
H-174	-0.3500395119190216	Colecalciferol Vitamin D3 may increase the risk of hypercalcaemia and/ or hypercalciuria when given to patients with conditions associated with uncontrolled hyperproduction of calcitriol ( e. g. leucaemia , lymphoma , sarcoidosis ) .
D-174	-0.3500395119190216	Colecalciferol Vitamin D3 may increase the risk of hypercalcaemia and/ or hypercalciuria when given to patients with conditions associated with uncontrolled hyperproduction of calcitriol ( e. g. leucaemia , lymphoma , sarcoidosis ) .
P-174	-1.1328 -0.1596 -0.2443 -0.1288 -0.0940 -0.1876 -0.6859 -0.0469 -0.0996 -0.2311 -0.1484 -0.6953 -0.1252 -3.4699 -0.2165 -0.0828 -0.0702 -0.0930 -0.0503 -0.3671 -0.0616 -0.1452 -0.1615 -0.0539 -0.0602 -0.1445 -0.1027 -0.1435 -0.1972 -0.6929 -0.1837 -0.2717 -0.1140 -1.1490 -0.1154 -0.1378 -0.0776 -0.2668 -1.5314 -1.1273 -0.1584 -0.0881 -0.1719 -0.1201 -0.2135 -0.4762 -0.1458 -0.1045 -0.0907 -0.0123 -0.9017 -0.0298 -0.1888 -0.1480 -0.0452 -0.0387 -0.1476 -2.2120 -1.4749 -0.2672 -0.0679 -0.0940 -0.1489 -0.1564 -0.1830
S-731	Sehr häufig : es sind mehr als 1 von 10 Patienten betroffen Häufig : betrifft zwischen 1 und 10 von 100 Patienten Gelegentlich : betrifft zwischen 1 und 10 von 1.000 Patienten Selten : betrifft zwischen 1 und 10 von 10.000 Patienten Sehr selten : betrifft weniger als 1 von 10.000 Patienten Nicht bekannt : ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-731	Side effects may occur with certain frequencies , which are defined as follows : very common : affects more than 1 user in 10 common : affects 1 to 10 users in 100 uncommon : affects 1 to 10 users in 1,000 rare : affects 1 to 10 users in 10,000 very rare : affects less than 1 user in 10,000 not known : frequency cannot be estimated from the available data .
H-731	-0.2098870426416397	Very common : affects more than 1 in 10 patients Common : affects between 1 and 10 in 100 patients Uncommon : affects between 1 and 10 in 1,000 patients Rare : affects between 1 and 10 in 10,000 patients Very rare : affects less than 1 in 10,000 patients Unknown : ( frequency cannot be estimated from the available data ) .
D-731	-0.2098870426416397	Very common : affects more than 1 in 10 patients Common : affects between 1 and 10 in 100 patients Uncommon : affects between 1 and 10 in 1,000 patients Rare : affects between 1 and 10 in 10,000 patients Very rare : affects less than 1 in 10,000 patients Unknown : ( frequency cannot be estimated from the available data ) .
P-731	-0.3383 -0.1211 -0.1387 -2.7874 -0.1068 -0.1162 -0.1616 -0.1555 -0.1608 -0.2339 -0.0570 -0.1008 -0.1469 -0.6126 -0.1406 -0.1626 -0.1670 -0.1428 -0.1609 -0.0507 -0.5068 -0.1082 -0.0213 -0.1360 -0.3528 -0.1112 -0.1354 -0.1661 -0.1474 -0.1634 -0.0688 -0.3640 -0.1957 -0.1133 -0.1385 -0.3547 -0.2426 -0.1240 -0.1698 -0.1532 -0.1585 -0.0671 -0.1548 -0.0842 -0.0463 -0.1447 -0.3193 -0.0847 -0.1384 -0.1087 -0.1662 -0.0570 -0.1404 -1.1246 -0.0587 -0.1481 -0.1919 -0.1508 -0.0592 -0.0697 -0.1473 -0.0622 -0.0973 -0.1073 -0.1181 -0.0772 -0.1612 -0.1972 -0.2055
S-14	In der ersten Studie hatten 48 % ( 126 von 262 ) der Patienten , die Adenuric in einer Dosis von einmal täglich 80 mg einnahmen , und 65 % ( 175 von 269 ) der Patienten , die einmal täglich 120 mg einnahmen , bei den letzten drei Messungen einen Harnsäurespiegel im Blut von unter 6 mg<unk> dl .
T-14	In the first study , 48 % of the patients taking 80 mg Adenuric once a day ( 126 out of 262 ) and 65 % of the patients taking 120 mg once a day ( 175 out of 269 ) had levels of uric acid below 6 mg/ dl in the final three measurements .
H-14	-0.3410134017467499	In the first trial , 48 % ( 126 out of 262 ) of patients taking adenuric at doses of 80 mg once a day and 65 % ( 175 out of 269 ) of patients taking 120 mg once a day had a uric acid level in the blood of less than 6 mg/ dl in the last three measurements .
D-14	-0.3410134017467499	In the first trial , 48 % ( 126 out of 262 ) of patients taking adenuric at doses of 80 mg once a day and 65 % ( 175 out of 269 ) of patients taking 120 mg once a day had a uric acid level in the blood of less than 6 mg/ dl in the last three measurements .
P-14	-0.2323 -0.1212 -0.1614 -1.3926 -0.1546 -0.0714 -0.1269 -0.1601 -0.1672 -0.1798 -0.2016 -0.1446 -0.0933 -0.1873 -0.1567 -0.1362 -0.6344 -0.1189 -1.2697 -0.0517 -0.1523 -0.2464 -2.6633 -0.1114 -0.2030 -0.2282 -0.1485 -0.0095 -0.8535 -0.3002 -0.2425 -0.1138 -0.1509 -0.1758 -0.0740 -0.2164 -0.1512 -0.0789 -0.1726 -0.1482 -0.1385 -0.7809 -0.1328 -0.0811 -0.0654 -0.0109 -0.4083 -0.2995 -0.0891 -0.5093 -2.1900 -0.1289 -0.2596 -0.1970 -0.1305 -0.2030 -0.0509 -0.2773 -0.3237 -0.1258 -0.1468 -0.1596 -0.1020 -0.1334 -0.0456 -2.0834 -0.1180 -0.3994 -0.1825 -2.0489 -0.1228 -0.7637 -0.1554 -0.1686
S-689	BEDINGUNGEN ODER EINSCHRÄNKUNGEN FÜR DIE ABGABE UND DEN GEBRAUCH , DIE DEM INHABER DER GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN AUFERLEGT WERDEN
T-689	CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
H-689	-0.07237547636032104	CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
D-689	-0.07237547636032104	CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
P-689	-0.0927 -0.0430 -0.0167 -0.0744 -0.0348 -0.1054 -0.0828 -0.1132 -0.3064 -0.0088 -0.0220 -0.0508 -0.0307 -0.1014 -0.1004 -0.1248 -0.0264 -0.0520 -0.0188 -0.0347 -0.0301 -0.0288 -0.0147 -0.0198 -0.6797 -0.0111 -0.1291 -0.0253 -0.0094 -0.0407 -0.0036 -0.0776 -0.1019 -0.0749 -0.0782 -0.0544 -0.0141 -0.1003 -0.0428 -0.0233 -0.0173 -0.0049 -0.1488 -0.0289 -0.0135 -0.0285 -0.1597
S-513	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-513	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-513	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-513	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-513	-0.1606 -0.5029 -0.1912 -0.0841 -1.3886 -0.0755 -0.1401 -0.1131 -2.8865 -0.8290 -0.1367 -0.2056 -1.2919 -0.8708 -0.0565 -0.0492 -0.1553 -0.2194 -0.1698 -0.1820 -0.0690 -0.1384 -0.1862 -0.3141 -0.1658 -0.1182 -0.3511 -0.1875 -0.1195 -0.6467 -0.1288 -0.1285 -0.1001 -0.0135 -0.2290 -1.8591 -1.9823 -0.0972 -0.4070 -1.2962 -0.1621 -0.0883 -0.8612 -0.5895 -0.4665 -0.0277 -0.1507 -0.1491 -0.1645 -0.1603 -0.2206 -0.1693 -0.0449 -1.3639 -0.2538 -0.2424 -0.0177 -0.1350 -0.1766 -0.3703 -0.1940 -1.8528 -0.1456 -0.1315 -0.1722
S-373	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-373	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-373	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-373	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-373	-0.1606 -0.5029 -0.1912 -0.0841 -1.3886 -0.0755 -0.1401 -0.1131 -2.8865 -0.8290 -0.1367 -0.2056 -1.2919 -0.8708 -0.0565 -0.0492 -0.1553 -0.2194 -0.1698 -0.1820 -0.0690 -0.1384 -0.1862 -0.3141 -0.1658 -0.1182 -0.3511 -0.1875 -0.1195 -0.6467 -0.1288 -0.1285 -0.1001 -0.0135 -0.2290 -1.8591 -1.9823 -0.0972 -0.4070 -1.2962 -0.1621 -0.0883 -0.8612 -0.5895 -0.4665 -0.0277 -0.1507 -0.1491 -0.1645 -0.1603 -0.2206 -0.1693 -0.0449 -1.3639 -0.2538 -0.2424 -0.0177 -0.1350 -0.1766 -0.3703 -0.1940 -1.8528 -0.1456 -0.1315 -0.1722
S-443	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-443	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-443	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-443	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-443	-0.1606 -0.5029 -0.1912 -0.0841 -1.3886 -0.0755 -0.1401 -0.1131 -2.8865 -0.8290 -0.1367 -0.2056 -1.2919 -0.8708 -0.0565 -0.0492 -0.1553 -0.2194 -0.1698 -0.1820 -0.0690 -0.1384 -0.1862 -0.3141 -0.1658 -0.1182 -0.3511 -0.1875 -0.1195 -0.6467 -0.1288 -0.1285 -0.1001 -0.0135 -0.2290 -1.8591 -1.9823 -0.0972 -0.4070 -1.2962 -0.1621 -0.0883 -0.8612 -0.5895 -0.4665 -0.0277 -0.1507 -0.1491 -0.1645 -0.1603 -0.2206 -0.1693 -0.0449 -1.3639 -0.2538 -0.2424 -0.0177 -0.1350 -0.1766 -0.3703 -0.1940 -1.8528 -0.1456 -0.1315 -0.1722
S-304	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-304	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-304	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-304	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-304	-0.1606 -0.5029 -0.1912 -0.0841 -1.3886 -0.0755 -0.1401 -0.1131 -2.8865 -0.8290 -0.1367 -0.2056 -1.2919 -0.8708 -0.0565 -0.0492 -0.1553 -0.2194 -0.1698 -0.1820 -0.0690 -0.1384 -0.1862 -0.3141 -0.1658 -0.1182 -0.3511 -0.1875 -0.1195 -0.6467 -0.1288 -0.1285 -0.1001 -0.0135 -0.2290 -1.8591 -1.9823 -0.0972 -0.4070 -1.2962 -0.1621 -0.0883 -0.8612 -0.5895 -0.4665 -0.0277 -0.1507 -0.1491 -0.1645 -0.1603 -0.2206 -0.1693 -0.0449 -1.3639 -0.2538 -0.2424 -0.0177 -0.1350 -0.1766 -0.3703 -0.1940 -1.8528 -0.1456 -0.1315 -0.1722
S-89	Laborwerte In klinischen Studien wurden asymptomatische , leichte und vorübergehende Abnahmen des Serum- Calciums und -Phosphats bei ca. 18 % beziehungsweise 10 % der Patienten beobachtet , die Alendronat 10 mg<unk> Tag einnahmen , gegenüber ca. 12 % und 3 % derjenigen , die Plazebo einnahmen .
T-89	Laboratory test findings In clinical studies , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % , respectively , of patients taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
H-89	-0.23661881685256958	Laboratory values In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients , respectively , taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
D-89	-0.23661881685256958	Laboratory values In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients , respectively , taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
P-89	-0.6510 -0.0917 -0.4340 -0.2624 -0.0593 -0.1841 -0.1624 -0.2906 -0.0940 -0.0477 -0.1211 -0.1400 -0.4658 -0.6278 -0.2738 -0.0987 -0.0710 -0.6109 -0.1520 -0.6681 -0.0342 -0.1218 -0.0575 -0.0691 -0.1277 -0.1300 -0.0938 -0.0829 -0.0971 -0.1494 -0.6065 -0.1438 -0.7181 -0.1139 -0.1618 -0.1326 -0.1704 -0.1456 -0.1416 -0.3317 -0.5835 -0.3214 -0.1302 -0.5480 -0.2108 -0.1582 -0.1018 -0.1678 -0.1269 -0.1453 -0.0811 -0.1308 -0.6756 -1.4587 -0.2103 -0.2082 -0.1192 -0.1469 -0.1984 -0.1196 -0.1278 -0.3032 -0.1347 -0.0445 -0.1353 -0.1275 -0.1440 -0.1624 -0.1687
S-653	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-653	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-653	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-653	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-653	-0.1606 -0.5029 -0.1912 -0.0841 -1.3886 -0.0755 -0.1401 -0.1131 -2.8865 -0.8290 -0.1367 -0.2056 -1.2919 -0.8708 -0.0565 -0.0492 -0.1553 -0.2194 -0.1698 -0.1820 -0.0690 -0.1384 -0.1862 -0.3141 -0.1658 -0.1182 -0.3511 -0.1875 -0.1195 -0.6467 -0.1288 -0.1285 -0.1001 -0.0135 -0.2290 -1.8591 -1.9823 -0.0972 -0.4070 -1.2962 -0.1621 -0.0883 -0.8612 -0.5895 -0.4665 -0.0277 -0.1507 -0.1491 -0.1645 -0.1603 -0.2206 -0.1693 -0.0449 -1.3639 -0.2538 -0.2424 -0.0177 -0.1350 -0.1766 -0.3703 -0.1940 -1.8528 -0.1456 -0.1315 -0.1722
S-56	Ösophageale Reaktionen , wie Ösophagitis , ösophageale Ulzera und ösophageale Erosionen , selten gefolgt von ösophagealen Strikturen , wurden bei Patienten unter der Einnahme von Alendronat berichtet ( teilweise waren diese schwerwiegend und erforderten eine Krankenhauseinweisung ) .
T-56	Oesophageal reactions ( sometimes severe and requiring hospitalisation ) , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients receiving alendronate .
H-56	-0.2653079628944397	Oesophageal reactions , such as oesophagitis , oesophageal ulcera , and oesophageal erosions , rarely followed by oesophageal strictures , have been reported in patients taking alendronate ( some of which were severe and required hospitalisation ) .
D-56	-0.2653079628944397	Oesophageal reactions , such as oesophagitis , oesophageal ulcera , and oesophageal erosions , rarely followed by oesophageal strictures , have been reported in patients taking alendronate ( some of which were severe and required hospitalisation ) .
P-56	-0.0443 -0.1609 -0.3849 -0.0490 -0.1283 -0.1293 -0.2710 -0.0682 -0.1176 -0.2892 -0.1519 -0.6312 -0.0756 -0.1349 -0.1113 -0.1120 -0.1732 -0.1393 -0.6624 -0.1167 -0.2707 -0.0500 -0.1990 -0.1377 -0.1572 -0.6877 -0.5581 -0.4308 -0.1847 -0.3124 -0.1269 -0.1209 -0.0470 -0.1358 -0.1403 -1.0289 -0.1551 -0.1133 -0.0610 -0.3682 -0.1119 -0.1285 -0.1167 -0.1172 -0.0482 -0.1463 -0.1301 -0.8608 -0.8619 -0.0149 -0.1252 -0.1480 -0.1392 -0.0643 -0.1305 -0.1628 -0.2470 -0.2101 -0.1328 -0.1265 -0.0320 -0.1481 -0.7427 -0.1210 -1.4417 -0.3395 -0.1261 -0.1878 -0.6304 -0.8074 -1.5307 -0.0783 -0.1308 -0.1412 -0.1804
S-583	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-583	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-583	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-583	-0.4085790514945984	The ADRs occurring in the largest number of patients were inhibitors of factor VIII ( 5 patients ) , all of which occurred in previously untreated patients at higher risk for inhibitors , headaches ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-583	-0.1606 -0.5029 -0.1912 -0.0841 -1.3886 -0.0755 -0.1401 -0.1131 -2.8865 -0.8290 -0.1367 -0.2056 -1.2919 -0.8708 -0.0565 -0.0492 -0.1553 -0.2194 -0.1698 -0.1820 -0.0690 -0.1384 -0.1862 -0.3141 -0.1658 -0.1182 -0.3511 -0.1875 -0.1195 -0.6467 -0.1288 -0.1285 -0.1001 -0.0135 -0.2290 -1.8591 -1.9823 -0.0972 -0.4070 -1.2962 -0.1621 -0.0883 -0.8612 -0.5895 -0.4665 -0.0277 -0.1507 -0.1491 -0.1645 -0.1603 -0.2206 -0.1693 -0.0449 -1.3639 -0.2538 -0.2424 -0.0177 -0.1350 -0.1766 -0.3703 -0.1940 -1.8528 -0.1456 -0.1315 -0.1722
S-188	Laborwerte In klinischen Studien wurden asymptomatische , leichte und vorübergehende Abnahmen des Serum- Calciums und -Phosphats bei ca. 18 % beziehungsweise 10 % der Patienten beobachtet , die Alendronat 10 mg<unk> Tag einnahmen , gegenüber ca. 12 % und 3 % derjenigen , die Plazebo einnahmen .
T-188	Laboratory test findings In clinical studies , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % , respectively , of patients taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
H-188	-0.23661881685256958	Laboratory values In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients , respectively , taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
D-188	-0.23661881685256958	Laboratory values In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients , respectively , taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
P-188	-0.6510 -0.0917 -0.4340 -0.2624 -0.0593 -0.1841 -0.1624 -0.2906 -0.0940 -0.0477 -0.1211 -0.1400 -0.4658 -0.6278 -0.2738 -0.0987 -0.0710 -0.6109 -0.1520 -0.6681 -0.0342 -0.1218 -0.0575 -0.0691 -0.1277 -0.1300 -0.0938 -0.0829 -0.0971 -0.1494 -0.6065 -0.1438 -0.7181 -0.1139 -0.1618 -0.1326 -0.1704 -0.1456 -0.1416 -0.3317 -0.5835 -0.3214 -0.1302 -0.5480 -0.2108 -0.1582 -0.1018 -0.1678 -0.1269 -0.1453 -0.0811 -0.1308 -0.6756 -1.4587 -0.2103 -0.2082 -0.1192 -0.1469 -0.1984 -0.1196 -0.1278 -0.3032 -0.1347 -0.0445 -0.1353 -0.1275 -0.1440 -0.1624 -0.1687
S-156	Ösophageale Reaktionen , wie Ösophagitis , ösophageale Ulzera und ösophageale Erosionen , selten gefolgt von ösophagealen Strikturen , wurden bei Patienten unter der Einnahme von Alendronat berichtet ( teilweise waren diese schwerwiegend und erforderten eine Krankenhauseinweisung ) .
T-156	Oesophageal reactions ( sometimes severe and requiring hospitalisation ) , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients receiving alendronate .
H-156	-0.2653079628944397	Oesophageal reactions , such as oesophagitis , oesophageal ulcera , and oesophageal erosions , rarely followed by oesophageal strictures , have been reported in patients taking alendronate ( some of which were severe and required hospitalisation ) .
D-156	-0.2653079628944397	Oesophageal reactions , such as oesophagitis , oesophageal ulcera , and oesophageal erosions , rarely followed by oesophageal strictures , have been reported in patients taking alendronate ( some of which were severe and required hospitalisation ) .
P-156	-0.0443 -0.1609 -0.3849 -0.0490 -0.1283 -0.1293 -0.2710 -0.0682 -0.1176 -0.2892 -0.1519 -0.6312 -0.0756 -0.1349 -0.1113 -0.1120 -0.1732 -0.1393 -0.6624 -0.1167 -0.2707 -0.0500 -0.1990 -0.1377 -0.1572 -0.6877 -0.5581 -0.4308 -0.1847 -0.3124 -0.1269 -0.1209 -0.0470 -0.1358 -0.1403 -1.0289 -0.1551 -0.1133 -0.0610 -0.3682 -0.1119 -0.1285 -0.1167 -0.1172 -0.0482 -0.1463 -0.1301 -0.8608 -0.8619 -0.0149 -0.1252 -0.1480 -0.1392 -0.0643 -0.1305 -0.1628 -0.2470 -0.2101 -0.1328 -0.1265 -0.0320 -0.1481 -0.7427 -0.1210 -1.4417 -0.3395 -0.1261 -0.1878 -0.6304 -0.8074 -1.5307 -0.0783 -0.1308 -0.1412 -0.1804
S-537	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-537	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-537	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
D-537	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
P-537	-0.0235 -0.1477 -0.7308 -0.1463 -0.1014 -0.0603 -1.0404 -0.1507 -0.0583 -0.1417 -0.1976 -0.0520 -0.1458 -0.1593 -0.1677 -0.4208 -0.1444 -0.4372 -0.1576 -0.0648 -0.1629 -0.1297 -0.1144 -0.2164 -0.1699 -0.2208 -0.3861 -0.1124 -0.5037 -0.1581 -0.0741 -0.1464 -0.1406 -0.0462 -0.1469 -0.1201 -0.9872 -0.1742 -0.0662 -0.1412 -0.2866 -1.8435 -0.0956 -0.1585 -1.6064 -0.1553 -1.9986 -0.5960 -0.1632 -0.5106 -0.1518 -0.1793 -0.0365 -0.1856 -1.2449 -0.3009 -1.1761 -0.1063 -0.3645 -0.4384 -0.4732 -0.4435 -0.1774 -0.0426 -0.0944 -0.9774 -0.2077
S-677	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-677	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-677	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
D-677	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
P-677	-0.0235 -0.1477 -0.7308 -0.1463 -0.1014 -0.0603 -1.0404 -0.1507 -0.0583 -0.1417 -0.1976 -0.0520 -0.1458 -0.1593 -0.1677 -0.4208 -0.1444 -0.4372 -0.1576 -0.0648 -0.1629 -0.1297 -0.1144 -0.2164 -0.1699 -0.2208 -0.3861 -0.1124 -0.5037 -0.1581 -0.0741 -0.1464 -0.1406 -0.0462 -0.1469 -0.1201 -0.9872 -0.1742 -0.0662 -0.1412 -0.2866 -1.8435 -0.0956 -0.1585 -1.6064 -0.1553 -1.9986 -0.5960 -0.1632 -0.5106 -0.1518 -0.1793 -0.0365 -0.1856 -1.2449 -0.3009 -1.1761 -0.1063 -0.3645 -0.4384 -0.4732 -0.4435 -0.1774 -0.0426 -0.0944 -0.9774 -0.2077
S-467	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-467	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-467	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
D-467	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
P-467	-0.0235 -0.1477 -0.7308 -0.1463 -0.1014 -0.0603 -1.0404 -0.1507 -0.0583 -0.1417 -0.1976 -0.0520 -0.1458 -0.1593 -0.1677 -0.4208 -0.1444 -0.4372 -0.1576 -0.0648 -0.1629 -0.1297 -0.1144 -0.2164 -0.1699 -0.2208 -0.3861 -0.1124 -0.5037 -0.1581 -0.0741 -0.1464 -0.1406 -0.0462 -0.1469 -0.1201 -0.9872 -0.1742 -0.0662 -0.1412 -0.2866 -1.8435 -0.0956 -0.1585 -1.6064 -0.1553 -1.9986 -0.5960 -0.1632 -0.5106 -0.1518 -0.1793 -0.0365 -0.1856 -1.2449 -0.3009 -1.1761 -0.1063 -0.3645 -0.4384 -0.4732 -0.4435 -0.1774 -0.0426 -0.0944 -0.9774 -0.2077
S-397	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-397	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-397	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
D-397	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
P-397	-0.0235 -0.1477 -0.7308 -0.1463 -0.1014 -0.0603 -1.0404 -0.1507 -0.0583 -0.1417 -0.1976 -0.0520 -0.1458 -0.1593 -0.1677 -0.4208 -0.1444 -0.4372 -0.1576 -0.0648 -0.1629 -0.1297 -0.1144 -0.2164 -0.1699 -0.2208 -0.3861 -0.1124 -0.5037 -0.1581 -0.0741 -0.1464 -0.1406 -0.0462 -0.1469 -0.1201 -0.9872 -0.1742 -0.0662 -0.1412 -0.2866 -1.8435 -0.0956 -0.1585 -1.6064 -0.1553 -1.9986 -0.5960 -0.1632 -0.5106 -0.1518 -0.1793 -0.0365 -0.1856 -1.2449 -0.3009 -1.1761 -0.1063 -0.3645 -0.4384 -0.4732 -0.4435 -0.1774 -0.0426 -0.0944 -0.9774 -0.2077
S-607	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-607	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-607	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
D-607	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
P-607	-0.0235 -0.1477 -0.7308 -0.1463 -0.1014 -0.0603 -1.0404 -0.1507 -0.0583 -0.1417 -0.1976 -0.0520 -0.1458 -0.1593 -0.1677 -0.4208 -0.1444 -0.4372 -0.1576 -0.0648 -0.1629 -0.1297 -0.1144 -0.2164 -0.1699 -0.2208 -0.3861 -0.1124 -0.5037 -0.1581 -0.0741 -0.1464 -0.1406 -0.0462 -0.1469 -0.1201 -0.9872 -0.1742 -0.0662 -0.1412 -0.2866 -1.8435 -0.0956 -0.1585 -1.6064 -0.1553 -1.9986 -0.5960 -0.1632 -0.5106 -0.1518 -0.1793 -0.0365 -0.1856 -1.2449 -0.3009 -1.1761 -0.1063 -0.3645 -0.4384 -0.4732 -0.4435 -0.1774 -0.0426 -0.0944 -0.9774 -0.2077
S-327	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-327	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-327	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
D-327	-0.3400099277496338	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl ) MRT ( h ) VSS ( dl ) VSS ( dl ) * Geometric mean
P-327	-0.0235 -0.1477 -0.7308 -0.1463 -0.1014 -0.0603 -1.0404 -0.1507 -0.0583 -0.1417 -0.1976 -0.0520 -0.1458 -0.1593 -0.1677 -0.4208 -0.1444 -0.4372 -0.1576 -0.0648 -0.1629 -0.1297 -0.1144 -0.2164 -0.1699 -0.2208 -0.3861 -0.1124 -0.5037 -0.1581 -0.0741 -0.1464 -0.1406 -0.0462 -0.1469 -0.1201 -0.9872 -0.1742 -0.0662 -0.1412 -0.2866 -1.8435 -0.0956 -0.1585 -1.6064 -0.1553 -1.9986 -0.5960 -0.1632 -0.5106 -0.1518 -0.1793 -0.0365 -0.1856 -1.2449 -0.3009 -1.1761 -0.1063 -0.3645 -0.4384 -0.4732 -0.4435 -0.1774 -0.0426 -0.0944 -0.9774 -0.2077
S-4	Adenuric wird bei Patienten angewendet , die bereits Anzeichen von Kristallablagerungen aufweisen , einschließlich Arthritis ( Schmerzen und Entzündung in den Gelenken ) oder Gichtknoten ( Steine d. h. größere Uratkristallablagerungen , die zu Gelenk- und Knochenschädigungen führen können ) .
T-4	Adenuric is used in patients who already have signs of a build-up of crystals , including arthritis ( pain and inflammation in the joints ) or tophi ( stones , larger deposits of urate crystals that can cause joint and bone damage ) .
H-4	-0.5080327391624451	Adenuric is used in patients who already show signs of crystalline deposition , including arthritis ( joint pain and inflammation ) or gout nodes ( stones , i. e. larger urine crystalline deposition that may lead to joint and bone damage ) .
D-4	-0.5080327391624451	Adenuric is used in patients who already show signs of crystalline deposition , including arthritis ( joint pain and inflammation ) or gout nodes ( stones , i. e. larger urine crystalline deposition that may lead to joint and bone damage ) .
P-4	-0.0910 -0.2092 -0.0539 -0.1618 -0.1165 -0.4293 -0.1994 -0.7049 -0.0841 -2.3745 -0.1040 -0.2644 -0.1512 -4.3309 -0.0481 -0.4161 -0.1642 -0.2568 -0.1469 -0.1410 -0.1302 -0.0915 -0.0993 -0.0981 -0.1505 -0.1994 -0.2194 -0.1369 -0.0557 -0.2758 -0.1022 -0.1413 -0.1467 -2.0005 -1.1136 -1.2108 -0.9099 -0.1769 -2.9256 -1.4276 -1.2318 -0.1373 -0.2101 -0.1765 -0.4917 -1.3270 -0.6634 -0.9864 -0.0345 -0.5308 -0.1297 -0.2024 -0.0809 -0.7976 -0.7743 -1.3915 -0.1538 -0.0232 -0.1456 -0.0445 -0.4385 -0.1573 -0.1468 -0.1780
S-98	Die Hauptwirkung von 1,25-Dihydroxyvitamin D3 ist die Erhöhung der intestinalen Resorption von Calcium und Phosphat sowie die Regulierung von Serum-Calcium , der renalen Ausscheidung von Calcium und von Phosphat , der Knochenbildung und Knochenresorption .
T-98	The principal action of 1,25-dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium , renal calcium and phosphate excretion , bone formation and bone resorption .
H-98	-0.2098412811756134	The main effect of 1.25 dihydroxy vitamin D3 is to increase intestinal absorption of calcium and phosphate , and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
D-98	-0.2098412811756134	The main effect of 1.25 dihydroxy vitamin D3 is to increase intestinal absorption of calcium and phosphate , and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
P-98	-0.1393 -0.1368 -0.1610 -0.1462 -0.4129 -0.3454 -0.2135 -0.0795 -0.1379 -0.1032 -0.0793 -0.0964 -0.2121 -0.1308 -0.1566 -0.1255 -0.6421 -0.0493 -0.0746 -0.2503 -0.0699 -0.1391 -0.0649 -0.0619 -0.1430 -0.1315 -0.0649 -0.0758 -0.1011 -1.2678 -0.3687 -0.1169 -2.2951 -0.1404 -0.0542 -0.1387 -0.0501 -0.0454 -0.1335 -0.1802 -0.1760 -0.1045 -0.2107 -0.1213 -0.1561 -0.1370 -0.0573 -0.0625 -0.1430 -0.1293 -0.0970 -0.0664 -0.0983 -0.1267 -0.1849 -0.3212 -0.1363 -0.0692 -1.0366 -0.1079 -0.0274 -0.1373 -0.1771
S-111	Die Wirkungen von Alendronat auf Knochenmasse und Frakturinzidenz bei postmenopausalen Frauen wurden in zwei Phase-III-Studien von identischem Design ( n<unk> 944 ) sowie in der Fraktur-Interventions- Studie ( FIT : n<unk> 6.459 ) untersucht .
T-111	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design ( n<<unk>> 994 ) as well as in the Fracture Intervention Trial ( FIT : n<<unk>> 6,459 ) .
H-111	-0.2172234207391739	Effects of alendronate on bone mass and fracture incidence in post-menopausal women have been studied in two phase II studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
D-111	-0.2172234207391739	Effects of alendronate on bone mass and fracture incidence in post-menopausal women have been studied in two phase II studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
P-111	-0.3388 -0.1234 -0.1251 -0.1896 -0.1387 -0.1044 -0.1027 -0.1075 -0.0330 -0.9421 -0.1381 -0.6225 -0.0388 -0.1895 -0.1920 -0.1214 -0.0184 -0.1811 -0.0442 -0.1551 -0.0267 -0.1042 -0.0683 -0.2442 -0.1768 -0.3865 -0.1323 -0.1351 -0.5834 -0.4481 -0.1087 -0.1449 -0.1313 -0.0937 -1.4118 -0.1611 -0.1414 -0.6188 -0.1098 -0.1235 -0.1607 -0.1328 -1.1741 -0.1229 -0.1130 -0.0443 -0.2268 -0.0593 -0.4723 -0.0463 -0.1576 -0.0797 -0.1013 -0.1827 -0.1411 -0.1218 -0.2299 -0.1054 -0.0681 -0.1389 -0.1576 -0.1739
S-196	Die Hauptwirkung von 1,25-Dihydroxyvitamin D3 ist die Erhöhung der intestinalen Resorption von Calcium und Phosphat sowie die Regulierung von Serum-Calcium , der renalen Ausscheidung von Calcium und von Phosphat , der Knochenbildung und Knochenresorption .
T-196	The principal action of 1,25-dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium , renal calcium and phosphate excretion , bone formation and bone resorption .
H-196	-0.2098412811756134	The main effect of 1.25 dihydroxy vitamin D3 is to increase intestinal absorption of calcium and phosphate , and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
D-196	-0.2098412811756134	The main effect of 1.25 dihydroxy vitamin D3 is to increase intestinal absorption of calcium and phosphate , and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
P-196	-0.1393 -0.1368 -0.1610 -0.1462 -0.4129 -0.3454 -0.2135 -0.0795 -0.1379 -0.1032 -0.0793 -0.0964 -0.2121 -0.1308 -0.1566 -0.1255 -0.6421 -0.0493 -0.0746 -0.2503 -0.0699 -0.1391 -0.0649 -0.0619 -0.1430 -0.1315 -0.0649 -0.0758 -0.1011 -1.2678 -0.3687 -0.1169 -2.2951 -0.1404 -0.0542 -0.1387 -0.0501 -0.0454 -0.1335 -0.1802 -0.1760 -0.1045 -0.2107 -0.1213 -0.1561 -0.1370 -0.0573 -0.0625 -0.1430 -0.1293 -0.0970 -0.0664 -0.0983 -0.1267 -0.1849 -0.3212 -0.1363 -0.0692 -1.0366 -0.1079 -0.0274 -0.1373 -0.1771
S-214	Die Wirkungen von Alendronat auf Knochenmasse und Frakturinzidenz bei postmenopausalen Frauen wurden in zwei Phase-III-Studien von identischem Design ( n<unk> 944 ) sowie in der Fraktur-Interventions- Studie ( FIT : n<unk> 6.459 ) untersucht .
T-214	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design ( n<<unk>> 994 ) as well as in the Fracture Intervention Trial ( FIT : n<<unk>> 6,459 ) .
H-214	-0.2172234207391739	Effects of alendronate on bone mass and fracture incidence in post-menopausal women have been studied in two phase II studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
D-214	-0.2172234207391739	Effects of alendronate on bone mass and fracture incidence in post-menopausal women have been studied in two phase II studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
P-214	-0.3388 -0.1234 -0.1251 -0.1896 -0.1387 -0.1044 -0.1027 -0.1075 -0.0330 -0.9421 -0.1381 -0.6225 -0.0388 -0.1895 -0.1920 -0.1214 -0.0184 -0.1811 -0.0442 -0.1551 -0.0267 -0.1042 -0.0683 -0.2442 -0.1768 -0.3865 -0.1323 -0.1351 -0.5834 -0.4481 -0.1087 -0.1449 -0.1313 -0.0937 -1.4118 -0.1611 -0.1414 -0.6188 -0.1098 -0.1235 -0.1607 -0.1328 -1.1741 -0.1229 -0.1130 -0.0443 -0.2268 -0.0593 -0.4723 -0.0463 -0.1576 -0.0797 -0.1013 -0.1827 -0.1411 -0.1218 -0.2299 -0.1054 -0.0681 -0.1389 -0.1576 -0.1739
S-173	Jedoch wurden selten Fälle symptomatischer Hypocalcämie berichtet , manche auch 15 schwer , die oft bei Patienten mit entsprechenden prädisponierenden Faktoren auftraten ( z. B. Hypoparathyreoidismus , Vitamin-D-Mangel und Calcium-Malabsorption ) ( siehe Abschnitt 4.8 ) .
T-173	However , there have been rare reports of symptomatic hypocalcaemia , which have occasionally been severe and often occurred in patients with predisposing conditions ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
H-173	-0.26691585779190063	However , cases of symptomatic hypocalcaemia have been rarely reported , some of which are severe and occur frequently in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
D-173	-0.26691585779190063	However , cases of symptomatic hypocalcaemia have been rarely reported , some of which are severe and occur frequently in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
P-173	-0.3172 -0.1370 -2.2038 -0.1365 -0.0659 -0.0552 -0.1329 -0.0283 -0.0771 -0.0711 -0.0839 -0.1530 -1.1523 -0.1296 -0.2716 -0.1196 -0.1376 -0.2329 -1.1267 -0.5366 -0.1894 -0.1192 -0.9421 -2.7539 -0.0573 -0.1334 -0.2138 -0.1102 -1.8164 -0.1441 -0.3681 -0.0725 -0.2014 -0.4342 -0.1773 -0.1319 -0.1058 -0.0936 -0.1743 -0.0522 -0.1873 -0.1526 -0.1104 -0.0927 -0.0640 -0.1234 -0.0946 -0.1099 -0.1455 -0.0577 -0.0247 -0.0510 -0.0312 -0.0295 -0.0911 -0.4000 -0.0414 -0.0761 -0.1465 -0.0715 -0.0660 -0.0729 -0.1432 -0.1453 -0.0487 -0.0907 -0.1621 -0.1842 -0.1570 -0.1451 -0.1751
S-210	Studien mit Alendronat Die therapeutische Gleichwertigkeit von Alendronat einmal wöchentlich 70 mg ( n<unk> 519 ) und Alendronat 10 mg täglich ( n<unk> 370 ) wurde in einer Ein-Jahres-Multicenter-Studie an postmenopausalen Frauen mit Osteoporose nachgewiesen .
T-210	Alendronate studies The therapeutic equivalence of alendronate once weekly 70 mg ( n<<unk>> 519 ) and alendronate 10 mg daily ( n<<unk>> 370 ) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis .
H-210	-0.3121046721935272	Therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year , multi-centre study in post-menopausal women with osteoporosis .
D-210	-0.3121046721935272	Therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year , multi-centre study in post-menopausal women with osteoporosis .
P-210	-2.6277 -0.5058 -0.1357 -0.0578 -0.1648 -0.9210 -0.2267 -1.0412 -0.1534 -0.1043 -0.0857 -0.8999 -0.8088 -0.2374 -0.0862 -0.1355 -0.1716 -0.5041 -0.0756 -0.1064 -0.1404 -0.2261 -1.9063 -0.1429 -0.1454 -0.0545 -0.1689 -0.0455 -0.0219 -0.1511 -0.1803 -0.1274 -0.0442 -0.1376 -0.8393 -0.7730 -0.1272 -0.2258 -0.9379 -0.2249 -0.1036 -0.3683 -0.2190 -0.2725 -0.4494 -0.6066 -0.1392 -0.0273 -0.2752 -0.0539 -0.1584 -0.0346 -0.1018 -0.0537 -0.1315 -0.0722 -0.1432 -0.1419 -0.0844 -0.0994 -0.0964 -0.1762 -0.1838
S-19	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass Adenuric bei der Senkung des Harnsäurespiegels im Blut wirksamer war als Allopurinol , dafür aber auch ein höheres Risiko von Nebenwirkungen im Zusammenhang mit dem Herzen und den Blutgefäßen bergen könnte .
T-19	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that Adenuric was more effective than allopurinol at lowering blood uric acid levels , but that it could carry a greater risk of side effects affecting the heart and blood vessels .
H-19	-0.4581274092197418	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass Adenuric was more effective than Allopurinol in lowering the uric acid level in the blood , jedoch auch eine höhere Risiko von Nebenwirkungen im Zusammenhang mit dem Blut und den BlutVesVesVesVessels geraten . However , Adenuric may also be associated with a higher risk of undesirable effects associated with the heart and the blood vessels .
D-19	-0.4581274092197418	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass Adenuric was more effective than Allopurinol in lowering the uric acid level in the blood , jedoch auch eine höhere Risiko von Nebenwirkungen im Zusammenhang mit dem Blut und den BlutVesVesVesVessels geraten . However , Adenuric may also be associated with a higher risk of undesirable effects associated with the heart and the blood vessels .
P-19	-0.0339 -0.0116 -0.0201 -0.0150 -0.1092 -0.0108 -0.0279 -0.0124 -0.1538 -0.0732 -0.0539 -0.1391 -0.0335 -0.0403 -0.0145 -0.0127 -0.0301 -0.1261 -0.0081 -0.1034 -0.1887 -0.0472 -0.1538 -4.0677 -0.0752 -0.2270 -1.4340 -1.1964 -0.0960 -0.7691 -0.1486 -0.0744 -0.5997 -0.3301 -0.0212 -0.1335 -0.8939 -0.1307 -0.1986 -0.4581 -0.1462 -0.1168 -0.0490 -0.1108 -1.7273 -0.1029 -1.0513 -1.0678 -0.0545 -0.0285 -0.0139 -0.0932 -0.5453 -0.0613 -1.2909 -0.9806 -2.9001 -0.0380 -0.5864 -0.0534 -0.3488 -1.1350 -1.2143 -1.2341 -1.3485 -3.4682 -0.0622 -1.7494 -0.1378 -2.3161 -0.1979 -0.0426 -0.1437 -1.9291 -0.5820 -0.6625 -0.2995 -0.1404 -0.1231 -0.1624 -0.0704 -0.1627 -0.2518 -0.0762 -0.0708 -0.2256 -1.5985 -0.1372 -0.1376 -0.0661 -0.1448 -0.4161 -0.0476 -0.0557 -0.0846 -0.1293 -0.1743
S-74	Jedoch wurden selten Fälle symptomatischer Hypocalcämie berichtet , manche auch schwer , die oft bei Patienten mit entsprechenden prädisponierenden Faktoren auftraten ( z. B. Hypoparathyreoidismus , Vitamin-D-Mangel und Calcium-Malabsorption ) ( siehe Abschnitt 4.8 ) .
T-74	However , there have been rare reports of symptomatic hypocalcaemia , which have occasionally been severe and often occurred in patients with predisposing conditions ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
H-74	-0.2411617636680603	However , cases of symptomatic hypocalcaemia have been rarely reported , some of which are severe and common in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
D-74	-0.2411617636680603	However , cases of symptomatic hypocalcaemia have been rarely reported , some of which are severe and common in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
P-74	-0.2818 -0.1392 -1.9151 -0.1357 -0.0630 -0.0571 -0.1321 -0.0268 -0.0749 -0.0725 -0.0866 -0.1531 -0.6519 -0.1322 -0.3608 -0.1197 -0.1264 -0.2695 -0.8002 -0.4163 -0.1649 -0.1294 -0.9446 -1.9421 -0.1335 -0.2020 -0.1139 -1.7788 -0.1438 -0.3759 -0.1187 -0.1559 -0.4705 -0.1781 -0.1181 -0.1046 -0.0972 -0.1721 -0.0503 -0.1897 -0.1483 -0.1054 -0.0955 -0.0574 -0.1203 -0.0907 -0.1124 -0.1458 -0.0516 -0.0247 -0.0524 -0.0292 -0.0347 -0.0902 -0.3806 -0.0412 -0.0779 -0.1455 -0.0633 -0.0772 -0.0738 -0.1416 -0.1546 -0.0476 -0.0947 -0.1662 -0.1808 -0.1559 -0.1485 -0.1740
S-806	Bei der Behandlung von folgenden Patientengruppen wird zur Vorsicht geraten : Patienten unter Digitalis Patienten mit Herzrhythmusstörungen Patienten mit Hypertonie Patienten mit einem Myokardinfarkt in der Anamnese , Diabetes mellitus , Blasenhalsobstruktion oder Bronchospasmus in der Anamnese .
T-806	Caution should be exercised in the following patient groups : Patients receiving digitalis Patients with cardiac arrhythmias Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder neck obstruction , or positive anamnesis of bronchospasm .
H-806	-0.35119685530662537	Caution is advised in the treatment of the following population groups : patients with cardiac dysrhythmia Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder neck instruction or history of bronchospasm .
D-806	-0.35119685530662537	Caution is advised in the treatment of the following population groups : patients with cardiac dysrhythmia Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder neck instruction or history of bronchospasm .
P-806	-0.0053 -0.0696 -0.1647 -0.1680 -0.4999 -0.1506 -0.9426 -0.1398 -0.5993 -0.0464 -1.7196 -1.4056 -0.1682 -0.9251 -0.5062 -0.6685 -0.0513 -0.4520 -0.0359 -0.0495 -0.3601 -0.1058 -0.1268 -0.0369 -0.0275 -0.1250 -0.1065 -0.1230 -0.1914 -0.1934 -0.1493 -0.1864 -0.0722 -0.0376 -0.1085 -0.0511 -0.0308 -0.0718 -0.1317 -0.1505 -0.0971 -0.0872 -0.0456 -0.1405 -0.1044 -0.0944 -0.8219 -1.9308 -1.2238 -0.9603 -1.4804 -0.1500 -0.5296 -0.3195 -0.1743 -0.4246 -0.4572 -0.3435 -0.1815
S-107	Studien mit Alendronat Die therapeutische Gleichwertigkeit von Alendronat einmal wöchentlich 70 mg ( n<unk> 519 ) und Alendronat 10 mg täglich ( n<unk> 370 ) wurde in einer Ein-Jahres-Multicenter-Studie an postmenopausalen Frauen mit Osteoporose nachgewiesen .
T-107	Alendronate studies The therapeutic equivalence of alendronate once weekly 70 mg ( n<<unk>> 519 ) and alendronate 10 mg daily ( n<<unk>> 370 ) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis .
H-107	-0.3121046721935272	Therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year , multi-centre study in post-menopausal women with osteoporosis .
D-107	-0.3121046721935272	Therapeutic equivalence of alendronate once weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year , multi-centre study in post-menopausal women with osteoporosis .
P-107	-2.6277 -0.5058 -0.1357 -0.0578 -0.1648 -0.9210 -0.2267 -1.0412 -0.1534 -0.1043 -0.0857 -0.8999 -0.8088 -0.2374 -0.0862 -0.1355 -0.1716 -0.5041 -0.0756 -0.1064 -0.1404 -0.2261 -1.9063 -0.1429 -0.1454 -0.0545 -0.1689 -0.0455 -0.0219 -0.1511 -0.1803 -0.1274 -0.0442 -0.1376 -0.8393 -0.7730 -0.1272 -0.2258 -0.9379 -0.2249 -0.1036 -0.3683 -0.2190 -0.2725 -0.4494 -0.6066 -0.1392 -0.0273 -0.2752 -0.0539 -0.1584 -0.0346 -0.1018 -0.0537 -0.1315 -0.0722 -0.1432 -0.1419 -0.0844 -0.0994 -0.0964 -0.1762 -0.1838
S-690	Pharmakovigilanz-System Der Zulassungsinhaber muss sicherstellen , dass ein Pharmakovigilanz-System , wie im Abschnitt 1.1 des Kapitels 1.8.1 der Arzneimittelzulassung beschrieben , eingerichtet wurde und dass dieses System während des gesamten Zeitraumes , in dem sich das Produkt auf dem Markt befindet , in Kraft bleibt .
T-690	Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance , as described in version 1.1 presented in Module 1.8.1 . of the Marketing Authorisation , is in place and functioning before and whilst the product is on the market .
H-690	-0.2617189288139343	Pharmacovigilance system The MAH must ensure that a pharmacovigilance system is in place as described in section 1.1 of section 1.8.1 of the Marketing Authorisation and that this system is in place throughout the period the product is on the market .
D-690	-0.2617189288139343	Pharmacovigilance system The MAH must ensure that a pharmacovigilance system is in place as described in section 1.1 of section 1.8.1 of the Marketing Authorisation and that this system is in place throughout the period the product is on the market .
P-690	-0.3173 -0.0311 -0.0942 -0.1258 -0.0340 -0.0578 -0.0930 -0.1195 -1.3113 -0.0255 -0.0151 -0.3335 -0.1939 -0.0972 -0.1814 -0.9038 -0.1493 -0.0336 -0.0919 -0.1405 -0.0349 -0.1822 -0.0737 -0.0427 -0.4695 -0.1450 -0.1259 -0.0612 -0.2349 -0.3005 -1.1833 -0.1382 -0.1020 -0.1539 -0.2811 -1.1077 -0.3167 -0.0057 -0.1103 -0.0625 -0.2706 -0.1686 -0.4672 -0.0343 -0.3373 -0.4223 -0.0441 -1.3882 -0.1137 -0.3492 -1.1700 -0.1433 -0.1071 -0.1187 -0.1226 -0.1255 -0.1376 -0.1776
S-215	In den Phase-III-Studien betrugen die mittleren Anstiege der BMD mit Alendronat 10 mg<unk> Tag im Verhältnis zu Plazebo nach 3 Jahren 8,8 % an der Wirbelsäule , 5,9 % am Femurhals und 7,8 % am Trochanter .
T-215	In the initial efficacy studies , the mean BMD increases with alendronate 10 mg/ day relative to placebo at three years were 8.8 % , 5.9 % and 7.8 % at the spine , femoral neck and trochanter , respectively .
H-215	-0.2746654748916626	In the phase II trials mean increases in BMD with alendronate 10 mg/ day relative to placebo at 3 years were 8.8 % at the spine , 5.9 % at the femoral neck , and 7.8 % at the trochanter .
D-215	-0.2746654748916626	In the phase II trials mean increases in BMD with alendronate 10 mg/ day relative to placebo at 3 years were 8.8 % at the spine , 5.9 % at the femoral neck , and 7.8 % at the trochanter .
P-215	-0.1556 -0.1430 -0.1034 -0.4110 -0.3681 -1.1490 -0.1923 -0.3997 -0.0801 -0.1091 -0.1169 -0.1750 -0.1411 -0.1214 -0.1229 -0.4047 -0.1259 -0.1100 -0.1311 -0.5293 -1.7408 -0.1455 -0.0745 -0.1549 -0.1463 -0.1407 -0.1519 -0.5239 -0.1465 -0.3578 -0.0622 -0.1755 -0.1164 -0.7810 -0.1027 -0.0774 -0.0626 -0.1511 -0.1228 -0.1918 -0.1315 -0.1136 -0.1082 -0.0850 -1.4887 -0.0422 -1.1866 -0.1275 -0.1996 -0.1868 -0.1233 -0.1112 -0.1077 -0.0736 -0.7464 -0.2647 -0.1473 -0.1707
S-25	ADROVANCE ist eine weiße Tablette in Kapselform , die zwei arzneilich wirksame Bestandteile enthält : Natriumalendronat 3 H2O ( 70 mg ) und Colecalciferol ( Vitamin D3 , 70 Mikrogramm entsprechend 2800 internationalen Einheiten I.E . ) .
T-25	ADROVANCE is a white capsule-shaped tablet containing two active substances : alendronate sodium trihydrate ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2,800 international units ) .
H-25	-0.2779000401496887	ADROVANCE is a white capsule tablet containing two active drug ingredients : sodium alendronate 3 H2O ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2800 international units IU ) .
D-25	-0.2779000401496887	ADROVANCE is a white capsule tablet containing two active drug ingredients : sodium alendronate 3 H2O ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2800 international units IU ) .
P-25	-0.8080 -0.0594 -0.1613 -0.0932 -0.0783 -0.1164 -0.1628 -0.7026 -0.8790 -0.8019 -0.6023 -0.1586 -0.0558 -0.0611 -0.1322 -0.5398 -3.0869 -0.6697 -0.6465 -0.0052 -0.0378 -0.1221 -0.1205 -0.2586 -0.0960 -0.2441 -0.1290 -0.3285 -0.1407 -0.1534 -0.0763 -0.0436 -0.1435 -0.1758 -0.1247 -0.1920 -0.2387 -0.1481 -0.0779 -0.0906 -0.1424 -0.2249 -0.0444 -0.0945 -0.1998 -0.3492 -0.0842 -0.1261 -0.0946 -0.5405 -0.1482 -0.1992 -0.3150 -0.2915 -0.1628 -0.3267 -0.0690 -0.1696 -0.1469 -0.1819
S-789	Aerinaze darf bei Patienten , die möglicherweise überempfindlich ( allergisch ) gegen Desloratadin , Pseudoephedrin oder einen der anderen Bestandteile , gegen adrenerge Wirkstoffe oder Loratadin ( ein anderes Arzneimittel zur Behandlung von Allergien ) sind , nicht angewendet werden .
T-789	Aerinaze should not be used in people who may be hypersensitive ( allergic ) to desloratadine , pseudoephedrine or any of the other ingredients , to adrenergic agents or to loratadine ( another medicine used to treat allergies ) .
H-789	-0.34524908661842346	Aerinaze should not be used in people who may be allergic ( hypersensitive ) to desloratadine , pseudoephedrine or any of the other ingredients , to adrenergic agents or to loratadine , another anti-allergic medicine .
D-789	-0.34524908661842346	Aerinaze should not be used in people who may be allergic ( hypersensitive ) to desloratadine , pseudoephedrine or any of the other ingredients , to adrenergic agents or to loratadine , another anti-allergic medicine .
P-789	-0.9713 -0.1430 -0.1223 -0.3182 -0.0896 -0.2746 -0.1303 -0.1701 -0.1067 -0.1212 -0.2392 -0.1102 -0.1485 -0.1299 -0.6064 -0.0376 -0.2874 -0.0659 -0.0855 -0.1430 -0.1655 -1.8848 -0.0453 -0.1732 -0.4186 -0.4321 -0.1470 -0.2765 -3.4502 -0.2014 -0.0652 -0.1615 -0.2232 -0.0958 -1.0164 -0.2646 -0.1395 -0.1293 -0.1294 -0.1195 -0.1645 -0.8411 -1.1913 -0.0535 -0.1228 -0.0421 -0.0591 -0.1691 -0.1463 -0.0238 -0.1860 -0.2342 -0.9261 -0.6678 -0.1811 -0.2860 -0.0368 -1.2182 -0.1131 -0.3543 -0.3588 -0.1897
S-76	Patienten mit der seltenen hereditären Fructose-Intoleranz , Galactose-Intoleranz , Lactase-Mangel , Glucose-Galactose-Malabsorption oder Sucrase-Isomaltase-Insuffizienz sollten dieses Arzneimittel nicht einnehmen .
T-76	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the Lapp lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product .
H-76	-0.17312023043632507	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the lapp lactase deficiency , glucose-galactose malabsorption , or sucrase-isomaltase insufficiency , should not take this medicine .
D-76	-0.17312023043632507	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the lapp lactase deficiency , glucose-galactose malabsorption , or sucrase-isomaltase insufficiency , should not take this medicine .
P-76	-0.1305 -0.0987 -0.1530 -0.0855 -0.0739 -0.1103 -0.0614 -1.0890 -0.1711 -0.0572 -0.0696 -0.0393 -0.0398 -0.0231 -0.1168 -0.1417 -0.0993 -0.1267 -0.0406 -0.1463 -0.0234 -0.1076 -0.1441 -0.8566 -0.2979 -0.0037 -0.0143 -0.0220 -0.0477 -0.0502 -0.0347 -0.1126 -0.1404 -0.1136 -0.3686 -0.0880 -0.1010 -0.0575 -0.0797 -0.0192 -0.1001 -0.0516 -0.0606 -0.5720 -0.1171 -0.1270 -0.2790 -0.0578 -0.2769 -0.0658 -0.0999 -0.0244 -0.0680 -0.7942 -0.1073 -0.0395 -0.1030 -0.2687 -0.3157 -0.1445 -0.1741 -0.1685 -1.3571 -0.1395 -0.1839
S-175	Patienten mit der seltenen hereditären Fructose-Intoleranz , Galactose-Intoleranz , Lactase-Mangel , Glucose-Galactose-Malabsorption oder Sucrase-Isomaltase-Insuffizienz sollten dieses Arzneimittel nicht einnehmen .
T-175	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the Lapp lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product .
H-175	-0.17312023043632507	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the lapp lactase deficiency , glucose-galactose malabsorption , or sucrase-isomaltase insufficiency , should not take this medicine .
D-175	-0.17312023043632507	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the lapp lactase deficiency , glucose-galactose malabsorption , or sucrase-isomaltase insufficiency , should not take this medicine .
P-175	-0.1305 -0.0987 -0.1530 -0.0855 -0.0739 -0.1103 -0.0614 -1.0890 -0.1711 -0.0572 -0.0696 -0.0393 -0.0398 -0.0231 -0.1168 -0.1417 -0.0993 -0.1267 -0.0406 -0.1463 -0.0234 -0.1076 -0.1441 -0.8566 -0.2979 -0.0037 -0.0143 -0.0220 -0.0477 -0.0502 -0.0347 -0.1126 -0.1404 -0.1136 -0.3686 -0.0880 -0.1010 -0.0575 -0.0797 -0.0192 -0.1001 -0.0516 -0.0606 -0.5720 -0.1171 -0.1270 -0.2790 -0.0578 -0.2769 -0.0658 -0.0999 -0.0244 -0.0680 -0.7942 -0.1073 -0.0395 -0.1030 -0.2687 -0.3157 -0.1445 -0.1741 -0.1685 -1.3571 -0.1395 -0.1839
S-112	In den Phase-III-Studien betrugen die mittleren Anstiege der BMD mit Alendronat 10 mg<unk> Tag im Verhältnis zu Plazebo nach 3 Jahren 8,8 % an der Wirbelsäule , 5,9 % am Femurhals und 7,8 % am Trochanter .
T-112	In the initial efficacy studies , the mean BMD increases with alendronate 10 mg/ day relative to placebo at three years were 8.8 % , 5.9 % and 7.8 % at the spine , femoral neck and trochanter , respectively .
H-112	-0.2746654748916626	In the phase II trials mean increases in BMD with alendronate 10 mg/ day relative to placebo at 3 years were 8.8 % at the spine , 5.9 % at the femoral neck , and 7.8 % at the trochanter .
D-112	-0.2746654748916626	In the phase II trials mean increases in BMD with alendronate 10 mg/ day relative to placebo at 3 years were 8.8 % at the spine , 5.9 % at the femoral neck , and 7.8 % at the trochanter .
P-112	-0.1556 -0.1430 -0.1034 -0.4110 -0.3681 -1.1490 -0.1923 -0.3997 -0.0801 -0.1091 -0.1169 -0.1750 -0.1411 -0.1214 -0.1229 -0.4047 -0.1259 -0.1100 -0.1311 -0.5293 -1.7408 -0.1455 -0.0745 -0.1549 -0.1463 -0.1407 -0.1519 -0.5239 -0.1465 -0.3578 -0.0622 -0.1755 -0.1164 -0.7810 -0.1027 -0.0774 -0.0626 -0.1511 -0.1228 -0.1918 -0.1315 -0.1136 -0.1082 -0.0850 -1.4887 -0.0422 -1.1866 -0.1275 -0.1996 -0.1868 -0.1233 -0.1112 -0.1077 -0.0736 -0.7464 -0.2647 -0.1473 -0.1707
S-450	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-450	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-450	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
D-450	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
P-450	-0.2228 -0.1288 -1.4139 -0.9268 -0.1530 -0.1131 -0.0670 -0.1430 -0.1129 -0.1029 -0.1585 -0.1485 -3.0017 -0.4350 -0.1236 -0.1622 -0.1475 -0.1458 -0.0485 -0.2822 -1.0598 -0.2144 -0.2759 -0.1774 -0.1226 -0.1445 -0.2209 -1.4137 -0.1292 -0.1566 -0.2083 -0.1843 -0.0927 -0.0995 -0.1405 -0.1441 -1.4383 -0.2565 -0.0439 -0.1633 -0.2341 -1.5558 -0.4162 -0.6163 -0.1550 -0.1570 -0.1454 -0.1295 -0.1248 -0.1956 -0.2562 -0.3671 -1.7183 -0.2369 -0.7096 -0.1243 -0.0704 -0.0815 -0.1380 -0.1679 -0.9819 -0.0606 -0.1287 -0.1805
S-310	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-310	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-310	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
D-310	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
P-310	-0.2228 -0.1288 -1.4139 -0.9268 -0.1530 -0.1131 -0.0670 -0.1430 -0.1129 -0.1029 -0.1585 -0.1485 -3.0017 -0.4350 -0.1236 -0.1622 -0.1475 -0.1458 -0.0485 -0.2822 -1.0598 -0.2144 -0.2759 -0.1774 -0.1226 -0.1445 -0.2209 -1.4137 -0.1292 -0.1566 -0.2083 -0.1843 -0.0927 -0.0995 -0.1405 -0.1441 -1.4383 -0.2565 -0.0439 -0.1633 -0.2341 -1.5558 -0.4162 -0.6163 -0.1550 -0.1570 -0.1454 -0.1295 -0.1248 -0.1956 -0.2562 -0.3671 -1.7183 -0.2369 -0.7096 -0.1243 -0.0704 -0.0815 -0.1380 -0.1679 -0.9819 -0.0606 -0.1287 -0.1805
S-380	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-380	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-380	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
D-380	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
P-380	-0.2228 -0.1288 -1.4139 -0.9268 -0.1530 -0.1131 -0.0670 -0.1430 -0.1129 -0.1029 -0.1585 -0.1485 -3.0017 -0.4350 -0.1236 -0.1622 -0.1475 -0.1458 -0.0485 -0.2822 -1.0598 -0.2144 -0.2759 -0.1774 -0.1226 -0.1445 -0.2209 -1.4137 -0.1292 -0.1566 -0.2083 -0.1843 -0.0927 -0.0995 -0.1405 -0.1441 -1.4383 -0.2565 -0.0439 -0.1633 -0.2341 -1.5558 -0.4162 -0.6163 -0.1550 -0.1570 -0.1454 -0.1295 -0.1248 -0.1956 -0.2562 -0.3671 -1.7183 -0.2369 -0.7096 -0.1243 -0.0704 -0.0815 -0.1380 -0.1679 -0.9819 -0.0606 -0.1287 -0.1805
S-587	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-587	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-587	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
D-587	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
P-587	-0.4465 -0.1594 -1.7749 -0.2675 -0.1247 -1.1981 -0.2742 -1.6023 -0.0613 -0.1266 -0.2228 -0.1057 -2.2954 -0.2209 -0.1449 -0.1519 -0.1562 -0.1347 -0.0969 -0.0762 -0.1590 -0.5685 -0.1499 -0.1382 -1.5528 -0.2333 -0.7075 -0.1294 -0.1295 -1.1729 -0.3410 -0.0524 -0.1384 -0.2070 -0.8990 -0.8761 -0.0203 -0.0146 -1.0327 -0.1476 -1.2734 -0.7480 -0.5825 -0.3822 -0.4378 -0.3493 -0.1470 -0.1136 -0.1697 -0.0504 -0.1118 -0.2055 -0.0786 -1.0814 -0.2322 -0.0835 -0.1058 -0.9934 -0.2175 -0.1719 -0.1902
S-520	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-520	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-520	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
D-520	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
P-520	-0.2228 -0.1288 -1.4139 -0.9268 -0.1530 -0.1131 -0.0670 -0.1430 -0.1129 -0.1029 -0.1585 -0.1485 -3.0017 -0.4350 -0.1236 -0.1622 -0.1475 -0.1458 -0.0485 -0.2822 -1.0598 -0.2144 -0.2759 -0.1774 -0.1226 -0.1445 -0.2209 -1.4137 -0.1292 -0.1566 -0.2083 -0.1843 -0.0927 -0.0995 -0.1405 -0.1441 -1.4383 -0.2565 -0.0439 -0.1633 -0.2341 -1.5558 -0.4162 -0.6163 -0.1550 -0.1570 -0.1454 -0.1295 -0.1248 -0.1956 -0.2562 -0.3671 -1.7183 -0.2369 -0.7096 -0.1243 -0.0704 -0.0815 -0.1380 -0.1679 -0.9819 -0.0606 -0.1287 -0.1805
S-590	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-590	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-590	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
D-590	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
P-590	-0.2228 -0.1288 -1.4139 -0.9268 -0.1530 -0.1131 -0.0670 -0.1430 -0.1129 -0.1029 -0.1585 -0.1485 -3.0017 -0.4350 -0.1236 -0.1622 -0.1475 -0.1458 -0.0485 -0.2822 -1.0598 -0.2144 -0.2759 -0.1774 -0.1226 -0.1445 -0.2209 -1.4137 -0.1292 -0.1566 -0.2083 -0.1843 -0.0927 -0.0995 -0.1405 -0.1441 -1.4383 -0.2565 -0.0439 -0.1633 -0.2341 -1.5558 -0.4162 -0.6163 -0.1550 -0.1570 -0.1454 -0.1295 -0.1248 -0.1956 -0.2562 -0.3671 -1.7183 -0.2369 -0.7096 -0.1243 -0.0704 -0.0815 -0.1380 -0.1679 -0.9819 -0.0606 -0.1287 -0.1805
S-660	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-660	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-660	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
D-660	-0.36993399262428284	Moreover , in none of the 53 paediatric patients with less than 6 years of age and diagnosed severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrations ( 50 days ) , an FVIII inhibitor was detected .
P-660	-0.2228 -0.1288 -1.4139 -0.9268 -0.1530 -0.1131 -0.0670 -0.1430 -0.1129 -0.1029 -0.1585 -0.1485 -3.0017 -0.4350 -0.1236 -0.1622 -0.1475 -0.1458 -0.0485 -0.2822 -1.0598 -0.2144 -0.2759 -0.1774 -0.1226 -0.1445 -0.2209 -1.4137 -0.1292 -0.1566 -0.2083 -0.1843 -0.0927 -0.0995 -0.1405 -0.1441 -1.4383 -0.2565 -0.0439 -0.1633 -0.2341 -1.5558 -0.4162 -0.6163 -0.1550 -0.1570 -0.1454 -0.1295 -0.1248 -0.1956 -0.2562 -0.3671 -1.7183 -0.2369 -0.7096 -0.1243 -0.0704 -0.0815 -0.1380 -0.1679 -0.9819 -0.0606 -0.1287 -0.1805
S-657	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-657	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-657	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
D-657	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
P-657	-0.4465 -0.1594 -1.7749 -0.2675 -0.1247 -1.1981 -0.2742 -1.6023 -0.0613 -0.1266 -0.2228 -0.1057 -2.2954 -0.2209 -0.1449 -0.1519 -0.1562 -0.1347 -0.0969 -0.0762 -0.1590 -0.5685 -0.1499 -0.1382 -1.5528 -0.2333 -0.7075 -0.1294 -0.1295 -1.1729 -0.3410 -0.0524 -0.1384 -0.2070 -0.8990 -0.8761 -0.0203 -0.0146 -1.0327 -0.1476 -1.2734 -0.7480 -0.5825 -0.3822 -0.4378 -0.3493 -0.1470 -0.1136 -0.1697 -0.0504 -0.1118 -0.2055 -0.0786 -1.0814 -0.2322 -0.0835 -0.1058 -0.9934 -0.2175 -0.1719 -0.1902
S-447	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-447	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-447	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
D-447	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
P-447	-0.4465 -0.1594 -1.7749 -0.2675 -0.1247 -1.1981 -0.2742 -1.6023 -0.0613 -0.1266 -0.2228 -0.1057 -2.2954 -0.2209 -0.1449 -0.1519 -0.1562 -0.1347 -0.0969 -0.0762 -0.1590 -0.5685 -0.1499 -0.1382 -1.5528 -0.2333 -0.7075 -0.1294 -0.1295 -1.1729 -0.3410 -0.0524 -0.1384 -0.2070 -0.8990 -0.8761 -0.0203 -0.0146 -1.0327 -0.1476 -1.2734 -0.7480 -0.5825 -0.3822 -0.4378 -0.3493 -0.1470 -0.1136 -0.1697 -0.0504 -0.1118 -0.2055 -0.0786 -1.0814 -0.2322 -0.0835 -0.1058 -0.9934 -0.2175 -0.1719 -0.1902
S-517	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-517	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-517	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
D-517	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
P-517	-0.4465 -0.1594 -1.7749 -0.2675 -0.1247 -1.1981 -0.2742 -1.6023 -0.0613 -0.1266 -0.2228 -0.1057 -2.2954 -0.2209 -0.1449 -0.1519 -0.1562 -0.1347 -0.0969 -0.0762 -0.1590 -0.5685 -0.1499 -0.1382 -1.5528 -0.2333 -0.7075 -0.1294 -0.1295 -1.1729 -0.3410 -0.0524 -0.1384 -0.2070 -0.8990 -0.8761 -0.0203 -0.0146 -1.0327 -0.1476 -1.2734 -0.7480 -0.5825 -0.3822 -0.4378 -0.3493 -0.1470 -0.1136 -0.1697 -0.0504 -0.1118 -0.2055 -0.0786 -1.0814 -0.2322 -0.0835 -0.1058 -0.9934 -0.2175 -0.1719 -0.1902
S-307	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-307	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-307	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
D-307	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
P-307	-0.4465 -0.1594 -1.7749 -0.2675 -0.1247 -1.1981 -0.2742 -1.6023 -0.0613 -0.1266 -0.2228 -0.1057 -2.2954 -0.2209 -0.1449 -0.1519 -0.1562 -0.1347 -0.0969 -0.0762 -0.1590 -0.5685 -0.1499 -0.1382 -1.5528 -0.2333 -0.7075 -0.1294 -0.1295 -1.1729 -0.3410 -0.0524 -0.1384 -0.2070 -0.8990 -0.8761 -0.0203 -0.0146 -1.0327 -0.1476 -1.2734 -0.7480 -0.5825 -0.3822 -0.4378 -0.3493 -0.1470 -0.1136 -0.1697 -0.0504 -0.1118 -0.2055 -0.0786 -1.0814 -0.2322 -0.0835 -0.1058 -0.9934 -0.2175 -0.1719 -0.1902
S-197	In schweren Fällen kann ein Mangel zu sekundärem Hyperparathyreoidismus , Hypophosphatämie , Schwäche der proximalen Muskulatur und Osteomalazie und so zu einem weiter erhöhten Risiko für Stürze und Knochenbrüche bei osteoporotischen Personen führen .
T-197	In severe cases , deficiency results in secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic individuals .
H-197	-0.2708442807197571	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , weakness in proximal muscle and osteomalacia , thus increasing the risk of falls and bone fractures in osteoporotic patients .
D-197	-0.2708442807197571	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , weakness in proximal muscle and osteomalacia , thus increasing the risk of falls and bone fractures in osteoporotic patients .
P-197	-0.2173 -0.0440 -0.1409 -0.1789 -0.2487 -0.1764 -0.0911 -0.2044 -0.0657 -0.1608 -0.0289 -0.0611 -0.0840 -0.0840 -0.1315 -0.0413 -0.0996 -0.1099 -0.1069 -0.1455 -0.3468 -0.0417 -0.2010 -0.0532 -0.2059 -0.4029 -0.0386 -0.1422 -0.1447 -0.3685 -0.6240 -0.1354 -0.2827 -0.1034 -1.0140 -0.0676 -0.1072 -0.1321 -0.2004 -0.2196 -0.2563 -0.0776 -0.1133 -3.5583 -1.1003 -0.1983 -0.1385 -0.1503 -0.2128 -0.1519 -0.2042 -0.4820 -0.0540 -0.1457 -0.0913 -0.1538 -0.1580 -0.0972 -0.5522 -0.5372 -1.0764 -0.1257 -0.1750
S-99	In schweren Fällen kann ein Mangel zu sekundärem Hyperparathyreoidismus , Hypophosphatämie , Schwäche der proximalen Muskulatur und Osteomalazie und so zu einem weiter erhöhten Risiko für Stürze und Knochenbrüche bei osteoporotischen Personen führen .
T-99	In severe cases , deficiency results in secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic individuals .
H-99	-0.2708442807197571	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , weakness in proximal muscle and osteomalacia , thus increasing the risk of falls and bone fractures in osteoporotic patients .
D-99	-0.2708442807197571	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , weakness in proximal muscle and osteomalacia , thus increasing the risk of falls and bone fractures in osteoporotic patients .
P-99	-0.2173 -0.0440 -0.1409 -0.1789 -0.2487 -0.1764 -0.0911 -0.2044 -0.0657 -0.1608 -0.0289 -0.0611 -0.0840 -0.0840 -0.1315 -0.0413 -0.0996 -0.1099 -0.1069 -0.1455 -0.3468 -0.0417 -0.2010 -0.0532 -0.2059 -0.4029 -0.0386 -0.1422 -0.1447 -0.3685 -0.6240 -0.1354 -0.2827 -0.1034 -1.0140 -0.0676 -0.1072 -0.1321 -0.2004 -0.2196 -0.2563 -0.0776 -0.1133 -3.5583 -1.1003 -0.1983 -0.1385 -0.1503 -0.2128 -0.1519 -0.2042 -0.4820 -0.0540 -0.1457 -0.0913 -0.1538 -0.1580 -0.0972 -0.5522 -0.5372 -1.0764 -0.1257 -0.1750
S-200	Die Patienten erhielten ADROVANCE in der niedrigeren Stärke ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 350 ) oder FOSAMAX ( Alendronat ) 70 mg einmal wöchentlich ( n<unk> 332 ) ; weitere Vitamin-D-Ergänzungsmittel waren untersagt .
T-200	Patients received the lower strength ( 70 mg/ 2800 IU ) of ADROVANCE ( n<<unk>> 350 ) or FOSAMAX ( alendronate ) 70 mg ( n<<unk>> 332 ) once a week ; additional vitamin
H-200	-0.30435115098953247	Patients were treated with lower strength ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n/ 332 ) with no other vitamin D supplements .
D-200	-0.30435115098953247	Patients were treated with lower strength ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n/ 332 ) with no other vitamin D supplements .
P-200	-0.1921 -0.0880 -1.0059 -0.0838 -0.1529 -0.5934 -0.4558 -0.9289 -0.0651 -0.1704 -0.1000 -0.0857 -0.1115 -0.1053 -0.1187 -0.1073 -0.0953 -0.4608 -0.0957 -0.1279 -0.0473 -0.1307 -0.8853 -0.1364 -0.2173 -0.7541 -0.1272 -0.1245 -1.2229 -0.0562 -0.1439 -0.1595 -0.0915 -0.1411 -0.1170 -0.1421 -0.2805 -0.0608 -0.1479 -0.2670 -0.0610 -0.0199 -0.5469 -0.1469 -0.1915 -0.1329 -0.1816 -0.1877 -0.1288 -0.5294 -2.4680 -0.9827 -1.0991 -0.0391 -0.1001 -0.0213 -0.3284 -0.2113 -0.1826
S-377	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-377	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-377	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
D-377	-0.42683592438697815	a ) The percentage of the patients was calculated using the total of the individual patients ( 234 ) . b ) The unexpected decrease in blood clotting factor VIII occurred postoperative ( 10 - 14 postoperative days ) in a patient receiving continuous ADVATE infusion .
P-377	-0.4465 -0.1594 -1.7749 -0.2675 -0.1247 -1.1981 -0.2742 -1.6023 -0.0613 -0.1266 -0.2228 -0.1057 -2.2954 -0.2209 -0.1449 -0.1519 -0.1562 -0.1347 -0.0969 -0.0762 -0.1590 -0.5685 -0.1499 -0.1382 -1.5528 -0.2333 -0.7075 -0.1294 -0.1295 -1.1729 -0.3410 -0.0524 -0.1384 -0.2070 -0.8990 -0.8761 -0.0203 -0.0146 -1.0327 -0.1476 -1.2734 -0.7480 -0.5825 -0.3822 -0.4378 -0.3493 -0.1470 -0.1136 -0.1697 -0.0504 -0.1118 -0.2055 -0.0786 -1.0814 -0.2322 -0.0835 -0.1058 -0.9934 -0.2175 -0.1719 -0.1902
S-774	Aerinaze wird zur Behandlung der Symptome der saisonalen allergischen Rhinitis ( Heuschnupfen , durch eine Allergie gegen Pollen hervorgerufene Entzündung der Nasenwege ) bei Patienten mit Nasenschleimhautschwellung ( verstopfter Nase ) angewendet .
T-774	Aerinaze is used to treat the symptoms of seasonal allergic rhinitis ( hayfever , inflammation of the nasal passages caused by an allergy to pollen ) in patients who have nasal congestion ( a blocked nose ) .
H-774	-0.34397050738334656	Aerinaze is used to treat the symptoms of seasonal allergic rhinitis ( hayfever , nasal tract inflammation caused by allergic reaction to pollen ) in patients with nasal mucosal swelling ( nasal constipation ) .
D-774	-0.34397050738334656	Aerinaze is used to treat the symptoms of seasonal allergic rhinitis ( hayfever , nasal tract inflammation caused by allergic reaction to pollen ) in patients with nasal mucosal swelling ( nasal constipation ) .
P-774	-0.1157 -0.1362 -0.1273 -0.3697 -0.0947 -0.1075 -0.8136 -0.2814 -0.0571 -0.7265 -0.1448 -0.1552 -2.3036 -0.1453 -0.1546 -0.0823 -0.1145 -0.0579 -0.1109 -0.0748 -0.1467 -0.4401 -1.0076 -0.1922 -0.0358 -0.1626 -0.3253 -0.1476 -0.1594 -2.7533 -0.1484 -0.0614 -0.1892 -0.1024 -1.2627 -0.0889 -1.5537 -0.7337 -1.0379 -0.1833 -0.2056 -1.4120 -0.1194 -0.1694 -0.3560 -0.1200 -0.1233 -0.0674 -0.1599 -0.1052 -0.0531 -0.2122 -0.3088 -0.1630 -0.1171 -0.1906 -0.0646 -0.1294 -0.4462 -0.2093 -0.1056 -0.1073 -0.1465 -0.1779 -0.1823
S-102	Die Patienten erhielten ADROVANCE in der niedrigeren Stärke ( 70 mg <unk> 2.800 I.E. ) ( n<unk> 350 ) oder FOSAMAX ( Alendronat ) 70 mg einmal wöchentlich ( n<unk> 332 ) ; weitere Vitamin-D-Ergänzungsmittel waren untersagt .
T-102	Patients received the lower strength ( 70 mg/ 2800 IU ) of ADROVANCE ( n<<unk>> 350 ) or FOSAMAX ( alendronate ) 70 mg ( n<<unk>> 332 ) once a week ; additional vitamin D supplements
H-102	-0.3053012788295746	Patients were treated with lower strength ADROVANCE ( 70 mg <unk> 2,800 IU ) ( n<unk> 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n<unk> 332 ) with no other vitamin D supplements .
D-102	-0.3053012788295746	Patients were treated with lower strength ADROVANCE ( 70 mg <unk> 2,800 IU ) ( n<unk> 350 ) or FOSAMAX ( alendronate ) 70 mg once weekly ( n<unk> 332 ) with no other vitamin D supplements .
P-102	-0.2081 -0.0890 -1.1154 -0.0680 -0.1649 -0.5853 -0.3867 -0.6743 -0.0670 -0.1727 -0.0984 -0.0849 -0.1133 -0.0977 -0.0596 -0.0530 -0.2543 -0.1100 -0.1244 -0.0477 -0.1262 -0.3757 -0.1378 -0.7447 -0.6351 -0.1185 -0.1254 -0.8542 -0.0582 -0.1367 -0.1555 -0.0945 -0.1436 -0.1228 -0.1416 -0.3338 -0.0705 -0.1448 -0.2584 -0.0661 -0.0195 -0.5493 -0.1471 -0.1902 -0.5994 -0.1941 -0.1802 -0.1331 -0.5240 -2.3642 -1.1203 -1.3023 -0.0420 -0.1032 -0.0200 -0.3730 -0.2435 -0.1835
S-748	Li-Fraumeni-Krebs ist eine Art von Krebs , der bei Patienten mit Li- Fraumeni-Syndrom auftritt , bei dem das so genannte p53-Gen aufgrund einer Mutation defekt ist . Bei Menschen , die diese Mutation aufweisen , besteht eine höhere Wahrscheinlichkeit , an Krebs zu erkranken .
T-748	Li-Fraumeni cancer is a type of cancer that occurs in patients with Li-Fraumeni syndrome , a condition where a gene called p53 is defective because of a mutation .
H-748	-0.4309926927089691	Li-woman-meni cancer is a type of cancer that occurs in patients with Li-woman-meni syndrome , in whom the so called p53 gene is defective due to a mutation , and people with this mutation are more likely to develop cancer .
D-748	-0.4309926927089691	Li-woman-meni cancer is a type of cancer that occurs in patients with Li-woman-meni syndrome , in whom the so called p53 gene is defective due to a mutation , and people with this mutation are more likely to develop cancer .
P-748	-1.1062 -0.1964 -1.9543 -1.6007 -0.4402 -0.0303 -0.7952 -0.3424 -0.1240 -0.5953 -0.2080 -0.1366 -0.0567 -0.2808 -0.6724 -0.0914 -0.1300 -0.2907 -0.1217 -0.7768 -1.1863 -0.6749 -0.1153 -0.1530 -1.1822 -0.7078 -0.8739 -0.0837 -0.7658 -0.9270 -0.2311 -0.1593 -0.4373 -0.3493 -0.1742 -0.0963 -0.0400 -0.1103 -0.1525 -0.7162 -0.6742 -0.1586 -0.1871 -0.1325 -0.1657 -0.2638 -0.0783 -2.4095 -0.4560 -0.3259 -0.1049 -0.1415 -0.2152 -0.1799 -0.2018 -0.1396 -0.4460 -0.1579 -0.1539 -0.1805
S-804	Die Patienten müssen darüber informiert werden , dass die Behandlung bei Auftreten einer Hypertonie oder einer Tachykardie oder von Palpitationen , Herzrhythmusstörungen , Übelkeit oder etwaigen sonstigen neurologischen Symptomen ( wie Kopfschmerzen oder einer Verstärkung der Kopfschmerzen ) abgesetzt werden muss .
T-804	Patients should be informed that the treatment should be discontinued in case of hypertension , tachycardia , palpitations or cardiac arrhythmias , nausea or any other neurological sign ( such as headache or increased headache ) .
H-804	-0.330265611410141	Patients should be informed that treatment has to be discontinued if hypertension or tachycardia or palpitations , cardiac dysrhythmia , nausea or any other neurologic symptoms , such as headaches or an increase in headaches , occur .
D-804	-0.330265611410141	Patients should be informed that treatment has to be discontinued if hypertension or tachycardia or palpitations , cardiac dysrhythmia , nausea or any other neurologic symptoms , such as headaches or an increase in headaches , occur .
P-804	-0.0890 -0.0933 -0.4953 -0.1807 -0.5877 -0.1995 -0.2962 -1.2783 -0.1635 -0.0918 -0.1616 -0.0620 -0.2721 -0.0243 -0.0316 -0.1257 -0.1085 -0.0495 -0.1293 -0.2434 -0.0549 -0.2926 -0.0392 -0.3586 -0.2072 -0.1599 -2.1223 -0.0523 -0.3379 -0.0215 -0.0358 -0.1312 -0.0308 -0.0588 -0.1289 -0.1276 -0.2680 -0.0353 -2.0979 -0.0839 -0.5124 -1.6390 -0.2084 -0.1444 -0.0629 -0.0300 -0.0729 -0.1387 -2.5187 -0.7506 -0.1325 -0.1751 -0.0389 -0.2645 -0.2145 -0.6151 -0.1309 -0.1780
S-162	Eine zahnärztliche Untersuchung mit geeigneten Präventionsmaßnahmen sollte einer Behandlung mit Bisphosphonaten vorangehen , wenn die Patienten entsprechende Risikofaktoren aufweisen ( z. B. Krebs , Chemotherapie , Strahlentherapie , Kortikosteroide , schlechte Mundhygiene , Parodontitis ) .
T-162	A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontal disease ) .
H-162	-0.268323689699173	Dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates , if patients have relevant risk factors ( e. g. cancer , chemotherapy , radiation therapy , corticosteroids , poor oral hygiene , periodontitis ) .
D-162	-0.268323689699173	Dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates , if patients have relevant risk factors ( e. g. cancer , chemotherapy , radiation therapy , corticosteroids , poor oral hygiene , periodontitis ) .
P-162	-0.1543 -0.3821 -1.1361 -0.3227 -0.2393 -0.2621 -0.7122 -0.0947 -0.7620 -0.3494 -0.7987 -0.2275 -0.2717 -0.0852 -0.0790 -0.1289 -0.0897 -0.0510 -0.0576 -0.1680 -0.1115 -0.9659 -0.8226 -0.7411 -0.6157 -2.1079 -0.0467 -0.2364 -0.2333 -0.1504 -0.1124 -0.0937 -0.0372 -0.1420 -0.0938 -0.0637 -0.0827 -0.1375 -0.6164 -0.0847 -0.1389 -0.0777 -0.0745 -0.0987 -0.1593 -0.1937 -0.0236 -0.1356 -0.1354 -0.1348 -0.0994 -0.0662 -0.1397 -0.0526 -0.0495 -0.0438 -0.1396 -0.1496 -0.1456 -0.1736
S-814	4 leistungsmindernde Wirkung von Alkohol jedoch nicht verstärkt . Bei den Ergebnissen des psychomotorischen Tests konnten keine signifikanten Unterschiede zwischen den mit Desloratadin und den mit Placebo behandelten Patienten festgestellt werden , unabhängig davon , ob Desloratadin alleine oder mit Alkohol eingenommen wurde .
T-814	No significant differences were found in the psychomotor test results between desloratadine and placebo groups , whether administered alone or with alcohol .
H-814	-0.4250689744949341	Results of the psychomotor test did not reveal significant differences between patients treated with desloratadine and those treated with placebo , whether desloratadine was taken on its own or with alcohol .
D-814	-0.4250689744949341	Results of the psychomotor test did not reveal significant differences between patients treated with desloratadine and those treated with placebo , whether desloratadine was taken on its own or with alcohol .
P-814	-0.5924 -0.0981 -0.1422 -0.1732 -2.0271 -0.1799 -0.2481 -0.7976 -0.2120 -0.9405 -0.1045 -0.5058 -0.2523 -0.0993 -0.1622 -1.0379 -0.4922 -0.1282 -2.1423 -0.0511 -0.1478 -0.4009 -0.2323 -0.1719 -0.4686 -0.0632 -0.1168 -0.0558 -0.1390 -0.1209 -0.1601 -0.1224 -0.4332 -2.9089 -0.0861 -0.1414 -0.3123 -1.0707 -0.3831 -1.3161 -0.3329 -0.0771 -0.0759 -0.1119 -0.1617 -0.1030 -0.1199 -0.1823
S-813	Andere Wirkstoffe mit gefäßverengender Wirkung , die oral oder nasal als abschwellende Rhinologika angewendet werden ( Phenylpropanolamin , Phenylephrin , Ephedrin , Oxymetazolin , Naphazolin etc . ) :
T-813	Other vasoconstrictors used as nasal decongestant , by oral or nasal route ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazoline ) : risk of vasoconstriction .
H-813	-0.4167129397392273	Other vascular constricting agents used orally or nasally as degrading rhinologic agents ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazolin , naphazolin etc. ) :
D-813	-0.4167129397392273	Other vascular constricting agents used orally or nasally as degrading rhinologic agents ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazolin , naphazolin etc. ) :
P-813	-0.1697 -3.2948 -0.0062 -0.5550 -2.9228 -0.6958 -0.6998 -0.0304 -0.7684 -0.5270 -0.0695 -0.1454 -0.3373 -0.1564 -0.0920 -0.1704 -0.1929 -1.7598 -0.1173 -0.1119 -0.0496 -0.4464 -1.7422 -0.0049 -0.1651 -0.0198 -1.0768 -0.0707 -0.1741 -0.1881 -0.0738 -0.1491 -0.0741 -0.2272 -0.0606 -0.2651 -0.3245 -0.1162 -0.1468 -0.2046 -0.1681 -0.0668 -0.0723 -0.1512 -0.3196 -0.0794 -0.0937 -0.0545 -1.6814 -0.2106 -0.1539 -0.1986 -0.6569 -0.1301 -0.1558 -1.9486 -0.1814 -0.1506 -0.1599 -0.1890 -0.1945
S-63	Eine zahnärztliche Untersuchung mit geeigneten Präventionsmaßnahmen sollte einer Behandlung mit Bisphosphonaten vorangehen , wenn die Patienten entsprechende Risikofaktoren aufweisen ( z. B. Krebs , Chemotherapie , Strahlentherapie , Kortikosteroide , schlechte Mundhygiene , Parodontitis ) .
T-63	A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontal disease ) .
H-63	-0.268323689699173	Dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates , if patients have relevant risk factors ( e. g. cancer , chemotherapy , radiation therapy , corticosteroids , poor oral hygiene , periodontitis ) .
D-63	-0.268323689699173	Dental examination with appropriate preventive measures should be preceded by treatment with bisphosphonates , if patients have relevant risk factors ( e. g. cancer , chemotherapy , radiation therapy , corticosteroids , poor oral hygiene , periodontitis ) .
P-63	-0.1543 -0.3821 -1.1361 -0.3227 -0.2393 -0.2621 -0.7122 -0.0947 -0.7620 -0.3494 -0.7987 -0.2275 -0.2717 -0.0852 -0.0790 -0.1289 -0.0897 -0.0510 -0.0576 -0.1680 -0.1115 -0.9659 -0.8226 -0.7411 -0.6157 -2.1079 -0.0467 -0.2364 -0.2333 -0.1504 -0.1124 -0.0937 -0.0372 -0.1420 -0.0938 -0.0637 -0.0827 -0.1375 -0.6164 -0.0847 -0.1389 -0.0777 -0.0745 -0.0987 -0.1593 -0.1937 -0.0236 -0.1356 -0.1354 -0.1348 -0.0994 -0.0662 -0.1397 -0.0526 -0.0495 -0.0438 -0.1396 -0.1496 -0.1456 -0.1736
S-649	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-649	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-649	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
D-649	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
P-649	-0.2721 -0.1791 -0.0660 -0.0998 -0.3152 -0.1644 -0.1738 -0.1400 -1.3285 -0.1350 -0.1213 -1.2809 -0.1204 -0.0994 -0.6284 -0.1634 -0.0560 -0.3063 -0.5310 -0.0549 -0.1464 -0.2985 -0.1296 -0.0972 -0.9265 -0.1983 -0.1315 -0.8051 -0.0735 -0.0909 -0.1620 -0.1417 -0.3580 -0.6504 -0.2912 -0.9061 -1.2147 -0.1630 -0.1336 -0.0744 -0.0499 -0.1220 -0.3816 -1.1670 -0.3345 -0.1663 -0.1335 -0.2122 -0.1398 -0.1274 -0.1170 -0.1681 -0.1374 -0.9756 -1.0014 -0.1401 -0.1515 -0.0951 -0.1473 -0.1775
S-369	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-369	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-369	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
D-369	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
P-369	-0.2721 -0.1791 -0.0660 -0.0998 -0.3152 -0.1644 -0.1738 -0.1400 -1.3285 -0.1350 -0.1213 -1.2809 -0.1204 -0.0994 -0.6284 -0.1634 -0.0560 -0.3063 -0.5310 -0.0549 -0.1464 -0.2985 -0.1296 -0.0972 -0.9265 -0.1983 -0.1315 -0.8051 -0.0735 -0.0909 -0.1620 -0.1417 -0.3580 -0.6504 -0.2912 -0.9061 -1.2147 -0.1630 -0.1336 -0.0744 -0.0499 -0.1220 -0.3816 -1.1670 -0.3345 -0.1663 -0.1335 -0.2122 -0.1398 -0.1274 -0.1170 -0.1681 -0.1374 -0.9756 -1.0014 -0.1401 -0.1515 -0.0951 -0.1473 -0.1775
S-351	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-351	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-351	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
D-351	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
P-351	-0.7975 -0.0480 -0.1256 -1.1340 -0.1541 -0.1542 -0.5073 -1.1163 -0.1150 -0.1606 -0.2885 -0.0903 -0.1213 -0.5049 -0.2090 -1.4191 -0.1445 -0.1412 -0.1694 -0.4869 -0.0578 -0.1485 -0.1207 -0.9647 -1.0385 -0.2524 -0.1176 -0.1793 -0.8504 -0.3489 -0.0304 -0.1090 -0.0849 -0.1039 -0.1266 -1.1515 -0.7549 -0.0194 -0.3434 -0.8392 -1.0103 -0.4757 -0.0425 -0.1008 -0.9969 -0.2144 -0.1511 -0.1483 -0.1596 -0.0916 -0.1693 -0.0771 -0.1400 -0.1275 -0.1720
S-579	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-579	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-579	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
D-579	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
P-579	-0.2721 -0.1791 -0.0660 -0.0998 -0.3152 -0.1644 -0.1738 -0.1400 -1.3285 -0.1350 -0.1213 -1.2809 -0.1204 -0.0994 -0.6284 -0.1634 -0.0560 -0.3063 -0.5310 -0.0549 -0.1464 -0.2985 -0.1296 -0.0972 -0.9265 -0.1983 -0.1315 -0.8051 -0.0735 -0.0909 -0.1620 -0.1417 -0.3580 -0.6504 -0.2912 -0.9061 -1.2147 -0.1630 -0.1336 -0.0744 -0.0499 -0.1220 -0.3816 -1.1670 -0.3345 -0.1663 -0.1335 -0.2122 -0.1398 -0.1274 -0.1170 -0.1681 -0.1374 -0.9756 -1.0014 -0.1401 -0.1515 -0.0951 -0.1473 -0.1775
S-509	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-509	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-509	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
D-509	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
P-509	-0.2721 -0.1791 -0.0660 -0.0998 -0.3152 -0.1644 -0.1738 -0.1400 -1.3285 -0.1350 -0.1213 -1.2809 -0.1204 -0.0994 -0.6284 -0.1634 -0.0560 -0.3063 -0.5310 -0.0549 -0.1464 -0.2985 -0.1296 -0.0972 -0.9265 -0.1983 -0.1315 -0.8051 -0.0735 -0.0909 -0.1620 -0.1417 -0.3580 -0.6504 -0.2912 -0.9061 -1.2147 -0.1630 -0.1336 -0.0744 -0.0499 -0.1220 -0.3816 -1.1670 -0.3345 -0.1663 -0.1335 -0.2122 -0.1398 -0.1274 -0.1170 -0.1681 -0.1374 -0.9756 -1.0014 -0.1401 -0.1515 -0.0951 -0.1473 -0.1775
S-439	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-439	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-439	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
D-439	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
P-439	-0.2721 -0.1791 -0.0660 -0.0998 -0.3152 -0.1644 -0.1738 -0.1400 -1.3285 -0.1350 -0.1213 -1.2809 -0.1204 -0.0994 -0.6284 -0.1634 -0.0560 -0.3063 -0.5310 -0.0549 -0.1464 -0.2985 -0.1296 -0.0972 -0.9265 -0.1983 -0.1315 -0.8051 -0.0735 -0.0909 -0.1620 -0.1417 -0.3580 -0.6504 -0.2912 -0.9061 -1.2147 -0.1630 -0.1336 -0.0744 -0.0499 -0.1220 -0.3816 -1.1670 -0.3345 -0.1663 -0.1335 -0.2122 -0.1398 -0.1274 -0.1170 -0.1681 -0.1374 -0.9756 -1.0014 -0.1401 -0.1515 -0.0951 -0.1473 -0.1775
S-282	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-282	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-282	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
D-282	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
P-282	-0.7975 -0.0480 -0.1256 -1.1340 -0.1541 -0.1542 -0.5073 -1.1163 -0.1150 -0.1606 -0.2885 -0.0903 -0.1213 -0.5049 -0.2090 -1.4191 -0.1445 -0.1412 -0.1694 -0.4869 -0.0578 -0.1485 -0.1207 -0.9647 -1.0385 -0.2524 -0.1176 -0.1793 -0.8504 -0.3489 -0.0304 -0.1090 -0.0849 -0.1039 -0.1266 -1.1515 -0.7549 -0.0194 -0.3434 -0.8392 -1.0103 -0.4757 -0.0425 -0.1008 -0.9969 -0.2144 -0.1511 -0.1483 -0.1596 -0.0916 -0.1693 -0.0771 -0.1400 -0.1275 -0.1720
S-91	Alendronat Infolge einer oralen Überdosis können Hypocalcämie , Hypophosphatämie und Nebenwirkungen im oberen Gastrointestinaltrakt wie Magenverstimmung , Sodbrennen , Ösophagitis , Gastritis oder Ulzera auftreten .
T-91	Alendronate Hypocalcaemia , hypophosphataemia and upper gastrointestinal adverse reactions , such as upset stomach , heartburn , oesophagitis , gastritis , or ulcer , may result from oral overdose .
H-91	-0.19458019733428955	Alendronate Hypocalcaemia , hypophosphataemia , and upper gastro-intestinal tract undesirable effects such as indigestion , heartburn , oesophagitis , gastritis , or ulcera may occur as a consequence of oral overdose .
D-91	-0.19458019733428955	Alendronate Hypocalcaemia , hypophosphataemia , and upper gastro-intestinal tract undesirable effects such as indigestion , heartburn , oesophagitis , gastritis , or ulcera may occur as a consequence of oral overdose .
P-91	-0.2563 -0.1317 -0.1233 -0.0621 -0.1572 -0.0702 -0.0404 -0.1561 -0.0518 -0.1420 -0.1481 -0.2817 -0.0393 -0.2362 -0.0623 -0.1835 -0.5133 -0.0428 -0.1420 -0.3092 -0.1370 -0.9916 -0.3078 -0.0919 -0.3300 -0.0291 -0.0767 -0.0594 -0.7568 -0.0598 -0.4556 -0.1738 -0.0626 -0.0683 -0.4909 -0.1487 -0.1496 -0.0405 -0.0861 -0.1457 -0.2839 -0.0367 -0.1525 -0.4224 -0.0659 -0.0488 -0.1331 -0.1062 -0.1525 -0.1532 -0.0155 -0.0672 -0.0916 -0.0882 -0.2540 -0.3727 -0.1616 -0.7982 -0.2448 -0.0600 -0.2495 -0.1279 -0.1740 -0.1026 -0.1363 -0.4287 -0.3792 -0.1805 -0.1451 -0.1764
S-733	In Verbindung mit Operationen Katheterinfektionen , geringere Anzahl der roten Blutkörperchen , Anschwellen von Gliedmaßen und Gelenken , verlängerte Blutung nach der Entfernung einer Drainage , verminderter Faktor-VIII-Spiegel und postoperative Hämatome .
T-733	Related to surgery catheter-related infection , decreased red cell blood count , swelling of limbs and joints , prolonged bleeding after drain removal , decreased Factor VIII level and post-operative bruise .
H-733	-0.41798293590545654	In association with surgery , catheter infections , decreased red blood cell count , swelling of limbs and joints , prolonged haemorrhage following drainage removal , decreased factor VII and postoperative haematoma .
D-733	-0.41798293590545654	In association with surgery , catheter infections , decreased red blood cell count , swelling of limbs and joints , prolonged haemorrhage following drainage removal , decreased factor VII and postoperative haematoma .
P-733	-0.6892 -0.7081 -0.1285 -0.9992 -0.3202 -1.4477 -0.2148 -2.9454 -0.9658 -0.0284 -0.1497 -1.0402 -0.0785 -0.0689 -0.0308 -0.0710 -0.4616 -0.1423 -0.2910 -0.1352 -0.3958 -0.4108 -0.4944 -0.0871 -0.1462 -0.0959 -0.0307 -0.1413 -0.2050 -0.1096 -0.0790 -0.6941 -0.0966 -0.0092 -0.1390 -0.9529 -1.4125 -0.2411 -0.1326 -0.3642 -0.1639 -0.1152 -0.0574 -0.3857 -0.4017 -1.0648 -0.7817 -0.0139 -0.2204 -0.0861 -0.0338 -0.1404 -0.9138 -1.2718 -0.1837
S-421	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-421	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-421	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
D-421	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
P-421	-0.7975 -0.0480 -0.1256 -1.1340 -0.1541 -0.1542 -0.5073 -1.1163 -0.1150 -0.1606 -0.2885 -0.0903 -0.1213 -0.5049 -0.2090 -1.4191 -0.1445 -0.1412 -0.1694 -0.4869 -0.0578 -0.1485 -0.1207 -0.9647 -1.0385 -0.2524 -0.1176 -0.1793 -0.8504 -0.3489 -0.0304 -0.1090 -0.0849 -0.1039 -0.1266 -1.1515 -0.7549 -0.0194 -0.3434 -0.8392 -1.0103 -0.4757 -0.0425 -0.1008 -0.9969 -0.2144 -0.1511 -0.1483 -0.1596 -0.0916 -0.1693 -0.0771 -0.1400 -0.1275 -0.1720
S-561	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-561	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-561	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
D-561	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
P-561	-0.7975 -0.0480 -0.1256 -1.1340 -0.1541 -0.1542 -0.5073 -1.1163 -0.1150 -0.1606 -0.2885 -0.0903 -0.1213 -0.5049 -0.2090 -1.4191 -0.1445 -0.1412 -0.1694 -0.4869 -0.0578 -0.1485 -0.1207 -0.9647 -1.0385 -0.2524 -0.1176 -0.1793 -0.8504 -0.3489 -0.0304 -0.1090 -0.0849 -0.1039 -0.1266 -1.1515 -0.7549 -0.0194 -0.3434 -0.8392 -1.0103 -0.4757 -0.0425 -0.1008 -0.9969 -0.2144 -0.1511 -0.1483 -0.1596 -0.0916 -0.1693 -0.0771 -0.1400 -0.1275 -0.1720
S-631	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-631	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-631	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
D-631	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
P-631	-0.7975 -0.0480 -0.1256 -1.1340 -0.1541 -0.1542 -0.5073 -1.1163 -0.1150 -0.1606 -0.2885 -0.0903 -0.1213 -0.5049 -0.2090 -1.4191 -0.1445 -0.1412 -0.1694 -0.4869 -0.0578 -0.1485 -0.1207 -0.9647 -1.0385 -0.2524 -0.1176 -0.1793 -0.8504 -0.3489 -0.0304 -0.1090 -0.0849 -0.1039 -0.1266 -1.1515 -0.7549 -0.0194 -0.3434 -0.8392 -1.0103 -0.4757 -0.0425 -0.1008 -0.9969 -0.2144 -0.1511 -0.1483 -0.1596 -0.0916 -0.1693 -0.0771 -0.1400 -0.1275 -0.1720
S-62	Osteonekrose des Kiefers , üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) , wurde bei Krebspatienten berichtet , deren Therapieregime vorwiegend intravenös verabreichte Bisphosphonate enthält .
T-62	Osteonecrosis of the jaw , generally associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in patients with cancer who are receiving treatment regimens including primarily intravenously administered bisphosphonates .
H-62	-0.19739259779453278	Osteonecrosis of the jaw , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in cancer patients whose treatment regimens contain predominantly intravenously administered bisphosphonates .
D-62	-0.19739259779453278	Osteonecrosis of the jaw , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in cancer patients whose treatment regimens contain predominantly intravenously administered bisphosphonates .
P-62	-0.0901 -0.1119 -0.1191 -0.1105 -0.0197 -0.1841 -0.1469 -0.1004 -0.1589 -0.0969 -0.1355 -1.0417 -0.2463 -0.1575 -0.1530 -0.0728 -0.1697 -0.1059 -0.0464 -0.1756 -0.1616 -0.4965 -0.0767 -0.1862 -0.1310 -0.1209 -0.1419 -0.1851 -0.1460 -0.0565 -0.0563 -0.1387 -0.4839 -0.1422 -0.0783 -0.1315 -0.0358 -0.2148 -0.1819 -0.7800 -0.0845 -0.1438 -0.5423 -0.0783 -0.0836 -0.0816 -0.1587 -0.0367 -0.0401 -2.1353 -0.1464 -0.0901 -0.1495 -0.0408 -0.0315 -0.0435 -0.0405 -0.1503 -0.1804
S-491	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-491	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-491	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
D-491	-0.35648688673973083	Repeat injection every 8 24 hours ( 6 24 hours in patients less than 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain a factor VIII activity of 30 60 % ( IU/ dl ) .
P-491	-0.7975 -0.0480 -0.1256 -1.1340 -0.1541 -0.1542 -0.5073 -1.1163 -0.1150 -0.1606 -0.2885 -0.0903 -0.1213 -0.5049 -0.2090 -1.4191 -0.1445 -0.1412 -0.1694 -0.4869 -0.0578 -0.1485 -0.1207 -0.9647 -1.0385 -0.2524 -0.1176 -0.1793 -0.8504 -0.3489 -0.0304 -0.1090 -0.0849 -0.1039 -0.1266 -1.1515 -0.7549 -0.0194 -0.3434 -0.8392 -1.0103 -0.4757 -0.0425 -0.1008 -0.9969 -0.2144 -0.1511 -0.1483 -0.1596 -0.0916 -0.1693 -0.0771 -0.1400 -0.1275 -0.1720
S-161	Osteonekrose des Kiefers , üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) , wurde bei Krebspatienten berichtet , deren Therapieregime vorwiegend intravenös verabreichte Bisphosphonate enthält .
T-161	Osteonecrosis of the jaw , generally associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in patients with cancer who are receiving treatment regimens including primarily intravenously administered bisphosphonates .
H-161	-0.19739259779453278	Osteonecrosis of the jaw , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in cancer patients whose treatment regimens contain predominantly intravenously administered bisphosphonates .
D-161	-0.19739259779453278	Osteonecrosis of the jaw , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in cancer patients whose treatment regimens contain predominantly intravenously administered bisphosphonates .
P-161	-0.0901 -0.1119 -0.1191 -0.1105 -0.0197 -0.1841 -0.1469 -0.1004 -0.1589 -0.0969 -0.1355 -1.0417 -0.2463 -0.1575 -0.1530 -0.0728 -0.1697 -0.1059 -0.0464 -0.1756 -0.1616 -0.4965 -0.0767 -0.1862 -0.1310 -0.1209 -0.1419 -0.1851 -0.1460 -0.0565 -0.0563 -0.1387 -0.4839 -0.1422 -0.0783 -0.1315 -0.0358 -0.2148 -0.1819 -0.7800 -0.0845 -0.1438 -0.5423 -0.0783 -0.0836 -0.0816 -0.1587 -0.0367 -0.0401 -2.1353 -0.1464 -0.0901 -0.1495 -0.0408 -0.0315 -0.0435 -0.0405 -0.1503 -0.1804
S-190	Alendronat Infolge einer oralen Überdosis können Hypocalcämie , Hypophosphatämie und Nebenwirkungen im oberen Gastrointestinaltrakt wie Magenverstimmung , Sodbrennen , Ösophagitis , Gastritis oder Ulzera auftreten .
T-190	Alendronate Hypocalcaemia , hypophosphataemia and upper gastrointestinal adverse reactions , such as upset stomach , heartburn , oesophagitis , gastritis , or ulcer , may result from oral overdose .
H-190	-0.19458019733428955	Alendronate Hypocalcaemia , hypophosphataemia , and upper gastro-intestinal tract undesirable effects such as indigestion , heartburn , oesophagitis , gastritis , or ulcera may occur as a consequence of oral overdose .
D-190	-0.19458019733428955	Alendronate Hypocalcaemia , hypophosphataemia , and upper gastro-intestinal tract undesirable effects such as indigestion , heartburn , oesophagitis , gastritis , or ulcera may occur as a consequence of oral overdose .
P-190	-0.2563 -0.1317 -0.1233 -0.0621 -0.1572 -0.0702 -0.0404 -0.1561 -0.0518 -0.1420 -0.1481 -0.2817 -0.0393 -0.2362 -0.0623 -0.1835 -0.5133 -0.0428 -0.1420 -0.3092 -0.1370 -0.9916 -0.3078 -0.0919 -0.3300 -0.0291 -0.0767 -0.0594 -0.7568 -0.0598 -0.4556 -0.1738 -0.0626 -0.0683 -0.4909 -0.1487 -0.1496 -0.0405 -0.0861 -0.1457 -0.2839 -0.0367 -0.1525 -0.4224 -0.0659 -0.0488 -0.1331 -0.1062 -0.1525 -0.1532 -0.0155 -0.0672 -0.0916 -0.0882 -0.2540 -0.3727 -0.1616 -0.7982 -0.2448 -0.0600 -0.2495 -0.1279 -0.1740 -0.1026 -0.1363 -0.4287 -0.3792 -0.1805 -0.1451 -0.1764
S-300	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-300	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-300	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
D-300	-0.31955814361572266	In pre-treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titre ) inhibitors was observed after transfer from one recombinant factor VII product to another .
P-300	-0.2721 -0.1791 -0.0660 -0.0998 -0.3152 -0.1644 -0.1738 -0.1400 -1.3285 -0.1350 -0.1213 -1.2809 -0.1204 -0.0994 -0.6284 -0.1634 -0.0560 -0.3063 -0.5310 -0.0549 -0.1464 -0.2985 -0.1296 -0.0972 -0.9265 -0.1983 -0.1315 -0.8051 -0.0735 -0.0909 -0.1620 -0.1417 -0.3580 -0.6504 -0.2912 -0.9061 -1.2147 -0.1630 -0.1336 -0.0744 -0.0499 -0.1220 -0.3816 -1.1670 -0.3345 -0.1663 -0.1335 -0.2122 -0.1398 -0.1274 -0.1170 -0.1681 -0.1374 -0.9756 -1.0014 -0.1401 -0.1515 -0.0951 -0.1473 -0.1775
S-222	Resorption Bezogen auf eine intravenöse Referenzdosis betrug die mittlere orale Bioverfügbarkeit von Alendronat bei Frauen 0,64 % für Dosen zwischen 5 und 70 mg nach nächtlichem Fasten und zwei Stunden vor Aufnahme eines standardisierten Frühstücks .
T-222	Absorption Relative to an intravenous reference dose , the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast .
H-222	-0.3837279975414276	Absorption For a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after night fasting and two hours prior to the initiation of a standardized breakfast .
D-222	-0.3837279975414276	Absorption For a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after night fasting and two hours prior to the initiation of a standardized breakfast .
P-222	-0.2292 -0.0044 -0.0846 -1.1876 -1.7585 -0.1165 -0.0824 -0.0557 -0.0505 -0.0897 -0.0988 -0.1574 -0.1274 -0.0670 -0.1636 -0.1394 -0.0525 -0.1412 -0.1738 -0.1452 -0.1129 -0.0708 -0.5292 -0.7092 -0.1324 -0.2275 -0.0810 -0.1503 -0.1229 -0.2791 -0.1285 -1.1913 -0.1578 -0.1927 -0.0894 -0.0565 -0.4629 -1.3320 -1.3515 -0.6355 -0.1417 -0.5507 -0.0887 -1.4235 -0.1410 -2.3161 -1.4313 -0.0845 -0.1387 -0.3525 -0.6899 -0.4917 -0.2392 -0.0811 -0.2086 -0.1708
S-384	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-384	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-384	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
D-384	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
P-384	-0.4726 -0.1055 -0.0322 -0.1656 -0.0539 -0.1884 -0.9464 -0.1043 -0.0144 -0.0818 -0.1435 -0.1789 -0.1971 -0.2564 -0.2072 -0.1257 -0.2086 -2.2076 -0.1904 -0.0905 -0.1005 -0.0756 -0.6495 -1.7502 -2.3667 -0.1287 -0.7128 -0.0992 -0.0464 -0.0524 -0.2452 -0.2612 -0.1443 -0.8328 -0.2372 -0.3213 -0.2648 -1.4064 -0.0892 -0.0971 -0.9214 -0.7938 -0.1272 -0.4363 -0.0609 -0.1171 -0.5432 -1.1187 -0.1336 -0.1253 -0.1686
S-119	Resorption Bezogen auf eine intravenöse Referenzdosis betrug die mittlere orale Bioverfügbarkeit von Alendronat bei Frauen 0,64 % für Dosen zwischen 5 und 70 mg nach nächtlichem Fasten und zwei Stunden vor Aufnahme eines standardisierten Frühstücks .
T-119	Absorption Relative to an intravenous reference dose , the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast .
H-119	-0.3837279975414276	Absorption For a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after night fasting and two hours prior to the initiation of a standardized breakfast .
D-119	-0.3837279975414276	Absorption For a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after night fasting and two hours prior to the initiation of a standardized breakfast .
P-119	-0.2292 -0.0044 -0.0846 -1.1876 -1.7585 -0.1165 -0.0824 -0.0557 -0.0505 -0.0897 -0.0988 -0.1574 -0.1274 -0.0670 -0.1636 -0.1394 -0.0525 -0.1412 -0.1738 -0.1452 -0.1129 -0.0708 -0.5292 -0.7092 -0.1324 -0.2275 -0.0810 -0.1503 -0.1229 -0.2791 -0.1285 -1.1913 -0.1578 -0.1927 -0.0894 -0.0565 -0.4629 -1.3320 -1.3515 -0.6355 -0.1417 -0.5507 -0.0887 -1.4235 -0.1410 -2.3161 -1.4313 -0.0845 -0.1387 -0.3525 -0.6899 -0.4917 -0.2392 -0.0811 -0.2086 -0.1708
S-314	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-314	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-314	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
D-314	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
P-314	-0.4726 -0.1055 -0.0322 -0.1656 -0.0539 -0.1884 -0.9464 -0.1043 -0.0144 -0.0818 -0.1435 -0.1789 -0.1971 -0.2564 -0.2072 -0.1257 -0.2086 -2.2076 -0.1904 -0.0905 -0.1005 -0.0756 -0.6495 -1.7502 -2.3667 -0.1287 -0.7128 -0.0992 -0.0464 -0.0524 -0.2452 -0.2612 -0.1443 -0.8328 -0.2372 -0.3213 -0.2648 -1.4064 -0.0892 -0.0971 -0.9214 -0.7938 -0.1272 -0.4363 -0.0609 -0.1171 -0.5432 -1.1187 -0.1336 -0.1253 -0.1686
S-113	In der mit Alendronat behandelten Gruppe wurde im Vergleich zur Plazebo-Gruppe eine Reduktion um 48 % ( Alendronat 3,2 % gegenüber Plazebo 6,2 % ) bei dem Anteil von Patientinnen , die eine oder mehrere Wirbelfrakturen erlitten , erreicht .
T-113	There was a 48 % reduction ( alendronate 3.2 % vs placebo 6.2 % ) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo .
H-113	-0.29968321323394775	In the alendronate treated group there was a 48 % reduction ( 3.2 % alendronate versus 6.2 % placebo ) in the proportion of patients who experienced one or more vertebral fractures compared to placebo .
D-113	-0.29968321323394775	In the alendronate treated group there was a 48 % reduction ( 3.2 % alendronate versus 6.2 % placebo ) in the proportion of patients who experienced one or more vertebral fractures compared to placebo .
P-113	-0.1805 -0.1085 -0.2397 -0.1446 -0.1226 -0.1154 -0.0482 -0.2162 -2.2888 -0.1716 -0.1705 -0.1970 -0.1463 -0.1544 -0.2531 -1.7203 -0.1466 -0.1219 -0.6053 -0.1337 -0.1817 -0.0600 -0.5992 -0.2695 -0.1442 -0.1479 -0.0815 -0.1725 -0.2208 -0.1483 -0.1661 -0.3531 -0.1003 -0.0716 -0.1368 -0.7764 -0.3069 -1.9159 -0.5235 -0.1652 -0.0577 -0.5812 -0.1873 -0.0470 -0.0844 -0.0375 -0.0832 -0.1153 -0.1805 -0.3594 -0.1395 -0.1155 -0.1573 -0.3315 -0.1787
S-454	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-454	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-454	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
D-454	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
P-454	-0.4726 -0.1055 -0.0322 -0.1656 -0.0539 -0.1884 -0.9464 -0.1043 -0.0144 -0.0818 -0.1435 -0.1789 -0.1971 -0.2564 -0.2072 -0.1257 -0.2086 -2.2076 -0.1904 -0.0905 -0.1005 -0.0756 -0.6495 -1.7502 -2.3667 -0.1287 -0.7128 -0.0992 -0.0464 -0.0524 -0.2452 -0.2612 -0.1443 -0.8328 -0.2372 -0.3213 -0.2648 -1.4064 -0.0892 -0.0971 -0.9214 -0.7938 -0.1272 -0.4363 -0.0609 -0.1171 -0.5432 -1.1187 -0.1336 -0.1253 -0.1686
S-524	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-524	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-524	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
D-524	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
P-524	-0.4726 -0.1055 -0.0322 -0.1656 -0.0539 -0.1884 -0.9464 -0.1043 -0.0144 -0.0818 -0.1435 -0.1789 -0.1971 -0.2564 -0.2072 -0.1257 -0.2086 -2.2076 -0.1904 -0.0905 -0.1005 -0.0756 -0.6495 -1.7502 -2.3667 -0.1287 -0.7128 -0.0992 -0.0464 -0.0524 -0.2452 -0.2612 -0.1443 -0.8328 -0.2372 -0.3213 -0.2648 -1.4064 -0.0892 -0.0971 -0.9214 -0.7938 -0.1272 -0.4363 -0.0609 -0.1171 -0.5432 -1.1187 -0.1336 -0.1253 -0.1686
S-594	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-594	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-594	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
D-594	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
P-594	-0.4726 -0.1055 -0.0322 -0.1656 -0.0539 -0.1884 -0.9464 -0.1043 -0.0144 -0.0818 -0.1435 -0.1789 -0.1971 -0.2564 -0.2072 -0.1257 -0.2086 -2.2076 -0.1904 -0.0905 -0.1005 -0.0756 -0.6495 -1.7502 -2.3667 -0.1287 -0.7128 -0.0992 -0.0464 -0.0524 -0.2452 -0.2612 -0.1443 -0.8328 -0.2372 -0.3213 -0.2648 -1.4064 -0.0892 -0.0971 -0.9214 -0.7938 -0.1272 -0.4363 -0.0609 -0.1171 -0.5432 -1.1187 -0.1336 -0.1253 -0.1686
S-664	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-664	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-664	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
D-664	-0.3999691605567932	Of the 182 treated patients tested for antibodies to CHO cell protein , 3 showed statistically significant upticks in linear regression analysis , and 4 of these exhibited sustained peaks or transient spikes .
P-664	-0.4726 -0.1055 -0.0322 -0.1656 -0.0539 -0.1884 -0.9464 -0.1043 -0.0144 -0.0818 -0.1435 -0.1789 -0.1971 -0.2564 -0.2072 -0.1257 -0.2086 -2.2076 -0.1904 -0.0905 -0.1005 -0.0756 -0.6495 -1.7502 -2.3667 -0.1287 -0.7128 -0.0992 -0.0464 -0.0524 -0.2452 -0.2612 -0.1443 -0.8328 -0.2372 -0.3213 -0.2648 -1.4064 -0.0892 -0.0971 -0.9214 -0.7938 -0.1272 -0.4363 -0.0609 -0.1171 -0.5432 -1.1187 -0.1336 -0.1253 -0.1686
S-20	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der chronischen Hyperurikämie , wenn bereits Uratablagerungen auftraten , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen .
T-20	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der chronischen Hyperurikämie , wenn bereits Uratablagerungen auftraten , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen . The Committee recommended that Adenuric be given marketing authorisation .
H-20	-0.27514150738716125	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der Chronic Hyperurikämie , if already Uratdeposition occurred , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen . The Committee recommended that Adenuric be given marketing authorisation .
D-20	-0.27514150738716125	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der Chronic Hyperurikämie , if already Uratdeposition occurred , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen . The Committee recommended that Adenuric be given marketing authorisation .
P-20	-0.2685 -0.0062 -0.1058 -0.0429 -0.0189 -0.0124 -0.0322 -0.1073 -0.0029 -0.0079 -0.0949 -0.0324 -0.0969 -0.2621 -0.0549 -0.1681 -0.0333 -0.0711 -0.0137 -0.0810 -1.2782 -2.2433 -0.0817 -0.1098 -0.0637 -0.0173 -0.0824 -0.1172 -4.6302 -2.5672 -1.1575 -0.1105 -0.3238 -0.4021 -0.5317 -0.1608 -0.0594 -0.1424 -0.1191 -0.0170 -0.1310 -0.1460 -0.0396 -0.1976 -0.0046 -0.1174 -0.0290 -0.0635 -0.0460 -0.1371 -0.0740 -0.0247 -0.0268 -0.1679 -0.1147 -0.2617 -0.0607 -0.1977 -0.0476 -0.0222 -0.0330 -0.1111 -1.5409 -0.0559 -0.0657 -0.1701 -0.4505 -0.2895 -0.0455 -0.1559 -0.0727 -0.0451 -0.0089 -0.0245 -0.0842 -0.2204 -0.1735
S-216	In der mit Alendronat behandelten Gruppe wurde im Vergleich zur Plazebo-Gruppe eine Reduktion um 48 % ( Alendronat 3,2 % gegenüber Plazebo 6,2 % ) bei dem Anteil von Patientinnen , die eine oder mehrere Wirbelfrakturen erlitten , erreicht .
T-216	There was a 48 % reduction ( alendronate 3.2 % vs placebo 6.2 % ) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo .
H-216	-0.29968321323394775	In the alendronate treated group there was a 48 % reduction ( 3.2 % alendronate versus 6.2 % placebo ) in the proportion of patients who experienced one or more vertebral fractures compared to placebo .
D-216	-0.29968321323394775	In the alendronate treated group there was a 48 % reduction ( 3.2 % alendronate versus 6.2 % placebo ) in the proportion of patients who experienced one or more vertebral fractures compared to placebo .
P-216	-0.1805 -0.1085 -0.2397 -0.1446 -0.1226 -0.1154 -0.0482 -0.2162 -2.2888 -0.1716 -0.1705 -0.1970 -0.1463 -0.1544 -0.2531 -1.7203 -0.1466 -0.1219 -0.6053 -0.1337 -0.1817 -0.0600 -0.5992 -0.2695 -0.1442 -0.1479 -0.0815 -0.1725 -0.2208 -0.1483 -0.1661 -0.3531 -0.1003 -0.0716 -0.1368 -0.7764 -0.3069 -1.9159 -0.5235 -0.1652 -0.0577 -0.5812 -0.1873 -0.0470 -0.0844 -0.0375 -0.0832 -0.1153 -0.1805 -0.3594 -0.1395 -0.1155 -0.1573 -0.3315 -0.1787
S-595	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-595	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-595	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
D-595	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
P-595	-1.3522 -0.0930 -1.4229 -0.2694 -0.3060 -0.0225 -0.0962 -0.1128 -0.1269 -0.3451 -2.1635 -0.1428 -0.2510 -0.0593 -0.0210 -0.2103 -0.0223 -0.5935 -0.8256 -0.3404 -0.2918 -0.2972 -0.0821 -0.2413 -0.3172 -0.1393 -0.2679 -0.3464 -0.2367 -1.1636 -0.1228 -0.1089 -0.2331 -0.1021 -1.5989 -0.0136 -0.9546 -0.6656 -0.1269 -0.3172 -0.0940 -0.0987 -0.1087 -0.1169 -0.0341 -0.0770 -0.1712 -0.1813
S-316	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-316	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-316	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
D-316	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
P-316	-0.3981 -0.1082 -0.0326 -0.1655 -0.0383 -0.7388 -0.5621 -0.1007 -0.0152 -0.0711 -0.1672 -0.4197 -0.4510 -0.8368 -0.1647 -0.1350 -0.1380 -2.3108 -0.2061 -0.0909 -0.0960 -0.0653 -0.7228 -2.8566 -1.1647 -0.0560 -1.3093 -0.1259 -0.2243 -0.0993 -0.0601 -0.0553 -0.2555 -0.1685 -1.4033 -0.2421 -0.1582 -0.4861 -0.1198 -0.2194 -1.2714 -0.0814 -0.1948 -0.0323 -0.1584 -0.9226 -0.0594 -0.0999 -0.0966 -0.1281 -0.1720
S-665	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-665	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-665	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
D-665	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
P-665	-1.3522 -0.0930 -1.4229 -0.2694 -0.3060 -0.0225 -0.0962 -0.1128 -0.1269 -0.3451 -2.1635 -0.1428 -0.2510 -0.0593 -0.0210 -0.2103 -0.0223 -0.5935 -0.8256 -0.3404 -0.2918 -0.2972 -0.0821 -0.2413 -0.3172 -0.1393 -0.2679 -0.3464 -0.2367 -1.1636 -0.1228 -0.1089 -0.2331 -0.1021 -1.5989 -0.0136 -0.9546 -0.6656 -0.1269 -0.3172 -0.0940 -0.0987 -0.1087 -0.1169 -0.0341 -0.0770 -0.1712 -0.1813
S-456	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-456	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-456	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
D-456	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
P-456	-0.3981 -0.1082 -0.0326 -0.1655 -0.0383 -0.7388 -0.5621 -0.1007 -0.0152 -0.0711 -0.1672 -0.4197 -0.4510 -0.8368 -0.1647 -0.1350 -0.1380 -2.3108 -0.2061 -0.0909 -0.0960 -0.0653 -0.7228 -2.8566 -1.1647 -0.0560 -1.3093 -0.1259 -0.2243 -0.0993 -0.0601 -0.0553 -0.2555 -0.1685 -1.4033 -0.2421 -0.1582 -0.4861 -0.1198 -0.2194 -1.2714 -0.0814 -0.1948 -0.0323 -0.1584 -0.9226 -0.0594 -0.0999 -0.0966 -0.1281 -0.1720
S-525	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-525	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-525	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
D-525	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
P-525	-1.3522 -0.0930 -1.4229 -0.2694 -0.3060 -0.0225 -0.0962 -0.1128 -0.1269 -0.3451 -2.1635 -0.1428 -0.2510 -0.0593 -0.0210 -0.2103 -0.0223 -0.5935 -0.8256 -0.3404 -0.2918 -0.2972 -0.0821 -0.2413 -0.3172 -0.1393 -0.2679 -0.3464 -0.2367 -1.1636 -0.1228 -0.1089 -0.2331 -0.1021 -1.5989 -0.0136 -0.9546 -0.6656 -0.1269 -0.3172 -0.0940 -0.0987 -0.1087 -0.1169 -0.0341 -0.0770 -0.1712 -0.1813
S-455	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-455	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-455	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
D-455	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
P-455	-1.3522 -0.0930 -1.4229 -0.2694 -0.3060 -0.0225 -0.0962 -0.1128 -0.1269 -0.3451 -2.1635 -0.1428 -0.2510 -0.0593 -0.0210 -0.2103 -0.0223 -0.5935 -0.8256 -0.3404 -0.2918 -0.2972 -0.0821 -0.2413 -0.3172 -0.1393 -0.2679 -0.3464 -0.2367 -1.1636 -0.1228 -0.1089 -0.2331 -0.1021 -1.5989 -0.0136 -0.9546 -0.6656 -0.1269 -0.3172 -0.0940 -0.0987 -0.1087 -0.1169 -0.0341 -0.0770 -0.1712 -0.1813
S-385	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-385	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-385	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
D-385	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
P-385	-1.3522 -0.0930 -1.4229 -0.2694 -0.3060 -0.0225 -0.0962 -0.1128 -0.1269 -0.3451 -2.1635 -0.1428 -0.2510 -0.0593 -0.0210 -0.2103 -0.0223 -0.5935 -0.8256 -0.3404 -0.2918 -0.2972 -0.0821 -0.2413 -0.3172 -0.1393 -0.2679 -0.3464 -0.2367 -1.1636 -0.1228 -0.1089 -0.2331 -0.1021 -1.5989 -0.0136 -0.9546 -0.6656 -0.1269 -0.3172 -0.0940 -0.0987 -0.1087 -0.1169 -0.0341 -0.0770 -0.1712 -0.1813
S-386	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-386	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-386	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
D-386	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
P-386	-0.3981 -0.1082 -0.0326 -0.1655 -0.0383 -0.7388 -0.5621 -0.1007 -0.0152 -0.0711 -0.1672 -0.4197 -0.4510 -0.8368 -0.1647 -0.1350 -0.1380 -2.3108 -0.2061 -0.0909 -0.0960 -0.0653 -0.7228 -2.8566 -1.1647 -0.0560 -1.3093 -0.1259 -0.2243 -0.0993 -0.0601 -0.0553 -0.2555 -0.1685 -1.4033 -0.2421 -0.1582 -0.4861 -0.1198 -0.2194 -1.2714 -0.0814 -0.1948 -0.0323 -0.1584 -0.9226 -0.0594 -0.0999 -0.0966 -0.1281 -0.1720
S-315	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-315	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-315	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
D-315	-0.3601221740245819	One patient showed both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise there was no evidence or symptom indicative of allergic reaction or hypersensitivity .
P-315	-1.3522 -0.0930 -1.4229 -0.2694 -0.3060 -0.0225 -0.0962 -0.1128 -0.1269 -0.3451 -2.1635 -0.1428 -0.2510 -0.0593 -0.0210 -0.2103 -0.0223 -0.5935 -0.8256 -0.3404 -0.2918 -0.2972 -0.0821 -0.2413 -0.3172 -0.1393 -0.2679 -0.3464 -0.2367 -1.1636 -0.1228 -0.1089 -0.2331 -0.1021 -1.5989 -0.0136 -0.9546 -0.6656 -0.1269 -0.3172 -0.0940 -0.0987 -0.1087 -0.1169 -0.0341 -0.0770 -0.1712 -0.1813
S-526	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-526	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-526	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
D-526	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
P-526	-0.3981 -0.1082 -0.0326 -0.1655 -0.0383 -0.7388 -0.5621 -0.1007 -0.0152 -0.0711 -0.1672 -0.4197 -0.4510 -0.8368 -0.1647 -0.1350 -0.1380 -2.3108 -0.2061 -0.0909 -0.0960 -0.0653 -0.7228 -2.8566 -1.1647 -0.0560 -1.3093 -0.1259 -0.2243 -0.0993 -0.0601 -0.0553 -0.2555 -0.1685 -1.4033 -0.2421 -0.1582 -0.4861 -0.1198 -0.2194 -1.2714 -0.0814 -0.1948 -0.0323 -0.1584 -0.9226 -0.0594 -0.0999 -0.0966 -0.1281 -0.1720
S-596	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-596	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-596	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
D-596	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
P-596	-0.3981 -0.1082 -0.0326 -0.1655 -0.0383 -0.7388 -0.5621 -0.1007 -0.0152 -0.0711 -0.1672 -0.4197 -0.4510 -0.8368 -0.1647 -0.1350 -0.1380 -2.3108 -0.2061 -0.0909 -0.0960 -0.0653 -0.7228 -2.8566 -1.1647 -0.0560 -1.3093 -0.1259 -0.2243 -0.0993 -0.0601 -0.0553 -0.2555 -0.1685 -1.4033 -0.2421 -0.1582 -0.4861 -0.1198 -0.2194 -1.2714 -0.0814 -0.1948 -0.0323 -0.1584 -0.9226 -0.0594 -0.0999 -0.0966 -0.1281 -0.1720
S-666	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-666	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-666	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
D-666	-0.39718326926231384	Of the 182 treated subjects tested for antibodies to murine IgG , 10 showed statistically significant uptrend of titers in linear regression analysis , and 2 of the patients exhibited sustained peak or transient peak .
P-666	-0.3981 -0.1082 -0.0326 -0.1655 -0.0383 -0.7388 -0.5621 -0.1007 -0.0152 -0.0711 -0.1672 -0.4197 -0.4510 -0.8368 -0.1647 -0.1350 -0.1380 -2.3108 -0.2061 -0.0909 -0.0960 -0.0653 -0.7228 -2.8566 -1.1647 -0.0560 -1.3093 -0.1259 -0.2243 -0.0993 -0.0601 -0.0553 -0.2555 -0.1685 -1.4033 -0.2421 -0.1582 -0.4861 -0.1198 -0.2194 -1.2714 -0.0814 -0.1948 -0.0323 -0.1584 -0.9226 -0.0594 -0.0999 -0.0966 -0.1281 -0.1720
S-127	Ausscheidung Nach intravenöser Gabe einer einzelnen Dosis von 14C-Alendronat wurden etwa 50 % der radioaktiv markierten Substanz innerhalb von 72 Stunden mit dem Urin ausgeschieden und wenig oder keine Radioaktivität wurde in den Fäzes wiedergefunden .
T-127	Elimination Following a single intravenous dose of <<unk>> 14C<<unk>> alendronate , approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
H-127	-0.20419611036777496	Excretion Following a single intravenous dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
D-127	-0.20419611036777496	Excretion Following a single intravenous dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
P-127	-0.0777 -0.0824 -0.1119 -0.0781 -0.9268 -0.0302 -0.3433 -0.0320 -0.0361 -0.0991 -0.0771 -0.1516 -0.4069 -0.1238 -0.9455 -0.0755 -0.1255 -0.1119 -0.0672 -0.1394 -0.1306 -0.2570 -0.1255 -0.1433 -0.1371 -0.9599 -0.1047 -0.0076 -0.0193 -0.5965 -0.2230 -0.0419 -0.0146 -0.1070 -0.2473 -0.1058 -0.0983 -0.1425 -0.5947 -0.1194 -0.1282 -0.5612 -0.2963 -0.1591 -0.1877 -0.5327 -0.0484 -0.1231 -0.0541 -0.1531 -0.1160 -0.4034 -0.0301 -0.1147 -0.1337 -0.1752
S-230	Ausscheidung Nach intravenöser Gabe einer einzelnen Dosis von 14C-Alendronat wurden etwa 50 % der radioaktiv markierten Substanz innerhalb von 72 Stunden mit dem Urin ausgeschieden und wenig oder keine Radioaktivität wurde in den Fäzes wiedergefunden .
T-230	Elimination Following a single intravenous dose of <<unk>> 14C<<unk>> alendronate , approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
H-230	-0.20419611036777496	Excretion Following a single intravenous dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
D-230	-0.20419611036777496	Excretion Following a single intravenous dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
P-230	-0.0777 -0.0824 -0.1119 -0.0781 -0.9268 -0.0302 -0.3433 -0.0320 -0.0361 -0.0991 -0.0771 -0.1516 -0.4069 -0.1238 -0.9455 -0.0755 -0.1255 -0.1119 -0.0672 -0.1394 -0.1306 -0.2570 -0.1255 -0.1433 -0.1371 -0.9599 -0.1047 -0.0076 -0.0193 -0.5965 -0.2230 -0.0419 -0.0146 -0.1070 -0.2473 -0.1058 -0.0983 -0.1425 -0.5947 -0.1194 -0.1282 -0.5612 -0.2963 -0.1591 -0.1877 -0.5327 -0.0484 -0.1231 -0.0541 -0.1531 -0.1160 -0.4034 -0.0301 -0.1147 -0.1337 -0.1752
S-786	Bei Betrachtung aller Heuschnupfensymptome außer der Verstopfung der Nase berichteten die Patienten , die Aerinaze einnahmen , über eine Abnahme der Symptome um 46,0 % , verglichen mit 35,9 % bei den Patienten , die Pseudoephedrin allein einnahmen .
T-786	When looking at all hayfever symptoms except for nasal congestion , patients taking Aerinaze reported a reduction in symptoms of 46.0 % , compared with 35.9 % in those taking pseudoephedrine alone .
H-786	-0.33376505970954895	When looking at all hayfever symptoms except nasal constipation , patients taking Aerinaze reported a 46.0 % decrease in symptoms compared to 35.9 % in those taking pseudoephedrine alone .
D-786	-0.33376505970954895	When looking at all hayfever symptoms except nasal constipation , patients taking Aerinaze reported a 46.0 % decrease in symptoms compared to 35.9 % in those taking pseudoephedrine alone .
P-786	-0.1768 -0.4111 -0.1162 -0.1249 -1.3169 -1.2098 -0.1523 -0.0426 -0.1676 -0.0924 -0.3087 -0.0768 -0.1754 -0.1674 -0.1129 -0.0896 -0.0990 -0.1519 -0.0891 -0.0523 -0.5719 -0.1311 -0.1362 -0.3338 -0.1211 -0.0395 -0.1462 -0.1538 -0.1468 -0.1862 -0.1205 -1.3233 -0.2858 -0.1181 -0.2850 -0.6981 -0.2057 -0.2719 -0.1470 -0.1761 -0.1285 -0.3156 -0.6688 -0.1819 -0.2942 -4.3032 -0.2154 -0.1007 -0.1315 -0.3305 -0.1071 -0.1561 -0.1848 -0.1733
S-90	Dennoch traten Abnahmen des Serum-Calciums bis <unk> 8,0 mg<unk> dl ( 2,0 mmol<unk> l ) und des Serum- Phosphats bis 2,0 mg<unk> dl ( 0,65 mmol<unk> l ) in beiden Behandlungsgruppen mit ähnlicher Häufigkeit auf .
T-90	However , the incidences of decreases in serum calcium to <<unk>> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were similar in both treatment groups .
H-90	-0.2301468551158905	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were observed in both treatment groups with similar frequency .
D-90	-0.2301468551158905	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were observed in both treatment groups with similar frequency .
P-90	-0.9755 -0.1568 -1.2964 -0.1413 -0.5906 -0.0735 -0.1125 -0.0929 -0.0908 -0.1187 -0.1276 -0.0030 -0.0555 -0.1501 -0.1568 -0.1172 -0.1425 -0.0558 -0.1584 -0.0699 -0.0930 -0.1691 -0.1368 -0.0721 -0.1306 -0.1608 -0.0824 -0.1220 -0.1131 -0.0366 -0.0932 -0.1339 -0.0804 -0.2045 -0.1174 -0.1245 -0.0275 -0.1593 -0.1723 -0.1175 -0.1637 -0.1806 -0.1377 -0.1038 -0.1287 -0.3229 -1.2338 -0.3415 -0.1244 -0.4963 -0.1008 -0.1542 -0.9938 -0.9801 -0.3148 -0.1289 -0.1794
S-189	Dennoch traten Abnahmen des Serum-Calciums bis <unk> 8,0 mg<unk> dl ( 2,0 mmol<unk> l ) und des Serum- Phosphats bis 2,0 mg<unk> dl ( 0,65 mmol<unk> l ) in beiden Behandlungsgruppen mit ähnlicher Häufigkeit auf .
T-189	However , the incidences of decreases in serum calcium to <<unk>> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were similar in both treatment groups .
H-189	-0.2301468551158905	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were observed in both treatment groups with similar frequency .
D-189	-0.2301468551158905	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were observed in both treatment groups with similar frequency .
P-189	-0.9755 -0.1568 -1.2964 -0.1413 -0.5906 -0.0735 -0.1125 -0.0929 -0.0908 -0.1187 -0.1276 -0.0030 -0.0555 -0.1501 -0.1568 -0.1172 -0.1425 -0.0558 -0.1584 -0.0699 -0.0930 -0.1691 -0.1368 -0.0721 -0.1306 -0.1608 -0.0824 -0.1220 -0.1131 -0.0366 -0.0932 -0.1339 -0.0804 -0.2045 -0.1174 -0.1245 -0.0275 -0.1593 -0.1723 -0.1175 -0.1637 -0.1806 -0.1377 -0.1038 -0.1287 -0.3229 -1.2338 -0.3415 -0.1244 -0.4963 -0.1008 -0.1542 -0.9938 -0.9801 -0.3148 -0.1289 -0.1794
S-816	Desloratadin hemmt in-vivo CYP3A4 nicht , und in-vitro-Studien haben gezeigt , dass das Arzneimittel CYP2D6 nicht hemmt und weder ein Substrat noch ein Inhibitor des P-Glykoproteins ist .
T-816	Desloratadine does not inhibit CYP3A4 in vivo , and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein .
H-816	-0.21156544983386993	Desloratadine does not inhibit CYP3A4 in vivo and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is not a substrate or an inhibitor of P-glycoprotein .
D-816	-0.21156544983386993	Desloratadine does not inhibit CYP3A4 in vivo and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is not a substrate or an inhibitor of P-glycoprotein .
P-816	-1.3489 -0.0399 -0.1591 -0.2649 -0.2328 -0.0970 -0.1110 -0.2096 -0.0425 -0.0197 -0.5852 -0.1174 -0.1677 -0.1772 -0.0510 -0.3268 -0.0467 -0.0391 -0.2186 -0.1691 -0.1055 -0.1320 -0.3270 -0.1943 -0.0373 -0.1026 -0.3451 -1.0533 -0.0619 -0.0454 -0.0707 -0.1158 -0.1647 -0.0926 -0.0250 -0.1668 -0.1142 -0.1709 -0.0995 -0.1031 -0.1629 -0.4823 -0.1145 -0.6491 -0.1807 -0.2333 -0.0559 -0.1146 -0.7478 -0.9596 -0.2505 -0.0568 -0.0475 -0.1549 -0.1372 -0.2963 -0.1877 -0.1166 -0.0774 -0.0670 -0.0769 -0.0970 -0.1449 -0.1766
S-124	Bei gesunden Probanden führte die Gabe von oralem Prednison ( 20 mg dreimal täglich über fünf Tage ) zu keiner klinisch bedeutsamen Veränderung der oralen Bioverfügbarkeit von Alendronat ( Anstieg im Mittel im Bereich von 20 % bis 44 % ) .
T-124	In healthy subjects , oral prednisone ( 20 mg three times daily for five days ) did not produce a clinically meaningful change in oral bioavailability of alendronate ( a mean increase ranging from 20 % to 44 % ) .
H-124	-0.33488866686820984	In healthy subjects , administration of oral prednisone ( 20 mg 3 times daily for five days ) produced no clinically important change in oral bioavailability of alendronate ( average increase in the range of 20 % to 44 % ) .
D-124	-0.33488866686820984	In healthy subjects , administration of oral prednisone ( 20 mg 3 times daily for five days ) produced no clinically important change in oral bioavailability of alendronate ( average increase in the range of 20 % to 44 % ) .
P-124	-0.0944 -0.7880 -0.3020 -0.8675 -0.2111 -0.1451 -0.0467 -0.1824 -0.1145 -1.7966 -0.2284 -0.1125 -0.1241 -0.0634 -1.0881 -0.0485 -0.2238 -0.1834 -0.8169 -0.2434 -0.1353 -2.0470 -0.1068 -0.0384 -0.0805 -0.2099 -0.0748 -0.1254 -0.3772 -0.0353 -0.0725 -0.1472 -0.1668 -0.1384 -0.1007 -0.0637 -0.1783 -1.3687 -0.1845 -0.6738 -0.1264 -0.8846 -0.7984 -0.1745 -0.2112 -0.2102 -0.0870 -0.1210 -0.1437 -0.1367 -0.1799
S-745	Hinweise zur Herstellung der Lösung Nicht nach dem auf Durchstechflaschen und Umkarton angegebenen Haltbarkeitsdatum verwenden . Den BAXJECT II nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist , wie in dem Symbol
T-745	Instructions for reconstitution Do not use after the expiry date stated on the labels and carton . Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-745	-0.3956349790096283	Production instructions Do not use after the expiry date stated on the vial and on the carton .
D-745	-0.3956349790096283	Production instructions Do not use after the expiry date stated on the vial and on the carton .
P-745	-0.6726 -0.4839 -1.4066 -0.5118 -0.1103 -0.0304 -0.8834 -0.1072 -0.5812 -0.0450 -0.0640 -0.1702 -0.0983 -0.1682 -0.1766 -0.8581 -0.1609 -1.2357 -0.1278 -0.1411 -0.0411 -0.6430 -0.3821
S-227	Bei gesunden Probanden führte die Gabe von oralem Prednison ( 20 mg dreimal täglich über fünf Tage ) zu keiner klinisch bedeutsamen Veränderung der oralen Bioverfügbarkeit von Alendronat ( Anstieg im Mittel im Bereich von 20 % bis 44 % ) .
T-227	In healthy subjects , oral prednisone ( 20 mg three times daily for five days ) did not produce a clinically meaningful change in oral bioavailability of alendronate ( a mean increase ranging from 20 % to 44 % ) .
H-227	-0.33488866686820984	In healthy subjects , administration of oral prednisone ( 20 mg 3 times daily for five days ) produced no clinically important change in oral bioavailability of alendronate ( average increase in the range of 20 % to 44 % ) .
D-227	-0.33488866686820984	In healthy subjects , administration of oral prednisone ( 20 mg 3 times daily for five days ) produced no clinically important change in oral bioavailability of alendronate ( average increase in the range of 20 % to 44 % ) .
P-227	-0.0944 -0.7880 -0.3020 -0.8675 -0.2111 -0.1451 -0.0467 -0.1824 -0.1145 -1.7966 -0.2284 -0.1125 -0.1241 -0.0634 -1.0881 -0.0485 -0.2238 -0.1834 -0.8169 -0.2434 -0.1353 -2.0470 -0.1068 -0.0384 -0.0805 -0.2099 -0.0748 -0.1254 -0.3772 -0.0353 -0.0725 -0.1472 -0.1668 -0.1384 -0.1007 -0.0637 -0.1783 -1.3687 -0.1845 -0.6738 -0.1264 -0.8846 -0.7984 -0.1745 -0.2112 -0.2102 -0.0870 -0.1210 -0.1437 -0.1367 -0.1799
S-251	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-251	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-251	-0.09191258251667023	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
D-251	-0.09191258251667023	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
P-251	-0.0046 -0.0054 -0.0142 -0.0069 -0.0118 -0.0439 -0.0047 -0.0128 -0.0986 -0.0145 -0.0133 -0.0109 -0.0315 -0.0006 -0.0329 -0.0163 -0.0912 -0.1491 -0.0616 -0.0334 -0.1329 -0.1379 -0.0874 -0.1000 -0.0294 -0.1608 -0.1374 -0.0155 -0.0847 -0.0030 -0.0256 -0.0355 -0.1065 -0.0089 -0.0194 -0.0085 -0.1286 -0.0666 -0.0441 -0.1315 -0.0631 -0.0367 -0.0707 -0.0059 -0.0163 -0.0578 -0.0142 -0.1397 -0.0023 -0.0483 -0.0213 -0.1722 -0.1084 -1.4818 -0.0100 -0.0788 -0.0139 -0.0620 -0.0296 -0.0190 -0.1235 -0.0219 -0.0207 -0.0819 -0.1079 -0.0584 -0.1371 -0.0123 -0.0417 -1.2558 -0.1431 -0.1196 -0.1726 -0.0215 -0.1431 -0.0575 -0.0340 -0.1436 -0.0319 -0.0150 -0.1160 -0.1088 -0.0301 -0.1393 -0.0863 -0.0318 -0.0868 -0.1036 -0.0483 -0.0374 -0.1605 -0.0505 -0.1186 -0.0908 -0.1319 -0.1653
S-207	Die Patientinnen der 2.800-I.E.-Vitamin-D3-Gruppe erhielten ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 299 ) und die Patientinnen der 5.600-I.E.-Vitamin-D3-Gruppe erhielten ADROVANCE ( 70 mg<unk> 2.800 I.E. ) sowie zusätzlich 2.800 I.E. Vitamin D3 ( n<unk> 309 ) einmal wöchentlich ; weitere Vitamin-D- Ergänzungsmittel waren erlaubt . Nach 24-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher in der 5.600-I.E.-Vitamin-D3-Gruppe ( 69 nmol<unk> l <unk> 27,6 ng<unk> ml <unk> ) als in der 2.800-I.E.-Vitamin-D3-Gruppe ( 64 nmol<unk> l <unk> 25,5 ng<unk> ml <unk> ) .
T-207	After 24-weeks of treatment , the mean serum 25- hydroxyvitamin D levels were significantly higher in the Vitamin D3 5600 group ( 69 nmol/ l <<unk>> 27.6 ng/ ml <<unk>> ) than in the Vitamin D3 2800 group ( 64 nmol/ l <<unk>> 25.5 ng/ ml <<unk>> ) .
H-207	-0.27860701084136963	Patients in the 2,800 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 299 ) and patients in the 5,600 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) and an additional 2,800 IU ) of vitamin D3 ( n/ 309 ) once weekly ; additional vitamin D supplements were allowed ; after 24 weeks of treatment , mean serum levels of 25 hydroxyvitamin D were significantly higher in the 5,600 IU vitamin D3 group ( 69 n/ 27.6 ng/ ml ) than in the 2,800 IU ) .
D-207	-0.27860701084136963	Patients in the 2,800 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 299 ) and patients in the 5,600 IU vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) and an additional 2,800 IU ) of vitamin D3 ( n/ 309 ) once weekly ; additional vitamin D supplements were allowed ; after 24 weeks of treatment , mean serum levels of 25 hydroxyvitamin D were significantly higher in the 5,600 IU vitamin D3 group ( 69 n/ 27.6 ng/ ml ) than in the 2,800 IU ) .
P-207	-0.1315 -0.0886 -0.1204 -0.0981 -0.5248 -0.1284 -0.0636 -0.2270 -0.7799 -0.0862 -0.1427 -0.1947 -0.1766 -1.3137 -0.0732 -0.0617 -0.1596 -0.1156 -0.0636 -0.1491 -0.0923 -0.1197 -0.1360 -0.0946 -0.3896 -0.1164 -0.1062 -0.0716 -0.1232 -0.1501 -0.1856 -0.1830 -0.0856 -0.0449 -0.1275 -0.1760 -0.6772 -0.1308 -0.1099 -0.2640 -0.1718 -0.1560 -0.0569 -0.2184 -0.1574 -0.1270 -0.2295 -0.0834 -0.5516 -0.1673 -0.1173 -0.1623 -0.1211 -0.0603 -0.1563 -0.0915 -0.1351 -0.1220 -0.0945 -0.2033 -0.0846 -0.1239 -0.0721 -0.1254 -1.1452 -0.1088 -0.0903 -0.3135 -0.0887 -0.1351 -0.0450 -0.5843 -0.9738 -0.1057 -0.0425 -0.1143 -0.1931 -0.1157 -0.1583 -0.1277 -0.1220 -0.1289 -0.1421 -0.0995 -0.9985 -0.7223 -0.7412 -0.1609 -0.1085 -0.1973 -0.0256 -0.0705 -0.1675 -0.1827 -0.4093 -2.0167 -0.2558 -0.0466 -0.1228 -0.3475 -0.3193 -0.5762 -0.5282 -0.1138 -0.3226 -0.1232 -0.5219 -0.3616 -0.9658 -0.1235 -0.4362 -0.0970 -0.3224 -0.3008 -0.1848 -0.1216 -0.1307 -0.1198 -1.5638 -0.2735 -0.2373 -0.0618 -0.3119 -0.1330 -0.1512 -0.2771 -0.3614 -0.1577 -0.0592 -0.1760 -1.1639 -1.2965 -0.1596 -0.3021 -1.1609 -0.1230 -0.1264 -0.3723 -0.4757 -0.1196 -0.1188 -2.0269 -0.0865 -0.6048 -0.0559 -0.1359 -0.2022 -0.1885
S-800	- Harnverhalt , - Herz-Kreislauf-Erkrankungen wie ischämische Herzerkrankung , Tachyarrhythmie und schwere Hypertonie , - Hyperthyreose , - einem hämorrhagischen Schlaganfall in der Anamnese oder Risikofaktoren , die das Risiko für das Auftreten eines hämorrhagischen Schlaganfalls erhöhen können . Dies ist auf die alphamimetische Aktivität bei kombinierter Anwendung von Pseudoephedrin mit anderen Vasokonstriktoren wie Bromocripitin , Pergolid , Lisurid , Cabergolin , Ergotamin , Dihydroergotamin oder anderen Dekongestiva , die peroral oder nasal als abschwellendes Rhinologikum angewendet werden ( Phenylpropanolamin , Phenylephrin , Ephedrin , Oxymetazolin , Naphazolin etc. ) zurückzuführen .
T-800	This is due to the alpha-mimetic activity of pseudoephedrine in combination with other vasoconstrictors such as bromocripitine , pergolide , lisuride , cabergoline , ergotamine , dihydroergotamine or any other decongestant medicinal product used as a nasal decongestant , either by oral route or by nasal route ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazoline ) .
H-800	-0.5620003938674927	This is attributable to the alphamimetic activity of the combined administration of pseudoephedrine with other vasoconstrictors , such as bromocripine , pergolide , lisuride , cabergolin , ergotamine , dihydroergotamine , or other decongestives used perorally or nasally as degrading rhinologic agents ( phenylephrine , ephedrine , naphazolin etc. ) .
D-800	-0.5620003938674927	This is attributable to the alphamimetic activity of the combined administration of pseudoephedrine with other vasoconstrictors , such as bromocripine , pergolide , lisuride , cabergolin , ergotamine , dihydroergotamine , or other decongestives used perorally or nasally as degrading rhinologic agents ( phenylephrine , ephedrine , naphazolin etc. ) .
P-800	-2.5428 -0.3978 -0.8370 -0.0879 -0.1343 -0.1727 -0.2246 -0.0533 -0.0433 -0.1316 -0.1657 -0.1992 -0.0666 -0.3766 -2.5951 -1.7469 -1.3750 -0.1609 -0.3609 -3.6843 -0.3072 -0.0468 -0.2475 -0.3820 -0.0863 -0.2904 -0.0736 -0.8841 -0.1066 -0.3512 -0.1908 -0.1497 -2.2574 -2.1084 -0.1750 -0.1483 -0.2106 -0.1943 -0.0461 -0.5221 -0.3680 -0.1424 -0.2290 -0.3113 -0.0632 -0.4919 -0.1490 -0.3385 -0.5499 -1.9176 -0.3153 -0.1447 -3.2970 -1.9156 -1.4733 -0.2830 -0.1434 -0.2856 -0.2306 -0.1353 -0.0753 -0.1569 -0.4705 -0.0701 -3.6144 -0.1024 -0.1193 -0.3187 -0.4811 -0.1247 -0.1411 -0.1150 -0.3104 -2.1164 -0.5389 -0.6201 -1.1145 -0.0466 -0.1474 -0.2112 -0.1525 -0.0753 -0.1365 -1.7364 -0.4926 -0.1851 -0.5146 -0.0818 -2.1239 -0.4265 -0.0021 -0.3562 -0.4246 -0.7203 -0.9499 -0.3464 -0.7707 -0.1142 -0.1462 -0.1234 -0.2528 -0.2750 -0.0833 -0.1333 -1.0642 -0.4812 -0.6288 -0.2132 -1.9506 -0.2873 -0.4167 -0.1666 -0.1963 -0.2252
S-106	In dieser Studie stiegen nach 15 Wochen die mittleren Serumwerte von 25-Hydroxyvitamin D bei Patienten mit Vitamin-D-Insuffizienz bei Studienbeginn ( 25-Hydroxyvitamin D 22,5 bis 37,5 nmol<unk> l <unk> 9 - <unk> 15 ng<unk> ml <unk> ) von 30 nmol<unk> l ( 12,1 ng<unk> ml ) auf 40 nmol<unk> l ( 15,9 ng<unk> ml ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 75 ) und sanken von 30 nmol<unk> l ( 12,0 ng<unk> ml ) bei Studienbeginn auf 26 nmol<unk> l ( 10,4 ng<unk> ml ) in der Gruppe unter Alendronat allein ( n<unk> 70 ) .
T-106	In this study , mean 25-hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline ( 25- hydroxyvitamin D , 22.5 to 37.5 nmol/ l <<unk>> 9 to <<unk>> 15 ng/ ml <<unk>> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) at week 15 in the ADROVANCE ( 70 mg/ 2800 IU ) group ( n<<unk>> 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at baseline to 26 nmol/ l ( 10.4 ng/ ml ) at week 15 in the alendronate-only group ( n<<unk>> 70 ) .
H-106	-0.29883435368537903	In this trial mean serum concentrations of 25-hydroxyvitamin D in patients with vitamin D insufficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l <unk> 9 <unk> 15 ng/ ml <unk> ) increased to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 ng/ ml ) ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) after 15 weeks .
D-106	-0.29883435368537903	In this trial mean serum concentrations of 25-hydroxyvitamin D in patients with vitamin D insufficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l <unk> 9 <unk> 15 ng/ ml <unk> ) increased to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 ng/ ml ) ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) after 15 weeks .
P-106	-1.1690 -0.2213 -1.1333 -0.2798 -0.3107 -0.1368 -1.2420 -0.0081 -0.0530 -0.3197 -0.3638 -0.1098 -0.0723 -0.2758 -0.1187 -0.1682 -0.0740 -0.0719 -0.1341 -0.5952 -0.1256 -0.4544 -0.0518 -0.0663 -1.7413 -0.0885 -0.0374 -0.0902 -0.2520 -0.1421 -0.2100 -0.4673 -0.1289 -0.7099 -0.1129 -1.3973 -0.1279 -0.0455 -0.2715 -0.1299 -0.1864 -0.0703 -0.0725 -0.0878 -0.1326 -0.1906 -0.1117 -0.0804 -0.1352 -0.5350 -0.1994 -0.2920 -0.1308 -0.1001 -1.9134 -0.2337 -0.2023 -0.1978 -0.1243 -0.0457 -0.1481 -0.1175 -0.9256 -0.3732 -0.0695 -0.1808 -1.1582 -0.1414 -0.1492 -0.1724 -0.1139 -0.1096 -0.2059 -0.2447 -0.1314 -0.1030 -0.1403 -0.1349 -0.0978 -0.1246 -0.1337 -0.2037 -0.1818 -0.0493 -0.1154 -0.0770 -0.1526 -0.1477 -0.1267 -1.0182 -0.0884 -0.1395 -0.0756 -0.1272 -0.2811 -0.1698 -0.6079 -0.0458 -0.1492 -1.3481 -0.2076 -0.0823 -0.1728 -0.1156 -0.1897 -0.5068 -0.1413 -0.1172 -0.1642 -0.1613 -0.1512 -0.1528 -0.4313 -0.1238 -0.0863 -0.1445 -0.1860 -0.1221 -0.2322 -0.1348 -0.1140 -0.0385 -0.1212 -0.2384 -0.1836 -0.6401 -0.1314 -0.6650 -0.1984 -0.1677 -0.0934 -0.1890 -0.2490 -0.5276 -0.1331 -1.6824 -0.1446 -0.1599 -0.1163 -1.7598 -0.1501 -0.4791 -0.0501 -1.1506 -0.1028 -0.1955 -0.3148 -0.0653 -1.5722 -1.5921 -0.1841 -0.0499 -0.1192 -0.1865
S-204	In dieser Studie stiegen nach 15 Wochen die mittleren Serumwerte von 25-Hydroxyvitamin D bei Patienten mit Vitamin-D-Insuffizienz bei Studienbeginn ( 25-Hydroxyvitamin D 22,5 bis 37,5 nmol<unk> l <unk> 9 - <unk> 15 ng<unk> ml <unk> ) von 30 nmol<unk> l ( 12,1 ng<unk> ml ) auf 40 nmol<unk> l ( 15,9 ng<unk> ml ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 75 ) und sanken von 30 nmol<unk> l ( 12,0 ng<unk> ml ) bei Studienbeginn auf 26 nmol<unk> l ( 10,4 ng<unk> ml ) in der Gruppe unter Alendronat allein ( n<unk> 70 ) .
T-204	In this study , mean 25- hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline ( 25- hydroxyvitamin D , 22.5 to 37.5 nmol/ l <<unk>> 9 to <<unk>> 15 ng/ ml <<unk>> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) at week 15 in the ADROVANCE ( 70 mg/ 2800 IU ) group ( n<<unk>> 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at baseline to 26 nmol/ l ( 10.4 ng/ ml ) at week 15 in the alendronate-only group ( n<<unk>> 70 ) .
H-204	-0.29883435368537903	In this trial mean serum concentrations of 25-hydroxyvitamin D in patients with vitamin D insufficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l <unk> 9 <unk> 15 ng/ ml <unk> ) increased to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 ng/ ml ) ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) after 15 weeks .
D-204	-0.29883435368537903	In this trial mean serum concentrations of 25-hydroxyvitamin D in patients with vitamin D insufficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l <unk> 9 <unk> 15 ng/ ml <unk> ) increased to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 ng/ ml ) ( 10.4 ng/ ml ) in the alendronate alone ( n/ 70 ) after 15 weeks .
P-204	-1.1690 -0.2213 -1.1333 -0.2798 -0.3107 -0.1368 -1.2420 -0.0081 -0.0530 -0.3197 -0.3638 -0.1098 -0.0723 -0.2758 -0.1187 -0.1682 -0.0740 -0.0719 -0.1341 -0.5952 -0.1256 -0.4544 -0.0518 -0.0663 -1.7413 -0.0885 -0.0374 -0.0902 -0.2520 -0.1421 -0.2100 -0.4673 -0.1289 -0.7099 -0.1129 -1.3973 -0.1279 -0.0455 -0.2715 -0.1299 -0.1864 -0.0703 -0.0725 -0.0878 -0.1326 -0.1906 -0.1117 -0.0804 -0.1352 -0.5350 -0.1994 -0.2920 -0.1308 -0.1001 -1.9134 -0.2337 -0.2023 -0.1978 -0.1243 -0.0457 -0.1481 -0.1175 -0.9256 -0.3732 -0.0695 -0.1808 -1.1582 -0.1414 -0.1492 -0.1724 -0.1139 -0.1096 -0.2059 -0.2447 -0.1314 -0.1030 -0.1403 -0.1349 -0.0978 -0.1246 -0.1337 -0.2037 -0.1818 -0.0493 -0.1154 -0.0770 -0.1526 -0.1477 -0.1267 -1.0182 -0.0884 -0.1395 -0.0756 -0.1272 -0.2811 -0.1698 -0.6079 -0.0458 -0.1492 -1.3481 -0.2076 -0.0823 -0.1728 -0.1156 -0.1897 -0.5068 -0.1413 -0.1172 -0.1642 -0.1613 -0.1512 -0.1528 -0.4313 -0.1238 -0.0863 -0.1445 -0.1860 -0.1221 -0.2322 -0.1348 -0.1140 -0.0385 -0.1212 -0.2384 -0.1836 -0.6401 -0.1314 -0.6650 -0.1984 -0.1677 -0.0934 -0.1890 -0.2490 -0.5276 -0.1331 -1.6824 -0.1446 -0.1599 -0.1163 -1.7598 -0.1501 -0.4791 -0.0501 -1.1506 -0.1028 -0.1955 -0.3148 -0.0653 -1.5722 -1.5921 -0.1841 -0.0499 -0.1192 -0.1865
S-85	Uveitis , Skleritis , Episkleritis . Häufig : Bauchschmerzen , Dyspepsie , Verstopfung , Durchfall , Flatulenz , ösophageales Ulkus* , Dysphagie* , aufgetriebenes Abdomen , saures Aufstoßen . Gelegentlich : Übelkeit , Erbrechen , Gastritis , Ösophagitis* , ösophageale Erosionen* , Meläna . Selten : Ösophagusstriktur* , oropharyngeale Ulzerationen* , Perforationen , Ulzera und Blutungen im oberen Gastrointestinaltrakt ( siehe Abschnitt 4.4<unk> . * Siehe Abschnitte 4.2 und 4.4 .
T-85	Rare : uveitis , scleritis , episcleritis Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcer* , dysphagia* , abdominal distension , acid regurgitation Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena Rare : oesophageal stricture* , oropharyngeal ulceration* , upper gastrointestinal PUBs ( perforation , ulcers , bleeding<<unk>> <<unk>> see section 4.4 ) . <<unk>> See sections 4.2 and 4.4
H-85	-0.34319740533828735	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophagitis* , oesophageal erosion* , dysphagiars* , inflated abdomen , acid relapse . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melanina . Rare : oesophagus strict* , oropharyngeal ulceration* , perforations , ulcera , and haemorrhage in the upper gastro-intestinal tract ( see sections 4.4 ) .
D-85	-0.34319740533828735	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophagitis* , oesophageal erosion* , dysphagiars* , inflated abdomen , acid relapse . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melanina . Rare : oesophagus strict* , oropharyngeal ulceration* , perforations , ulcera , and haemorrhage in the upper gastro-intestinal tract ( see sections 4.4 ) .
P-85	-0.5270 -0.1569 -0.1180 -0.1488 -0.2134 -1.8562 -0.0350 -0.2181 -0.1524 -0.3523 -0.4304 -0.1169 -0.2326 -0.3352 -0.0101 -0.1030 -0.1506 -0.1209 -0.0301 -0.0934 -0.1151 -0.1431 -0.2235 -0.0802 -0.0934 -0.0440 -0.1390 -0.0659 -0.0368 -0.0968 -0.1104 -0.1406 -0.1962 -0.0470 -0.0338 -0.0996 -0.1451 -0.8865 -0.0492 -0.1829 -0.1457 -0.1954 -0.1010 -3.1888 -0.1834 -0.2684 -1.3906 -0.1649 -0.1507 -0.2243 -0.1117 -0.1767 -0.0745 -0.0706 -0.1301 -1.0898 -0.0165 -0.0818 -0.1461 -0.2816 -0.0577 -0.2767 -3.7830 -3.0385 -0.1963 -0.1421 -0.1786 -2.1372 -0.2133 -0.1911 -0.0484 -1.8443 -0.1454 -0.2386 -0.6993 -0.6091 -0.2942 -0.2605 -0.1215 -0.0107 -0.1524 -0.0747 -0.0319 -0.1452 -0.0939 -0.0295 -0.1153 -0.1454 -0.0307 -0.1095 -0.1932 -0.1430 -0.2406 -0.0898 -0.1887 -0.1111 -0.1898 -1.0506 -0.1686 -0.1496 -0.2238 -0.1352 -0.2761 -0.0678 -0.0559 -0.1378 -0.9193 -0.0569 -0.0576 -0.1483 -0.0276 -3.5428 -2.1099 -0.1460 -0.4328 -0.0973 -0.1817 -0.2622 -0.1576 -0.2665 -0.1593 -0.3278 -0.1112 -0.6737 -0.2971 -0.1508 -0.1059 -0.1428 -0.5070 -0.2741 -0.2155 -0.4617 -0.2685 -0.0776 -1.4852 -0.0664 -0.1446 -0.0276 -0.1442 -0.1773 -0.1403 -0.2623 -0.5952 -0.8023 -0.4159 -0.1400 -1.2112 -0.0375 -0.0929 -1.2616 -0.1622 -0.1081 -0.2693 -0.1063 -0.1553 -0.1422 -0.0117 -0.0820 -0.0338 -0.0573 -0.0430 -0.2031 -0.0882 -0.2354 -0.1805 -0.5544 -0.4687 -0.1687 -0.3866
S-184	Uveitis , Skleritis , Episkleritis . Häufig : Bauchschmerzen , Dyspepsie , Verstopfung , Durchfall , Flatulenz , ösophageales Ulkus* , Dysphagie* , aufgetriebenes Abdomen , saures Aufstoßen . Gelegentlich : Übelkeit , Erbrechen , Gastritis , Ösophagitis* , ösophageale Erosionen* , Meläna . Selten : Ösophagusstriktur* , oropharyngeale Ulzerationen* , Perforationen , Ulzera und Blutungen im oberen Gastrointestinaltrakt ( siehe Abschnitt 4.4<unk> . * Siehe Abschnitte 4.2 und 4.4 .
T-184	Rare : uveitis , scleritis , episcleritis Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcer* , dysphagia* , abdominal distension , acid regurgitation Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena Rare : oesophageal stricture* , oropharyngeal ulceration* , upper gastrointestinal PUBs ( perforation , ulcers , bleeding<<unk>> <<unk>> see section 4.4 ) . <<unk>> See sections 4.2 and 4.4
H-184	-0.34319740533828735	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophagitis* , oesophageal erosion* , dysphagiars* , inflated abdomen , acid relapse . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melanina . Rare : oesophagus strict* , oropharyngeal ulceration* , perforations , ulcera , and haemorrhage in the upper gastro-intestinal tract ( see sections 4.4 ) .
D-184	-0.34319740533828735	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophagitis* , oesophageal erosion* , dysphagiars* , inflated abdomen , acid relapse . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosion* , melanina . Rare : oesophagus strict* , oropharyngeal ulceration* , perforations , ulcera , and haemorrhage in the upper gastro-intestinal tract ( see sections 4.4 ) .
P-184	-0.5270 -0.1569 -0.1180 -0.1488 -0.2134 -1.8562 -0.0350 -0.2181 -0.1524 -0.3523 -0.4304 -0.1169 -0.2326 -0.3352 -0.0101 -0.1030 -0.1506 -0.1209 -0.0301 -0.0934 -0.1151 -0.1431 -0.2235 -0.0802 -0.0934 -0.0440 -0.1390 -0.0659 -0.0368 -0.0968 -0.1104 -0.1406 -0.1962 -0.0470 -0.0338 -0.0996 -0.1451 -0.8865 -0.0492 -0.1829 -0.1457 -0.1954 -0.1010 -3.1888 -0.1834 -0.2684 -1.3906 -0.1649 -0.1507 -0.2243 -0.1117 -0.1767 -0.0745 -0.0706 -0.1301 -1.0898 -0.0165 -0.0818 -0.1461 -0.2816 -0.0577 -0.2767 -3.7830 -3.0385 -0.1963 -0.1421 -0.1786 -2.1372 -0.2133 -0.1911 -0.0484 -1.8443 -0.1454 -0.2386 -0.6993 -0.6091 -0.2942 -0.2605 -0.1215 -0.0107 -0.1524 -0.0747 -0.0319 -0.1452 -0.0939 -0.0295 -0.1153 -0.1454 -0.0307 -0.1095 -0.1932 -0.1430 -0.2406 -0.0898 -0.1887 -0.1111 -0.1898 -1.0506 -0.1686 -0.1496 -0.2238 -0.1352 -0.2761 -0.0678 -0.0559 -0.1378 -0.9193 -0.0569 -0.0576 -0.1483 -0.0276 -3.5428 -2.1099 -0.1460 -0.4328 -0.0973 -0.1817 -0.2622 -0.1576 -0.2665 -0.1593 -0.3278 -0.1112 -0.6737 -0.2971 -0.1508 -0.1059 -0.1428 -0.5070 -0.2741 -0.2155 -0.4617 -0.2685 -0.0776 -1.4852 -0.0664 -0.1446 -0.0276 -0.1442 -0.1773 -0.1403 -0.2623 -0.5952 -0.8023 -0.4159 -0.1400 -1.2112 -0.0375 -0.0929 -1.2616 -0.1622 -0.1081 -0.2693 -0.1063 -0.1553 -0.1422 -0.0117 -0.0820 -0.0338 -0.0573 -0.0430 -0.2031 -0.0882 -0.2354 -0.1805 -0.5544 -0.4687 -0.1687 -0.3866
S-35	Es hemmt die Aktivität der Osteoklasten , das sind Zellen , die am Abbau des Knochengewebes beteiligt sind . Indem es die Aktivität dieser Zellen blockiert , verlangsamt Alendronat den Knochenverlust . Vitamin D3 ist ein Nährstoff , der in manchen Lebensmitteln enthalten ist , aber auch bei Bestrahlung mit natürlichem Sonnenlicht in der Haut hergestellt wird . Vitamin D3 wird , genauso wie andere Formen des Vitamins D , für die Calciumaufnahme und die normale Knochenbildung benötigt . Da Patientinnen mit Osteoporose möglicherweise nicht genügend Vitamin D3 durch Sonnenbestrahlung bilden , ist das Vitamin in ADROVANCE enthalten .
T-35	Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight , it is included in ADROVANCE .
H-35	-0.3216840326786041	It inhibits the activity of the osteoclasts , the cells involved in breaking down the bone tissue . By blocking the activity of these cells , alendronate slows down bone loss . Vitamin D3 is a nutrient found in some foods but also produced by exposure to natural sunlight on the skin . Vitamin D3 , as well as other forms of vitamin D , is required for calcium intake and normal bone formation .
D-35	-0.3216840326786041	It inhibits the activity of the osteoclasts , the cells involved in breaking down the bone tissue . By blocking the activity of these cells , alendronate slows down bone loss . Vitamin D3 is a nutrient found in some foods but also produced by exposure to natural sunlight on the skin . Vitamin D3 , as well as other forms of vitamin D , is required for calcium intake and normal bone formation .
P-35	-0.9661 -0.1615 -0.0661 -0.1449 -0.1235 -0.1441 -0.1305 -0.5618 -0.1937 -0.1502 -0.2105 -0.0302 -0.1554 -0.1640 -0.4339 -0.0841 -0.4228 -0.1180 -0.2563 -0.1653 -1.3673 -0.0913 -0.0481 -0.5342 -0.7694 -0.0933 -0.1436 -0.0629 -0.1213 -0.1876 -0.0559 -0.1297 -0.1591 -0.1239 -0.0950 -0.0902 -0.2566 -0.2815 -0.9404 -0.6095 -0.0323 -0.1391 -1.6540 -0.0439 -0.1120 -0.2330 -0.3176 -0.1393 -0.1745 -0.0761 -0.5496 -0.1486 -0.0523 -0.8210 -0.7663 -0.1887 -0.2724 -1.9181 -0.5292 -0.1591 -0.1478 -0.6506 -0.0960 -0.9113 -0.1236 -0.0689 -0.2966 -1.4370 -0.0528 -0.1203 -0.2453 -0.4214 -0.9140 -0.3276 -0.1363 -0.0972 -0.1735 -0.1345 -0.0450 -0.0277 -0.0811 -0.1104 -0.1417 -1.8358 -0.1040 -0.0478 -0.0703 -0.1289 -0.8278 -0.0565 -0.1480 -0.3031 -0.0450 -0.7098 -0.5180 -0.1558
S-783	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu <unk> EMEA 2007 Reproduction and<unk> or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Aerinaze Tabletten bestehen aus zwei Schichten , von denen eine Desloratadin und die andere Pseudoephedrin enthält . Desloratadin wird sofort nach der Einnahme aus seiner Schicht freigesetzt , während Pseudoephedrin langsam über 12 Stunden hinweg freigesetzt wird . Daher muss die Tablette nur zweimal täglich eingenommen werden .
T-783	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu <<unk>> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Desloratadine has been available in the European Union ( EU ) since 2001 , and pseudoephedrine is widely used in medicines that have been available over-the-counter for many years .
H-783	-0.2246015965938568	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Aerinaze tablets consist of two layers , one of which contains desloratadine and the other contains pseudoephedrine .
D-783	-0.2246015965938568	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Aerinaze tablets consist of two layers , one of which contains desloratadine and the other contains pseudoephedrine .
P-783	-0.1213 -0.0941 -0.1253 -0.1176 -0.1474 -0.0638 -0.2072 -0.0358 -0.2897 -0.0425 -0.1437 -0.0815 -0.1199 -0.1358 -0.1398 -0.0497 -0.1170 -0.0424 -0.1313 -0.0478 -0.1261 -0.0977 -0.1583 -0.0256 -0.0731 -0.0383 -0.1375 -0.1462 -0.0206 -0.1300 -1.5907 -0.0502 -0.0478 -0.1550 -0.1634 -0.0101 -0.2480 -0.0798 -0.1449 -0.0741 -0.1397 -0.1526 -0.0012 -0.1434 -0.1970 -0.0605 -1.0765 -0.1013 -0.0744 -0.1277 -0.1113 -0.0965 -0.1573 -0.0614 -0.1652 -0.1391 -0.0979 -0.1451 -0.1530 -0.0778 -0.1131 -0.0349 -0.0892 -0.1232 -0.2442 -0.0353 -0.0739 -0.0749 -0.0064 -0.1182 -0.1184 -0.0694 -0.1145 -0.0674 -0.0181 -0.1904 -0.1324 -0.1400 -0.3059 -0.1319 -0.1338 -0.1260 -0.4469 -0.0882 -0.1238 -0.1195 -0.7497 -0.2073 -0.1706 -0.1308 -0.3637 -0.0912 -0.2777 -0.8684 -0.0952 -0.1777 -0.9030 -0.5342 -0.1418 -0.1341 -0.1141 -1.1160 -0.1948 -3.9881 -0.2198 -0.0421 -0.1395 -0.4784 -0.0872 -0.7319 -0.6838
S-262	Aus diesem Grund wurde Advate in einer Hauptstudie an 111 Patienten , die an Hämophilie A leiden , mit Recombinate verglichen , um zu zeigen , dass beide Arzneimittel äquivalent sind . In der Studie wurde bei 107 Patienten , die alle Advate erhielten , zudem die Anzahl der Blutungsepisoden untersucht und die Wirksamkeit von Advate bei der Blutstillung auf einer Skala von unwirksam bis ausgezeichnet bewertet . In drei zusätzlichen Studien an Patienten mit schwerer bis mittelschwerer Hämophilie A , darunter eine Studie mit 53 Kindern unter sechs Jahren , wurde die Anwendung des Arzneimittels zur Vorbeugung von Blutungen sowie bei chirurgischen Eingriffen untersucht .
T-262	Three additional studies looked at the use of the medicine in the prevention of bleeding and in surgery in patients with severe or moderately severe haemophilia A , including one study in 53 children under the age of six years .
H-262	-0.5397818088531494	An additional study in patients with severe to moderate haemophilia A , including a study in 53 children less than six years of age , looked at the use of the medicine to prevent haemorrhage and performed surgical procedures .
D-262	-0.5397818088531494	An additional study in patients with severe to moderate haemophilia A , including a study in 53 children less than six years of age , looked at the use of the medicine to prevent haemorrhage and performed surgical procedures .
P-262	-3.5152 -0.3504 -0.1520 -0.1192 -0.3185 -0.1255 -0.0655 -1.5649 -0.2224 -0.4801 -0.0780 -0.4522 -1.3062 -0.1292 -0.2056 -0.2504 -0.3718 -0.4601 -0.1380 -0.1248 -0.2705 -1.3600 -0.1216 -0.3303 -0.1270 -0.1190 -0.0587 -0.1431 -1.3518 -0.0731 -0.1263 -0.3795 -0.1406 -0.1494 -0.8354 -1.6992 -0.0762 -1.7390 -0.2457 -0.0083 -0.1797 -0.1449 -1.5315 -2.5692 -0.1915 -0.0763 -1.4768 -0.3297 -0.1649
S-199	Studien mit ADROVANCE Die Wirkung der niedrigeren Dosis von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) auf den Vitamin-D-Status wurde in einer 15-wöchigen , multinationalen Studie an 682 postmenopausalen Frauen mit Osteoporose gezeigt ( mittlerer Serum-Ausgangswert von 25-Hydroxyvitamin D : 56 nmol<unk> l <unk> 22,3 ng<unk> ml <unk> ; Bereich : 22,5-225 nmol<unk> l <unk> 9-90 ng<unk> ml <unk> ) .
T-199	ADROVANCE studies The effect of the lower dose of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) on vitamin D status was demonstrated in a 15-week , multinational study that enrolled 682 osteoporotic post- menopausal women ( serum 25-hydroxyvitamin D at baseline : mean , 56 nmol/ l <<unk>> 22.3 ng/ ml <<unk>> ; range , 22.5-225 nmol/ l <<unk>> 9-90 ng/ ml <<unk>> ) .
H-199	-0.2637849748134613	Trial of ADROVANCE The effect of the lower dose of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15-week , multi-national trial in 682 post-menopausal women with osteoporosis ( mean serum baseline 25-hydroxyvitamin D : 56 nmol/ l <unk> 22.3 ng/ ml <unk> ) .
D-199	-0.2637849748134613	Trial of ADROVANCE The effect of the lower dose of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15-week , multi-national trial in 682 post-menopausal women with osteoporosis ( mean serum baseline 25-hydroxyvitamin D : 56 nmol/ l <unk> 22.3 ng/ ml <unk> ) .
P-199	-4.8209 -0.5226 -0.1605 -0.1497 -0.0614 -0.1775 -0.0910 -0.0645 -0.2666 -0.0911 -0.1277 -0.1398 -0.1629 -0.0928 -0.1490 -0.0844 -0.0627 -0.1782 -0.1116 -0.0841 -0.1372 -0.0712 -0.0465 -0.1835 -0.1210 -0.1054 -0.2307 -1.2108 -0.1117 -0.3358 -0.1440 -0.1013 -0.0768 -0.1819 -0.0527 -0.0476 -0.3129 -0.2558 -0.1666 -0.0845 -0.3261 -0.0890 -0.2300 -0.0156 -0.1586 -0.6252 -0.1285 -0.1440 -0.6791 -0.1596 -0.0636 -0.1469 -0.1782 -0.1709 -0.0435 -0.5714 -0.1661 -0.1964 -0.0268 -0.0292 -0.3054 -0.0602 -0.1701 -0.0322 -0.0978 -0.0433 -0.1276 -0.0771 -0.1924 -0.1295 -0.1193 -0.1311 -0.1373 -0.1496 -0.5774 -0.2120 -0.1238 -0.0156 -0.0149 -2.3556 -0.0938 -0.0531 -0.2131 -0.1331 -0.2139 -0.0601 -0.0674 -0.1731 -0.1280 -0.1502 -0.2850 -0.1986 -0.1605 -1.0300 -0.1603 -0.2101 -0.1522 -0.2018 -0.1282 -0.0600 -1.3395 -1.0348 -0.1593 -0.2297
S-155	Aufgrund der möglichen Verschlechterung der zugrunde liegenden Erkrankung sollte Alendronat bei Patienten mit aktiven gastrointestinalen Erkrankungen , wie Dysphagie , Erkrankungen des Ösophagus , Gastritis , Duodenitis , Ulzera , oder mit kürzlich aufgetretenen ( innerhalb des letzten Jahres ) , schweren gastrointestinalen Erkrankungen , wie z. B. peptisches Ulkus , aktive gastrointestinale Blutungen oder chirurgische Eingriffe im oberen Gastrointestinaltrakt außer Pyloroplastik , nur unter besonderer Vorsicht gegeben werden ( siehe Abschnitt 4.3 ) .
T-155	Because there is a potential for worsening of the underlying disease , caution should be used when alendronate is given to patients with active upper gastrointestinal problems , such as dysphagia , oesophageal disease , gastritis , duodenitis , ulcers , or with a recent history ( within the previous year ) of major gastrointestinal disease such as peptic ulcer , or active gastrointestinal bleeding , or surgery of the upper gastrointestinal tract other than pyloroplasty ( see section 4.3 ) .
H-155	-0.3017844557762146	Due to the potential for worsening of the underlying disease , alendronate should only be given to patients with active gastro-intestinal disease , such as dysphagia , oesophagus , gastritis , duodenitis , ulcera , or with recent ( within the last year ) severe gastro-intestinal disease , such as peptic ulcus , active gastro-intestinal haemorrhage , or surgery in the upper gastro-intestinal tract except pyloroplasty ( see section 4.3 ) .
D-155	-0.3017844557762146	Due to the potential for worsening of the underlying disease , alendronate should only be given to patients with active gastro-intestinal disease , such as dysphagia , oesophagus , gastritis , duodenitis , ulcera , or with recent ( within the last year ) severe gastro-intestinal disease , such as peptic ulcus , active gastro-intestinal haemorrhage , or surgery in the upper gastro-intestinal tract except pyloroplasty ( see section 4.3 ) .
P-155	-0.5338 -0.0918 -0.1419 -0.8154 -0.8091 -0.7723 -0.6765 -0.0421 -0.3556 -0.1374 -0.1157 -0.0218 -0.3365 -0.1468 -1.1141 -0.1340 -0.1105 -0.1252 -0.1941 -1.7265 -0.1361 -0.7057 -0.3513 -0.2054 -0.1136 -0.1137 -0.0378 -0.4061 -0.2734 -0.0758 -0.1158 -0.1074 -0.8077 -0.2333 -0.1322 -0.1685 -0.2187 -0.0695 -0.1616 -0.0442 -0.1330 -0.1871 -0.0957 -0.3106 -0.1061 -0.1273 -0.1477 -0.0265 -0.0877 -0.1512 -0.1432 -0.0153 -0.1880 -0.2144 -0.1093 -0.0599 -0.1366 -0.2254 -0.2757 -0.3436 -0.1373 -0.1510 -0.1282 -0.3498 -0.7967 -0.1465 -0.1589 -0.8379 -0.1191 -0.1570 -1.3581 -0.0254 -0.1891 -0.4436 -0.1829 -0.0869 -0.0899 -0.9838 -0.1709 -0.1779 -0.1487 -0.1800 -0.1326 -0.1224 -0.2815 -2.2935 -0.1355 -0.1192 -0.0326 -0.2640 -0.2720 -0.2214 -0.0883 -0.0828 -0.4320 -0.0120 -0.0073 -0.7762 -0.1740 -0.1169 -2.4276 -0.1332 -0.1157 -0.2717 -0.0418 -0.1708 -0.2852 -0.0150 -0.0520 -0.0474 -0.0817 -0.0269 -0.3546 -0.6942 -0.0293 -0.1516 -0.5844 -2.2259 -0.8159 -0.0490 -0.0837 -0.1644 -0.2018 -0.1529 -0.1251 -0.1760
S-55	Aufgrund der möglichen Verschlechterung der zugrunde liegenden Erkrankung sollte Alendronat bei Patienten mit aktiven gastrointestinalen Erkrankungen , wie Dysphagie , Erkrankungen des Ösophagus , Gastritis , Duodenitis , Ulzera , oder mit kürzlich aufgetretenen ( innerhalb des letzten Jahres ) , schweren gastrointestinalen Erkrankungen , wie z. B. peptisches Ulkus , aktive gastrointestinale Blutungen oder chirurgische Eingriffe im oberen Gastrointestinaltrakt außer Pyloroplastik , nur unter besonderer Vorsicht gegeben werden ( siehe Abschnitt 4.3 ) .
T-55	Because there is a potential for worsening of the underlying disease , caution should be used when alendronate is given to patients with active upper gastrointestinal problems , such as dysphagia , oesophageal disease , gastritis , duodenitis , ulcers , or with a recent history ( within the previous year ) of major gastrointestinal disease such as peptic ulcer , or active gastrointestinal bleeding , or surgery of the upper gastrointestinal tract other than pyloroplasty ( see section 4.3 ) .
H-55	-0.3017844557762146	Due to the potential for worsening of the underlying disease , alendronate should only be given to patients with active gastro-intestinal disease , such as dysphagia , oesophagus , gastritis , duodenitis , ulcera , or with recent ( within the last year ) severe gastro-intestinal disease , such as peptic ulcus , active gastro-intestinal haemorrhage , or surgery in the upper gastro-intestinal tract except pyloroplasty ( see section 4.3 ) .
D-55	-0.3017844557762146	Due to the potential for worsening of the underlying disease , alendronate should only be given to patients with active gastro-intestinal disease , such as dysphagia , oesophagus , gastritis , duodenitis , ulcera , or with recent ( within the last year ) severe gastro-intestinal disease , such as peptic ulcus , active gastro-intestinal haemorrhage , or surgery in the upper gastro-intestinal tract except pyloroplasty ( see section 4.3 ) .
P-55	-0.5338 -0.0918 -0.1419 -0.8154 -0.8091 -0.7723 -0.6765 -0.0421 -0.3556 -0.1374 -0.1157 -0.0218 -0.3365 -0.1468 -1.1141 -0.1340 -0.1105 -0.1252 -0.1941 -1.7265 -0.1361 -0.7057 -0.3513 -0.2054 -0.1136 -0.1137 -0.0378 -0.4061 -0.2734 -0.0758 -0.1158 -0.1074 -0.8077 -0.2333 -0.1322 -0.1685 -0.2187 -0.0695 -0.1616 -0.0442 -0.1330 -0.1871 -0.0957 -0.3106 -0.1061 -0.1273 -0.1477 -0.0265 -0.0877 -0.1512 -0.1432 -0.0153 -0.1880 -0.2144 -0.1093 -0.0599 -0.1366 -0.2254 -0.2757 -0.3436 -0.1373 -0.1510 -0.1282 -0.3498 -0.7967 -0.1465 -0.1589 -0.8379 -0.1191 -0.1570 -1.3581 -0.0254 -0.1891 -0.4436 -0.1829 -0.0869 -0.0899 -0.9838 -0.1709 -0.1779 -0.1487 -0.1800 -0.1326 -0.1224 -0.2815 -2.2935 -0.1355 -0.1192 -0.0326 -0.2640 -0.2720 -0.2214 -0.0883 -0.0828 -0.4320 -0.0120 -0.0073 -0.7762 -0.1740 -0.1169 -2.4276 -0.1332 -0.1157 -0.2717 -0.0418 -0.1708 -0.2852 -0.0150 -0.0520 -0.0474 -0.0817 -0.0269 -0.3546 -0.6942 -0.0293 -0.1516 -0.5844 -2.2259 -0.8159 -0.0490 -0.0837 -0.1644 -0.2018 -0.1529 -0.1251 -0.1760
S-34	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu <unk> EMEA 2007 Reproduction and<unk> or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Menopause ) auf , wenn der Spiegel des weiblichen Hormons Östrogen sinkt , denn das Hormon Östrogen unterstützt die Knochengesundheit . Die arzneilich wirksamen Bestandteile in ADROVANCE sind Alendronat und Vitamin D3 .
T-34	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu <<unk>> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Vitamin D3 is a nutrient that is found in some foods , but is also made in the skin through exposure to natural sunlight .
H-34	-0.17718710005283356	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged menopause , because the hormone oestrogen helps bone health .
D-34	-0.17718710005283356	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea . europa . eu http : / <unk> www . emea . europa . eu <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged menopause , because the hormone oestrogen helps bone health .
P-34	-1.1155 -0.1021 -0.1209 -0.1175 -0.1467 -0.0643 -0.2160 -0.0387 -0.3186 -0.0521 -0.1487 -0.0842 -0.1253 -0.1375 -0.1358 -0.0546 -0.1265 -0.0433 -0.1329 -0.0486 -0.1526 -0.0967 -0.1606 -0.0262 -0.0816 -0.0413 -0.1396 -0.1455 -0.0240 -0.1272 -1.3164 -0.0498 -0.0534 -0.1549 -0.1739 -0.0111 -0.2817 -0.0733 -0.1460 -0.0628 -0.1394 -0.1477 -0.0019 -0.1404 -0.2033 -0.0563 -0.8318 -0.1003 -0.0830 -0.1263 -0.1072 -0.0958 -0.1615 -0.0479 -0.1688 -0.1380 -0.0885 -0.1457 -0.1593 -0.0858 -0.0992 -0.0410 -0.0927 -0.1237 -0.2690 -0.0438 -0.0618 -0.0798 -0.0060 -0.1159 -0.0983 -0.0728 -0.1161 -0.0686 -0.0158 -0.2436 -0.1815 -0.0245 -0.9786 -1.1255 -0.3736 -0.3330 -0.0314 -0.1773 -0.2413 -0.1450 -0.0478 -0.4979 -0.3293 -0.2501 -0.1651 -0.1738
S-101	Studien mit ADROVANCE Die Wirkung von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) auf den Vitamin-D- Status wurde in einer 15-wöchigen , multinationalen Studie an 682 postmenopausalen Frauen mit Osteoporose gezeigt ( mittlerer Serum-Ausgangswert von 25-Hydroxyvitamin D : 56 nmol<unk> l <unk> 22,3 ng<unk> ml <unk> ; Bereich : 22,5-225 nmol<unk> l <unk> 9-90 ng<unk> ml <unk> ) .
T-101	ADROVANCE studies The effect of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) on vitamin D status was demonstrated in a 15-week , multinational study that enrolled 682 osteoporotic post-menopausal women ( serum 25-hydroxyvitamin D at baseline : mean , 56 nmol/ l <<unk>> 22.3 ng/ ml <<unk>> ; range , 22.5- 225 nmol/ l <<unk>> 9-90 ng/ ml <<unk>> ) .
H-101	-0.2673514485359192	Trial of ADROVANCE The effect of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15-week , multi-national trial in 682 post-menopausal women with osteoporosis ( mean serum baseline 25-hydroxy vitamin D : 56 nmol/ l <unk> 22.3 ng/ ml <unk> ) .
D-101	-0.2673514485359192	Trial of ADROVANCE The effect of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15-week , multi-national trial in 682 post-menopausal women with osteoporosis ( mean serum baseline 25-hydroxy vitamin D : 56 nmol/ l <unk> 22.3 ng/ ml <unk> ) .
P-101	-5.1616 -0.6675 -0.1705 -0.1516 -0.0593 -0.1771 -0.0917 -0.0639 -1.6822 -0.0358 -0.1410 -0.0658 -0.0562 -0.1685 -0.1050 -0.0781 -0.1408 -0.0664 -0.0378 -0.2990 -0.1192 -0.1026 -0.2319 -1.2697 -0.1290 -0.2897 -0.1164 -0.1127 -0.0536 -0.1902 -0.0695 -0.0519 -0.1857 -0.1919 -0.1170 -0.0836 -0.2035 -0.0667 -0.1169 -0.0132 -0.1887 -0.4780 -0.1333 -0.1447 -0.8031 -0.1515 -0.0705 -0.1489 -0.1791 -0.1911 -0.0372 -0.6847 -0.1498 -0.1986 -0.0263 -0.0279 -0.3295 -0.0558 -0.1862 -0.0316 -0.1020 -0.0446 -0.1257 -0.1080 -0.1775 -0.1448 -0.1000 -0.1223 -0.1426 -0.1489 -0.6185 -0.1697 -0.1221 -0.0187 -0.0161 -1.9250 -0.0962 -0.0500 -1.0087 -0.1148 -0.0494 -0.0759 -0.1564 -0.1218 -0.1668 -0.3161 -0.1700 -0.0911 -0.2729 -0.2430 -0.2236 -0.1695 -0.3591 -0.1257 -0.0647 -0.3130 -0.4641 -0.1482 -0.2289
S-40	Die häufigsten Nebenwirkungen ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Kopfschmerzen , Schmerzen des Bewegungsapparats ( Muskeln , Knochen oder Gelenke ) und Symptome des Verdauungsapparats wie Bauchschmerzen , Dyspepsie ( Verdauungsstörungen ) , Verstopfung , Diarrhoe ( Durchfall ) , Flatulenz ( Blähungen ) , Geschwüre ( Ulcera ) der Speiseröhre , Dysphagie ( Schluckbeschwerden ) , aufgetriebenes Abdomen ( geblähter Bauch ) sowie saures Aufstoßen .
T-40	The most common side effects ( seen in between 1 and 10 patients in 100 ) are headache , musculoskeletal ( bone , muscle or joint ) pain and gastro-intestinal symptoms such as abdominal ( tummy ) pain , dyspepsia ( indigestion ) , constipation , diarrhoea , flatulence ( wind ) , oesophageal ( gullet ) ulcers , dysphagia ( difficulty swallowing ) , abdominal distension ( swollen tummy ) and acid regurgitation .
H-40	-0.3421909511089325	The most common side effects ( seen in 1 to 10 patients in 100 ) are headaches , musculoskeletal pains ( muscles , bones or joints ) and symptoms of the digestive system , such as abdominal pain , dyspepsia ( indigestion ) , constipation , diarrhoea , flatulence , oesophageal ulcera , dysphagia ( difficulty in swallowing ) , swollen abdomen and acid belching .
D-40	-0.3421909511089325	The most common side effects ( seen in 1 to 10 patients in 100 ) are headaches , musculoskeletal pains ( muscles , bones or joints ) and symptoms of the digestive system , such as abdominal pain , dyspepsia ( indigestion ) , constipation , diarrhoea , flatulence , oesophageal ulcera , dysphagia ( difficulty in swallowing ) , swollen abdomen and acid belching .
P-40	-0.1257 -0.0929 -0.7968 -0.4133 -0.1486 -0.1816 -0.0967 -0.1307 -0.7996 -0.1686 -0.1259 -0.3284 -0.1157 -0.1082 -0.5599 -0.0994 -0.0814 -0.0157 -0.0619 -0.2059 -0.8250 -0.0538 -0.0203 -0.0033 -0.1578 -0.1145 -1.3458 -0.0756 -0.1622 -0.0929 -0.1313 -0.5126 -0.4806 -0.0629 -0.0234 -0.1369 -0.1957 -2.3425 -0.1342 -0.1408 -0.1305 -0.0680 -0.0517 -0.6691 -0.4976 -0.6705 -0.1641 -0.1172 -0.0867 -0.0726 -0.1170 -0.1407 -0.3243 -0.0868 -0.0651 -0.0543 -0.3385 -1.4821 -0.0106 -2.7392 -0.1677 -0.1666 -0.1077 -0.0126 -0.1126 -0.1414 -0.1437 -0.2020 -0.0490 -0.0530 -0.1604 -0.2000 -0.0544 -0.0096 -0.2024 -0.3608 -2.7190 -0.0141 -0.0632 -0.0141 -0.0331 -0.1369 -0.1556 -0.0192 -0.6604 -0.1434 -0.2251 -0.0452 -0.1288 -0.0598 -0.1659 -0.8922 -0.1629 -0.0312 -0.0426 -0.1443 -0.1693 -2.9988 -0.0413 -0.0870 -0.0106 -2.4215 -0.6748 -0.3033 -2.1688 -0.1987 -0.1488 -0.1771
S-791	Aerinaze darf auch nicht bei Patienten angewendet werden , die an einem Engwinkelglaukom ( erhöhtem Augeninnendruck ) , Harnverhaltung ( erschwertem Wasserlassen ) , Herz- oder Gefäßerkrankungen einschließlich Hypertonie ( Bluthochdruck ) , Hyperthyreose ( Überfunktion der Schilddrüse ) leiden oder bereits einen hämorrhagischen Schlaganfall ( durch eine Gehirnblutung verursachten Schlaganfall ) hatten oder ein Risiko für einen hämorrhagischen Schlaganfall haben .
T-791	Aerinaze should also not be taken by people who have narrow- angle glaucoma ( increased pressure inside the eye ) , urinary retention ( difficulty in passing urine ) , heart or blood vessel diseases including hypertension ( high blood pressure ) , hyperthyroidism ( an overactive thyroid gland ) , or a history or risk of haemorrhagic stroke ( stroke caused by bleeding within the brain ) .
H-791	-0.4958619773387909	Aerinaze should also not be used in patients who have anaemia ( increased eye pressure ) , retention of urine ( difficult urination ) , cardiovascular disease including hypertension , hyperthyroidism ( thyroid hyperfunction ) , have a previous haemorrhagic stroke ( cerebral haemorrhage ) or have a risk of haematological stroke .
D-791	-0.4958619773387909	Aerinaze should also not be used in patients who have anaemia ( increased eye pressure ) , retention of urine ( difficult urination ) , cardiovascular disease including hypertension , hyperthyroidism ( thyroid hyperfunction ) , have a previous haemorrhagic stroke ( cerebral haemorrhage ) or have a risk of haematological stroke .
P-791	-0.7699 -0.1478 -0.1284 -0.4095 -0.0903 -0.4486 -1.4889 -0.1505 -0.1713 -0.1302 -0.1161 -0.9313 -0.7770 -0.6687 -4.3709 -0.0504 -0.7667 -0.1628 -0.1182 -0.3444 -2.5152 -0.1690 -0.1502 -0.1440 -3.5119 -0.2326 -0.6108 -0.0100 -0.2849 -0.1386 -1.5288 -0.0936 -0.0653 -0.1309 -0.1591 -0.0606 -0.0973 -0.1172 -0.1166 -0.3575 -0.3904 -0.0505 -0.0239 -0.2267 -0.1371 -0.1104 -0.2182 -0.1117 -2.0105 -1.2842 -0.2663 -0.1652 -1.7004 -0.1489 -0.0871 -0.1248 -0.0482 -1.8848 -0.1449 -0.1739 -0.9686 -0.3499 -1.6283 -0.1089 -0.6540 -0.1235 -0.2051 -0.0775 -0.0626 -0.1577 -0.0526 -0.0143 -0.0511 -0.1267 -0.0061 -0.0118 -0.4068 -0.7952 -0.5105 -0.7717 -0.1569 -0.6127 -0.1806 -1.3391 -0.6771 -0.9281 -1.0434 -0.2024 -0.1765 -0.1839
S-788	Die häufigsten Nebenwirkungen von Aerinaze ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Tachykardie ( Herzjagen ) , Mundtrockenheit , Schwindel , psychomotorische Hyperaktivität ( Ruhelosigkeit ) , Pharyngitis ( Rachenentzündung ) , Anorexie ( Appetitlosigkeit ) , Verstopfung , Kopfschmerzen , Müdigkeit , Insomnie ( Schlaflosigkeit ) , Somnolenz ( Schläfrigkeit ) , Schlafstörungen und Nervosität .
T-788	The most common side effects with Aerinaze ( seen in between 1 and 10 patients in 100 ) are tachycardia ( fast heart rate ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( sore throat ) , anorexia ( loss of appetite ) , constipation , headache , fatigue ( tiredness ) , insomnia ( difficulty sleeping ) , somnolence ( sleepiness ) , sleep disorders and nervousness .
H-788	-0.26744648814201355	The most common side effects with Aerinaze ( seen in between 1 and 10 patients in 100 ) are tachycardia ( heart racing ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( inflammation of the throat ) , anorexia ( loss of appetite ) , constipation , headache , tiredness , insomnia ( sleeplessness ) , somnolence , trouble sleeping and nervousness .
D-788	-0.26744648814201355	The most common side effects with Aerinaze ( seen in between 1 and 10 patients in 100 ) are tachycardia ( heart racing ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( inflammation of the throat ) , anorexia ( loss of appetite ) , constipation , headache , tiredness , insomnia ( sleeplessness ) , somnolence , trouble sleeping and nervousness .
P-788	-0.1271 -0.0968 -0.6326 -0.2022 -0.1659 -0.0986 -0.2543 -0.1208 -0.1316 -0.2694 -0.1075 -0.1532 -0.0335 -0.1261 -1.5218 -0.1116 -0.1572 -0.1368 -0.1203 -0.1086 -0.0677 -0.1004 -0.1030 -0.0750 -0.0581 -0.1253 -0.1798 -0.0216 -0.1379 -0.9589 -2.7611 -0.1794 -0.1557 -0.2579 -0.0113 -0.1361 -0.2196 -0.0316 -0.0701 -0.1535 -2.6423 -0.1657 -0.1146 -0.3917 -0.0563 -0.0791 -0.1520 -0.0866 -0.0652 -0.1177 -0.1408 -0.1556 -0.4981 -0.2019 -0.0380 -0.1826 -0.0869 -0.1576 -0.4318 -0.1926 -0.1091 -0.1398 -0.0922 -0.5431 -0.1374 -0.1485 -0.0550 -0.0698 -0.0689 -0.0652 -0.1576 -1.0384 -0.1476 -0.2421 -0.0698 -0.1432 -0.1563 -0.2207 -0.0078 -0.1182 -0.1263 -0.1503 -0.0320 -0.0250 -0.7273 -0.1406 -1.3279 -0.0333 -0.1109 -0.1603 -0.1656 -0.0391 -0.0251 -0.4809 -1.2683 -0.0235 -1.0120 -0.1230 -0.1476 -0.1518 -0.1440 -0.1433 -0.0991 -0.1284 -1.6407 -0.5976 -0.0151 -0.1887 -0.1400 -0.1077 -0.1332 -0.1776
S-118	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet .
T-118	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet . 5.8 % , a reduction of 50 % ) .
H-118	-0.3032444417476654	This study observed a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % reduction ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % reduction ; 50 % reduction ) in the analysis of the subgroup of osteoporosis women ( 37 % of the total number suffering from osteoporosis as defined above ) .
D-118	-0.3032444417476654	This study observed a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % reduction ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % reduction ; 50 % reduction ) in the analysis of the subgroup of osteoporosis women ( 37 % of the total number suffering from osteoporosis as defined above ) .
P-118	-1.4455 -0.1520 -1.7311 -0.2649 -0.0584 -0.1981 -0.1308 -0.1086 -0.0111 -0.0580 -0.1472 -0.0351 -0.0400 -0.0919 -0.1375 -0.8959 -0.1282 -0.1037 -0.0963 -0.2986 -0.1379 -0.1786 -1.2594 -0.1859 -0.1669 -0.2476 -0.1479 -0.1328 -0.1518 -0.1483 -0.9661 -0.4779 -0.1424 -0.1554 -0.1486 -0.0272 -0.0674 -0.1378 -0.0751 -0.0985 -0.1492 -1.1674 -0.0830 -0.0330 -0.0862 -0.2859 -0.0546 -0.1494 -0.1106 -0.1701 -0.1336 -0.0853 -0.1887 -0.1884 -0.1702 -0.3332 -2.4598 -0.0927 -0.1150 -0.1101 -0.1400 -0.2113 -0.1215 -0.1153 -0.1246 -0.1097 -0.1485 -0.9588 -0.1467 -0.1734 -0.1332 -0.1683 -0.1043 -0.4322 -0.1534 -0.1418 -0.1762 -0.1138 -0.1398 -0.1469 -0.1170 -0.0761 -0.6007 -4.4098 -0.2011 -0.0721 -0.0863 -0.1370 -0.1028 -0.1225 -0.0537 -1.1265 -0.0400 -0.4346 -0.1321 -0.2023 -0.1876
S-221	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet .
T-221	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet . 5.8 % , a reduction of 50 % ) .
H-221	-0.3032444417476654	This study observed a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % reduction ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % reduction ; 50 % reduction ) in the analysis of the subgroup of osteoporosis women ( 37 % of the total number suffering from osteoporosis as defined above ) .
D-221	-0.3032444417476654	This study observed a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % reduction ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % reduction ; 50 % reduction ) in the analysis of the subgroup of osteoporosis women ( 37 % of the total number suffering from osteoporosis as defined above ) .
P-221	-1.4455 -0.1520 -1.7311 -0.2649 -0.0584 -0.1981 -0.1308 -0.1086 -0.0111 -0.0580 -0.1472 -0.0351 -0.0400 -0.0919 -0.1375 -0.8959 -0.1282 -0.1037 -0.0963 -0.2986 -0.1379 -0.1786 -1.2594 -0.1859 -0.1669 -0.2476 -0.1479 -0.1328 -0.1518 -0.1483 -0.9661 -0.4779 -0.1424 -0.1554 -0.1486 -0.0272 -0.0674 -0.1378 -0.0751 -0.0985 -0.1492 -1.1674 -0.0830 -0.0330 -0.0862 -0.2859 -0.0546 -0.1494 -0.1106 -0.1701 -0.1336 -0.0853 -0.1887 -0.1884 -0.1702 -0.3332 -2.4598 -0.0927 -0.1150 -0.1101 -0.1400 -0.2113 -0.1215 -0.1153 -0.1246 -0.1097 -0.1485 -0.9588 -0.1467 -0.1734 -0.1332 -0.1683 -0.1043 -0.4322 -0.1534 -0.1418 -0.1762 -0.1138 -0.1398 -0.1469 -0.1170 -0.0761 -0.6007 -4.4098 -0.2011 -0.0721 -0.0863 -0.1370 -0.1028 -0.1225 -0.0537 -1.1265 -0.0400 -0.4346 -0.1321 -0.2023 -0.1876
S-144	Mikrokristalline Cellulose ( E 460 ) Lactose Mittelkettige Triglyceride Gelatine Croscarmellose-Natrium Sucrose Hochdisperses Siliciumdioxid Magnesiumstearat ( Ph.Eur. ) ( E 572 ) Butylhydroxytoluol ( Ph.Eur. ) ( E 321 ) Stärke , modifiziert ( Mais ) Aluminiumnatriumsilicat ( E 554 )
T-144	Microcrystalline cellulose ( E460 ) Lactose anhydrous Medium chain triglycerides Gelatin Croscarmellose sodium Sucrose Colloidal silicon dioxide Magnesium stearate ( E572 ) Butyl hydroxytoluene ( E321 ) Modified starch ( maize ) Sodium aluminium silicate ( E554 )
H-144	-0.17816637456417084	Microcrystalline cellulose ( E460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( E572 ) Butylated hydroxytoluene ( E321 ) Starch , modified ( maize ) Sodium aluminium ( E554 )
D-144	-0.17816637456417084	Microcrystalline cellulose ( E460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( E572 ) Butylated hydroxytoluene ( E321 ) Starch , modified ( maize ) Sodium aluminium ( E554 )
P-144	-0.0306 -0.1133 -0.0939 -0.0552 -0.0825 -0.1155 -0.0861 -0.1574 -0.0723 -0.1674 -0.1290 -0.1090 -0.0779 -0.1414 -0.5915 -0.0511 -0.0443 -0.2084 -0.1849 -1.3828 -0.1014 -0.1215 -0.2019 -0.0575 -0.1143 -0.0431 -0.1912 -0.0837 -0.0277 -0.1252 -0.0976 -0.1310 -0.0801 -0.0043 -0.0275 -0.1755 -0.0617 -0.0603 -0.4927 -0.0329 -0.0921 -0.1739 -0.1238 -0.0306 -0.1052 -0.1863 -0.0402 -0.0455 -0.0515 -0.0841 -0.1580 -0.0979 -0.0917 -0.0594 -0.1658 -0.1493 -0.0622 -0.1135 -0.1381 -0.0119 -0.4286 -0.3410 -0.1482 -0.1619 -0.1712 -0.1681 -0.2043 -0.1344 -1.3586 -0.1504 -0.1633 -0.1149 -0.0915 -0.1353 -1.4241 -0.1329 -0.1979 -0.0979 -0.0912 -0.1757 -0.0777 -0.0717 -0.0468 -0.1474 -0.5420 -0.0467 -0.1917 -0.1614 -0.5194 -0.1223 -0.0861 -0.0983 -0.1374 -0.5007
S-248	Mikrokristalline Cellulose ( E 460 ) Lactose Mittelkettige Triglyceride Gelatine Croscarmellose-Natrium Sucrose Hochdisperses Siliciumdioxid Magnesiumstearat ( Ph.Eur. ) ( E 572 ) Butylhydroxytoluol ( Ph.Eur. ) ( E 321 ) Stärke , modifiziert ( Mais ) Aluminiumnatriumsilicat ( E 554 )
T-248	Microcrystalline cellulose ( E460 ) Lactose anhydrous Medium chain triglycerides Gelatin Croscarmellose sodium Sucrose Colloidal silicon dioxide Magnesium stearate ( E572 ) Butyl hydroxytoluene ( E321 ) Modified starch ( maize ) Sodium aluminium silicate ( E554 )
H-248	-0.17816637456417084	Microcrystalline cellulose ( E460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( E572 ) Butylated hydroxytoluene ( E321 ) Starch , modified ( maize ) Sodium aluminium ( E554 )
D-248	-0.17816637456417084	Microcrystalline cellulose ( E460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( E572 ) Butylated hydroxytoluene ( E321 ) Starch , modified ( maize ) Sodium aluminium ( E554 )
P-248	-0.0306 -0.1133 -0.0939 -0.0552 -0.0825 -0.1155 -0.0861 -0.1574 -0.0723 -0.1674 -0.1290 -0.1090 -0.0779 -0.1414 -0.5915 -0.0511 -0.0443 -0.2084 -0.1849 -1.3828 -0.1014 -0.1215 -0.2019 -0.0575 -0.1143 -0.0431 -0.1912 -0.0837 -0.0277 -0.1252 -0.0976 -0.1310 -0.0801 -0.0043 -0.0275 -0.1755 -0.0617 -0.0603 -0.4927 -0.0329 -0.0921 -0.1739 -0.1238 -0.0306 -0.1052 -0.1863 -0.0402 -0.0455 -0.0515 -0.0841 -0.1580 -0.0979 -0.0917 -0.0594 -0.1658 -0.1493 -0.0622 -0.1135 -0.1381 -0.0119 -0.4286 -0.3410 -0.1482 -0.1619 -0.1712 -0.1681 -0.2043 -0.1344 -1.3586 -0.1504 -0.1633 -0.1149 -0.0915 -0.1353 -1.4241 -0.1329 -0.1979 -0.0979 -0.0912 -0.1757 -0.0777 -0.0717 -0.0468 -0.1474 -0.5420 -0.0467 -0.1917 -0.1614 -0.5194 -0.1223 -0.0861 -0.0983 -0.1374 -0.5007
S-234	Resorption Bei gesunden erwachsenen Probanden ( Frauen und Männer ) betrug nach der Gabe von ADROVANCE ( 70 mg<unk> 5.600 I.E. ) nach nächtlichem Fasten und zwei Stunden vor Aufnahme einer Mahlzeit die mittlere Fläche unter der Serum-Konzentration-Zeit-Kurve ( AUC0-80 h ) für Vitamin D3 490,2 ng h<unk> ml ( ohne Berücksichtigung endogener Vitamin-D3-Spiegel ) .
T-234	Absorption In healthy adult subjects ( males and females ) , following administration of ADROVANCE 70 mg/ 5600 IU after an overnight fast and two hours before a meal , the mean area under the serum- concentration-time curve ( AUC0-80 hrs ) for vitamin D3 ( unadjusted for endogenous vitamin D3 levels ) was 490.2 ng hr/ ml .
H-234	-0.4258049726486206	Absorption In healthy adult subjects ( women and men ) , the mean area under the serum concentration time curve ( AUC0-80 h ) for vitamin D3 was 490.2 ng h/ ml ( without regard to endogenous vitamin D3 levels ) after nocturnal fasting and two hours before the start of a meal , when ADROVANCE ( 70 mg/ 5,600 IU ) was administered .
D-234	-0.4258049726486206	Absorption In healthy adult subjects ( women and men ) , the mean area under the serum concentration time curve ( AUC0-80 h ) for vitamin D3 was 490.2 ng h/ ml ( without regard to endogenous vitamin D3 levels ) after nocturnal fasting and two hours before the start of a meal , when ADROVANCE ( 70 mg/ 5,600 IU ) was administered .
P-234	-0.1936 -0.0046 -0.0828 -0.2994 -0.7290 -0.2050 -0.3590 -0.1562 -0.9140 -0.1296 -0.1987 -0.1329 -1.5615 -2.8162 -0.0986 -0.3585 -0.8036 -0.1189 -0.6328 -0.1380 -0.0742 -0.1912 -0.6446 -0.0550 -0.1564 -0.0711 -0.1455 -0.1014 -0.2287 -0.0734 -1.7023 -0.1419 -0.1586 -0.1178 -0.0552 -0.0970 -0.2124 -0.7491 -0.0675 -0.1497 -0.1475 -0.1483 -0.1193 -0.8603 -0.3281 -0.0712 -0.4567 -1.3810 -1.2574 -0.1520 -0.2192 -0.2074 -0.0665 -0.2823 -0.0562 -0.1101 -0.1988 -0.1953 -0.1289 -0.6746 -1.3814 -0.1698 -0.1831 -1.9399 -0.0471 -0.4047 -0.1786 -0.6214 -0.1134 -0.6585 -2.2730 -1.4427 -0.1507 -0.8398 -0.1625 -1.0575 -3.4560 -0.7230 -0.0668 -0.1719 -0.1184 -0.0536 -0.0983 -0.0845 -0.1134 -0.1103 -0.1177 -0.9484 -0.1099 -0.1349 -0.0571 -0.1373 -0.1445 -0.3142 -0.0933 -0.2478 -0.1908
S-131	Resorption Bei gesunden erwachsenen Probanden ( Frauen und Männer ) betrug nach der Gabe von ADROVANCE nach nächtlichem Fasten und zwei Stunden vor Aufnahme einer Mahlzeit die mittlere Fläche unter der Serum-Konzentration-Zeit-Kurve ( AUC0-120 h ) für Vitamin D3 296,4 ng h<unk> ml ( ohne Berücksichtigung endogener Vitamin-D3-Spiegel ) .
T-131	Absorption In healthy adult subjects ( males and females ) , following administration of ADROVANCE after an overnight fast and two hours before a meal , the mean area under the serum-concentration-time curve ( AUC0-120 hrs ) for vitamin D3 ( unadjusted for endogenous vitamin D3 levels ) was 296.4 ng hr/ ml .
H-131	-0.406013548374176	Absorption In healthy adult subjects ( women and men ) , the mean area below the serum concentration time curve ( AUC0-120 hours ) for vitamin D3 was 296.4 ng h/ ml ( excluding endogenous vitamin D3 levels ) after nocturnal fasting and two hours before meal intake .
D-131	-0.406013548374176	Absorption In healthy adult subjects ( women and men ) , the mean area below the serum concentration time curve ( AUC0-120 hours ) for vitamin D3 was 296.4 ng h/ ml ( excluding endogenous vitamin D3 levels ) after nocturnal fasting and two hours before meal intake .
P-131	-0.1748 -0.0046 -0.0832 -0.2094 -0.8059 -0.2228 -0.3342 -0.1603 -0.9047 -0.1336 -0.1895 -0.1326 -0.6965 -1.9867 -0.0867 -0.5143 -1.2390 -0.1410 -0.6556 -0.1196 -0.0851 -0.2045 -0.6467 -0.0512 -0.1620 -0.0812 -0.1363 -0.0795 -0.3408 -0.1891 -1.7969 -0.1426 -0.1677 -0.1144 -0.0440 -0.1000 -0.2094 -0.6468 -0.1031 -0.1250 -0.1574 -0.1536 -0.1224 -0.8673 -0.1650 -0.0619 -0.3151 -1.8422 -0.1346 -0.2154 -0.1096 -0.0535 -0.2626 -0.0552 -0.1000 -0.2047 -0.1430 -0.1351 -1.2664 -1.3042 -0.1652 -0.1932 -2.1023 -0.0624 -0.3686 -0.1526 -0.3166 -0.1063 -0.4206 -2.9748 -0.4794 -0.0694 -0.5580 -0.1856
S-151	ADROVANCE soll nach dem Aufstehen des Tages nur mit einem vollen Glas Wasser ( mindestens 200 ml ) geschluckt werden . Die Patienten sollen die Tablette nicht kauen oder die Tablette im Mund zergehen lassen , da ein Risiko für oropharyngeale Ulzera besteht . Die Patienten sollen sich nicht vor der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , hinlegen .
T-151	ADROVANCE should only be swallowed after getting up for the day with a full glass of water ( not less than 200ml or 7fl . oz . ) .
H-151	-0.4114115238189697	Patients should not chew or melt the tablet in the mouth because of the risk of oropharyngeal ulcera .
D-151	-0.4114115238189697	Patients should not chew or melt the tablet in the mouth because of the risk of oropharyngeal ulcera .
P-151	-0.6384 -0.0898 -0.2240 -0.0989 -0.3211 -0.1143 -0.1144 -2.0011 -1.6818 -0.1819 -0.0643 -0.0554 -0.1807 -0.5798 -0.0296 -0.6131 -0.1657 -0.4150 -0.1994 -0.2959 -0.2299 -0.1591 -0.2970 -0.3083 -0.1371 -0.1328 -0.2095 -0.4143 -1.7130 -0.5051 -0.5831
S-50	ADROVANCE soll nach dem Aufstehen des Tages nur mit einem vollen Glas Wasser ( mindestens 200 ml ) geschluckt werden . Die Patienten sollen die Tablette nicht kauen oder die Tablette im Mund zergehen lassen , da ein Risiko für oropharyngeale Ulzera besteht . Die Patienten sollen sich nicht vor der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , hinlegen .
T-50	ADROVANCE should only be swallowed after getting up for the day with a full glass of water ( not less than 200ml or 7fl . oz . ) .
H-50	-0.4114115238189697	Patients should not chew or melt the tablet in the mouth because of the risk of oropharyngeal ulcera .
D-50	-0.4114115238189697	Patients should not chew or melt the tablet in the mouth because of the risk of oropharyngeal ulcera .
P-50	-0.6384 -0.0898 -0.2240 -0.0989 -0.3211 -0.1143 -0.1144 -2.0011 -1.6818 -0.1819 -0.0643 -0.0554 -0.1807 -0.5798 -0.0296 -0.6131 -0.1657 -0.4150 -0.1994 -0.2959 -0.2299 -0.1591 -0.2970 -0.3083 -0.1371 -0.1328 -0.2095 -0.4143 -1.7130 -0.5051 -0.5831
S-319	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen . ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-319	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions . ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-319	-0.3615202009677887	The factor VIII/ of willebrand factor complex consists of two proteins ( factor VIII and Willebrand factor ) with varying physiological functions . ADVATE contains recombinant blood clotting factor VIII ( Octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
D-319	-0.3615202009677887	The factor VIII/ of willebrand factor complex consists of two proteins ( factor VIII and Willebrand factor ) with varying physiological functions . ADVATE contains recombinant blood clotting factor VIII ( Octocog alfa ) , a glycoprotein equivalent to glycoprotein present in human plasma .
P-319	-0.3924 -0.1950 -0.2143 -0.2505 -0.7447 -0.2246 -0.5981 -5.0339 -0.1881 -0.5204 -0.1427 -0.0845 -0.1767 -0.0847 -0.1282 -0.1453 -0.0787 -0.0508 -0.1346 -0.3929 -0.1850 -0.1084 -0.1662 -4.4781 -0.1434 -0.2655 -0.5185 -0.1585 -0.1456 -2.0616 -0.1393 -0.2629 -0.1762 -0.5063 -0.1400 -0.0587 -0.1926 -0.0613 -0.1439 -0.1202 -0.1415 -0.1583 -0.1427 -0.1552 -0.8395 -0.6669 -0.0296 -0.1046 -0.0522 -0.2021 -0.0933 -0.1483 -1.1030 -0.0953 -0.0992 -0.1133 -0.0553 -0.0741 -0.1467 -0.1674 -0.1431 -0.1238 -0.1145 -0.0860 -0.1154 -0.0513 -0.1488 -0.1577 -1.5056 -0.1085 -0.1112 -0.0887 -0.0595 -1.1842 -0.1308 -0.1466 -0.1159 -0.0954 -0.0850 -0.1305 -0.1792
S-691	Risiko-Management-Plan Der Zulassungsinhaber verpflichtet sich , alle Studien und Pharmakovigilanz-Aktivitäten durchzuführen , die detailliert im Pharmakovigilanz-Plan beschrieben sind . Dieser Pharmakovigilanz- Plan wurde mit der Version 3.0 des Risiko-Management-Plans ( RMP ) festgelegt . Der RMP wurde mit dem CHMP abgestimmt und ist im Kapitel 1.8.2 der Arzneimittelzulassung enthalten .
T-691	Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan , as agreed in version 3.0 of the Risk Management Plan ( RMP ) presented in Module 1.8.2 . of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP .
H-691	-0.2601271867752075	Risk Management Plan MAH commits to performing all studies and pharmacovigilance activities detailed in the Pharmacovigilance Plan This Pharmacovigilance Plan is defined in version 3.0 of the Risk Management Plan ( RMP ) and is agreed with the CHMP and is included in section 1.8.2 of the Marketing Authorisation .
D-691	-0.2601271867752075	Risk Management Plan MAH commits to performing all studies and pharmacovigilance activities detailed in the Pharmacovigilance Plan This Pharmacovigilance Plan is defined in version 3.0 of the Risk Management Plan ( RMP ) and is agreed with the CHMP and is included in section 1.8.2 of the Marketing Authorisation .
P-691	-0.0808 -0.0890 -0.0688 -0.0688 -1.1312 -0.0366 -0.1163 -0.0493 -0.1711 -0.0679 -0.1445 -1.0656 -0.1454 -0.2358 -0.1016 -0.0212 -0.0602 -0.0986 -0.0303 -0.0739 -0.0995 -0.2735 -0.0906 -0.0417 -0.1159 -0.0952 -0.0304 -0.0581 -0.1032 -0.0545 -1.3745 -0.1751 -0.0608 -0.1061 -0.1106 -0.0333 -0.0978 -0.1200 -0.0458 -0.4238 -0.9327 -0.4023 -0.6439 -0.2783 -0.1132 -0.1823 -0.1420 -0.0602 -0.0827 -0.0955 -0.0604 -0.1329 -0.1179 -0.0464 -0.1375 -0.7289 -1.3715 -0.4177 -0.1202 -0.2091 -0.0683 -0.0233 -0.1335 -1.3745 -0.7609 -0.1204 -1.0770 -0.1704 -0.0868 -0.1861 -0.1935 -0.2108 -1.5860 -0.0183 -0.1893 -0.0472 -0.2176 -0.1830
S-659	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 12 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-659	During clinical trials with ADVATE in 145 paediatric and adult patients 12 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-659	-0.3103845417499542	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-659	-0.3103845417499542	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-659	-0.1031 -0.1984 -0.0321 -0.4223 -0.0835 -0.2009 -0.0653 -0.1492 -0.1147 -0.1918 -0.1586 -0.1819 -0.1763 -1.1483 -0.0888 -0.0343 -0.1540 -0.1203 -1.0963 -0.1885 -0.3272 -0.5606 -0.2182 -0.1094 -0.1072 -0.2476 -1.4310 -0.1344 -0.1663 -0.1738 -0.1784 -0.1040 -0.0984 -0.1215 -0.2279 -0.1846 -1.0364 -0.0273 -0.1576 -0.7007 -1.4321 -0.3825 -0.5875 -0.1070 -0.0882 -0.1492 -0.0684 -0.1351 -0.3130 -0.1593 -0.1778 -0.1720 -0.0871 -1.4561 -0.6679 -0.1256 -0.1537 -0.1201 -0.0775 -0.4842 -0.0426 -0.8604 -0.1422 -0.1124 -0.1598 -0.2185 -0.0751 -0.1622 -0.1728 -0.0900 -0.0880 -0.9828 -0.0356 -0.0572 -3.5025 -0.1347 -0.4884 -0.2992 -0.0935 -0.1322 -0.0733 -0.2581 -0.2385 -0.1992 -0.0567 -0.1261 -0.1682 -0.1784
S-157	Der Arzt soll deshalb aufmerksam auf alle Anzeichen und Symptome achten , die auf mögliche ösophageale Reaktionen hinweisen , und die Patienten sollen darauf hingewiesen werden , beim Auftreten von Symptomen ösophagealer Irritation wie Dysphagie , Schmerzen beim Schlucken oder retrosternale Schmerzen oder neues oder sich verschlimmerndes Sodbrennen das Arzneimittel abzusetzen und ärztliche Beratung einzuholen ( siehe Abschnitt 4.8 ) .
T-157	Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia , pain on swallowing or retrosternal pain or new or worsening heartburn ( see section 4.8 ) .
H-157	-0.3574680984020233	The physician should therefore be alert to all signs and symptoms indicative of possible oesophageal reactions and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation appear , such as dysphagia , pain in swallowing or retrostatic pain or new or worsening heartburn ( see section 4.8 ) .
D-157	-0.3574680984020233	The physician should therefore be alert to all signs and symptoms indicative of possible oesophageal reactions and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation appear , such as dysphagia , pain in swallowing or retrostatic pain or new or worsening heartburn ( see section 4.8 ) .
P-157	-0.1925 -0.0653 -0.0510 -0.7963 -0.3608 -0.9530 -0.5993 -0.1533 -1.4008 -0.1898 -0.1704 -0.0815 -0.8953 -0.4288 -0.1499 -0.3221 -0.2997 -0.0879 -0.2002 -0.0548 -0.0959 -0.1277 -0.4185 -0.0831 -0.1998 -0.8895 -0.1523 -0.1865 -0.1848 -0.2475 -0.0828 -0.0281 -0.5820 -1.5651 -0.2827 -0.4419 -0.5274 -0.0339 -0.0981 -0.2961 -0.1277 -0.2168 -0.1506 -0.1141 -0.0573 -0.1226 -0.1376 -0.0912 -0.1192 -0.8304 -0.8037 -0.1229 -0.1539 -0.0861 -0.0833 -0.1328 -0.0504 -0.1543 -0.9779 -1.4863 -0.5437 -0.0941 -0.1541 -0.1509 -0.0680 -3.7830 -1.5741 -0.2487 -0.3786 -0.1599 -0.1623 -0.5355 -0.0550 -0.4298 -0.5090 -0.0418 -0.1931 -0.0446 -0.0782 -0.1613 -0.1963 -0.1537 -0.1351 -0.1811
S-519	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 8 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-519	During clinical trials with ADVATE in 145 paediatric and adult patients 8 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-519	-0.2984466254711151	In clinical trials of ADVATE in 145 adult and paediatric patients 8 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-519	-0.2984466254711151	In clinical trials of ADVATE in 145 adult and paediatric patients 8 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-519	-0.1036 -0.2075 -0.0327 -0.3510 -0.0869 -0.2010 -0.0651 -0.1503 -0.1105 -0.1358 -0.1608 -0.1543 -0.1777 -0.7906 -0.0840 -0.0371 -0.1403 -0.3173 -0.3162 -0.1436 -0.1935 -0.3488 -0.4497 -0.2249 -0.1079 -0.1034 -0.2368 -1.4449 -0.1312 -0.1658 -0.1688 -0.1749 -0.1037 -0.0987 -0.1222 -0.1955 -0.1821 -1.0400 -0.0229 -0.1574 -0.6385 -1.4504 -0.3779 -0.5448 -0.1061 -0.0892 -0.1499 -0.0673 -0.1507 -0.2994 -0.1486 -0.1562 -0.1845 -0.0884 -1.6154 -0.6026 -0.1246 -0.1502 -0.1189 -0.0763 -0.4858 -0.0430 -0.8621 -0.1431 -0.1146 -0.1616 -0.2212 -0.0747 -0.1610 -0.1745 -0.0893 -0.0868 -0.9841 -0.0378 -0.0569 -3.5125 -0.1348 -0.5047 -0.3083 -0.0915 -0.1305 -0.0713 -0.5150 -0.3053 -0.1988 -0.0558 -0.1280 -0.1511 -0.1786
S-449	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 6 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-449	During clinical trials with ADVATE in 145 paediatric and adult patients 6 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-449	-0.3010174036026001	In clinical trials of ADVATE in 145 adult and paediatric patients 6 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-449	-0.3010174036026001	In clinical trials of ADVATE in 145 adult and paediatric patients 6 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-449	-0.1018 -0.1912 -0.0337 -0.3562 -0.0861 -0.1998 -0.0657 -0.1510 -0.1096 -0.1604 -0.1595 -0.1664 -0.1796 -1.3585 -0.0846 -0.0363 -0.1342 -0.1513 -0.3199 -0.1344 -0.1969 -0.3433 -0.4771 -0.2244 -0.1108 -0.1051 -0.2423 -1.4520 -0.1335 -0.1665 -0.1711 -0.1751 -0.1045 -0.0992 -0.1216 -0.1974 -0.1830 -1.0131 -0.0228 -0.1561 -0.6406 -1.4424 -0.3739 -0.5252 -0.1079 -0.0899 -0.1497 -0.0670 -0.1504 -0.3029 -0.1490 -0.1486 -0.1877 -0.0863 -1.5925 -0.6198 -0.1250 -0.1515 -0.1207 -0.0764 -0.4886 -0.0423 -0.8658 -0.1440 -0.1150 -0.1611 -0.2199 -0.0746 -0.1612 -0.1716 -0.0883 -0.0874 -0.9805 -0.0371 -0.0573 -3.5147 -0.1338 -0.4946 -0.3096 -0.0925 -0.1307 -0.0711 -0.3682 -0.2831 -0.2005 -0.0567 -0.1280 -0.1497 -0.1790
S-379	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 4 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-379	During clinical trials with ADVATE in 145 paediatric and adult patients 4 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-379	-0.3010413646697998	In clinical trials of ADVATE in 145 adult and paediatric patients 4 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-379	-0.3010413646697998	In clinical trials of ADVATE in 145 adult and paediatric patients 4 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-379	-0.1010 -0.2228 -0.0320 -0.3538 -0.0858 -0.1998 -0.0648 -0.1505 -0.1073 -0.1129 -0.1592 -0.1459 -0.1821 -1.0177 -0.0904 -0.0362 -0.1359 -0.1464 -0.5719 -0.1350 -0.2083 -0.3338 -0.4517 -0.2251 -0.1090 -0.1039 -0.2445 -1.4452 -0.1328 -0.1670 -0.1684 -0.1757 -0.1032 -0.0984 -0.1216 -0.1924 -0.1858 -0.9998 -0.0226 -0.1575 -0.6397 -1.4829 -0.3821 -0.5181 -0.1078 -0.0899 -0.1515 -0.0672 -0.1514 -0.3024 -0.1498 -0.1548 -0.1871 -0.0869 -1.6217 -0.6016 -0.1241 -0.1496 -0.1205 -0.0758 -0.4923 -0.0425 -0.8684 -0.1426 -0.1148 -0.1616 -0.2213 -0.0761 -0.1625 -0.1752 -0.0889 -0.0862 -0.9919 -0.0375 -0.0568 -3.5065 -0.1337 -0.4929 -0.3040 -0.0918 -0.1315 -0.0716 -0.4786 -0.2877 -0.2003 -0.0555 -0.1288 -0.1496 -0.1786
S-309	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 2 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-309	During clinical trials with ADVATE in 145 paediatric and adult patients 2 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-309	-0.2921200096607208	In clinical trials of ADVATE in 145 adult and paediatric patients 2 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-309	-0.2921200096607208	In clinical trials of ADVATE in 145 adult and paediatric patients 2 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-309	-0.0997 -0.2110 -0.0332 -0.3609 -0.0860 -0.1996 -0.0652 -0.1488 -0.1074 -0.1343 -0.1591 -0.1381 -0.1788 -0.8634 -0.0916 -0.0369 -0.1356 -0.1979 -0.2717 -0.1337 -0.2222 -0.3516 -0.4472 -0.2114 -0.1062 -0.1015 -0.2430 -1.4386 -0.1280 -0.1674 -0.1679 -0.1760 -0.1027 -0.0991 -0.1220 -0.1906 -0.1891 -1.0187 -0.0225 -0.1573 -0.6372 -1.4682 -0.3871 -0.4768 -0.1096 -0.0895 -0.1516 -0.0659 -0.1547 -0.2945 -0.1530 -0.1586 -0.1927 -0.0889 -1.4588 -0.5973 -0.1243 -0.1503 -0.1189 -0.0763 -0.4882 -0.0425 -0.8727 -0.1432 -0.1145 -0.1618 -0.2203 -0.0753 -0.1607 -0.1775 -0.0880 -0.0863 -0.9846 -0.0379 -0.0573 -3.4677 -0.1328 -0.4891 -0.3073 -0.0901 -0.1324 -0.0734 -0.3806 -0.2366 -0.1992 -0.0556 -0.1276 -0.1478 -0.1781
S-145	Etui mit versiegelten Aluminium<unk> Aluminium-Blisterpackungen in Umkartons zu 2 ( 1 Etui mit 2 Tabletten ) , 4 ( 1 Etui mit 4 Tabletten ) , 6 ( 3 Etuis mit 2 Tabletten ) , 12 ( 3 Etuis mit 4 Tabletten ) oder 40 ( 10 Etuis mit 4 Tabletten ) Tabletten .
T-145	Wallet with sealed aluminium/ aluminium blisters , in cartons containing 2 ( 1 wallet x 2 tablets ) , 4 ( 1 wallet x 4 tablets ) , 6 ( 3 wallets x 2 tablets ) , 12 ( 3 wallets x 4 tablets ) or 40 ( 10 wallets x 4 tablets ) tablets .
H-145	-0.1615390032529831	Case of sealed aluminium/ aluminium blisters in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 6 ( 3 cases of 2 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
D-145	-0.1615390032529831	Case of sealed aluminium/ aluminium blisters in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 6 ( 3 cases of 2 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
P-145	-0.3389 -0.4095 -0.1836 -0.1128 -0.0921 -0.3624 -0.1083 -0.1329 -0.1103 -0.0271 -0.1195 -0.0432 -0.2008 -0.0748 -0.1104 -0.0742 -0.0441 -0.1623 -0.1160 -0.1524 -0.1178 -0.7669 -0.1544 -0.1894 -0.0320 -0.0293 -0.1377 -0.1485 -0.2565 -0.1638 -0.1373 -0.3073 -0.1513 -0.1805 -0.0251 -0.0222 -0.1399 -0.1614 -0.1418 -0.1676 -0.1696 -0.6141 -0.1490 -0.1352 -0.0292 -0.0196 -0.1382 -0.1465 -0.1680 -0.1723 -0.1481 -0.2921 -0.1468 -0.1743 -0.0244 -0.0312 -0.1339 -0.3932 -0.1327 -0.1809 -0.1810 -0.5757 -0.1364 -0.1942 -0.0221 -0.0257 -0.1416 -0.0468 -0.0330 -0.1350 -0.1724
S-57	Der Arzt soll deshalb aufmerksam auf alle Anzeichen und Symptome achten , die auf mögliche ösophageale Reaktionen hinweisen , und die Patienten sollen darauf hingewiesen werden , beim Auftreten von Symptomen ösophagealer Irritation wie Dysphagie , Schmerzen beim Schlucken oder retrosternale Schmerzen oder neues oder sich verschlimmerndes Sodbrennen das Arzneimittel abzusetzen und ärztliche Beratung einzuholen ( siehe Abschnitt 4.8 ) .
T-57	Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia , pain on swallowing or retrosternal pain or new or worsening heartburn ( see section 4.8 ) .
H-57	-0.3574680984020233	The physician should therefore be alert to all signs and symptoms indicative of possible oesophageal reactions and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation appear , such as dysphagia , pain in swallowing or retrostatic pain or new or worsening heartburn ( see section 4.8 ) .
D-57	-0.3574680984020233	The physician should therefore be alert to all signs and symptoms indicative of possible oesophageal reactions and patients should be advised to discontinue the product and seek medical advice if symptoms of oesophageal irritation appear , such as dysphagia , pain in swallowing or retrostatic pain or new or worsening heartburn ( see section 4.8 ) .
P-57	-0.1925 -0.0653 -0.0510 -0.7963 -0.3608 -0.9530 -0.5993 -0.1533 -1.4008 -0.1898 -0.1704 -0.0815 -0.8953 -0.4288 -0.1499 -0.3221 -0.2997 -0.0879 -0.2002 -0.0548 -0.0959 -0.1277 -0.4185 -0.0831 -0.1998 -0.8895 -0.1523 -0.1865 -0.1848 -0.2475 -0.0828 -0.0281 -0.5820 -1.5651 -0.2827 -0.4419 -0.5274 -0.0339 -0.0981 -0.2961 -0.1277 -0.2168 -0.1506 -0.1141 -0.0573 -0.1226 -0.1376 -0.0912 -0.1192 -0.8304 -0.8037 -0.1229 -0.1539 -0.0861 -0.0833 -0.1328 -0.0504 -0.1543 -0.9779 -1.4863 -0.5437 -0.0941 -0.1541 -0.1509 -0.0680 -3.7830 -1.5741 -0.2487 -0.3786 -0.1599 -0.1623 -0.5355 -0.0550 -0.4298 -0.5090 -0.0418 -0.1931 -0.0446 -0.0782 -0.1613 -0.1963 -0.1537 -0.1351 -0.1811
S-589	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 10 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-589	During clinical trials with ADVATE in 145 paediatric and adult patients 10 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-589	-0.3091929256916046	In clinical trials of ADVATE in 145 adult and paediatric patients 10 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-589	-0.3091929256916046	In clinical trials of ADVATE in 145 adult and paediatric patients 10 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and prior exposure to factor VIII concentrations ( 150 days ) , only one patient demonstrated a low inhibitor titre ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-589	-0.1003 -0.1996 -0.0319 -0.4017 -0.0839 -0.2009 -0.0657 -0.1512 -0.1091 -0.1687 -0.1582 -0.1627 -0.1850 -1.0447 -0.0866 -0.0353 -0.1421 -0.1302 -1.2107 -0.1756 -0.1962 -0.3428 -0.4510 -0.2340 -0.1095 -0.1051 -0.2338 -1.4500 -0.1284 -0.1666 -0.1709 -0.1755 -0.1040 -0.0981 -0.1219 -0.2004 -0.1844 -1.0937 -0.0234 -0.1570 -0.6482 -1.4155 -0.3733 -0.5319 -0.1086 -0.0902 -0.1500 -0.0670 -0.1468 -0.3006 -0.1491 -0.1719 -0.1724 -0.0842 -1.6572 -0.6071 -0.1246 -0.1490 -0.1191 -0.0769 -0.4823 -0.0427 -0.8633 -0.1436 -0.1111 -0.1602 -0.2204 -0.0763 -0.1617 -0.1706 -0.0889 -0.0869 -0.9790 -0.0372 -0.0565 -3.5084 -0.1346 -0.4799 -0.3010 -0.0918 -0.1314 -0.0728 -0.4025 -0.2682 -0.1993 -0.0566 -0.1303 -0.1486 -0.1774
S-479	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-479	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-479	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-479	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-479	-2.1526 -0.0807 -0.1616 -0.1462 -0.4438 -0.1416 -0.1432 -0.0739 -0.5334 -1.6422 -0.2571 -0.2396 -0.1558 -0.0791 -0.0913 -0.1145 -0.5935 -0.4754 -0.1719 -0.6238 -1.9176 -0.0675 -2.9958 -0.1715 -0.1158 -0.2451 -0.1791 -0.8259 -0.6521 -1.2303 -0.1779 -0.1007 -0.0810 -0.2821 -3.0140 -0.4511 -0.0706 -0.7002 -0.1291 -0.1232 -0.0650 -0.1746 -0.0377 -1.4717 -0.1088 -0.5725 -0.7841 -0.2488 -0.3513 -0.0693 -0.9397 -0.0305 -0.1259 -0.0989 -0.1546 -0.0956 -0.9439 -0.5105 -0.7917 -0.1073 -0.1357 -0.1623 -0.0163 -0.0154 -0.1251 -0.6586 -0.0702 -0.0548 -0.1123 -0.2062 -0.1695 -0.1372 -0.0847 -0.0590 -0.1219 -0.0664 -0.1205 -0.1404 -0.1494 -0.1742
S-271	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-271	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-271	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-271	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-271	-2.1526 -0.0807 -0.1616 -0.1462 -0.4438 -0.1416 -0.1432 -0.0739 -0.5334 -1.6422 -0.2571 -0.2396 -0.1558 -0.0791 -0.0913 -0.1145 -0.5935 -0.4754 -0.1719 -0.6238 -1.9176 -0.0675 -2.9958 -0.1715 -0.1158 -0.2451 -0.1791 -0.8259 -0.6521 -1.2303 -0.1779 -0.1007 -0.0810 -0.2821 -3.0140 -0.4511 -0.0706 -0.7002 -0.1291 -0.1232 -0.0650 -0.1746 -0.0377 -1.4717 -0.1088 -0.5725 -0.7841 -0.2488 -0.3513 -0.0693 -0.9397 -0.0305 -0.1259 -0.0989 -0.1546 -0.0956 -0.9439 -0.5105 -0.7917 -0.1073 -0.1357 -0.1623 -0.0163 -0.0154 -0.1251 -0.6586 -0.0702 -0.0548 -0.1123 -0.2062 -0.1695 -0.1372 -0.0847 -0.0590 -0.1219 -0.0664 -0.1205 -0.1404 -0.1494 -0.1742
S-409	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-409	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-409	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-409	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-409	-2.1526 -0.0807 -0.1616 -0.1462 -0.4438 -0.1416 -0.1432 -0.0739 -0.5334 -1.6422 -0.2571 -0.2396 -0.1558 -0.0791 -0.0913 -0.1145 -0.5935 -0.4754 -0.1719 -0.6238 -1.9176 -0.0675 -2.9958 -0.1715 -0.1158 -0.2451 -0.1791 -0.8259 -0.6521 -1.2303 -0.1779 -0.1007 -0.0810 -0.2821 -3.0140 -0.4511 -0.0706 -0.7002 -0.1291 -0.1232 -0.0650 -0.1746 -0.0377 -1.4717 -0.1088 -0.5725 -0.7841 -0.2488 -0.3513 -0.0693 -0.9397 -0.0305 -0.1259 -0.0989 -0.1546 -0.0956 -0.9439 -0.5105 -0.7917 -0.1073 -0.1357 -0.1623 -0.0163 -0.0154 -0.1251 -0.6586 -0.0702 -0.0548 -0.1123 -0.2062 -0.1695 -0.1372 -0.0847 -0.0590 -0.1219 -0.0664 -0.1205 -0.1404 -0.1494 -0.1742
S-549	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-549	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-549	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-549	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-549	-2.1526 -0.0807 -0.1616 -0.1462 -0.4438 -0.1416 -0.1432 -0.0739 -0.5334 -1.6422 -0.2571 -0.2396 -0.1558 -0.0791 -0.0913 -0.1145 -0.5935 -0.4754 -0.1719 -0.6238 -1.9176 -0.0675 -2.9958 -0.1715 -0.1158 -0.2451 -0.1791 -0.8259 -0.6521 -1.2303 -0.1779 -0.1007 -0.0810 -0.2821 -3.0140 -0.4511 -0.0706 -0.7002 -0.1291 -0.1232 -0.0650 -0.1746 -0.0377 -1.4717 -0.1088 -0.5725 -0.7841 -0.2488 -0.3513 -0.0693 -0.9397 -0.0305 -0.1259 -0.0989 -0.1546 -0.0956 -0.9439 -0.5105 -0.7917 -0.1073 -0.1357 -0.1623 -0.0163 -0.0154 -0.1251 -0.6586 -0.0702 -0.0548 -0.1123 -0.2062 -0.1695 -0.1372 -0.0847 -0.0590 -0.1219 -0.0664 -0.1205 -0.1404 -0.1494 -0.1742
S-619	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-619	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-619	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-619	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-619	-2.1526 -0.0807 -0.1616 -0.1462 -0.4438 -0.1416 -0.1432 -0.0739 -0.5334 -1.6422 -0.2571 -0.2396 -0.1558 -0.0791 -0.0913 -0.1145 -0.5935 -0.4754 -0.1719 -0.6238 -1.9176 -0.0675 -2.9958 -0.1715 -0.1158 -0.2451 -0.1791 -0.8259 -0.6521 -1.2303 -0.1779 -0.1007 -0.0810 -0.2821 -3.0140 -0.4511 -0.0706 -0.7002 -0.1291 -0.1232 -0.0650 -0.1746 -0.0377 -1.4717 -0.1088 -0.5725 -0.7841 -0.2488 -0.3513 -0.0693 -0.9397 -0.0305 -0.1259 -0.0989 -0.1546 -0.0956 -0.9439 -0.5105 -0.7917 -0.1073 -0.1357 -0.1623 -0.0163 -0.0154 -0.1251 -0.6586 -0.0702 -0.0548 -0.1123 -0.2062 -0.1695 -0.1372 -0.0847 -0.0590 -0.1219 -0.0664 -0.1205 -0.1404 -0.1494 -0.1742
S-339	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-339	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-339	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-339	-0.403923362493515	Activity ( International Units ) is determined using chromogenic assay against an in house standard related to WHO standard , and the specific activity is approximately 4,000-10,000 IU/ mg of protein . <unk> <unk> Blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-339	-2.1526 -0.0807 -0.1616 -0.1462 -0.4438 -0.1416 -0.1432 -0.0739 -0.5334 -1.6422 -0.2571 -0.2396 -0.1558 -0.0791 -0.0913 -0.1145 -0.5935 -0.4754 -0.1719 -0.6238 -1.9176 -0.0675 -2.9958 -0.1715 -0.1158 -0.2451 -0.1791 -0.8259 -0.6521 -1.2303 -0.1779 -0.1007 -0.0810 -0.2821 -3.0140 -0.4511 -0.0706 -0.7002 -0.1291 -0.1232 -0.0650 -0.1746 -0.0377 -1.4717 -0.1088 -0.5725 -0.7841 -0.2488 -0.3513 -0.0693 -0.9397 -0.0305 -0.1259 -0.0989 -0.1546 -0.0956 -0.9439 -0.5105 -0.7917 -0.1073 -0.1357 -0.1623 -0.0163 -0.0154 -0.1251 -0.6586 -0.0702 -0.0548 -0.1123 -0.2062 -0.1695 -0.1372 -0.0847 -0.0590 -0.1219 -0.0664 -0.1205 -0.1404 -0.1494 -0.1742
S-732	Gelegentliche Nebenwirkungen Juckreiz , verstärktes Schwitzen , ungewöhnliches Geschmacksempfinden , Hitzewallungen , Migräne , Gedächtnisstörungen , Schüttelfrost , Durchfall , Übelkeit , Erbrechen , Kurzatmigkeit , rauher Hals , Entzündungen der Lymphgefäße , Blässe , Augenentzündungen , Hautausschläge , extremes Schwitzen ,
T-732	Uncommon side effects
H-732	-0.3278171718120575	Uncommon side effects itching , increased sweating , unusual taste sensation , hot flushes , migraine , memory impairment , chills , diarrhoea , nausea , vomiting , shortness of breath , rough neck , inflammatory lymphatic vessels , pallidity , eye inflammation , skin rashes , extreme sweating ,
D-732	-0.3278171718120575	Uncommon side effects itching , increased sweating , unusual taste sensation , hot flushes , migraine , memory impairment , chills , diarrhoea , nausea , vomiting , shortness of breath , rough neck , inflammatory lymphatic vessels , pallidity , eye inflammation , skin rashes , extreme sweating ,
P-732	-0.2743 -0.0128 -0.0351 -0.1916 -2.3665 -0.0821 -0.1564 -0.3130 -0.0516 -0.1842 -0.1557 -0.0524 -0.7522 -0.0273 -0.2195 -0.1383 -0.0281 -0.6668 -0.0665 -0.1249 -0.0541 -0.1399 -0.6607 -0.1579 -1.0166 -1.5974 -0.0501 -0.0958 -0.0990 -0.1444 -0.0531 -0.0516 -0.1269 -0.1338 -0.0232 -0.0481 -0.0388 -0.1559 -0.1324 -0.0318 -0.1508 -0.1463 -0.0179 -0.1174 -0.1599 -0.2218 -0.1403 -0.1499 -0.0364 -0.1514 -2.4947 -0.0750 -0.1455 -1.8476 -0.6978 -0.0336 -0.1099 -0.1907 -0.7645 -0.0859 -0.2462 -0.0518 -0.1364 -0.2241 -0.8342 -1.2180 -0.1363 -0.0706 -0.3964 -0.1381 -0.1944 -0.1452 -1.8368 -0.0847 -0.2656 -0.1405 -0.4088 -0.2129 -0.1820 -0.3362 -0.8457
S-201	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( 56 nmol<unk> l <unk> 23 ng<unk> ml <unk> ) als in der Gruppe unter Alendronat allein ( 46 nmol<unk> l <unk> 18,2 ng<unk> ml <unk> ) .
T-201	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<<unk>> 2.800 I.E. ) ( 56 nmol<<unk>> l <<unk>> 23 ng<<unk>> ml <<unk>> ) als in der Gruppe unter Alendronat allein ( 46 nmol<<unk>> l <<unk>> 18,2 ng<<unk>> ml <<unk>> ) . After 15 weeks of treatment , the mean serum 25-hydroxyvitamin D levels were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2800 IU ) group ( 56 nmol/ l <<unk>> 23 ng/ ml <<unk>> ) than in the alendronate-only group ( 46 nmol/ l <<unk>> 18.2 ng/ ml <<unk>> ) .
H-201	-0.216736301779747	Following 15 weeks of treatment , mean serum levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> group alone .
D-201	-0.216736301779747	Following 15 weeks of treatment , mean serum levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> group alone .
P-201	-0.5802 -0.8088 -0.0754 -0.1341 -0.4220 -0.1573 -0.3185 -0.1277 -0.1268 -0.4118 -0.1447 -0.3399 -0.0934 -0.0577 -0.2782 -0.1094 -0.2171 -0.0760 -0.0839 -0.2379 -0.1259 -0.2089 -0.2278 -0.2238 -0.1462 -0.1409 -0.1116 -0.1055 -0.1774 -0.0787 -0.1834 -0.0898 -0.0547 -0.1067 -0.0805 -0.1269 -0.1191 -0.1167 -0.5681 -0.1082 -0.1166 -0.0577 -0.1310 -0.1088 -0.1100 -0.1261 -0.3659 -0.1372 -0.1176 -1.5811 -0.1358 -0.1730 -0.1296 -0.1156 -0.0427 -0.0681 -0.1656 -0.6612 -0.4333 -0.1221 -0.1133 -0.8620 -0.1333 -0.1654 -0.0535 -0.3264 -0.0604 -0.1693 -0.2351 -0.1222 -0.1023 -0.0224 -0.1042 -0.1680 -0.1684 -0.1783 -0.1203 -0.0528 -0.0405 -0.5096 -0.3836 -0.9070 -0.1907
S-103	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( 56 nmol<unk> l <unk> 23 ng<unk> ml <unk> ) als in der Gruppe unter Alendronat allein ( 46 nmol<unk> l <unk> 18,2 ng<unk> ml <unk> ) .
T-103	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<<unk>> 2.800 I.E. ) ( 56 nmol<<unk>> l <<unk>> 23 ng<<unk>> ml <<unk>> ) als in der Gruppe unter Alendronat allein ( 46 nmol<<unk>> l <<unk>> 18,2 ng<<unk>> ml <<unk>> ) . After 15 weeks of treatment , the mean serum 25-hydroxyvitamin D levels were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2800 IU ) group ( 56 nmol/ l <<unk>> 23 ng/ ml <<unk>> ) than in the alendronate-only group ( 46 nmol/ l <<unk>> 18.2 ng/ ml <<unk>> ) .
H-103	-0.216736301779747	Following 15 weeks of treatment , mean serum levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> group alone .
D-103	-0.216736301779747	Following 15 weeks of treatment , mean serum levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> group alone .
P-103	-0.5802 -0.8088 -0.0754 -0.1341 -0.4220 -0.1573 -0.3185 -0.1277 -0.1268 -0.4118 -0.1447 -0.3399 -0.0934 -0.0577 -0.2782 -0.1094 -0.2171 -0.0760 -0.0839 -0.2379 -0.1259 -0.2089 -0.2278 -0.2238 -0.1462 -0.1409 -0.1116 -0.1055 -0.1774 -0.0787 -0.1834 -0.0898 -0.0547 -0.1067 -0.0805 -0.1269 -0.1191 -0.1167 -0.5681 -0.1082 -0.1166 -0.0577 -0.1310 -0.1088 -0.1100 -0.1261 -0.3659 -0.1372 -0.1176 -1.5811 -0.1358 -0.1730 -0.1296 -0.1156 -0.0427 -0.0681 -0.1656 -0.6612 -0.4333 -0.1221 -0.1133 -0.8620 -0.1333 -0.1654 -0.0535 -0.3264 -0.0604 -0.1693 -0.2351 -0.1222 -0.1023 -0.0224 -0.1042 -0.1680 -0.1684 -0.1783 -0.1203 -0.0528 -0.0405 -0.5096 -0.3836 -0.9070 -0.1907
S-104	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant nach 15 Wochen den Anteil an Patienten mit Vitamin-D-Insuffizienz ( Serumwert von 25-Hydroxyvitamin D <unk> 37,5 nmol<unk> l <unk> <unk> 15 ng<unk> ml <unk> ) um 62,5 % im Vergleich zu Alendronat allein ( 12 % vs .
T-104	The percentage of patients with vitamin D insufficiency ( serum 25-hydroxyvitamin D <<unk>> 37.5 nmol/ l <<unk>> <<unk>> 15 ng/ ml <<unk>> ) was significantly reduced by 62.5 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 12 % vs.
H-104	-0.33323273062705994	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxyvitamin D <unk> 37.5 nmol/ l <unk> <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs. 37.5 ng/ ml <unk> ) at 15 weeks .
D-104	-0.33323273062705994	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxyvitamin D <unk> 37.5 nmol/ l <unk> <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs. 37.5 ng/ ml <unk> ) at 15 weeks .
P-104	-0.9305 -0.0599 -0.1737 -0.1058 -0.0760 -0.1649 -0.0815 -0.1411 -0.1015 -0.1154 -0.4239 -0.0990 -0.1154 -0.0550 -0.1356 -0.1468 -0.3741 -0.0926 -1.3622 -0.1057 -0.1384 -1.2229 -0.1221 -0.1572 -0.0602 -0.0583 -1.9208 -0.0749 -0.1175 -0.1459 -0.2279 -0.0889 -0.5845 -0.5323 -0.1743 -0.9357 -0.1298 -0.3341 -0.0831 -0.0805 -0.0263 -0.1219 -0.0589 -0.1014 -0.6121 -0.2025 -0.2793 -0.0304 -0.7698 -0.3921 -0.1562 -0.1893 -0.1291 -0.0466 -0.0403 -0.1310 -0.7003 -0.1195 -0.0539 -0.1607 -0.5173 -0.1696 -0.3991 -0.1290 -0.1582 -0.0690 -0.1316 -0.1247 -0.1645 -0.1598 -0.4835 -2.7329 -0.3088 -0.2655 -0.1584 -0.1316 -0.7552 -0.4864 -1.1148 -0.8463 -0.9655 -0.0771 -1.0765 -0.1949
S-202	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant nach 15 Wochen den Anteil an Patienten mit Vitamin-D-Insuffizienz ( Serumwert von 25-Hydroxyvitamin D <unk> 37,5 nmol<unk> l <unk> <unk> 15 ng<unk> ml <unk> ) um 62,5 % im Vergleich zu Alendronat allein ( 12 % vs .
T-202	The percentage of patients with vitamin D insufficiency ( serum 25-hydroxyvitamin D <<unk>> 37.5 nmol/ l <<unk>> <<unk>> 15 ng/ ml <<unk>> ) was significantly reduced by 62.5 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 12 % vs.
H-202	-0.33323273062705994	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxyvitamin D <unk> 37.5 nmol/ l <unk> <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs. 37.5 ng/ ml <unk> ) at 15 weeks .
D-202	-0.33323273062705994	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25 hydroxyvitamin D <unk> 37.5 nmol/ l <unk> <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs. 37.5 ng/ ml <unk> ) at 15 weeks .
P-202	-0.9305 -0.0599 -0.1737 -0.1058 -0.0760 -0.1649 -0.0815 -0.1411 -0.1015 -0.1154 -0.4239 -0.0990 -0.1154 -0.0550 -0.1356 -0.1468 -0.3741 -0.0926 -1.3622 -0.1057 -0.1384 -1.2229 -0.1221 -0.1572 -0.0602 -0.0583 -1.9208 -0.0749 -0.1175 -0.1459 -0.2279 -0.0889 -0.5845 -0.5323 -0.1743 -0.9357 -0.1298 -0.3341 -0.0831 -0.0805 -0.0263 -0.1219 -0.0589 -0.1014 -0.6121 -0.2025 -0.2793 -0.0304 -0.7698 -0.3921 -0.1562 -0.1893 -0.1291 -0.0466 -0.0403 -0.1310 -0.7003 -0.1195 -0.0539 -0.1607 -0.5173 -0.1696 -0.3991 -0.1290 -0.1582 -0.0690 -0.1316 -0.1247 -0.1645 -0.1598 -0.4835 -2.7329 -0.3088 -0.2655 -0.1584 -0.1316 -0.7552 -0.4864 -1.1148 -0.8463 -0.9655 -0.0771 -1.0765 -0.1949
S-433	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-433	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-433	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
D-433	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
P-433	-0.3940 -0.0961 -0.2785 -0.1441 -0.5479 -0.7328 -0.9102 -0.1524 -2.3867 -0.0321 -0.0818 -0.0704 -0.5370 -0.4684 -0.1525 -0.0755 -0.0278 -0.1489 -0.0653 -0.0729 -0.1517 -0.0484 -0.1896 -0.0535 -0.0375 -0.0696 -0.1466 -0.0625 -0.1135 -0.0315 -0.0526 -0.0886 -0.1442 -0.1050 -0.0371 -0.0941 -0.0021 -0.1668 -0.2322 -0.1207 -0.1016 -0.4348 -0.1260 -0.0639 -0.1051 -0.1240 -0.1013 -0.1870 -0.1711 -0.1425 -0.1574 -0.0743 -0.0248 -0.0510 -0.0371 -0.1395 -1.2357 -0.8227 -0.0906 -0.1184 -0.0654 -0.1578 -0.0465 -2.5031 -0.1255 -0.1614 -1.5627 -0.0935 -0.7589 -0.1417 -0.1520 -0.1770
S-363	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-363	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-363	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
D-363	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
P-363	-0.3940 -0.0961 -0.2785 -0.1441 -0.5479 -0.7328 -0.9102 -0.1524 -2.3867 -0.0321 -0.0818 -0.0704 -0.5370 -0.4684 -0.1525 -0.0755 -0.0278 -0.1489 -0.0653 -0.0729 -0.1517 -0.0484 -0.1896 -0.0535 -0.0375 -0.0696 -0.1466 -0.0625 -0.1135 -0.0315 -0.0526 -0.0886 -0.1442 -0.1050 -0.0371 -0.0941 -0.0021 -0.1668 -0.2322 -0.1207 -0.1016 -0.4348 -0.1260 -0.0639 -0.1051 -0.1240 -0.1013 -0.1870 -0.1711 -0.1425 -0.1574 -0.0743 -0.0248 -0.0510 -0.0371 -0.1395 -1.2357 -0.8227 -0.0906 -0.1184 -0.0654 -0.1578 -0.0465 -2.5031 -0.1255 -0.1614 -1.5627 -0.0935 -0.7589 -0.1417 -0.1520 -0.1770
S-294	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-294	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-294	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
D-294	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
P-294	-0.3940 -0.0961 -0.2785 -0.1441 -0.5479 -0.7328 -0.9102 -0.1524 -2.3867 -0.0321 -0.0818 -0.0704 -0.5370 -0.4684 -0.1525 -0.0755 -0.0278 -0.1489 -0.0653 -0.0729 -0.1517 -0.0484 -0.1896 -0.0535 -0.0375 -0.0696 -0.1466 -0.0625 -0.1135 -0.0315 -0.0526 -0.0886 -0.1442 -0.1050 -0.0371 -0.0941 -0.0021 -0.1668 -0.2322 -0.1207 -0.1016 -0.4348 -0.1260 -0.0639 -0.1051 -0.1240 -0.1013 -0.1870 -0.1711 -0.1425 -0.1574 -0.0743 -0.0248 -0.0510 -0.0371 -0.1395 -1.2357 -0.8227 -0.0906 -0.1184 -0.0654 -0.1578 -0.0465 -2.5031 -0.1255 -0.1614 -1.5627 -0.0935 -0.7589 -0.1417 -0.1520 -0.1770
S-503	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-503	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-503	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
D-503	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
P-503	-0.3940 -0.0961 -0.2785 -0.1441 -0.5479 -0.7328 -0.9102 -0.1524 -2.3867 -0.0321 -0.0818 -0.0704 -0.5370 -0.4684 -0.1525 -0.0755 -0.0278 -0.1489 -0.0653 -0.0729 -0.1517 -0.0484 -0.1896 -0.0535 -0.0375 -0.0696 -0.1466 -0.0625 -0.1135 -0.0315 -0.0526 -0.0886 -0.1442 -0.1050 -0.0371 -0.0941 -0.0021 -0.1668 -0.2322 -0.1207 -0.1016 -0.4348 -0.1260 -0.0639 -0.1051 -0.1240 -0.1013 -0.1870 -0.1711 -0.1425 -0.1574 -0.0743 -0.0248 -0.0510 -0.0371 -0.1395 -1.2357 -0.8227 -0.0906 -0.1184 -0.0654 -0.1578 -0.0465 -2.5031 -0.1255 -0.1614 -1.5627 -0.0935 -0.7589 -0.1417 -0.1520 -0.1770
S-573	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-573	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-573	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
D-573	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
P-573	-0.3940 -0.0961 -0.2785 -0.1441 -0.5479 -0.7328 -0.9102 -0.1524 -2.3867 -0.0321 -0.0818 -0.0704 -0.5370 -0.4684 -0.1525 -0.0755 -0.0278 -0.1489 -0.0653 -0.0729 -0.1517 -0.0484 -0.1896 -0.0535 -0.0375 -0.0696 -0.1466 -0.0625 -0.1135 -0.0315 -0.0526 -0.0886 -0.1442 -0.1050 -0.0371 -0.0941 -0.0021 -0.1668 -0.2322 -0.1207 -0.1016 -0.4348 -0.1260 -0.0639 -0.1051 -0.1240 -0.1013 -0.1870 -0.1711 -0.1425 -0.1574 -0.0743 -0.0248 -0.0510 -0.0371 -0.1395 -1.2357 -0.8227 -0.0906 -0.1184 -0.0654 -0.1578 -0.0465 -2.5031 -0.1255 -0.1614 -1.5627 -0.0935 -0.7589 -0.1417 -0.1520 -0.1770
S-643	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-643	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-643	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
D-643	-0.27190619707107544	Patients should be advised about signs of immediate hypersensitivity reaction such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory symptoms ( e. g. chest tightness , wheezing ) .
P-643	-0.3940 -0.0961 -0.2785 -0.1441 -0.5479 -0.7328 -0.9102 -0.1524 -2.3867 -0.0321 -0.0818 -0.0704 -0.5370 -0.4684 -0.1525 -0.0755 -0.0278 -0.1489 -0.0653 -0.0729 -0.1517 -0.0484 -0.1896 -0.0535 -0.0375 -0.0696 -0.1466 -0.0625 -0.1135 -0.0315 -0.0526 -0.0886 -0.1442 -0.1050 -0.0371 -0.0941 -0.0021 -0.1668 -0.2322 -0.1207 -0.1016 -0.4348 -0.1260 -0.0639 -0.1051 -0.1240 -0.1013 -0.1870 -0.1711 -0.1425 -0.1574 -0.0743 -0.0248 -0.0510 -0.0371 -0.1395 -1.2357 -0.8227 -0.0906 -0.1184 -0.0654 -0.1578 -0.0465 -2.5031 -0.1255 -0.1614 -1.5627 -0.0935 -0.7589 -0.1417 -0.1520 -0.1770
S-655	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-655	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-655	-0.19804954528808594	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
D-655	-0.19804954528808594	Frequency categories are defined using the following convention : Very common ( 1/ 10 ) , Common ( 1/ 100 to <unk> 1/ 10 ) , Uncommon ( 1/ 1,000 to <unk> 1/ 100 ) , Rare ( 1/ 10,000 to <unk> 1/ 1,000 ) , Very rare <unk> 1/ 10,000 ) , Not known ( frequency cannot be estimated from the available data ) .
P-655	-1.2148 -0.0964 -0.0917 -2.8156 -0.1306 -0.0515 -0.0521 -0.1270 -0.0818 -0.0065 -0.1082 -0.5365 -0.1381 -0.1574 -0.0548 -0.1234 -0.1773 -0.1291 -0.1409 -0.3619 -0.1004 -0.1699 -0.0565 -0.1025 -0.0857 -0.1888 -0.9408 -0.0924 -0.1032 -0.4713 -0.1303 -0.1348 -0.5026 -0.0074 -0.1718 -0.0738 -0.1083 -0.1125 -0.1572 -0.0474 -0.1017 -0.1158 -0.0919 -0.1528 -0.1551 -0.1657 -0.1167 -0.1702 -0.0636 -0.1136 -0.0898 -0.1560 -0.0183 -0.2233 -0.1131 -0.2806 -0.1417 -0.1370 -0.1765 -0.0706 -0.0860 -0.3224 -0.1101 -0.1023 -0.1484 -0.1389 -0.4619 -0.0687 -0.1763 -0.1353 -0.0585 -0.0779 -0.1469 -0.0574 -0.0903 -0.1289 -0.1104 -0.0934 -0.1421 -0.1837 -0.1953
2021-01-23 10:27:33 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-23 10:27:33 | INFO | fairseq_cli.generate | Translated 822 sentences (37137 tokens) in 11.5s (71.23 sentences/s, 3218.11 tokens/s)
2021-01-23 10:27:33 | WARNING | root | That's 100 lines that end in a tokenized period ('.')
2021-01-23 10:27:33 | WARNING | root | It looks like you forgot to detokenize your test data, which may hurt your score.
2021-01-23 10:27:33 | WARNING | root | If you insist your data is detokenized, or don't care, you can suppress this message with '--force'.
Generate test with beam=5: BLEU = 41.67 73.1/50.7/37.0/27.6 (BP = 0.945 ratio = 0.946 hyp_len = 26211 ref_len = 27702)
